TW200401770A - Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof - Google Patents

Abstract

Novel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity: wherein: A represents aryl or heteroaryl; R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N- (alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy; R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio; X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; and Y represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

Description

200401770 发明 Description of the invention: [Technical field to which the invention belongs] The present invention relates to a novel fused cyclopyrimidine-4 (3H) -one derivative or a pharmacologically acceptable salt or ester thereof, which exhibits excellent Anti-arteriosclerotic and anti-inflammatory activity, and the ability of these derivatives to modulate the liver X receptor (LXR) based on the ability of these derivatives to improve dysregulation of fat metabolism and / or through its regulation of the manufacture of inflammatory mediators. The invention further relates to a medicinal composition comprising a fused cyclopyrimidin-4 (3H) -one derivative or a pharmacologically acceptable salt or ester thereof as an active ingredient, and the medicinal composition is preferably used to include derivatization Treatment and / or prevention of arteriosclerosis from the following diseases: atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, such as Chronic rheumatoid arthritis, osteoarthritis, allergic diseases, asthma, sepsis, xerobia and osteoporosis, autoimmune diseases such as systemic lupus erythematosus, ulcerative colitis and Crohn's disease , Cardiovascular diseases such as anemia heart disease and heart failure, cerebrovascular disease, kidney disease, diabetes, diabetic eruption, such as retinopathy, nephropathy, neuropathy and coronary artery disease, obesity, nephritis, hepatitis, cancer And Alzheimer's disease; medicinal composition is better used to treat and / or prevent arteriosclerosis, atherosclerosis Arteriosclerosis, which is derived from diabetes, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, and diabetes; and pharmaceutical compositions are optimally used for the treatment and / or prevention of arteriosclerosis. 200401770 The present invention further relates to the use of a fused ring pyrimidine-4 (3H) -one derivative or a pharmacologically acceptable salt or ester thereof in the preparation of a pharmaceutical composition, preferably the pharmaceutical composition is used for the above diseases Treatment and / or prevention. The invention further relates to a method for the treatment and / or prevention of a disease, preferably as described above, the method comprising administering a pharmaceutically effective amount of a fused cyclopyrimidin-4 (3H) -one derivative or a method thereof Pharmacologically acceptable salts or esters are administered to warm-blooded animals, preferably humans. The present invention further relates to a method for preparing a fused ring pyrimidine-4 (3H) -one derivative or a pharmacologically acceptable salt or ester thereof. [Prior art] For example, cardiovascular disease (including heart disease), cerebrovascular disease and kidney disease (caused by local blood pressure), hyperlipidemia and hyperglycemia are the main social problems in the industrial society. In Japan, heart disease, cerebrovascular disease, and kidney disease are the second, third, and eighth leading causes of death in 1999, and the death rates caused by these diseases per 100,000 population are 120.4, 110.8, and 14.1. (Vital statistic of Japan 1999, volume 1; Health and Welfare Statistics Association). In the United States, 46,000, and 60,000 people each died of coronary heart disease and coronary heart disease-related diseases (American Heart Association, Dallas, Texas: 2000) in 1 998 ° Attempted treatment And prevention of these cardiovascular diseases, antihypertensive agents, antihyperlipidemic agents and antidiabetic agents have been used for the treatment of hypertension, hyperlipidemia and hyperglycemia, α- and / 3-blockers, Diuretics, calcitonin inhibitors, ACE inhibitors, A-II receptor antagonists, etc. have been used clinically as antihypertensive agents; 200401770 HMG-CoA reductase inhibitors, anion exchange resins, propofol, Fabert ( fib rates) have been used clinically for the treatment of hyperlipidemia; and insulin, sulfonylurea, metformin, glitazones, etc. have been used clinically as anti-diabetic agents. These drugs have the ability to adjust the blood pressure level and the concentration of fat and glucose in the blood. However, unfortunately, despite the use of these drugs, mortality rates due to heart disease, cerebrovascular disease, and kidney disease have not been effectively improved. Exploratory trials and another way to deal with these diseases more effectively are needed. The direct risk factors of vascular diseases, such as heart disease, cerebrovascular disease and kidney disease, are arteriosclerosis accompanied by the proliferation of arterial wall, which is characterized by the oxidation of LDL-cholesterol (LDL-C) on the arterial wall Formation of accumulated foci (Ross, R ·, Annu · Rev. Physiol ·, 1 995, 57, 79 1 -804: Steinberg, D ·, J. Biol · Chem., 1 997, 272, 20963 -20966) These lesions block blood flow and promote blood clot formation. The development of novel drugs to treat or prevent vascular diseases has focused on the unknown biosynthetic pathway of oxidized LDL-C. This knowledge is being used to develop and regulate oxidized LD L- C. Pharmacy. Recently, it has been proven that LX R plays an important role in the regulation of fat metabolism in orphan members of the Nuclear Receptor Family (Janowski BA, et al ·, Nature, 1 996, 3 8 3, 72 8- 7 3 1), LXR has two isoforms, namely LXR α and LXR / 3. High concentrations of LXR α in mammals are found in the liver, lower amounts in the kidney, and a small amount in the small intestine, spleen and adrenal glands. in. LXR / 3 is found in most organs and tissues of the body. The transcriptional activity of LXR has been shown to be regulated by oxidative sterols in giant 200401770 phagocytes located in the vessel wall. LX R induces ATP-binding cassettes The expression of ATP Binding Cassette Transporter-1 (ABCA1) and carrier protein (Apolipoprotein E; ApoE), which makes the cell's cholesterol easily flow out from the blood vessel wall and transfer cholesterol to the liver. Furthermore, LXR also induces ABCA1 expression in the small intestine, which reduces cholesterol absorption. In addition, LXRa is a transcription factor in the liver that regulates the performance of cytochrome P45 0 7A (Cytochrome P45 0 7A; CYP7A). It is a rate-limiting enzyme that synthesizes cholic acid from cholesterol. Acid secretion. Given the absolute importance of LXRs in cholesterol metabolism, agents that regulate LXRs can be expected to benefit the treatment and / or prevention of arteriosclerosis, atherosclerosis, arteries derived from diabetes, hyperlipidemia, and / or fat-related diseases hardening.

Atherosclerosis is also considered a chronic inflammatory disease (Ross, R., N. Engl. J. Med., 1986, 314, 488-500). Recently, it has also been reported that LXR is adjusting the inflammatory mediator ( For example, the expression of nitric oxide synthase, cyclooxygenase-2 (COX-2) and interleukin-6 (IL-6)) also plays an important role in controlling immune function (M angels dor f, D. J., Tontonoz, P. et. al., Nat. Med., 2 003, 9, 213-219). Therefore, in addition to improving fat metabolism, LXR ligands can be expected to The anti-inflammatory effect inhibits the onset and development of arteriosclerosis. In addition, it has also been proven that both natural and synthetic LXR activators can chemically reduce dermatitis in animal models (Fowler, AJ et. Al., J. Invest. Dermatol, 2003, 120, 246-2 5 5) . Therefore, LXR modulators are expected to be used in the treatment of a wide variety of different inflammatory diseases. -10- 200401770 The compounds described in WO 00/54759, WO 01/41704 and WO 02/24632 have been shown as LXR ligands. However, it has not previously disclosed publicly that the present invention has a compound of formula (I), which has a fused ring pyridine 4 (3H) -one skeleton, and exhibits binding affinity for LXR. The application under review PCT / US 0 3/0 6793 discloses quinazolinone derivatives which are claimed to have nuclear receptor-regulating activity, especially FXR-regulating activity. [Summary of the Invention] The present inventors have pointed out an investigation on the synthesis and pharmacological activity of fused ring pyrimidine-4 (3H) -one compounds in order to obtain compounds exhibiting excellent binding affinity for LXR. As a result, the following formula ( I) The compound exhibits excellent binding affinity for LXR, and the present invention has been completed. The present invention provides fused ring pyrimidine-4 (3H) -one derivatives and pharmacologically acceptable salts and esters thereof, which are manufactured due to their ability to improve fat metabolism disorders and / or inflammatory mediators adjusted by them, and Produces excellent anti-arteriosclerosis and anti-inflammatory activity, both of which are based on the ability of these derivatives to regulate nuclear receptors, liver X receptors (LXR). The present invention further provides a medicinal composition comprising a fused cyclopyrimidin-4 (3Η) -one derivative or a pharmacologically acceptable salt or ester thereof as an active ingredient. The medicinal composition is preferably used for treatment and / Or prevent arteriosclerosis, including diseases derived from 'atherosclerosis, arteriosclerosis derived from diabetes, dyslipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, such as chronic rheumatoid arthritis, Osteoarthritis, allergic diseases, asthma, sepsis, dry addiction and osteoporosis, autoimmune diseases, such as systemic lupus erythematosus, ulcerative colitis and Crohn's disease, heart disease 200401770 tube diseases, such as anemia heart Disease and heart failure, cerebrovascular disease, kidney disease, diabetes, diabetic dysfunction such as retinopathy, nephropathy, neuropathy and coronary artery disease, obesity, nephritis, hepatitis, cancer and Alzheimer's disease; medical composition More preferably used for the treatment and / or prevention of arteriosclerosis, atherosclerosis, arteriosclerosis, which is derived from diabetes, hyperemia Disease, fat-related diseases, via disease, diabetes and inflammatory regulation of inflammatory cytokines; and most preferably a pharmaceutical composition for treating arteriosclerosis and / or prophylaxis. The present invention further provides the use of fused ring pyrimidine-4 (3H) -one derivatives or pharmacologically acceptable salts or esters thereof in the preparation of a pharmaceutical composition, and the pharmaceutical composition is preferably used for the treatment of the above-mentioned diseases. And / or prevention. The invention further relates to a method for the treatment and / or prevention of a disease, preferably as described above, the method comprising administering a pharmaceutically effective amount of a fused cyclopyrimidin-4 (3H) -one derivative or a method thereof Pharmacologically acceptable salts or esters are administered to warm-blooded animals, preferably humans.

The present invention further relates to a method for preparing a fused ring pyrimidine-4 (3H) -one derivative or a pharmacologically acceptable salt or ester thereof. In a first aspect of the present invention, a compound of the following formula (I) or a pharmacologically acceptable salt or ester thereof is provided:

F

-12- 200401770 where: A represents C6_C〗 4 or 5 to 7 member heteroaryl; R, R and R are the same or different and each represents a hydrogen atom, hydroxyl, nitro 'cyano, amine, halogen Atom, carboxyl, carbamoyl, hydrogenthio, cc 1 6 alkyl, C "C6 alkyl, alkylcarbonyloxy, cvq alkoxy, c" c6 alkyl substituted with 1 to 7 halogen atoms Thio 'alkylsulfinyl, alkylsulfinyl, Ci-C, alkylamino, bis (c "c6 alkyl) amino (where alkyl groups are the same or different), C ^ C: 7 alkylcarbonylamino, N- (C2_C7 alkylcarbonyl) -NU6 alkyl) amino, C2_c7 alkyloxycarbonylamino, n_ (C2_C7 alkyloxyfluorenyl) -N- (CVC6 alkyl) Amine group, Ci_c6 alkylsulfonylamino group, N- (CVC6 alkyl base), n- (c "c6 alkyl) amino group, Cl_c6_alkylsulfonylamino group (wherein A haloalkylsulfonylamino group is a "C6 alkyl fluorenylamino group" substituted with 1 to 7 halogen atoms, n_ (Ci_C6 haloalkylsulfonyl) _KCVC6 alkyl) amino group (wherein the ^-^ Haloalkylsulfonyl is Ci-C ^ alkylsulfonyl substituted by 1 to 7 halogen atoms), C2-C7 alkylcarbonyl , C2_ C: 7 oxygen oxy group, C2_C7 alkylaminocarbonyl group or bis (C "C6 alkyl) aminocarbonyl group (wherein the group may be the same or different), or ... and R2 can form Cl_c4 together Alkanedioxy; R and R5 are the same or different and each represents a hydrogen atom, a hydroxyl group, an amine group, a halogen atom, a hydrogen thio group, an alkyl group, a Ci-c0 alkyl group substituted with 1 to 7 halogen atoms, CVC , Alkoxy, c2_C7 alkoxycarbonyl or Ci_c6 alkylthio; X represents a hydrogen atom, a hydroxyl group, a halogen atom, Ci_c6 alkoxy or 01-(: 6 alkoxy substituted by 1 to 7 _ prime atoms ; Y represents C "C0 alkyl group, substituted with 1 to 7 substituents 0" (: 6 alkyl group (the 200401770: the group is the same or different 'and is selected from the following substituent group α;), C〆 " Circumferential group 'cvc, substituted by 1 to 7 ear radicals. Circental radical (the ear radicals are (identical or different' and selected from the following substituent group α) ' Heterocyclic group, 5 to 9-membered heterocyclic group substituted with 1 to 7 substituents (the substituents are the same or different and are selected from the following substituent group a), aryl, and Up to 4 substituents replacing Γ P ^ Square group (the substituents are the same or different and are selected from the group of substituent groups described below), C4_c "cycloalkylalkyl, C ^ c! 4cycloalkylalkyl substituted with 丨 to 7 substituents (The substituents are the same or different, and

From the following substituent group α), (5 to 9-membered heterocyclic group ((VC4 alkyl), (5 to 9-membered heterocyclic group) substituted with 1 to 7 substituents) _ (C "C4 院(The substituents are the same or different and are selected from the following substituent groups a), c7_Ci4 aryl: or C7_C14 aralkyl substituted with i to 5 substituents (the substituents are the same or different Is iso 'and is selected from the following substituent groups: (a) The substituent group α represents a group consisting of a halogen atom, an acyl group, a cyano group, an amine group, a c2-c7 alkylcarbonyloxy group, and a Ci_C6 alkyl group. Group, Ci_C6 alkoxy group, cvc, alkylthio group, C6C6 alkylsulfinylfluorenyl group, C6C6 alkylsulfonyl group, main group, c6C6 alkylamino group, di (c6C6 alkyl group Group) amine group (where the alkyl groups are the same or different), c ^ -c: 7 alkylcarbonylamino group, Ci_C6 alkylsulfonylamino group, and C "haloalkylsulfonylamino group (wherein C "C6 halogen compound based amines whose amine group is Ci_C 6 alkylsulfonylamino group substituted with 1 to 7 halogen atoms); and the reference substituent group β represents a group consisting of , /, ", Control group, nitro, cyano, amine CrC, alkyl, c "c6 alkyl, c2-c7 alkylcarbonyloxy, substituted with 1 to 7 halogen atoms, (" ": (6 alkoxy, c" c sulfanylthio, CVC, alkyl Sulfinyl sulfenyl, Cl-C6 alkyl sulfonyl, alkoxy-14- 200401770 ylamino, bis (c "c6 alkyl) amino (where the alkyl groups are the same or different), c2匸 7 alkylcarbonylamino group, heart (0: 2-(: 7 alkylcarbonyl) -N- (cvc6 alkyl) amino group, c2-c7 alkoxycarbonylamino group, N- (C2-C7 alkoxy group) Carbonyl group) -n- (cvc6 alkyl) amino group, cvc6 alkylsulfonylamino group, N- (cvc6 alkylsulfonyl C6 alkyl) amine group, c "c6 haloalkylsulfonylamino group (Wherein the "c6 haloalkylsulfonylamino group is an alkylsulfonylamino group substituted with 1 to 7 halogen atoms), N- (C" C6 haloalkylsulfonylamino) -N- ( C "C6 alkyl" amine group (wherein "C6 haloalkylsulfonyl is C" C6 alkyl_fluorenyl substituted with 1 to 7 halogen atoms), CVC1Q aryl, C7-C14 aralkyloxy , C "C4 alkylene dioxy, C2-C7 alkylcarbonyl, c2-c7 alkyloxycarbonyl, c2-c7 alkylaminocarbonyl, and: (C" c6 alkyl) aminocarbonyl ( Of which alkane The radicals are the same or different); if Y is the following options ⑴ to (vii), and A is phenyl, then R4 and R5 represent a hydrogen atom and -C (CF3) connected to the 3 or 4 position of phenyl Part 2 (X) represents, part c (cf3) 2 (oh): (i) an alkyl group at the 1st position with an amine group, an alkylamino group, a dialkyl moonyl group, an alkylcarbonylamino group , Alkylsulfonylamino or haloalkylsulfonylamine, and optionally substituted with an alkyl or phenyl group at the first position; (ii) a cycloalkyl group with an amine group, An alkylamino group, a dialkylamino group, an alkylcarbonylamino group, an alkylsulfonylamino group, or a haloalkylsulfonylamino group, and optionally 1 to 6 selected from the substituents α (Iii) a heterocyclic group having at least one nitrogen atom, which is optionally substituted with one or two other groups selected from alkyl, alkylsulfinyl, alkylsulfonyl and phenyl (Iv) a cycloalkylalkyl group having an amine group, an alkylamine group, a dialkylamine group, an alkylcarbonylamino group, an alkylsulfonylamino group, or a haloalkyl group at the first position of the alkyl portion; -15- 200401770 Substituted by stilbylamino, the cycloalkylalkyl optionally To 6 substituents selected from the substituent α; (ν) a cyclic group, the alkyl group of the alkyl group is at the first position with an amine group, an alkylamine group, a k-base group, and an alkylcarbonyl group; Amino group, alkylsulfonylamino group or haloalkyl extended amino group, the heterocyclic alkyl group is optionally substituted with 1 to 6 groups selected from the substituent α; (vi) a heterocyclic ring Methyl, whose heterocyclyl moiety has at least one nitrogen atom, and is optionally substituted with 1 to 7 groups selected from substituents α, and the methyl moiety is optionally substituted with a radical or phenyl; and (Vii) Aromatic radical, in the first position of the alkyl part, there are amine, alkylamine, monoamine, radical amine, alkoxycarbonylamino, alkylsulfonyl Amine group, halogenated sulfonylamino group, N_ (alkylcarbonyl (alkyl) amino group, N- (alkoxycarbonyl) -N- (alkyl) amino group, N_ (alkylsulfonyl group ( Alkyl) amino or N- (haloalkylsulfonyl) _N_ (alkyl) amino substituted, the aralkyl is optionally substituted with another 1 to 6 groups selected from the substituent θ. The invention also provides a pharmaceutical composition comprising an effective amount of a pharmacologically active compound and a carrier or diluent, wherein the pharmacologically active compound is a compound of formula (I) as defined above or a pharmacologically acceptable salt or ester thereof. In particular, the composition is provided for treatment and / or prevention in a warm-blooded animal, and the composition can treat and / or prevent a human disease by adjusting LXR function in the warm-blooded animal. Preferably, the composition is used in a warm-blooded animal to treat and / or prevent a human disease selected from arteriosclerosis derived from the following diseases: atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia , Fat-related diseases, Inflammatory diseases regulated by inflammatory cytokines, Autolog-16-200401770 Immune disease, Cardiovascular disease, Cerebrovascular disease, Kidney disease, Diabetes, Diabetic outbreak, Obesity, Nephritis, Hepatitis , Cancer and Alzheimer's disease. More preferably, the composition is used for treating and / or preventing human diseases selected from the group consisting of arteriosclerosis, atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-relatedness in warm-blooded animals. Diseases, inflammatory diseases regulated by inflammatory cytokines, and diabetes. Optimally, the composition is used to treat and / or prevent arteriosclerosis in humans in warm-blooded animals. The present invention further provides a compound of formula (I) or a pharmacologically acceptable salt or ester thereof for use as a medicament. Φ The present invention also provides the use of at least one compound of the above formula (I) or a pharmacologically acceptable salt or ester thereof for the manufacture of a drug in a warm-blooded animal, which can be used in the Modulating LXR function in warm-blooded animals can treat and / or prevent human diseases. Preferably, the disease is treatable and / or preventable by adjusting LXR function in warm-blooded animals, and comprises a disease selected from arteriosclerosis derived from the following diseases, atherosclerosis, and arteries derived from diabetes Sclerosis, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, autoimmune diseases, cardiovascular diseases *, cerebrovascular diseases, kidney diseases, diabetes, diabetic dysplasia, obesity, Nephritis, hepatitis, cancer and Alzheimer's disease. More preferably, the disease is selected from the group consisting of atherosclerosis, atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, and diabetes. Optimally, the composition is used to treat and / or prevent arteriosclerosis in humans in warm-blooded animals. Optimally, the disease is arteriosclerosis. -17- 200401770 In another aspect, the present invention also provides a method for treatment and / or prevention in the warm-blooded animal, which can be treated and / or preventable by adjusting LXR function in the warm-blooded animal A human disease comprising administering to the warm-blooded animal an effective amount of a compound of formula (I) as defined above, or a pharmacologically acceptable salt or ester thereof. Preferably, the disease is treatable and / or preventable by adjusting LXR function in warm-blooded animals, and comprises a disease selected from arteriosclerosis derived from the following diseases, atherosclerosis, and arteries derived from diabetes Sclerosis, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, autoimmune diseases, cardiovascular diseases, cerebrovascular diseases, kidney diseases, diabetes, diabetic rupture, obesity, nephritis, Hepatitis, cancer and Alzheimer's disease. More preferably, the disease is selected from the group consisting of arteriosclerosis, atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, and diabetes. Optimally, the disease is arteriosclerosis. In another aspect of the present invention, it also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmacologically acceptable salt or ester thereof as defined above and at least one pharmaceutically active agent selected from the group consisting of: HMG-CoA Reductase inhibits Qi [J, ACAT inhibits Qi IJ, vasodilatin II inhibits Qi U and diuretics, and contains a carrier or diluent. Preferably, the pharmaceutically active agent is a HMG-CoA reductase inhibitor. Preferred classes of the compounds of the present invention are compounds of formula (I) and their pharmacologically acceptable salts and esters, where: (1) R1, R2 and R3 are interrelated or different and each is a gas atom or a radical. , Nitro, cyano, amine, fluorine, chlorine, bromine, carboxy, carbamoyl, C4C4 alkyl, C4C4 alkyl substituted with 1 to 5 halogen atoms, c4c4 200401770 alkoxy, c "c4 alkylthio, baseamino, bis (C" C4 alkyl) amino (where alkyl is the same or different), c2_c5 alkylcarbonylamino, N_ (C2_C5 alkyl Carbonyl group) -n- (cvc4 alkyl) amino group, C2_C5 alkoxycarbonylamino group, c2_cj alkynyl group · group or mono (Ci-C # yuan group) amino group (where the base group is the same or similar Iso), or R1 and R2 together can form Cl_c3 butanedioxy; (2) R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, a cyano group, an amine group, a fluorine atom, Chlorine, bromine, carboxy, carbamoyl, methyl, ethyl, propyl, trifluoromethyl, pentafluoroethyl, methoxy, ethoxy, isopropoxy, methylthio, ethyl Sulfur, isopropyl sulfur Methyl, methylamino, dimethylamino, acetamido, N-methylacetamido, methoxycarbonyl, ethoxycarbonyl, methylaminoformyl or dimethylaminoformamyl, Or ... and! ^ Can form methylenedioxy or ethylenedioxy together; (3) R1, R2 and R3 are the same or different and each is a hydrogen atom, a radical, a fluorine atom, a chlorine atom, a methyl group , Ethyl, trifluoromethyl, methoxy, ethoxy, or acetamido, or R1 and R2 may together form a methylenedioxy group; (4) R3 is a hydrogen atom; (5) R4 and R5 are The same or different and each is a hydrogen atom, a fluorine atom, a chlorine atom, a CVC4 alkyl group, an alkyl group substituted with 1 to 5 halogen atoms, a cvc4 methoxy group, a C2-C5 "7Coxy ^ group, or a Ci- CA-based thio group, (6) R4 and R5 are the same or different and each is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, an ethyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, and a methoxy group Carbonyl, ethoxycarbonyl, methylthio, or ethylthio; (7) R4 and R5 are the same or different and each is a hydrogen atom, a chlorine atom, a methyl group, or a methoxy group; -19- 200401770 ( 8) R4 and R5 are each a hydrogen atom; (9) X is hydrogen Atom, substituted by radical, ci-C4 alkoxy or hydrazone (: "0: 4 alkoxy; 1 to 5 halogen atoms (10) X is hydrogen atom, hydroxyl group, methoxy group or hydrazone oxygen (1 1) X is a hydroxyl group; A ® substituted 0-1-0: 4 alkanes (the substituents are the same or different and are selected from the definitions above and now ^ β substituents α); d3) γ is cvc: 5 radicals or ^-^ fire finished with 丨 to 4 substituents (the substituents are the same or different, and are selected from the following definitions of the substituent α 1);

(I4) Υ is ethyl, propyl, butyl, isopropyl, trifluoromethyl, dichloromethyl, 1-bromoethyl, methyl, or diisopropylaminomethyl; Butyl, 3-pentyl 1-chloroethyl, diethylamine (15) Υ is 03-06 cycloalkyl or 5 to 9-membered heterocyclic group; (16) Υ is cyclobutyl, cyclopentyl, cyclohexyl , Hexahydropyridine, perhydroazepinyl or perhydrooγ octyl ring; (17) Y is Cg-Ci. Squaryl 'or 匚 _caryl substituted with 1 to 4 substituents (the substituents are the same or different and are selected from the substituents 々1 defined below); (18) Y is phenyl, 1 -Naphthyl or 2-naphthyl; (19) Y is CVCh cycloalkylalkyl, and is substituted with 1 to 7 substituents (the substituents are the same or different and are selected from the above definitions) (Α-), (5- to 9-membered heterocyclyl)-(Ci-C3 alkyl), or (5- to 9-membered heterocyclyl)-(C! -C, substituted with 1 to 7 substituents) 3 alkyl) (the substituents are the same or different-20- 200401770 different and are selected from the substituents a) as defined above; (20) Y is (CVC !. cycloalkyl) methyl or (5 to 9 members Heterocyclyl) methyl; (21) Y is cyclopentylmethyl, cyclohexylmethyl, cycloheptylmethyl, 2-thienylmethyl, pyrrolidinylmethyl, 1-hexahydropyridylmethyl Or 1-perhydroazepine cyclomethyl; (2 2) Y is C 7 -C i 4 aralkyl, or c 7-C i 4 aralkyl substituted with 1 to 4 substituents (the substitution The radicals are the same or different, and are selected from the substituents β) ′ (23) Υ as (CVCi. Aryl) methyl. (Aryl) ethyl, (C6_C1Qaryl) methyl substituted with 1 to 4 substituents (the substituents are the same or different 'and selected from substituents 1 as defined below), or 1 to 4 (CfC! .Aryl) ethyl substituted with three substituents (the substituents are the same or different and selected from the substituents defined below / 3 1); (24) Y is benzyl, 1-naphthalene Methyl, 2-naphthylmethyl, or benzyl substituted with 1 to 4 substituents on the phenyl moiety (the substituents are the same or different and are selected from substituents 32 as defined below) (25) A is phenyl, naphthyl or pyridyl; and Lu (26) A is phenyl; wherein the substituent a 1 represents a group consisting of: a halogen atom, an amine group, and a "ce alkylamine" And bis (c "cδalkyl) amino groups (wherein the alkyl groups are the same or different); the substituent / 3i represents the following groups: fluorine atom, chlorine atom, bromine atom, mesogen, nitro, Cyano, amino, methyl, ethyl, propyl, isopropyl, butyl, dibutyl, tertiary butyl, trifluoromethyl, pentafluoroethyl, -21- 200401770

Oxyalkyl, methoxy, ethoxy, isopropoxy, methylthio, isopropylthio, dimethylamino, acetamido, methanesulfonylmethyldioxy, ethylenedioxy, Ethyl, propionyl, methylethoxycarbonyl, and dimethylamine formamyl; and the substituent / 3 2 represents a group consisting of: fluorine atom, chlorine atom, bromine atom, hydroxyl group, nitro group, methyl group , Ethyl, isopropyl, trifluoromethyl, methoxy, ethoxy, methylthio, ethylthio, dimethylamino, methylenedioxy and ethylenedioxy. (1) to (3), (5) to (8), (9) to (11), (12) to (14), (15) to (16), (17) to (18), ( In each of the groups 19) to (21), (22) to (24), and (25) to (26), compounds having substituents in the following larger count groups are more preferable. From R1, R2 and R3 selected from (1) to (3), R3 selected from (4), R4 and R5 selected from (5) to (8), and X selected from (9) to (11) A compound obtained by a selective combination of Y selected from (12) to (24) and A selected from (25) to (2 6) is also preferable. Compounds of formula (I) and their salts and esters having the following combinations are particularly preferred: (i) Ri, R2, = (1) 'R4 and R5 = (5), X = (9), γ = ( 12) and A = (25); (ii) R1, R2, R3 = (1), R1R5 = (5), X = (9), Y = (15) and A = (25); (iii) Ri , R2, R3 = (1), R4 and r5 = = (5), X = (9), Υ = 〇7) and A = (25); (iv) R1, R2, R3 = (1), r4 & r5 = (5), x = (9) 'Y = (19) and A = (2 5); 200401770 (V) R1, R2, R3 = (1), R4 and R5 = (5), X two: (9), Y = (22) and A-(25); (vi) R1, R2, R3 = (2), R4 and R5 = (6), X = (10), Y = (13) and A = (25); (vii) R1, R2, R3 = (2), R4 and R5 = (6), X = (10), Y = (15) and A = (25); (viii) R1, R2 , R3: = (2), R4 and R, = (6), X = (10), Y = (17), and A = (25); (ix) R1, R2 > R3 = (2), R4 And R5 = (6), X = (10), Y = (19) and A = (25); (x) R1, R2, R3 = (2), R4 and R5 = (6), X = (10 ), Y = (22) and A = (25); (xi) R1, R2, R3 = (3), R4 and R5 = (7), X = (11), Y = (13) and A = ( 26); (xii) R1, R2, R3 = (3), R4 and R5 = (7), X = (11), Y = (16) and A = (26); (xiii) R1, R2, R3 = (3 ), R4 and R5 = (7), X = (1 1), Y = (18) and A = (26); (xiv) R1, R2, R3 = (3), R4 and R5 = (7), X = (11) 5 Y = (20) and A = (2 6); (xv) R1, R2, R3 = (3), R4 and R5 = (7), X = (1 1), Y = ( 23) and A = (26); (xvi) R1, R2 = (3), R3 = (4), R4 and R5 = (8), X = (1 1), Y = (14)

• 23- 200401770 (xvii) Ri, R2 = (3), R3 = (4), R4 and R5 two (8), x = (11), γ = (16) and A = (26); (xviii) R1, R2 = (3), R3 = (4), R4 and R5 = (8), X = (1 1), Y two (18) and A = (26); (xix) R1, R2 = (3 ), R, (4), R4 and R5 = (8), X = (11), Y = (2 1) and A = (2 6); and (xx) R1, R2 = (3), R3 = (4), R4 and R5 = (8), X = (11), Y = (24) and A = (26). In the above formula (I), the "halogen atom" in the definitions of R1, R2, R3, R4, R5, X, substituent α and substituent / 3 is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom; It is preferably a fluorine atom or a chlorine atom. The "C6-C14 aryl group" in the definition of formula (I) A is an aromatic hydrocarbon group having 6 to 14 carbon atoms, and may be, for example, phenyl, indenyl,? Radical, phenanthryl or anthracenyl; and preferably phenyl. The "5 to 7-membered heteroaryl group" in the definition of formula (I) A is a 5 to 7-membered heteroaryl group containing 1 to 4 members selected from a nitrogen atom, an oxygen atom, and a sulfur atom, and may be, for example, a furyl group , Thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, Tetrazolyl, thiadiazolyl, piperanyl, pyridyl, daphnyl, pyrimidinyl, or pyridyl (pyradinyl); and preferably pyridyl. "CVCe alkyl" in the definition of R1, R2, R3, R4, R5, γ, substituent a and substituent / 5 in formula (I) is one having 1 to 6 carbon atoms. Linear or branched alkyl carbon atom, and may be, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, second butyl, third butyl, pentyl, isopentyl , Neopentyl, -24- 200401770 second pentyl, 1-methylbutyl, hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, butylethyl or 2- Ethylbutyl; preferably a group such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, second butyl, or third butyl; more preferably methyl, ethyl Group, propyl or isopropyl; and most preferably methyl or ethyl. In the definitions of R1, R2, R3, R4, R5 and substituent / 3 in formula (I), "c 1 -C 6 alkyl substituted with i to 7 halogen atoms" is substituted with 1 to 7 halogen atoms Substitute the above definition Ci-C: 6 courtyards and may be, for example, trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl, fluoromethyl, 2,2,2 -Trifluoroethyl, 2,2,2-trichloroethyl, 2-bromoethyl, 2-chloroethyl, 2-fluoroethyl, 2-ethylethyl, 3-chloropropyl, 4-fluoro Butyl, 6-iodohexyl, 2,2-dibromoethyl or pentafluoroethyl; preferably difluoromethyl, dichloromethyl, difluoromethyl or pentafluoroethyl; and most preferably Is a trifluoromethyl group. In the definition of R1, R2, R3, and the substituent / 5 in the formula (I), "C2_C7 alkyl polyoxy" is a carbonyloxy group (-COO-), and its carbon atom passes through the above-mentioned Cl -C: 6 substituted, and may be, for example, ethoxyl, propionyloxy, butyryloxy, isobutyryloxy, pentamyloxy or hexamethyleneoxy; it is preferably c2_c5 Alkylcarbonyloxy, such as ethenyloxy, propionyloxy, butyryloxy or isobutyryloxy; and more preferably ethynyloxy. In the definitions of R1, R2, R3, R4, R5, χ, substituent α, and substituent stone of formula (I), "c" C6 alkoxy group is a hydroxyl group, wherein the hydrogen atom is It may be substituted, and may be, for example, methoxy, ethoxy, n-propoxy, isovaporyl, η-butoxy, isobutoxy, second butoxy, third butoxy, ^ Pentyloxy, isopentyloxy, 2-methylbutoxy, neopentyloxy, n-hexyloxy, -25- 200401770 4-methylpentyloxy, 3-methylpentyloxy, 2- Methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethylbutoxy, 1,1-dimethylbutoxy, L2-dimethylbutoxy, 1, 3-monomethylbutoxy or 2,3-dimethylbutoxy; it is preferably a C! -C4 alkoxy group such as methoxy, ethoxy, cardiac propoxy or cardiac butoxy And more preferably a methoxy group. "C" C6alkylthio "in the cold definition of R1, R2, R3, R4, R5, substituent α and substituents of formula (I) is as defined in the above C "C6 alkyl substituted hydrogenthio, and may be, for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, Second butylthio, third butylthio, η-pentylthio, isopentylthio, 2-methylbutylthio, neopentylthio, [_ethylpropylthio, cardiac hexylthio, Isohexylthio, 4-methylpentylthio, 3-methylpentylthio, 2-methylpentylthio, 1-methylpentylthio, 3,3-dimethylbutylthio, 2,2 -Dimethylbutylthio, 1, dimethyldimethylthio, 1,2-dimethylbutylthio, 13-dimethylbutylthio, 2,3-dimethylbutylthio, or 2 -Ethylbutylthio; preferably Cl-c4 alkylthio, such as methylthio, ethylthio, n-propylthio or n-butylthio; and more preferably methylthio. (C) "c" C6alkylsulfinylsulfonyl "in the definition of R1, R2, R3, substituent α and the substituent is a sulfinamilide substituted with the above C! -C6 alkyl ( _s 〇 1), and may be, for example, methanesulfinyl sulfenyl, ethanesulfinyl sulfinyl, η-propanesulfinyl sulfinyl, isopropanesulfinyl sulfinyl, η-butanesulfinyl sulfinyl, isobutylene Sulfenylene, second butanesulfinylene, third butanesulfinylene, η-pentanesulfinylene, isopentanesulfinylene, methylbutanesulfinylene, Pentanesulfinyl sulfenyl, η-hexanesulfinyl sulfinyl, 4-methylpentanesulfinyl sulfinyl, 3-methylpentanesulfinyl sulfinyl, 2-methylpentanesulfinyl sulfinyl, 3 , 3-dimethylbutanesulfenylsulfonyl-26- 200401770 group, 2,2-dimethylbutanesulfinylsulfenyl group, 1,1-dimethylbutanesulfinylsulfenyl group, 1,2-di Methylbutanesulfinamido, 1,3-dimethylbutanesulfenamido or 2,3-dimethylbutanesulfenamido; preferably alkylsulfinamido, such as methane Sulfinyl sulfenyl, ethanesulfinyl sulfinyl, n-propanesulfinyl sulfinyl, isopropanesulfinyl sulfinyl, or n-butanesulfinyl sulfinyl; and more preferably methanesulfinyl sulfinyl. "CV C6 alkylsulfonyl" in the definition of R1, R2, R3, substituent α and substituent point of formula (I) is a sulfonyl group (-S02) substituted with the above-mentioned "C6 alkyl group, and It may be, for example, methanesulfonyl, ethanesulfonyl, η-propanesulfonyl, isopropanesulfonyl, η-butanesulfonyl, isobutanesulfonyl, second butanesulfonyl, Third butanesulfonyl, II-pentanesulfonyl, isopentanesulfonyl, 2-methylbutanesulfonyl, neopentanesulfonyl, η-hexanesulfonyl, 4- Methylpentanesulfonyl, 3-methylpentanesulfonyl, 2-methylpentanesulfonyl, 3,3-dimethylbutanesulfonyl, 2,2-dimethylbutane Sulfonyl, 1, dimethylbutanesulfonyl, 1,2-dimethylbutanesulfonyl, 1,3-dimethylbutanesulfonyl, or 2,3-dimethylbutane Alkylsulfonyl; preferably alkylsulfonyl, such as methanesulfonyl, ethanesulfonyl, n-propanesulfonyl or n-butanesulfonyl; and more preferably methanesulfonyl The nC "C6 alkylamino group" in the definitions of R1, R2, R3, substituent α and substituents of formula (I) is an amine substituted with the above 01-06 alkyl group. And may be, for example, methylamino, ethylamino, η-propylamino, isopropylamine, η-butylamine, isobutylamine, second butylamine, third butylamine, η-pentylamine , Isoamylamine, 2-methylbutylamine, neopentylamine, 1-ethylpropylamine, η-hexylamine, isohexylamine, 4-methylpentylamine, 3-methylpentylamine Methyl, 2-methylpentylamino, 1-methylpentylamino, 3,3-dimethylbutylamino, 2,2-dimethylbutylamino, 1,1-bis-27- 200401770 Butylamine, 1,2-dimethylbutylamine, dimethylbutylamine, 2,3-dimethylbutylamine, or 2-ethylbutylamine; preferably ci-C 4 Alkylamino, such as methylamino, ethylamino, n-propylamino, isopropylamino, or n-butylamino; and more preferably methylamino or ethylamino. R1, R2, R3 in formula (I) In the definitions of substituents α and substituents / 3, di (C "C6 alkyl) amino" is an amine group substituted with two of the same or different Cl-C6 alkyl groups as described above, and may be, for example, dimethyl Amino, methylethylamino, diethylamino, —-propyl) | feminine, monoisopropylamino, N- (n-propyl) -N-ethylamino, bis (n-butyl) amine , Diisobutylamino, di (second butyl) amino, di (third butyl) · amino, bis (η-pentyl) amino, diisopentylamino, bis (2-methyl Butyl) amino, dineopentylamino, bis (butylethylpropyl) amino, bis (η-hexyl) amino, bis (isohexyl;) amino, bis (4-methylpentyl) amine Base, bis (3-methylpentyl) amino, bis (2-methylpentyl) amino, bis (1-methylpentyl) amino, bis (3,3-dimethylbutyl) Amine, bis (2,2-dimethylbutyl) amino, bis (1,1-dimethylbutyl) amino, bis (1,2-dimethylbutyl) amine, bis ( 1,3-dimethylbutyl) amino, bis (2,3-dimethylbutyl) amino or bis (2-ethylbutyl) amino; preferably bis (c "c4 alkyl Group), such as dimethylamino, methylethylamino, * diethylamino, bis (η-propyl) amino, diisopropylamino, N- (n-propyl)- N-ethylamino, bis (η-butyl) amino, diisobutylamino, bis (secondbutyl) amino or bis (thirdbutyl) amine; and more preferably dimethyl Diamino or diethyl Amine. "C2-c7 alkylcarbonylamino" in the definitions of R1, R2, R3, substituents ^ and substituents of formula (I) is a carbonylamino group (-CONH-), the carbon atom of which is as described above. C ! -C 6 alkyl substituted, and may be, for example, acetamido, propylamido, butyl-28-28200401770 amino, isobutylamido, pentamidine or hexamidine; preferably To c2-c5 alkylcarbonylamino, such as acetamido, propylamido, butylamido or isobutylamidoamino; and more preferably acetamidoamino.  The "N- (C2-C7 alkylcarbonyl) -N- (C" C6 alkyl) amino "in the definition of R1, R2, R3 and substituents / 3 of the formula (I) is the above CVC6 alkyl and The following C2-C7 alkylcarbonyl-substituted amine groups may be, for example, ethenyl (N-methyl) amine, ethenyl (N-ethyl) amine, ethenyl (N-propyl) Amino, ethyl (N-butyl) amino, ethyl (N-pentyl) amino, ethyl (N-hexyl) amino, propanyl (N-methyl) amino, Propionyl (N-ethyl) amino, propionyl (N-propyl) amino, butyl (N-methyl) amino, isobutyl (N-methyl) amino, pentamyl (N -Methyl) amino or hexamethylene (N-methyl) amino; preferably N- (C2-C5 alkylcarbonyl) -N- (C "C4 alkyl) amino, such as ethyl (N-methyl) amino, propionyl (N-methyl) amino, butylfluorenyl (N-methyl) amino or isobutylfluorenyl (N-methyl) amino; and more preferably ethenyl (N-methyl) amino group. The "C2-C7 alkoxycarbonylamino group" in the cold definition of R1, R2, R3 and substituents of formula (I) is a carbonylamino group (-CONH-), the carbon of which Atom via ^-(: 6 alkoxy substituted, and may be, for example, methoxycarbonylamino, ethoxycarbonylamino, η-propoxycarbonylamino, isopropoxycarbonylamino, η-butoxy Carbonylamino, isobutoxycarbonylamino, second butoxycarbonylamino, third butoxycarbonylamino, η-pentoxycarbonylamino, isopentoxycarbonylamino, 2- Methylbutoxycarbonylamino, neopentyloxycarbonylamino, η-hexyloxycarbonylamino, 4-methylpentyloxycarbonylamino, 3-methylpentyloxycarbonylamino, methyl Pentyloxycarbonylamino, 3,3-dimethylbutoxycarbonylamino, 2,2-dimethylbutoxycarbonylamino, 1,1-dimethylbutoxymineamino, 1,2-- 2. 9- 200401770 dimethylbutoxycarbonylamino, 1,3-dimethylbutoxycarbonylamino or 2,3-dimethylbutoxycarbonylamino; preferably C2-C5 alkoxy A carbonylamino group, such as a methoxycarbonylamino group, an ethoxycarbonylamino group, an η-propoxycarbonylamino group, or an η-butoxycarbonylamino group; and more preferably a methoxycarbonylamino group. "N- (C2-C7 alkoxycarbonyl) -N- (C" C6 alkyl) amino "in the definition of R1, R2, R3 and substituents / 3 of formula (I) is the same as" C6 An alkyl group and an amine group substituted with the following C2-〇7 alkoxycarbonyl group, and may be, for example, a methoxycarbonyl (N-methyl) amino group, an ethoxycarbonyl (N-methyl) amino group, or η- Propoxycarbonyl (N-methyl) amino, isopropoxycarbonyl (N-methyl) amino, η-butoxycarbonyl (N-methyl) amino, isobutoxycarbonyl (N- Methyl) amino, second butoxycarbonyl (N-methyl) amino, third butoxycarbonyl (N-methyl) amino, n-pentoxycarbonyl (N-methyl) amino , Isoamyloxycarbonyl (N-methyl) amino, 2-methylbutoxycarbonyl (N-methyl) amino, neopentyloxycarbonyl (N-methyl) amino, η-hexyloxy Carbonyl (N_methyl) amino, 4-methylpentyloxycarbonyl (N-methyl) amino, 3-methylpentyloxy (N -methyl) amino, 2-methylpentyl N-methyl (N-methyl) amino, 3,3-methylbutoxycarbonyl (N-methyl) amino, 2,2-dimethylbutoxyfluorenyl (N-methyl) ) Amine , 1,1-monomethylbutoxyfluorenyl (N-methyl) amino, ι, 2-dimethylbutoxycarbonyl (N -methyl) amino, 1,3-dimethylbutyl Oxycarbonyl (N-methyl) amino or 2,3-dimethylbutoxycarbonyl (N-methyl) amino; preferably C2-C5 (alkoxycarbonyl) -N- (C "C4 Alkyl) amino, such as methoxycurtain (N_methyl) amino, ethoxymine (N-methyl) amino, n_propoxymine (n-methyl) amino, or n-butoxycarbonyl (N-methyl) amino; and more preferably methoxycarbonyl (N-methyl) amino. R1, [, R3, substituent α and substitution in formula (I) In the definition of group 0, c "-30-200401770 C6 alkylsulfonylamino" is an amine group substituted with the above alkylsulfonyl, and may be, for example, methanesulfonylamino, ethanesulfonyl Propylamino, η-propanesulfonylamino, isopropanesulfonylamino, η-butanesulfonylamino, isobutanesulfonylamino, second butanesulfonylamino, Tertiary butanesulfonylamino, η-pentanesulfonylamino, isopentanesulfonylamino, 2-methylbutanesulfonylamino, neo Alkylsulfonylamino group, 1-ethylpropanesulfonylamino group, η-hexanesulfonylamino group, isohexanesulfonylamino group, 4-methylpentanesulfonylamino group, 3- Methylpentanesulfonylamino, 2-methylpentanesulfonylamino, 1-methylpentanesulfonylamino, 3,3-dimethylbutanesulfonylamino, 2 2,2-dimethylbutanesulfonamidoamino group, 1,1-dimethylbutanesulfonamidoamino group, 1,2-dimethylbutanesulfonamidoamino group, 1,3-dimethylformamide Butanesulfonylamino, 2,3-dimethylbutanesulfonylamino, or 2-ethylbutanesulfonylamino; preferably alkylsulfonylamino , Such as methanesulfonylamino, ethanesulfonylamino, η-propanesulfonylamino, isopropanesulfonylamino, or η-butanesulfonylamino; and more preferably methane Sulfonylamino or ethanesulfonylamino. The "N- (C" C6alkylsulfonyl) -N- (C "C6alkyl) amino" in the definition of R1, R2, R3 and substituents of formula (I) is the above-mentioned alkyl and "0: 6 alkylsulfonyl substituted amino group, and may be, for example, methanesulfonyl (N-methyl) amino, methanesulfonyl (N-ethyl) amino, methanesulfonyl (N -Propyl) amino, ethanesulfonyl (N-methyl) amino, n-propanesulfonyl (N-methyl) amino, isopropanesulfonyl (N-methyl) amino, η-butanesulfonyl (N-methyl) amino, isobutanesulfonyl (N-methyl) amino, second butanesulfonyl (N-methyl) amino, dimethyl dibutyl Sulfonyl (N-methyl) amino, η-pentanyl (N-methyl) amine-31- 200401770, isopentanesulfonyl (N-methyl) amino, 2- Methylbutanesulfonyl (N-methyl) amino, neopentanesulfonyl (N-methyl) amino, ethyl ethylpropanesulfonyl (N-methyl) amino, η-hexanesulfonate Fluorenyl (N-methyl) amine, isohexanesulfonyl (N-methyl) amine, 4-methylpentanesulfonyl (N-methyl) amine, 3-methylpentane ore Brewing base -Methyl) amino, 2-methylpentanyl (N -methyl) amino, 1 -methylpentanesulfonyl (N -methyl) amino, 3,3-dimethylbutane Alkylsulfonyl (N-methyl) amino, 2,2-dimethylbutanesulfonyl (N-methyl) amino, 1,1-dimethylbutanesulfonyl (N-formyl) Group) amino group, 1,2-dimethylbutanesulfonyl (N-methyl) amino group, 1,3-dimethylbutanesulfonyl (N-methyl) amino group, 2,3 -Dimethylbutanesulfonyl (N-methyl) amino or ethylbutanesulfonyl (N-methyl) amino; preferably N- (C "C4 alkylsulfonyl ) -N- (CVC4 alkyl) amino groups, such as methanesulfonyl (N-methyl) amino, ethanesulfonyl (N-methyl) amino, n-propanesulfonyl (N-formyl) Group) amino group, isopropanesulfonyl (N-methyl) amino group or n-butanesulfonyl (N-methyl) amino group; and more preferably methane fluorenyl (N-methyl) Amino or ethanesulfonyl (N-methyl) amino. "C" C6 haloalkylsulfonyl in the definition of R1, R2, R3, substituent α and substituent / 3 in formula (I) "Amine" is the alkylsulfonylamino group described above, The alkyl group is substituted by the above 1 to 7 halogen atoms, and may be, for example, trifluoromethanesulfonylamino, trichloromethanesulfonylamino, difluoromethanesulfonylamino, dichloromethanesulfonyl Amine group, dibromomethanesulfonylamino group, fluoromethanesulfonylamino group, 2,2,2-trifluoroethanesulfonylamino group, 2,2,2-trichloroethanesulfonylamino group , 2-bromoethanesulfonylamino, 2-chloroethanesulfonylamino, 2-fluoroethanesulfonylamino, 2-iodoethanesulfonylamino, 3-chloropropanesulfonyl Fluorenylamino, 4-fluorobutanesulfonylamino, 6-iodohexanesulfonylamino, 2,2-dibromo-32- 200401770 ethanesulfonylamino or pentafluoroethanesulfonyl Fluorenylamino; preferably trifluoromethanesulfonylamino, trichloromethanesulfonylamino, difluoromethanesulfonylamino or pentafluoroethanesulfonylamino; more preferably Trifluoromethanesulfonylamino. "N- (CVC6haloalkylsulfonyl) -N ^ CVC, alkyl) amino" in the definition of R1, R2, R3 and substituents in formula (I) is the above mentioned alkyl ^ Fluorenyl) -N ^ C ^ C ^ alkyl) amino, in which the alkylsulfonyl moiety is substituted with the above 1 to 7 halogen atoms, and may be, for example, trifluoromethanesulfonyl (N-methyl) Amine, trifluoromethanesulfonyl (N-ethyl) amino, trifluoromethanesulfonyl (N-propyl) amino, trichloromethanesulfonyl (N-methyl) amino, difluoro Methanesulfonyl (N-methyl) amine, methylene chloride sulfonyl (N-methyl) amine, dibromomethanesulfonyl (N-methyl) amine, fluoromethanesulfonyl (N- Methyl) amino, 2,2,2-trifluoroethanesulfonyl (N-methyl) amino, 2,2,2-trichloroethanesulfonyl (N-methyl) amino, Bromoethanesulfonyl (N-methyl) amino, 2-chloroethanesulfonyl (N-methyl) amino, 2-fluoroethanesulfonyl (N-methyl) amino, 2 -Iodoethanesulfonyl (N-methyl) amino, 3-chloropropanesulfonyl (N-methyl) amino, 4-fluorobutanesulfonyl (N-methyl) amino, 6 -Iodohexanesulfonyl (N-methyl ) Amino, 2,2-dibromoethanesulfonyl (N-methyl) amino or pentafluoroethanesulfonyl (N-methyl) amino; preferably via a fluorine atom or a chlorine atom Substituted N- (C1-C4 alkylsulfonyl) -N- (C "C4 alkyl) amino groups, such as trifluoromethanesulfonyl (N-methyl) amino, chlorochlorosulfonyl ( N-methyl) amino, difluoromethanesulfonyl (N-methyl) amino or pentafluoroethanesulfonyl (N-methyl) amino; more preferably trifluoromethanesulfonyl ( N-methyl) amine group. "C2-c7 alkylcarbonyl" in the definition of R1, R2, R3 and substituents / 3 of formula (I) is a carbonyl group (-CO-) substituted with the above alkyl group, and May be, for example, ethenyl-33-200401770, propionyl, butylfluorenyl, isobutylfluorenyl, pentylfluorenyl, trimethylethynyl, or hexamethylene; preferably c2-c5 alkylcarbonyl, such as ethynyl , Propionyl or butylfluorenyl; and more preferably ethynyl. The "c2-c7 alkoxycarbonyl" in the definition of R1, R2, R3, R4, R5 and substituents / 3 in formula (I) is Carbonyl (-CO-) substituted with the above alkoxy group, and may be, for example, methoxycarbonyl, ethoxycarbonyl, η-propoxy Carbonyl, isopropoxycarbonyl, η-butoxycarbonyl, isobutoxycarbonyl, second butoxycarbonyl, third butoxycarbonyl, α-pentoxycarbonyl, isopentoxycarbonyl, 2- Methylbutoxycarbonyl, neopentyloxycarbonyl, η-hexyloxycarbonyl, 4-methylpentyloxy, 3-methylpentyloxy, 2-methylpentyloxy, 3,3-dimethylbutoxycarbonyl, 2,2-dimethylbutoxycarbonyl, 1,1-dimethylbutoxycarbonyl, 1,2-dimethylbutoxycarbonyl, 1, 3-dimethylbutoxycarbonyl or 2,3-dimethylbutoxycarbonyl; preferably C2-C5 alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, η-propoxy Carbonyl or n-butoxycarbonyl; and more preferably methoxycarbonyl. The "C2-C7 alkylaminocarbonyl group" in the definitions of R1, R2, R3 and substituents / 3 of the formula (I) is a carbonyl group (-CO-) substituted with the aforementioned alkylamino group, and may be, for example, Methylaminocarbonyl, ethylaminocarbonyl, η-propylaminocarbonyl, isopropylaminocarbonyl, η-butylaminocarbonyl, isobutylaminocarbonyl, second butylaminocarbonyl, third butylaminocarbonyl, η- Amylaminocarbonyl, isoamylaminocarbonyl, 2-methylbutylaminocarbonyl, neopentylaminocarbonyl, 1-ethylpropylaminocarbonyl, η-hexylaminocarbonyl, isohexylaminocarbonyl, 4-methyl Amylaminocarbonyl, 3-methylpentylaminocarbonyl, 2-methylpentylaminocarbonyl, 1-methylpentylaminocarbonyl, 3,3-dimethylbutylaminocarbonyl, 2,2-dimethyl Butylaminocarbonyl, 1,1-dimethylbutylamino-34- 200401770 carbonyl, 1,2-dimethylbutylaminocarbonyl, 1,3-dimethylbutylaminocarbonyl, 2,3- Dimethylbutylaminocarbonyl or 2-ethylbutylaminocarbonyl; preferably (2-05 alkylaminocarbonyl, such as methylaminocarbonyl, ethylaminocarbonyl, cardipropylamino, isopropyl Propylaminocarbonyl or eta-butylaminocarbonyl; and more preferably methylamino "Di (C" C6 alkyl) aminocarbonyl "in the definition of R1, R2, R3 and the substituent yS in formula (I) is a carbonyl group substituted with a di (C" C6 alkyl) amino group ( -CO-), wherein the alkyl groups may be the same or different as described above, and may be, for example, dimethylaminocarbonyl, methylethylaminocarbonyl, diethylaminocarbonyl, bis (η-propyl) aminocarbonyl, Diisopropylaminocarbonyl, N- (η-propyl) -N · ethylaminocarbonyl, di (η-butyl) aminocarbonyl, diisobutylaminocarbonyl, di (second butyl) aminocarbonyl , Di (third butyl) aminocarbonyl, di (η-pentyl) aminocarbonyl, diisopentylaminocarbonyl, bis (2-methylbutyl) aminocarbonyl, dineopentylaminocarbonyl, Di (1-ethylpropyl) aminocarbonyl, di (η-hexyl) aminocarbonyl, diisohexylaminocarbonyl, bis (4-methyl) pentylaminocarbonyl, bis (3-methylpentyl) Aminocarbonyl, bis (2-methylpentyl) aminocarbonyl, bis (1-methylpentyl) aminocarbonyl, bis (3,3-dimethylbutyl) aminocarbonyl, bis (2, 2-dimethylbutyl) aminocarbonyl, bis (1,1-dimethylbutyl) ) Aminocarbonyl. Bis (1,2-dimethylbutyl) aminocarbonyl, bis (1,3-dimethylbutyl) aminocarbonyl, bis (2,3-dimethylbutyl) aminocarbonyl, or bis (1,2-dimethylbutyl) aminocarbonyl 2-ethylbutyl) aminocarbonyl; preferably di (C "C4alkyl) aminocarbonyl, such as dimethylaminocarbonyl, methylethylaminocarbonyl, diethylaminocarbonyl, di (n -Propyl) amino-based, monoisopropylamino-based, N- (n-propyl) -N-ethylaminofluorenyl, bis (η-butyl) aminocarbonyl, diisobutylaminocarbonyl Bis (second butyl) aminocarbonyl or bis (thirdbutyl) aminocarbonyl; and more preferably dimethylamino-35-200401770 carbonyl. R 1, R 2, R 3 in formula (I) And in the cold definition of substituents, 'C i -C 4 butanedioxy' is an butanedioxy group having 1 to 4 carbon atoms, and may be, for example, methylenedioxy, butylene- 1,2-dioxy, 1-methylmethylenedioxy, propylene-1,3-dioxy, 1-methylethylene-1,2-dioxy, 2-methyl Diethyl-1,2-dioxy, diethylmethylenedioxy, dibutyl-1,4-dioxy, 1-methyldipropyl-1,3-dioxy, 2- Propylidene-1,3-dioxy, 3-methylidene-1,3-mono * oxy, 1-ethylidene-1,2-monooxy, 2-ethylidene -1,2-dioxy, 1,2-dimethylethylene-i, 2-dioxy or 1-propylmethylenedioxy; preferably methylenedioxy, ethylene -12-dioxy or ^ methylmethylenedioxy; and more preferably methylenedioxy. In the definition of X of the formula (I), the substituent α and the point of the substituent " 7-halogen atom substituted alkoxy group "is the above-mentioned (^-(: 6 alkoxy group) substituted by 丨 to 7 halogen atoms, and may be, for example, trifluoromethoxy, trichloromethoxy, difluoromethyl Oxy, dichloromethoxy, dibromomethoxy, fluoromethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy, 2-bromoethoxy , 2-chloroethoxy, 2-fluoroethoxy, 2-iodoethoxy, 3-chloropropoxy, 4-fluorobutoxy, 6-iodohexyloxy, 2,2-dibromoethyl Oxy or pentafluoroethoxy; preferably 匚 substituted with a fluorine or chlorine atom!-^ Alkoxy, such as trifluoromethoxy, trichloromethoxy, difluoromethoxy or pentafluoro Ethoxy; and more Ground is trifluoromethoxy. The "C3-C1Q cycloalkyl" in the definition of Y in formula (I) may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbium Alkenyl or adamantyl; preferably C ^ C, cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and more preferably cyclobutyl or cyclohexyl. 3 6 -200401770 The "5 to 9-membered heterocyclic group" in the definition of Y in formula (I) contains! To 4 5 to 9-membered heterocyclic groups selected from nitrogen, oxygen and sulfur atoms, and may be, for example, Unsaturated heterocyclic groups such as furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3- Oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, piperanyl, pyridyl, daquatyl, pyrimidinyl, pyridyl, azepinyl, azecinyl, or azenonyl ; Or the partially or completely reduced unsaturated heterocyclic group described above, such as morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, imidazolyl, imidazoline, pyrazolyl, pyrazolinyl , Hexahydropyridyl, hexa Pyridyl, perhydroazepine, perhydroazepine or perhydroazepine; preferably 5 to 5 oxygen atoms and / or sulfur atoms which are selective for one or more nitrogen atoms To 7-membered heterocyclic groups, for example, unsaturated heterocyclic groups, such as pyrrolyl, azepine, pyrazolyl, imidazolyl, oxazolyl, oxazolyl, thiazolyl, isothiazolyl, 1,2 , 3-Azodiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, dacrotyl, pyrimidinyl, or pyridyl; or this unsaturated heterocyclic group is partially or completely reduced, For example, morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, hexahydropyridyl, or hexahydropyridyl; and more preferably Ground is pyridyl. "Aromatic" in the definition of hydrazone and substituent / 5 of formula (I) is an aromatic hydrocarbon group having 6 to 10 carbon atoms, and may be, for example, phenyl, indenyl,? Yl, phenanthryl Or anthracenyl; preferably phenyl or yl; and more preferably phenyl. "C4-C14 cycloalkylalkyl" in the definition of Y in formula (I) is a C6-C10 ring Alkyl-substituted C i -C 4 alkyl, and may be, for example, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl-37- 200401770 group, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl, cycloheptylmethyl, norbornenylmethyl or adamantylmethyl; preferably (: 4-08 cycloalkylalkane Radicals such as cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl or cyclohexylethyl; and more preferably cyclopentylmethyl or cyclohexylmethyl "(5 to 9-membered heterocyclic group MCi-C, alkyl)" in the definition of Y in formula (I) is an alkyl group substituted with the above 5- to 9-membered heterocyclic group, which is, for example, furylmethyl Methyl, thienylmethyl, pyrrolylmethyl, azepinyl Methyl, pyrazolylmethyl, imidazolylmethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, thienylmethyl, isothiazolylmethyl, 1,2,3- 噚Diazolylmethyl, triazolylmethyl, tetrazolylmethyl, thiadiazolylmethyl, piperanylmethyl, pyridylmethyl, pyridylethyl, pyridylpropyl, pyridylbutyl , Daphnylmethyl, pyrimidinylmethyl, pyrrolylmethyl, morpholinylmethyl, thiomorpholinylmethyl, pyrrolidylmethyl, pyrrolidylmethyl, imidazolylmethyl, imidazole Phenylmethyl, pyrazolidylmethyl, pyrazolinylmethyl, hexahydropyridylmethyl, hexahydropyridinemethyl, perhydroazepinyl methyl, perhydroazepinyl methyl or all Hydroazinylmethyl; preferably thienylmethyl, pyrazolylmethyl, morpholinylmethyl, pyridylmethyl, perhydroazepinylmethyl or pyridylethyl; and more Preferably, it is pyridylmethyl. The "C 7 -C 1 4 aryl group" in the definition of Y in formula (I) is a "C 6 alkyl group or a C 9- C !. arylaryl-substituted Ci-C4 alkyl, such as Methyl, p-naphthylmethyl, 2-naphthylmethyl, indenylmethyl, 1-phenethyl, 2-phenethyl, p-naphthylethyl, 2-naphthylethyl, 1-phenylpropyl, 2 --Phenylpropyl, 3-phenylpropyl, naphthylpropyl, 2-naphthylpropyl, 3-naphthylpropyl, -38- 200401770 1-phenylbutyl, 2-phenylbutyl, 3 -Phenylbutyl, 4-phenylbutyl, 1-naphthylbutyl, 2-naphthylbutyl, 3-naphthylbutyl, 4-naphthylbutyl, 1-phenylpentyl, 2- Phenylpentyl, 3-phenylpentyl, phenylpentyl, 5-phenylpentyl, phenylhexyl, 2-phenylhexyl, 3-phenylhexyl, 4-phenylhexyl, 5-benzene Hexyl or 6-phenylhexyl; preferably C "C4 alkyl" substituted with a C6_cioaryl group such as benzyl, bzekiylmethyl, 2-naphthylmethyl, bopenthyl, 2-phenylethyl, Benzylethyl, 2-naphthylethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl, or 1-naphthylpropyl, and more preferably is methyl. The "C7-C14 aralkyloxy group" in the definition of the substituent / 3 of the formula (I) is a hydroxy group substituted with the above-mentioned c7-c14 aralkyl group, and is, for example, a benzyloxy group, a 1-naphthylmethoxy group , 2-naphthylmethoxy, indenylmethoxy, 1-phenethoxy, 2-phenethoxy, p-naphthylethoxy, 2-naphthylethoxy, 1-phenylpropoxy, 2-phenylpropoxy, 3-phenylpropoxy, 1-naphthylpropoxy, 2-naphthylpropoxy, 3-naphthylpropoxy, 1-phenylbutoxy, 2_ Phenylbutoxy, 3-phenylbutoxy, 4-phenylbutoxy, 1-naphthylbutoxy, 2-naphthylbutoxy, 3-naphthylbutoxy, 4-naphthyl Butoxy, 1-phenylpentoxy, 2-phenylpentoxy, 3-phenylpentoxy, 4-phenylpentoxy, 5-phenylpentoxy, 1-phenylhexyloxy Methyl, 2-phenylhexyloxy, 3-phenylhexyloxy, 4-phenylhexyloxy, 5-phenylhexyloxy or 6-phenylhexyloxy; preferably C6-C1 () Aryl-substituted Cl_c4 ^ oxy, such as benzyloxy, 1-naphthylmethoxy, 2-naphthylmethoxy, 1-phenethoxy, 2-phenethoxy, 1 · naphthalene Ethoxy, 2-naphthylethoxy, 1-phenylpropoxy, 2-phenyl Group, 3-phenyl-propoxy-propoxy, or 1-naphthyl; and more preferably is benzyloxy. In the case where the compound of formula (I) of the present invention or a pharmacologically acceptable ester thereof has -39-200401770 test group, the compound can be converted into a salt by reacting with an acid, and if the formula (I) of the present invention ) When the compound or its pharmacologically acceptable ester has an acid group, the compound can be converted into a salt by reacting with a base, and the compound of the present invention includes such a salt. Where the salts are to be used for therapeutic purposes, they must be pharmacologically acceptable. Preferred examples of salts with bases in the compounds of formula (I) of the present invention include.  Include inorganic salts such as hydrohalides (such as hydrochloric acid, hydrobromic acid, and hydroiodic acid), nitrates, perchlorates, sulfates, and phosphates; organic acid salts, such as C6 C6 alkanesulfonate substituted with fluorine atom, in which Ci-C, alkyl portion is as defined above (for example, methanesulfonate, trifluoromethanesulfonate and ethanesulfonate), C6-C1Q arylsulfonate Acid salt, of which c6_Ci. The aryl moiety is as defined above (eg benzenesulfonate or P-toluenesulfonate), acetate, malate, fumarate, succinate, citrate, ascorbic acid Salts, tartrates, oxalates and cis; and amino acids such as glycine, lysine, spermine, ornithine, glutamate and aspartate. Hydrohalides Acid salts are particularly preferred. Preferred examples of the salts with acid groups in the compounds of formula (I) of the present invention include metal salts, such as alkali metal salts (such as sodium, potassium, and lithium salts), and alkaline earth metals. Salts (such as # 5 salts and magnesium salts), Ming salts, iron salts, zinc salts, copper salts, nickel salts, and cobalt salts; amine salts such as inorganic amines (Such as ammonium salts) and organic amine salts (such as t-octylamine salt, benzhydrylamine salt, morpholine salt, glucosamine salt, phenylglycylic acid alkyl ester salt, and ethylenediamine salt) , N-methyl glucosamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N, N, -diphenylmethyl ethylene diamine salt, cloprox Caine salt (chloroprocaine -40- 200401770 salt), diethanolamine salt, N-benzylphenethylamine salt, hexahydropyridine salt, tetramethylammonium salt and tri (hydroxymethyl) aminomethane salt) And amino acid salts, such as glycine, lysine, spermine, ornithine, glutamate and aspartate. Alkali metal salts are particularly preferred. The formula ( I) Compounds and their pharmacologically acceptable salts and esters can sometimes absorb moisture when exposed to the environment, or this hydrate is included in the scope of the present invention when recrystallized to absorb moisture or form a hydrate. In addition, certain other solvents can be absorbed by the compounds of the invention to make solvates, which also form part of the invention. _ The compounds of formula (I) of the invention are sometimes Contains one or more asymmetric centers, and thus can form optical isomers (including diastereomers). Regarding the compounds of the present invention, the isomers and mixtures of the isomers are each described by a separate general formula, That is, formula (I). Therefore, the present invention encompasses individual isomers and mixtures thereof in various proportions, including racemic mixtures. The present invention includes esters of compounds of formula (I), and these esters are compounds of formula (I) Wherein the hydroxyl or carboxyl group of the compound of the formula (I) is modified by adding a protecting group by using a conventionally known technique in this technology (see, for example, "Protective Groups in Organic Synthesis, Second Edition", Theodora W.

Greene and Peter G.M.Wuts5 1991, John Wiley & Sons,

Inc.) o There is no particular limitation on the type of this protecting group, as long as the ester is intended for therapeutic purposes, it must be pharmacologically acceptable, i.e., the compound is administered to the body of a living mammal For a compound of formula (1) or a salt thereof, the protecting group must be capable of being removed (eg, hydrolyzed) by a metabolic process. In other words, -41- 200401770 medically acceptable esters are prodrugs of the compound of formula (i) of the present invention. However, the ester of the compound of formula (I) of the present invention is intended for non-therapeutic purposes (for example, for the preparation of intermediates of other compounds), so the pharmacologically acceptable element is not applicable to the ester. Whether the compound of formula (I) of the present invention is a pharmacologically acceptable ester can be easily determined, the compound to be studied is administered intravenously to an experimental animal (such as a rat or a mouse), and then the body fluid of the animal is studied, If the compound of formula (I) or a pharmacologically acceptable salt thereof can be measured in a body fluid, the investigated compound is judged to be a pharmacologically acceptable ester. The compounds of formula (I) according to the invention can be converted into esters which, for example, include hydroxyl groups in the compounds of formula (I) which are esterified. In the case where an esterified compound is used as an intermediate, the ester residue may be a general protecting group, or in the case where the esterified compound is pharmacologically acceptable, in order to be able to be removed in vivo by metabolic processes (e.g. Hydrolysis). General ester protecting groups according to the above are ester protecting groups which can be removed by chemical methods, such as hydrolysis, hydrogenation, electrolysis or photodecomposition. Preferred examples of these general protecting groups for the synthesis of compounds of formula (I) in which the hydroxyl group in I is synthesized include: (i) aliphatic fluorenyl groups, examples of which include alkylcarbonyl groups having 1 to 25 carbon atoms, such as Contains methyl, ethyl, propyl, propyl, butyl, isobutyl, pentyl, trimethyl ethyl, pentyl, isopentyl, octyl, nonyl, decyl, 3- Methylnonyl, 8-methylnonyl, 3-ethyloctyl, 3,7-dimethyloctyl, undecyl, dodecyl, tridecyl, tetradecyl, ten Pentamethyl, hexadecyl, 1-methylpentadecyl, 14-methylpentadecyl, 13, 13-bis-42- 200401770 methyl tetradecyl, heptadecyl, 15- Methylhexadecyl, octadecyl, 1-methylhexadecyl, nonadecanyl, eicosyl, and twenty-one, forming saturated or unsaturated C 2 -C i aliphatic di Esters of carboxylic acid residues, such as fumarate, maleate, oxalate, malonate or succinate, halogenated alkylcarbonyl groups having 1 to 25 carbon atoms, in which Alkyl moiety via at least one halogen atom Examples include chloroethenyl, dichloroethenyl, trichloroethenyl and trifluoroethenyl, lower alkoxyalkylcarbonyl groups having 1 to 25 carbon atoms in alkylcarbonyl groups, in which alkyl Partially substituted with at least one of the above-mentioned alkoxy groups, examples of the lower alkoxyalkylcarbonyl group include a methoxyethylfluorenyl group and an unsaturated alkylcarbonyl group having 1 to 25 carbon atoms, and examples thereof include acrylfluorenyl group, Propynyl, methacryl, crotonyl, isocrotonyl, and (E) -2-methylbutenyl; among these, alkylcarbonyl having 1 to 6 carbon atoms is preferred; ( ii) Aromatic fluorenyl groups, examples of which include arylcarbonyl groups including carbonyl groups substituted with the above-mentioned aryl groups, examples of which include benzamidine, 1-naphthylmethyl, and 2-naphthylmethyl, halogenated arylcarbonyl groups, which Contains the above-defined aryl iron group substituted with at least one halogen atom, examples include 2-bromobenzyl, 4-chlorobenzyl, and 2,4,6-trifluorobenzyl, low alkylation Arylcarbonyl, which includes the above-defined arylcarbonyl substituted with at least one alkyl group, examples include 2,4,6-trimethylbenzyl and 4-toluene Fluorenyl, -43- 200401770 low alkoxylated aryl carbonyl, which contains aryl carbonyl as defined above through at least one low jp alkoxy group, examples include I-methoxyphenyl & methyl alcohol, nitration Arylcarbonyl 'which includes arylcarbonyl via at least one nitro group, examples include 4-nitrobenzyl and nitro% methyl group, low alkoxycarbonylated arylcarbonyl group, which contains ^ r

Taking the arylcarbonyl group as defined above substituted by the C alkoxy group mentioned above, examples of ^ _ ^% include oxycarbonyl group, benzamidine group, and squaryl carbonyl group which contains at least one of the above Macro # 、、 疋 我方 _ 取 佧

Examples of the above-mentioned aryl ore groups include 4-phenylbenzyl groups. (Iii) Alkoxycarbonyl groups, examples include lower alkoxycarbonyl groups, which include Cl-C6 alkoxy groups as defined above. Examples include methoxycarbonyl, ethoxycarbonyl, propoxy, oxygen, and

Carbonyl group, second butoxycarbonyl group, t-butoxycarbonyl group, and lotustin group, each group is a carbonyl group, and the above definition is a low-oxygen group, which is at least one selected from the group consisting of C 6 courtyard) Sand courtyard (where the C i-C 6 courtyard is as described above) replaced it, examples include 2,2,2-trichloroethoxycarbonyl and trimethyl sand burning Ethoxycarbonyl; (iv) tetrahydropiperanyl or tetrahydrothiopiperanyl, which may optionally be selected from at least one selected from the group consisting of alkyl groups, alkyl groups, halogen atoms, and oxygen as defined above; Examples include tetrahydropiperan-2-yl, 3-bromotetrahydropulsan-2, methyl, 4-methoxytetrahydropiperanyl, and tetrahydrothiopiperan-2-yl. And 'methoxytetrahydrothiopiperan_4-yl; (V) tetrahydrofuranyl or tetrahydrothiofuranyl, which may be optionally selected from at least one Examples of the halogen atom and the above-mentioned substituents substituted with d-alkyloxy include tetrahydrofuran-2-yl and tetrahydrothiofuran-2-yl; (vi) silyl groups, and examples include tri (C6 alkyl ) Silyl (where the Cl_c 6 alkyl as described above), examples include trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, second butyldimethylsilane, methyldiisopropyl sand Nominal, methyl-mono-third-butylsilyl and triisopropylsilyl, tri (C "c6alkyl) silyl, at least one of which is a CrCe alkyl substituted with 1 or 2 aryl groups, Examples include diphenylmethylsilyl, diphenylbutylsilyl, diphenylisopropylsilyl, and phenyldiisopropylsilyl; (vii) alkoxymethyl, examples include (C " C6 alkoxy) methyl, which includes methyl substituted with C6 alkoxy as defined above, examples include methoxymethyl, 1,1-dimethyl-butoxymethoxy, ethoxy Methyl, propoxymethyl, isopropoxymethyl, butoxymethyl, and butoxymethyl, (: "€ 6 alkoxylated (C" C6 alkoxy) methyl, Including the above definition (C "C6 alkoxy) methyl" substituted with the alkoxy moiety of the above definition, examples include 2-methoxyethoxymethyl, and halogenated (C "C6 alkoxy) methyl Group containing an alkoxy moiety (C "C6 alkoxy) methyl, as defined above, substituted with at least ~ halogen atoms, examples include 2,2,2-trichloroethoxymethyl and bis (2-chloroethoxy) methyl; ( viii) Substituted ethyl groups, examples include 200401770 C "C6 alkoxylated ethyl groups, which include ethyl groups substituted with the above definition (^-(^ alkoxy substituted ethyl groups, examples include 1-ethoxyethyl and 1 -(Isopropoxy) ethyl, and halogenated ethyl, such as 2 5 2,2-trichloroethyl; (ix) the above definition of aralkyl, examples include the above definition substituted by 1 to 3 of the above aryl groups Cl_c6 alkyl, examples include benzyl, 1-naphthylmethyl, 2-naphthylmethyl, diphenylmethyl, triphenylmethyl, 1-naphthyldiphenylmethyl, and 9-anthryl Methyl, and Ci_c6 alkyl, as defined above, substituted with 1 to 3 of the above aryl groups, wherein the aryl moiety is substituted with at least one selected from the above definitions C ^ -C, alkyl, alkoxy, nitro, halogen as defined above Atoms and cyano substituents are substituted, examples include 4-methylbenzyl, 2,4,6-trimethylbenzyl, 3,4,5-trimethyl-benzyl, 4-methyl Oxybenzyl, 4-methoxyphenyldiphenylmethyl 2-nitrobenzyl, 4-nitrobenzyl, 4-chlorobenzyl, 4-bromobenzyl, and 4-cyanobenzyl; (X) an alkenyloxycarbonyl group comprising Examples of alkenyl-substituted ^^ 'groups of 2 to 6 carbon atoms include ethanoxyl and propanyloxy; aryl alkoxycarbonyl, which includes Is an oxygen atom substituted with an aralkyl group as defined above, wherein the aryl moiety can be optionally substituted with one or two substituents selected from the above-mentioned alkoxy and nitro groups. Examples include tolueneoxycarbonyl , 4-methoxytolyloxycarbonyl, 3,4-dimethoxytolyloxycarbonyl, 2-nitrotolyloxycarbonyl, and 4-nitro-tolyloxycarbonyl; (xii) forming sulfonic acid residues Esters such as methanesulfonyl, trifluoromethane, methylbenzene, methylbenzene, benzenesulfonyl, or toluene fluorenyl; -46- 200401770 (xiii) carbonate; (χΐν) Mono- or bis (CVC, alkyl) esters such as monomethyl carboxylate, dimethyl carboxylate, monoethyl carboxylate, diethyl carboxylate, monopropyl carboxylate, or monobutyl carboxylate ; (X v) having a carboxylic acid Or bis (C 6 -C i 0 aromatic hydrocarbon) esters, such as monophenyl dicarboxylic acid or diphenyl carboxylic acid; (xvi) phosphate; (xvii) bis (C ^ -C6 base) esters of vinegar, such as monomethyl phosphate, dimethyl phosphate, monoethyl phosphate or diethyl phosphate; and (xviii) mono- or bis (C6-C1 () aromatic hydrocarbons with phosphoric acid ) Ester esters, such as monophenyl phosphate or diphenyl phosphate. An ester group capable of being removed by a metabolic process (eg, hydrolysis) in a living body is a drug administered to a living mammal that can be removed by a metabolic process (eg, hydrolysis) to obtain a compound of formula (I) or Salts thereof, and preferred examples of the protecting group for the ester residue include: (i) 1- (fluorenyloxy) groups' Examples include 1- (aliphatic alkoxyalkyl) groups, which include The above-defined C ^ C6 alkyl group substituted with an alkylcarbonyloxy group having 1 to 6 carbon atoms, examples of which include methylmethoxymethyl, ethoxymethyl, propoxymethyl, butoxy Methyl, trimethylacetoxymethyl, pentamyloxymethyl, isoamyloxymethyl, hexamethyleneoxymethyl, 1-methylamyloxyethyl, 1-acetamyloxy Ethyl, 1-propionyloxyethyl, butylbutoxyethyl, trimethylacetoxyethyl, 1-pentyloxyethyl, benzopentyloxyethyl, butyl Hexyloxyethyl, 1-methoxymethylpropyl, 1-ethyloxypropyl, i-propylmethyloxypropyl, 1-butylamino-47- 200401770 oxypropyl, 1-trimethyl Methylacetoxypropyl, pentamyloxypropyl, isoamyl Propyl, 1-acyl group - propyl, [kappa] acetyl-methoxybutyl, propoxy acyl oxygen Bu butyl, 1-acyl-methoxybutyl, trimethyl acetyl Bu butyl oxygen,! Ethyloxypentyl, 1-propylamyloxypentyl, 1-butylamyloxypentyl, p-dimethylacetamyloxypentyl and 1-trimethylacetamyloxyhexyl, 1- ( Cycloalkylcarbonyloxy MC ^ -C, alkyl) group, which comprises a ^ g meaning q-C6 alkyl group substituted with a cycloalkyl alkoxy group (where the carbonyloxy group is substituted with a cycloalkyl group as defined above) Examples include cyclopentylcarbonyloxymethyl, cyclohexylmineoxymethyl, 1-cyclopentylcarbonyloxyethyl, cyclohexylcarbonyloxyethyl, and cyclopentyl p-oxypropyl , 1-cyclohexyl oxypropyl, 1-cyclopentyloxy its butyl and 1-cyclohexylcarbonyloxybutyl, and 1-(cubic fluorenyloxy)-(C i-C6 alkyl) Group 'which includes the above definition CI_C6 @ S substituted with an arylcarbonyloxy group containing an oxygen atom (substituted with an arylcarbonyl group), examples include benzyloxymethyl; (ii) substituted carbonyloxyalkyl Examples include d-C6 oxo) oxo oxo radicals, which include via (C ^ -C ^ oxo 丨 oxo (carbonyloxy via the above Ci-C6 alkoxy or cycloalkoxy) Radical substitution) of the above-mentioned meanings C ^ -C: 6 radicals or the above-defined ring radicals, examples include methoxyl Methyl, ethoxycarbonyloxymethyl, propoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl, butoxycarbonyloxymethyl, isobutoxycarbonyloxymethyl , Pentyloxycarbonyloxymethyl, hexyloxycarbonyloxymethyl, cyclohexyloxycarbonyloxymethyl, cyclohexyloxycarbonyloxy (cyclohexyl) methyl, 1- (methoxycarbonyl Oxy) ethyl, 1- (ethoxycarbonyloxy) ethyl, 1- (propoxycarbonyloxy) ethyl, 1- (isopropoxycarbonyloxy) ethyl, 1- (butyl Oxycarbonyloxy) ethyl, 1- (isobutoxy-48- 200401770oxy) ethyl, i- (t -butoxycarbonyloxy) ethyl, ι __ (pentyloxy-mineoxy) ) Ethyl, 1- (hexyloxycarbonyloxy) ethyl, 1- (cyclopentyloxycarbonyloxy) -ethyl, 1- (cyclopentyloxycarbonyloxy) propyl, 1- (cyclo Hexyloxycarbonyloxy) propyl, 1- (cyclopentyloxycarbonyloxy) butyl, 1- (cyclohexyloxycarbonyloxy) butyl, 1- (cyclohexyloxycarbonyloxy) ethyl Methyl, 1- (methoxycarbonyloxy) propyl, ethoxycarbonyloxy) propyl, 1- (propoxycarbonyloxy) propyl, 1- (isopropoxycarbonyloxy) propyl Base, 1- (butoxylineoxy) propene , 1- (isobutoxy-mineoxy) propyl, 1_ (pentyloxycarbonyloxy) propyl, 1- (hexyloxycarbonyloxy) -propyl, (methoxycarbonyloxy) Butyl, ι- (ethoxycarbonyloxy) butyl, ι- (propoxy-carbonyloxy) butyl, 1- (isopropoxycarbonyloxy) butyl, 1- (butoxy Carbonyloxy) butyl, 1- (isobutoxycarbonyloxy) butyl, 1- (methoxycarbonyloxy) pentyl, 1- (ethoxy-carbonyloxy) pentyl, 1- (methyl Oxymineoxy) hexyl and 1- (ethoxycarboxy) hexyl, and oxodifluorenylmethyl, which contains methyl substituted with oxodifluorenyl, the oxo The disocenenyl can be optionally substituted by a group selected from the above-defined Ci-c6 alkyl group and optionally substituted by at least one of the above-defined Cl-C6 alkyl group, the above-defined c ^ c: 6-oxyl group, or a halogen atom. By definition aryl is substituted, examples include (5-phenyl-2 -keto-1,3-diphosphone-4 -yl) methyl, [5- (4-methylphenyl) -2-one 1,3-Difluorenyl-4-yl] methyl, methoxyphenyl 2-keto-1,3-difluorenyl-4-yl] methyl, [5- (4-fluoro Phenyl) -2-keto-1,3-difluorenene-4- ] Methyl, [5- (4-chlorophenyl) -2-one-l, 3-difluorenyl-4-yl] methyl, (2-keto-1,3-difluorenylene 4-yl) methyl, (5-methyl-2-keto-I, 3-difluorenyl-4 · yl) methyl, (5-ethyl-2-keto-1,3- Difluorenyl-4-yl) methyl, (5-propylketo-1, difluorenyl-4-yl) methyl, (5-isopropyl-2-keto4,3-difluorene (Cenocenyl) methyl and (5-butyl-2_keto)--49- 200401770 1,3-difluorenyl-4-yl) methyl; (Hi) phthalo, which optionally includes Phthaloyl groups substituted with a substituent selected from the above-defined lower alkyl groups and the above-defined lower alkoxy groups, examples include phthaloyl, dimethylphthaloyl, and dimethoxyphthaloyl; (iv) those related to a hydroxyl protecting group The aliphatic fluorenyl groups as defined and exemplified above; (v) the aromatic fluorenyl groups as defined and exemplified above in relation to the hydroxyl protecting group; (vi) the half ester salt residues of succinic acid; (vii) the phosphate salt residues (Viii) ester residues formed by amino acids, such as glutamate and aspartate; (ix) carbamate groups optionally substituted with 1 or 2 lower alkyl groups as defined above; and (X) 1-(fluorenyloxy) Hydroxy ortho, which includes a low alkoxycarbonyl group in which the lower oxygen moiety is substituted with an aliphatic alkoxy group as defined above or an aromatic alkoxy group as defined above, examples include trimethylethoxymethoxycarbonyl . The above-defined protective group capable of being removed (eg, hydrolyzed) by a metabolic process in vivo is used to synthesize compounds of formula (I) with modified hydroxy residues, with C 1 -C25 alkylcarbonyl groups and substituted carbonyloxy groups Alkyl is preferred. Specific examples of the compound of the formula (I) include the compounds in the following Tables 1 to 8, and the compounds of the present invention are not limited to these compounds. The following abbreviations are used in Tables 1 to 8 ...

Ac stands for ethenyl,

Azc represents a perhydroacin ring- 丨 _ group, Αζη represents a perhydroacron ring- 丨 _ group, -50 ′ 200401770

Azp represents perhydroheptan-1-yl,

Bu represents η-butyl, Βζ represents benzyl,

Car represents carbamoyl, cBu represents cyclobutyl, cHx represents cyclohexyl, COOMe represents methoxycarbonyl, cPn represents cyclopentyl, cPr represents cyclopropyl, and diEtCar represents N, N-diethylamine formamidine , DiMeCar represents N, N-dimethylaminomethylamino, diMeN represents dimethylamino, diMePro represents 2,2-dimethylpropanylamino, and diMeTcr represents N, N-dimethylthiamine Fluorenyl, diPrCar represents N, N-diisopropylamine formamidine,

Et stands for ethyl,

Fur stands for furan-3-yl,

Hx represents hexyl, iPr represents isopropyl, I s ο X represents isoxazole-3 -yl,

Me stands for methyl,

MeEtCai * stands for N-methyl-N-ethylaminomethyl, 200401770

MeEtN represents methylethylamino, M o r represents morpholin-1 -yl,

Mtdo stands for methylenedioxy,

Nap stands for naphthyl,

Oxa represents oxazol-2-yl, pentaFPh represents pentafluorophenyl, P h represents phenyl,

Pip represents hexahydropyridin-1-yl, Pr represents propyl, 2-Pyr represents 2-pyridyl, 3-Pyr represents 3-pyridyl, 4-Pyr represents 4-pyridyl,

Pyrd stands for pyrrolidin-1-yl,

Pyrm stands for pyrimidinyl,

Pyzi stands for Pycnogenol,

Pyzo stands for pyrazol-2-yl, t-Bu stands for third butyl, 2,2,3,3-tetraMe-cPr stands for 2,2,3,3-tetramethylcyclopropyl, and Tim stands for trifluoromethyl base,

Thi represents 2-thienyl, T h i z-2 represents 1,3-thiazole-2 -yl,

Thiz-4 represents 1,3-thiazol-4-yl, -52- 200401770

Thiz-5 represents 1,3-thiazol-5-yl,

Ex emp. Comp. No. represents the example compound number, and Su b. Po s · represents the substitution position.

-53- 200401770 Table 1

F

Exemp. R1 R2 R3 X Y Comp. No. 1-2-3-45 6-7-8-9 1 1 1 111 1- 1 1 hhhhhhhhhhhhhhhh hhhhhhhhhhhhhhhhhh hhhhhhhhhhhhhhhh gggIJrggggHHgggOHgg

Me Et Pr iPr Bu tBu Amyl- (CH2) -tBu Hx Tfm Fluoromethyldifluoromethylchloromethyldichloromethylbromomethyldibromomethyl-54 200401770 147 Η Η Η 〇Η 1-Bromoethyl 1-18 Η Η Η 〇Η 1-chloroethyl 1-19 Η Η Η 〇Η pentafluoroethyl: 1-20 Η Η Η 〇 Η aminomethyl 1-21 Η Η Η 〇 Ν, Ν -Dimethylaminomethyl 1-22 Η Η Η ΟΗ Ν, N-diethylaminomethyl 1-23 1-C1 Η Η ΟΗ Me 1-24 1-C1 Η Η ΟΗ Et 1-25 1-C1 Η Η ΟΗ Pr 1-26 1-C1 Η Η ΟΗ iPr 1-27 1-C1 Η Η ΟΗ Βυ 1-28 1-C1 Η Η ΟΗ tBu 1-29 ι-α Η Η ΟΗ pentyl 1-30 ι- α Η Η ΟΗ-(CH2) -tBu 1-31 1-C1 Η Η ΟΗ Hx 1-32 ι-α Η Η ΟΗ Tfm 1-33 ι-α Η Η ΟΗ Fluoromethyl 1-34 1-C1 Η Η Η ΟΗ difluoromethyl 1-35 ι-α Η Η ΟΗ chloromethyl 1-36 ι-α Η Η Ο Η dichloromethyl 1-37 ι-α Η Η ΟΗ bromomethyl 1-38 1-C1 Η Η 〇Η Dibromomethyl 1-39 ι-α Η Η ΟΗ 1-Bromoethyl 1-40 ι-α Η Η ΟΗ 1-Chloroethyl 1:41 1-C1 Η Η ΟΗ Pentafluoroethyl 1-42 1 -C1 Η Η ΟΗ Aminomethyl 1-43 ι-α Η Η ΟΗ Nji- Dimethylaminomethyl1-44 ι-α Η Η ΟΗ N, N-Diethylaminomethyl1-45 2-Βγ Η Η ΟΗ Me 1-46 2-Βγ Η Η ΟΗ Et 1-47 2- Βγ Η Η ΟΗ Pr 1-48 2-Βγ Η Η ΟΗ iPr 1-49 2-Βγ Η Η ΟΗ Bu 1-50 2-Βγ Η Η ΟΗ tBu 1-51 2-Βγ Η Η ΟΗ pentyl 1-52 2 -Βγ Η Η ΟΗ-(CH2) -tBu 1-53 2-Βγ Η Η ΟΗ • Hx 200401770 1-54 1-55 1-56 1-57 1-58 1-59 1-60 1-61 1-62 1-63 1-64 1-65 1-66 1-67 1-68 1-69 1-70 1-71 1-72 1-73 1-74 1-75 1-76 1-77 1-78 1- 79 1-80 1-81 1-82 1-83 1-84 1-85 1-86 1-87 1-88 1-89 1-90 2-Br HH OH Tfm 2-Br HH OH fluoromethyl 2- Br HH OH difluoromethyl. 2-Br HH OH chloromethyl 2-Br HH OH dichloromethyl 2-Br HH OH bromomethyl 2-Br HH OH dibromomethyl 2-Br HH OH 1 -bromo Ethyl 2-Br KH OH 1-chloroethyl 2-Br HH OH pentafluoroethyl 2-Br H. H OH aminomethyl 2-Br HH OH N, N-dimethylaminomethyl 2-Br HH OH 丨 N? N-Diethylaminomethyl 2-C1 HH OH Me 2-C1 HH OH Et 2-C1 HH OH Pr 2-C1 HH OH iPr 2-C1 HH OH Bu 2-C1 HH OH tBu 2 -C1 HH OH Amyl 2-C1 HH OH -(CH2) -tBu 2-C1 HH OH Hx 2-C1 HH OH Tfm 2-C1 HH OH Fluoromethyl 2-C1 HH OH Difluoromethyl 2-C1 HH OH Chloromethyl 2-C1 HH OH Dichloro Methyl 2-C1 HH OH bromomethyl 2-C1 HH OH dibromomethyl 2-C1 HH OH 1-bromoethyl 2-C1 HH OH 11-chloroethyl 2-C1 HH OH pentafluoroethyl 2- C1 HH OH .aminomethyl 2-C1 HH OH N, N-dimethylaminomethyl 2-C1 HH OH N, N-diethylaminomethyl 2-C1 HH OH Me 2-FHH OH Et

-56- 200401770 1-91 1-92 1-93 1-94 1-95 1-96 1-97 1-98 1-99 1-100 1-101 1-102 1-103 1-104 1-105 1 -106 1-107 1-108 1-109 1-110 1-111 1-112 1-113 1-114 1-115 1-116 1-117 1-118 1-119 1-120 1-121 1-122 1-123 1-124 1-125 1.126 1-127

2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2-F 2- F 2-F 2-F 2-F 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2-OH 2 -OH 2-OH 2-OH 2-OH

H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H H

H

H H H H H H H H H H H H • H H H H H H H H H H H H H H H H H H H H H

H OH Pr OH iPr OH Bu OH tBu OH 'amyl OH-(CH2) -tBu OH Hx OH Tfm OH fluoromethyl OH difluoromethyl OH chloromethyl OH dichloromethyl · OH bromomethyl OH dibromo Methyl OH 1-bromoethyl OH 1-chloroethyl OH pentafluoroethyl OH amino methyl OH 5N, N-dimethylamino methyl OH In, n-diethylamino methyl OH Me, ' OH Et OH Pr · OH iPr OH Bu OH tBu OH Amyl OH-(CH2) -tBu OH Hx OH Tfm OH Fluoromethyl OH Difluoromethyl OH Chloromethyl OH Dichloromethyl OH Bromomethyl OH Dibromo Methyl OH 1-bromoethyl

-57- 200401770 1-128 2-OH HH OH 1-chloroethyl 1-129 2-OH HH OH pentafluoroethyl 1-130 2-OH HH OH aminomethyl, 1-131 2-OH HH OH N, N-Dimethylaminomethyl 1-132 2-OH HH OH N, N-Diethylaminomethyl 1-133 2-OMe HH OH Me 1-134 2-OMe HH OH Et 1-135 2 -OMe HH OH Pr 1-136 2-OMe HH OH iPr 1-137 2-OMe HH OH Bu 1-138 2-OMe HH OH tBu 1-139 2-OMe HH OH Amyl 1-140 2-OMe HH OH -(CH2 > tBu 1-141 2-OMe HH OH Hx 1-142 2-OMe HH OH Tfm 1-143 2-OMe HH OH fluoromethyl 1-144 2-OMe HH OH difluoromethyl 1-145 2 -OMe HH OH chloromethyl 1-146 2-OMe HH OH dichloromethyl 1-147 2-OMe HH OH momethyl 1-148 2-OMe HH OH dibromomethyl 1-149 2-OMe HH OH 1-bromoethyl 1-150 2-OMe HH OH 1-chloroethyl 1-151 2-OMe HH OH pentafluoroethyl 1-152 2-OMe HH OH aminomethyl 1-153 2-OMe HH OH N, N-Dimethylaminomethyl 1-154 2-OMe HH OH N, N-Diethylaminomethyl 1-155 2-AcNH HH OH Me 1-156 2-AcNH HH OH Et 1-157 2 -AcNH HH OH Pr 1-158 2-AcNH HH OH iPr M59 2-AcNH H .H OH Bu 1-160 2-AcNH HH OH tBu 1-161 2-AcNH HH OH Amyl 1-162 2-AcNH HH OH-(CH2) -tBu 1-163 2-AcNH HH OH Hx 1-164 2-AcNH HH OH Tim 200401770 1-165 2-AcNH HH OH fluoromethyl_, 1-166 2-AcNH HH OH difluoromethyl 1-167 2-AcNH HH OH chloromethyl 1-168 · 2-AcNH HH OH dichloromethyl 1-169 2-AcNH HH OH bromomethyl 1-170 2-AcNH HH OH dibromomethyl 1-171 2-AcNH HH OH 1-bromoethyl 1-172 2-AcNH HH OH 11-chloroethyl 1-173 2-AcNH HH OH .Pentafluoroethyl 1-174 2-AcNH HH OH aminomethyl 1-175 2-AcNH HH OH dimethylamino methyl 1-176 2-AcNH HH OH N, N, diethylamino methyl 1 -177 2-OMe 3-OMe H OH Me 1-178 2-OMe 3-OMe H OH Et 1-179 2-OMe H-OH Pr 1-180 2-OMe 3-OMe H OH iPr 1-181 2-OMe 3-OMe H OH Βυ 1-182 2-OMe 3-OMe H OH tBu 1-183 2-OMe 3-OMe H OH female 1-184 2-OMe 3-OMe H OH-(CH2) -tBu . 1-185 2-OMe 3-OMe H OH Hx 1-186 2-OMe 3-OMe H OH Tfm 1-187 2-OMe 3-OMe H OH Fluoromethyl 1-188 2-OMe 3-OMe H OH Difluoromethyl 1-189 2-OMe 3-OMe H OH Chloromethyl 1-190 2-OMe 3-OMe H OH Dichloromethyl 1-191 2-OMe 3-OMe H OH Bromomethyl. 1-192 2-OMe 3-OMe H OH Dibromomethyl 1-193 2-OMe 3-OMe H OH 1-Moethyl 1-194 2-OMe 3-OMe H OH 1-chloroethyl 1-195 2-OMe 3-OMe H OH pentafluoroethyl '1-196 2-OMe 3-OMe H OH aminomethyl 1-197 2-OMe 3-OMe H OH N, N-dimethylamine Methyl 1-198 2-OMe 3-OMe H OH N, N-diethylamino methyl 1-199 2? 3-Mtdo H OH Me 1-200 2,3-Mtdo H OH Et 1-201 2 , 3-Mtdo H OH Pr 59- 200401770 1-202 2,3-Mtdo H OH iPr 1-203 2,3-Mtdo H OH Bu 1-204 2,3-Mtdo H OH tBu 1-205 2,3- Mtdo H OH pentyl 1-206 2,3-Mtdo H OH-(CH2) -tBu 1-207 2,3-Mtdo H OH Hx 1-208 2,3-Mtdo H OH Tfm '* 1-209 2, 3-Mtdo H OH fluoromethyl 1-210 2,3-Mtdo H OH difluoromethyl 1-211 2,3-Mtdo H OH: chloromethyl 1-212 2,3-Mtdo H OH dichloromethyl 1-213 2,3-Mtdo H OH Bromomethyl 1-214 2,3-Mtdo H OH 丨 Dibromo Duck 1-215 2,3-Mtdo H OH 1-Bromoethyl 1-216 2,3- Mtdo H OH 1-chloroethyl 1-217 2,3-Mtdo H OH '' pentaethyl 1-218 2,3-Mtdo H OH aminomethyl 1-219 2,3-Mtdo H OH N, N-di Methylaminomethyl 1-220 2 > Mtdo H OH diethylamine Methyl 1-221 1-C1 2-C1 3-C1 OH Me 1-222 1-C1 2-C1 3-C1 OH Et 1-223 i-ci 2-C1 3-C1 OH Pr 1-224 1- C1 2-C1 3-C1 OH iPr 1-225 1 -Cl 2-C1 3-C1 OH Βυ 1-226 1-C1 2-C1 3-C1 OH tBu 1-227 1-C1 2-C1 3-C1 OH Amyl 1-228 1-C1 2-C1 3-C1 OH-(CH2) -tBu 1-229 1-C1 2-C1 3-C1 OH Hx 1-230 1-C1 2-Cl 3-C1 OH Tfm 1 -231 1-C1 2-C1 3-C1 OH m methyl ~ 1-232 1-C1 2-Cl 3-C1 OH difluoromethyl 1-233 1-C1 2-Cl 3-C1 OH chloromethyl 1 -234 1-C1 2-Cl 3-C1 OH dichloromethyl 1-235 1-C1 2-Cl 3-C1 OH bromomethyl 1-236 1-C1 2-Cl 3-C1 OH dibromomethyl 1 -237 1-C1 2-Cl 3-C1 OH 1-bromoethyl 1-238 1-C1 2-Cl 3-C1 OH 1-chloroethyl-60- 200401770

Table 2 F

1-239 1-C1 2-C1 3-C1 OH pentafluoroethyl 1-240 1-C1 2-C1 3-C1 OH aminomethyl. 1-241 1-C1 2-C1 3-C1 OH N, N-dimethylaminomethyl 1-242 1-C1 2-C1 3-C1 OH N, N-diethylaminomethyl

Exemp. Comp. No. R1 R2 R3 X Υ 2-1 Η Η Η ΟΗ cPr 2-2 Η Η Η ΟΗ 2,2,3,3-tetraMe-cPr 2-3 Η Η Η ΟΗ 2-Ph-cPr 2 -4 Η Η ΟΗ cBu 2-5 Η Η Η ΟΗ cPn 2-6 Η Η Η ΟΗ cHx 2-7 Η Η Η ΟΗ-(CH2) -cPr 2-8 Η Η Η ΟΗ-(CH2) -cBu 2 -9 Η Η Η ΟΗ-(CH2) -cPn 2-10 Η Η Η ΟΗ-(CH2) -cHx 2-11 Η Η Η ΟΗ-(CH2) 2-cPr 2-12 Η Η Η ΟΗ-(CH2) 2 ~ cBu 2-13 Η Η Η ΟΗ-(CH2) 2-cPn 2-14 Η Η Η ΟΗ-(CH2) 2-cHx 2-15 Η Η Η Η-(CH2) 3-cPr 2-16 Η Η Η ΟΗ-(CH2) 3-cBu 2-17 Η Η Η ΟΗ-(CH2) 3-cPn 2-18 Η Η Η ΟΗ-(CH2) 3-cHx 61-200401770 2-19 Η Η Η ΟΗ-(CH2 ) 4-cPr 2-20 Η Η Ο Η > (CH2) 4-cBu 2-21 Η Η Η Ο Η-(CH2) 4-cPn 2-22 Η Η Η Ο Η-(CH2) 4-cHx 2-23 Η Η Ο Η Pyrd 2-24 Η Η Η ΟΗ Pip 2-25 Η Η Η ΟΗ Azp Azc 2-26 Η Η Η ΟΗ 2-27 Η Η Η ΟΗ Azn 2-28 Η Η Η Ο Η Mor 2-29 Η Η Η Η ΟΗ-(CH2) -Pyrd 2-30 Η Η Ο Η-(CH2) -Pip 2-31 Η Η Η ΟΗ-(CH2) -Azp 2-32 Η Η Η ΟΗ-(CH2) -Azc 2-33 Η Η ΟΗ-(CH2) -Azn 2-34 Η Η Η ΟΗ-(CH2) -Mor 2-35 Η Η Η ΟΗ-(CH2) 2-Pyrd 2-36 Η Η Η ΟΗ-(CH2) 2-Pip 2- 37 Η Η Η ΟΗ-(CH2) 2-Azp 2-38 Η Η Η ΟΗ-(CH2) 2-Azc 2-39 Η Η Η ΟΗ-(CH2) 2-Azn 2-40 Η Η Η ΟΗ-(CH2 ) 2-Mor 2-41 Η Η Η ΟΗ-(CH2) 3-Pyrd 2-42 Η Η Η ΟΗ-(CH2) 3-Pip 2-43 Η Η Η Η-(CH2) 3-Azp 2-44 Η Η Η ΟΗ-(CH2) 3-Azc 2-45 Η Η Η ΟΗ-(CH2) 3-Azn 2-46 Η Η Η ΟΗ-(CH2) rMor 2-47 Η Η Η ΟΗ-(CH2) 4-Pyrd 2-48 Η Η Η ΟΗ > (CH2) 4-Pip 2-49 Η Η Η ΟΗ-(CH2) 4-Azp 2-50 Η Η Η ΟΗ-(CH2) 4-AZC 2-51 Η Η Η ΟΗ -(CH2) 4-Azn 2-52 Η Η Η ΟΗ-(CH2) 4-Mor 2-53 Η Η Η ΟΗ Thi 2-54 Η Η Ο Η 2-Pyr 2 > 55 Η Η Η ΟΗ 3-Pyr- 62- 200401770 2-56 Η Η 2-57 Η Η 2-58 Η Η 2-59 Η Η 2-60 Η Η 2-61 Η Η 2-62 Η Η 2-63 Η Η 2-64 Η Η 2- 65 Η Η 2-66 Η Η 2-67 Η Η 2-68 Η Η 2-69 Η Η 2-70 Η Η 2-71 Η Η 2-72 Η Η 2-73 Η Η 2-74 'Η Η 2 -75 Η Η 2-76 Η Η 2-77 Η Η 2-78 Η Η 2-79 Η Η 2-80 Η Η 2-81 Η Η 2-82 Η Η 2-83 Η Η 2-84 Η Η 2-85 Η Η 2-86 Η Η 2-87 Η Η 2-88 Η Η 2-89 Η Η 2-90 Η Η 2-91 Η Η 2-92 Η Η Η 〇Η 4-Pyr Η ΟΗ Pyzo Η ΟΗ Oxa Η ΟΗ Isox Η ΟΗ Fur Η ΟΗ-(CH2)- Thi Η ΟΗ-(CH2) -2-Pyr Η ΟΗ-(CH2) -3-Pyr Η ΟΗ-(CH2) -4-Pyr Η ΟΗ-(CH2) -Pyzo Η ΟΗ-(CH2) -Oxa Η ΟΗ- (CH2) -Isox Η ΟΗ-(CH2) -Fur Η ΟΗ-(CH2) 2-Thi Η ΟΗ-(CH2) 2-2-Pyr Η ΟΗ-(CH2) 2-3-Pyr Η ΟΗ-(CH2) 2-4. Pyr Η ΟΗ-(CH2) 2-Pyzo Η ΟΗ-(CH2) 2-〇xa Η ΟΗ-(CH2) 2-Isox Η ΟΗ-(CH2) 2-Fur Η ΟΗ-(CH2) 3- Thi Η ΟΗ-(CH2) 3-2-Pyr Η ΟΗ-(CH2) 3-3-Pyr Η ΟΗ-(CH2) 3-4-Pyr Η ΟΗ-(CH2) 3, Pyzo Η ΟΗ-(CH2) 3 -Oxa Η ΟΗ-(CH2) 3-Isox Η ΟΗ-(CH2) 3-Fur Η ΟΗ-(CH2) 4-Thi Η ΟΗ-(CH2) 4-2-Pyr Η ΟΗ • (CH2) 4-3- Pyr Η ΟΗ-(CH2) 4 «4-Pyr Η ΟΗ-(CH2) 4-Pyzo Η ΟΗ-(CH2) 4-〇xa Η ΟΗ-(CH2) 4-Isox Η ΟΗ-(CH2) 4-Fur 63 -200401770 2-93 1-C1 HH OH cPr 2-94 1-C1 HH OH 2,2,3,3-tetraMe-cPr 2-95 1-C1 HH OH 2-Ph-cPr 2-96 1-C1 HH OH cBu 2-97 1-C1 HH OH cPn 2-98 1-C1 HH OH cHx 2-99 1: C1 HH OH-(CH2) -cPr 2-100 1-C1 HH OH-(CH2) -cBu 2-101 1-C1 HH OH-(CH2) -cPn 2-102 1- C1 HH OH-(CH2) -cHx 2-103 1-C1 HH OH-(CH2) 2-cPr 2-104 1-C1 HH OH .- (CH2) 2-cBu 2-105 1-C1 HH OH-( CH2) 2-cPn 2-106 1-C1 HH OH-(CH2) 2-cHx 2-107 1-G1 HH OH-(CH2) 3-cPr 2-108 1-C1 HH OH-(CH2) 3-cBu 2-109 1-C1 HH OH-(CH〗) 3-cPn 2-110 1-C1 HH OH _- (CH2) rcHx 2-111 1-C1 HH OH-(CH2) 4-cPr 2-112 1- C1 HH OH-(CH2) 4-cBu 2-113 1-C1 HH OH-(CH2) 4-cPn 2-114 1-C1 HH OH-(CH2) 4-cHx 2-115 1-C1 HH OH Pyrd 2 -116 1-C1 HH OH Pip 2-117 1-C1 HH OH Azp Azc 2-118 1-C1 HH OH 2-119 1-C1 HH OH Azn 2-120 1-C1 HH OH Mor 2-121 1-C1 HH OH-(CH2) -Pyrd 2-122 1-C1 HH OH-(CH2) -Pip 2-123 1-C1 HH OH-(CH2) -Azp 2-124 1-C1 HH OH-(CH2) -Azc 2-125 1-C1 HH OH-(CH2) -Azn 2-126 1-C1 HH OH-(CH2) -Mor 2-127 1-C1 HH OH-(CH2) 2-Pyrd 2-128 1-C1 HH OH • (CH2) rPip 2-129 1-C1 HH OH > (CH2) 2-Azp 64- 200401770 2-130 2-131 2-132 2-133 2-134 2-135 2-136 2-137 2-138 2-139 2 -140 2-141 2-142 2-143 2-144 2-145 2-146 2-147 2-148 2-149 2-150 2-151 2-152 2-153 2-154 2-155 2-156 2-157 2-158 2-159 2-160 2-161 2-162 2-163 2-164 2-165 2-166

1-C1 HH ι-α HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl, HH l -Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl HH l-Cl H. H OH > (CH2) 2-Azc OH-(CH2) 2 ~ Azn OH-(CH2) 2 ~ Μ〇Γ OH-(CH2) 3-Pyrd OH-(CH2) 3-Pip OH-(CH2) 3 -Azp OH-(CH2) 3-Azc OH-(CH2) 3-Azn OH-(CH2) 3-Mor OH-(CH2) 4-Pyrd OH-(CH2) 4-Pip OH-(CH2) 4-Azp OH-(CH2) 4-AzC OH-(CH2) 4-Azn OH-(CH2) 4-Mor OH Thi OH 2-Pyr OH 3-Pyr OH 4-Pyr OH Pyzo OH Oxa OH Isox OH Fur OH-(CH2 ) -Thi OH-(CH2) -2-Pyr OH-(CH2) -3-Pyr OH-(CH2) -4-Pyr OH-(CH2), Pyzo OH-(CH2) -Oxa OH-(CH2)- 1sox OH-(CH2) -Fur OH-(CH2) 2-Thi OH-(CH2) 2-2-Pyr OH-(CH2) 2-3-Pyr OH-(CH2) 2_4-Pyr OH-(CH2) 2 -Pyzo OH-(CH2) 2-〇xa -65- 200401770 2-167 1-C1 Η Η ΟΗ-(CH2) 2-Is〇X 2-168 1-C 1 Η Η ΟΗ-(CH2) 2-Fur 2-169 1-C1 Η Η ΟΗ-(CH2) 3-Thi 2-170 1-C1 Η Η ΟΗ-(CH2) r2-Pyr 2-171 1-C1 Η Η ΟΗ-(CH2) 3-3-Pyr 2-172 1-G1 Η Η Ο Η-(CH2) 3-4-Pyr 2-173 1-C1 Η Η Ο Η-(CH2) 3-Pyzo 2-174 1- C1 Η Η ΟΗ •-(CH2) 3-Oxa 2-175 1-CI Η Η Ο Η-(CH2) 3-Isox 2-176 1-C1 Η Η ΟΗ-(CH2) 3-Fur 2-177 1-C1 Η Η ΟΗ-(CH2) 4-Thi 2-178 1-C1 Η Η ΟΗ-(CH2) 4-2-Pyr 2-179 1-C1 Η Η ΟΗ-(CH2) 4-3-Pyr 2-180 1 -C1 Η Ο Η-(CH2) 4-4-Pyr 2-181 1-C1 Η Η ΟΗ-(CH2) 4-Pyzo 2-182 1-C1 Η Η ΟΗ-(CH2) 4-〇xa 2-183 1-C1 Η Η ΟΗ-(CH2) 4-Isox 2-184 1-C1 Η Η ΟΗ-(CH2) 4-Fur 2-185 2-Br Η Η ΟΗ cPr 2-186 2-Βγ Η Η ΟΗ 2, 2,3,3-tetraMe-cPr 2-187 2-Βγ Η Η ΟΗ 2-Ph-cPr 2-188 2-Βγ Η Η ΟΗ cBu 2-189 2-Βγ Η Η ΟΗ cPn 2-190 2-Βγ Η Η ΟΗ cHx 2-191 2-Βγ Η Η ΟΗ-(CH2) -cPr 2-192 2-Βγ Η Η ΟΗ-(CH2) -cBu 2-193 2-Βγ Η Η ΟΗ-(CH2) -cPn 2- 194 2-Βγ Η Η ΟΗ-(CH2) -cHx 2-195 2-Βγ Η Η ΟΗ-(CH2) 2-cPr 2-196 2-Βγ Η Η ΟΗ-(CH2) 2-cBu 2-197 2-Βγ Η Η ΟΗ-(CH2) 2-cPn 2-198 2-Βγ Η Η ΟΗ-(CH2) rcHx 2-199 2-Βγ Η Η ΟΗ-(CH2 ) 3-cPr 2-200 2-Βγ Η Η ΟΗ-(CH2) 3-cBu 2-201 2-Βγ Η Η ΟΗ-(CH2) 3-cPn 2-202 2-Βγ Η Η ΟΗ-(CH2) 3 -cHx 2-203 2-Βγ Η Η ΟΗ-(CH2) 4-cPr _66 '200401770

2-204 2-Br HH OH-(CH2) 4-cBu 2-205 2-Br HH OH-(CH2) 4-cPn 2-206 2-Br HH OH-(CH2) 4-cHx 2-207 2- Βγ HH OH Pyrd 2-208 2-Br HH OH Pip 2-209 2-Br HH OH Azp Azc 2-210 2-Br HH OH 2-211 2-Br HH OH Azn 2-212 2-Br HH OH Mor 2 -213 2-Br HH OH-(CH2) -Pyrd 2-214 2-Br HH OH-(CH2) -Pip 2-215 2-Br HH OH-(CH2) -Azp 2-216 2-Br HH OH- (CH2) -Azc 2-217 2-Br HH OH-(CH2) -Azn 2-218 2-Br HH OH-(CH2) -Mor 2-219 2-Br HH OH-(CH2) 2-Pyrd 2- 220 2-Br HH OH-(CH2) 2-Pip 2-221 2-Br HH OH-(CH2) 2-Azp 2-222 2-Br HH OH-(CH2) 2-Azc 2-223 2-Br HH OH-(CH2) 2-Azn 2-224 2-Br HH OH (CH2) 2 ~ Μ〇Γ 2-225 2-Br HH OH-(CH2) rPyrd 2-226 2-Br HH OH-(CH2) 3-Pip 2-227 2-Br HH OH-(CH2) 3-Azp 2-228 2-Br HH OH .- (CH2) 3-Azc 2-229 2-Br HH OH-(CH2) 3-Azn 2 -230 2-Br HH OH-(CH2) 3-Μ0Γ 2-231 2-Br HH OH-(CH2) 4-Pyrd 2-232 2-Br HH OH-(CH2) 4-Pip 2-233 2-Br HH OH > (CH2) 4-A2P 2-234 2-Br HH OH-(CH2) 4-A2C 2-235 2-Br HH OH-(CH2) 4-Azn 2-236 2-Br HH OH-( CH2) 4-M01 2 -237 2-Br HH OH Thi 2-238 2-Br HH OH 2-Pyr 2-239 2-Br HH OH 3-Pyr 2-240 2-Br HH OH 4-Pyr -67 ^ 200401770 2-241 2- Βτ Η Η ΟΗ Pyzo 2-242 2-Br Η Η ΟΗ 〇xa 2-243 2-Βγ Η Η ΟΗ Isox 2-244 2-Βγ Η Η ΟΗ Fur 2-245 2-Βγ Η Η ΟΗ-(CH2)- Thi 2-246 2-Br Η Η ΟΗ-(CH2) -2-Pyr 2-247 2-Βγ Η Η Ο Η-(CH2) -3-Pyr 2-248 2-Βγ Η Η ΟΗ-(CH2) -4 -Pyr 2-249 2-Βγ ΤΓΊΓ Η ΟΗ-(CH2) -Pyzo 2-250 2-Βγ Η Η ΟΗ-(CH2) -Oxa 2-251 2-Βγ Η Η ΟΗ-(CH2) -Isox 2-252 2-Βγ Η Η ΟΗ-(CH2) -Fur 2-253 2-Βγ Η Η ΟΗ-(CH2) 2-Thi 2-254 2-Βγ Η Η ΟΗ-(CH2) 2-2-Pyr 2-255 2 -Βγ Η Η ΟΗ-(CH2) 2-3-Pyr 2-256 2-Br Η Η ΟΗ-(CH2) 2-4-Pyr 2-257 2-Βγ Η Η ΟΗ-(CH2) 2-Pyzo 2- 258 2-Βγ Η Η ΟΗ-(CH2) 2-〇xa 2-259 2-Βγ Η Η ΟΗ-(CH2) rIsox 2-260 2-Βγ Η Η ΟΗ-(CH2) rFur 2-261 2-Βγ Η Η ΟΗ-(CH2) 3-Thi 2-262 2-Βγ Η Η ΟΗ-(CH2) 3-2.Pyr 2-263 2-Βγ Η Η ΟΗ-(CH2) 3-3-Pyr 2-264 2- Βγ Η Η ΟΗ-(CH2) 3-4-Pyr 2-265 2-Β Η Η ΟΗ-(CH2) 3-Pyzo 2-266 2-Βγ Η Η ΟΗ-(CH2) 3-Oxa .2-267 2-Βγ Η ΟΗ-(CH2) 3-Fur 2-269 2-Βγ Η Η ΟΗ-(CH2) 4-Thi 2-270 2-Βγ Η Η ΟΗ-(CH2) 4-2-Pyr 2-271 2-Βγ Η Η ΟΗ-(CH2) 4-3-Pyr 2-272 2-Βγ Η Η ΟΗ-(CH2) 4-4-Pyr 2-273 2-Βγ Η Η ΟΗ-(CH2) 4-Pyz〇2-274 2 -Βγ Η Η ΟΗ '(CH2) 4-〇xa 2-275 2-Βγ Η Η ΟΗ-(CH2) 4-Isox 2-276 2-Βγ Η Η ΟΗ-(CH2) 4-Fur 2-277 2- C1 Η Η ΟΗ cPr -68-200401770 2-278 2-279 2-280 2-281 2-282 2-283 2-284 2-285 2-286 2-287 2-288 2-289 2-290 2- 291 2-292 2-293 2-294 2-295 2-296 2-297 2-298 2-299 2-300 2-301 2-302 2-303 2-304 2-305 2-306 2-307 2 -308 2-309 2-310 2-311 2-312 2-313 2-314

2-C1 HH 2-C1HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2 -C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1. HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2- C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH OH 2,2,3,3-tetraMe-cPr OH 2-Ph-cPr OH cBu OH cPn OH cHx OH-(CH2) -cPr OH • (CH2) -cBu OH-(CH2) -cPn OH-(CH2) -cHx OH-(CH2) 2-cPr ΟΙΓ • (CH2) rcBu OH-(CH2) 2-cPn OH-(CH2) 2-cHx OH-(CH2) 3-cPr OH-(CH2) 3-cBu OH- (CH2) 3-cPn OH-(CH2) 3-cHx OH-(CH2) 4-cPr OH-(CH2) 4-cBu OH-(CH2) 4-cPn OH-(CH2) 4-cHx OH Pyrd OH Pip OH OH Azp Azc OH Azn OH Mor OH-(CH2) -Pyrd OH-(CH2) -Pip OH-(CH2) -Azp OH-(CH2) -Azc OH-(CH2) -Azn OH-(CH2) -Mor OH-(CH2) 2-Pyrd OH-(CH2) 2-Pip 'OH-(CH2)? ~ Azp OH-(CH2) 2-Azc

69 200401770 2-315 2-316 2-317 2-318 2-319 2-320 2-321 2-322 2-323 2-324 2-325 2-326 2-327 2-328 2-329 2-330 2-331 2-332 2-333 2-334 2-335 2-336 2-337 2-338 2-339 2-340 2-341 2-342 2-343 2-344 2-345 2-346 2- 347 2-348 2-349 2-350 2-351 2-C1 HH OH-(CH2) rAzn 2 · α HH OH-(CH2) 2-Mor 2-C1 HH OH-(CH2) 3-Pyrd 2-C1 HH OH-(CH2) 3-Pip 2-C1 HH OH-(CH2) 3-Azp 2-C1 HH OH-(CH2) 3-Azc 2-C1 HH OH-(CH2) 3-Azn 2-C1 HH OH -(CH〗) 3-Mor 2-C1 HH OH-(CH2) 4-Pyrd 2-C1 HH OH-(CH2) 4-Pip 2-C1 HH OH-(CH2) 4-Azp 2-C1 HH OH- (CH2) 4-AzC 2-C1 HH OH-(CH2) 4-AziX 2-C1 HH OH-(CH2) 4-Mor 2-C1 HH OH Thi 2-C1 HH OH 2-Pyr 2-C1 HH OH 3 -Pyr 2-C1 HH OH 4-Pyr 2-C1 HH OH Pyzo 2-C1 HH OH Oxa 2-C1 HH OH Isox 2-C1 HH OH Fur 2-C1 HH OH-(CH2) -Thi 2-C1 HH OH -(CH2) -2-Pyr 2-C1 HH OH-(CH2) -3-Pyr 2-C1 HH OH-(CH2) -4-Pyr 2-C1 HH OH-(CH2) -Pyzo 2-C1 HH OH -(CH2) -Oxa 2-C1 HH OH-(CH2) -Isox 2-C1 HH OH-(CH2) -Fur 2-C1 HH OH-(CH2) 2-Thi 2-C1 HH OH-(CH2) 2 -2-Pyr 2- C1, HH OH-(CH2) 2-3-Pyr 2-C1 HH OH-(CH2) 2-4-Pyr 2-C1 HH OH-(CH2) 2-Py2〇2-C1 HH OH-(CH2) 2 -〇xa 2-C1 HH OH-(CH2) 2-kox

70- 200401770 2-352 2-C1 HH OH-(CH2) 2-Fur 2-353 2-C1 HH OH-(CH2) rThi 2-354 2-C1 HH OH-(CH2) r2-Pyr 2-355 2 -C1 HH OH-(CH2) 3 each Pyr 2-356 2-C1 HH OH-(CH2) 3-4-Pyr 2-357 2-C1 HH OH-(CH2) 3-Pyzo 2-358 2-C1 HH OH-(CH2) 3-Oxa 2-359 · 2-C1 HH OH-(CH2) 3-Isox 2-360 2-C1 HH OH-(CH2) 3-Fur 2-361 2-C1 HH OH • (CH2 ) 4-Thi 2-362 2-C1 HH OH-(CH2) 4-2-Pyr 2-363 2-C1 HH OH-(CH2) 4-3-Pyr 2-364 2-C1 HH OH-(CH2) 4-4-Pyr 2-365 2-C1 HH OH-(CH2) 4-Pyzo 2-366 2-C1 HH OH-(CH2) 4_〇xa 2-367 2-C1 HH OH-(CH2) 4- Isox 2-368 2-C1 HH OH-(CH2) 4-Fur 2-369 2-FHH OH cPr 2-370 2-FHH OH 2? 2? 3? 3-tetraMe-cPr 2-371 2-FHH OH 2 -Ph-cPr 2-372 2-FHH OH cBu 2-373 2-FHH OH cPn 2-374 2-F -HH OH cHx 2-375 2-FHH OH-(CH2) -cPr 2-376 2-FHH OH -(CH2) -cBu 2-377 2-FHH OH-(CH2) -cPn 2-378 2-FHH OH-(CH2) -cHx 2-3.79 2-FHH OH-(CH2) 2-cPr 2-380 2 -FHH OH-(CH2) 2-cBu 2-381 2-FHH OH-(CH2) 2-cPn • 2-382 2-FHH OH-(CH2) 2-cHx 2-383 2-FHH OH-(CH2) 3-cPr 2-384 2-FH H OH-(CH2) 3-cBu 2-385 2-FHH OH-(CH2) 3-cPn 2-386 2-FHH OH-(CH2) 3-cHx 2-387 2-FHH OH-(CH2) 4-cPr 2-388 2-FHH OH-(CH2) 4-cBu 200401770 2-389 2-390 2-391. 2-392 2-393 2-394 2-395 2-396 2-397 2-398 2 -399 2-400 2-401 2-402 2-403 2-404 2-405 2-406 2-407 2-408 2-409 2-410 2-411 2-412 2-413 2-414 2-415 2-416 2-417 2-418 2-419 2-420 2-421 2-422 2-423 2-424 2-425

2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2- FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2-FHH 2 -FHH 2-FHH 2-FHH 2-FHH OH-(CH2) 4-cPn OH-(CH2) 4-cHx OH Pyrd OH Pip OH OH Azp Azc OH Azn OH Mor OH-(CH2) -Pyrd OH-(CH2 ) -Pip OH-(CH2) -Azp OH-(CH2) -Azc OH-(CH2) -Azn OH-(CH2) -Mor OH-(CH2) 2-Pyrd OH-(CH2) 2-Pip OH-( CH2) 2-Azp OH, (CH2) rAzc OH-(CH2) 2-Azn OH-(CH2) 2 " Μ〇Γ OH-(CH2) 3-Pyrd OH-(CH2) 3-Pip OH-(CH2) 3-Azp OH-(CH2) 3-Azc OH-(CH2) 3-Azn OH-(CH2) 3 " Μ〇Γ OH-(CH2) 4-Pyrd OH-(CH2) 4-Pip OH-(CH2) 4-Azp OH-(CH2) 4-Azc OH-(CH2) 4-Azn OH-(CH2) 4-Mor OH Thi OH 2-Pyr OH 3-Pyr OH 4-Pyr OH Pyzo -72- 200401770 2-426 2-FHH OH Ox a 2-427 2-FHH OH Isox 2-428 2-FHH OH Fur 2-429 2-FHH OH-(CH2) -Thi 2-430 2-FHH OH -(CH2) -2-Pyi 2-431 2-FHH OH-(CH2) -3-Pyr 2-432 2-FHH OH-(CH2) -4 ^ Pyr 2-433 2-FHH OH • (CH2 > Pyzo 2-434 2-FHH OH-(CH2) -Oxa 2-435 2-FHH OH-(CH2) -Isox 2-436 2-FHH OH-(CH2) -Fur 2-437 2-FHH OH-(CH2) 2-Thi 2-438 2-FHH OH-(CH2) 2-2-Pyr 2-439 2-FHH OH-(CH2) 2-3-Pyr 2-440 2-FHH OH-(CH2) 2-4- Pyr 2-441 2-FHH OH-(CH2) 2-Pyzo 2-442 2-FHH OH-(CH2) 2-〇xa 2-443 2-FHH OH-(CH2) 2-Isox 2-444 2-FHH OH-(CH2) 2-Fur 2-445 2-FHH OH-(CH2) 3-Thi 2-446 2-FHH OH-(CH2) 3-2-Pyr 2-447 2-FHH OH-(CH2) 3 -3-Pyr 2-448 2-FHH OH-(CH2) 3-4-Pyr 2-449 2-FHH OH-(CH2) 3-Pyzo 2-450 2-FHH OH-(CH2) 3- Oxa 2- 451 2-FHH OH • (CH2) 3_IS0X 2-452 2-FHH OH-(CH2) 3-Fur 2-453 2-FHH OH-(CH2) 4-Thi 2-454 2-FHH OH-(CH2) 4 -2-Pyr 2-455 2-FHH OH-(CH2) 4-3-Pyr 2-456 2-FHH OH-(CH2) 4-4-Pyr 2-457 2-FHH OH-(CH2) 4-Pyzo 2-458 2-FHH OH-(CH: 2) 4-Oxa 2-459 2-FHH OH-(CH2) 4-Isox 2-460 2-FHH OH-(CH2) 4-Fur 2-461 2-OH HH OH cPr 2-462 2-OH H H. OH 2,2,3,3 -tetiaMe-cPr 200401770 2-463 2-464 2-465 2-466 2-467 2-468 2-469 2-470 2-471 2-472 2-473 2-474 2-475 2-476 2-477 2-478 2-479 2-480 2-481 2-482 .2-483 2-484 2-485 2-486 2-487 2-488 2-489 2-490 2-491 2-492 2-493 2 -494 2-495 2-496 2-497 2-498

2-499 2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

2-OH

H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H. OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH 2-Ph-cPr cBu cPn cHx-(CH2) -cPr-(CH2) -cBu-(CH) cPn -(CH2) -cHx-(CH2) 2-cPr-(CH2) 2-cBu-(CH2) 2-cPn-(CH2) 2-cHx-(CH2) 3-cPr-(CH2) rcBu-(CH2) 3-cPn-(CH2) 3-cHx-(CH2) 4-cPr-(CH2) 4-cBu-(CH2) 4-cPn-(CH2) 4-cHx Pyrd Pip Azp Azc Azn Mor-(CH2) -Pyrd -(CH2) -Pip-(CH2) -Azp-(CH2) -Azc-(CH2) -Azn-(CH2) -Mor-(CH2) rPyrd-(CH2) 2-Pip-(CH2) 2 ~ Azp- (CH2) 2-AzC-(CH2) 2-Azn -74- 200401770

2-500 2-OH 2-501 2-OH 2-502 2-OH 2-503 2-OH 2-504 2-OH 2-505 2-OH 2-506 2-OH 2-507 2-OH 2- 508 2-OH 2-509 2-OH 2-510 2-OH 2-511 2-OH 2-512 2-OH 2-513 2-OH 2-514 2-OH 2-515 2-OH 2-516 2 -OH 2-517 2-OH 2-518 2-OH 2-519 2-OH 2-520 2-OH 2-521 2-OH 2-522 2-OH 2-523 2-OH 2-524 2-OH 2-525 2-OH 2-526 2-OH 2-527 2-OH 2-528 2-OH 2-529 2-OH 2-530 2-OH 2-531 2-OH 2-532 2-OH 2- 533 2-OH 2-534 2-OH 2-535 2-OH 2-536 2-OH

hhhhhhhhhhhhhhh HHHHHHHHHHHHHHHHHHHHHH hhhhhhhhh.hhhhhhhhhhhhhhhhhhhhhhhhhhhh TTTTHgJTTTggggggTTggggtJgJJsggQJJQIJgOTggOTSS.SOHsQJJs -. (CH2) 2 * Μ〇Γ - (CH2) rPyrd - (CH2) 3-Pip - (CH2) 3_Azp - (CH2) 3-Azc - (CH2) 3-Azn - (CH2) 3-Mor-(CH2) 4-Pyrd-(CH2) 4-Pip-(CH2) 4-Azp-(CH2) 4 * -AzC-(CH2) 4-Azn-(CH2) 4-Mor Thi 2- Pyr 3- Pyr. 4- Pyr Pyzo Oxa Isox Fur-(CH2) -Thi • (CH2) -2-Pyr-(CH2) -3-Pyr-(CH2) -4-Pyr-(CH2) -Pyzo -(CH2) -Oxa-(CH2) -Isox-(CH2) -Fur • (CH2) 2-Thi-(CH2) 2-2-Pyr-(CH2) 2-3-Pyr-(CH2) 2-4 -Pyr-(CH2) 2-Pyzo-(CH2) 2-〇xa-(CH2) 2-Isox-(CH2) 2-Fur -75- 200401770

2-537 2 > OH HH OH-(CH2) 3-Thi 2-538 2-OH HH OH-(CH2) 3-2-Pyr 2-539 2-〇HHH OH-(CH2) 3-3-Pyr 2 -540 2-OH HH OH-(CH?) 3 ~ 4-Pyr 2-541 2-OH HH OH-(CH2) 3-Pyzo 2-542 2-OH HH OH-(CH2) 3_Oxa 2-543 2- OH HH OH-(CH2) 3-Isox 2-544 2-OH HH OH-(CH2) 3-Fur 2-545 2-OH TT H OH _ (CH2) 4-Thi 2-546 2-OH HH OH- (CH2) 4-2-Pyr 2-547 2-OH HH OH-(CH2) 4-3-Pyr 2-548 2-OH HH OH-(CH2) 4-4-Pyr 2-549 2-OH HH OH -(CH2) 4-Pyz〇2-550 2-OH HH OH-(CH2) 4-Oxa 2-551 2-OH HH OH-(CH2) 4-Is〇X 2-552 2-OH HH OH-( CH2) 4-Fur 2-553 2-OMe HH OH cPr 2-554 2-OMe HH OH 2,2,3,3-tetraMe-cPr 2-555 2-OMe * HH OH 2-Ph-cPr 2-556 2-OMe HH OH cBu 2-557 2-OMe. HH OH cPn 2-558 2-OMe HH OH cHx 2-559 2-OMe HH OH-(CH2) -cPr 2-560 2-OMe HH OH-(CH2 ) -cBu 2-561 2-OMe HH OH-(CH2) -cPn 2-562 2-OMe HH OH-(CH2) -cHx 2-563 2-OMe HH OH-(CH2) 2-cPr 2-564 2 -OMe HH OH-(CH2) 2-cBu 2-565 2-OMe HH OH-(CH2) 2-cPn 2-566 2-OMe HH OH-(CH2) 2-cHx 2-567 2-OMe HH OH- (CH2) 3-cPr 2-568 2-OMe HH OH-(CH2) 3-cBu 2-569 2-OMe HH OH-(CH2) 3-cPn 2-570 2-OMe HH OH-(CH2) 3-cHx 2-571 2-OMe HH OH-(CH2) 4-cPr 2- 572 2-OMe HH OH-(CH2) 4-cBu 2-573 2-OMe HH OH-(CH2) 4-cPn -76- 200401770

2-574 2-OMe HH OH-(CH2) 4-cHx 2-575 2-OMe HH OH Pyrd 2-576 2-OMe HH OH Pip 2-577 2-OMe HH OH Azp Azc 2-578 2-OMe HH OH 2-579 2-OMe HH OH Azn 2-580 2-OMe HH, OH Mor 2-581 2-OMe HH OH-(CH2) -Pyrd 2-582 2-OMe HH OH-(CH2) -Pip 2- 583 2-OMe HH OH-(CH2) -Azp 2-584 2-OMe HH OH-(CH2) -Azc 2-585 2-OMe HH OH-(CH2) -Azn 2-586 2-OMe HH OH-( CH2) -Mor 2-587 2-OMe HH OH-(CH2) 2-Pyrd 2-588 2-OMe HH OH-(CH2) 2-Pip 2-589 2-OMe HH OH-(CH2) 2-590 2 -OMe HH OH _ (CH2) 2-Azc 2-591 2-OMe HH OH-(CH2) 2-592 2-OMe HH OH-(CH2) 2-Mor 2-593 2-OMe HH OH-(CH2) 3-Pyrd 2-594 2-OMe HH OH-(CH2) 3-Pip 2-595 2-OMe HH OH-(CH2) 3 ~ Azp 2-596 2-OMe HH OH-(CH2) 3-Azc 2- 597 2-OMe HH OH-(CH2) 3-Azn 2-598 2-OMe HH OH-(CH2) 3-Mor 2-599 2-OMe HH OH-(CH2) 4-Pyrd 2-600 2-OMe HH OH-(CH2) 4-Pip 2-601. 2-OMe HH OH-(CH2) 4-Azp 2-602 2-OMe HH OH-(CH2) 4-Azc 2-603 2-OMe HH OH-(CH2 ) 4-Azn 2-604 2-OMe HH OH-(CH2) 4-Mor 2-605 2-OMe HH OH Thi 2-606 2-OMe HH OH 2-Pyr 2-6 07 2-OMe HH OH 3-Pyr 2-608 2-OMe HH OH 4-Pyr 2-609 2-OMe HH OH Pyzo 2-610 2-OMe HH OH Oxa -77- 200401770 2-611 2-OMe HH OH Isox 2-612 2 * OMe HH OH Fur 2-613 2-OMe HH OH-(CH2) -Thi 2-614 2-OMe HH OH-(CH2) -2-Pyr 2-615 2-OMe HH OH-( CH2) -3-Pyr 2-616 2-OMe HH OH-(CH2) -4-Pyr 2-617 2-OMe HH OH-(CH2) -Pyzo 2-618 2-OMe HH OH-(CH2) -Oxa 2-619 2-OMe HH OH-(CH2) -Isox 2-620 2-OMe HH OH-(CH2) -Fur 2-621 2-OMe HH OH-(CH2) 2-Thi 2-622 2-OMe HH OH-(CH2) 2-2-Pyr 2-623 2-OMe HH OH-(CH2) 2-3-Pyr 2-624 · 2-OMe HH OH-(CH2) 2-4-Pyr 2-625 2- OMe HH OH-(CH2) 2-Pyz〇2-626 2-OMe HH OH-(CH2) 2-〇xa 2-627 2-OMe HH OH-(CH2) 2-Isox 2-628 2-OMe HH OH -(CH2) 2-Fur 2-629 2-OMe HH OH-(CH2) 3-Thi 2-630 2-OMe HH OH-(CH2) 3-2-Pyr 2-631 2-OMe HH OH-(CH2 ) 3-3-Pyr 2-632 2-OMe HH OH-(CH2) 3-4-Pyr 2-633 2-OMe HH OH-(CH2) 3-Pyzo 2-634 2-OMe HH OH-(CH2) 3-Oxa 2-635 2-OMe HH OH-(CH2) 3-Is〇X 2-636 2-OMe HH OH-(CH2) 3-Fur 2-637 2-OMe HH. OH-(CH2) 4- Thi 2-638 2-OMe HH OH-(CH2) 4-2-Pyr 2-639 2-OMe HH OH-(CH2) 4-3-Pyr 2-640 2-OMe HH OH-(CH2) 4-4-Pyr 2-641 2- OMe HH OH-(CH2) 4-Pyz〇2-642 2-OMe HH OH-(CH2) 4-Oxa 2-643 2-OMe HH OH-(CH2) 4-Is〇X 2-644 2-OMe HH OH-(CH2) 4-Fur 2-645 2-AcNH HH OH cPr 2-646 2-AcNH HH OH 252? 353-tetraMe-cPx 2-647 2-AcNH HH OH 2-Ph-cPr -78- 200401770 2 -648 2-AcNH HH OH cBu 2-649 2-AcNH HH OH cPn 2-650 2-AcNH HH OH cHx 2-651 2-AcNH HH OH-(CH2) -cPr 2-652 2-AcNH HH OH-( CH2) -cBu 2-653 2-AcNH HH OH-(CH2) -cPn 2-654 2-AcNH HH OH-(CH2) -cHx 2-655 2-AcNH HH OH-(CH2) 2-cPr 2-656 2-AcNH HH OH-(CH2) 2_cJb5u 2-657 2-AcNH HH OH-(CH2) 2_cPn 2-658 2-AcNH HH OH-(CH2) 2-cHx 2-659 2-AcNH HH OH-(CH2) 3-cPr 2-660 2-AcNH HH OH-(CH2) 3 ~ cBu 2-661 2-AcNH HH OH-(CH2) 3-cpn 2-662 2-AcNH HH OH-(CH2) 3-cHx 2- 663 2-AcNH HH OH-(CH2) 4-cPr 2-664 2-AcNH HH OH-(CH2) 4_cBu 2-665 2-AcNH HH OH-(CH2) 4-cPn 2-666 2-AcNH HH OH- (CH2) 4cHx 2-667 2-AcNH HH OH Pyrd 2-668 2-AcNH HH OH Pip 2-669 2-Ac NH HH OH Azp Azc 2-670 2-AcNH HH OH 2-671 2-AcNH ... HH OH Azn 2-672 2-AcNH HH OH Mor 2-673 2-AcNH. HH OH-(CH2) -Pyrd 2 -674 2-AcNH HH OH-(CH2) -Pip. 2-675 2-AcNH HH OH-(CH2) -Azp 2-676 2-AcNH HH OH-(CH2) -Azc 2-677 2-AcNH HH OH -(CH2) -Azn 2-678 2-AcNH HH OH-(CH2) -Mor 2-679 2-AcNH HH OH-(CH2) 2-Pyrd 2-680 2-AcNH HH OH-(CH2) 2-Pip 2-681 2-AcNH HH OH `` (CH2) 2-Azp 2-682 2-AcNH HH OH-(CH2) rAzc 2-683 2-AcNH HH OH-(CH2) 2-Azn 2-684 2-AcNH HH OH-(CH2) 2 ~ Μ〇Γ 79- 200401770 2-685 2-AcNH HH OH-(CH2) 3-Pyrd 2-686 2-AcNH HH OH-(CH2) 3-Pip 2-687 2-AcNH HH OH-(CH2) 3 ~ Azp 2-688 2-AcNH HH OH-(CH2) 3-Azc 2-689 2-AcNH HH OH-(CH2) 3-A2n 2-690 2-AcNH HH OH-(CH2) 3 ~ Μ [〇Γ 2-691 2-AcNH HH OH-(CH2) 4-Pyrd 2-692 2-AcNH HH OH-(CH2) 4-Pip 2-693 2-AcNH HK OH-(CH2) 4- A ^ p 2-694 2-AcNH HH OH-(CH9) 4 ~ AZC 2-695 2-AcNH HH OH-(CH2) 4-Azn 2-696 2-AcNH HH OH-(CH2) 4-Mor 2- 697 2-AcNH HH OH Thi 2-698 2-AcNH HH OH 2-Pyr 2-699 2-AcNH HH OH 3-Pyr 2-700 2-AcNH HH OH 4-Pyr 2-701 2-AcNH HH OH Pyzo 2-702 2-AcNH HH OH Oxa 2-703 2-AcNH HH OH. Isox 2-704 2-AcNH HH OH Fur 2- 705 2-AcNH HH OH • (CH2) -Thi 2-706 2-AcNH HH OH-(CH2) -2-Pyr 2-707 2-AcNH HH OH-(CH2) -3-Pyr 2-708 2-AcNH HH OH-(CH2) -4-Pyr 2-709 2-AcNH HH OH-(CH2) -Pyzo 2-710 2-AcNH HH OH-(CH2) -Oxa 2-711 2-AcNH HH OH-(CH2) -Isox .2-712 2-AcNH HH OH-(CH2) -Fur 2-713 2-AcNH HH OH-(CH2) 2-Thi 2-714 2-AcNH HH OH-(CH2) 2-2-Pyr 2 -715 2-AcNH HH OH-(CH2) 2-3-Pyr 2-716 2-AcNH HH OH-(CH2) 2-4-Pyr 2-717 2-AcNH HH OH-(CH2) 2-Pyzo 2- 718 2-AcNH HH OH-(CH2) r〇xa 2-719 2-AcNH HH OH-(CH2) 2-Isox 2-720 2-AcNH HH OH-(CH2) 2-Fur 2-721 2-AcNH HH OH-(CH2) 3-Thi

-80- 200401770 2-722 2-AcNH HH OH-(CH2) 3-2-Pyr 2-723 2-AcNH HH OH-(CH2) 3-3-Pyr 2-724 2-AcNH HH, OH-(CH2 ) 3-4-Pyr 2-725 2-AcNH HH OH-(CH2) 3-Pyzo 2-726 2-AcNH HH OH-(CH2) 3-Oxa 2-727 2-AcNH HH OH-(CH2) 3- Isox 2-728 2-AcNH HH OH _ (CH2) 3_Flir 2-729 2-AcNH HH OH-(CH2) 4-Thi 2-730 2-AcNH HH OH-(CH2) 4-2-Pyr 2-731 2 -AcNH HH OH-(CH2) 4-3-Pyr 2-732 2-AcNH HH OH-(CH2) 4-4-Pyr 2-733 2-AcNH HH OH-(CH2) 4-Pyz〇2-734 2 -AcNH HH OH-(CH2) 4-〇xa 2-735 2-AcNH HH OH-(CH2) 4-Isox 2-736 2-AcNH HH OH-(CH: 2) 4-Fur 2-737 2-OMe 3-OMe H OH cPr 2-738 2-OMe 3-OMe H OH 2,2,3,3-tetraMe-cPr 2-739 2-OMe 3-OMe H OH 2-Ph-cPr 2-740 2-OMe 3-OMe H OH cBu 2-741 2-OMe 3-OMe H OH cPn 2-742 2-OMe 3-OMe H OH cHx 2-743 2-OMe 3-OMe H OH-(CH2) -cPr 2-744 2-OMe 3-OMe H OH • (CH2) -cBu 2-745 2-OMe 3-OMe H OH-(CH2) -cPn 2-746 2-OMe 3-OMe H OH-(CH2) -cHx 2- 747 2-OMe 3-OMe H OH-(CH2) 2-cPr 2-748 2-OMe 3-OMe H OH-(CH2) 2-cBu 2-749 2-OMe 3-OMe H OH-(CH2) 2 -cPn 2-750 2-OMe 3-OMe H OH -(CH2) 2-cHx 2-751 2-OMe 3-OMe H OH-(CH2) rcPr 2-752 2-OMe 3-OMe H OH-(CH2) 3-cBu 2-753 2-OMe 3-OMe H OH-(CH2) 3-cPn 2-754 2-OMe 3-OMe H OH-(CH2) 3-cHx 2-755 2-OMe 3-OMe H OH-(CH2) 4-cPr 2-756 2- OMe 3-OMe H OH-(CH2) 4-cBu 2-757 2-OMe 3 > OMe H OH-(CH2) 4-cPn 2-758 2-OMe 3-OMe H OH-(CH2) 4-cHx 81 200401770 2-759 2-OMe 3-OMe H OH Pyrd 2-760 2-OMe 3-OMe H OH Pip 2-761 2-OMe 3-OMe H OH Azp Azc 2-762 2-OMe 3-OMe H OH 2 -763 2-OMe 3-OMe H OH Azn 2-764 2-OMe 3-OMe H OH Mor 2-765 2-OMe 3-OMe H OH-(CH2) -Pyrd 2-766 2-OMe 3-OMe H OH-(CH2) -Pip 2-767 2-OMe 3-uMe H OH • (CH2) -Azp 2-768 2-OMe 3-OMe H OH-(CH2) -Azc 2-769 2-OMe 3-OMe H OH-(CH2) -Azn 2-770 2-OMe 3-OMe H OH-(CH2) -Mor 2-771 2-OMe 3-OMe H OH-(CH2) 2-Pyrd 2-772 2-OMe 3 -OMe H OH-(CH2) 2-Pip 2-773 2-OMe 3-OMe H OH-(CH2) 2-Azp 2-774 2-OMe 3-OMe H OH-(CH2) 2-Azc 2-775 2-OMe 3-OMe H OH-(CH2) 2-Azn 2-776 2-OMe 3-OMe H OH-(CH2) 2 ~ Μ〇Γ 2-777 2-OMe 3-OMe H OH, (CH2) 3-Pyid 2-778 2-OMe 3-OMe H OH-(CH2) 3-Pip 2 -779 2-OMe 3-OMe H OH-(CH2) 3 ~ Azp 2-780 2-OMe 3-OMe H OH-(CH2) 3-Azc 2-781 2-OMe 3-OMe H OH-(CH2) 3-Azn 2-782 2-OMe 3-OMe H OH-(CH2) 3-Mor 2-783 2-OMe 3-OMe H OH-(CH2) 4-Pyrd 2-784 2-OMe 3-OMe H • OH-(CH2) 4-Pip 2-785 2-OMe 3-OMe H OH-(CH2) 4-Azp 2-786 2-OMe 3-OMe H OH-(CH2) 4-Azc 2-787 2-OMe * 3-OMe H OH-(CH2) 4 ~ Azn 2-788 2-OMe 3-OMe H OH-(CH2) 4-Mor 2-789 2-OMe 3-OMe H OH Thi 2-790 2-OMe 3 -OMe H OH 2-Pyr 2-791 2-OMe 3-OMe H OH 3-Pyx 2-792 2-OMe 3-OMe H OH 4-Pyr 2-793 2-OMe 3-OMe H OH Pyzo 2-794 2-OMe 3-OMe H OH 〇xa 2-795 2 > OMe 3-OMe H OH Isox 82 200401770

2-796 2-OMe 3-OMe H 2-797 2-OMe 3-OMe H 2-798 2-OMe 3-OMe H 2-799 2-OMe 3-OMe H 2-800 2-OMe 3-OMe H 2-801 2-OMe 3-OMe H 2-8022-OMe 3-OMe H 2-803 2-OMe 3-OMe H 2-804 2-OMe 3-OMe H 2-805 2-OMe 3-OMe H 2-806 2-OMe 3-OMe H 2-807 2-OMe 3-OMe H 2-808 2-OMe 3-OMe H 2-809 2-OMe 3-OMe H 2-810 2-OMe 3-OMe H 2-811 2-OMe 3-OMe H 2-812 2-OMe 3-OMe H 2-813 2-OMe 3-OMe H 2-814 2-OMe 3-OMe H 2-815 2-OMe 3-OMe H 2-816 2-OMe 3-OMe H 2-817 2-OMe 3-OMe H 2-818 2-OMe 3-OMe H 2-819 2-OMe 3-OMe H 2-820 2-OMe 3-OMe H 2-821 2-OMe 3-OMe H 2-822 2-OMe 3-OMe H 2-823 2-OMe 3-OMe H 2-824 2-OMe 3-OMe H 2-825 2-OMe 3-OMe H 2-826 2-OMe 3-OMe H 2-827 2-OMe 3-OMe H 2-828 2-OMe 3-OMe H 2-829 2,3-Mtdo H 2-830 2,3-Mtdo H 2 -831 2,3-Mtdo H 2-832 2,3-Mtdo H ohohohohohohohohohohohohohohohohohohohohohohohohohohohohohoho

Fut-(CH2) -Thi-(CH2) -2-Pyr-(CH2) -3-Pyr-(CH2) -4-Pyr-(CH2) -Pyzo-(CH2) -〇xa-(CH2) -Isox -(CH2) -Fur-(CH2) 2-Thi-(CH2) 2-2-Pyr-(CH2) 2-3-Pyr-(CH2) 2-4-Pyr-(CH2) 2-Pyzo-(CH2 ) 2-〇xa-(CH2) 2-Isox-(CH2) 2-Fur-(CH2) 3-Thi-(CH2) 3-2-Pyr. (CH2) 3-3-Pyr-(CH2) 3- 4.Pyr-(CH2) 3-Pyzo-(CH2) 3-Oxa

** (CH2) 3-Is〇X • (CH2) Female Fur-(CH2) 4-Thi-(CH2) 4-2-Pyr-(CH2) 4-3-Pyr-(CH2) 4-4-Pyr -(CH2) 4-Pyz〇-Ox 21-(CH2) 4-Isox-(CH2) 4-Fur cPr 2,2,3,3-tetraMe-cPr 2-Ph-cPi cBu 83- 200401770

2-833 233-Mtdo H OH cPn 2-834 2,3-Mtdo H OH cHx 2-835 2,3-Mtdo H OH-(CH2) -cPr 2-836 2,3-Mtdo H OH-(CH2) -cBu 2-837 253-Mtdo H OH-(CH2) -cPn 2-838 2; 3-Mtdo H OH-(CH2) -cHx 2-839 2,3-Mtdo H OH-(CH2) 2-cPr 2 -840 2,3-Mtdo H OH-(CH2) 2-cBu 2-841 2,3-Mtdo .H OH-(CH2) 2-cPn 2-842 2,3-Mtdo H OH-(CH2) rcHx 2 -843 2,3-Mtdo H OH-(CH2) 3-cPr 2-844 2,3-Mtdo H OH-(CH2) 3 ~ cBu 2-845 2,3-Mtdo H OH-(CH2) 3 ~ cPll 2-846 2,3-Nitdo H OH _ (CH2) rcHx 2-847 2,3-Mtdo H OH-(CH2) 4-cPr 2-848 2,3-Mtdo H OH-(CH2) 4 ~ cBu 2 -849 2,3-Mtdo H OH-(CH2) 4-cPn 2-850 2,3-Mtdo H OH-(CH2) 4-cHx 2-851 233-Mtdo H OH Pyrd 2-852 2,3-Mtdo H OH Pip 2-853 2,3-Mtdo H OH Azp Azc 2-854 2,3-Mtdo H OH 2-855 2,3-Mtdo H OH Azn 2-856 2,3-Mtdo H OH Mor 2-857 2,3-Mtdo H OH-(CH2) -Pyrd 2-858 2,3-Mtdo H OH *-(CH2) -Pip 2-859 2,3-Mtdo H OH-(CH2) -Azp 2-860 2 , 3-Mtdo H OH-(CH2) -Azc 2-861 2,3-Mtdo H OH-(CH2) -Azn 2-862 2,3-Mtdo H OH-(CH2) -Mor 2-863 2,3 -Mtdo H OH-(CH2) rPyrd 2-864 2,3-Mtdo H OH-(CH2) 2-Pip 2-865 2,3 -Mtdo H OH-(CH?) 2 " Ά ^, ρ 2-866 2,3-Mtdo H OH-(CH2) 2-^^ C 2-867 2,3-Mtdo H OH-(CH〇)? -Azn 2-868 -2,3-Mtdo H OH-(CH2) 2-Mor 2-869 2,3-Mtdo H OH «(CH2) 3-Pyrd 84 200401770 2-870 2,3-Mtdo H OH- (CH2) 3-Pip 2-871 2,3-Mtdo H OH-(CH2) 3-Azp 2-872 2,3-Mtdo H OH-(CH2) 3-Azc 2-873 2,3-Mtdo H OH -(CH2) 3-Azn 2-874 2,3-Mtdo H OH-(CH2) 3-Μ0Γ 2-875 2,3-Mtdo H OH-(CH2) 4-Pyrd 2-876 2,3-Mtdo H OH-(CH2) 4-Pip 2-877 2,3-Mtdo · H OH-(CH2) 4-Azp 2-878 2,3-Mtdo H OH-(CH2) 4 ~ AzC 2-879 2,3- Mtdo H OH-(CH2) 4 ~ Azn 2-880 2,3-Mtdo H OH-(CH2) 4-Mor 2-881 2,3-Mtdo H OH Thi 2-882 2,3-Mtdo H OH 2- Pyr 2-883 2,3-Mtdo H OH 3-Pyr 2-884 2,3-Mtdo H OH 4-Pyr 2-885 2,3-Mtdo H OH Pyzo 2-886 2,3-Mtdo H OH Oxa 2 -887 2,3-Mtdo H OH Isox 2-888 2,3-Mtdo H OH Fur 2-889 • 253-Mtdo H OH-(CH2) -Thi 2-890 2,3-Mtdo H OH-(CH2) -2-Pyr 2-891 2,3-Mtdo H OH • (CH2) -3-Pyr 2-892 2,3-Mtdo H OH-(CH2) -4-Pyr 2-893 2,3-Mtdo H OH -(CH2) -Pyzo 2-894 2,3-Mtdo H OH-(CH2) -Oxa 2-895 2,3-Mtdo H OH-(CH2) -Isox 2-896 2,3-Mtdo H OH-(CH2) -Fur 2-897 2,3-Mtdo H OH-(CH2) 2-Thi 2-898 2,3-Mtdo H OH-(CH2) 2 -2-Pyr 2-899 2,3-Mtdo H OH-(CH2) 2-3-Pyr 2-900 2,3-Kltdo H OH _ (CH2) 2-4-Pyr 2-901 2,3-Mtdo H OH-(CH2) 2-Pyzo 2-902 2,3-Mtdo H OH-(CH2) 2-〇xa 2-903 2,3-Mtdo H OH-(CH2) 2-Isox 2-904 2,3 -Mtdo H OH-(CH2) 2-Fur 2-905 2,3-Mtdo H OH-(CH2) rThi 2-906 2,3-Mtdo H OH-(CH2) 3-2-Pyr -85- 200401770

2-907 2? 3-Mtdo H OH-(CH2) 3-3-Pyr 2-908 2? 3-Mtdo H OH-(CH2) 3-4-Pyr 2-909 2,3-Mtdo H OH-( CH2) 3-Pyz〇2-910 2,3-Mtdo H OH-(CH2) 3-〇xa 2-911 2,3-Mtdo H OH-(CH2) 3-Isox 2-912 2,3-Mtdo H OH-(CH2) 3-Fur 2-913 2? 3-Mtdo H OH-(CH2) 4-Thi 2-914 2,3-Mtdo H OH-(CH2) 4-2-Pyr 2-915 2,3 -Mtdo H OH-(CH2) 4-3-Pyr 2-916 2,3-Mtdo H OH-(CH2) 4-4-Pyr 2-917 2,3-Mtdo H OH-(CH2) 4-Pyz〇 2-918 2,3-Mtdo H OH-(CH2) 4- Oxa 2-919 2,3-Mtdo H OH-(CH2) 4-Isox 2-920 2,3-Mtdo H OH-(CH2) 4- Fur 2-921 1-C1 2-C1 3-C1 OH cPr 2-922 1-C1 2-C1 3-C1 OH 2,2,3,3-tetraMe-cPr 2-923 1-C1 2-C1 3- C1 OH 2-Ph-cPr 2-924 1-C1 2-C1 3-C1 OH cBu 2-925 1-C1 2-C1 3-C1 OH cPn 2-926 1-C1 2-C1 3-C1 OH cHx 2 -927 1-C1 2-C1 3-C1 OH-(CH2) -cPr 2-928 1-C1 2-C1 3-C1 OH-(CH2) -cBu 2-929 1-C1 2-C1 3-C1 OH -(CH2) -cPn 2-930 1-C1 2-C1 3-C1 OH-(CH2) -cHx 2-931 1-C1 2-C1 3-C1 OH-(CH2) 2-cPr 2-932 1- C1 2-C1 3-C1 OH-(CH2) 2 ** cBu 2-933 1-C1 2-C1 3-C1 OH-(CH2) 2-cPn 2-934 1-C1 2-C1 3-C1 OH- (CH2) rcHx 2-935 1-C1 2- C1 3-C1 OH-(CH2) 3-cPr 2-936 1-C1 2-C1 3-C1 OH-(CH2) 3-cBu 2-937 1-C1 2-C1 3-C1 OH-(CH2) 3_cPn 2-938 1-C1 2-C1 3-C1 OH-(CH2) 3-cHx 2-939 1-C1 2-C1 3-C1 OH-(CH2) 4-cPr 2-940 1-C1 2-C1 3 -C1 OH-(CH2) 4-cBu 2-941 1-C1 2-C1 3-C1 OH-(CH2) 4-cPn 2-942 1-C1 2-C1 3-C1 OH-(CH2) 4-cHx 2-943 1-C1 2-C1 3-C1 OH Pyrd -86- 200401770

2-944 1-C1 2-C1 3-C1 OH Pip 2-945 1-C1 2-C1 1 3-C1 OH Azp Azc 2-946 1-C1 2-C1 3-C1 OH 2-947 1-C1 2 -C1 3-C1 OH Azn 2-948 1-C1 2-C1 3-C1 .OH Mor 2-949 1-C1 2-C1 3-C1 OH-(CH2) -Pyrd 2-950 1-C1 2-C1 3-C1 OH-(CH2) -Pip 2-951 1-C1 2-C1 3-C1 OH-(CH2) -Azp 2-952 1-C1 2-C1 3-C1 OH-(CH2) -Azc 2- 953 1-C1 2-C1 3-C1 OH-(CH2) -Azn 2-954 1-C1 2-C1 3-C1 OH-(CH2) -Mor 2-955 1-C1 2-C1 3-C1 OH- (CH2) 2-Pyrd 2-956 1-C1 2-C1. 3-C1 OH-(CH2) 2-Pip 2-957 1-C1 • 2-C1 3-C1 OH-(CH2) 2-Azp 2- 958 1-C1 2-C1 3-C1 OH-(CH2) 2-Azc 2-959 1-C1 2-C1 3-C1 OH-(CH2) 2-Azn 2-960 1-C1 2-C1 3-C1 OH-(CH2) 2 ~ Μ〇Γ 2-961 1-C1 2-C1 3-C1 OH-(CH2) 3-Pyrd 2-962 1-C1 2-C1 3-C1 OH-(CH2) 3-Pip 2-963 1-C1 2-C1 3-C1 OH-(CH2) 3-Azp 2-964 1-C1 2-C1 3-C1 OH-(CH2) rAzc 2-965 1-C1 2-C1 3-C1 OH-(CH2) 3-Azn 2-966 1-C1 2-C1 3-C1 OH-(CH〗) 3 ** M! Or 2-967 1-C1 2-C1 3-C1 OH .- (CH2) 4-Pyrd 2-968 1-C1 2-C1 3 * C1 OH-(CH2) 4-Pip 2-969 1-C1 2-C1 3-C1 OH-(CH2) 4-Azp 2-970 1-C1 2 -C1 3-C1 OH-(CH2) 4-Azc 2-971 1-C1 2-C1 3-C1 OH-(CH2) 4-Azn 2-972 1-C1 2-C1 3-C1 OH-(CH2) 4-Mor 2-973 1-C1 2-C1 3-C1 OH Thi 2-974 1- C1 '2-C1 3-C1 OH 2-Pyr 2-975 1-C1 2-C1 3-C1 OH 3-Pyr 2-976 1-C1 2-C1 3-C1 OH 4-Pyr 2-977 1-C1 2-C1 3-C1 OH Pyzo 2-978 1-C1 2-C1 3-C1 OH 〇xa 2-979 1-C1 2-C1 3-C1 OH Isox 2-980 1-C1 2-C1 3-C1 OH Fur -87- 200401770 2-981 1-C1 2-C1 3-C1 OH-(CH2) -Thi 2-982 1-C1 2-C1 3-C1 OH-(CH2) -2-Pyr 2-983 1- C1 2-C1 3-C1 OH-(CH2) -3-Pyr 2-984 1-C1 2-C1 3-C1 OH-(CH2) -4-Pyr 2-985 1-C1 2-C1 3-C1 OH -(CH2) -Pyzo 2-986 1-C1 2-C1 3-C1 OH-(CH2) -Oxa 2-987 1-C1 2-C1 3-C1 · OH-(CH2) -Isox 2-988 1- C1 2-C1 3-C1 OH-(CH2) -Fur 2-989 i-ci 2-C1 3-C1 OH-(CH2) 2-Thi 2-990 1-C1 2-C1 3-C1 OH-(CH2 ) 2-2-Pyr 2-991 1-C1 2-C1 3-C1 OH-(CH2) 2-3-Pyr 2-992 1-C1 2-C1 3-C1 OH-(CH2) 2-4-Pyr 2-993 1-C1 2-C1 3-C1 OH-(CH2) 2-Pyzo 2-994 1-C1 2-C1 3-C1 OH-(CH2) 2-〇xa 2-995 1-C1 2-C1 3-C1 OH-(CH2) 2-Isox 2-996 1-C1 2-C1 3-C1 OH-(CH2) 2-Fur 2-997 1-C1 2-C1 3-C1 OH-(CH2) 3- Thi 2-998 1-C1 2-C1 3-C1 OH-(CH2) 3-2-Pyr 2-9 99 1-C1 2-C1 3-C1 OH-(CH2) 3-3-Pyr 2-1000 1-C1 2-C1 3-C1 OH-(CH2) 3-4-Pyr 2-1001 1-C1 2- C1 3-C1 OH-(CH2) 3-Pyzo 2-1002 1-C1 2-C1 3-C1 OH-(CH2) 3-〇xa 2-1003 1-C1 2-C1 3-C1 OH-(CH2) 3-Isox 2-1004 1-C1 2-C1 3-C1 OH-(CH2) 3-Fur 2-1005 1-C1 2-C1 3-C1 OH-(CH2) 4-Thi 2-1006 1-C1 2 -C1 3-C1 OH-(CH2) 4-2-Pyr 2-1007 1-C1 2-C1 3-C1 OH-(CH2) 4-3-Pyr 2-1008 1-C1 2-C1 3-C1 OH -(CH2) 4-4-Pyr 2-1009 1-C1 2-C1 3-C1 OH-(CH2) 4-Pyzo 2-1010 1: C1 2-C1 3-C1 OH-(CH2) 4-〇xa 2-1011 1-C1 2-C1 3-C1 OH-(CH2) 4-Isox 2-1012 1-C1 2-C1 3-C1 OH-(CH2) 4-F \ it -88- 200401770

Exemp. R1 Comp. No. R2 R3 XY 3-1 HHHH Bz 3-2 HHH OMe Bz 3-3 HHH 〇Tfm Bz 3-4 HHH OH Ph 3-5 HHH OH 1-Nap 3-6 HHH OH 2-Nap 3-7 HHH OH Bz 3-8 HHH OH -CH (Me) -Ph 3-9 HHH OH -CH (NH2) -Ph 3-10 HHH OH -CH (NHMe) -Ph 3-11 HHH OH -CF2- Ph 3-12 HHH OH -CH (OH) -Ph 3-13 HHH OH -CH (OMe) -Ph 3-14 HHH OH-(CH2) -1-Nap 3-15 HHH OH-(CH2) -2- Nap 3-16 HHH OH-(CH2) 2-Ph 3-17 HHH OH-(CHPh)-(CH2) -Ph 3-18 HHH OH-(CH2) rl-Nap 3-19 HHH OH-(CH2) 2 -2-Nap 3-20 HHH OH-(CH2) 3-Ph 3-21 HHH OH-(CH2) rl-Nap 3-22 HHH OH • (CH2) r2-Nap 3-23 HHH OH-(CH2) 4 -Ph 3-24 HHH .OH-(ΟΗ2) 4-1-ΝηΡ -89- 200401770

3-25 Η Η Ο Η-(CH2) 4-2-Nap 3-26 Η Η Η ΟΗ -CH2-2-Me-Ph 3-27. Η Η Η ΟΗ -CH2-3-Me-Ph 3-28 Η Η Η ΟΗ -CH2-4-Me-Ph 3-29 Η Η Η ΟΗ -CH2-2-Br-Ph 3-30 Η Η Η ΟΗ -CH2-3-Br-Ph 3-31 Η Η Η ΟΗ- CH2-4-Br-Ph 3-32 Η Η Η Η CH -CH2-2-Cl-Ph 3-33 Η Η Η Η Η -CH2-3-Cl-Ph 3-34 Η Η Η Η CH -CH2-4-Cl -Ph 3-35 Η Η Ο Η -CH2-2-F-Ph 3-36 Η Η Η ΟΗ -CH2-3-F-Ph 3-37 Η Η Η Η -CH2-4-F-Ph 3-38 Η Η Η ΟΗ -CH2-2-Tfm-Ph 3-39 Η Η Η Ο Η -CH2-3-Tfm-Ph 3-40 Η Η Η Η CH CH CH CH CH CH CH Η Ο Η- CH2-2-OH-Ph 3-42 Η Η Ο Η -CH2-3-OH-Ph 3-43. Η Η Η Ο Η -CH2-4-OH-Ph 3-44 Η Η Η Η CH -CH2-2- OMe-Ph 3-45 Η Η Η Η CH -CH2-3-OMe-Ph 3-46 Η Η Η Η Η -CH2-4-OMe-Ph 3-47 Η Η Η Η CH -CH2-2-N〇2-Ph 3-48 Η Η Η Η CH -CH2-3-N02-Ph 3-49 Η Η CH Η Η CH -CH2-4-N02-Ph 3-50 Η Η Η CH CH -CH2-2-Et-Ph 3-51 Η Η Η ΟΗ -CHr3-Et-Ph 3-52 Η Η Η Ο Η -CH2-4-Et-Ph 3-53 Η Η Η ΟΗ -CH2-2-iPr-Ph 3-54 Η Η Η Ο Η -CH2-3- iPr- Ph 3-55 Η Η Η Η CH -CHr4-iPr-Ph 3-56 Η Η Η Η Η -CH2-2-CN-Ph 3-57 Η Η Η Η CH CH CH CH Η Η ΟΗ ^ CH2-4-CN-Ph 3-59. Η Η Η ΟΗ -CH2-2-NH2-Ph 3-60 Η Η Η ΟΗ -CH2-3-NH2-Ph 3-61 Η Η Η ΟΗ -CH2- 4-NH2-Ph > 90- 200401770 3-62 Η Η Η ΟΗ -CHr2-SMe-Ph 3-63 Η Η Η 〇Η -CH2-3-SMe-Ph 3-64 Η Η Η ΟΗ -CH2-4 -SMe-Ph 3-65 Η Η Η ΟΗ -CH2-4-NHMe-Ph 3-66 Η Η Η ΟΗ -CH2-4-NMe2-Ph 3-67 Η Η Η Η CH -CH2-4-SOMe-Ph 3 -68 Η Η Ο Η -CH2-4-S02Me-Ph 3-69 Η Η Η ΟΗ -CH2-4-AcNH-Ph 3-70 Η Η Η CH CH CH CH CH CH Η Η ΟΗ -CH2-4-tBu0C (= 0) NH-Ph 3-72 Η Η Η ΟΗ -CH2-4-MeS02NH-Ph 3-73 Η Η Η CH CH -CH2-4-TfmS02NH-Ph 3-74 Η Η Η ΟΗ -CH2 Ice Ac-Ph 3-75 Η Η Η ΟΗ -CHr4-AcO-Ph 3-76 Η Η Η Ο Η -CH2-4-MeCar-Ph 3-77 Η Η Η ΟΗ -CH2-4-diMeCar-Ph 3-78 Η Η Η 〇Η -CH2-253-diF-Ph 3-79 Η Η Η ΟΗ -CH2-2? 4-diF-Ph 3-80 Η Η Η ΟΗ -CH2-255-diF-Ph 3-81 Η Η Η ΟΗ -CH2-256-diF-Ph 3-82 Η Η Η ΟΗ -CH2 -354-diF-Ph 3-83 Η Η Ο Η -CH2-335-diF-Ph 3-84 Η Η Η Ο Η -CH2-253-diCl-Ph 3-85 Η Η Η ΟΗ -CH2-254-diCl- Ph 3-86, Η Η Η ΟΗ -CH2-2,5-diCl-Ph 3-87 Η Η Η ΟΗ -CH2-256-diCl-Ph 3-88 Η Η Η ΟΗ -CH2-3,4-diCl- Ph 3-89 Η Η Η ΟΗ -CHr3,5-diCl-Ph 3-90 Η Η Η ΟΗ -CH2-2-F-4-N02-Ph 3-91 Η Η Η ΟΗ -CHs ^ -Cl ^ -F -Ph 3-92 Η Η Η ΟΗ -CHr2-Cl-4-N02-Ph 3-93 Η Η Η ΟΗ -CH2-3-Cl-4-F-Ph 3-94 Η Η Η Η CH -CH2-2- Me-4-F-Ph 3-95 Η Η Η Η CH -CH2-2-Me-4-Cl-Ph 3-96 Η Η Η Η Η Η CH CH CH CH CH Η Η Η -CH2 Cl-4-Me-Ph 3-98 Η Η Η ΟΗ -CHr3-Me ice No.rPh 200401770

3-99 Η HH OH ^ CH2-3-N02-4-Cl-Ph 3-100 Η HH OH -CH2-253-diOH-Ph 3-101 Η HH OH -CHr2,4-diOH-Ph 3-102 Η HH OH -CH2-255-diOH-Ph 3-103 Η HH OH -CHr2,6-di〇H-Ph 3-104 Η HH OH -CH2-354-diOH ^ Ph 3-105 Η HH OH -CH2-335 -diOH-Ph 3-106 Η HH OH -CH2-253-diOMe-Ph 3-107 Η HH OH -CHr2,4-diOMe: Ph 3-108 Η HH OH -CH2-235-diOMe-Ph 3-109 Η HH OH -CH2-256-diOMe-Ph 3-110 Η HH OH -CH2-3? 4-di〇Me-Ph 3-111 Η HH OH -CH2-3? 5-diOMe-Ph 3-112 Η HH OH -CHr2,3-MtdoPh 3-113 Η HH OH -CH2-354-Mtdo-Ph 3-114 Η HH OH -CH2-253-diMe-Ph 3-115 Η HH OH -CH2-234-diMe-Ph 3- 116 Η HH OH -CHr2,5-diMe-Ph 3-117 Η HH OH -CH2-2; 6-diMe-Ph 3-118 Η HH OH -CH2-3? 4-diMe-Ph 3-119 Η HH OH -CHr3,5-diMe-Ph 3-120 Η HH OH -CH2-2,4,54riF-Ph 3-121 Η HH OH -CH2 ~ pentaFPh 3-125 Η HH OH -CH2- (4-Ph) -Ph 3-126 Η HHH -CH2-4-Tfm-Ph 3-127 Η HH OMe -CH2-4-Tfm-Ph 3-128 Η HH OTfm -CH2-4-Tfm-Ph 3-129 1-Me HH OH Ph 3-130 1-Me HH OH 1-Nap 3-131 1-Me HH OH 2-Nap 3-132 1-Me HH OH Bz 3-133 1-Me HH OH -CF2 -Ph 3-134 1-Me HH OH-(CH2) -2-Nap 3-135 1-Me HH OH -CH2-3-Me-Ph 3-136 1 -Me HH OH -CH2-4-Me-Ph 3-137 1-Me HH OH -CHr3-Br-Ph 3-138 1-Me HH OH -CH2-4-Br-Ph -92- 200401770 3-139 3 -140 3-141 3-142 3-143 3-144 3-145 3-146 3-147 .3-148 3-149 3-150 3-151 3-152 3-153 3-154 3-155 3- 156 3-157 3-158 3-159 3-160 3-161 3-162 3-163 3-164 3-165 3-166 3-167 3-168 3-169 3-170 3-171 3-172 3 -173 3-174 3-175 c ceceeceee6eee6eec c __- _- _.- 1 - - -.-MeMMMMMMMMM-mMMMMMMMMMM-cl-cccccccccccc-cL-cL-c 1 hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh gggTJggggg volumes ggggg volumes gggggTTgTT Mud gHHsggggsggg -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CHr3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2 -3-OMe-Ph -CH2-4-OMe-Ph -CHr2,3-diF-Ph -CHr2,4-diF-Ph -CH2-255-diF-Ph -CH2-2? 6-diF-Ph -CH2 -3,4-diF-Ph -CH2-3? 5-diF-Ph -CH2-3,4-dia-Ph -CH2-3,5-diCl-Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CH2-3? 4-Mtdo-Ph -CH2-3,4-diMe-Ph -CH2-355-diMe- Ph Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2-4-Me-Ph -CH2-3-Br-Ph -CH2-4- Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm- Ph -93- 200401770 3-176 3-177 3-178 3-179 3-180 3-181 3-182 3-183 3-184 3-185 3-186 3-187 3-188 3-189 3-190 3-191 3-192 3-193 3-194 3-195 3-196 3-197 3-198 3-199 3-200 3-201 3-202 3-203 3-204 3-205 3-206 3- 207 3-208 3-209 3-210 3-211 3-212

1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1-C1 HH 1- C1 HH 1-C1 HH 1-C1 HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH 1-Br HH OH- CH2-3-OMe-Ph OH -CH2-4-OMe-Ph OH -CH2-2,3-diF-Ph OH -CHr2,4-diF-Ph OH -CH2-2? 5-diF-Ph OH -CH2 -2,6-diF-Ph OH -CH2-3? 4-diF-Ph OH -CH2-355-diF-Ph OH -CHr3,4-diCKPh OH -CH2-355-diCl-Ph OH -CH2-3- Cl-4-F-Ph OH -CH2-3-Me-4-Cl-Ph OH -CH2-3? 4-Mtd〇.Ph OH -CH2-354-diMe-Ph OH -CH2-3,5-diMe -Ph OH Ph OH 1-Nap OH 2-Nap OH Bz OH -CF2 -Ph. OH-(GH2) -2-Nap OH -CH2-3-Me-Ph OH -CH2-4-Me-Ph OH -CH2 -3-Br-Ph OH -CH2-4-Br-Ph OH -CH2-3-Cl-Ph OH -CH2-4-Cl-Ph OH -CH2-3-F-Ph OH -CH2-4-F- Ph OH -CH2-3-Tfm-Ph OH -CH2-4-Tfm-Ph OH -CH2-3-OMe-Ph OH -CH2-4-OMe-Ph OH -CHr2,3-diF-Ph OH -CH2- 234-diF-Ph OH -CH2-2,5-diF-P h OH -CHr256-diF-Ph

94- 200401770 3-213 3-214 3-215 3-216 3-217 3-218 3-219 3-220 3-221 3-222 3-223 3-224 3-225 3-226 3-227 3- 228 3-229 3-230 3-231 3-232 3-233 3-234 3-235 3-236 3-237 3-238 3-239 3-240 3-241 3-242 3-243 3-244 3 -245 3-246 3-247 3-248 3-249 1-Br Η Η ΟΗ -CHr3,4-diF-Ph 1-Br Η Η ΟΗ -CH2-355-diF-Ph 1-Br Η Η. ΟΗ- CH2-354-diCl-Ph 1 · Βγ Η Η ΟΗ -CHr3,5-diCl-Ph 1-Βγ Η Η ΟΗ -CH2-3-Cl-4-F-Ph 1-Br Η Η ΟΗ -CH2-3- Me-4-Cl-Ph 1-Br Η Η ΟΗ -CHr3,4-Mtdo-Ph 1-Βγ Η Η ΟΗ -CHr3,4-diMe-Ph 1-Βγ Η Η ΟΗ -CH2-3? 5-diMe- Ph 1-ΟΗ Η Ο Η Ph 1-ΟΗ Η Η ΟΗ 1-Nap 1-ΟΗ Η Η ΟΗ 2-Nap 1-ΟΗ Η Ο Η Bz 1-〇z Η Η ΟΗ -CF2 -Ph 1-ΟΗ Η. Η ΟΗ -(CH2) -2-Nap 1-〇Η Η Η ΟΗ -CH2- 3-Me-Ph 1-〇Η Η Η ΟΗ -CH2 ~ 4-Me-Ph 1-〇Η Η Η ΟΗ -CH2-3-Br-Ph 1-ΟΗ Η Η ΟΗ-CHr4-Br-Ph 1-ΟΗ Η Η ΟΗ -CH2-3-Cl-Ph 1-ΟΗ Η Η ΟΗ -CHr4-Cl-Ph 1-〇Η Η Η ΟΗ -CH2-3-F -Ph 1-ΟΗ Η Η ΟΗ -CH2-4-F-Ph 1-〇Η Η Η ΟΗ -CH2-3-Tfm-Ph 1-〇Η Η ΟΗ -CH2-4-Tfm-Ph 1-ΟΗ Η Η ΟΗ -CH2-3-OMe-Ph 1-〇Η Η Η ΟΗ -CHr4-OMe-Ph 1-〇Η Η Η ΟΗ -CH2-2,3-diF- Ph 1-ΟΗ Η Η ΟΗ -CHr2,4-diF-Ph 1-ΟΗ Η Η ΟΗ -CHr2,5-diF-Ph 1-ΟΗ Η Η ΟΗ -CHr2,6-diF-Ph 1-ΟΗ Η Η ΟΗ-- CH2-3,4-diF-Ph 1-ΟΗ Η Η ΟΗ -CH2-3,5-diF-Ph 1-ΟΗ Η Η Ο Η -CH2-3,4-diCl-Ph 1-〇Η Η Η ΟΗ -CH2- 3? 5-diCl-Ph 1-〇Η Η Η ΟΗ-CHr3-Cl-4-F-Ph 1-〇Η Η Η ΟΗ -CHr3-Me-4-Cl-Ph

95- 200401770 3-250 1-OH HH OH -CH2-3? 4-Mtdo-Ph 3-251 1-OH HH OH _CHr3,4-diMe-Ph 3-252 1-OH HH OH • CHr3,5-diMe -Ph 3-253 1-Tfm HH OH Ph 3-254 1-Tfm HH OH 1-Nap 3-255 1-Tfm HH OH 2-Nap 3-256 1-Tfm HH OH Bz 3-257 1-Tfm HH OH -CF2 -Ph 3-258 1-Tfm HH OH-(CH2) -2-Nap 3-259 1-Tfm HH OH -CH2-3-Me-Ph 3-260 1-Tfm HH OH -CH2—4-Mc -Ph 3-261 1-Tfm HH OH -CH2-3-Br-Ph 3-262 1-Tfm HH OH -CH2-4-Br-Ph 3-263 1-Tfm HH OH -CH2-3-Cl-Ph 3-264 1-Tfm HH OH -CH2-4-Cl-Ph 3-265 1-Tfm HH OH -CH2-3-F-Ph 3-266 1-Tfm HH OH -CH2-4-F-Ph 3- 267 1-Tfm HH OH -CH2-3-Tfm-Ph 3-268 1-Tfm HH OH -CH2-4-Tfm-Ph 3-269 1-Tfm HH OH -CH2-3-OMe-Ph 3-270 1 -Tfm HH OH -CH2-4-OMe-Ph 3-271 1-Tfm HH OH -CHr2,3-diF-Ph 3-272 1-Tfm HH OH -CH2-234-diF-Ph 3-273 1-Tfm HH OH -CH2-2? 5-diF-Ph 3-274 1-Tfm HH OH -CH2-236-diF-Ph 3-275 1-Tfm HH OH -CH2-3,4-diF-Ph 3-276 1 -Tfm HH OH -CH2-355-diF-Ph 3-277 _ 1-Tfm HH OH -CH2-354-diCl-Ph 3-278 1-Tfm HH OH -CH2-3,5-diCl-Ph 3-279 1-Tfm HH OH -CH2-3-C l-4-F-Ph 3-280 1-Tfm HH OH -CH2-3-Me-4-Cl-Ph 3-281 1-Tfm HH OH -CH2-354-Mtdo-Ph 3-282 1-Tfm HH OH -CH2-354-diMe-Ph 3-283 1-Tfm HH OH > CH2-355-diMe-Ph 3-284 1-OMe HH OH Ph 3-285 1-OMe HH OH 1-Nap 3-286 1 -OMe HH OH 2-Nap 96- 200401770 3-287 1-OMe HH OH Bz 3-288 1-OMe HH OH -CF2 -Ph 3-289 1-OMe HH OH-(CH2) -2-Nap 3-290 1-OMe HH OH -CH2-3-Me-Ph 3-291 1-OMe HH OH -CH2-4-Me-Ph 3-292 1-OMe HH OH -CH2-3-Br-Ph 3-293 1- OMe HH OH -CHr4-Br-Ph 3-294 1-OMe HH OH -CH2-3-Cl-Ph 3-295 1-OMe HH OH -CH2-4-Cl-Ph 3-296 1-OMe HH OH- CH2-3-F-Ph 3-297 1-OMe HH OH -CH2-4-F-Ph 3-298 1-OMe HH OH -CH2-3-Tfm-Ph 3-299 1-OMe HH OH -CH2- 4-Tfm-Ph 3-300 l > OMe HH OH -CH2-3-OMe-Ph 3-301 1-OMe HH OH -CH2-4-OMe-Ph 3-302 1-OMe HH OH -CH2-253- diF-Ph 3-303 1-OMe HH OH -CH2-2? 4-diF-Ph 3-304 1-OMe HH OH -CHr2,5-diF-Ph 3-305 l-OMe HH OH -CH2-236- diF-Ph 3-306 1-OMe HH OH -CH2-3,4-diF-Ph 3-307 1-OMe HH OH, -CH2-3,5-diF-Ph 3-308 1-OMe HH OH -CH2 -3,4-diCl-Ph 3-309 1-OMe HH OH -CH2-355-diCl-Ph 3-310 1-OMe HH OH -CH2-3-Cl-4-F-Ph 3-311 1-OMe HH OH -CH2-3-Me-4- Cl-Ph 3-312 1-OMe HH OH -CH2-354-Mtdo-Ph 3-313 1-OMe HH OH -CH2-3? 4-diMe-Ph 3-314 1-OMe HH OH -CH2-355- diMe-Ph 3-315 1-AcNH HH OH Ph 3-316 1-AcNH HH OH 1-Nap 3-317 1-AcNH HH OH 2-Nap 3-318 1-AcNH HH OH Bz 3-319 1-AcNH HH OH -CF2 -Ph 3-320 1-AcNH .HH OH-(CH2) -2-Nap 3-321 1-AcNH HH OH • CH2-3-Me-Ph 3-322 1-AcNH HH OH -CH2-4 -Me-Ph 3-323 1-AcNH HH OH -CH2-3-Br-Ph 97- 200401770 3-324 1-AcNH HH OH -CH2-4-Br-Ph 3-325 1-AcNH HH OH -CH2- 3-Cl-Ph 3-326 1-AcNH HH OH -CH2-4-Cl-Ph 3-327 1-AcNH HH OH -CH2 F-Ph 3-328 1-AcNH HH OH -CH2-4-F- Ph 3-329 1-AcNH HH OH -CH2 each Tfm-Ph 3-330 1-AcNH HH OH -CH2-4-Tfm-Ph 3-331 1-AgNH HH OH -CH2-3-OMe-Ph 3-332 1-AcNH HH OH -CH2-4-OMe-Ph. 3-333 1-AcNH HH OH -CH2-2,3-diF-Ph 3-334 1-AcNH HH OH -CH2-234-diF-Ph 3- 335 1-AcNH HH OH -CH2-235-diF-Ph 3-336 1-AcNH HH OH-CH2-2,6-diF-Ph 3-337 1-AcNH HH OH -CH2-354-diF-P h 3-338 1-AcNH HH OH -CH2-3,5-diF-Ph 3-339 1-AcNH HH OH -CH2-3,4-diCl-Ph 3-340 1-AcNH HH OH -CH2-3, 5-diCl-Ph 3-341 1-AcNH HH OH -CH2-3-Cl-4-F-Ph 3-342 1-AcNH HH OH -CHs-S-Me ^ -Cl-Ph 3-343 1-AcNH HH OH -CH2-3,4-Mtdo-Ph 3-344 1-AcNH HH OH • CH2-3,4-diMe-Ph 3-345 1-AcNH HH OH -CH2-355-diMe-Ph 3-346 2 -Me HH OH Ph 3-347 2-Me HH OH 1-Nap 3-348 2-Me HH OH 2-Nap 3-349 2-Me HH OH Bz 3-350 2-Me .HH OH -CF2 -Ph 3 -351 2-Me HH OH-(CH2) -2-Nap 3-352 2-Me HH OH-CH2-3-Me-Ph 3-353 2-Me HH OH -CH2-4-Me-Ph 3-354 2-Me HH OH -CH2-3-Br.Ph 3-355 2-Me HH OH -CH2-4-Br-Ph 3-356 2-Me HH OH -CH2-3-Cl-Ph 3-357 2- Me HH OH -CH2-4-Cl-Ph 3-358 2-Me HH OH -CH2-3-FPh 3-359 2-Me HH OH -CH2-4-F-Ph 3-360 2-Me HH OH- CH2-3-Tfm-Ph 98- 200401770 3-361 3-362 3-363 3-364 3-365 3-366 3-367 3-368 3-369 3-370 3-371 3-372 3-373 3 -374 3-375 3-376 3-377 3-378 3-379 3-380 3-381 3-382 3-383 3-384 3-385 3-386 3-387 3-388 3-389 3-390 3-391 3-392 3-393 3-394 3-395 3-396 3-397

2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2-Me HH 2- Me HH 2-Me HH 2-Me HH 2-Me HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH 2-C1 HH OH- CH2-4-Tfm-Ph OH -CH2-3-OMe-Ph OH -CH2-4-OMe-Ph OH • CH2-2,3-diF-Ph OH -CH2-234-diF-Ph OH -CH2-255 -diF-Ph OH -CH2-2? 6-diF-Ph OH -CH2-3,4-diF-Ph OH -CH2-3,5-diF-Ph OH -CHW-diCl-Ph OH -CH2-3? 5-diCl-Ph OH -CH2-3-Cl-4-F-Ph OH -CH2-3-Me-4-Cl-Ph OH -CH2-334-Mtdo-Ph OH -CH2-354-diMe-Ph OH -CH2-335-diMe-Ph OH Ph OH 1-Nap OH 2-Nap OH Bz OH -CF2 -Ph OH-(CH2) -2-Nap OH -CH2-3-Me-Ph OH -CH2-4-Me -Ph OH -CH2-3-Br-Ph OH -CH2-4-Br-Ph OH -CH2-3-Cl-Ph OH -CH2-4-Cl-Ph OH -CH2-3-F-Ph OH -CH2 -4-F-Ph OH -CH2-3-Tfm-Ph OH -CH2-4-Tfm-Ph OH -CH2-3-OMe-Ph OH -CH2-4-OMe-Ph OH -CH2-253-diF- Ph OH -CH2-2? 4 > diF- Ph OH -CH2-255-diF-Ph

礴 99- 200401770 3-398 2-C1 HH OH -CH2-256-diF-Ph 3-399 2-C1 HH OH -CH2-354-diF-Ph 3-400 2-C1 HH OH -CH2-355-diF -Ph 3-401 2-C1 HH OH -CH2-354-diCl-Ph 3402 2-C1 HH OH -CHr3,5-diCl-Ph 3-403 2-C1 HH OH -CH2-3-Cl-4-F -Ph 3-404 2-C1 HH OH -CH2-3-Me-4-Cl-Ph 3-405 2-C1 HH OH -CH2-354-Mtdo-Ph 3-406 2-C1 HH OH -CH2-354 -diMe-Ph 3-407 2-C1 HH OH -CH2-355-diMe-Ph 3-408 2-Br HH OH Ph 3-409 2-Br HH OH 1-Nap 3-410 2-Br HH OH 2- Nap 3-411 2-Br HH OH Bz 3-412 2-Br HH OH -CF2 -Ph 3-413 2-Br HH OH-(CH2) -2-Nap 3-414 2-Bt HH OH -CH2-3 -Me-Ph 3-415 2-Br HH OH -CH2-4-Me-Ph 3-416 2-Br HH OH -CH2-3-Br-Ph 3-417 2-Br HH OH -CH2-4-Br -Ph 3-418 2-Bt HH OH -CH2-3-Cl-Ph 3-419 2-Br HH OH -CH2-4-Cl-Ph 3-420 2-Br HH OH -CH2-3-F-Ph 3-421 2-Br HH OH -CHr4-F-Ph 3-422 2-Br HH OH -CH2-3-Tfm-Ph 3-423 2-Br HH OH -CH2-4-Tfm-Ph 3-424 2 -Br HH OH -CH2-3-OMe-Ph 3-425 2-Br HH OH -CH2-4-OMe-Ph 3-426 2-Br HH OH -CHr2,3-diF-Ph 3-427 2-Br HH OH -CH2-2,4-diF-Ph 3-428 2-Br HHO H -CH2-2? 5-diF-Ph 3-429 2-Br HH OH -CHr2,6-diF-Ph 3-430 2-Br HH OH -CHr3,4-diF-Ph 3-431 2-Br HH OH -CH2-3,5-diF-Ph 3-432 2-Br HH OH -CH2-3? 4-diCl-Ph 3-433 2-Br HH OH -CHr3,5-diCl-Ph 3-434 2- Br HH OH -CH2-3-Cl-4 ^ Ph * m 100- 200401770 3-435 2 · Βγ Η Η 〇Η -CH2-3-Me-4-Cl-Ph 3-436 2-Βγ Η Η 〇Η -CHr3, 'Mtdo-Ph 3-437 2-Βγ Η Η 〇Η -CH2-3? 4-diMe-Ph 3-438 2-Βγ Η Η Ο Η -CH2-355-diMe-Ph 3-439 2-〇Η Η Ο Η Ph 3-440 2-ΟΗ Η Η ΟΗ 1-Nap 3-441 2-ΟΗ Η Η ΟΗ 2-Nap 3-442 2-〇Η Η Η ΟΗ Bz 3-443 2-〇Η Η Η ΟΗ -CF2- Ph 3-444 2-ΟΗ Η Η ΟΗ-(CH2) -2-Nap 3-445 2-ΟΗ Η Η ΟΗ -CH2-3-Me-Ph 3-446 2-〇Η Η Η ΟΗ -CH2 ~ 4-Me -Ph 3-447 2-〇Η Η Η ΟΗ -CH2-3-Br-Ph 3-448 2-〇Η Η Η ΟΗ -CH2-4-Br-Ph 3-449 2-〇Η Η Η ΟΗ -CH2-3- Cl-Ph 3-450 2-ΟΗ Η Η ΟΗ -CH2-4-Cl-Ph 3-451 2-〇Η Η Η ΟΗ -CH2-3-F-Ph 3-452 2-〇Η Η Η CHΗ-CH2-4 -F-P1i 3-453 2-〇Η Η Η ΟΗ -CH2-3-Tfm-Ph 3-454 2-ΟΗ Η Η Ο Η -CH2-4-Tfm-Ph 3-455 2 -〇Η Η Ο Η -CH2-3-OMe-Ph 3-456 2-ΟΗ Η Η Ο Η -CH2-4-OMe-Ph 3-457 2-〇Η Η Η ΟΗ -CH2-2,3-diF-Ph. 3-458 2-ΟΗ Η Η ΟΗ -CH2-254-diF-Ph 3-459 2-ΟΗ Η Η ΟΗ -CH2-2,5-diF-Ph 3-460 2-〇Η Η Η ΟΗ-CH2-2, 6-diF-Ph 3-461 2-〇Η Η Η ΟΗ -CHr3,4-diF-Ph 3-462 2-〇Η Η Η ΟΗ -CH2-3,5-diF-Ph 3-463 2-〇Η Η Η ΟΗ -CHr3,4-diCl-Ph 3-464 2-ΟΗ Η Η ΟΗ -CHr3,5-diCl-Ph 3-465 2-〇Η Η Η ΟΗ -CH2-3-Cl-4-F-Ph 3-466 2 -ΟΗ Η Η ΟΗ -CH2-3-Me-4-Cl-Ph 3-467 2-〇Η Η Η ΟΗ -CH2-3,4-MtdoPh 3-468 2-〇Η Η Η ΟΗ -CHr3,4-diMe- Ph 3-469 2-ΟΗ Η Η ΟΗ -CH2-335-diMe-Ph 3-470 2-Tfm Η Η ΟΗ Ph 3-471 2-Tfm Η Η ΟΗ 1-Nap -101-200401770 3-472 2-Tfm HH OH 2-Nap 3-473 2-Tfm HH OH Bz 3-474 2-Tfm HH OH -CF2 -Ph 3-475 2-Tfm HH OH-(CH2) -2-Nap 3-476 2-Tfm HH OH -CH2-3-Me-Ph 3-477 2-Tfm HH OH -CH2-4-Me-Ph 3-478 2-Tfm HH OH -CH2-3-Br-Ph 3-479 2-Tfm HH OH -CH2 -4-Br-Ph 3-480 2-Tfm HH OH -CH2-3-Cl-Ph 3-481 2-Tfm HH OH -CH2-4-Cl-Ph 3-482 2- Tfra HH OH -CH2-3-F-Ph 3-483 2-Tfm HH OH -CH2-4-F-Ph 3-484 2-Tfm HH OH -CH2-3-Tfm-Ph 3-485 2-Tfm HH OH -CH2-4-Tfm-Ph 3-486 2-Tfm HH OH -CH2-3-OMe-Ph 3-487 2-Tfm HH OH -CH2-4-OMe-Ph 3-488 2-Tfm HH OH- CH2-2? 3-diF-Ph 3-489 2-Tfm HH OH -CH2-2? 4-diF-Ph 3-490 2-Tfm HH OH -CH2-2,5-diF-Ph 3-491 2- Tfm HH OH -CHr2,6-diF-Ph 3-492 2-Tfm HH OH -CH2-3,4-diF-Ph 3-493 2-Tfm HH OH -CH2-355-diF-Ph 3-494 2- Tfm HH OH -CH2-354-diCl-Ph 3-495 2-Tfm HH OH -CHr3,5-diCl-Ph 3-496 2-Tfm HH OH -CH2-3-Cl-4-F-Ph 3-497 2-Tfm HH OH -CH2-3-Me-4-Cl-Ph 3-498 2-Tfm HH OH • CHr3,4-Mtdo-Ph 3-499 2-Tfm HH OH -CH2-3? 4-diMe- Ph 3-500 2-Tfm HH OH -CH2-335-diMe-Ph 3-501 2-OMe HH OH Ph 3-502 2-OMe HH OH 1-Nap 3-503 2-OMe HH OH 2-Nap 3- 504 2-OMe HH OH Bz 3-505 2-OMe HH OH -CF2 -Ph 3-506 2-OMe HH OH-(CH2) -2-Nap 3-507 2-OMe HH OH _CH2-3-Me-Ph 3-508 2-OMe HH OH -CH24Me-Ph 螩 102- 200401770 3-509 2-OMe HH OH -CHr3-Br-Ph 3-510 2-OMe HH OH -CH2-4-Br-Ph 3-511 2 -OMe HH OH -CHr3- Cm 3-512 2-OMe HH OH -CH2-4-Cl-Ph 3-513 2-OMe HH OH -CH2-3-F-Ph 3-514 2-OMe HH OH -CH2-4-F-Ph 3 -515 2-OMe HH OH -CH2-3-Tfm-Ph 3-516 2-OMe HH OH -CH2-4-Tfm-Ph 3-517 2-OMe HH OH -CH2-3-OMe-Ph 3-518 2-OMe HH OH -CHr4-OMe-Ph 3-519 2-OMe HH OH -CH2-2,3-diF-Ph 3-520 2-OMe HH OH -CH2-2,4-diF-Ph 3-521 2-OMe HH OH -CH2-2,5-diF-Ph 3-522 2-OMe HH OH -CH2-2,6-diF-Ph 3-523 2-OMe HH OH -CH2-3,4-diF- Ph 3-524 2-OMe HH OH -CH2-355-diF-Ph 3-525 2-OMe HH OH -CH2-334-diCl-Ph 3-526 2-OMe HH OH -CHr3,5-diCl-Ph 3 -527 2-OMe HH OH -CH2-3-Cl-4-F-Ph 3-528 2-OMe HH OH -CH2-3-Me-4-Cl-Ph 3-529 2-OMe HH OH -CH2- 354-Mtdo-Ph 3-530 2-OMe HH OH -CH2-3,4-diMe-Ph 3-531 2-OMe HH OH -CH2-3? 5-diMe-Ph 3-532 2-AcNH HH OH Ph 3-533 2-AcNH HH OH 1-Nap 3-534 2-AcNH HH OH 2-Nap 3-535 2-AcNH HH OH Bz 3-536 2-AcNH HH OH -CF2 -Ph 3-537 2-AcNH HH OH-(CH2), 2_Nap 3-538 2-AcNH HH OH -CH2-3-Me-Ph 3-539 2-AcNH HH OH -CH2 ~ 4-Me-Ph 3-540 2-AcNH HH OH -CH2- 3-Br-Ph 3-541 2-AcNH HH OH -CH2-4-Br-Ph 3-542 2-AcNH HH OH -CH2-3-Cl-Ph 3-543 2-AcNH HH OH -CH2-4-Cl-Ph 3-544 2-AcNH HH OH- CH2-3-F-Ph 3-545 2-AcNH HH OH -CH2-4-F-Ph 103- 200401770

3-546 2-AcNH H 3-547 2-AcNH H 3-548 2-AcNH H 3-549 2-AcNH H 3-550 2-AcNH H 3-551 2-AcNH H 3-552 2-AcNH H 3 -553 2-AcNH H 3-554 2-AcNH H 3-555 2-AcNH H 3-556 2-AcNH H 3-557 2-AcNH H 3-558 2-AcNH H 3-559 2-AcNH H 3- 560 2-AcNH H 3-561 2-AcNH H 3-562 2-AcNH H 3-563 3-Me H 3-564 3-Me H 3-565. 3-Me H 3-566 3-Me H 3- 567 3-Me H 3-568 3-Me H 3-569 3-Me H '3-570 3-Me H 3-571 3-Me H 3-572 3-Me H 3-573 3-Me H 3- 574 3-Me H 3-575 3-Me H 3-576 3-Me H 3-577 3-Me H 3-578 3-Me H 3-579 3-Me 3-580 3-Me H 3-581 3 -Me H 3-582 3-Me H 〇000000 CH2-2? 3-diF-Ph -CHr2,4-diF-Ph -CH2-2,5-diF-Ph -CH2-2,6-diF-Ph -CH2-354-diF-Ph -CH2-355- diF-Ph -CH2-3,4-diCl-Ph -CH2-3,5-diCl, Pli -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CH2- 334-Mtdo-Ph -CH2-354-diMe-Ph -CH2-3? 5-diMe-Ph Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me- Ph -CH2-4-Me-Ph -CH2-3-Br-Ph -CH2- 4-Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4- Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CH2-253-diF-Ph -CH2-254-diF-Ph 104- 200401770 3-583 3-Me HH OH -CH2-2 , 5-diF-Ph 3-584 3-Me HH OH -CHr2,6-diF-Ph 3-585 3-Me HH OH • CH2-3,4-diF-Ph 3-586 3-Me HH OH -CHr3 , 5-diF-Ph 3-587 3-Me HH OH • CH2-3,4-diCl-Ph 3-588 3-Me HH OH -CHr3,5-diCl-Ph 3-589 3-Me HH OH -CH2 -3-Cl-4-F-Ph 3-590 3-Me HH OH -CH2-3-Me-4-Cl-Ph 3-591 3-Me HH OH -CH2-334-Mtdo-Ph 3-592 3 -Me HH OH -CH2-354-diMe-Ph 3-593 3-Me HH OH -CH2-355-diMe-Ph 3-594 3-C1 HH OH Ph 3-595 3-C1 HH OH 1-Nap 3- 596 3-C1 HH OH 2-Nap 3-597 3.α HH OH Bz 3-598 3-C1 HH OH -CF2 -Ph 3-599 3-C1 HH OH-(CH2) -2-Nap 3-600 3 -C1 HH OH -CH2-3-Me-Ph 3-601 3-C1 HH OH -CH24Me-Ph 3-602 3-C1 HH OH -CH2-3-Br-Ph 3-603 3-C1 HH OH -CH2 -4-Br-Ph 3-604 3-C1 HH OH -CH2-3-Cl-Ph 3-605 3-C1 HH OH -CH2-4-Cl-Ph 3-606 3-C1 HH OH • CH2-3 -F-Ph 3-607 3-C1 HH OH -CH2-4-F-Ph 3-608 3-C1 HH OH -CH2-3-Tfm-Ph 3-6 09 3-C1 HH OH -CH2-4-Tfm-Ph 3-610 3-C1 HH OH -CH2-3-OMe-Ph 3-611 3-C1 HH OH -CHr4-OMe-Ph 3-612 3-C1 HH OH -CHr2,3-diF-Ph 3-613 3-C1 HH OH -CH2-2,4-diF-Ph 3-614 3-C1 HH OH -CHr2,5-diF-Ph 3-615 3-C1 HH OH -CHr2,6-diF-Ph 3-616 3-C1 HH OH -CH2-3, 'diF-Ph 3-617 3-C1 HH OH -CHr3,5-diF-Ph 3-618 3-C1 HH OH -CH2-3? 4-diCl-Ph 3-619 3-C1 HH OH • 〇V3,5-diCl-Ph -105- 200401770 3-620 3-621 3-622 3-623 3-624 3-625 3-626 3-627 3-628 3-629 3-630 3-631 3-632 3-633 3-634 3-635 3-636 3-637 3-638 3-639 3-640 3-641 3- 642 3-643 3-644 3-645 3-646 3-647 3-648 3-649 3-650 3-651 3-652 3-653 3-654 3-655 3-656 3-C1 HH OH -CH2 Each Cl_4-F-Ph 3-C1 HH OH -CH2-3-Me-4 > Cl-Ph 3-C1 HH OH -CHr3,4-Mtdo-Ph 3-C1 HH OH -CH2-354-diMe-Ph 3 -C1 HH OH -CHr3,5-diMe-Ph 3-Br HH OH Ph 3-Br HH OH 1-Nap 3-Br HH OH 2-Nap 3-Br HH OH Bz 3-Br HH OH -CF2 -Ph 3 -Br HH OH-(CH2) -2-Nap 3-Br HH OH -CH2-3-Me-Ph 3-Br HH OH -CH2-4-Me-Ph 3-Br HH OH -CH2-3-Br- Ph 3-Br HH OH -CH2-4-Br-Ph 3-Br HH OH -CH2-3-Cl-Ph 3-Br HH OH -CH2-4-Cl-Ph 3-Br. HH OH -CH2-3-F-Ph 3-Br HH OH -CH2-4-F-Ph 3 -Br HH OH -CH2-3-Tfm-Ph 3-Br HH OH -CH2-4-Tfm-Ph 3-Br HH OH -CHr3-OMe-Ph 3-Br HH OH -CH2-4-OMe-Ph 3 -Br HH OH -CH2-2? 3-diF-Ph 3-Br HH OH -CH2-234-diF-Ph 3-Br HH OH -CH2-235-diF-Ph 3-Br HH OH -CHr2,6- diF-Ph 3-Br HH OH -CH2-354-diF-Ph 3-Br HH OH -CH2-335-diF-Ph 3-Br HH OH -CH2-3? 4-diCl-Ph 3-Br HH OH- CH2-335-diCl-Ph 3-Br HH OH -CH2-3-Cl-4-F-Ph 3-Br HH OH -CH2-3-Me-4-Cl-Ph 3-Br HH OH -CH2-354 -Mtdo-Ph 3-Br HH OH -CH2-334-diMe-Ph 3-Br HH OH -CH2-355-diMe-Ph 3-OH HH OH Ph

-106- 200401770 3-657 3-OH HH OH 1-Nap 3-658 3-OH HH OH 2-Nap 3-659 3-OH HH OH Bz 3-660 3-OH HH OH -CF2 -Ph 3-661 3-OH HH OH-(CH2) -2-Nap 3-662 3-OH HH OH -CH2-3-Me-Ph 3-663 3-OH HH OH -CH2-4-Me-Ph 3-664 3- OH HH OH -CH2-3-Br-Ph 3-665 3-OH HH OH -CH2-4-Br-Ph 3-666 3-OH HH OH -CH2-3-Gl-Ph 3-667 3-OH HH OH -CH2-4-Cl-Ph 3-668 3-OH HH OH -CH2-3-F-Ph 3-669 3-OH HH OH -CH2-4-F-Ph 3-670 3-OH HH OH- CH2-3-Tfm-Ph 3-671 3-OH HH OH -CH2-4-Tfm-Ph 3-672 3-OH HH OH -CHr3-OMe-Ph 3-673 3-OH HH OH -CH2-4- OMe-Ph 3-674 3-OH HH OH -CH2-2,3-diF-Ph 3-675 3-OH HH OH -CH2-2,4-diF-Ph 3-676 3-OH HH OH -CH2 -2? 5-diF-Ph 3-677 3-OH HH OH -CH2-236-diF-Ph 3-678 3-OH HH OH -CH2-354-diF-Ph 3-679 3-OH HH OH -CH2 -355-diF-Ph 3-680 3-OH HH .OH -CH2-354-diCl-Ph 3-681 3-OH HH OH -CH2-355-diCl-Ph 3-682 3-OH HH OH -CH2- 3-Cl-4-F-Ph 3-683. 3-OH HH OH -CH2-3-Me-4-Cl-Ph 3-684 3-OH HH OH -CHr3,4-Mtdo-Ph 3-685 3 -OH HH OH -CHr334.diMe-Ph 3-686 3-OH HH OH -CH2-3? 5-diMe-Ph 3-687 3-Tfm HH OH Ph 3-688 3-Tfm HH OH 1-Nap 3-689 3-Tfm HH OH 2-Nap 3-690 3-Tfm HH OH Bz 3-691 3-Tfm HH OH -CF2 -Ph 3-692 3-Tfm HH OH-(CH2) -2-Nap 3-693 .3-Tfm HH OH -CH2 ~ 3-Me-Ph -107- 3-694 3-Tfm HH OH -CH2-4 -Me-Ph 3-695 3-Tfm HH OH -CH2-3-Br-Ph 3-696 3-Tfm HH OH -CH2-4-Br-Ph 3-697 3-Tfm HH OH -CHr3-Cl-Ph 3-698 3-Tfm HH OH -CH2-4-Cl-Ph 3-699 3-Tfm HH OH -CH2-3-F-Ph 3-700 3-Tfm HH OH -CH2-4-F-Ph 3- 701 3-Tfm HH OH -CH2-3-Tfm-Ph 3-702 3-Tfm HH OH -CH2-4 ^ Tfm-Ph 3-703 3-TfmHH OH -CH2-3-OMe-Ph 3-704 3-Tfm HH OH -CH2-4-OMe-Ph 3-705 3-Tfm HH OH -CHr2,3-diF-Ph 3-706 3-Tfm HH OH -CH2-254-diF-Ph 3-707 3- Tfm HH OH -CHr2,5-diF-Ph 3-708 3-Tfm HH OH -CH2-236-diF-Ph 3-709 3-Tfm HH OH -CHr3,4-diF-Ph 3-710 3-Tfm H ; H OH -CH2-3,5-diF-Ph 3-711 3-Tfm HH OH -CH2-3,4-diCl-Ph 3-712 3-Tfm HH OH -CH2-3,5-diCl-Ph 3 -713 3-Tfm HH OH -CH2-3-Cl-4-F-Ph 3-714 3-Tfm HH OH -CH2-3-Me-4-Cl-Ph 3-715 3-Tfm HH OH -CHr3, 4-MtdoPh 3-716 3-Tfm HH OH -CH2-3,4-diMe-P h 3-717 3-Tfm HH OH -CHr3,5-diMe-Ph 3-718 3-OMe HH OH Ph 3-719 3-OMe HH OH 1-Nap 3-720 3-OMe HH OH 2-Nap 3- 721 3-OMe HH .OH Bz 3-722 3-OMe HH OH -CF2 -Ph 3-723 3-OMe HH OH-(CH2) -2-Nap 3-724 3-OMe HH OH -CH2-3-Me -Ph 3-725 3-OMe HH OH -CH2-4-Me-Ph 3-726 3-OMe HH OH -CH2-3-Br-Ph 3-727 3-OMe HH OH -CH2-4-Br-Ph 3-728 3-OMe HH OH -CHr3-Cl-Ph 3-729 3-OMe HH OH -CHr4-Cl-Ph 3-730 3-OMe HH OH • -CH2-3-F-Ph 108- 200401770

3-731 3-OMe HH OH -CH2-4-F-Ph 3-732 3-OMe HH OH -CH2-3-Tfm-Ph 3-733 3-OMe H • H OH -CH2-4-Tfm-Ph 3-734 3-OMe HH OH -CHr3-OMe-Ph 3-735 3-OMe HH OH • CH2-4-OMe-Ph 3-736 3-OMe HH OH -CH2-2? 3 > diF-Ph 3- 737 3-OMe HH OH -CH2-2,4-diF-Ph 3-738 3-OMe HH OH -CHr2,5-diF-Ph 3-739 3-OMe HH OH -CH2-236-diF-Ph 3- 740 3-OMe HH OH -CH2-354-diF-Ph 3-741 3-OMe HH OH -CHr3,5-diF-Ph 3-742 3-OMe HH OH > CH2-354-diCl-Ph 3-743 3-OMe HH OH -CH2-355-diCl-Ph 3-744 3-OMe HH OH -CH2-3-Cl-4-F-Ph 3-745 3-OMe HH OH -CH2-3-Me-4- Cl-Ph 3-746 3-OMe HH OH -CH2-3,4-Mtdo-Ph 3-747 3-OMe HH OH -CH2-3,4-diMe_Ph 3-748 3-OMe HH OH -CH2-355- diMe-Ph 3-749 3-AcNH HH OH Ph 3-750 3-AcNH HH OH 1-Nap 3-751 3-AcNH HH OH 2-Nap 3-752 3-AcNH HH OH Bz 3-753 3-AcNH HH OH -CF2 -Ph 3-754 3-AcNH HH OH-(CH2) -2 ^ Nap 3-755 3-AcNH HH OH -CH2-3-Me-Ph 3-756 3-AcNH HH OH -CH2-4- Me-Ph 3-757 3-AcNH HH OH -CH2-3-Br-Ph 3-758 3-AcNH HH OH -CHr4-Br-Ph 3-759 3-AcNH HH OH -CH2-3-Cl-Ph 3 -760 3-AcNH HH OH -CHr4-Cl-Ph 3-761 3-AcNH HH OH -CHr3-F-Ph 3-762 3-AcNH HH OH -CH2-4-F-Ph 3-763 3-AcNH HH OH -CH2-3 -Tfm-Ph 3-764 3-AcNH HH OH -CH2-4-Tfm-Ph 3-765 3-AcNH HH OH -CH2-3-OMe-Ph 3-766 3-AcNH HH OH • CH2-4-〇 Me-Ph 3-767 3-AcNH H • .H OH -CHr2,3-diF-Ph 109-. 200401770 3-768 3-AcNH HH OH -CHr2,4-diF-Ph 3-769 3-AcNH HH OH -CH2-2? 5-diF-Ph 3-770 3-AcNH HH OH -CH2-236-diF-Ph 3-771 3-AcNH HH OH -CHr3,4-diF-Ph 3-772 3-AcNH HH OH -CH2-335-diF-Ph 3-773 3-AcNH HH OH -CH2-3,4-diCl-Ph 3-774 3-AcNH HH OH -CH2-335-diCl-Ph 3-775 3-AcNH HH OH -CH2-3-CM-F-Ph 3-776 3-AcNH HH OH -CH2-3-Me-4-Cl-Ph 3-777 3-AcNH HH OH -CH2-3,4-MtdoPh 3-778 3 -AcNH HH OH -CH2-374-diMe-Ph 3-779 3-AcNH HH OH -CH2-355-diMe-Ph 3-780 4-Me HH OH Ph 3-781 4-Me HH OH 1-Nap 3- 782 4-Me HH OH 2-NaP 3-783 4-Me HH OH Bz 3-784 4-Me HH OH -CF2 -Ph 3-785 4-Me HH OH-(CH2) -2-Nap 3-786 4 -Me HH OH -CH2-3-Me-Ph 3-787. 4-Me HH OH .CH2-4-Me-Ph 3-788 4-Me HH OH -CH2-3-Br-Ph 3-789 4- Me HH OH -CH2-4-Br-Ph 3-790 4-Me HH OH -CH2-3-Cl-Ph 3-791 4-Me HH OH -CH2-4-Cl-Ph 3-792 4-Me HH OH- CH2-3-F-Ph 3-793 4-Me. HH OH -CH2-4-F-Ph 3-794 4-Me HH OH -CH2-3-Tfm-Ph 3-795 4-Me HH OH -CH2 > 4-Tfm-Ph 3-796 4-Me HH OH -CH2-3-OMe-Ph 3-797 4-Me HH OH -CH2-4-OMe-Ph 3-798 4-Me HH OH -CH2-2 , 3-diF-Ph 3-799 4-Me HH OH -CH2-2? 4-diF-Ph 3-800 4-Me HH OH -CH2-2,5-diF-Ph 3-801 4-Me HH OH -CHr2,6-diF-Ph 3-802 4-Me HH OH -CH2-3,4-diF-Ph 3-803 4-Me HH OH -CH2-355-diF-Ph 3-804 4-Me HH OH -ΟΗ2-3,4- (ϋα-Ριι 110- 200401770 3-805 3-806 3-807 3-808 3-809 3-810 3-811 3-812 3-813 3-814 3-815 3-816 3-817 3-818 3-819 3-820 3-821 • 3-822 3-823 3-824 3-825 3-826 3-827 3-828 3-829 3-830 3-831 3-832 3 -833 3-834 3-835 3-836 3-837 3-838 3-839 3-840 3-841 4-Me HH OH -CH2-355-diCl-Ph 4-Me HH OH -CH2-3-Cl -4-F-Ph 4-Me HH OH -ΟΗ2-3-Μ & 4-α-Ρ1ι 4-Me HH OH -CH2-334-Mtdo-Ph 4-Me HH OH -CH2-354-diMe-Ph 4 -Me HH OH -CHr3,5-diMe-Ph 4-C1 H. H OH Ph 4-C1 HH OH 1-Nap 4-C1 HH OH 2-Nap 4-C1 HH OH Bz 4-C1 HH OH -CF2 -Ph 4-C1 HH OH-(CH2) -2-Nap 4-C1 HH OH -CH2 ~ 3-Me-Ph 4-C1 HH OH -CH2-4-Me-Ph 4-C1 HH OH -CH2-3-Br-Ph 4-C1 HH OH -CH2-4-Br-Ph 4-C1 HH OH -CH2-3-Cl-Ph 4- C1 HH OH -CH2-4-Cl-Ph 4-C1 HH OH -CH2-3-F-Ph 4-C1 HH OH -CH2-4-F-Ph 4-C1 HH OH -CH2-3-Tfm-Ph 4-C1 HH OH -CH2-4-Tfm-Ph 4-C1 HH OH -CH2-3-OMe-Ph 4-C1 HH OH -CH2-4-OMe-Ph 4-C1 HH OH -CHr2,3-diF -Ph 4-C1 HH OH -CH2-254-diF-Ph 4-C1 HH OH -CH2-255-diF-Ph 4-C1 HH OH -CH2-256-diF-Ph 4-C1 HH OH -CHr3,4 -diF-Ph 4-C1 HH OH -CH2-355-diF-Ph 4-C1 HH OH -ΟΗ2-354- (1ία ^ 4-C1 HH OH -Οί2-3,5- (ϋα-Ρ1ι 4-C1 HH OH -CH2-3-Cl-4-F-Ph 4-C1 HH OH .-CH2-3-Me-4-Cl-Ph 4-C1 HH OH -CH2-3,4-Mtdo-Ph 4-C1 HH OH -CHr3,4-diMe-Ph 4-C1 HH OH -CHr3,5-diMe-Ph

111-200401770 3-842 4-Br HH OH Ph 3-843 4-Βγ HH OH 1-Nap 3-844 4-Br HH OH 2-Nap 3-845 4-Br HH OH Bz 3-846 4-Br HH OH -CF2 -Ph 3-847 4-Br HH OH-(CH2) -2-Nap 3-848 4-Br HH OH -CH2-3-Me-Ph 3-849 4-Br HH OH -CH2-4- Me-Ph 3-850 4-Br HH OH -CH2-3-Br-Ph 3-851 4-Br HH OH -CH2-4-Br-Ph 3-852 4-Br HH OH -CH2-3-Cl- Ph 3-853 4-Br HH OH -CH2-4-Cl-Ph 3-854 4-Br HH OH -CH2 F-Ph 3-855 4-Br HH OH -CH2-4-F-Ph 3-856 4-Br HH nu JL JL -CH2 each Tfm-Ph 3-857 4-Br HH OH -CH2-4-Tfm-Ph '3-858 4-Br HH OH -CH2-3-OMe-Ph 3-859 4 -Br HH OH -CH2-4-OMe-Ph 3-860 4-Br HH OH -CH2-2? 3-diF-Ph 3-861 4-Br HH OH -CH2-254-diF-Ph 3-862 4 -Br H .H OH -CH2-2,5-diF-Ph 3-863 4-Br HH OH -CHr2,6-diF-Ph 3-864 4-Br HH OH -CHr3,4-diF-Ph 3- 865 4-Br HH OH -CH2-355-diF-Ph 3-866 4-Br HH OH -CH2-354-diCl-Ph 3-867 4-Br HH OH -CHr3,5-diCl-Ph 3-868 4 -Br HH OH -CH2-3-Cl-4-F-Ph 3-869 4-Br HH OH -CHs-S-Me ^ -Cl ^ Ph 3-870 4-Br HH OH -CHr3,4-Mtdo- Ph 3-871 4-Br HH OH -CH2-354-diMe-Ph 3-872 4-Br HH OH-CHr3,5-diMe-Ph 3-873 4-OH HH OH Ph 3-874 4-OH HH OH 1-Nap 3-875 4-OH HH OH 2-Nap 3-876 4-OH HH OH Bz 3-877 4-OH HH OH -CF2 -Ph 3-878 4-OH HH OH-(CH2) -2-Nap

112- 200401770 3-879 4-OH HH OH -CH2-3-Me-Ph 3-880 4-OH HH OH -CH2-4-Me-Ph 3-881 4-OH HH OH -CHr3-Br-Ph 3 -882 4-OH HH OH -CH2-4-Br-Ph 3-883 4-OH HH OH -CH2-3-Cl-Ph 3-884 4-OH HH OH -CHr4-Cl-Ph 3-885 4- OH HH OH -CH2-3-F-Ph 3-886 4-OH HH OH -CH2-4-F-Ph 3-887 4-OH HH OH -CH2-3-Tfm-Ph 3-888 4-OH HH OH -CH2-4-Tfm-Ph 3-889 4-OH HH OH -CH2-3-OMe-Ph 3-890 4-OH HH OH -CH2-4-OMe-Ph 3-891 4-OH HH OH- CH2-2,3-diF-Ph 3-892 4-OH HH OH -CH2-2,4-diF-Ph 3-893 4-OH XJ H OH -CH2-255-diF-Ph 3-894 4-OH HH OH -CH2-256-diF-Ph 3-895 4-OH HH OH -CH2-3,4-diF-Ph 3-896 4-OH HH OH -CH2-335-diF-Ph 3-897 4-OH HH OH -CH2-334-diCl-Ph 3-898 4-OH HH OH -CH2-355-diCl-Ph 3-899 4-OH HH OH 3-900 4-OH HH OH -CH2-3-Me-4 -Cl-Ph 3-901 4-OH HH OH -CHr3,4-Mtdo-Ph 3-902 4-OH HH OH -CH2-3,4-diMe-Ph 3-903 4-OH HH OH -CH2-3 , 5-diMe-Ph 3-904 4-Tfm HH OH Ph 3-905 4-Tfm _ HH OH 1-Nap 3-906 4-Tfm HH OH 2-Nap 3-907 4-Tfm HH OH Bz 3-908 4-Tfm HH. OH -CF2 -Ph 3-909 4-Tfm HH OH-(CH 2) -2-Nap 3-910 4-Tfm HH OH -CH2-3-Me-Ph 3-911 4-Tfm HH OH -CHa-4-Me-Ph 3-912 4-Tfm HH OH -CH2-3 -Br-Ph 3-913 4-Tfm HH OH -CH2-4-Br-Ph 3-914 4-Tfm HH OH -CH2-3-Cl-Ph 3-915 4-Tfm HH OH -CH2-4-Cl -Ph

113- 200401770 3-916 4-Tfm HH OH -CH2-3-F ^ Ph 3-917. 4-Tfm HH OH -CH2-4-F-Ph 3-918 4-Tfm HH OH -CH2-3-Tfm -Ph 3-919 4-Tfm HH OH -CHr4-Tfm-Ph 3-920 4-Tfm HH OH -CH2-3-OMe-Ph 3-921 4-Tfm HH OH -CH2-4-OMe-Ph 3- 922 4-Tfm HH OH • -CH2-233-diF-Ph 3-923 4-Tfm HH OH -CH2-2? 4-diF-Ph 3-924 4-Tfm HH OH -CH2-2? 5-diF- Ph 3-925 4-Tfm HH OH -CH2-2,6-diF-Ph 3-926 4-Tfm HH OH -CH2-354-diF-Ph 3-927 4-Tfm HH OH -CH2-355-diF- Ph 3-928 4-Tfm HH OH -CH2-3? 4-diCl-Ph 3-929 4-Tfm HH OH -CH2-335-diCl-Ph 3-930 4-Tfm HH OH -ΓΤΤ ~ 3_ΓΊ-Λ- Τ7- · ρΐη, • ^ JL JL / 1 JL JL JLA 3-931 4-Tfm HH OH -CH2-3-Me-4-Cl-Ph 3-932 4-Tfm HH OH -CH2-334-Mtdo-Ph 3-933 4-Tfm HH OH -CH2-3? 4-diMe-Ph 3-934 4-Tfm HH OH -CH2-335-diMe.Ph 3-935 4-OMe HH OH Ph 3-936 4-OMe HH OH 1-Nap 3-937 4-OMe HH OH 2-Nap · 3-938 4-OMe HH OH Bz 3-939 4-OMe HH OH -CF2 -Ph 3-940 4-OMe HH OH-(CH2)- 2-Nap 3-941 4-OMe HH OH -CH2—3-Me-Ph 3-942 4-OMe HH OH -CH2-4-Me-Ph 3-943 4-OMe HH OH -CH2-3-Br- Ph 3-944 4-OMe HH OH -CH2-4-Br-Ph 3-945 4-OMe HH OH -CH2-3-Cl-Ph 3-946 4-OMe HH OH -CH2-4-Cl-Ph 3- 947 4-OMe HH OH -CH2-3-F-Ph 3-948 4-OMe HH. OH -CH2-4-F-Ph 3-949 4-OMe HH OH -CH2-3-Tfm-Ph 3-950 4-OMe HH OH -CH2-4-Tfm-Ph 3-951 4-OMe HH OH -CH2-3-OMe-Ph 3-952 4-OMe HH OH • CHr4-〇Me-Ph 114- 200401770 3-953 4-OMe HH OH -CH2-253-diF-Ph 3-954 4-OMe HH OH -CH2-2, this diF-Ph 3-955 4-OMe HH OH -CH2-255-diF-Ph 3-956 4 -OMe HH OH -CH2-2,6-diF-Ph 3-957 4-OMe HH OH -CH2-3,4-diF-Ph 3-958 4-OMe HH OH -CH2-3? 5-diF-Ph 3-959 4-OMe HH OH -〇Η2-3,4-ώα-Ρ1ι 3-960 4-OMe HH OH -CH2-3,5-diCl-Ph 3-961 4-OMe HH OH -CH2-3-Cl -4-F-Ph 3-962 4-OMe HH OH -CH2-3-Me-4-Cl-Ph 3-963 4-OMe HH OH -CH2-3,4-Mtdo-Ph 3-964 4-OMe HH OH -CH2-3,4-diMe-Ph 3-965 4-OMe HH OH -CH2-3,5-diMe-Ph 3-966 4-AcNH HH OH Ph 3-967 4-AcNH HH OH 1-Nap 3-968 4-AcNH HH OH 2-Nap 3-969 4-AcNH HH OH Bz 3-970 4-AcNH HH OH -CF2 -Ph 3-971 4-AcNH HH OH-(CH2) -2-Nap 3- 972 4-AcNH HH OH -CH2-3-Me -Ph 3-973 4-AcNH HH OH -CH2-4-Me-Ph 3-974 4-AcNH HH OH -CH2-3-Br-Ph 3-975 4-AcNH HH OH -CH2-4-Br-Ph 3-976 4-AcNH HH OH -CH2-3-Cl-Ph 3-977 4-AcNH HH OH -CH2-4-Cl-Ph 3-978 4-AcNH HH OH -CH2-3-F-Ph 3- 979 4-AcNH HH OH -CH2-4-F-Ph 3-980 4-AcNH HH • OH -CH2-3-Tfm-Ph 3-981 4-AcNH HH OH -CH2-4-Tfm-Ph 3-982 4-AcNH HH OH -CH2-3-OMe-Ph 3-983 4-AcNH HH OH -CH2-4-OMe-Ph 3-984 4-AcNH HH OH -CHr2,3-diF-Ph 3-985 4- AcNH HH OH -CH2-254-diF-Ph 3-986 4-AcNH HH OH -CHr2,5-diF-Ph 3-987 4-AcNH HH OH -GH2-2? 6-diF-Ph 3-988 4- AcNH HH OH -CH2-354-diF-Ph 3-989 4-AcNH HH OH -CH2-3? 5-diF-Ph -115- 200401770 3-990 4-AcNH HH OH -CH2-354-diCl-Ph 3 -991 4-AcNH HH OH -CH2-335-diCl-Ph 3-992 4-AcNH HH OH -CH2 Each CM-F-Ph 3-993 4-AcNH HH OH -CH2-3-Me-4-Cl- Ph 3-994 4-AcNH HH OH -CH2-334-Mtdo-Ph 3-995 4-AcNH HH OH -CH2-3? 4-diMe-Ph 3-996 4-AcNH HH OH -CHr3,5-diMe- Ph 3-997 1-FHH OH Ph 3-998 1-FHH OH 1-Nap 3-999 1-FHH OH 2-Nap 3-1000 1-FHH OH Bz 3-1001 1-FHH OH -CF2 -Ph 3-1002 1-FHH OH-(CH2) -2-Nap 3-1003 1-FHH OH -CH2-3-Me-Ph 3-1004 1-FHH OH -CH2-4-Me-Ph 3-1005 1-FHH OH -CH2-3-Br-Ph 3-1006 1-FHH OH -CH2-4-Br »Ph 3-1007 1-FHH OH -CH2-3-Cl-Ph 3-1008 1-FHH OH- CH2-4-Cl-Ph 3-1009 1-FHH OH -CH2 Each F-Ph 3-1010 1-FHH OH -CH2-4-F-Ph 3-1011 1-FHH OH -CH2-3-Tfm-Ph 3-1012 1-FHH OH -CH2-4-Tfm-Ph 3-1013 1-FHH OH -CH2-3-OMe-Ph 3-1014 1-FHH OH -CH2-4-OMe-Ph 3-1015 1- FHH OH -CH2-2,3-diF-Ph 3-1016 1-FHH OH -CH2-2,4-diF-Ph 3-1017 1-FHH OH -CH2-2,5-diF-Ph 3-1018 1 -FHH .OH -CH2-2,6-diF-Ph 3-1019 1-FHH OH -CH2-3? 4-diF-Ph 3-1020 1-FHH OH -CH2-3,5-diF-Ph 3- 1021 1-FHH OH -CH2-354-diCl-Ph 3-1022 1-FHH OH -CH2-3? 5-diCl-Ph 3-1023 1-FHH OH -CHr3-Cl Outer F-Ph 3-1024 1- FHH OH -CH2-3-Me-4-Cl-Ph 3-1025 1-FHH OH -CH2-3? 4-Mtdo-Ph 3-1026 1-FHH OH > CH2-354-diMe-Ph -116- 200401770 3-1027 1-FHH OH -CH2-3? 5-diMe-Ph 3-1028 2-FHH OH Ph 3-1029 2-FHH OH 1-Nap 3-1030 2-FHH OH 2-Nap 3-1031 2 -FHH OH Bz 3-1032 2-FHH OH -CF2 -Ph 3-1033 2-FHH OH-(CH2) -2-Nap 3-1034 2-FHH OH -CH2-3-Me-Ph 3-1035 2-FHH OH. CH2-4-Me-Ph 3-1036 2-FHH OH -CH2-3-Br-Ph 3-1037 2-FHH OH -CH2-4-Br-Ph 3-1038 2-FHH OH -CH2-3-Cl -Ph 3-1039 2-FHH OH -CH2-4-Cl-Ph 3-1040 2-FHH OH -CH2-3-F-Ph 3-1041 2-FHH OH -CH2-4-F-Ph 3-1042 2-FHH OH -CH2-3-Tfm-Ph 3-1043 2-FHH OH -CH2-4-Tfm-Ph 3-1044 2-FHH OH -CH2-3-OMe-Ph 3-1045 2-FHH OH- CH2-4-OMe-Ph 3-1046 2-FHH OH -CH2-253-diF-Ph 3-1047 2-FHH OH -CH2-2? 4-diF-Ph 3-1048 2-FHH OH -CH2-2 , 5-diF-Ph 3-1049 2-FHH OH -CH2-2,6-diF-Ph 3-1050 2-FHH OH -CH2-3,4-diF-Ph 3-1051 2-FHH OH -CH2- 355-diF-Ph 3-1052 2-FHH OH -CH2-354-diCl-Ph 3-1053 2-FHH OH -CH2-3? 5-diCl-Ph 3-1054 2-FHH OH -CH2-3-Cl -4.F-Ph 3-1055 2-FHH OH -CH2-3-Me-4-Cl-Ph 3-1056 2-FHH OH -CH2-3? 4-Mtdo-Ph 3-1057 2-FHH OH- CH2-334-diMe-Ph 3-1058 2-FHH OH -CH2-335-diMe-Ph 3-1059 3-FHH OH Ph 3-1060 3-FHH OH 1-Nap '3-1061 3-FHH OH 2- Nap 3-1062 3-FH H OH Bz 3-1063 3-FHH OH -CF2 -Ph -117- 200401770 3-1064 3-FHH OH-(CH2) -2-Nap 3-1065 3-FHH OH -CH2-3-Me-Ph 3- 1066 3-FHH OH -CH2-4-Me-Ph 3-1067 3-FHH OH -CH2-3-Br-Ph 3-1068 3-FHH OH -CH2-4-Br-Ph 3-1069 3-FHH OH -CH2-3-Cl-Ph 3-1070 3-FHH OH -CHM-CI-Ph 3-1071 3-FHH OH -CH2-3-F-Ph 3-1072 3-FHH OH -CH2-4-F- Ph 3-1073 3-FHH OH -CH2-3-Tfm-Ph 3-1074 3-FHH OH -CH2-4-Tfm-Ph 3-1075 3-FHH OH -CH2-3-OMe-Ph 3-1076 3 -FHH OH -CH2-4-OMe-Ph 3-1077 3-FHH OH -CH2-2,3-diF-Ph 3-1078 3-FHH OH -CH2-2,4-diF-Ph 3-1079 3- FHH OH -CH2-235-diF-Ph 3-1080 3-FHH OH -CH2-256-diF-Ph 3-1081 3-FHH OH -CH2-354-diF-Ph 3-1082 3-FHH OH -CH2- 3,5-diF-Ph 3-1083 3-FHH OH -CHr3,4-diCl-Ph 3-1084 3-FHH OH -CHr3,5-diCl-Ph 3-1085 3-FHH OH -CH2-3-Cl -4-F-Ph 3-1086 3-FHH OH -CH2-3-Me-4-Cl-Ph 3-1087 3-FHH OH -CH2-354-Mtdo-Ph 3-1088 3-FHH OH -CH2- 354-diMe-Ph 3-1089 3-FHH OH -CH2-3,5-diMe-Ph 3-1090 4-FHH OH Ph 3-1091 4-FHH OH 1-Nap, 3-1092 4-FHH OH 2 -Nap 3-1093 4-FHH OH Bz 3-1094 4-FHH OH -CF2 -Ph 3-1095 4-FHH OH-(CH2) -2-Nap 3-1096 4-FHH OH -CH2-3-Me- Ph 3-1097 4-FHH OH -CH2-4-Me-Ph 3-1098 4-FHH OH -CH2-3-Br-Ph 3-1099 4-FHH OH -CH2-4-Br-Ph 3-1100. 4-FHH OH -CHr3-Cl-Ph 118- 200401770 3-1101 4-FHH OH -CHs ^ -Cl-Ph 3-1102 4-FHH OH -CH2-3-F «Ph 3-1103 4-FHH OH- CH2-4-F-Ph 3-1104 4-FHH OH -CHr3Tfm-Ph 3-1105 4-FHH OH -CH2-4-Tfm-Ph 3-1106 4-FHH OH -CH2-3-OMe-Ph 3- 1107 4-FHH OH -CH2-4-OMe-Ph 3-1108 4-FHH OH -CH2-253-diF-Ph 3-1109 4-FHH OH -CH2-254-diF-Ph 3-1110 4-FHH OH -CH2-2? 5-diF-Ph 3-1111 4-FHH OH -CH2-2,6-diF-Ph 3-1112 4-FHH OH -CHr3,4-diF-Ph 3-1113 4-FHH OH- CH2-3,5-diF-Ph 3-1114 4-FHH OH -CHr3,4-diCl-Ph 3-1115 4-FHH OH -CH2-3? 5-diCl-Ph 3-1116 4-FHH OH -CH2 -3-Cl-4-F-Ph 3-1117 4-FHH OH -CH2-3-Me-4-Cl-Ph 3-1118 4-FHH OH -CHr3,4-Mtdo-Ph 3-1119 4-FHH OH -CH2-3,4-diMe-? H 3-1120 4-FHH OH -CH2-3,5-diMe-Ph 3-1121 1-OMe 2-OMe H OH Ph 3-1122 1-OMe 2-OMe H OH 1-Nap 3-1123 1-OMe 2-OMe H OH 2-Nap 3-1124 1-OMe 2-OMe H OH Bz 3-1125 1-OMe 2-OMe H OH -CF2 -Ph 3-1126 1-OMe 2-OMe H OH-(CH2) -2-Nap 3-1127 1-OMe 2-OMe H OH -CH2-3-Me-Ph 3-1128 1-OMe 2-OMe H OH -CH2-4-Me- Ph 3-1129 1-OMe 2-OMe H OH -CH2-3-Br-Ph 3-1130 1-OMe 2-OMe H OH -CH2-4-Br-Ph 3-1131 1-OMe 2-OMe H OH -CHr3-Cl-Ph 3-1132 1-OMe 2-OMe H OH -CH2-4-Cl-Ph 3 -1133 1-OMe 2-OMe H OH -CH2-3-F-Ph 3-1134 1-OMe 2-OMe H OH -CH2-4-F-Ph 3-1135 1-OMe 2-OMe H OH -CH2-3-Tfm-Ph 3-1136 1-OMe 2-OMe H OH > CH2-4-Tfm -Ph 3 -1137 1-OMe 2-OMe H OH -CH2-3-OMe-Ph 119- 200401770 3-1138 1-OMe 2-OMe H OH -CHr4-〇Me-Ph 3-1139 1-OMe 2- OMe H OH -CHr2,3-diF-Ph 3-1140 1-OMe 2-OMe H OH -CH2-254-diF-Ph 3-1141 1-OMe 2-OMe H OH -CH2-255-diF-Ph 3 -1142 1-OMe 2-OMe H OH -CH2-256-diF-Ph 3-1143. 1-OMe 2-OMe H OH -CH2-354-diF-Ph 3-1144 1-OMe 2-OMe H OH- CH2-3,5-diF-Ph 3-1145 1-OMe 2-OMe H OH -CH2-354-diCl-Ph 3-1146 1-OMe 2-OMe H OH -CH2-335-diCl-Ph 3-1147 1-OMe 2-OMe H OH -CH2 each HF-Ph 3-1148 1-OMe 2-OMe H OH -CH2-3-Me-4-Cl-Ph 3-1149 1-OMe 2-OMe H OH -CHr3,4-Mtdo-Ph 3-1150 1-OMe 2-OMe H OH -CH2- 3,4-diMe-Ph 3-1151 1-OMe 2-OMe H OH ^ CH2-3? 5-diMe-Ph 3-1152 2-OMe 3-OMe H OH Ph 3-1153 2-OMe 3-OMe H OH 1-Nap 3-1154 2-OMe 3-OMe H OH 2-Nap 3-1155 2-OMe 3-OMe H OH Bz 3-1156 2-OMe 3-OMe H 'OH -CF2 -Ph 3-1157 2 -OMe 3-OMe H OH-(CH2) -2-Nap 3-1158 2-OMe 3-OMe H OH -CH2-3-Me-Ph 3-1159 2-OMe 3-OMe H OH -CH2-4- Me-Ph 3-1160 2-OMe 3-OMe H OH -CH2-3-Br-Ph 3-1161 2-OMe 3-OMe H OH -CH2-4-Br-Ph 3-1162 2-OMe 3-OMe H OH -CHr3-Cl-Ph 3-1163 2-OMe 3-OMe H OH -CHr4-Cl-Ph 3-1164 2-OMe 3-OMe H OH -CHr3-F-Ph 3-1165 2-OMe 3- OMe H OH -CH2-4-F-Ph 3-1166 2-OMe 3-OMe H OH -CH2-3-Tfm-Ph 3-1167 2-OMe 3-OMe H OH -CH2-4-Tfm-Ph 3 -1168 2-OMe 3-OMe H OH -CH2-3-OMe-Ph 3-1169 2-OMe 3-OMe H • OH -CH2-4-OMe-Ph 3-1170 2-OMe 3-OMe H OH- CH2-253-diF-Ph 3-1171 2-OMe 3-OMe H OH -CHr2,4-diF-Ph 3-1172 2-OMe 3-OMe H OH -CHr2,5-diF-Ph 3-1173 2- OMe 3-OMe H OH -CHr2,6-diF-Ph 3-1174 2-OMe 3-OMe H OH -CH2 -334-diF-Ph 120- 200401770 3-1175 2-OMe 3-OMe H OH -CHr3,5-diF-Ph 3-1176 2-OMe 3-OMe H OH -CH2-354-diCl-Ph 3-1177 2-OMe 3-OMe H OH -CH2-3,5-diCl-Ph 3-1178 2-OMe 3-OMe H OH -CH2-3-Cl-4-F-Ph 3-1179 2-OMe 3-OMe H. OH -CH2-3-Me-4-Cl-Ph 3-1180 2-OMe 3-OMe H OH -CHr3,4-Mtdo-Ph 34181 2-OMe 3-OMe H OH -CHr3,4-diMe- Ph 3-1182 2-OMe 3-OMe H OH -CHr3,5-diMe-Ph 3-1183 l, 2-Mtdo H OH Ph 3-1184 l, 2-Mtdo H OH 1-Nap 3-1185 1,2 -Mtdo H OH 2-Nap 3-1186 1,2-Mtdo H OH Bz 3-1187 1,2-Mtdo H OH -CF2 -Ph 3-1188 1,2-Mtdo H OH-(CH2) -2-Nap 3-1189 l52-Mtdo H OH -CH2-3-Me-Ph 3-1190 l32-Mtdo H OH -CHo-4-Me-Ph 3-1191 l, 2-Mtdo H OH -CH2-3-Br-Ph 3-1192 1,2-Mtdo H OH -CH2-4-Br-Ph 3-1193 1,2-Mtdo H OH -CHr3-Cl-Ph 3-1194 l, 2-Mtdo H OH -CH2-4-Cl -Ph 3-1195 l, 2-Mtdo H OH -CH2-3-F-Ph 3-1196 1,2-Mtdo H OH -CHr4-F-Ph 3-1197 l, 2-Mtdo H OH -CH2-3 -Tfm-Ph 34198 1,2-Mtdo H OH -CHr4-Tfm-Ph 3-1199 1,2-Mtdo H OH -CH2-3-OMe-Ph 3-1200 1,2-Mtdo H OH -CH2-4 -OMe-Ph 3-1201 l, 2-Mtdo H OH -CHr2,3-diF-Ph 3-1202 1,2-Mtdo H OH -CHr2,4-diF-Ph • 3-1203 1,2-Mtdo H OH -CH2-2? 5-diF-Ph 3- 1204 l, 2-Mtdo H OH -CH2-2? 6-diF-Ph 3-1205 1,2-Mtdo H OH • CH2-3,4-diF-Ph 3-1206 l? 2-Mtdo H OH -CHr3 , 5-diF-Ph 3-1207 l? 2-Mtdo H OH -CHr3,4-diCl-Ph 3-1208 l, 2-Mtdo H OH -CHr3,5-diCl-Ph 3-1209 1,2-Mtdo H OH -CH2 > 3-Cl-4-F-Ph 3-1210 1,2-Mtdo H OH -CHr3-Me-4-Cl-Ph 3-1211 1,2-Mtdo H OH -CHr3,4-Mtdo -Ph -121 200401770

3-1212 l? 2-Mtdo H OH 3-1213 l, 2-Mtdo H OH 3-1214 2,3-Mtdo H OH 3-1215 2,3-Mtdo H OH 3-1216 2,3-Mtdo H OH 3-1217 2,3-Mtdo H OH 3-1218 2,3-Mtdo H OH 3-1219 2,3-Mtdo H OH 3-1220 2,3-Mtdo H OH 3-1221 2,3-Mtdo H OH 3-1222 2,3-Mtdo H OH 3-1223 2,3-Mtdo H OH 3-1224 2,3-Mtdo H OH 3-1225 2,3-Mtdo H OH 3-1226 2,3-Mtdo H OH 3-1227 2,3-Mtdo H OH 3-1228 2,3-Mtdo H OH 3-1229 2,3-Mtdo H OH 3-1230 2,3_Mtdo H OH 3-1231 233-Mtdo H OH 3-1232 2 , 3-Mtdo H OH 3-1233 2,3-Mtdo H OH 3-1234 2,3-Mtdo H OH 3-1235 2,3-Mtdo H OH 3-1236 2,3-Mtdo H OH 3-1237 2 , 3-Mtdo H OH 3-1238 2,3-Mtdo H OH 3-1239 2,3-Mtdo H OH 3-1240 2,3-Mtdo H OH 3-1241 2,3-Mtdo H OH 3-1242 2 , 3-Mtdo H OH 3-1243 2,3-Mtdo H OH 3-1244 2,3-Mtdo H OH 3-1245 2-F 3-FH OH 3-1246 2-F 3-FH OH 3-1247 2 -F 3-FH OH 34248 2-F 3-FH OH -CHr3,4-diMe-Ph -CH2-3? 5-diMe-Ph

Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2-4-Me-Ph -CH2-3-Br-Ph -CH2-4-Br -Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CH2-233-diF-Ph -CH2-2,4-diF-Ph -CH2-255-diF-Ph -CHr2,6-diF-Ph -CH2-354-diF-Ph -GH2-355-diF-Ph -CH2-334-diCl-Ph -CH2-3? 5-diCl-Ph -CH2-3-Cl-4-F-Ph -Οί2-3 -Μ ^ 4-ΟΡ1ι -CH2-354-Mtdo-Ph -CH2-354-diMe-Ph -CHr3,5_diMe-Ph Ph 1-Nap 2-Nap

Bz 122- 200401770 3-1249 2-F 3-FH OH -CF2 -Ph 3-1250 2-F 3-FH OH-(CH2) -2-Nap 3-1251 2-F 3-FH OH -CH2-3 -Me-Ph 3-1252 2-F 3-FH OH -CH2-4-Me-Ph 3-1253 2-F 3-FH OH -CH2-3-Br-Ph 3-1254 2-F 3-FH OH -CH2-4-Br-Ph 3-1255 2-F 3-FH OH -CH2-3-Cl-Ph 3-1256 2-F 3-FH OH -CH2-4-CKPh 3-1257 2-F 3- FH OH -CH2-3-F-Ph 3-1258 2-F 3-FH OH -CH2-4-F-Ph 3-1259 2-F 3-FH OH -CH2-3-Tfm-Ph 3-1260 2 -F 3-FH OH -CHr4-Tfm-Ph 3-1261 2-F 3-FH OH -CH2-3-OMe-Ph 3-1262 2-F 3-FH OH -CH2-4-OMe-Ph 3- 1263 2-F 3-FH OH -CHr2,3-diF-Ph 3-1264 2-F 3-FH OH -CH2-2,4-diF-Ph 3-1265 2-F 3-FH OH -CH2-2 , 5-diF-Ph 3-1266 2-F 3-FH OH -CH2-2? 6-diF-Ph 3-1267 2-F 3-FH OH -CH2-3,4-diF-Ph 3-1268 2 -F 3-FH OH -CH2-3? 5-diF-Ph 3-1269 2-F 3-FH OH -CHs-S ^ -diCl-Ph 3-1270 2-F 3-FH OH -CH2 > 335- diCl-Ph 3-1271 2-F 3-FH OH -CH2-3-Cl-4-F-Ph 3-1272 2-F 3-FH OH -CH2-3-Me-4-Cl-Ph 3-1273 2-F 3-FH OH -CH2-3,4-Mtdo-Ph 3-1274 2-F 3-FH OH -CH2-334-diMe-Ph 3-1275 2-F 3-FH OH -CH2-355- diMe-Ph 3 -1276 1 * C1 2-OMe H OH Ph 3-1277 l-Cl 2-OMe H OH 1-Nap 3-1278 1-C1 2-OMe H OH 2-Nap 3-1279 1-C1 2-OMe H OH Bz 3-1280 1-C1 2 -OMe H OH -CF2 -Ph 3-1281 1-C1 2-OMe H OH-(CH2) -2-Nap 3-1282 1-C1 2-OMe H OH -CH2-3-Me-Ph 3-1283 1 -C1 2-OMe H OH -CH24Me-Ph 3-1284 1-C1 2-OMe H OH -CH2 Each Br-Ph 3-1285 1-C1 2-OMe H OH > CH2-4-Br-Ph 123- 200401770 3-1286 1-C1 2-OMe H OH -CH2-3-Cl-Ph 3-1287 1-C1 2-OMe H OH -CH2-4-Cl-Ph 3-1288 1-Ce 2-OMe H OH -CH2-3-F-Ph 3-1289 1-C1 2-OMe H OH -CHr4-F-Ph 3-1290 1-C1 2-OMe H OH -CH2-3-Tfm-Ph 3-1291 1-C1 2-OMe H OH -CH2-4-Tfm-Ph 3-1292 ι · α 2-OMe H OH -CHr3-OMe-Ph 3-1293 l-Cl 2-OMe H OH -CHr4-OMe-Ph 3-1294 1-C1 2-OMe H OH -CHr2,3-diF-Ph 3-1295 1-C1 2-OMe H OH -CH2-2? 4-diF-Ph 3-1296 1-C1 2-OMe H OH -CHr2 , 5-diF-Ph 3-1297 1-C1 2-OMe H OH -CH2-256-diF-Ph 3-1298 1-C1 2-OMe H OH -CHr3,4-diF-Ph 3-1299 1-C1 2-OMe H OH -CHr3,5-diF-Ph 3-1300 1-C1 2-OMe H OH -CK2-354-diCl-Ph 3-1301 1-C1 2-OMe H OH -CHr3,5-diCl- Ph 3-1302 1-C1 2-OMe H OH -CH2 ^ C1_4-F-Ph 3-1303 1-C1 2- OMe H OH -CHr3-Me-4-Cl-Ph 3-1304 1-C1 2-OMe H OH -CH2-3? 4-Mtdo-Ph 3-1305 1-C1 2-OMe H OH -CHr3,4- diMe-Ph 3-1306 1-C1 2-OMe H OH -CHr3,5-diMe-Ph 3-1307 1-OMe 2-C1 H OH Ph 3-1308 1-OMe 2-C1 H OH 1-Nap 3- 1309 1-OMe 2-C1 H OH 2-Nap 3-1310 1-OMe 2-C1 H OH Bz 3-1311 1-OMe 2-C1 H OH -CF2 -Ph 3-1312 1-OMe 2-C1 H OH -(CH2) -2-Nap 3-1313 1-OMe 2-C1 H OH -CH2-3-Me-Ph 3-1314 1-OMe 2-C1 H OH -CH2-4-Me-Ph 3-1315 1 -OMe 2-C1 H OH .-CH2-3-Br-Ph 3-1316 1-OMe 2-C1 H OH -CH2-4-Br-Ph 3-1317 1-OMe 2-C1 H OH -CHr3-Cl -Ph 3-1318 1-OMe 2-C1 H OH -CH2-4-Cl-Ph 3-1319 1-OMe 2-C1 H OH -CH2-3-F-Ph 3-1320 · 1-OMe 2-C1 H OH -CH2-4-F-Ph 3-1321 1-OMe 2-C1 H OH -CH2-3-Tfm-Ph 3-1322 1 -〇Me 2-C1 H OH -CH2-4-Tfm-Ph 124 -200401770 3-1323 1-OMe 2-C1 H OH -CH2-3-OMe-Ph 3-1324 1-OMe 2-C1 H OH -CHr4-〇Me-Ph 3-1325 1-OMe 2-C1 H OH -CH2-2,3-diF-Ph 3-1326 1-OMe 2-Cl H OH -CHr2,4-diF-Ph 3-1327 1-OMe 2-C1 H OH -CH2-255-diF-Ph 3- 1328 1-OMe 2-C1 H OH -CH2-256-diF-Ph 3-1329 1-OMe 2-C1 H OH -CHr3,4-diF-Ph 3-1330 1-OMe 2-C1 H OH -CH2-3,5-diF-Ph 3-1331 1-OMe 2-C1 H OH -CH2-354-diCl-Ph 3-1332 1-OMe 2-C1 H OH -CHr3,5-diCl-Ph 3-1333 1-OMe 2-C1 H OH -CH2-3-Cl-4-F-Ph 3-1334 1-OMe 2-C1 H OH -CH2-3-Me- 4-a-Ph 3-1335 1-OMe 2-C1 H OH diCH2-3,4-Mtdo-Ph 3-1336 1-OMe 2-C1 H OH -CH2-3,4-diMe-Ph 3-1337 1-OMe 2-C1 H OH -CHr3,5-diMe-Ph 3-1338 1-OMe 2-Me H OH Ph 3-1339 1-OMe 2-Me H OH 1-Nap 3-1340 1-OMe 2- Me H OH 2-Nap 3-1341 1-OMe 2-Me H OH Bz 3-1342 1-OMe 2-Me H OH -CF2 -Ph 3-1343 1-OMe 2-Me H OH-(CH2) -2 -Nap 3-1344 1-OMe 2-Me H OH -CH2-3-Me-Ph 3-1345 1-OMe 2-Me H OH -CH2-4-Me-Ph 3-1346 1-OMe 2-Me H OH -CH2-3-Br-Ph 3-1347 1-OMe 2-Me H OH -CH2-4-Br-Ph 3-1348 1-OMe 2-Me H OH -CH2-3-Cl-Ph 3-1349 1-OMe 2-Me H OH -CH2-4-Cl-Ph 3-1350 1-OMe 2-Me H OH -CH2-3-F-Ph 3-1351 1-OMe 2-Me H OH -CH2-4 -F-Ph 3-1352 1-OMe 2-Me H OH -CH2-3-Tfm-Ph 3-1353 1-OMe 2-Me H OH -CH2 Ice Tfm-Ph 3-1354 1-OMe. 2-Me H OH -CH2-3-OMe-Ph 3-1355 1-OMe 2-Me H OH -CH2-4-OMe-Ph 3-1356 1-OMe 2-Me H OH -CH2-233-diF-P h 3-1357 1-OMe 2-Me H OH -CHr2,4-diF-Ph 3-1358 1-OMe 2-Me H OH -CHr2,5-diF-Ph 3-1359 .1-OMe .2-Me H OH > CH2-2? 6-diF-Ph 125- 200401770

3-1360 1-OMe 2-Me H OH -CHr3,4-diF-Ph 3-1361 1-OMe 2-Me H OH -CH2-3,5-diF-Ph 3-1362 1-OMe 2-Me H OH -CH2-354-diCl-Ph 3-1363 1-OMe 2-Me H OH -CH2-335-diCl-Ph 3-1364 1-OMe 2-Me H OH .-CH2-3-Cl-4-F -Ph 3-1365 1-OMe 2-Me H OH -CH2 Me-4-Cl-Ph 3-1366 1-OMe 2-Me H OH -CH2-3,4-Mtdo-Ph 3-1367 1-OMe 2-Me H OH -CH2-354-diMe-Ph 3-1368 1-OMe 2-Me H OH -CH2-3? 5-diMe-Ph 3-1369 1-OMe 3-OMe H OH Ph 3-1370 1 -OMe 3-OMe H OH 1-Nap 3-1371 1-OMe 3-OMe H OH 2-Nap 3-1372 1-OMe 3-OMe H OH Bz 3-1373 1-OMe 3-OMe H OH -CF2- Ph 3-1374 1-OMe 3-OMe H OH-(CH2) -2-Nap 3-1375. 1-OMe 3-OMe H OH -CH2-3-Me-Ph 3-1376 1-OMe 3-OMe H OH -CH2-4-Me-Ph 3-1377 1-OMe 3-OMe H OH -CH2-3-Br-Ph 3-1378 1-OMe 3-OMe H OH -CH2-4-Br-Ph 3-1379 1-OMe 3-OMe H OH -CH2-3-Cl-Ph 3-1380 1-OMe 3-OMe H OH -CH2-4-Cl-Ph 3-1381 1-OMe 3-OMe H OH -CH2-3 -F-Ph 3-1382 1-OMe 3-OMe H OH -CH2-4-F-Ph 3-1383 1-OMe 3-OMe H OH -CH2-3-Tfm-Ph 3-1384 1-OMe 3- OMe H OH -CH2-4-Tfm-Ph 3-1385 1-OMe 3-OMe H OH -CH2-3-OMe-Ph 3-1386 1-OMe 3-OM e H OH -CH2-4-OMe-Ph 3-1387 1-OMe 3-OMe H OH -CH2-2? 3-diF-Ph 3-1388 1-OMe 3-OMe H OH -CHr254-diF-Ph 3 -1389 1-OMe 3-OMe H OH -CHr235-diF-Ph 3-1390 1-OMe 3-OMe H OH (-CH2-2? 6-diF-Ph 3-1391 1-OMe 3-OMe H OH- CH2-3? 4-diF-Ph 3-1392 1-OMe 3-OMe H OH -CH2-3? 5-diF-Ph 3-1393 1-OMe 3-OMe H OH -CH2-3,4-diCl- Ph 3-1394 1-OMe 3-OMe H OH -CHr3,5-diCl-Ph 3 -1395 1-OMe 3-OMe H OH -CHs ^ -Cl ^ -F-Ph 3-1396 1-OMe 3-OMe H OH -CH2-3-Me-4-Cl-Ph 126- 200401770 3-1397 1-OMe 3-OMe H OH -CHr3,4-Mtdo-Ph 3-1398 1-OMe 3-OMe H OH -CH2- 354-diMe-Ph 3-1399 1-OMe 3-OMe H OH -CH2-355-diMe-Ph 3-1400 1-Me 2-Me H OH Ph 3-1401 1-Me 2-Me H OH 1-Nap 3-1402 1-Me 2-Me H OH 2-Nap 3-1403 1-Me 2-Me H OH Bz 3-1404 1-Me 2-Me H OH -CF2 -Ph 3-1405 1-Me 2-Me H OH-(CH2) -2-Nap 3-1406 1-Me 2-Me H OH -CH2 -3-Me-Ph 3 -1407 1-Me 2-Me H OH -CH2-4-Me-Ph 3- 1408 1-Me 2-Me H OH -CH2-3-Br-Ph 3-1409 1-Me 2-Me H OH -CH2-4-Br-Ph 3-1410 1-Me 2-Me H OH -CH2- 3-Cl-Ph 3-1411 1-Me 2-Me H OH -CH2-4-Cl-Ph 3-1412 1-Me 2-Me H OH -CH2-3-F- Ph 3-1413 1-Me 2-Me H OH -CH2-4-F-Ph 3-1414 1-Me 2-Me H OH -CH2-3-Tfm-Ph 3-1415 1-Me 2-Me. H OH -CH2-4-Tfm-Ph 3-1416 .1-Me 2-Me H OH -CH2-3-OMe-Ph 3-1417 1-Me 2-Me. H OH -CH2-4-OMe-Ph 3 -1418 1-Me 2-Me H OH -CH2-253-diF-Ph 3-1419 1-Me 2-Me H OH -CH2-2? 4-diF-Ph 3-1420 1-Me 2-Me H OH -CHr2,5-diF-Ph 3-1421 1-Me 2-Me H OH -CH2-2? 6-diF-Ph 3-1422 1-Me 2-Me H OH -CH2-354-diF-Ph 3- 1423 1-Me 2-Me H OH -CH2-355-diF-Ph 3-1424 1-Me 2-Me H OH -CH2-3,4-diCl-Ph 3-1425 1-Me 2-Me H OH- ΟΗ2-335-ώα-Ρ1ι 3-1426 1-Me 2-Me H OH -CHr3-Cl-4-F-Ph 3-1427 1-Me 2-Me H OH -CH2-3-Me-4-Cl- Ph 3-1428 1-Me 2-Me H OH -CH2-354-Mtdo-Ph 3-1429 1-Me 2-Me H OH -CH2-354-diMe-Ph 3-1430 1-Me 2-Me H OH • CHr3,5-diMe-Ph 3-1431 1-Me 3-Me H OH Ph 3-1432 1-Me 3-Me H OH 1-Nap 3-1433 1-Me 3-Me H OH 2-Nap 127- 200401770 3-1434 3-1435 3-1436 3-1437 3-1438 3-1439 3-1440 3-1441 3-1442 3-1443 3-1444 3-1445 3-1446 3-1447 3-1448 3-1449 3 -1450 3-1451 3-1452 3-1453 3-1454 3-1455 3-1456 3-1457 3-1458 3-1459 3-1460 3-1 461 3-1462 3-1463 3-1464 3-1465 3-1466 3-1467 3-1468 3-1469 3-1470 1-Me 3-Me 1-Me 3-Me 1-Me 1-Me 3 -Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1- Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 3-Me 1-Me 2 -C1 1-Me 2-C1 1-Me 2-C1 1-Me 2-C1 1-Me 2-C1 1-Me 2-C1 1-Me 2-C1 1-Me 2-C1 1-Me 2-C1

H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH

Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2-4-Me-Ph -CH2-3-Br-Ph -CH2-4-Br-Ph -CH2-3- Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3-OMe- Ph -CH2-4-OMe * Ph -CH2-253-diF-Ph -CH2-254-diF-Ph -CH2-255-diF-Ph -CH2-236-diF-Ph -CH2-334-diF-Ph- CH2-3,5-diF-Ph -CHr354-diCl-Ph -CH2-355-diCl-Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CH2- 3? 4-Mtdo-Ph -CH2-3,4-diMe-Ph -CH2-3,5-diMe-Ph

Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap _CH2-3-Me-Ph -CH2-4-Me-Ph -CH2-3-Br-Ph

128- 200401770 3-1471 1-Me 2-C1 H OH -CH2-4-Br-Ph 3-1472 1-Me 2-C1 H OH -CH2-3-Cl-Ph 3-1473 1-Me 2-C1 H OH -CH2-4-Cl-Ph 3-1474 1-Me 2-C1 H OH -CH2-3-F-Ph 3-1475 1-Me 2-C1 H OH -CH2 bucket F-Ph 3-1476 1 -Me 2-C1 H OH -CHr3-Tfm-Ph 3-1477 1-Me 2-C1 H OH -CH2-4-Tfm-Ph 3-1478 1-Me 2-C1 H OH -CH2-3-OMe- Ph 3-1479 1-Me 2-C1 H OH -CH2-4-OMe-Ph 3-1480 1-Me 2-C1 H OH -CHr2,3-diF-Ph 3-1481 1-Me 2-C1 H OH -CH2-2,4-diF-Ph 3-1482 .1-Me 2-C1 H OH -CH2-2,5-diF-Ph 3-1483 1-Me 2-C1 H OH -CH2-256-diF- Ph 3-1484 1-Me 2-C1 H OH -CH2-3? 4-diF-Ph 3-1485 1-Me 2-C! H OH -CH2-355-diF-Ph 3-1486 1-Me 2- C1 H OH -CH2-334-diCl-Ph 3-1487 1-Me 2-C1 H OH -CH2-355-diCl-Ph 3-1488 1-Me 2-C1 H OH -CH2-3-Cl-4- F-Ph 3-1489 1-Me 2-C1 H OH -CH2-3-Me-4-Cl-Ph 3-1490 1-Me 2-C1 H OH -CH2-3,4-Mtdo-Ph 3-1491 1-Me 2-C1 H OH -CH2-354-diMe-Ph 3-1492 1-Me 2-C1 H OH -CH2-3? 5-diMe-Ph 3-1493 1-Me 2-OMe H OH Ph 3 -1494 1-Me 2-OMe H OH 1-Nap 3-1495 1-Me 2-OMe H OH 2-Nap 3-1496 1-Me 2-OMe H OH Bz 3-1497 1-Me 2-OMe H OH -CF2 -Ph 3-1498 1-Me 2-OMe H OH-(CH2) -2-Nap 3-1499 1-Me 2-OMe H OH -CH2-3-Me-Ph 3-1500 1-Me 2-OMe H OH- CH2-4-Me-Ph 3-1501 1-Me 2-OMe H OH -CHr3-Br-Ph 3-1502 1-Me 2-OMe H OH -CH2-4-Br-Ph 3-1503 1-Me 2 -OMe H OH -CH2-3-Cl-Ph 3-1504 1-Me 2-OMe H OH -CH2-4-Cl-Ph 3-1505 1-Me 2-OMe H OH -CH2-3-F-Ph 3-1506 1-Me 2-OMe H OH -CH2-4-F-Ph 3-1507 1-Me 2-OMe H OH -CH2-3-Tfm-Ph 129- 200401770 3-1508 1-Me 2-OMe H OH -CH2-4-Tfm-Ph 3-1509 1-Me 2-OMe H OH -CHr3-OMe-Ph 3-1510 1-Me 2-OMe H OH -CH2-4-OMe-Ph 3-1511 1 -Me 2-OMe H OH -CH2-233-diF-Ph 3-1512 1-Me 2-OMe H OH -CH2-254-diF-Ph 3-1513 1-Me 2-OMe H OH -CH2-2? 5-diF-Ph 3-1514 1-Me 2-OMe H OH -CHr2? 6-diF-Ph 3-1515 1-Me 2-OMe H OH -CH2-354-diF-Ph 3-1516 1-Me 2 -OMe H OH -CH2-355-diF-Ph 3-1517 1-Me 2-OMe H OH -CH2-354.diCl-Ph 3-1518 1-Me 2-OMe H OH -CH2-335-diCl-Ph 3-1519 1-Me 2-OMe H OH -CH2-3-Cl-4-F-Ph 3-1520 1-Me 2-OMe H OH -CH2-3-Me-4-Cl-Ph 3-1521 1 -Me 2-OMe H OH -CH2-3? 4-Mtdo-Ph 3-1522 1-Me 2-OMe H OH A? "//, 1 V« «. W Ο. XX 3 -1523 1-Me 2-OMe H OH -CH2-3,5-diMe-Ph 3-1524 1-C1 2-Me H OH Ph 3-1525 1-C1 2-Me H OH 1-Nap 3-1526 1 > C1 2-Me H OH 2-Nap 3-1527 1-C1 2-Me H OH Bz 3-1528 1-C1 2-Me H OH -CF2 -Ph 3-1529 1-C1 2-Me 'H OH- (CH2) -2-Nap 3-1530 1-C1 2-Me H OH -CH2-3-Me-Ph 3-1531 1-C1 2-Me H OH -CH2-4-Me-Ph 3-1532 1- C1 2-Me H OH -CH2 Each Br-Ph 3-1533 1-C1 2-Me H OH -CH2-4-Br-Ph 3-1534 1-C1 2-Me H OH -CH2-3-Cl-Ph 3-1535 1-C1 2-Me H OH -CH2-4-Cl-Ph 3-1536 1-C1 2-Me H OH -CH2-3-F-Ph 3-1537 1-C1 2-Me H OH- CH2-4-F-Ph 3-1538 1-C1 2-Me H OH -CH2-3-Tfm-Ph 3-1539 1-C1 2-Me H OH -CH2-4-Tfm-Ph 3 -1540 1- C1 2-Me H OH -CH2-3-OMe-Ph 3-1541 1-Cl 2-Me H OH -CHr4-OMe-Ph 3 -1542 1-C1 2-Me H OH -CHr2,3-diF-Ph 3-1543 1-C1 2-Me H OH -CH2-254 > diF-Ph 3-1544 1-C1 2-Me H OH -CHr2,5-diF-Ph -130- 200401770 3-1545 1-C1 2- Me H OH -CH2-256-diF-Ph 3-1546 1-C1 2-Me H OH-CH2-3,4Uh 3-1547 1-C1 2-Me H OH -CH2-355-diF-Ph 3-1548 1-C1 2-Me H OH -CH2-354-diCl-Ph 3-1549 1-C1 2-Me H OH -CH2-355-diCl-Ph 3-1550 1-C1 2 -Me H OH -CH2-3-Cl-4-F-Ph 3-1551 1-C1 2-Me H OH -CHr3-Me-4-Cl-Ph 3-1552 1-C1 2-Me H OH -CH2 -354-Mtdo-Ph 3-1553 1-C1 2-Me H OH -CH2-334-diMe-Ph 3-1554 1-C1 2-Me H OH -CH2-335-diMe-Ph 3-1555 1-C1 2-C1 H OH Ph 3-1556 1-C1 2-C1 H OH 1-Nap 3-1557 1-C1 2-C1 H OH 2-Nap 3-1558 1-C1 2-C1 H OH Bz 3-1559 1 -C1 2-C1 H OH -CF2 -Ph 3-1560 1-C1 2-C1 H OH-(CH2) -2-Nap 3-1561 1-C1 2-C1 H OH -CH2-3-Me-Ph 3 -1562 1-C1 2-C1 H OH -CH2-4-Me-Ph 3-1563 1-C1 2-C1 H OH -CH2-3-Br-Ph 3-1564 1-C1 2-C1 H OH -CH2 -4-Br-Ph 3-1565 1-C1 2-C1 H OH -CH2-3-Cl-Ph 3-1566 1-C1 2-C1 H OH -CH2-4-Cl-Ph 3-1567 1-C1 2-C1 H OH -CH2-3-F-Ph 3-1568 1-C1 2-C1 H OH -CH2-4-F-Ph 3-1569 1-C1 2-C1 H OH -CH2-3-Tfm- Ph 3-1570 1-C1 2-C1 H OH -CH2-4-Tfm ^ Ph 3-1571 1-C1 2-C1 H OH -CH2-3-OMe-Ph 3-1572 1-C1 2-C1 H OH -CH2-4-OMe-Ph 3-1573 1-C1 2-C1 H OH -CH2-2,3-diF-Ph 3-1574 1-C1 2-C1 H OH -CH2-254-diF-Ph 3- 1575 1-C1 2-C1 H OH -CHr2,5-diF-Ph 3-1576 1-C1 2-C1 H OH -CH2-236-diF-Ph 3-1577 1-C1 2-C1 H OH -CH2- 354-diF-Ph 3-157 8 1-C1 2-C1 H OH -CH2-3? 5-diF-Ph 3-1579 1-C1 2-C1 H OH -CH2-3? 4-diCl-Ph 3-1580 1-C1 2-C1 H OH -CH2-3? 5-diCl-Ph 3-1581 1-C1 2-C1 H OH -CH2-3-a-4-F-Ph 131- 200401770 3-1582 1-C1 2-C1 H OH -CH2 -3-Me-4-Cl-Ph 3-1583 1-C1 2-C1 H OH -CH2-3,4-Mtdo-Ph 3-1584 1-C1 2-C1 H OH -CH2-354-diMe-Ph 3-1585 1-C1 2-C1 H OH -CH2-355-diMe-Ph 3-1586 1-C1 3-C1 H OH Ph 3-1587 1-C1 3-C1 H OH 1-Nap 3-1588 1- C1 3-C1 H OH 2-Nap 3-1 Swallow 89 (1-C1 3-C1 H OH Bz 3-1590 1-C1 3-C1 H OH -CF2 -Ph 3-1591 1-C1 3-C1 H OH -(CH2) -2-Nap 3-1592 1-C1 3-C1 H OH -CH2-3-Me-Ph 3-1593 1-C1 3-C1 H OH -CH2-4-Me-Ph 3-1594 1 -C1 3-C1 H OH -CH2-3-Br-Ph 3-1595 1-C1 3-C1 H OH -CH2-4-Br-Ph 3-1596 1-C1 3-C1 H OH -CH2-3- Cl-Ph 3-1597 1-C1 3-C1 H OH -CH2-4-Cl-Ph 3-1598 1-C1 3-C1 H OH -CH2-3-F-Ph 3-1599 1-C1 3-C1 H OH -CH2-4-F-Ph 3-1600 1-C1 3-C1 H OH -CH2-3-Tfm-Ph 3-1601 1-C1 3-C1 H OH -CH2-4-Tfm-Ph 3- 1602 1-C1 3-C1 H OH -CH2-3-OMe-Ph 3-1603 1-C1 3-C1 H OH -CH2-4-OMe-Ph 3-1604 1-C1 3-C1 H OH -CH2- 2? 3-diF-Ph 3-1605 1-C1 3-C 1 H OH -CH2-2,4-diF-Ph 3-1606 1-C1 3-C1 H OH -CH2-235-diF-Ph 3-1607 1-C1 3-C1 H OH -CH2-236-diF- Ph 3-1608 1-C1 3-C1 H OH -CH2-354-diF-Ph 3-1609 1-C1 3-C1 H OH -CH2-3,5-diF-Ph 3-1610 1-C1 3-C1 H OH -CH2-334-diCl-Ph 3-1611 1-C1 3-C1 H OH -CH2-335-diCl-Ph 3-1612 1-C1 3-C1 H OH -CH2-3-Cl-4-F -Ph 3-1613 1-C1 3-C1 H OH -CH2-3-Me-4-Cl-Ph 3-1614 1-C1 3-C1 H OH -CH2-354-Mtdo-Ph 3-1615 1-C1 3-C1 H OH -CH2-354-diMe-Ph 3-1616 1-C1 3-C1 H OH -GH2-3? 5-diMe-Ph 3-1617 2-Me 3-Me H OH Ph 3-1618 2 -Me 3-Me H OH 1-Nap 132- 200401770 3-1619 2-Me 3-Me H OH 2-Nap 3-1620 2-Me 3-Me H OH Bz 3-1621 2-Me '3-Me H OH -CF2 -Ph 3-1622 2-Me 3-Me H OH-(CH2) -2-Nap 3-1623 2-Me 3-Me H OH -CH2-3-Me-Ph 3-1624 2-Me 3 -Me H OH -CH24Me-Ph 3-1625 2-Me 3-Me H OH -CH2-3-Br-Ph 3-1626 2-Me 3-Me H OH -CH2-4-Br-Ph 3-1627, 2-Me 3-Me H OH -CH2-3-Cl-Ph 3 -1628 2-Me 3-Me H OH -CH2-4-Cl-Ph 3-1629 2-Me 3-Me H OH -CH2-3 -F-Ph 3-1630 2-Me 3-Me H OH -CH2-4-F-Ph 3-.1631 2-Me 3-Me H OH -CH2-3-Tfm-Ph 3-1632 2-Me 3 -Me H OH -CH2-4-Tfm-Ph 3-1633 2-Me 3-Me H OH -CH2 OMe-Ph 3-1634 2-Me 3-Me H OH -CH2-4-OMe-Ph 3-1635 2 -Me 3-Me H OH -CH2-2,3-diF-Ph 3-1636. 2-Me 3-Me H OH -CH2-234-diF-Ph 3-1637 2-Me 3-Me H OH -CH2 -2,5-diF-Ph 3-1638 2-Me 3-Me H OH -CH2-256-diF-Ph 3-1639 2-Me 3-Me H OH -CH2-354-diF-Ph 3-1640 2 -Me 3-Me H OH -CH2-3,5-diF-Ph 3-1641 2-Me 3-Me H OH -CHs-S ^ -diCl-Ph 3-1642 2-Me 3-Me H OH -CH2 -3,5-diCl-Ph 3-1643 2-Me 3-Me H OH -CH2-3-Cl-4-F-Ph 3-1644 2-Me 3-Me H OH -CH2-3-Me.4 -Cl-Ph 3-1645 2-Me 3-Me H OH -CH2-354-Mtdo-Ph 3-1646 2-Me 3-Me H OH -CH2-3,4-diMe-Ph 3-1647 2-Me 3-Me H OH -CH2-335-diMe-Ph 3-1648 2-Me 3-C1 H OH Ph 3-1649 2-Me 3-C1 H OH 1-Nap 3-1650 2-Me '3-C1 H OH 2-Nap 3-1651 2-Me 3-C1 H OH Bz 3-1652 2-Me 3-C1 H OH -CF2 -Ph 3-1653 2-Me 3-C1 H OH-(CH2) -2-Nap 3-1654 2-Me 3-C1 H OH • CH2-3-Me-Ph 3-1655 2-Me 3-C1 H OH -CH2-4-Me-Ph 133 200401770 3-1656 2-Me 3-C1 H OH -CH2-3-Br-Ph 3-1657 2-Me 3-C1 H OH -CH2-4-Br-Ph 3-1658 2-Me 3-C1 H OH -CHa-S-Cl-Ph 3-1659 2-Me 3-C 1 H OH -CHr4-Cl-Ph 3-1660 2-Me 3-C1 H OH -CH2-3-F-Ph 3-1661 2-Me 3-C1 H OH -CH2-4-F-Ph 3-1662 2-Me 3-C1 H OH -CH2-3-Tfm-Ph 3-1663 2-Me 3-C1 H OH -CH2-4-Tfm-Ph 3-1664 2-Me 3-C1 H OH -CH2-3 -OMe-Ph 3-1665 2-Me 3-C1 H OH -CH2-4-OMe-Ph 3-1666 2-Me 3-C1 H OH -CH2-2? 3-diF-Ph 3-1667 2-Me 3-C1 H OH -CH2-2? 4-diF-Ph 3-1668 2-Me 3-C1 H OH -CH2-255-diF-Ph 3-1669 2-Me 3-C1 H OH -CH2-2, 6-diF-Ph 3-1670 2-Με 3-C1 H OH -CK2-3,4-diF-Ph. 3-1671 2-Me 3-C1 H OH -CH2-3,5-diF-Ph 3- 1672 2-Me 3-C1 H OH -CH2-3? 4-diCl-Ph 3-1673 2-Me 3-C1 H OH -CH2-3,5-diCl-Ph 3-1674 2-Me 3-C1 H OH .CH2-3-Cl-4-F-Ph 3-1675 2-Me 3-C1 H OH -CH2-3-Me-4-Cl-Ph 3-1676 2-Me 3-C1 H OH -CH2- 3,4-Mtdo-Ph 3-1677 2-Me 3-C1 H OH -CH2-354-diMe-Ph 3-1678 2-Me 3-C1 H OH -CH2-3,5-diMe-Ph 3-1679 2-Me 3-OMe H OH Ph 3-1680 2-Me • 3-OMe H OH 1-Nap 3-1681 2-Me 3-OMe H OH 2-Nap 3-1682 2-Me 3-OMe H OH Bz 3-1683 2-Me 3-OMe H OH -CF2 -Ph 3-1684 2-Me 3-OMe H OH-(CH2) -2-Nap 3-1685 2-Me 3-OMe H OH -CH2-3- Me-Ph 3-1686 2-Me 3-OM e H OH -CH24Me-Ph 3-1687 2-Me 3-OMe H OH -CH2-3-Br-Ph 3-1688 2-Me 3-OMe H OH -CH2-4-Br-Ph 3-1689 2- Me 3-OMe H OH -CHd-Cl-Ph 3-1690 2-Me 3-OMe H OH -CH2-4-Cl-Ph 3-1691 2-Me 3-OMe H OH -CHo-3-F-Ph 3-1692 2-Me 3-OMe H OH -CHr4-F-Ph 134- 200401770

3-1693 2-Me 3-OMe H OH -CH2-3-Tfm-Ph 3-1694 2-Me 3-OMe H OH -CH2-4-Tfm-Ph 3-1695 2-Me 3-OMe H OH- CH2-3-GMe-Ph 3-1696 2-Me 3-OMe H OH -CH2-4-OMe-Ph 3-1697 2-Me 3-OMe H OH -CH2-2,3-diF-Ph 3-1698 2-Me 3-OMe H OH -CHr2,4-diF-Ph 3-1699 2-Me 3-OMe H OH -CHr2,5-diF-Ph 3-1700 2-Me 3-OMe H OH -CH2-2 , 6-diF-Ph 3-1701 2-Me 3-OMe H OH -CHr3,4-diF-Ph 3-1702 2-Me 3-OMe H OH -CH2-335-diF-Ph 3-1703 2-Me 3-OMe H OH -CH2-354-diCl-Ph 3-1704 2-Me 3-OMe H OH -CH2-3? 5-diCl-Ph 3-1705 2-Me 3-OMe H OH -CH2-3- Cl-4-F-Ph 3-1706 2-Me 3-OMe H OH -CH2-3-Me-4-Cl-Ph 3-1707 2-Me 3-OMe H OH -CH2-3,4-Mtdo- Ph 3-1708 2-Me 3-OMe H OH -CH2-334-diMe-Ph 3-1709 2-Me 3-OMe H OH -CH2-335-diMe-Ph 3-1710 2-C1 3-Me H OH Ph 3-1711 2-C1 3-Me H OH 1-Nap 3-1712 2-C1 3-Me H OH 2-Nap 3-1713 2-C1 3-Me H OH Bz 3-1714 2-C1 3-Me H OH -CF2 -Ph 3-1715 2-C1 3-Me H OH-(CH2) -2-Nap 3-1716 2-C1 3-Me H OH -CH2-3-Me-Ph 3-1717 2-C1 3-Me. H OH -CH2-4-Me-Ph 3-1718 2-C1 3-Me H OH -CH2-3-Br-Ph 3-1719 2-C1 3-Me H OH -CH2-4-Br -Ph 34720 2-C1 3-Me H OH -CH2-3-Cl-Ph 3-1721 2-C1 3-Me H OH -CH2-4-Cl-Ph 3-1722 2-C1 3-Me H OH -CH2- 3-F-Ph 3-1723 2-C1 3-Me Ή OH -CH2-4-F-Ph 3-1724 2-C1 3-Me H OH -CH2-3-Tfm-Ph 3-1725 2-C1 3 -Me · H OH -CHr4-Tfm-Ph 3-1726 2-C1. 3-Me H OH -CHr3-OMe-Ph 3-1727 2-C1 3-Me H OH -CHr4-OMe-Ph 3-1728 2 -C1 3-Me H OH -CH2-233-diF-Ph 3-1729 2-C1 3-Me H OH -CH2-254-diF-Ph 135- 200401770 3-1730 2-C1 3-Me H OH -CH2 -2? 5-diF-Ph 3-1731 2-C1 3-Me H OH -CHr2,6-diF-Ph 3-1732 2-C1 3-Me H OH -CH2-354-diF-Ph 3-1733 2 -C1 3-Me H OH -CHr3,5-diF-Ph 3-1734 2-C1 3-Me H OH -CH2-354-diCl-Ph 3-1735 2-C1 3-Me H OH -CH2-3, 5-diCl-Ph 3-1736 2-C1 3-Me H OH -CH2-3-Cl-4-F-Ph 3-1737 2-C1 3-Me H OH -CH2 Me-lCl-Ph 3-1738 2-C1 3-Me H OH -CH2-334-Mtdo-Ph 3-1739 2-C1 3-Me H OH -CH2-354-diMe-Ph 3-1740 2-C1 3-Me H OH -CHr3,5 -diMe-Ph 3-1741 2-C1 3-C1 H OH Ph 3-1742 2-C1 3-C1 H OH 1-Nap 3-1743 2-C1 3-C1 H OH 2-Nap 3-1744 2-C1 3-C1 H OH Bz 3-1745 2-C1 3-C1 H OH -CF2 -Ph 3-1746 2-C1 3-C1 H OH-(CH2) -2-Nap 3- 1747 2-C1 3-C1 H OH -CH2-3-Me-Ph 3-1748 2-C1 3-C1 H OH -CH2-4-Me-Ph 3-1749 2-C1 3-C1 H OH -CH2- 3-Br-Ph 3-1750 2-C1 3-C1 H OH -CH2-4-Br-Ph 3-1751 2-C1 3-C1 H OH -CHr3-Cl-Ph 3-1752 2-C1 3-C1 H OH • CHr4-Cl-Ph 3-1753 2-C1 3-C1 H OH -CH2-3-F-Ph 3 -1754 2-C1 3-C1 H OH -CH2-4-F-Ph 3-1755 2 -C1 3-C1 H OH -CH2-3-Tfm-Ph 3-1756 2-C1 3-C1 H OH -CH2-4-Tfm-Ph 3-1757 2-C1 3-C1 H OH -CH2-3- OMe-Ph 3-1758 2-C1 3-C1 H OH -CH2-4-OMe-Ph 3-1759 2-C1 3-C1 H OH -CH2-2? 3-diF-Ph 3-1760 2-C1 3 -C1 H OH -CH2-254-diF-Ph 3-1761 2-C1 3-C1 H OH -CHr2,5-diF-Ph 3-1762 2-C1 3-C1 H OH -CHr2,6-diF, Ph 3-1763 2-C1 3-C1 H OH -CHr3,4-diF-Ph 3-1764 2-C1 3-C1 H OH -CH2-335-diF > Ph 3-1765 2-C1 3-C1 H OH- CHr3,4-diCl-Ph 3-1766 2-Cl 3-C1 • H OH -CHr3,5-diCl-Ph -136 200401770 3-1767 2-C1 3-C1 3-1768 2-C1 3-C1 3- 1769 2-C1 3-C1 3-1770 2-C1 3-C1 3-1771 2-C1 3-C1 3-1772 2-C1 3-OMe 3-1773 2-C1 3-OMe 3-1774 2-C1 3 -OMe 3-1775 2-C1 3-OMe 3-1776 2-C1 3-OMe 3-1777 2-C1 3-OMe 3-1778 2-C1 3-OMe 3-1779 2 -C1 3-OMe 3-1780 2-G1 3-OMe 3-1781 2-C1 3-OMe 3-1782 2-C1 3-OMe 3-1783 2-C1 3-OMe 3-1784 2-C1 3-OMe 3-1785 2-C1 3-OMe 3-1786 2-C1 3-OMe 3-1787 2-C1 3-OMe 3-1788 2-C1 3-OMe 3-1789 2-C1 3-OMe 3-1790 2- C1 3-OMe 3-1791 2-C1 3-OMe 3-1792 2-C1 3-OMe 3-1793 2-C1 3-OMe 3-1794 2-C1 3-OMe 3-1795 2-C1 3-OMe 3 -1796 2-C1 3-OMe 3-1797 2-C1 3-OMe 3-1798 2-C1 3-OMe 3-1799 2-C1 3-OMe 3-1800 2-C1 3-OMe 3-1801 2-C1 3-OMe 3-1802 2-C1 3-OMe 3-1803 2-OMe 3-Me hhhhhhhhhhhhhhhhhhhhh.hhhhhhhhhhhh) h) h) hh ΟΗΟΗΟΗΟΗΟΗΟΙ1ορορ.ορΟΙ-ο? ο ^ οοοοοοοοοοοοοοοοοοοοοοοοο hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh -CH2-3-Cl-4-F -Ph -CH2-3-Me-4-Cl-Ph -CH2-354-Mtdo-Ph -CH2-354-diMe-Ph -CHr3,5-diMe-Ph

Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2-4-Me-Ph -CH2-3-Br-Ph -CH2-4-Br -Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CH2-253-diF-Ph -CH2-2,4-diF-Ph -CH2-2,5-diF-Ph -CHr2,6-diF -Ph -CH2-3,4-diF-Ph -CHr3,5-diF-Ph -CHs-S ^ -diCl-Ph -CH2-355-diCl-Ph -CH2-3-Cl-4-F-Ph- CHr3-Me-4-Cl-Ph -CHr3,4-Mtdo-Ph -CH2-3,4-diMe-Ph -CH2-3,5-diMe-Ph

Ph -137- 200401770 3-1804 2-OMe 3-Me H OH 1-Nap 3-1805 2-OMe 3-Me H OH 2-Nap 3-1806 2-OMe 3-Me H OH Bz 34807 2-OMe 3 -Me H OH -CF2 -Ph 3-1808 2-OMe 3-Me H OH-(CH2) -2-Nap 3-1809 2-OMe 3-Me H OH -CH2-3-Me-Ph 3-1810 2 -OMe 3-Me H OH -CH2 ~ 4-Me-Ph 3-1811 2-OMe 3-Me H OH -CH2-3-Br-Ph 3-1812 2-OMe 3-Me H OH -CH2-4- Br-Ph 3-1813 2-OMe 3-Me H OH -CH2-3-Cl-Ph 3-1814 2-OMe 3-Me H OH -CH2-4-Cl-Ph 3-1815 2-OMe 3-Me H OH -CH2-3-F-Ph 3-1816 2-OMe 3-Me H OH -CH2-4-F-Ph 3-1817 2-OMe 3-Me H OH -CH2-3-Tfm-Ph 3- 1818 2-OMe 3-Me H OH -CH2-4-Tfm-Ph 3-1819 2-OMe 3-Me H OH -CH2-3-OMe-Ph 3-1820 2-OMe 3-Me H OH -CHr4- OMe_Ph 3-1821 2-OMe 3-Me · H OH -CH2-2,3-diF-Ph 3-1822 2-OMe 3-Me H OH -CH2-2,4-diF-Ph 3 -1823 2-OMe 3-Me H OH -CH2-2? 5-diF-Ph 3-1824 2-OMe 3-Me H OH -CHr2,6-diF-Ph 3-1825 2-OMe _ 3-Me H OH -CH2-3 , 4-diF-Ph 3-1826 2-OMe 3-Me H OH -CH2-3,5-diF-Ph 3-1827 2-OMe 3-Me H OH -CH2-3? 4-diCl-Ph 3- 1828 2-OMe 3-Me H OH -CH2-355-diCl-Ph 3-1829 2-OMe 3-Me H OH -CH2-3-Cl-4-F-Ph 3-1830 2-O Me 3-Me H OH -CH2-3-Me-4-Cl-Ph 3-1831 2-OMe 3-Me H OH -CH2-354-Mtdo-Ph 3-1832 2-OMe 3-Me H OH -CH2 -354-diMe-Ph 3-1833 2-OMe .3-Me H OH -CH2-3? 5-diMe-Ph 3-1834 2-OMe 3-C1 H OH Ph 3-1835 2-OMe 3-C1 H OH 1-Nap 3-1836 2-OMe 3-C1 H OH 2-Nap 3-1837 2-OMe 3-C1 H OH Bz 3-1838 2-OMe 3-C1 H OH -CF2 -Ph 3-1839 2- OMe 3-C1 H OH ~ (CH2) -2-Nap 3-1840 2-OMe 3-C1 H OH > CH2-3-Me-Ph 138- 200401770 3-1841 2-OMe 3-C1 H OH -CH24Me -Ph 3-1842 2-OMe 3-C1 H OH -CH2-3-Br-Ph 3-1843 2-OMe 3-C1 H OH -CH2-4-Br-Ph 3-1844 2-OMe 3-C1 H OH 3-1845 2-OMe 3-C1 H OH -CHr4-Cl-Ph 3-1846 2-OMe 3-C1 H OH -CH2 F-Ph 3-1847 2-OMe 3-C1 H OH -CH2-4 -F-Ph 3-1848 2-OMe 3-C1 H OH -CH2-3-Tfm-Ph 3-1849 2-OMe 3-C1 H OH -CH2-4-Tfm-Ph 3-1850 2-OMe 3- C1 H OH -CH2-3-OMe-Ph 3-1851 2-OMe 3-C1 H OH -CH2-4-OMe-Ph 3-1852 2-OMe 3-C1 H OH -CH2-2,3-diF- Ph 3-1853 2-OMe 3-C1 H OH -CH2-254 > diF-Ph 3-1854 2-OMe 3-C1 H OH -CHr2,5-diF-Ph 3-1855 2-OMe 3-C1 H OH -CH2-256-diF-Ph 3-1856 2-OMe 3-C1 H OH -CHr3,4-diF-Ph 3-1857 2- OMe 3-C1 H OH -CH2-355-diF-Ph 3-1858 2-OMe 3-C1 H OH -CH2-354-diCl-Ph 3-1859 2-OMe 3-C1 H OH -CH2-3? 5 -diCl-Ph 3-1860 2-OMe 3-G1 H OH -CH2-3-Cl-4-F-Ph 3 -1861 2-OMe 3-C1 H OH -CH2-3-Me-4-Cl-Ph 3-1862 2-OMe 3-C1 H OH -CH2-3,4-Mtdo-Ph 3-1863 2-OMe 3-C1 H OH -CH2-3,4-diMe-Ph 3-1864 2-OMe 3- C1 H OH -CH2-3,5-diMe-Ph 3-1865 1-F 2-FH OH Ph 3-1866 1-F 2-FH OH 1-Nap 3-1867 1-F 2-FH OH 2-Nap 3-1868 1-F 2-FH OH Bz 3-1869 1-F 2-FH OH -CF2 -Ph 3-1870 1-F 2-FH OH-(CH2) -2-Nap 3-1871 1-F 2 -FH OH -CH2-3-Me-Ph 3-1872 1-F 2-FH OH -CH2-4-Me-Ph 3-1873 1-F 2-FH OH -CH2-3-Br-Ph 3-1874 1-F 2 > FH OH -CH2-4-Br-Ph 3-1875 1-F 2-FH OH -CH2-3-Cl-Ph 3-1876 1-F 2-FH OH -CH2-4-Cl- Ph 3-1877 1-F 2-FH OH -CH2-3-F-Ph -139- 200401770 3-1878 1-F 2-FH OH -CH2-4-F-Ph 3-1879 1-F 2-FH OH -CH2-3-Tfm-Ph 3-1880 1-F 2-FH OH -CH2-4-Tfm-Ph 3-1881 1-F 2-FH OH -CH2-3-OMe-Ph 3-1882 1- F 2-FH OH -CHr4-OMe-Ph 3-1883 1-F 2-FH OH -CH2-253-diF-Ph 3-1884 1-F 2-FH OH -CH2-2? 4-diF-Ph 3 -1885 1-F 2-FH OH -CH2-2,5-diF-Ph 3-1886 1-F 2-FH OH -CH2-256-diF-Ph 3-1887 1-F 2-FH OH -CH2-3,4-diF -Ph 3-1888 1-F 2-FH OH -CH2-355-diF-Ph 3-1889 1-F 2-FH OH -CHr3,4-diCl-Ph 3-1890 1-F 2-FH OH -CH2 -3? 5-diGl-Ph 3-1891 1-F 2-FH OH -CH2-3-CM-F-Ph 3-1892 1-F 2-FH OH -CH2-3-Me-4-Cl-Ph 3-1893 1-F 2-FH OH -CH2-354-Mtdo-Ph 3-1894 1-F 2-FH OH -CH2-3,4-diMe-Ph 3-1895 1-F 2-FH OH -CH2 -355-diMe-Ph 3-1896 1-F 2-Me H OH Ph 3-1897 1-F 2-Me H OH 1-Nap 3-1898 1-F 2-Me H OH 2-Nap 3-1899 1 -F 2-Me H OH Bz 3-1900 1-F 2-Me H OH -CF2 -Ph 3-1901 1-F 2-Me H OH-(CH2) -2-Nap 3-1902 1-F 2- Me H OH -CH2-3 She-Ph 3-1903 1-F 2-Me H OH -CH24Me-Ph 3-1904 1-F 2-Me H OH -CHr3-Br-Ph 3-1905 1-F 2- MeH OH -CHr4-Br-Ph 3-1906 1-F 2-Me H OH -CH2-3-Cl-Ph 3-1907 1-F 2-Me H OH 3-1908 1-F 2-Me H OH -CH2-3-F-Ph 3-1909 1-F .2-Me H OH -CH2-4-F-Ph 3-1910 1-F 2-Me H OH -CH2-3-Tfm-Ph 34911 1 -F 2-Me H OH -CH2-4-Tfm-Ph 3-1912 1-F 2-Me H OH -CH2-3-OMe-Ph 3-1913 1-F 2-Me H OH -CHr4-〇Me -Ph 3-1914 1-F 2-Me H OH -CHr2,3-diF-Ph -140- 200401770 3-1915 1-F 2-Me H OH -CH2-254-diF-Ph 3-1916 1-F 2-Me H OH • CHr255-diF-Ph 3-1917 1-F 2-Me H OH -CH2-256-diF-Ph 3-1918 1-F 2-Me H OH -CH2-354-diF-Ph 3-1919 1-F 2-Me H OH- CH2-3,5-diF-Ph 3-1920 1-F 2-Me H OH -ΟΗ2-354- (ϋα ^ 3-1921 1-F 2-Me H OH -ΟΗ2-3,5- (ϋα-Ρ1ι 3-1922 1-F 2-Me H OH -CH2-3-Cl-4-F-Ph 3-1923 1-F 2-Me H OH -CH2-3-Me-4-Cl-Ph 3-1924 1 -F 2-Me H OH -CHr3,4-Mtdo-Ph 3-1925 1-F 2-Me H OH -CHr3,4-diMe-Ph 3-1926 1-F 2-Me H OH -CH2-335- diMe-Ph 3-1927 1-F 2-OMe H OH Ph 3-1928 1-F 2-OMe H OH 1-Nap 3-1929 1-F 2-OMe H OH 2-Nap 3-1930 1-F 2 -OMe H OH Bz 3-1931 1-F 2-OMe H OH -CF2 -Ph 3-1932 · 1-F 2-OMe H OH-(CH2) -2-Nap 3-1933 1-F 2-OMe H OH -CH2-3-Me-Ph 3-1934 1-F 2-OMe H OH -CH2-4-Me-Ph 3-1935 1-F 2-OMe H OH -CH2-3-Br-Ph 3-1936 1-F 2-OMe H OH -CH2-4-Br-Ph 3-1937 1-F 2-OMe H OH -CH2-3-Cl-Ph 3-1938 1-F 2-OMe H OH -CH2-4 -Cl-Ph 3-1939 1-F 2-OMe H OH -CH2-3-F-Ph 3-1940 1-F 2-OMe H OH -CH2-4-F-Ph 3-1941 1-F 2- OMe H OH -CH2-3 -Tfm-Ph 3-1942 1-F 2-OMe H OH -CH2-4-Tfm-Ph 3-1943 1-F 2-OMe H OH -CH2-3-OMe-Ph 3-1944 1-F 2- OMe H OH -CH2-4-OMe-Ph 3-1945 1-F 2-OMe H OH -CH2-253-diF-Ph 3-1946 1-F 2-OMe H OH -CH2-2,4-diF- Ph 3-1947 1-F 2-OMe H OH -CHr235-diF-Ph 3-1948 1-F 2-OMe H OH .CH2-2,6-diF > Ph 3-1949 1-F 2-OMe H OH -CHr3,4-diF-Ph 3-1950 1-F 2-OMe H OH -CH2-3? 5-diF-Ph 3-1951 1-F 2-OMe H OH -CHr334-diCl-Ph -141- 200401770 3-1952 1-F 2-OMe H OH -CH2-3? 5-diCl-Ph 3-1953 1-F 2-OMe H OH -CH2-3-Cl-4-F-Ph 3-1954 1-F 2-OMe H OH > CH2-3-Me-4-Cl-Ph 3-1955 1-F 2-OMe H OH -CHr3,4-Mtdo-Ph 3-1956 1-F 2-OMe H OH -CH2 -354-diMe-Ph 3-1957 1-F 2-OMe H OH .-CH2-355-diMe-Ph 3-1958 1-F 2-Br H OH Ph 3-1959 1-F 2-Br H OH 1 -Nap 3-1960 1-F 2-Br H OH 2-Nap 3-1961 1-F 2-Br H OH Bz 3.1962 1-F 2-Br H OH -CF2 -Ph 3-1963 1-F 2 -Br H OH-(CH2) -2-Nap 3-1964 1-F 2-Br H OH -CH2-3-Me-Ph 3-1965 1-F 2-Br H OH -CH2-4-Me-Ph 3-1966 1-F 2-Br H OH -CH2-3-Br-Ph 3-1967 1-F 2-Br H OH -CH2-4-Br-Ph 3-1968 1-F 2-Br H OH- CH2-3-Cl-Ph 3-1969 1-F 2-Br H, OH -CH2-4-Cl-Ph 3-1970 1-F 2-Br H OH -CH2-3-F-Ph 3-1971 1-F 2-Br H OH -CH2-4-F-Ph 3-1972 1-F 2-Br H OH -CH2-3-Tfm-Ph 3-1973 1-F 2-Br H OH -CH2-4-Tfm-Ph 3-1974 1 -F 2-Br H OH -CH2-3-OMe-Ph 3-1975 1-F 2-Br H OH -CH2-4-OMe-Ph 3-1976 1-F 2-Br H OH -CH2-2, 3-diF-Ph 3-1977 1-F 2-Br H OH -CHr2,4-diF-Ph 3-1978 1-F 2-Br H OH -CH2-255-diF-Ph 3-1979 1-F 2 -Br H OH -CH2-256-diF-Ph 3-1980 1-F 2-Br H OH -CHr3,4-diF-Ph 3-1981 1-F 2-Br H OH -CH2-3,5-diF -Ph 3-1982 1-F 2-Br H OH -CH2-3,4-diCl-Ph 3-1983 1-F 2-Br H OH -CH2-3,5-diCl-Ph 3-1984 1-F 2-Br H OH -CH2-3-Cl-4-F-Ph 3-1985 1-F 2-Br H OH -CH2-3-Me-4-Cl-Ph 3-1986 1-F 2-Br H OH -CH2-354-Mtdo-Ph 3-1987 1-F 2-Br H OH -CHr3? 4-diMe-Ph 3-1988 1-F 2-Br H OH -CHr3,5-diMe-Ph -142 200401770 3-1989 2-F 3-C1 H OH Ph 3-1990 2-F 3-C1 H OH 1-Nap 3-1991 2-F 3-C1 H OH 2-Nap 3-1992 2-F 3-C1 H OH Bz 3-1993 2-F 3-C1 H OH -CF2 -Ph 3-1994 2-F 3-C1 H OH-(CH2) -2-Nap 3-1995 2-F. 3-C1 H OH -CH2 -3-Me-Ph 3-1996 2-F 3-C1 H OH -CH24M e-Ph 3-1997 2-F 3-C1 H OH -CH2-3-Br-Ph 3-1998 2-F 3-C1 H OH -CH2-4-Br-Ph 3-1999 2-F 3-C1 H OH -CH2-3-Cl-Ph 3-2000 2-F 3-C1 H OH -CH2-4-Cl-Ph 3-2001 2-F 3-C1 H OH -CH2-3-F-Ph 3- 2002 2-F 3-C1 H OH -CH2-4-F-Ph 3-2003 2-F 3-C1 H OH -CH2-3-Tfm-Ph 3-2004 2-F 3-C1 H OH -CH2- 4-Tfm-Ph 3-2005 2-F 3-C1 H OH -CH2-3-OMe-Ph 3-2006 2-F 3-C1 H OH -CH2-4-OMe-Ph 3-2007 2-F 3 -C1 H OH -CH2-233-diF-Ph 3-2008 2-F 3-C1 H OH -CH2-2? 4-diF-Ph 3-2009 2-F 3-C1 H OH -CH2-2? 5 -diF-Ph 3-2010 2-F 3-C1 H OH -GH2-256-diF-Ph 3-2011 2-F 3-C1 H OH -CH2-3,4-diF-Ph 3-2012 2-F 3-C1 H OH -CH2-3,5-diF-Ph 3-2013 2-F 3-C1 H OH -CH2-354-diCl-Ph 3-2014 2-F 3-C1. H OH -CH2-355 -diCl-Ph 3-2015 2-F 3-C1 H OH -CH2-3-Cl-4-F-Ph 3-2016 2-F 3-C1 H OH -CH2-3-Me-4-Cl-Ph 3-2017 2-F 3-C1 H OH -CH2-3,4-Mtdo-Ph 3-2018 2-F 3-C1 H OH -CH2-354-diMe-Ph 3-2019 2-F 3-C1 H OH -CHr3,5-diMe-Ph 3-2020 2-F 3-Me H OH Ph 3-2021 2-F 3-Me H OH 1-Nap 3-2022 2-F 3-Me H OH 2-Nap 3 -2023 2-F 3-Me H OH Bz 3-2024 2-F 3-Me H OH -CF2 -Ph 3- 2025 2-F 3-Me H OH-(CH2) -2-Nap 143- 200401770 3-2026 2-F 3-Me H OH -CH2-3-Me-Ph 3-2027 2-F 3-Me H OH -CH2-4-Me-Ph 3-2028 2-F 3-Me H OH -CH2-3-Br-Ph 3-2029 2-F 3-Me H OH -CH2-4-Br-Ph 3-2030 2 -F 3-Me H OH -CH2-3-Cl-Ph 3-2031 2-F 3-Me H OH -CH2-4.C1-Ph 3-2032 2-F 3-Me H OH -CHr3-F- Ph 3-2033 2-F 3-Me H OH -CHr4-F-Ph 3-2034 2-F 3-Me H OH -CHr3-Tfm-Ph 3-2035 2-F 3-Me H OH -CH2-4 -Tfm-Ph 3-2036 2-F 3-Me H OH -CH2-3-OMe-Ph 3-2037 2-F 3-Me H OH -CH2-4-OMe-Ph 3-2038 2-F 3- Me H OH -CH2-253-diF-Ph 3-2039 2-F 3-Me H OH -CH2-2,4-diF-Ph 3-2040 2-F 3-Me H OH -CHr2,5-diF- Ph 3-2041 2-F 3-Me H OH -CH2-2? 6-diF-Ph 3-2042 2-F 3-Me H OH -CH2-354-diF-Ph 3-2043 2-F 3-Me H OH -CHr3,5-diF-Ph 3-2044 2-F 3-Me H OH -CH2-354-diCl-Ph. 3-2045 2-F 3-Me H OH -CH2-335-diCl-Ph 3 -2046 2-F 3-Me H OH -CH2-3-Cl-4-F-Ph 3-2047 2-F 3-Me H OH -CH2-3-Me-4-Cl-Ph 3-2048 2- F 3-Me H OH -CH2-354-Mtdo-Ph 3-2049 2-F 3-Me H OH -CH2-3? 4-diMe-Ph 3-2050 2-F 3-Me H OH -CH2-335 -diMe-Ph 3-2051 1-Me 2-FH OH Ph 3-205 2 1-Me 2-FH OH 1-Nap 3-2053 1-Me 2-FH OH 2-Nap 3-2054 1-Me 2-FH OH Bz 3-2055 1-Me 2-FH OH -CF2 -Ph 3 -2056 1-Me 2-FH OH-(CH2) -2-Nap 3-2057 1-Me 2-FH OH -CH2-3-Me-Ph 3-2058 1-Me 2-FH. OH -CH2 ~ 4 -Me-Ph 3-2059 1-Me 2-FH OH -CH2-3-Br-Ph 3-2060 1-Me 2-FH OH -CH2-4-Br-Ph 3-2061 1-Me 2-FH OH -CH2-3-Cl-Ph 3-2062 1-Me 2-FH OH -CH9-4-Cl-Ph 144- 200401770 3-2063 1-Me 2-FH OH -CH2-3-F-Ph 3-2064 1-Me 2-FH OH -CH2-4-F-Ph 3-2065 1-Me 2-FH OH -CH2-3-Tfm-Ph 3-2066 1-Me 2-FH OH -CH2-4-Tfm- Ph 3-2067 1-Me 2-FH OH -CH2-3-OMe-Ph 3-2068 .1-Me 2-FH OH -CH2-4-OMe-Ph 3-2069 1-Me 2-FH OH -CHr2 , 3-diF-Ph 3-2070 1-Me 2-FH OH -CH2-254-diF-Ph 3-2071 1-Me 2-FH OH -CH2-2,5-diF-Ph 3-2072 1-Me 2-FH OH -CH2-256-diF-Ph 3-2073 1-Me 2-FH OH -CH2-3,4-diF-Ph 3-2074 1-Me 2-FH OH -CH2-3,5-diF -Ph 3-2075 1-Me 2-FH OH -CH2-354-diCl-Ph 3-2076 1-Me 2-FH OH -CH2-3,5-diCl-Ph 3-2077 1-Me 2-FH OH -CH2-3-Cl-4-F-Ph 3-2078 1-Me 2-FH OH -CH2-3-Me-4-Cl-Ph 3-2079 1-Me 2-FH OH -CH2-3,4 -Mtdo- Ph 3-2080 1-Me 2-FH OH -CHr3,4-diMe-Ph 3-2081 1-Me .2-FH OH -CH2-3,5-diMe-Ph 3-2082 2-Me 3-FH OH Ph 3-2083 2-Me 3-FH OH 1-Nap 3-2084 2-Me 3-FH OH 2-Nap 3-2085 2-Me 3-FH OH Bz 3-2086 2-Me 3-FH OH -CF2 -Ph 3-2087 2-Me 3-FH OH-(CH2) -2-Nap 3-2088 2-Me 3-FH OH -CH2-3-Me-Ph 3-2089 2-Me 3-FH OH -CH2 -4-Me-Ph 3-2090 2-Me 3-FH OH -CH2-3-Br-Ph 3-2091 2-Me 3-FH OH -CH2-4-Br-Ph 3-2092 2-Me 3- FH OH -CH2-3-Cl-Ph 3-2093 2-Me 3-FH OH -CH2-4-Cl-Ph 3-2094 2-Me 3-FH OH -CH2-3-F-Ph 3-2095 2 -Me 3-FH OH -CH2-4-F-Ph 3-2096 2-Me 3-FH OH -CH2-3 > Tfm-Ph 3-2097 2-Me 3-FH OH -CH2-4-Tfm-Ph 3-2098 2-Me 3-F, H OH -CH2-3-OMe-Ph 3-2099 2-Me 3-FH OH -CH2-4-OMe-Ph 145- 200401770 3-2100 2-Me 3-FH OH -CH2-273-diF-Ph 3-2101 2-Me 3-FH OH -CHr2,4-diF-Ph 3-2102 2-Me 3-FH OH -CH2-2? 5-diF ^ Ph 3-2103 2-Me 3-FH OH -CH2-2? 6-diF-Ph 3-2104 2-Me 3-FH OH -CHr3,4-diF-Ph 3-2105 2-Me 3-FH OH -CHr3,5- diF-Ph 3-2106 2-Me 3-FH OH -ΟΗ2-3,4- (ϋα-Ρ1ι 3-2107 2-Me 3-FH OH • CH2-3,5-di Cl-Ph 3-2108 2-Me 3-FH OH -CH2-3-Cl-4-F-Ph 3-2109 2-Me 3-FH OH -CH2-3-Me-4-Cl-Ph 3-2110 2-Me 3-FH OH -CH2-354-Mtdo-Ph 3-2111 2-Me 3-FH OH -CH2-354-diMe-Ph 3-2112 2-Me 3-FH OH -CH2-3,5- diMe-Ph 3-2113 1-C1 2-FH OH Ph 3-2114 1-C1 2-FH OH 1-Nap 3-2115 1-C1 2-FH OH 2-Nap 3-2116 1-C1 2-FH OH Bz 3-2117 1-C1 2-FH OH -CF2 -Ph 3-2118 1-C1 2-FH OH-(CH2) -2-Nap 3-2119 1-C1 2-FH OH -CH2-3-Me- Ph 3-2120 1-C1 2-FH OH -CH2-4-Me-Ph 3-2121 1-C1 2-FH OH -CH2-3-Br-Ph 3-2122 1-C1 2-FH OH -CHr4- Br-Ph 3-2123 1-C1 2-FH OH -CH2-3-Cl-Ph 3-2124 1-C1 2-FH OH -CH2-4-Cl-Ph 3-2125 1-C1 2-FH OH- CH2-3-F-Ph 3-2126 1-C1 2-FH OH -CH2-4-F-Ph 3-2127 1-C1 2-FH OH -CH2-3-Tfm-Ph 3-2128 1-C1 2 -FH OH -CH2-4-Tfm-Ph 3-2129 1-C1 2-FH OH -CH2-3-OMe-Ph 3-2130 1-C1 2-FH OH -CH2-4-OMe-Ph 3-2131 1-C1 2-FH OH -CH2-253-diF-Ph 3-2132 1-C1 2-FH OH -CH2-254-diF-Ph 3-2133 1-C1 2-FH OH -CH2-255-diF- Ph 3-2134 1-C1 2-FH OH -CH2-256-diF-Ph 3-2135 1-C1 2-FH OH -CHr3,4-diF-Ph 3-2136 1-C1 2-F H OH -CH2-3,5-diF-Ph

146- 200401770 3-2137 1-C1 2-FH OH -ΟΗ2 · 3,4-άία-Κι 3-2138 i-ci 2-FH OH -CH2-335-diCl-Ph 3-2139 1-C1 2-FH OH -CHs-S-Cl ^ -F-Ph 3-2140 1-C1 2-FH OH -CH2-3-Me-4-Cl-Ph 3-2141 1-C1 2-FH OH -CH2-3,4 -Mtdo-Ph 3-2142 1-C1 2-FH OH -CH2-334-diMe-Ph 3-2143 1-C1 2-FH OH -CHr3,5-diMe-Ph 3-2144 1-Tfm 2-C1 H OH Ph 3-2145 1-Tfm 2-C1 H OH 1-Nap 3-2146 1-Tfm 2-C1 H OH 2-Nap 3-2147 1-Tfm 2-C1 H OH Bz 3-2148 1-Tfm 2- C1 H OH -CF2 -Ph 3-2149 1-Tfm 2-C1 H OH-(CH2) -2-Nap 3-2150 1-Tfm 2-C1. H OH -CH2-3-Me-Ph 3-2151 1 -Tfm 2 «C1 H OH -CH2-4-Me-Ph 3-2152 1-Tfm 2-C1 H OH -CH2-3-Br-Ph 3-2153 1-Tfm 2-C1 H OH -CH2-4- Br-Ph 3-2154 1-Tfm 2-C1 H OH -CH2-3-Cl-Ph 3-2155 1-Tfm 2-C1 Ή OH -CH2-4-Cl-Ph 3-2156 1-Tfm 2-C1 H OH -CH2-3-F-Ph 3-2157 1-Tfm 2-C1 H OH -CH2-4-F-Ph 3-2158 1-Tfm 2-C1 H OH -CH2-3-Tfm-Ph 3- 2159 1-Tfm 2-C1 H OH -CH2-4-Tfm-Ph 3-2160 1-Tfm 2-C1 H OH -CH2-3-OMe-Ph 3-2161 1-Tfm 2-C1 H OH -CH2- 4-OMe-Ph 3-2162 1-Tfm 2-C1 H OH -CH2-2? 3-diF-Ph 3-2163 1-Tfm 2-C1 H OH -CH2-2, 4-diF-Ph 3-2164 1-Tfm 2-C1 H OH -CH2-2,5-diF-Ph 3-2165 1-Tfm 2-C1 H OH -CH2-256-diF-Ph 3-2166 1- Tfm 2-C1 H OH -CH2-354-diF-Ph 3-2167 1-Tfm 2-C1 H OH -CH2-355-diF-Ph 3-2168 1-Tfm 2-C1 H OH -CH2-354-diCl -Ph 3-2169 1-Tfm 2-C1 H OH -CH2-355-diCl-Ph 3-2170 1-Tfm 2-C1 H OH -CH2-3-Cl-4-F-Ph 3-2171 1-Tfm 2-C1 H OH -ΟΗ2-3-Με-4-α ^ 3-2172 1-Tfm 2-C1 H OH -CH2-3? 4-Mtdo-Ph 3-2173 1-Tfm 2-C1 H OH -CH2 -334-diMe-Ph

-147- 200401770 3-2174 1-Tfm 2-C1 H OH .-CH2-335-diMe-Ph 3-2175 1-OMe 2-OMe 3-OMe OH Ph 3-2176 1-OMe 2-OMe 3-OMe OH 1-Nap 3-2177 1-OMe 2-OMe 3-OMe OH 2-Nap 3-2178 1-OMe 2-OMe 3-OMe OH Bz 3-2179 1-OMe 2-OMe 3-OMe OH -CF2- Ph 3-2180 1-OMe 2-OMe 3-OMe OH-(CH2) -2-Nap 3-2181 1-OMe 2-OMe 3-OMe OH -CH2-3-Me-Ph 3-2182 1-OMe 2 -OMe 3-OMe OH -CH2-4-Me-Ph 3-2183 1-OMe 2-OMe 3-OMe OH -CH2-3-Br-Ph 3-2184 1-OMe 2-OMe 3-OMe OH -CH2 -4-Br-Ph 3-2185 1-OMe 2-OMe 3-OMe OH .-CH2-3-Cl-Ph 3-2186 1-OMe 2-OMe 3-OMe OH -CH2-4-Cl-Ph 3 -2187 1-OMe 2-OMe 3-OMe OH -CH2-3-F-Ph 3-2188 1-OMe 2-OMe 3-OMe OH .CH2-4-F-Ph 3-2189 1-OMe 2-OMe 3-OMe OH -CH2-3-Tfm-Ph 3-2190 1-OMe 2-OMe 3-OMe. OH -CHr4-Tfm-Ph 3-2191 1-OMe 2-OMe 3-OMe OH -CH2-3- OMe-Ph 3-2192 1-OMe 2-OMe 3-OMe OH -CH2-4-OMe-Ph 3-2193 1-OMe 2-OMe 3-OMe OH -CH2-253-diF-Ph 3-2194 1- OMe 2-OMe 3-OMe OH ^ CH2-254-diF-Ph 3-2195 1-OMe 2-OMe 3-OMe OH -CH2-2,5-diF-Ph 3-2196 1-OMe 2-OMe 3- OMe OH -CH2-2? 6-diF-Ph 3-2197 1-OMe 2-OMe 3-OMe OH -CH2-354 -diF-Ph 3-2198 1-OMe 2-OMe 3-OMe OH -CH2-335-diF-Ph 3-2199 1-OMe 2-OMe 3-OMe OH -CHr3,4-diCl-Ph 3-2200 1 -OMe 2-OMe 3-OMe OH -CH2-3,5-diCl-Ph 3-2201 1-OMe 2-OMe 3-OMe OH -CH2-3-Cl-4-F-Ph 3-2202 1-OMe 2-OMe 3-OMe OH -CH2-3-Me-4-Cl-Ph 3-2203 1-OMe 2-OMe 3-OMe OH -CH2-3? 4-Mtdo-Ph 3-2204 1-OMe 2- OMe 3-OMe OH -CH2-354-diMe-Ph 3-2205 1-OMe 2-OMe 3-OMe OH -CH2-3? 5-diMe-Ph 3-2206 1-C1 2-OMe 3-OMe OH Ph 3-2207 1-C1 2-OMe 3-OMe OH 1-Nap 3-2208 1-C1 2-OMe 3-OMe OH 2-Nap 3-2209 1-C1 2-OMe 3-OMe OH Bz 3-2210 1 -C1 2-OMe 3-OMe OH -CF2 -Ph -148- 200401770 3-2211 1-C1 2-OMe 3-OMe OH-(CH2) -2-Nap 3-2212 1-C1 2-OMe 3-〇 Me OH -CH2—3-Me-Ph 3-2213 1-C1 2-OMe 3-OMe OH • CH2-4-Me-Ph 3-2214 1-C1 2-OMe 3-OMe OH -CH2-3- Br-Ph 3-2215 1-C1 2-OMe 3-OMe OH ^ CH2-4-Br-Ph 3-2216 1-C1 2-OMe 3-OMe OH -CH2-3-Cl-Ph 3-2217 1- C1 2-OMe 3-OMe OH -CH2-4-Cl-Ph 3-2218 1-C1 2-OMe 3-OMe OH -CH2-3-F-Ph 3-2219 1-C1 2-OMe 3-OMe OH -CH2-4-F-Ph 3-2220 1-C1 2-OMe 3-OMe OH -CH2-3-Tfm-Ph 3-2221 1-C1 2-OMe 3-OMe OH -CH2-4-Tfm-Ph 3-2222 1-C1 2-OMe 3-OMe OH -CH2-3-OMe-Ph 3-2223 1-C1 2-OMe 3-OMe OH -CH2-4-OMe- Ph 3-2224 1-C1 2-OMe 3-OMe OH -CHr2,3-diF-Ph 3-2225 1-Cl 2-OMe 3-OMe OH -CH2-2,4-diF-Ph 3-2226 1- C1 2-OMe 3-OMe OH -CH2-2,5-diF-Ph 3-2227 1-C1 2-OMe 3-OMe OH -CH2-2,6-diF-Ph 3-2228 1-C1 2-OMe 3-OMe OH -CHr3,4-diF-Ph 3-2229 1-C1 2-OMe 3-OMe OH -CH2-3,5-diF-Ph 3-2230 1-C1 2-OMe 3-OMe OH -CH2 -354-diCl-Ph 3-2231 1-C1 · 2-OMe 3-OMe OH -CH2-3,5-diCl-Ph 3-2232 1-C1 2-OMe 3-OMe OH -CH2-3-Cl- 4-F > Ph 3-2233 1-C1 2-OMe 3-OMe OH -CH2-3-Me-4-Cl-Ph 3-2234 l-Cl 2-OMe 3-OMe OH -CH2-3,4- Mtdo-Ph 3-2235 1-C1 2-OMe 3-OMe OH -CH2-354-diMe-Ph 3-2236 l-Cl 2-OMe 3-OMe OH -CH2-355-diMe-Ph 3-2237 l- Cl 2-C1 3-C1 OH Ph 3-2238 l-Cl 2-C1 3-C1 OH 1-Nap 3-2239 .l-Cl 2-C1 3-C1 OH 2-Nap 3-2240 l-Cl 2- C1 3-CI OH Bz 3-2241 l-Cl 2-C1 3-C1 OH -CF2 -Ph 3-2242 l-Cl 2-C1 3-CI OH-(CH2) -2-Nap 3-2243 l- Cl 2-Cl 3-CI OH -CH2-3-Me-Ph 3-2244 l-Cl 2-C1 3-CI OH -CH24Me-Ph 3-2245 l-Cl 2-C1 3-CI OH -CH2-3 - Bi-Ph 3-2246 l-Cl 2-C1 3-CI OH -CH2-4-Br-Ph 3-2247 l-Cl 2-C1 3-CI OH -CH2-3-Cl-Ph -149- 200401770 3 -2248 3-2249 3-2250 3-2251 3-2252 3-2253 3-2254 3-2255 3-2256 3-2257 3-2258 3-2259 3-2260 3-2261 3-2262 3-2263 3-2264 3-2265 3-2266 3-2267 3-2268 3-2269 3-2270 3-2271 3-2272 3-2273 3-2274 3-2275 3-2276 3-2277 3-2278 3-2279 3-2280 3- 2281 3-2282 3-2283 3-2284 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2 -C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-C1 2- C1 3-C1 1-C1 2-C1 3-C1 1-C1 2-C1 3-C1 1-Cl 2-C1 3-C1 1-C1 2-C1 3-C1 1-Me 2-OMe 3-Me 1 -Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe .3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1 -Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2-OMe 3-Me 1-Me 2 > OMe 3-Me 1-Me 2-OMe 3-Me OH -CH2-4- Cl-Ph OH -CH2 each F-Ph OH -CH2-4-F-Ph OH -CH2-3-Tfm-Ph OH -CH2-4-Tfm-Ph OH -CH2-3-OMe-Ph OH -CH2-4-OMe-Ph OH- CH2-2? 3-diF-Ph OH -CHr2,4-diF-Ph OH -CH2-2,5-diF-Ph OH -CH2-256-diF-Ph OH -CH2-3,4-diF-Ph OH -CH2-3? 5-diF-Ph OH -CHs-S ^ -diCl-Ph OH -CH2-335-diCl-Ph OH -CH2-3-Cl-4-F-Ph OH -CH2-3-Me- 4-Cl-Ph OH-CH2-3,4-Mtdo-Ph OH -CH2-354-diMe-Ph OH -CH2-355-diMe-Ph OH Ph OH 1-Nap OH 2-Nap OH Bz OH -CF2- Ph OH-(CH2) -2-Nap OH -CH2-3-Me-Ph OH -CH2-4-Me-Ph OH -CH2-3-Br-Ph OH -CH2-4-Br-Ph OH -CH2- 3-Cl-Ph OH -CH2-4-Cl-Ph OH -CH2-3-F-Ph OH -CH2-4-F-Ph OH -CH2-3-Tfm-Ph OH -CH2-4-Tfm-Ph OH -CHr3-OMe-Ph

-150- 200401770 3-2285 1-Me 2-OMe 3-Me OH -CH2-4-OMe-Ph 3-2286 1-Me 2-OMe 3-Me OH -CH2-253-diF-Ph 3-2287 1 -Me 2-OMe 3-Me OH -CH2-234-diF-Ph 3-2288 1-Me 2-OMe 3-Me OH -CH2-2? 5-diF-Ph 3-2289 1-Me 2-OMe 3 -Me OH -CHr2,6-diFPh 3-2290 1-Me 2-OMe 3-Me OH -CH2-354-diF-Ph 3-2291 1-Me 2-OMe 3-Me OH -CH2-355-diF- Ph 3-2292 1-Me 2-OMe 3-Me OH -CH2-354-diCl-Ph 3-2293 1-Me 2-OMe 3-Me OH -CH2-335-diCl-Ph 3-2294 1-Me 2 -OMe 3-Me OH -CH2-3-Cl-4-F-Ph 3-2295 1-Me 2-OMe 3-Me OH -Οί2-3-Μ ^ 4-α-Ρ1α 3-2296 1-Me 2 -OMe 3-Me OH -CH2-3,4-Mtdo-Ph 3-2297 1-Me 2-OMe • 3-Me OH -CH2-3? 4-diMe-Ph 3: 2298 1-Me 2-OMe 3 -Me OH -CH2-3? 5-diMe-Ph 3-2299 HHH OH -CH2-2-BzO-Ph 3-2300 2-N〇2 HH OH Bz 3-2301 1-OEt HH OH Bz 3-2302 2 -NH2 HH OH Bz 3-2303 1-C1 2-OH H OH Bz 3-2304 1-C1 2-OMe 3-C1 OH Bz 3-2305 1-Br 2-C1 H OH Bz 3-2306 2 · ΟΗ 3 -OH H OH Bz 3-2307 2-C1 3-Br H OH Bz 3-2308 2-OMe 3-FH OH Bz 3-2309 2-OiPr HH OH Bz 3-2310 2-OH 3-OMe H OH Bz 3 -2311 2-OiPr 3-OMe H OH Bz 3-2312 2-1 HH OH Bz 3-2313 2-OEt HH OH Bz 3-2314 2-OMe 3-OH H OH Bz 3-2315 2-CN HH OH Bz 3-2316 2-OEt 3-OMe H OH Bz 3-2317 1-OH 2- OH H OH Bz 3-2318 2-OMe 3-OMe H OH -CHr4-NOrPh 3-2319 2-OMe 3-OMe H OH -CH2-4 ^ SMe-Ph 3-2320 2-OMe 3-OMe H OH- CH2-4-NH2-Ph 3-2321 2-OMe 3-OEt H OH. Bz -151-200401770 3-2322 2-OMe 3-OiPr H OH Bz 3-2323 2-C1 3-OMe H OH -CH2- 2-Me-Thiz-4 3-2324 2-OMe 3-OMe H OH -CH2-6-Me-3-Pyr 3-2325 2-diMePro HH OH Bz 3-2326 2-OMe 3-OMe H OH -CH2 -4-Me-Thiz-2 3-2327 2-C1 3-OMe H OH -CH2-4-Me-Thiz-2 3-2328 2-Pr HH OH Bz 3-2329 2-OMe 3-OMe H OH- CH2-4-CN-Ph 3-2330 2-OMe 3-OMe H OH -CH2-CN 3-2331 2-OMe HH OH -CH2-2-Me-Thiz-5 3-2332 2-OMe 3-OMe H OH -CH2-2-Me-Thiz-5 3-2333 2-C1 3-OMe H OH -CH2-2-Me-Thiz-5 3-2334 2-OMe. HH OH -CH2-6-Me-3- Pyr 3-2335 2-C1 3-OMe H OH -CH2-6-Me-3-Pyr 3-2336 2-COOMe HH OH Bz 3-2337 2-NHiPr -HH OH Bz 3-2338 2-COOH HH OH Bz 3-2339 2-OMe HH OH -CH2-2-Me-Thiz-4 3-2340 2-OMe HH OH -CH2-5-Me-2-Pyzi 3-2341 · 2-OMe HH OH -CH2-2- Me-5-Pyr m Table 4

F

Exemp. Comp. No. Sub. Pos. X Y 4-1 m OH Ph 4-2 m OH 1-Nap 4-3 m OH 2-Nap .-152- 200401770

4-4 ΙΏ OH Bz 4-5 m OH -CH (Me) -Ph 4-6 m OH -CH (NH2) -Ph 4-7 m OH -CH (NHMe) -Ph 4-8 m OH -CF2- Ph 4-9 m OH -CH (OH) -Ph 4-10 m OH -CH (OMe) -Ph 4-11 m OH-(CH2) -1-Nap 4-12 m OH-(CH2) -2- Nap 4-13 m OH-(CH2) 2-Ph 4-14 m OH-(CHPh)-(CH2) -Ph 4-15 m OH-(CH2) 2-1-Nap 4-16 m OH-(CH2 ) 2-2-Nap 4-17 m .OH-(CH2) 3-Ph 4-18 m OH-(CH2) 3-1-Nap 4-19 m OH-(CH2) 3-2-Nap 4-20 m OH-(CH2) 4-Ph 4-21 m OH-(CH2) 4-1-Nap 4-22 m OH-(CH2) 4-2-Nap 4-23 m OH -CH2-2-Me-Ph 4-24 m OH -CH2-3-Me-Ph 4-25 m OH -CH2-4-Me-Ph 4-26 m OH -CH2-2-Br-Ph 4-27 m OH -CH2-3-Br -Ph 4-28 m OH -CH2-4-Br-Ph 4-29 m OH -CH2-2-Cl-Ph 4-30 m OH -CH2-3-Cl-Ph 4-31 m OH -CH2-4 -Cl-Ph 4-32 m OH -CH2-2-F-Ph 4-33 m OH -CH2-3-F-Ph 4-34 m OH -CH2-4-F-Ph 4-35 m OH -CH2 -2-Tfm-Ph Φ36 m OH -CH2-3-Tfm-Ph 4-37 m OH -CHr4-Tfm-Ph 4-38 m OH -CH2-2-OH-Ph 4-39 m OH -CH2-3 -OH-Ph 4-40 m OH -CH2-4-OH-Ph -153- 200401770 4-41 m OH -CH2 ~ 2-〇Me-Ph 4-42 m OH-CH2 each OMe-Ph 4-43 m OH -CH2-4-OMe-Ph 4-44 m OH -CH2-2-N02-Ph 4-45 m OH -CH2-3-N02-Ph 4-46 m OH -CH2-4-N02-Ph 4-47 m OH -CH2-2-Et-Ph 4-48 m OH -CH2 Et-Ph 4-49 m OH -CH2-4-Et-Ph 4-50 m OH -CH2-2-iPr-Ph 4-51 m OH -CH2-3-iPr-Ph 4-52 m OH -CH2-4-iPr-Ph 4- 53 m OH -CH2-2-CN-Ph 4-54 m OH -CH2-3-CN-Ph 4-55 m OH -CH2-4-CN-Ph 4-56 m OH -CH2-2-NH2-Ph 4-57 m OH -CH2-3-NH2-Ph 4-58 m OH -CH2-4-NH2-Ph 4-59 m OH -CH2-2-SMe-Ph 4-60 m OH -CH2-3-SMe -Ph 4-61 m OH -CH2-4-SMe-Ph 4-62 m OH -CH2-4-NHMe-Ph 4-63 m OH -CH2-4-NMe2-Ph 4-64 m OH -CH2-4 -SOMe-Ph 4-65 m OH -CH2-4-S02Me-Ph 4-66 m. OH -CH2-4-AcNH-Ph 4-67 m OH -CH2-4-AcN (Me) -Ph 4-68 m OH -CH2-4-tBu0C (= 0) NH-Phh 4-69 m OH -CH2-4-MeS02NH-Ph 4-70 m OH -CH2-4-TfmS02NH-Ph 4-71 m OH -CH2 ~ 4 -Ac-P h 4-72 m OH -CH2-4-AcO-Ph 4-73 m OH .-CH2-4-MeCar-Ph 4-74 m OH -CH2-4-diMeCar-Ph 4-75 m OH -CH2-2,3-diF-Ph 4-76 m OH -CH2-2,4-diF-Ph 4-77 m OH -CHr2,5-diF-Ph

-154- 200401770 4-78 m OH -CHr2,6-diF-Ph 4-79 m OH -CHr3,4-diF-Ph 4-80 m OH -CH2-355-diF-Ph 4-81 m OH -CH2 -2? 3-diCl-Ph 4-82 m OH -CH2-254-diCl-Ph 4-83 m OH -CHs ^^-diCl-Ph 4-84 m OH -CH2-2? 6-diCl-Ph 4 -85 m OH -CH2-3? 4-diCl-Ph 4-86 m OH -CH2-3,5-diCl-Ph 4-87 m OH -CH2-2-F-4-N02-Ph 4-88 m OH -CH2-2-Cl-4-F-Ph 4-89 m OH -CH2-2-Cl-4-N02-Ph 4-90 m OH -CH2-3-Cl-4-F > Ph 4-91 m OH -CH2-2-Me-4-F-Ph 4-92 m OH -CH2-2-Me-4-Cl-Ph 4-93 m OH -CH2-3-Me-4-Cl-Ph 4- 94 m OH -CH2-3-Me-4-Me-Ph 4-95 in OH -CH2-3-Me-4-N02-Ph 4-96 m OH -CH2-3-N02-4-Cl-Ph 4 -97 m OH -CH2-2? 3-diOH-Ph 4-98 m OH -CH2-234-diOH-Ph 4-99 m OH -CH2-2,5-diOH-Ph 4-100 m OH -CH2- 236-diOH-Ph 4-101 m OH -CH2-3,4-diOH-Ph 4-102 m OH -CH2-3? 5-diOH-Ph 4-103 m OH -CH2-233-diOMe-Ph 4- 104 m OH -CH2-2,4-diOMe-Ph 4-105 m OH -CH2-2? 5-diOMe-Ph 4-106 m OH -CH2-256-diOMe-Ph 4-107 m OH -CH2-354 -diOMe-Ph 4-108 m OH -CH2-3,5-diOMe-Ph 4-109 m OH • CH2-2,3-MtdoPh .4-110 m OH -CH2-354-Mtdo-Ph '111 m OH -CH2-2? 3-diMe-Ph 4- 112 m OH -CH2-2? 4-diMe-Ph 4-113 in OH -CH2-255-diMe-Ph 4-114 m OH -CH2-2? 6-diMe-Ph. -155- 200401770

4-115 m OH -CH2-354-diMe-Ph 4-116 m OH -CHr3,5-diMe-Ph 4-1Π m OH -CH2-2? 4? 5-triF-Ph 4-118 m OH -CH2 -pentaFPh 4-119 P OH Ph 4-120 P OH 1-Nap 4-121 P OH 2-Nap 4-122 P OH Bz 4-123 P OH -CH (Me) -Ph 4-124 P OH -CH ( NH2) -Ph 4-125 P OH -CH (NHMe) -Ph 4-126 P OH -CF2 -Ph 4-127 P OH -CH (OH) -Ph 4-128 P OH -CH (OMe) -Ph 4 -129 p OH-(CH2) -1-Nap 4-130. P OH-(CH2) -2-Nap 4-131 P OH-(CH2) 2-Ph 4-132 P OH-(CHPh)-(CH2 ) -Ph 4-133 P OH • (CH2) 2-1-Nap 4-134 P OH-(CH2) 2-2-Nap 4-135 P OH-(CH2) 3-Ph 4-136 P OH-( CH2) 3-1-Nap 4-137 P OH-(CH2) 3-2-Nap 4-138 P OH-(CH2) 4-Ph 4-139 P OH-(CH2) 4-1-Nap 4-140 P OH-(CH2) 4-2-Nap 4-141 P OH -CH2-2-Me-Ph 4-142 P OH -CH2 ~ 3-Me-Ph 4-143 P OH -CH2-4-Me-Ph 4-144 P OH -CHr2-Br-Ph 4-145 P OH -CH2-3-Br-Ph 4-146 P OH -CHr4-Br-Ph 4-147 P OH -CH2-2-Cl-Ph 4- 148 P OH -CHr3-Cl-Ph 4-149 P OH -CH2-4-Cl-Ph 4-150 P OH ^ CH2-2-F-Ph '151 P OH -CH2-3-F-Ph -156- 200401770

4-152 P OH 4-153 'P OH 4-154 P OH 4-155 P OH 4-156 P OH 4-157 P OH 4-158 P OH 4-159 P OH 4-160 P OH 4-161 P OH 4-162 P OH 4-163 P OH 4-164 P OH 4-165 P OH 4-166 p OH 4-167 P OH 4-168 P OH 4-169 P OH 4-170 P OH 4-171 P OH 4-172 P OH 4-173 P OH 4-174 P OH 4-175 P OH 4-176 P OH 4-177 P OH 4-178 P OH 4-179 P OH 4-180 P OH 4-181 P OH 4-182 P OH 4-183 P OH 4-184 P OH 4-185 P OH 4-186 P OH 4-187 P OH 4-188 P OH -CH2-4-F-Ph -CH2-2-Tfm -Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-2-OH-Ph -CH2-3-OH-Ph -CH2-4-OH-Ph -CH2-2-OMe-Ph -CH2-3-OMe-Ph • CH2 ice OMe-Ph -CH2-2-N02-Ph -CH2-3-N02-Ph -CH2-4-N02-Ph -CH2-2-Et-Ph -CH2-3 -Et-Ph -CH2-4-Et-Ph -CH2-2-iPr-Ph -CH2-3-iPr-Ph -CH2-4-iPr-Ph -CH2-2-CN-Ph -CH2-3-CN -Ph -CH2-4-CN-Ph -CH2-2-NH2-Ph -CH2-3-NH2-Ph -CH2-4-NH2-Ph -CH2-2-SMe-Ph -CH2-3-SMe-Ph -CH2-4-SMe-Ph -CH2-4-NHMe-Ph -CH2-4-NMe2-Ph -CH2-4-SOMe-Ph -CH2-4-S〇2Me-Ph -CH2-4-AcNH-Ph -CH2-4-AcN (Me) -Ph -CH2-4-tB \ i0C (= 0) NH-Phh -CH2-4-MeS02NH-Ph -CH2-4-TfmS02NH ^ Ph -157- 20040177 0 4-189 P OH -CH2-4-Ac-Ph 4-190 P OH -CH2-4-AcO-Ph 4-191 P OH -CH2-4-MeCar-Ph 4-192 P OH -CH2-4- diMeCar-Ph 4-193 P OH -CH2-253-diF-Ph 4-194 P OH .CH2-234-diF-Ph 4-195 P OH -CH2-2,5-diF-Ph 4-196 P OH- CH2-256-diF-Ph 4-197 P OH -CH2-354-diF-Ph 4-198 P OH -CH2-3? 5-diF-Ph 4-199 P OH -CH2-2? 3-diCl-Ph 4-200 P OH -CH2-2,4-diCl-Ph 4-201 P OH -CH2-2,5-diCl-Ph 4-202 P OH -CH2-256-diCl-Ph 4-203 p OH -CH2 -354-diCl-Ph 4-204 P OH, CH2-3,5-diCl-Ph 4-205 P OH -CH2-2-F-4-N02-Ph 4-206 P OH -CH2-2.Cl- 4-F-Ph 4-207 P OH -CH2-2-Cl-4-N02-Ph 4-208 P OH -CH2-3-Cl-4-F-Ph 4-209 P OH -CHr2-Me-4 -F-Ph 4-210 P OH -CH2-2-Me-4-Cl-Ph 4-211 P OH -CH2-3-Me-4-Cl-Ph 4-212 P OH -CH2-3-Me- 4-Me-Ph 4-213 P OH -CH2-3-Me-4-N02-Ph 4-214 P OH -CH2-3-N02-4-Cl-Ph 4-215 P OH -CHr2,3-diOH -Ph 4-216 P OH -CHr2? 4-diOH-Ph 4-217 P OH -CH2-2,5-diOH-Ph 4-218 P OH • CHr2,6-diOH-Ph 4-219 P OH -CHr3 , 4-diOH-Ph 4-220 P OH -CHr3,5-diOH-Ph 4-221 P OH -CH2-2? 3-diOMe-Ph 4-222 P OH -CHr2,4-diOMe-Ph 4-223 P OH -CH2- 255-diOMe-Ph 4-224 P OH -CH2-2? 6-diOMe-Ph 4-225 P OH -CH2-334-diOMe-Ph -158- 200401770 4-226 P OH -CHr3,5-diOMe-Ph 4-227 P OH -CH2-2? 3-Mtdo-Ph 4-228 P OH -CH2-3,4-Mtdo-Ph 4-229 P OH -CH2-253-diMe-Ph 4-230 P OH -CHr2 , 4-diMe-Ph 4-231 P OH -CH2-2,5-diMe-Ph 4-232 P OH -CH2-2,6-diMe-Ph 4-233 P OH -CH2-354-diMe-Ph 4 -234 P OH -CH2-3,5-diMe-Ph 4-235 P OH -CH2-2? 435-triF-Ph 4-236 P OH -CH2-pentaFPh Table 5

F

Exemp. Sub. X Y

Comp. No. Pos. 5-1 m OH Ph 5-2 m OH 1-Nap 5-3 m OH 2-Nap 5-4 m OH Bz 5-5 m OH -CH (Me) -Ph 5-6 m OH -CH (NH2) -Ph 5-7 m OH -CH (NHMe) -Ph 5-8 m OH -CF2 -Ph 5-9. M OH -CH (OH) -Ph 5-10 m OH -CH ( OMe) -Ph 5-11 m OH-(CH2) -1-Nap 5-12 m OH-(CH2) -2-Nap -159- 200401770 5-13 5-14 5-15 5-16 5-17 5 -18 5-19 5-20 5-21 5-22 5-23 5-24 5-25 5-26 5-27 5-28 5-29 5-30 5-31 5-32 5-33 5-34 5-35 5-36 5-37 5-38 5-39 5-40 5-41 5-42 5-43 5-44 5-45 5-46 5-47 5-48 5-49 m OH-(CH2 ) 2-Ph m OH-(CHPh)-(CH2) -Ph m OH-(CH2) 2-1-Nap m OH-(CH2) 2-2-Nap m OH-(CH2) rPh m OH-(CH2 ) 3-1-Nap m OH-(CH2) 3-2-Nap m OH-(CH2) 4-Ph m OH-(CH2) 4-1-Nap m OH-(CH2) 4-2-Nap m OH -CH2-2-Me-Ph m OH -CH2 -3-Me-Ph m OH -CH2-4-Me-Ph m OH -CH2-2-Br-Ph m OH -CH2-3-Br-Ph m OH -CH2-4-Br-Ph m OH -CHs ^ -Cl-Ph m OH -CH2-3-Cl-Ph m OH -CH2-4-Cl-Ph m OH -CH2-2-F-Ph m OH- CH2-3-F-Ph m OH. -CH2-4-F-Ph m • OH -CH2-2-Tfm-Ph m OH -CH2-3-Tfm-Ph m OH -CH2-4-butylfm-Ph m OH -CH2-2-OH-Ph m .OH -CH2-3-OH-Ph m OH -CH2-4-OH-Ph in OH -CH2-2-OMe-Ph m OH -CH2-3-OMe-Ph m OH -CHr4-OMe-Ph m OH -CH2-2-N02-Ph m OH -CH2-3-N02-Ph m OH -CH2-4-N02-Ph m OH -CH2-2-Et-Ph m OH »CHr3-Et-Ph m OH -CH2 * 4-Et-Ph -160- 200401770

5-50 m OH 5-51 m OH 5-52 m OH 5-53 m OH 5-54 m OH 5-55 m OH 5-56 m OH 5-57 m OH 5-58 m OH 5-59 m OH 5-60 m OH 5-61 m OH 5-62 m OH 5-63 m OH 5-64 m OH 5-65 m OH 5-66 m OH 5-67 m OH 5-68 m OH 5-69 m OH 5-70 m OH 5-71 m OH 5-72 m OH 5-73 m OH 5-74 m OH 5-75. M OH 5-76 m OH 5-77 m OH 5-78 m OH 5-79 m OH 5-80 m OH 5-81 m OH 5-82 m OH 5-83 m OH 5-84 m OH 5-85 m OH 5-86 m OH -CH2 ~ 2-iPr-Ph -CH2-3-iPr -Ph -CH2-4-iPr-Ph -CH2-2-CN-Ph -CH2-3-CN-Ph -CHr4-CN-Ph -CH2-2-NH2-Ph -CH2-3-NH2-Ph -CH2 -4-NH2-Ph -CH2-2-SMe-Ph -CH2-3-SMe-Ph -CH2-4-SMe-Ph -CH2-4-NHMe-Ph -CH2-4-NMe2-Ph -CH2-4 -SOMe-Ph -CH2-4-S02Me-Ph -CH2-4-AcNH-Ph -CH2-4-AcN (Mc) -Ph -CH2-4-tBu0C (= 0) NH-Phh -CH2-4-MeS02NH -Ph -CH2-4-TfmS02NH-Ph -CH2-4-Ac-Ph -CH2-4-AcO-Ph -CH2-4-MeCar-Ph -CH2-4-diMeCar-Ph -CH2-233-diF-Ph -CH2-254-diF-Ph -CH2-255-diF-Ph -CHr2,6-diF-Ph -CH2-354-diF-Ph -CH2-3? 5-diF-Ph -CH2-253-diCl-Ph -CH2-254-diCl-Ph -CH2-235-diCl-Ph -CHr2,6-diCl-Ph -CH2-354-diCl-Ph -CH2-3? 5-diCl-Ph -161-20040177 0 5-87 m OH -CH2-2-F-4-N02-Ph 5-88 m OH -CH2-2-Cl-4-F-Ph 5-89 m OH -CH2-2-Cl-4-N02 -Ph 5-90 ΙΉ OH -CH2-3-Cl-4-F-Ph 5-91 m OH 5-92 m OH -CH2-2-Me-4-Cl-Ph 5-93 m OH -CH2-3 -Me-4-Cl-Ph 5-94 m OH -CH2-3-Me-4-Me-Ph 5-95 m OH -CH2-3-Me-4-N02-Ph 5-96 m OH -CH2- 3-N02-4-Cl-Ph 5-97 m OH -CH2-2,3-diOH-Ph 5-98 m OH -CH2-2,4-diOH-Ph 5-99 ΙΏ OH -CH2-2,5 -diOH-Ph 5-100 m OH -CH2-236-diOH-Ph 5-101 m OH -CH2-354-diGH-Ph 5-102 m OH -CH2-3,5-diOH-Ph 5-103 m OH -CH2-253-diOMe-Ph 5-104 m OH -CH2-234-diOMe-Ph 5-105 m OH -CH2-235-diOMe.?h 5-106 m OH -CH2-2,6-diOMe-Ph 5-107 m OH -CH2-3,4-diOMe-Ph 5-108 m OH -CH2-335-diOMe-Ph 5-109 m OH -CH2-233-Mtdo-Ph 5-110 m OH -CH2-334 -Mtdo-Ph 5-111 m OH 'CH2-2,3-diMe-Ph 5-112 m OH -CH2-2,4-diMe-Ph 5-113 m OH -CH2-2,5-diMe-Ph 5 -114 m OH -CH2-2? 6-diMe-Ph 5-115 m OH-CH2-3,4-diMe-Ph 5-116 m OH -CH2-355-diMe-Ph 5-117 m OH -CH2- 2,4,5-triF-Ph 5-118 m OH -CH2-pentaFPh 5-119 P OH Ph 5-120 P · OH 1-Nap 5-121 P OH 2-Nap 5-122 P OH Bz 5-123P OH -CH (Me) -Ph -162- 200401770 5-124 P OH -CH (NH2) -Ph 5-125 P OH -CH (NHMe) -Ph 5-126 P OH -CF2 -Ph 5-127 P OH -CH (OH) -Ph 5-128 P OH -CH (OMe) -Ph 5-129 P OH-(CH2) small Nap 5-130 P OH-(CH2) -2-Nap 5-131 P OH- (CH2) 2-Ph 5-132 P OH-(CHPh)-(CH2) -Ph 5-133 P OH-(CH2) 2-1-Nap 5-134 P OH-(CH2) 2-2-Nap 5 -135 P OH-(CH2) 3-Ph 5-136 P OH-(CH2) 3-1-Nap 5-137 P OH-(CH2) 3-2-Nap 5-138 P OH-(CH2) 4- Ph 5-139 P OH-(CH2) 4-1-Nap 5-140 P OH _ (CH2) 4-2-Nap 5-141 P OH -CH2-2-Me-Ph 5-142 P ΌΗ -CH〗 -3-Me_Ph 5-143 P OH -CH2-4-Me-Ph 5-144 P OH -CH2-2-Br-Ph 5-145 P OH -CHr3-Br-Ph 5-146 P OH -CH2-4 -Br-Ph 5-147 P OH -CHr2-Cl-Ph 5-148 P OH ~ CH2 ~ 3-Cl-Ph 5-149 P OH -CH2-4-Cl-Ph 5-150 P OH -CH2-2 -F-Ph 5-151 P OH -CH2-3: F-Ph 5-152 P OH -CH2-4-F-Ph 5-153 P OH -CH2-2.Tfm-Ph 5-154 P OH -CH2 -3-Tfm-Ph 5-155 P OH -CH2-4-Tfm-Ph 5-156 P OH -CH2-2-OH-Ph 5-157 P OH -CH2-3-OH-Ph 5-158 P OH -CH2-4-〇H-Ph 5-159 P OH -CH2-2-〇Me-Ph 5-160 P OH -CH2-3-OMe-Ph -163- 200401770

5-161 P OH 5-162 P OH 5-163 P OH 5-164 P OH 5-165 P OH 5-166 P OH 5-167 P OH 5-168 P OH 5-169 P OH 5-170 P OH 5-171 P OH 5-172 P OH 5-173 P OH 5-174 'P OH 5-175 P OH 5-176 P OH 5-177 P OH 5-178 P OH 5-179 P-OH 5-180 P OH 5-181 P OH 5-182 P OH 5-183 P OH 5-184 P OH 5-185 P OH 5-186 P OH 5-187 P • OH 5-188 P OH 5-189 P OH 5- 190 P OH 5-191 P OH 5-192 P OH 5-193 P OH 5-194 P OH 5-195 P OH 5-196 P OH 5-197 P OH -CH2-4-OMe-Ph -CH2-2 -N02-Ph -CH2-3-N02-Ph -CH2-4-N02-Ph -CH2-2-Et-Ph -CH2-3-Et-Ph -CH2-4-Et-Ph -CH2-2-iPr -Ph -CH2-3-iPr-Ph -CH2-4-iPr-Ph -CH2-2-CN-Ph -CH2-3-CN-Ph -CH2-4-CN-Ph -CH2-2-NH2-Ph -CH2-3-NH2-Ph -CH2-4-NH2-Ph -CH2-2-SMe-Ph -CH2-3-SMe-Ph -CH2-4-SMe-Ph -CH2-4-NHMe-Ph -CH2 -4-NMe2-Ph -CH2-4-SOMe-Ph -CH2-4-S02Me-Ph -CH2-4-AcNH-Ph -CH2-4-AcN (Me) -Ph -CH2-4-tBu0C (= 0 ) NH-Phh -CH2-4-MeS02NH-Ph -CH2-4-TfmS02NH-Ph -CH2-4-Ac-Ph -CH2-4-AcO-Ph -CH2-4-MeCar-Ph -CH2-4-diMeCar -Ph -CH2-253-diF-Ph -CH2-234-diF-Ph -CH2-255-diF-Ph -CH2-236-diF-Ph -CHr3,4-diF -Ph -164- 200401770 5-198 P OH -CH2-355-diF-Ph 5-199 P OH -CH2-233-diCl-Ph 5-200 P OH -CH2-2? 4-diCl-Ph 5-201 P .OH -CH2-255-diCl-Ph 5-202 P OH ^ Η2-256-άία ^ 5-203 P OH -CHr3,4-diCl-Ph 5-204 P OH -CH2-355-diCl-Ph 5 -205 P OH -CH2-2-F.4-N02-Ph 5-206 P OH -CH2-2-Cl-4-F-Ph 5-207 P OH -CH2-2-Cl-4-N02-Ph 5-208 P OH -CH2-3-Cl-4-F-Ph 5-209 P OH -CH2-2-Me-4-F-Ph 5-210 P OH -CH2-2-Me-4-Cl- Ph 5-211 P OH -CH2-3-Me-4-Cl-Ph 5-212 P OH -CH2-3-Me-4-Me-Ph 5-213 P OH -CH2-3-Me-4-N02 -Ph 5-214 P OH -CH2-3-N02-4-Cl-Ph 5-215 P OH -CHr2,3-diOH-Ph. 5-216 P OH -CH2-254-diOH-Ph 5-217 P OH -CH2-2,5-diOH-Ph 5-218 P OH -CH2-2,6-diOH-Ph 5-219 P OH -CH2-3,4-diOH-Ph 5-220 P OH -CH2-3 , 5-diOH-Ph 5-221 P OH -CH2-2: 3-diOMe-Ph 5-222 P OH -CH2-254-diOMe-Ph 5-223 P OH -CH2-2,5-diOMe-Ph 5 -224 P OH -CH2-256-diOMe-Ph 5-225 P OH -CH2-354-diOMe-Ph 5-226 P OH -CH2-3,5-diOMe-Ph 5-227 P OH -CH2-253- Mtdo-Ph 5-228 P OH -CH2-334-Mtdo-Ph 5-229 P OH -CH2-2,3-diMe-Ph 5-230 P OH -CHr2,4-diMe-Ph 5-231 P OH -CH2-235-diMe-Ph 5-232 P OH -CH2-256-diMe-Ph 5-233 P OH -CH2-3,4-diMe-Ph 5-234 P OH .CH2-335-diMe-Ph -165- 200401770 5-235 p OH -CH2-23435-triF-Ph 5-236 p OH -CHrpentaFPh Table 6

F

Exemp. Comp. No. Sub. Pos. XY 6-1 m OH Ph 6-2 m OH 1-Nap 6-3 m OH 2-Nap 6-4 m OH Bz 6-5 m OH -CH (Me)- Ph 6-6 m OH -CH (NH2) -Ph 6-7 m OH -CH (NHMe) -Ph 6-8 m OH -CF2 -Ph 6-9 m OH -CH (OH) -Ph 6-10 m OH -CH (OMe) -Ph 6-11 m OH-(CH2) -1-Nap 6-12 m OH.-(CH2) -2-Nap 6-13 m OH-(CH2) 2-Ph 6-14 m OH-(CHPh)-(CH2) -Ph 6-15 m OH-(CH2) 2-1-Nap 6-16 m OH-(CH2) r2-Nap 6-17 m OH-(CH2) 3-Ph 6-18 m OH-(CH2) 3-1-Nap 6-19 m OH-(CH2) 3-2-Nap 6-20 m OH-(CH2) 4-Ph 6-21 m OH-(CH2) 4 -1-Nap -166-200401770 6-22 m OH-(CH2) 4-2-Nap 6-23 m OH -CH2-2-Me-Ph 6-24 m OH -CH2-3-Me-Ph 6- 25 m OH -CH2-4-Me-Ph 6-26 m OH -CHr2-Br-Ph 6-27 m OH -CH2-3-Br-Ph 6-28 m OH -CH2-4-Br-Ph 6- 29 m OH -CH2-2-Cl-Ph 6-30 m OH -CH2-3-Cl-Ph 6-31 m OH -CH2-4-Cl-Ph 6-32 m OH -CH2-2-F-Ph 6-33 m OH -CH2-3-F-Ph 6-34 m OH -CH2-4-F-Ph 6-35 m OH -CH2-2-Tfm-Ph 6-36 m OH -CH2-3-Tfm -Ph 6-37 m OH -CH2-4-Tfm-Ph 6-38 m OH -CH2-2-OH-Ph 6-39 m OH -CH2-3-OH-Ph 6-40 m OH -CH2-4 -OH-Ph 6-41 m OH -CH2-2-OMe-Ph 6-42 m OH -CH2-3-OMe-Ph 6-43 m OH -CH2-4-OMe-Ph 6-44 m OH -CH2-2-N02-Ph 6-45 m OH -CH2-3-N02-Ph 6-46 m OH > CH2-4-N02-Ph 6-47 m OH -CH2-2-Et-Ph 6-48 m OH -CH2-3-Et-Ph 6-49 m OH -CH2-4-Et-Ph 6-50 m OH -CH2-2-iPr-Ph 6-51 m OH -CH2-3-iPr-Ph 6-52 m OH -CH2-4-iPr-Ph 6-53 m OH -CH2-2-CN -Ph 6-54 m OH -CH2-3-CN-Ph 6-55 m OH -CHr4-CN-Ph 6-56 m OH -CH2-2-NH2-Ph 6-57_ m OH -CH2-3-NH2 -Ph 6-58 m OH -CHr4-NHrPh -167- 200401770 6-59 6-60 6-61 6-62 6-63 6-64 6-65 6-66 6-67 6-68 6-69 6- 70 6-71 6-72 6-73 6-74 6-75 6-76 6-77 6-78 6-79 6-80 6-81 6-82 6-83 6-84 6-85 6-86 6 -87 6-88 6-89 6-90 6-91 6-92 6-93 6-94 6-95 in OH -CH2-2-SMe-Ph m OH -CH2-3-SMe-Ph m OH -CH2 -4-SMe-Ph m OH -CH2-4-NHMe-Ph m OH -CH2-4-NMe2-Ph m OH -CH2-4-SOMe-Ph m OH -CH2-4-S02Me-Ph m OH -CH2 -4-AcNH-Ph m OH -CH2-4-AcN (Me) -Ph m OH -CH2-4-tBu0C (= 0) NH-Phh m OH -CH2-4-MeS02NH-Ph m OH -CH2-4 -TfmS02NH-Ph m OH -CH2-4-Ac-Ph m OH -CH2-4-AcO-Ph m OH -CH2-4-MeCar-Ph m OH -CH2-4-diMeCar-Ph m OH -CH2-253 -diF-Ph m OH -CH2-234- diF-Ph m OH -CH2-255-diF-Ph m OH -CH2-2,6-diF-Ph m OH -CH2-3,4-diF-Ph m OH -CH2-335-diF-Ph m OH- CH2-253-diCl-Ph m OH -CH2-2,4-diCl-Ph m OH -CH2-255-diCl-Ph m OH -CH2-2,6-diCl-Ph m OH -CH2-3,4- diCl-Ph m OH -CH2-355-diCl-Ph ra OH -CH2-2-F-4-N02-Ph m OH -CH2-2-Cl-4-F-Ph m OH -CH2-2-Cl- 4-N02: Ph m OH -CH2-3-Cl-4-F-Ph m OH -CH2-2-Me-4-F-Ph m OH -CH2-2-Me-4-Cl-Ph m OH- CH2-3-Me-4-Cl-Ph m OH -CH2-3 > Me-4-Me-Ph m OH -CH2-3-Me-4-N02-Ph -168-200401770 6-96 m OH -CH2 -3-N02-4-CKPh 6-97 m OH -CH2-253-diOH-Ph 6-98 m OH -CH2-2,4-diOH-Ph 6-99 m OH -CH2-255-diOH-Ph 6 -100 m OH -CH2-2? 6-diOH ^ Ph 6-101 m. OH -CH2-3,4-diOH-Ph 6-102 m OH -CHr3,5-diOH-Ph 6-103 m OH -CHr2 , 3-di〇Me-Ph 6-104 m OH -CH2-2,4-diOMe-Ph 6-105 m OH -CHr2,5-diOMe-Ph 6-106 m OH -CH2-256-diOMe-Ph 6 -107 m OH -CH2-3,4-diOMe-Ph 6-108 m OH -CH2-355-diOMe-Ph 6-109 m OH -CH2-253-Mtdo-Ph 6-110 m OH -CH2-3, 4-Mtdo-Ph 6-111 m OH -CH2-2,3-diMe-Ph 6-112 m OH -CH2-2,4-diMe-Ph 6-113 m OH -CHr2,5-diMe-Ph 6- 114 m OH -CH2-256-diMe-Ph 6-115 m OH -CH2-354-diMe-Ph 6-116 m OH -CHr3,5-diMe-Ph 6-117 m OH -CH2-2,4,5- triF-Ph 6-118 m OH -CH2-pentaFPh 6-119 P OH Ph 6-120 P OH 1-Nap 6-121 P OH 2-Nap 6-122 P OH Bz 6-123 P OH -CH (Me) -Ph 6-124 P OH -CH (NH2) -Ph 6-125 P OH -CH (NHMe) -Ph 6-126 P OH -CF2 -Ph 6-127 P OH -CH (OH) -Ph 6-128 P OH -CH (OMe) -Ph 6-129 P OH-(CH2) -1-Nap 6-130 P OH-(CH2) -2-Nap 6-131 P OH-(CH2) 2-Ph 6-132 P OH-(CHPh)-(CH2) -Ph -169- 200401770 6-133 P OH-(CH: 2) 2-1-Nap 6-134 P OH-(CH2) 2-2-Nap 6-135 P OH-(CH2) 3-Ph 6-136 P OH-(CH2) 3-1-Nap 6-137 .P OH-(CH2) 3-2-Nap 6-138 P OH-(CH2) 4-Ph 6 -139 P OH-(CH2) 4-1-Nap 6-140 P OH-(CH2) 4-2-Nap 6-141 P OH -CH2-2-Me-Ph 6-142 P OH -CH2-3- Me-Ph 6-143 P OH -CH2-4-Me-Ph 6-144 P OH -CH2-2-Br-Ph 6-145 P OH -CH2-3-Br-Ph 6-146 P OH -CH2- 4-Br-Ph 6-147 P OH -CH2-2-Cl-Ph 6-148. P OH -CH2-3-Cl-Ph 6-149 P OH -CH2-4-Cl-Ph 6-150 P OH -CH2-2-F-Ph 6-151 P OH -CH2-3-F-Ph 6-152 P OH -CH2-4-F-Ph 6-153 P OH -CH2-2-Tfm-Ph 6-15 4 P OH -CH2-3-Tfm-Ph 6-155 P OH -CH2-4-Tfm-Ph 6-156 P OH, CH2-2-OH-Ph 6-157 P OH -CH2-3-OH-Ph 6-158 P OH -CH2-4-OH-Ph 6-159 P OH -CH2-2-OMe-Ph 6-160 P OH -CH2-3-OMe-Ph 6-161 P OH -CHr4-OMe-Ph 6-162 P OH -CH2-2-N02-Ph 6-163 P OH -CH2-3-N02-Ph 6-164 P OH -CH2-4-N02-Ph 6-165 P OH -CH2-2-Et -Ph 6-166 P OH -CH2-3-Et-Ph 6-167 P OH -CH2-4-Et-Ph 6-168 P OH -CH2-2-iPr-Ph 6-169 P OH -CH2-3 -iPr «Ph -170- 200401770 6-170 P OH -CH2-4-iPr-Ph 6-171 P-OH -CH2-2-CN-Ph 6-172 P OH -CH2-3-CN-Ph 6- 173 P OH -CH2-4-CN-Ph 6-174 P OH -CH2-2-NH2-Ph 6-175 P OH -CHr3-NHrPh 6-176 P OH -CH2-4-NH2-Ph 6-177 P OH -CH2-2-SMe-Ph 6-178 P OH -CH2-3-SMe-Ph 6-179 P OH -CH2-4-SMe-Ph 6-180 P OH -CH2-4-NHMe-Ph 6- 181 P OH -CH2-4-NMe2-Ph 6-182 P OH -CH2-4-SOMe-Ph 6-183 P OH -CH2-4-S02Me-Ph 6-184 P OH -CH2-4-AcNH-Ph 6-185 P OH -CH2-4-AcN (Me) -Ph 6-186 P OH -CH2-4-tBu0C (= 0) NH-Phh 6-187 P OH -CH2-4-MeS02NH-Ph 6-188 P OH -CH2-4-TfmS02NH-Ph 6-189 P OH -CH2-4-Ac-Ph 6-190 P OH -CH2-4-AcO-Ph 6-191 P OH -CH2-4-MeCar-Ph 6-192 P OH -CH2-4-diMeCar-Ph 6-193 P OH -CH2-253-diF-Ph 6-194 P OH -CH2-254-diF-Ph 6- 195 P OH -CH2-2,5-diF-Ph 6-196 P OH -CH2-236-diF-Ph 6-197 P OH -CH2-354-diF-Ph 6-198 P OH -CHr3,5-diF -Ph 6-199 P OH -CH2-233-diCl-Ph 6-200 P OH -CH2-254-diCl-Ph 6-201 P OH -CH2-255-diCl-Ph 6-202 P OH -CHr2,6 -diCm 6-203 P OH -CHr3,4-diCl-Ph 6-204 P OH -CH2-355-diCl-Ph 6-205 P OH -CH2-2-F-4-N02-Ph 6-206 P OH .-CH2-2-Cl-4-F-Ph -171-200401770

6-207 P OH -CH2-2-Cl-4-N02-Ph 6-208 P OH -CH2-3-Cl-4-F-Ph 6-209 P OH -CH2-2-Me-4-F- Ph 6-210 P OH -CHs ^ -Me ^ -Cl-Ph 6-211 P OH -aU-MdCl-Ph 6-212 P OH -CH2-3-Me-4-Me-Ph 6-213 P OH- CH2-3-Me-4-N02-Ph 6-214 P OH -CH2-3-N02-4-Cl-Ph 6-215 P OH -CH2-2? 3-diOH-Ph 6-216 P OH -CH2 -2,4-diOH-Ph 6-217 P OH -CH2-2? 5-diOH-Ph 6-218 P OH -CH2-256-diOH-Ph 6-219 P OH -CH2-3? 4-diOH- Ph 6-220 P OH -CH2-3,5-diOH-Ph 6-221 P OH -CH2-253-diOMe-Ph 6-222 P OH -CH2-234-diOMe-Ph 6-223 P OH -CH2- 2? 5-diOMe-Ph 6-224 P OH -CH2-2? 6-diOMe-Ph 6-225 P OH -CH2-334-diOMe-Ph 6-226 P OH -CH2-3,5-diOMe-Ph 6-227 P OH -CH2-2,3-Mtdo-Ph 6-228 P OH -CH2-334-Mtdo-Ph 6-229 P OH -CH2-2? 3-diMe-Ph 6-230 P OH -CH2 -234-diMe-Ph 6-231 P OH -CH2-2? 5-diMe-Ph 6-232 P OH -CH2-2,6-diMe-Ph 6-233 P OH _CH2-3,4-diMe-Ph 6-234 P OH -CH2-355-diMe-Ph 6-235 P OH -CHr2,4,54riF-Ph 6-236 P OH -CH2-pentaFPh -172- 200401770 Table 7 〇R2-

R5 F | 1 J F ▲ | 1 -X -F

N Y

Sub. Pos .: R1 2 0 R4 R5

-X-F r 3,

, Y

Sub. Pos .: 〇

c Γ | R5 F 1 I〉 3 ”F 1-F -X -F, NY Exemp. Comp. No. R1 R2 R4 R5 Sub. Pos. XY 7-1 HH 4, -Me H m OH Ph 7-2 HH 4, -Me H m OH 1-Nap 7-3 HH 4, -Me H m OH 2-Nap 7-4 HH 4, -Me H m OH Bz 7-5 HH 4J-Me H m OH -CF2- Ph 7-6. HH 4, —Me H m OH-(CH2) -2-Nap 7-7 HH 4J-Me H m OH -CH2-3— 7-8 HH · 4, —Me H m OH -CH2 -~ 4-Me-Ph 7-9 HH 4, -Me H m OH -CH2-3-Br-Ph 7-10 HH 45-Me H m OH -CH2-4-Br-Ph -173 · 200401770 7- 11 Η Η 45-Me H m OH -CH2-3-Cl-Ph 7-12 Η Η 4, -Me H m OH -CH2-4-Cl-Ph 7-13 Η Η 4, -Me H m OH- CH2-3-F-Ph 7-14 Η Η 4J-Me H m OH -CH2-4-F-Ph 7-15 Η Η 4, -Me H m OH -CH2-3-Tfm-Ph 7-16 Η Η 4, -Me H m OH -CH2-4-Tfm-Ph 7-17 Η Η 4, -Me H m OH -CHr3-OMe-Ph 7-18 Η Η 4, -Me H m OH -CH2-4 -OMe-Ph 7-19 Η Η 4, -Me H m OH -CH2-253-diF-Ph 7-20 Η Η 4, -Me H m OH -CH2-254-diF-Ph 7-21 Η Η 4 ， -Me H m OH -CH2-2,5-diF-Ph 7-22 Η Η 4, -Me H m OH -CH2-2? 6-diF-Ph 7-23 Η Η 4, -Me H m OH -CHr3,4-diF-Ph 7-24 Η Η 4, -Me H m OH -CH2-335-diF-Ph 7-25 Η Η 4, -Me H m OH -CH2-3? 4-diCl-Ph 7-26 Η Η 4, -Me H m OH -CH2-355-diCl- Ph 7-27 Η Η 4, -Me H m OH -CH2-3-Cl-4-F-Ph 7-28 7 Η 4, -Me H m OH -CH2-3-Me-4-Cl-Ph 7 -29 Η Η 4'-Me H m OH -CH2-3? 4-Mtdo-Ph 7-30 Η-4, -Me H m OH -CH2-3,4-diMe-Ph 7-31 Η ， 4, -Me H m OH -CH2-3,5-diMe-Ph 7-32 Η Η 4, -Cl H m OH Ph 7-33 Η Η 4, -Cl H m OH 1-Nap 7-34 Η ， 4, -Cl H m OH 2-Nap 7-35 Η Η 4, -Cl H m OH Bz 7-36 Η Η 4, -Cl H m OH -CF2 -Ph 7-37 Η Η 4, -Cl H m OH- (CH2) -2-Nap 7-38 Η Η 4 ,, Cl H m OH -CH2-3-Me-Ph 7-39 Η Η 4, -Cl H m OH -CH24Me-Ph 7-40 Η Η 4, -Cl H m OH -CH2-3-Br-Ph 7-41 Η Η 4, -Cl H m OH -CH2-4-Br-Ph 7-42 Η Η 4, -Cl H m OH -CH2-3- Cl-Ph 7-43 Η Η 4, -Cl H m OH -CH2-4-Cl-Ph 7-44 Η Η 4, -Cl H m OH -CH2-3-F-Ph 7-45 Η ， 4, -CI H m OH -CH2-4-F-Ph 7-46 Η Η 4, C1 H m OH -CH2-3-Tfm-Ph 7-47 Η Η 4J-C1 H m _ OH -CH2-4-Tfm -Ph

-174- 200401770 7-48 Η Η 4, -Cl H m OH -CH2-3-OMe ~ Ph 7-49 Η Η 4, -Cl H m OH -CH2-4-OMe-Ph 7-50 Η Η 4 , -Cl H m OH -CH2-2,3-diF-Ph 7-51 Η Η 4, -Cl H m OH -CHr254-diF-Ph 7-52 Η Η 4, C1 H m OH -CH2-255- diF-Ph 7-53 Η Η 4, -Cl H m OH -CHr2,6-diF-Ph 7-54 Η Η 4, -Cl H m OH -CHr3,4-diF-Ph 7-55 Η Η 4, -Cl H m OH -CH2-3,5-diF-Ph 7-56 Η Η 4, -Cl H m OH -CH2-3? 4-diCl-Ph 7-57 Η Η 4, -Cl H m OH- CHr3,5-diOUPh 7-58 Η Η 4, -Cl H m OH -CH2-3-Cl-4-F-Ph 7-59 Η Η 4, -Cl H m OH -CH2-3-Me-4- Cl-Ph 7-60 Η Η 4, -Cl H m OH -CH2-354-Mtdo-Ph 7-61 Η Η 4, -Cl H m OH -CH2-354-diMe-Ph 7-62 Η Η 4, -Cl H m OH -CH2-3? 5-diMe-Ph .7-63 Η Η 1 ,, -Me HP OH Ph 7-64 Η Η 1 ,, -Me HP OH 1-Nap 7-65 Η Η l ,, Me HP OH 2-Nap 7-66 Η Η 1 ,, -Me HP OH Bz 7-67 Η Η 1 ,, -Me HP OH -CF2 -Ph 7-68 Η Η 1 ,, -Me HP OH- (CH2) -2-Nap 7-69 Η Η 1 ”-Me HP · OH -CH2- 3-Me-Ph 7-70 Η Η 1, -Me HP OH -CH2-4-Me-Ph 7-71 Η Η 1 ,，-Me HP OH -CH2 -3-Br-Ph 7-72 Η ， 1 ,, -Me HP OH > CH2-4-Br-Ph 7-73 Η Η 155-Me HP OH -CH2-3-Cl-Ph 7-74 Η Η 1 ,, -Me HP OH -CH2-4-Cl-Ph 7-75 Η Η 1 ;, -Me HP OH -CH2-3-F-Ph 7-76 Η Η 1 ,, -Me HP OH -CH2- 4-F-Ph. 7-77 Η Η l ,, _Me HP OH -CH2-3-Tfm-Ph 7-78 Η Η 1 ,, -Me H. P OH -CH2-4-Tfm-Ph 7-79 Η Η l5J-Me HP OH -CH2-3-OMe-Ph 7-80 Η ”1” -Me HP OH -CH2-4-OMe-Ph 7-81 Η Η 1, -Me HP OH -CH2-2 ? 3-diF-Ph 7-82 Η Η 1 ,, -Me HP OH ^ CH2-254-diF-Ph 7-83 Η di 1 ,, -Me HP OH -CH2-255-diF-Ph 7-84 Η Η 1 ,, -Me HP OH -CH2-256-diF-Ph -175- 200401770 7-85 Η ”1" -Me HP OH -CHr3,4-diF-Ph 7-86 Η ， 1 ,, Me HP OH -CHr3,5-diF-Ph 7-87 Η Η 1 ,, -Me HP OH -CHr3,4-diCI-Ph 7-88 Η ， 1 ,, -Me HP OH -CH2-355-diCl-Ph 7- 89 Η Η 1 ,, -Me HP OH -CH2-3-Cl-4-F-Ph 7-90 Η ”1" -Me HP OH -CH2-3-Me-4-Cl-Ph 7-91 Η Η 1 ,, -Me HP OH -CHr3,4-Mtdo-Ph 7-92 Η Η 1 ,, -Me HP OH -CHr3,4-diMe-Ph 7-93 Η Η 1 ,, -Me H .P OH- CH2-3? 5-diMe -Ph 7-94 Η Η 1 ,, -C1 HP OH Ph 7-95 Η ， 1 ,, -C1 HP OH 1-Nap 7-96 Η Η '1, -C1 HP OH 2-Nap 7-97 Η Η. 1, -C1 HP OH Bz 7-98 Η Η l'Cl HP OH -CF2 -Ph 7-99 Η Η 1 ”-C1 HP OH-(CH2) -2-Nap 7-100 Η ， 1, , -C1 HP OH -CH2-3-Me-Ph 7-101 Η Η 1 ,, -C1 HP OH -CH2-4-Me-'Ph 7-102 Η Η 1, -C1 HP OH -CH2-3 -Br-Ph 7-103 Η Η 1 ,, -C1 HP OH -CH2-4-Br-Ph 7-104 Η Η 1 ,, -C1 HP OH -CH2-3-Cl-Ph 7-105 Η Η 1 ,, -C1 HP OH -CH2-4-Cl-Ph 7-106 Η Η 1 ,, -C1 HP OH -CH2-3-F-Ph 7-107 Η Η 1 ,, -C1 HP OH -CH2-4 -F-Ph 7-108 Η Η 1 ,, -C1 HP OH -CHr3-Tfm-Ph 7-109 Η Η 1 ,, -C1 HP OH -CH2-4-Tfm-Ph 7-110 Η Η 1 ,, -C1 HP OH -CH2-3-OMe-Ph 7-111 Η Η 1 ,, -C1 HP OH -CHr4-OMe-Ph 7412 Η Η 1 ,, -C1 HP OH -CHr2,3-diF-Ph 7- 113 Η Η 1 ,, -C1 HP OH -CHr2,4-diF-Ph 7-114 Η ， 1 ,, -C1 HP OH -CHr2,5-diF-Ph 7-115 Η Η 1 ,, -C1 HP OH -CHr2,6-diF-Ph 7416 Η Η 1 ,, -C1 HP OH -CHr3,4-diF-Ph 7-117 Η Η 1 ,, -C 1 HP OH -CH2-355-diF-Ph 7-118 Η Η 1,: C1 HP OH -CHr3,4-diCl-Ph 7-119 Η Η r, -ci HP OH -CHr3,5-diCl-Ph 7 -120 Η Η 1 ,, -C1 HP OH -CHr3-CM-F-Ph 7-121 Η Η 1 ,, -C1 HP OH -CHd-Me- ^ Cl-Ph -176- 200401770 7-122 Η Η 1 ,, -C1 Η P, OH -CH2-334-Mtdo-Ph 7-123 Η Η 1 ,,-C1 Η P OH -CH2-3? 4-diMe-Ph 7-124 Η Η 1 ,, -C1 Η P OH -CHr3,5-diMe-Ph 7-125 Η Η 1 ,, -Me0 Η P OH Ph 7-126 Η Η 1 ,, -Me0 Η P OH 1-Nap 7-127 Η Η 1 ,, -Me0 Η P OH 2-Nap 7-128 Η Η l ,, -MeOH P OH Bz 7-129 Η Η 1 ,, -Me0 Η P OH -CF2 -Ph 7-130 Η Η 1 ,, -Me0 Η P OH- (CH2) -2-Nap 7-131 Η Η 1 ,, -Me0 Η: P OH -CH2- 3-Me-Ph 7-132 Η Η 1 ,, -Me0 Η P OH -CHr-4-Me-Ph 7-133 Η Η 1 ,, -Me0 Η P OH -CH2-3-Br-Ph 7-134 Η Η lJ5-MeO Η P OH -CH2-4-Br-Ph 7-135 Η Η 1 ,, -Me0 Η P OH -CH2-3-Cl-Ph 7-136 Η Η 1 ,, -Me0 Η P OH -CH2-4-Cl-Ph 7-137 Η Η 1 ,, -Me0 Η P OH -CHr3-F- Ph 7-138 Η Η l, MeO Η P OH -CH2-4-F-Ph 7-139 Η ， 1 ,, -Me0 Η P OH -CH 2-3-Tfm-Ph 7-140 Η Η l ,, -MeOH P OH -CH2-4-Tfm-Ph 7-141 Η Η 1 ,, -Me0 Η P OH -CHr3-OMe-Ph 7-142 Η Η 1 ,, -Me0 Η P OH -CH2-4-OMe-Ph 7-143 Η ， 1 ,, -Me0 Η P OH -CH2-2,3-diF-Ph 7-144 Η ， 1 ,, -Me0 Η P OH > CH2-2? 4-diF-Ph 7-145 Η Η 1 ,, -Me0 Η P OH -CH2-235-diF-Ph 7-146 Η Η 1,, -Me0 Η P OH -CHr2 , 6-diF-Ph 7-147 Η Η 1 ,, -Me0 Η P OH -CHr3,4-diF-Ph 7-148 Η Η 1 ,, -Me0 Η P OH -CH2-3,5-diF-Ph 7-149 Η Η 1 ,, -Me0 Η P OH -CH2-354-diCl-Ph 7-150 Η Η 1 ,, -Me0 Η P OH -CH2-355-diCl-Ph 7-151 Η Η l ,, -MeOH P OH -CH2-3-Cl-4-F-Ph 7-152 Η Η 1 ,, -Me0 Η P OH -CH2-3-Me-4-Cl-Ph 7-153 Η ”1” -Me0 Η P OH -CH2-334-Mtdo-Ph 7-154 Η Η 1 ,, -Me0 Η P OH -CH2-354-diMe-Ph 7-155 Η Η 1, -Me0 Η P OH -CH2-355- diMe-Ph 7-156 Η Η 2 ,, -Me Η P OH Ph 7-157 Η ， 2 ,, -Me Η P OH 1-Nap 7-158 Η Η 2 ,, -Me Η P OH 2-Nap

-177- 200401770 7-159 Η Η 2 ,, -Me HP OH Bz 7-160 Η Η 2 ,, -Me HP OH > CF2 -Ph 7-161 Η Η 2 ,, -Me HP OH-(CH2) -2-Nap 7-162 Η Η 2 ,, -Me HP OH -CH2-3-Me-Ph 7-163 Η Η 2 ,, -Me HP OH -CH2-4-Me-Ph 7-164 Η Η 2 ,, -Me HP OH -CH2-3-Br-Ph 7-165 Η Η 2 ,, -Me HP OH -CH2-4-Br-Ph 7-166 Η Η 2 ,, -Me HP OH -CH2-3 -Cl-Ph 7-167 Η Η 2 ,, -Me HP OH -CH2-4-Cl-Ph 7-168 Η Η 2 ,, -Me HP OH -CH2-3-F-Ph 7-169 Η Η 2 ”-Me HP OH -CH2-4-F-Ph 7-170 Η Η 2 ,，-Me HP OH -CH2-3-Tfm-Ph 7-171 Η Η 2” -Me HP OH -CH2-4-Tfm -Ph 7-172 Η Η 2 ,, -Me HP OH -CH2-3-OMe-Ph 7-173 Η Η 2 ,, -Me HP. OH -CH2-4-OMe-Ph 7-174 Η ， 2, , -Me HP OH -CH2-2,3-diF-Ph 7-175 Η Η 2 ,, -Me HP OH -CH2-2,4-diF-Ph 7-176 Η Η 2 ,, -Me HP OH- CH2-2,5-diF-Ph 7-177 Η Η 2 ,, -Me HP OH -CH2-2,6-diF-Ph 7-178 Η Η 2 ,, -Me HP OH -CH2-3,4- diF-Ph 7-179 Η Η 2 ,, -Me HP OH -CH2-355-diF-Ph 7-180 Η ， 2 ,, -Me HP OH -CH2-3,4-diCl-Ph 7-181 Η Η. 2 ,, -Me HP OH -CH2-3,5-diCl-Ph 7-182 Η ， 2 ,, -Me HP OH -CH2-3-Cl-4-F-Ph 7-183 Η Η 2 ,, -Me HP OH -CH2-3-Me-4-Cl-Ph 7-184 Η Η 2 ,, -Me HP OH -CH2-354-Mtdo-Ph 7-185 Η Η 2,, -Me HP OH -CH2-3? 4-diMe-Ph 7-186 Η Η 2 ,, -Me HP OH -CH2-3,5-diMe_Ph 7-187 Η Η 2 ,, -Cl HP OH Ph 7-188 Η ， 2, , -Cl HP OH 1-Nap 7-189 Η Η 2 ,, -Cl HP OH 2-Nap 7-190 Η Η 2 ,, -Cl HP OH Bz 7-191 Η Η 2 ,, -Cl HP OH -CF2 -Ph 7-192 Η Η 2 ,, -Cl HP OH-(CH2) -2-Nap 7-193 Η Η 2 ,, -Cl HP OH -CH2 ~ 3-Me-Ph 7-194 Η ， 2 ,, C1 HP OH -CH2-4-Me-Ph 7-195 Η Η 2 ,, -Cl HP OH -CH2-3-Br-Ph -178- 200401770 7-196 Η: 2,: C1 HP OH -CH2-4 -Br-Ph 7-197 Η Η 2 ,, -Cl HP OH -OU-Cl-Ph 7-198 Η Η 2 ,, -Cl HP OH -CH2-4-Cl-Ph 7-199 Η Η 2 ,, -α HP OH -CH2-3-F-Ph 7-200 Η Η 2 ,, -α HP OH -CH2-4-F-Ph 7-201 Η Η 2 ,, α HP OH -CH2-3-Tfm- Ph 7-202 Η Η 2 ,,-α HP OH • CHr4-Tfm-Ph 7-203 Η ， 2 ,,-α HP OH -CH2-3-OMe- Ph 7-204 Η Η 2 ,, -α HP OH -CH2-4-OMe-Ph 7-205 Η ， 2 ,, -Cl H, P OH -CH2-253-diF-Ph 7-206 Η Η 2, , -Cl HP OH -CH2-2,4-diF-Ph 7-207 Η Η 2 ,, -α HP OH -CH2-255-diF-Ph 7-208 Η Η 2 ,, -Cl HP OH -CHr256- diF-Ph 7-209 Η Η 2 ,, -Cl HP OH -CH2-3,4-diF-Ph 7-210 Η Η 2 ,, -Cl HP OH -CH2-335-diF-Ph 7-211 Η Η 2 ,，-Cl HP OH -CH2-3? 4-diCl-Ph 7-212 Η Η 2 ,，-Cl HP OH -CH2-3,5-diCl-Ph 7-213 Η Η 2 ,，-Cl HP OH -CH2-3-Cl-4-F-Ph 7-214 Η Η 2 ,, -Cl HP OH -CH2-3-Me-4-Cl-Ph 7-215 Η Η 2 ,, -Cl HP OH- CH2-354-Mtdo-Ph 7-216 Η Η 2 ,, -Cl HP OH -CH2-3? 4-diMe-Ph 7-217 Η Η 2 ,, -Cl HP OH -CH2-3,5-diMe- Ph 7-218 Η Η 2 ,, -MeO HP OH Ph 7-219 Η ， 2 ,, -MeO HP OH 1-Nap 7-220 Η Η 2, -MeO HP OH 2-Nap 7-221 Η Η 2 ,, -MeO HP OH Bz 7-222 Η Η 2 ,, -MeO HP OH -CF2 -Ph 7-223 Η Η 2 ,, -Me〇HP OH-(CH2) -2-Nap 7-224 Η Η 2 ,, -MeO HP OH -CH2-3-Me-Ph 7-225 Η Η 2 ,, -MeO HP OH -CH2-4-Me-Ph 7-226 Η Η 2 " -MeO HP OH -CH2-3-Br-Ph 7-227 Η Η 2 ,, -MeO HP OH -CH2-4-Br-Ph 7-228 Η Η 2 ,, -MeO HP OH -CH2 -3-Cl-Ph 7-229 Η Η 2,?-MeO HP OH -CH2-4-Cl-Ph 7-230 Η ， 2, Me. HP OH -CH2-3-F-Ph 7-231 Η Η 2 ,, -Me〇HP OH -CH2-4-F-Ph 7-232 Η ”2" -Me〇HP OH -CH2-3-Tfm-Ph -179- 200401770 7-233 Η Η 2 ,, -MeO Η P OH -CH2 Tfm-Ph 7-234 Η Η 2 ,, -Me〇Me P OH -CH2-3-OMe-Ph 7-235 Η Η 2 ,, -MeO Η P OH -CH2-4 -OMe-Ph 7-236 Η Η 2 ,, -MeO Η P OH -CHr2,3-diF-Ph 7-237 Η Η 2 ,, -MeO Η P OH -CH2-2? 4-diF > Ph 7- 238 Η Η 2 ,, -MeO Η P OH -CH2-255-diF-Ph 7-239 Η Η 2 ,, -MeO Η P OH -CH2-2,6-diF-Ph 7-240 Η Η 2 ,, -MeO Η P OH -CH2-3? 4-diF-Ph 7-241 Η Η 2 ,, -MeO Η P OH -CH2-355-diF-Ph 7-242 Η Η 2 ,, -MeO Η P OH- CH2-354-diCl-Ph 7-243 Η Η 2 ,, -MeO Η P OH -CH2-355-diCl-Ph 7-244 Η Η 2 ,, -MeO Η P OH -CH2-3-Cl-4- F-Ph 7-245 Η Η 2 ,, -MeO Η P OH -CH2-3-Me-4-Cl-Ph 7: 246 Η Η 2 ,, -MeOH P OH -CH2-3, 4-Mtdo-Ph 7-247 Η Η 2 ”-MeO Η P OH -CH2-3,4-diMe-Ph 7-248 Η Η 2 ,, -MeO Η P OH -CH2-335-diMe-Ph 7- 249 Η Η 1 ,, -Me 4 ,, -Me P OH Ph 7-250 Η Η 1 ,, -Me 4 ,, -Me P OH 1-Nap 7-251 Η Η 1 ,, -Me 4 ,,- Me P OH 2-Nap 7-252 Η Η 1 ,, -Me 4 ,, -Me P OH Bz 7-253 Η Η 1 ,, -Me 4,, -Me P OH -CF2 -Ph 7-254 Η Η 1 ,, -Me 4 ,, -Me P OH-(CH2) -2-Nap 7-255 Η ， 1 ,, -Me: 4, -Me P OH -CH2-3-Me-Ph 7-256 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2 ~ 4-Me-Ph 7-257 Η ， 1 ,, -Me 4,, -Me P OH -CH2-3-Br-Ph 7-258. Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-4-Br-Ph 7-259 Η Η 1 ,, -Me 4,, -Me P OH -CH2-3-Cl-Ph 7-260 Η Η 1 ,，-Me 4 ”-Me P OH -CH2-4-Cl-Ph 7-261 Η ， 1 ,，-Me 4 ,，-Me P OH -CH2-3-F-Ph 7-262 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-4-F-Ph 7-263 Η ， 1 ,, -Me 4 ,, -Me P_ OH -CH2-3-Tfm-Ph 7-264 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-4-Tfm-Ph 7-265 Η ， 1 ,, -Me 4 ,, -Me P OH -CH2-3-OMe-Ph 7-266 Η Η 1 ,, -Me 4 ， -Me P OH -CH2-4-OMe-Ph 7-267 Η Η 1 ”-Me 4 ， ， Me P OH -CHr2,3-diF-Ph · 7-268 Η Η 1 ,，-Me 4 ,，, -Me P OH -CH2-2? 4-diF-Ph 7-269 Η Η 1 ,, -Me 4, and Me P OH -CHr2,5Uh

-180- 200401770 7-270 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-236-diF-Ph 7-271 Η Η 1 ,, -Me 4,, -Me P OH > CH2- 3? 4-diF-Ph 7-272 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-3? 5-diF-Ph 7-273 Η Η 1 ,, -Me 4,, -Me P OH -CHr3,4-diCl-Ph 7-274 Η Η 1 ,, -Me 4 ,, -Me P OH -CHr3,5-diCl-Ph 7-275 Η Η 1,, -Me 4,, -Me P OH -CH2-3-Cl-4-F-Ph 7-276 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-3-Me.4-Cl-Ph 7-277 Η Η 1 ,, -Me 4 ,, Me P OH -CH2-3,4-Mtdo-Ph 7-278 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-3? 4-diMe-Ph 7-279 Η Η 1 ,, -Me 4 ,, -Me P OH -CH2-3,5-diMe-Ph 7-280 1-C1 Η 4, -Me H m OH Ph 7-281 1-C1 Η 4, -Me H m OH 1-Nap 7-282 1-C1 Η 4, -Me H m OH .2-Nap 7-283 1-C1 Η 4, -Me H m OH Bz 7-284 1-C1 Η 4, -Me H m OH -CF2 -Ph 7-285 1-C1 Η 4? -Me H m OH-(CH2) -2-Nap 7-286 ι-α Η 4, -Me H m OH -CH2-3-Me-Ph 7 -287 1-C1 Η 4, -Me H m OH -CH2-4-Me-Ph 7-288 1-C1 Η 4, -Me H m OH -CH2-3-Br-Ph 7-289 1-C1 Η 4, -Me H m OH -CH2-4-Br-Ph 7-290 1-C1 Η 4, -Me H m OH -CHs-S-Cl-Ph 7-291 1-C1 Η 4, -Me H m OH -CH2-4-Cl-Ph 7-292 1-C1 Η 4, -Me H m OH -CH2- 3-F-Ph 7-293 1-C1 Η 4, -Me H m OH -CH2-4-F-Ph 7-294 1-C1 Η 4, -Me H m OH -CH2-3-Tfm-Ph 7 -295 1-C1 Η 4, -Me H m OH -CH2-4-Tfm-Ph 7-296 1-C1 Η 4, -Me H m OH -CHr3-OMe-Ph 7-297 1-C1 Η 4, -Me H m OH -CH2-4-OMe-Ph 7-298 1-C1 Η 4, -Me H m OH -CH2-2,3-diF-Ph 7-299 1-C1 Η 4, -Me H m OH -CHr2,4-diF-Ph 7-300 1-C1 Η 4, -Me H m OH -CHr2,5-diF-Ph 7-301 1-C1 Η 43-Me H m OH -CHr2,6-diF -Ph 7-302 1-C1 Η 4, -Me H m OH -CH2-354-diF-Ph 7-303 1-C1 Η 4, -Me H m OH -CHr3,5-diF-Ph 7-304 1 -C1 Η 4, -Me H m OH -CH2-3? 4-diCl-Ph 7-305 1-C1 Η 4, -Me H m OH -CHr355-diCl-Ph 7-306 1-C1 Η 4,- Me H m OH-CHrS-CW-F-Ph

-181-200401770 7-307 1-C1 H 4; -Me H m OH -Οί2-3-Μ ^ Φα-Ρ1ι 7-308 1-C1 H 4, -Me H IB OH -CH2-354-Mtdo-Ph 7-309 1-C1 H 4, ， Me H m OH -CHr3,4-diMe-Ph 7-310 1-C1 H 4, ， Me H m OH -CH2-355-diMe-Ph 7-311 1-C1 H 4 ， -Cl H m OH Ph 7-312 1-C1 H 4 ， -Cl H m OH 1-Nap 7-313 1-C1 H 4 ， _C1 H m OH 2-Nap 7-314 1-C1 H 4 ， -Cl H m OH Bz 7-315 1-C1 H 4 ， -Cl H m OH -CF2 -Ph 7-316 1-C1 H 4 ， -CI H m OH-(CH2) -2-Nap 7-317 1-C1 H 4, ， Cl H m OH -CH2-3-Me-Ph 7-318 1-C1 H 4, ， Cl H m OH -CH2-4-Me-Ph 7-319 1-C1 H 4 ,， -Cl H m OH -CHr3-Br-Ph 7-320 1-C1 H 4, -Cl H m OH -CH2-4-Br-Ph 7-321 1-C1 H 4, -Cl H m OH -CH2- 3-Cl-Ph 7-322 1-C1 H 4, —Cl H m OH -CH2-4-Cl-Ph 7-323 1-C1 H 4, —Cl .H m OH -CH2-3-F-Ph 7-324 1-C1 H 4, -Cl H m OH -CH2-4-F-Ph 7-325 1-C1 H 4, -a H m OH -CH2-3-Tfm-Ph 7-326 1-C1 H 4, —Cl H m OH -CH2-4-Tfm-Ph 7-327 1-C1 H 4, —Cl H m OH -CH2-3-OMe-Ph 7-328 1-C1 H 4, —Cl H m OH -CH2-4-OMe-Ph 7-329 1-C1 H 4, -Cl H m OH -CH2-2,3-diF-Ph 7-330 1-C1 H 4, -Cl H m OH -CH 2-2? 4-diF-Ph 7-331 1-C1 H 4, ， Cl H m OH-CHr2,5-diF-Ph 7-332 1-C1 H 4, -Cl H m OH -CH2-2? 6-diF-Ph 7-333 1-C1 H 4, —Cl H m OH -CHr3,4-diF-Ph 7-334 1-C1 H 4, —Cl H m OH -CH2-3? 5-diF- Ph 7-335 1-C1 H 4, ， Cl H m OH -CH2-354-diCl-Ph 7-336 1-C1 H 4, ， Cl H m OH -CH2-3,5-diCl-Ph 7-337 1-C1 H 4, —Cl H m OH -CH2-3-Cl-4-F-Ph 7-338 1-C1 H 4, —Cl H m OH -CHbiMe-ACl-Ph 7-339 1-C1 H 4, -Cl H m OH -CH2-354-Mtdo-Ph 7-340 1-C1 H 4, ， Cl H m OH -CH2-354-diMe-Ph 7-341 1-C1 H 4, -Cl H m OH -CH2-355-diMe-Ph 7-342 1-C1 H 155-Me HP OH Ph 7-343 1-C1 H 1 ,, -Me HP OH 1-Nap -182- 200401770 7-344 1-C1 H 1 ,, -Me HP OH 2-Nap 7-345 1-C1 H 1 ,, -Me HP OH Bz 7-346 1-C1 H 1 ,, -Me HP OH -CF2 -Ph 7-347 1-C1 H 1 ,, -Me HP OH-(CH2) -2-Nap 7-348 1-C1 H 1 ,, -Me HP OH -CH2-3-Me-Ph 7-349 1-C1 H 1 ,, -Me HP OH -CH2-4-Me-Ph 7-350 1-C1 H 1 ,, -Me HP OH -CH2-3-Br-Ph 7-351 1-C1 H 1 ,, -Me HP OH -CH2-4- Br-Ph 7-352 1-C1 H 1 ， Me HP OH -CH2-3-Cl-Ph 7-353 1-C1 H 1 , -Me HP OH -CH2-4-Cl-Ph 7-354 1-C1 H 1 ,, -Me HP OH -CH2-3-F-Ph 7-355 1-C1 H 1 ,, -Me HP OH- CH2-4-F-Ph 7-356 1-C1 H 1 ,, -Me HP OH -CH2-3-Tfm-Ph 7-357 1-C1 H 1 ,, -Me HP OH -CH2-4-Tfm- Ph 7-358 1-C1 H 1 ,, -Me HP OH -CH2-3-OMe-Ph 7-359 1-C1 H 1 ,, -Me HP OH -CH2-4-OMe-Ph 7-360 1- Cl H 1 ,, -Me HP OH -CH2-2,3-diF-Ph 7-361 1-C1 H 1 ,, -Me HP OH -CH2-254-diF-Ph 7-362 1-Cl H 1 ,, -Me HP OH -CH2-255-diF-Ph 7-363 1-Cl H 1, -Me HP OH -CHr2,6-diF-Ph 7-364 1-Cl H 1, -Me HP OH- CH2-354-diF-Ph 7-365 1-Cl H 1 ,, -Me HP OH -CH2-3,5-diF-Ph 7-366 1-Cl H 1 ,, -Me HP OH -CH2-3, 4-diCl-Ph 7-367 1-Cl H 1 ,, -Me HP OH -CH2-3,5-diCl_Ph 7-368 1-Cl H 1 ,, -Me HP OH -CH2-3-Cl-4- F > Ph 7-369 1-Cl H 1 ,, -Me HP OH -CH2-3-Me-4-Cl-Ph 7-370 1-Cl H 1 ,, -Me HP OH -CH2-3,4- Mtdo-Ph 7-371 1-Cl H 1 ,, -Me HP OH -CH2-3? 4-diMe-Ph 7-372 1-Cl H 1 "-Me HP OH -CH2-355-diMe-Ph 7- 373 1-Cl H 1 ,, -C1 HP OH Ph 7-374 1-Cl H 1 ,, -C1 HP OH 1- Nap 7-375 1-Cl H 1 ,, -C1 HP OH 2-Nap 7-376 1-Cl H 1 ,, C1 HP OH Bz 7-377 1-Cl H 1 ,, -C1 HP OH -CF2 -Ph 7-378 1-Cl H 1 ,, -C1 HP OH-(GH2) -2-Nap 7-379 1-Cl H 1 ,, -C1 HP OH -CH2-3-Me-Ph 7-380 1-Cl H 1 ~ C1 HP OH -CH2 ~ 4-Me-Ph -183- 200401770 7-381 1-C1 H 1 ,, -C1 HP OH -CH2-3-Br-Ph 7-382 [Cl H 1 ”-Cl HP OH -CH2-4-Br-Ph 7-383 1-C1 H 1 ”-C1 HP OH -CHACl-Ph 7-384 1-C1 H 1 ,, -C1 HP OH • CHr ^ Cl-Ph 7-385 1-C1 H 1 ”-C1 HP OH -CH2-3-F-Ph 7-386 1-C1 H i ,, -a HP OH -CH2 > 4-F-Ph 7-387 1-C1 H 1 ,, -C1 HP OH -CH2-3-Tfm-Ph 7-388 1-C1 H 1 ,, -C1 HP OH -CH2-4-Tfm-Ph 7-389 1-C1 H 1 ,, _C1 HP OH -CH2- 3-OMe-Ph 7-390 1-C1 H 1 ,, -C1 HP OH -CH2-4-OMe-Ph 7-391 1-C1 H 1 ,, -C1 HP OH -CH2-2,3-diF- Ph 7-392 1-C1 H 1 ,, -C1 HP OH -CH2-254-diF-Ph 7-393 1-C1 H 1 ,, -C1 HP OH -CH2-2,5-diF-Ph 7-394 1-C1 H 1 ,, -C1 HP OH -CH2-2,6-diF-Ph 7-395 1-C1 H 1 ,, -C1 HP OH -CH2-3, 'diF-Ph 7-396 1-C1 H 1 ,, -C1 HP OH -CH2-355-diF-Ph 7- 397 1-C1 H 1 ,, -C1 HP OH -CH2-3,4-diCl-Ph 7-398 1-C1 H 1 ,, -C1 HP OH -CH2-355-diCl-Ph 7-399 1-C1 H 1 ,, -C1 HP OH -CH2-3-Cl-4-F-Ph 7-400 1-C1 H 1 ,, -C1 HP OH -CH2-3-Me-4-Cl-Ph 7-401 1 -C1 H 1 ,, -C1 HP OH -CH2-3,4-MtdoPh 7-402 1-C1 H 1 ,, -C1 HP OH -CH2-354-diMe-Ph 7-403 1-C1 H 1 ,,, -C1 HP OH -CH2-3,5-diMe-Ph 7-404 1-C1 H 1 ,, -Me0 HP OH Ph 7-405 1-C1 H 1 ,, -Me0 HP OH 1-Nap 7-406 1 -C1 H 1 ,，-Me0 HP OH 2-Nap 7-407 1-C1 H 1 ,，-Me0 HP OH Bz 7-408 1-C1 H 1 ,，-Me0 HP OH -CF2 -Ph 7-409 1 -C1 H 1 ”-MeO HP OH-(CH2) -2-Nap 7-410 1-C1 H 1 ,，-Me0 HP OH -CH2-3-Me-Ph 7-411 1-C1 H 1 ,，- Me〇HP OH -CH2-4-Me-Ph 7-412 1-C1 H 1 ,, -Me〇HP OH -CH2-3-Br-Ph 7-413 1 -Cl H 1 ,, -Me〇HP OH -CH2-4-Br-Ph 7-414 1-C1 H 1 ,, -Me〇HP OH -CHrS-Cl-Ph 7-415 1-C1 H 1 ,, -Me〇HP OH -CHr4-Cl-Ph 7-416 1-C1 H 1 ,, -Me〇HP OH -CH2-3-F-Ph 7-417 1-C1 H 1 ,, -Me〇HP OH -CHr4-F-Ph. -184- 200401770 7 -418 1-C1 H 1 ”-Me0 HP OH -CH2-3-Tfm-Ph 7-419 1-C1 H 1 ,, she 0 HP OH -CH2-4-Tfm-Ph 7-420 1-C1 H 1 ,, -Me0 HP OH -CH2-3-OMe -Ph 7-421 1-C1 H 1 ,, -Me0 HP OH -CH2-4-OMe-Ph 7-422 1-C1 H 1 ,, -Me0 HP OH -eH2-253-diF-Ph 7-423 1 -C1 H l, MeO HP OH -CH2-2? 4-diF-Ph 7-424 1-C1 H 1 ??-Me0 HP OH -CH2-2,5-diF-Ph 7-425 1-C1 H 1 ,, -Me0 HP OH -CH2-256-diF-Ph 7-426 1-C1 H 1 ,, -Me0 HP OH -CH2-3? 4-diF-Ph 7-427 1-C1 H 1 ,,- Me0 HP OH -CH2-3? 5-diF-Ph. 7-428 1-C1 H 1 ,, -Me0 HP OH -CH2-3,4-diCl-Ph 7-429 1-C1 H 1 ,, -Me0 HP OH -CH2-355-diCl-Ph 7-430 1-C1 H 1 ,, -Me0 HP OH -CH2-3-Cl-4-F-Ph 7-431 1-C1 H 1,, -Me0 HP OH -CH2-3-Me-4-Cl-Ph 7-432 1-C1 H 1 ,, -Me0 HP OH -CH2-354-Mtdo-Ph 7-433 1-C1 H 1 ,, -Me0 HP OH -CH2 -3,4-diMe-Ph 7-434 1-C1 H 1 ,, -Me0 HP OH -CH2-3? 5-diMe-Ph 7-435 1-C1 H 2 ,, -Me HP OH Ph 7-436 1-C1 H 2 ,, -Me HP OH 1-Nap 7-437 1-C1 H 2 ,, -Me HP OH 2-Nap 7-438 1-C1 H 2 ,, -Me HP OH Bz 7-439 1 -C1 H 2 ,，-Me HP OH -CF2 -Ph 7-440 1-C1 H 2 ,, _Me HP OH-(CH2) -2-Nap 7-441 1-C1 H 2 ,, -Me HP OH -CH2-3-Me-Ph 7-442 1-C1 .. H 2 ”-Me HP OH -CH2-4-Me-Ph 7-443 1-C1 H 2 ,, -Me HP OH -CH2-3-Br-Ph 7-444 1-C1 H 2 ,, -Me HP OH -CH2-4-Br -Ph 7-445 1-C1 H 2 ,，-Me HP OH -CH2-3-Cl-Ph 7-446 1-C1 H 2 ″ -Me HP OH -CH2-4-Cl-Ph 7-447 1- C1 H 2 ,，-Me HP OH -CH2-3-F-Ph 7-448 1-C1 H 2 "-Me HP OH -CH2-4-F-Ph 7-449 1-C1 H 2 ,，-Me HP OH -CH2-3-Tfm-Ph 7-450 1-C1 H 2 ,, -Me HP OH -CH2-4-Tfm-Ph 7-451 1-C1 H 2 ,, -Me HP OH -CH2-3 -OMe-Ph 7-452 1-C1 H 2 ,, -Me HP OH -CH2-4-OMe-Ph 7-453 1-C1 H 2 ,, Me HP OH -CH2-253-diF-Ph 7-454 1-C1 H 2 ,, -Me HP OH -CH2-2,4-diF-Ph -185- 200401770 7-455 7-456 7-457 7-458 7-459 7-460 7-461 7-462 7 -463 7-464 7-465 7-466 7-467 7-468 7-469 7-470 7-471 7-472 7-473 7-474 7-475 7-476 7-477 7-478 7-479 7-480 7-481 7-482 7-483 7-484 7-485 7-486 7-487 7-488 7-489 7-490 7-491 1-C1 1-C1 1-C1 1-C1 1- C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1 * C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1-C1 1- C1

HHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHHH 2? 5-Me 2 ,, -Me 2 ,, -Me 2 ,, -Me 2 ,, -Me 2 ,, -Me 2 ,, -Me 2 ,, -Me 2 ,, -Me 2 "- Me 2 ,, -Me 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,,- Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl 2 "-Cl 2 ,, -Cl 2 "-Cl 2 ,, -Cl 2 ,, -Cl 2 ,, -Cl2 ,, -Cl 2 ,, -Cl

HHHHHHHHHHHHHHHHHHHHHH HHHHHHHHHHHHHHHH pppppppppppppppppppppppppppppppppp gggOTggOTggJJOTgggggJggggPJgHgggggggg-gggg-CH2-255-diF-Ph-CH2-256-CH2-256 Ρ1ι -CHr3,5-diCl-Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CH2-3,4-Mtdo-Ph -CH2-3? 4- diMe-Ph -CH2-3,5-diMe-Ph Ph 1-Nap 2-Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2-4-Me-Ph- CH2-3-Br-Ph -CH2-4-Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2- 3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CH2-253-diF-Ph -CH2-234-diF-Ph -CH2-2, 5-diF-Ph -CH2-236-diF-Ph -CHr3,4-diF-Ph -CHr3,5-diF-Ph -CHr3,4-diCl-Ph -CH2-355-diCl-Ph -186- 200401770 7 -492 1-C1 H 2 ,，-Cl HP OH -CH2-3-Cl-4-F-Ph 7-493 1-C1 H 2 ,，-Cl H. P OH -CHs-S-Me- ^ Cl -Ph 7-494 1-C1 H 2 ,，-Cl HP OH -CH2-354-Mtdo-Ph 7-495 1-C1 H 2 ,，-Cl HP OH -CHr3,4-diMe-Ph 7-496 1 -C1 H 2, ， C1 HP OH -CHr3,5-diMe-Ph 7-497 1-C1 H 2 ,，-MeO HP OH Ph 7-498 1-C1 H 2 ,，-MeO HP OH 1-Nap 7-499 1-C1 H 2 ,, -MeO HP OH 2-Nap 7-500 1-C1 H 2 ,, -MeO HP OH Bz 7-501 1-C1 H 2 ,, -MeO HP OH- CF2 -Ph 7-502 1-C1 H 2 ,，-MeO HP OH-(CH2) -2-Nap 7-503 1-C1 H 2 ,，-MeO HP OH -CH2-3-Me-Ph 7-504 1-C1 H 2 ,，-MeOH P OH -CH2-4-Me-Ph 7-505 1-C1 H 2 ， -MeO HP OH -CH2-3-Br-Ph 7-506 1-C1 H 2 ， ， -MeO HP OH -CH2-4-Br-Ph 7-507 1-C1 H 2 "-MeO HP OH -CH2-3-Cl-Ph 7-508 1-C1 H 2 ，-MeOH P OH -CH2 -4-Cl-Ph 7-509 1-C1 H 2 ,, -MeO HP OH -CH2-3-F-Ph 7-510 1-C1 H 2 ,, -MeO HP OH-CHr4-F-Ph 7- 511 1-G1 H 2 ,, -MeO HP OH -CH2-3-Tfm-Ph 7-512 1-C1 H 2 ,, -MeOH P OH -CH2-4-Tfm-Ph 7-513 1-C1 H 2 ,, -MeO HP OH -CH2-3-OMe-Ph 7-514 1-C1 H 2 ,, -MeO HP OH -CH2-4-OMe-Ph 7-515 1-C1 H 2,, -MeO HP OH -CH2-2,3-diF-Ph 7-516 1-C1 H 2 ,,-MeO HP OH -CH2-254-diF-Ph 7-517 1-C1 H 2 ,, -MeO HP OH -CH2-2 ? 5-diF-Ph 7 ^ 518 1-C1 H 2 ,, -MeO HP OH -CH2-2? 6-diF-Ph 7-519 1-C1 H 2 ,, -MeO HP OH -CH2-354-diF -Ph 7-520 1-C1 H 2 ,，-MeO HP OH -CH2- 355-diF-Ph 7-521 1-C1 H 2 ,, -MeO Ή P OH -CH2-3? 4-diCl-Ph 7-522 1-C1 H 2 ,, -MeO HP OH -CHr3,5-diCl -Ph 7-523 1-C1 H 2 ,，-MeO HP OH -CH2-3-Cl-4-F-Ph 7-524 1-C1 H 2 ″ -MeO HP OH -CH2-3-Me-4- Cl-Ph 7-525 1-C1 H 2 ,, -MeO HP OH -CHr3,4-MtdoPh 7-526 1-C1 H 2 ,, -MeOH P OH -CH2-3? 4-diMe-Ph 7-527 1-C1 H 2 ,，-MeO HP OH -CHr3,5-diMe-Ph 7-528 1-C1 H 1 ,，-Me 4? 3-Me P OH Ph -187- 200401770 7-529 1-C1 H 1 ,, -Me 4 ,, -Me P OH 1-Nap 7-530 1-C1 H 1 ,, -Me 4 ,, -Me P OH 2-Nap 7-531 1-C1 H 1 ,, -Me 4 ,, -Me P OH Bz 7-532 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CF2 -Ph 7-533 1-C1 H 1 ,, -Me 4 ,, -Me P OH- (CH2) -2-Nap 7-534 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CH2 -3-Me-Ph 7-535 1-C1 H 1 ,, -Me 4 ,,- Me P OH -CH2-4-Me-Ph 7-536 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CH2-3-Br-Ph 7-537 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CH2-4-Br-Ph 7-538 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CH2-3-Cl-Ph 7-539 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CH2-4-Cl-Ph 7-540 1-C1 H 1 ,,- Me 4 ,，-Me P OH -CH2-3-F-Ph 7-541 1-C1 H 1 ,，-Me 4 ,，-Me P OH -CH2-4-F-Ph 7-542 1-C1 H 1 ,, -Me 4 ,, -Me P OH -CH2-3-Tfm-Ph 7-543 1-C1 H 1 ,, -Me 4,, -Me P OH -CH2-4-Tfm-Ph 7-544 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CHr3-OMe-Ph 7-545 1-C1 H 1 ,, -Me 4,, -Me P OH -CH2-4-OMe-Ph 7 -546 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CH2-2? 3-diF-Ph 7-547 1-Cl H 1 ,, Me 4,, -Me P OH -CH2-2 ? 4-diF-Ph 7-548 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CH2-2,5-diF-Ph 7-549 1-Cl H 1 ,, -Me 4 ,,, -Me P OH -CH2-236-diF-Ph 7-550 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CH2-354-diF-Ph 7-551 1-Cl H 1 ,,- Me 4 ,, -Me P OH -CH2-335-diF-Ph 7-552 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CH2-354-diCl-Ph 7-553 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CH2-3,5-diCl-Ph 7-554 1-Cl H 1 ,, -Me 4,, -Me P OH -CH2-3-Cl-4- F-Ph 7-555 1-Cl H 1 ,, -Me 4 "-Me P OH -CH2-3-Me-4-Cl-Ph 7-556 1-Cl H 1 ,, -Me 4,, -Me P OH -CH2-3? 4-Mtdo-Ph 7-557 1-Cl H 1 ,, -Me 4 ,, -Me P OH -CH2-3? 4-diMe-Ph 7-558 1-C l H 1 ,，-Me 4 ”-Me P OH -CH2-3,5-diMe-Ph 7-559 2-MeO H 1 ,，-Me HP OH Bz 7-560 2-MeOH 1” -Et HP OH Bz 7-561 2-MeO H 1 ”-Pr HP OH Bz 7-562 2-MeO H l5MPr HP OH Bz 7-563 2-MeO H 1 ,, -C1 HP OH Bz 7-564 2-MeO H 1, Br HP OH Bz 7-565 2-MeO 3-MeO lJJ-Me HP OH Bz 188- 200401770 2-MeO 3-MeO 1 ”-Et H 2-MeO 3-MeO 15? -Pr H 2-MeO 3- MeO l5? -IPr H 2-MeO 3-MeO 1 ,，-C1 H 2-MeO 3-MeO 1 ”-Br H 2-C1 3-MeO 155-Me H 2-C1 3-MeO 1 ,，-Et H 2-C1 3-MeO 1 ,, -Pr H 2-C1 3-MeO 1 ,, iPr H 2-C1 3-MeO 1 ,, -C1 H 2-C1 3-MeO 1 ,, -Br H 2- OMe H 4, -Me H 2-OMe Η 7-566 7-567 7-568 7-569 7-570 7-571 7-572 7-573 7-574 7-575 7-576 7-577 7-578 7-579 2-1 Η 7-580 2-OMe Η 7-581 2-OMe Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ Ρ m 3, -NΗ2 4, -Me m 1 ,, -Me Η ρ 1 ,, -Me ρ ρ l ,, -COOMe Η ρ OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH Bz OH -CH2-5-Me-2 -Pyzi OH -Bz Table 8

F

Exemp. Comp. No. R1 R2 R3 .X Y 8-1 H H H H Bz 8-2 H H H OMe Bz 8-3 H H H OTfm Bz 8-4 H H H OH Ph 8-5 H H OH 1-Nap -189- 200401770

8-6 Η Η ΟΗ 2-Nap 8-7 Η Η Η ΟΗ Βζ 8-8 Η Η Η ΟΗ -CH (Me) -Ph .8-9 Η Η Η ΟΗ -CH (NH2) -Ph 8-10 Η Η Η ΟΗ -CH (NHMe) -Ph. 8-11 Η Η Η ΟΗ -CF2 -Ph 8-12 Η Η Η ΟΗ -CH (OH) -Ph 8-13 Η Η Η ΟΗ -CH (OMe)- Ph 8-14 Η Η Η Η (-(CH2) -1-Nap 8-15 Η Η Η Η Η-(CH2) -2-Nap 8-16 Η Η Η Η Η-(CH2) 2-Ph 8-17 Η Η Η ΟΗ-(CHPh)-(CH2) -Ph 8-18 Η Η Η Ο Η-(CH2) 2-1-Nap 8-19 Η Η Η ΟΗ-(CH2) 2-2-Nap 8-20 Η Η Η ΟΗ-(CH2) 3-Ph 8-21 Η Η Η ΟΗ-(CH2) 3-1-Nap 8-22 Η Η Η Ο Η-(CH2) 3-2-Nap 8-23 Η Η Η, ΟΗ-( CH2) 4-Ph 8-24 Η Η Η ΟΗ-(CH2) 4-1-Nap 8-25 Η Η Η ΟΗ-(CH2) 4-2-Nap 8-26 Η Η Η CHΗ -CH2-2-Me , Ph 8-27 Η Η. Η ΟΗ -CH2-3-Me-Ph 8-28 Η Η Η ΟΗ -CH2-4-Me-Ph 8-29 Η Η Η Η Η -CHr2-Br-Ph 8-30 Η Η Η ΟΗ -CH2-3-Br-Ph 8-31 Η Η Η ΟΗ -CH2-4-Br-Ph 8-32 Η Η Η ΟΗ -CH2-2-Cl-Ph 8-33 Η Η Η ΟΗ -CH2 -3-Cl-Ph 8-34 Η Η Η Η CH -CH2-4-Cl-Ph 8-35 Η Η Η Η Η -CH2-2-F-Ph 8-36 Η Η Η CH CH -CH2 -3-F-Ph. 8-37 Η Η Η Η CH -CH2-4-F-Ph 8-38 Η Η Η Η CH -CH2-2-Tfm-Ph 8-39 Η Η Η ΟΗ -CH2-3-Tfm -Ph 8-40 Η Η Η ΟΗ -CH2-4-Tfm-Ph 8-41 Η Η Η ΟΗ -CH2-2-OH-Ph 8-42 Η Η Η Η -CHr3-〇H-Ph -190- 200401770 8-43 Η Η 〇〇 -CH2-4-OH-Ph 8-44 Η Η Η 〇Η -CH2-2-OMe-Ph 8-45 Η Η CH CH -CH2-3-OMe-Ph 8- 46 Η Η Η 〇Η -CHr4-OMe-Ph 8-47 Η Η CH Η CH CH CH CH CH CH CH CH CH CH CH CH CH CH CH CH CH Η Ο Η -CH2-4-N02-Ph 8-50 Η Η Η ΟΗ -CH2-2-Et-Ph 8-51 Η. Η Η Ο Η -CH2-3-Et-Ph 8-52 Η Η Η ΟΗ -CH2-4 -Et-Ph 8-53 Η Η Η Η gt > CH2-2-iPr-Ph 8-54 Η Η Η Η CH -CH2-3-iPr-Ph 8-55 Η Η Η ΟΗ -CH2-4-iPr-Ph 8-56 Η Η Η Η CH -CH2-2-CN-Ph 8-57 Η Η Η ΟΗ -CH2 Each CN-Ph 8-58 Η Η Η CH CH CH CH Η Η Ο Η -CH2-2-NH2-Ph 8-60 Η Η Ο Η -CH2-3-NH2-Ph 8-61 Η Η Η ΟΗ -CH2-4-NH2-Ph 8-62 Η Η CH CH Η -CH2-2- SMe-Ph 8-63 Η Η Η Η CH -CH2-3-SMe-Ph 8-64 Η Η Η Η CH -CH2-4-SMe-Ph 8-65 Η Η Η ΟΗ -C H2-4-NHMe-Ph 8-66 Η Η Η ΟΗ -CH2-4-NMe2-Ph 8-67 Η Η Η Ο Η -CH2-4-SOMe-Ph 8-68 Η Η Η ΟΗ -CH2-4-S02Me -Ph 8-69 Η Η Η ΟΗ -CH2-4-AcNH-Ph 8-70 Η Η Η ΟΗ -CH2-3-AcNH-Ph 8-71 Η Η Η ΟΗ -CH2-4-tBu0C (= 0) NH -Ph 8-72 Η Η Η ΟΗ -CH2-4-MeS02NH-Ph 8-73 Η Η Ο Η .CH2-4-TfmS〇2NH-Ph 8-74 Η Η Η ΟΗ -CH2-4-Ac-Ph 8 -75 Η Η Η Η CH -CH2-4-AcO-Ph 8-76 Η Η Η Η CH -CH2-4-MeCar-Ph 8-77 Η Η Η CH -CH2-4-diMeCar-Ph 8-78 Η Η Η ΟΗ • CHr2,3-diF-Ph 8-79 Η Η Η Ο Η -CH2-2? 4-diF-Ph 200401770 8-80 Η Η CH CH -CH2-2? 5-diF-Ph 8-81 Η Η Η 〇Η -CH2-256-diF-Ph 8-82 Η Η Η Η CH CH CH CH CH CH CH CH Η CH CH CH CH CH CH CH CH CH CH CH CH CH CH CH Η 〇 Η -CHr2,3-diCl-Ph 8-85 Η Η Η 〇Η -CH2-2? 4-diCl-Ph 8-86 Η Η .Η ΟΗ -CH2-255-diCl-Ph 8-87 Η Η Η ΟΗ -CH2-2,6-diCl-Ph 8-88 Η Η Η Η CH -CH2-354-diCl-Ph 8-89 Η Η Η Ο Η -CH2-355-diCl-Ph 8-90 Η Η Η ΟΗ -CH2- 2, F-4-N02-Ph 8-91 Η Η Η ΟΗ -CH2-2-Cl-4-F-Ph 8-92 Η Η Η ΟΗ- CH2-2-Cl-4-N〇2-Ph 8-93 Η Η Η ΟΗ -CH2-3-Cl-4-F-Ph 8-94 Η Η Η ΟΗ -CH2-2-Me-4-F- Ph 8-95 Η Η Η ΟΗ -CH2-2-Me-4-Cl-Ph 8-96 Η Η Η ΟΗ -GH2-3-Me-4-Cl-Ph 8-97 Η Η Η Η Η -CH2-3 -Cl-4-Me-Ph 8-98 Η Η Η Η CH -CH2-3-Me-4-N02-Ph 8-99 Η Η Η Η CH -CH2-3-N02-4-Cl-Ph 8-100 Η Η Η ΟΗ -CH2-253-diOH-Ph 8-101 Η Η Η Ο Η -CH2-254-diOH-Ph 8-102 Η .Η Η Ο Η -CH2-235-diOH-Ph 8-103 Η Η Η ΟΗ- CH2-236-diOH-Ph 8-104 Η Η Η ΟΗ -CH2-334-diOH-Ph 8-105 Η Η Η Ο Η -CH2-355-diOH-Ph 8-106 Η Η Η ΟΗ -CH2-233-diOMe -Ph 8-107 Η Η Η ΟΗ -CH2-2,4-diOMe-Ph 8-108 Η Η Ο Η -CH2'5-di〇Me-Ph 8-109 Η Η Η ΟΗ -CH2-236-diOMe- Ph 8-110 Η Η Η 〇Η -CH2-3? 4-diOMe-Ph 8-111 Η Η Η Ο Η -CH2-3,5-diOMe-Ph 8-112 Η Η Η Η r -CHr2,3-MtdoPh 8- 113 Η Η Η ΟΗ -CHr3,4-Mtdo-Ph 8-114 Η Η Η ΟΗ -CH2-253-diMe-Ph 8-115 Η Η Η Η -CH2-2? 4-diMe-Ph 8-116 Η Η Η ΟΗ -CH2-2? 5 > diMe-Ph 192- 200401770 8-117 Η HH OH -CH2-2? 6-diMe-Ph 8-118 Η HH OH -CH2-3,4 ^ diMe-Ph 8-119 Η HH OH -CH2-3? 5-diMe-Ph 8-120 Η HH OH -CHr2,4,5-triF-Ph 8-121 Η HH OH- CH2-pentaFPh 8-125 Η HH OH -CH2- (4-Ph) -Ph 8-126 Η HHH -CH2-4-Tfm-Ph 8-127 Η HH OMe -CH2-4-Tfm-Ph 8-128 Η HH OTfm -CH2-4-Tfm-Ph 8-129 1-Me HH OH Ph 8-130 1-Me HH OH 1-Nap 8-131 1-Me HH OH 2-Nap 8-132 1-Me HH OH Bz 8-133 1-Me HH OH -CF2 -Ph 8-134 1-Me HH OH-(CH2) -2-Nap 8-135 1-Me HH OH -CH2-3-Me-Ph 8-136 1-Me HH OH -CH2-4-Me-Ph 8-137 1-Me HH OH -CH2-3-Br-Ph 8-138 1-Me HH OH -CH2-4-Br-Ph 8-139 1-Me HH OH -CH2-3-Cl-Ph 8-140 1-Me HH OH -CH2-4-Cl-Ph 8-141 1-Me HH OH -CH2-3-F-Ph 8-142 1-Me HH OH -CH2 -4-F-Ph 8-143 1-Me HH OH -CH2-3-Tfm-Ph 8-144 1-Me HH OH -CH2-4-Tfm-Ph 8-145 1-Me HH OH -CH2-3 -OMe-Ph 8-146 1-Me HH OH -CH2-4-OMe-Ph 8-147 1-Me HH OH -CH2-253-diF-Ph 8-148 1-Me .HH OH -CH2-254- diF-Ph 8-149 1-Me HH OH -CH2-2,5-diF-Ph 8-150 1-Me HH OH -CH2-236-diF-Ph 8-151 1-Me HH OH -CH2-354- diF-Ph 8-152 1-Me HH OH -CH2-355- diF-Ph 8-153 1-Me HH OH -CH2-354-diCl-Ph 8-154 1-Me HH OH -CH2 > 3? 5-diCl-Ph 8-155 1-Me HH OH -CH2-3- Cl-4-F-Ph 8456 1-Me HH OH -CH2-3-Me-4-Cl-Ph -193 200401770 8-157 1-Me HH OH -CH2-3? 4-Mtdo-Ph 8458 1-Me HH OH -CH2-3? 4-diMe-Ph 8-159 1-Me HH OH -CH2-335-diMe-Ph 8-160 1-C1 HH OH Ph 8-161 1-C1 HH OH 1-Nap 8- 162 1-C1 HH OH 2-Nap 8-163 1-C1 HH OH Bz 8-164 1-C1 HH OH -CF2 -Ph 8-165 1-C1 HH OH-(CH2) -2-Nap 8-166 1 -C1 HH OH -CH2-3-Me-Ph 8-167 1-C1 HH OH -CH2-4-Me-Ph 8-168 1-C1 HH OH -CH2-3-Br-Ph 8-169 1-C1 HH OH -CH2-4-Br-Ph 8-170 1-C1 HH OH -CH2-3-Cl-Ph 8-171 1-C1 HH OH -CH2-4-Cl-Ph 8-172 1-C1 HH OH -CH2-3-F-Ph 8-173 1-C1 HH OH -CH2-4-F-Ph 8-174 1-C1 HH OH -CH2 Tfm-Ph 8-175 1-C1 H-H OH -CH2 -4-Tfm-Ph 8-176 1-C1 HH OH -CH2-3-OMe-Ph 8-177 1-Cl HH OH -CH2-4-OMe-Ph 8-178 1-C1 HH OH -CH2-233 -diF-Ph 8-179 1-C1 HH OH -CH2-2,4-diF-Ph 8-180 1-C1 HH OH -CH2-255-diF-Ph 8-181 1-C1 HH OH -CH2-2 , 6-diF-Ph 8-182 1-C1 HH OH -CH2-3? 4-diF-Ph 8-183 1-C1 HH OH -CH2-3? 5-diF-Ph 8-184 1-C1 HH OH -CH2-3? 4.diCl-Ph 8-185 1-C1 HH OH -CH2-3? 5-diCl- Ph 8-186 1-C1 HH OH -CH2-3-Cl-4-F-Ph 8-187 1-C1. HH OH -CH2-3-Me-4-Cl-Ph 8-188 1-C1 HH OH -CH2-354-Mtdo-Ph 8-189 1-C1 HH OH -CH2-354-diMe-Ph 8-190 1-C1 .HH OH -CH2-355-diMe-Ph 8-191 1-Br HH OH Ph 8-192 1-Br HH OH 1-Nap 8-193 1-Br HH OH 2-Nap -194- 200401770 8-194 1-Br HH OH Bz 8-195 1-Br HH OH -CF2 -Ph 8-196 1-Br HH OH-(CH2) -2-Nap 8-197 1-BrHH OH -CH2-3-Me-Ph * 8-198 1-Br HH OH -CH2-4-Me-Ph 8-199 1-Br HH OH -CH2-3-Br-Ph 8-200 1-Br HH OH -CH2 Bucket Br-Ph 8-201 1-Br HH OH -CH2-3-Cl-Ph 8-202 1-Br HH OH -CH2-4-Cl-Ph 8-203 1-Br HH OH -CH2-3-F-Ph 8-204 1-Br HH OH -CH2-4-F-Ph 8-205 1-Br HH OH- CH2-3-Tfm-Ph 8-206 1-Br HH OH -CH2-4-Tfm-Ph 8-207 1-Br HH OH -CH2-3-OMe-Ph 8-208 1-Br HH OH -CH2- 4-OMe-Ph 8-209 1-Br HH OH -CH2-2? 3-diF-Ph 8-210 1-Br HH OH -CH2-2,4-diF-Ph 8-211 1-Br HH OH- CH2-235-diF-Ph 8-212 1-Br HH OH -CH2-236 ^ diF-Ph 8-213 1-Br H H OH -CH2-3,4-diF-Ph 8-214 1-Br HH OH -CH2-355-diF-Ph 8-215 1-Br HH OH -CH2-354-diCl-Ph 8-216 1-Br HH OH -CH2-3,5-diCl-Ph 8-217 1-Br HH OH -CHs-S-Cl ^ -F-Ph 8-218 1-Br HH OH -CHrS-Me- ^ Cl-Ph 8- 219 1-Br HH OH -CH2-3,4-Mtdo-Ph 8-220 1-Br HH OH -CH2-3,4-diMe-Ph 8-221 1-Br HH OH -CHr3,5-diMe-Ph 8-222 1-OH HH OH Ph 8-223 1-OH HH OH 1-Nap 8-224 l-OH HH OH 2-Nap 8-225 1-OH HH OH Bz 8-226 1-OH HH OH -CF2 -Ph 8-227 1-OH HH OH-(CH2) -2-Nap 8-228 1-OH HH OH -CH2-3-Me-Ph 8-229 1-OH HH OH -CH2 ^ -Me-Ph 8 -230 1-OH HH OH ^ CH2-3-Br-Ph 195- 200401770 8-231 1-OH. HH OH -CH2-4-Br-Ph 8-232 1-OH HH OH -CH2-3-Cl- Ph 8-233 1-OH HH OH -CHr4-a-Ph 8-234 1-OH HH OH -CH2-3-F-Ph 8-235 1-OH HH OH -CH2-4-F-Ph 8-236 1-OH HH OH -CH2-3-butylfm-Ph 8-237 1-OH HH OH -CH2-4-Tfm-Ph 8-238 1-OH HH OH -CH2-3-OMe-Ph 8-239 1 -OH HH OH -CH2-4-OMe-Ph 8-240 1-OH HH OH -CHr2,3-diF-Ph 8-241 1-OH HH OH -CH2-234-diF-Ph 8-242 1-OH HH OH -CH2-255-diF-Ph 8-243 1-OH HH OH -CHr2,6-diF-Ph 8-244 1-OH HH OH -CH2-3? 4-diF-Ph. 8-245 1-OH HH OH -CH2-355-diF-Ph 8-246 1-OH HH OH -CH2-3,4- diCl-Ph 8-247 1-OH HH OH -CHr3,5-diCl-Ph 8-248 1-OH HH OH -CHrS-ClW-F-Ph 8-249 1-OH HH OH -CH2-3-Me- 4-Cl-Ph 8-250 1-OH HH OH -CH2-374-Mtdo-Ph 8-251 1-OH HH OH -CHr3,4-diMe-Ph 8-252 1-OH HH OH -CH2-355- diMe-Ph 8-253 1-Tfm HH OH Ph 8-254 1-Tfm HH OH 1-Nap 8-255 1-Tfm HH OH 2-Nap 8-256 1-Tfm HH OH Bz 8-257 1-Tfm HH OH -CF2 -Ph 8-258 1-Tfm HH OH-(CH2) -2-Nap 8-259 1-Tfm HH OH -CH2-3-Me-Ph 8-260 1-Tfm HH OH -CH2-4- Me-Ph 8-261 1-Tfm HH OH -CH2-3-Br-Ph 8-262 1-Tfm HH OH -CH2-4-Br-Ph 8-263 1-Tfm HH OH -CH2 each CWPh 8-264 1-Tfm HH OH -CHr4-Cl-Ph 8-265 1-Tfm HH OH -CH2-3-F-Ph 8-266 1-Tfm HH OH -CH2-4-F-Ph 8-267 1-Tfm HH OH -CH2-3-Tfm ~ Ph 196- 200401770

8-268 1-Tfm H. H OH -CH2-4-Tfm-Ph 8-269 1-Tfm HH OH -CH2 Each OMe-Ph 8-270 1-Tfm HH OH -CHr4-OMe-Ph 8-271 1 -Tfm HH OH -CHr2,3-diF-Ph 8-272 1-Tfm HH OH -CH2-234-diF-Ph 8-273 1-Tfm HH OH -CH2-2,5-diF-Ph 8-274 1 -Tfm HH OH -CH2-236-diF-Ph 8-275 1-Tfm HH OH -CHr3,4-diF-Ph 8-276 1-Tfm HH OH -CH2-3,5-diF-Ph 8-277 1 -Tfm HH OH -CH2-3? 4-diCl-Ph 8-278 1-Tfm HH OH -CH2-355-diCl-Ph 8-279 1-Tfm HH OH -CH2-3-Cl-4-F-Ph 8-280 .1-Tfm HH OH -CH2-3-Me-4-Cl-Ph 8-281 1-Tfm HH OH -CH2-3,4-Mtdo-Ph 8-282 1-Tfm HH OH -CH2- 3,4-diMe-Ph 8-283 1-Tfm HH OH -CH2-355-diMe-Ph 8-284 1-OMe HH OH Ph 8-285 1-OMe HH OH 1-Nap 8-286 1-OMe HH OH 8-287 1-OMe HH OH Bz 8-288 1-OMe HH OH -CF2 -Ph 8-289 1-OMe HH OH-(CH2) -2-Nap 8-290 1-OMe HH OH -CH2-3 -Me-Ph 8-291 1-OMe HH OH -CH24Me-Ph 8-292 1-OMe HH OH -CH2-3-Br-Ph 8-293 1-OMe HH OH -CH2-4-Br-Ph 8- 294 1-OMe HH OH -CHr3-Cl-Ph 8-295 1-OMe HH OH -CH2-4-Cl-Ph 8-296 1-OMe HH OH -CH2-3-F > Ph 8-297 1-OMe HH OH -CH2-4-F-Ph 8 -298 1-OMe HH OH -CH2-3-Tfm-Ph 8-299 1-OMe HH OH -CH2-4-Tfm-Ph 8-300 1-OMe HH OH -CH2-3-OMe-Ph 8-301 1-OMe HH OH • CHr4-OMe-Ph 8-302 1-OMe HH OH -CH2-253-diF-Ph 8-303 1-OMe HH OH -CH2-234-diF-Ph 8-304 1-OMe HH OH -CH2-255-diF-Ph 197- 200401770 8-305 1-OMe HH OH -CH2-2,6-diF-Ph 8-306 1-OMe HH OH -CHr3,4-diF-Ph 8-307 1 -OMe HH OH -CHr3,5-diF-Ph 8-308 1-OMe HH OH -CH2-354-diCl-Ph 8-309 1-OMe HH OH -CH2-335-diCl-Ph 8-310 1-OMe HH OH -CHs-S-Cl- ^ F-Ph 8-311 1-OMe HH OH -CH2-3-Me-4-Cl-Ph 8-312 1-OMe HH OH -CHr3,4-Mtdo-Ph 8 -313 1-OMe HH OH -CH2-3,4-diMe-Ph 8-314 1-OMe HH OH -CH2-355-diMe-Ph 8-315 1-AcNH HH OH Ph 8-316 1-AcNH HH OH 1-Nap 8-317 1-AcNH HH OH 2-Nap 8-318 1-AcNH HH OH Bz 8-319 1-AcNH HH OH -CF2 -Ph 8-320 1-AcNH HH OH-(CH2) -2- Nap 8-321 1-AcNH HH OH -CH2-3-Me-Ph 8-322 1-AcNH HH OH -CH2-4-Me-Ph 8-323 .1-AcNH HH OH -CH2-3-Br-Ph 8-324 1-AcNH HH OH -CH2-4-Br-Ph 8-325 1-AcNH HH OH -CHr3-Cl-Ph 8-326 1-AcNH HH OH -CH2-4-Cl-Ph 8-327 1-AcNH HH OH -CH2-3-F-Ph 8-328 1-AcNH HH OH -CH2-4-F-Ph 8-329 1-AcNH HH OH, CH2-3-Tfm-Ph 8-330 1- AcNH HH OH -CH2-4-Tfm > Ph 8-331 1-AcNH HH OH -CH2-3-OMe-Ph 8-332 1-AcNH HH OH -CHr4-OMe-Ph 8-333 1-AcNH HH OH- CHr253-diF-Ph 8-334 1-AcNH HH OH -CH2-2? 4-diF-Ph 8-335 1-AcNH HH OH -CHr2,5-diF-Ph 8-336 1-AcNH HH OH -CHr2, 6-diF-Ph 8-337 1-AcNH HH OH -CH2-3,4-diF-Ph 8-338 1-AcNH HH OH -CH2-335-diF-Ph 8-339 1-AcNH HH OH -CH2- 3,4-diCl-Ph 8-340 1-AcNH HH OH -CHr3,5-diCl-Ph 8-341 1-AcNH HH OH -CH2-3-Cl-4-F-Ph 9 198- 200401770 8-342 1-AcNH HH OH -CH2-3-Me-4-Cl-Ph 8-343 1-AcNH HH OH -CH2-3? 4-Mtdo-Ph 8-344 1-AcNH HH OH -CHr3,4-diMe- Ph 8-345 1-AcNH HH OH -CH2-335-diMe-Ph 8-346 2-Me HH OH Ph 8-347 2-Me HH OH 1-Nap 8-348 2-Me HH OH 2-Nap 8- 349 2-Me HH OH Bz 8-350 2-Me HH OH -CF2 -Ph 8-351 2-Me HH OH-(CH2) -2-Nap 8-352 2-Me HH OH -CH2-3-Me- Ph 8-353 2-Me HH OH -CH2-4-Me-Ph 8-354 2-Me HH OH -CH2-3-Br-Ph 8-355 2-Me HH OH -CH2-4-Br-Ph 8 -356 2-Me H H OH -CH2-3-Cl-Ph 8-357 2-Me HH OH -CH2-4-Cl-Ph 8-358 2-Me HH OH -CH2-3-F-Ph 8-359 2-Me HH OH -CH2-4-F-Ph 8-360 2-Me HH OH -CH2-3-Tfm-Ph 8-361 2-Me HH OH -CH2-4-Tfm-Ph 8-362 2-Me HH OH -CH2 -3-OMe-Ph 8-363 2-Me HH OH -CH2-4-OMe-Ph 8-364 2-Me HH OH -CH2-233-diF-Ph 8-365 2-Me HH OH -CH2- 254-diF-Ph 8-366 2-Me HH OH -CH2-2,5-diF-Ph 8-367 2-Me HH OH -CH2-2? 6-diF-Ph 8-368 2-Me HH OH- CH2-334-diF-Ph 8-369 2-Me HH OH -CHr3,5-diF-Ph 8-370. 2-Me HH OH -CH2-334-diCl-Ph 8-371 2-Me HH OH -CH2 -335-diCl-Ph 8-372 2-Me HH OH -CH2-3-Cl-4-F-Ph 8-373 2-Me HH OH -CH2-3-Me-4-Cl-Ph 8-374 2 -Me H. H OH -CH2-334-Mtdo-Ph 8-375 2-Me HH OH -CH2-354-diMe-Ph 8-376 2-Me HH OH -CHr3,5-diMe-Ph 8-377 2 -C1 HH OH Ph 8-378 • 2-C1 HH OH 1-Nap 199- 200401770 8-379 2-C1 HH OH 2-Nap 8-380 2-C1 HH OH Bz 8-381 2-C1 HH OH -CF2 -Ph 8-382 2-C1 HH OH-(CH2) -2-Nap 8-383 2-C1 HH OH -CH2-3-Me-Ph 8-384 2-C1 HH OH -CH2-4-Me-Ph 8-385 2-C1 HH OH -CH2-3-Br »Ph 8-386 2-C1 HH OH -C H2-4-Br-Ph 8-387 2-C1 HH OH -CH2-3-Cl-Ph 8-388 2-C1 HH OH -CH2-4-Cl-Ph 8-389 2-C1 HH OH -CH2- 3-F-Ph 8-390 2-C1 HH OH -CH2-4-F-Ph 8-391 2-C1 HH OH -CH2-3-Tfm-Ph 8-392 2-C1 HH OH -CH2-4- Tfm-Ph 8-393 2-C1 HH OH -CH2-3-OMe-Ph 8-394 2-C1 HH OH -CH2-4-OMe-Ph 8-395 2-C1 HH OH -CH2-253-diF- Ph 8-396 2-C1 HH OH • CHr2,4-diF-Ph 8-397 2-C1 HH OH -CH2-2? 5-diF-Ph 8-398 2-C1 HH OH -CH2-2,6- diF-Ph 8-399 2-C1 HH OH -CH2-3,4-diF-Ph 8-400 2-C1 HH OH -CH2-335-diF-Ph 8-401 2-C1 HH OH -CH2-3? 4-diCl-Ph 8-402 2-C1 HH OH -CH2-335-diCl-Ph 8-403 2-C1 HH OH -CH2-3-Cl-4-F-Ph 8-404 2-C1 HH OH- CH2-3-Me-4-Cl-Ph 8-405 2-C1 HH OH -CH2 * 3,4-Mtdo-Ph 8-406 2-C1 HH OH -CH2-354-diMe-Ph 8-407 2- C1 HH OH -CH2-3? 5-diMe-Ph 8-408 2-Br HH OH Ph 8-409 2-Br HH OH 1-Nap 8-410 2-Br HH OH 2-Nap 8-411 2-Br HH OH Bz 8-412 2-Br HH OH -CF2 -Ph 8-413 2-Br HH OH-(CH2) -2 > Nap 8-414 2-Br HH OH-CH2-3-Me-Ph 8-415 2-Br HH OH -CH2-4-Me-Ph -200- 200401770 8-416 2-Br Η Η ΟΗ -CH2-3- Br-Ph 8-417 2-Βγ Η Η ΟΗ -CH2-4-Br > Ph 8-418 2-Βγ Η Η ΟΗ -ΟΪ2-3-α-Ρ1ι 8-419 2-Βγ Η Η ΟΗ -CH2-4 -Cl-Ph 8-420 2-Βγ Η Η ΟΗ -CH2-3-F-Ph 8-421 2-Βγ Η Η ΟΗ -CH2-4-F-Ph 8-422 2-Βγ Η Η .ΟΗ -CH2 -3-Tfm-Ph 8-423 2-Βγ Η Η ΟΗ -CH2-4-Tfm-Ph 8-424 2-Βγ Η Η ΟΗ -CH2-3-OMe-Ph 8-425 2-Βγ Η Η ΟΗ- CH2-4-OMe-Ph 8-426 2-Βγ Η Η Ο Η -CH2-253-diF-Ph 8-427 2-Βγ Η Η ΟΗ -CH2-254-diF-Ph 8-428 2-Βγ Η Η ΟΗ -CH2-255-diF-Ph 8-429 2-Βγ Η Η Ο Η -CHr2,6-diF-Ph 8-430 2-Βγ Η Η ΟΗ -CH2-3,4-diF'Ph 8-431 2-Βγ Η Η ΟΗ -CH2-355-diF-Ph 8-432 2-Βγ Η Η Ο Η -CH2-334-diCl-Ph 8-433 2-Βγ Η Η Η CH -CH2-355-diCl-Ph 8-434 2- Βγ Η Η ΟΗ -CH2-3-Cl-4-F-Ph 8-435 2-Βγ Η Η ΟΗ -CHr3-Me-4-CKPh 8-436 2-Βγ Η Η ΟΗ -CHr3,4-Mtdo-Ph 8-437 2-Βγ Η Η ΟΗ -CH2-354-diMe-Ph 8-438 2-Βγ Η Η ΟΗ -CH2-3,5-diMe-Ph 8-439 2-〇Η Η Η ΟΗ Ph 8-440 2 -ΟΗ Η Η ΟΗ 1-Nap 8-441 2-ΟΗ Η Η ΟΗ 2-Nap 8-442 2-〇Η Η Η ΟΗ Bz 8-443 2-〇Η Η Η ΟΗ -CF2 -Ph 8-444 2-〇Η Η Η Ο Η-(CH2) -2-Nap 8-445 2-〇Η Η Η ΟΗ -CH2-3-Me- Ph 8-446 2-〇Η Η Η ΟΗ -CH2-4-Me-Ph 8-447 2-〇Η Η Η ΟΗ -CH2-3-Br-Ph 8-448 2-〇Η Η Η CH CH -CH2-4-Br -Ph 8-449 2-〇Η Η Η ΟΗ -CH2-3-Cl-Ph 8.-450 2-〇Η Η Η ΟΗ -CH2-4-Cl-Ph 8-451 2-〇Η Η Η CHΗ-CH2-3 -F-Ph 8-452 2-ΟΗ Η Η ΟΗ -CH2-4-F-Ph -201-200401770 8-453 2-OH HH OH -CH2-3-Tfm-Ph 8-454 2-OH HH OH- CH2-4-Tfm-Ph 8-455 2-OH HH OH -CH2-3-OMe-Ph 8-456 2-OH HH OH -CH2-4-OMe-Ph 8-457 2-OH HH OH -CH2- 2? 3-diF-Ph 8-458 2-OH HH OH -CH2-254-diF-Ph 8-459 2-OH HH OH -CHr2,5-diF-Ph 8-460 2-OH HH OH -CH2- 2? 6-diF-Ph 8-461 2-OH HH OH -CH2-354-diF-Ph 8-462 2-OH HH OH -CH2-335-diF-Ph 8-463 2-OH HH OH • CHr3, 4-diCl-Ph 8-464 2-OH HH OH -CH2-355-diCl-Ph 8-465 2-OH HH OH -CH2-3-Cl-4-F-Ph 8-466 2-OH HH OH- CH2-3-Me-4-Cl-Ph 8-467 2-OH HH OH • CH2-3,4-Mtdo-Ph 8-468 2-OH HH OH -CH2-354-diMe-Ph 8-469 2- OH HH OH -CH2-355-diMe-P h 8-470 2-Tfm HH OH Ph 8-471 2-Tfm KH OH 1-Nap 8-472 2-Tfm HH OH 2-Nap 8-473 2-Tfm HH OH Bz 8-474 2-Tfm HH OH- CF2 -Ph 8-475 2-Tfm HH OH • (CH2) -2-Nap 8-476 2-Tfm HH OH -CH2-3-Me-Ph 8-477 2-Tfm HH OH -CH2 ~ 4-Me- Ph 8-478 2-Tfm HH OH -CH2-3-Br-Ph 8-479 2-Tfm HH OH -CH2-4-Br-Ph 8-480 2-Tfm HH OH -CH2-3-Cl-Ph 8 -481 2-Tfm HH OH -CH2-4-Cl-Ph 8-482 2-Tfm HH OH -CH2-3-F-Ph 8-483 2-Tfm HH OH -CH2-4-F-Ph 8-484 2-Tfm HH OH -CH2-3-Tfm-Ph 8-485 2-Tfm HH OH -CH2-4-Tfm-Ph 8-486 2-Tfm HH OH -CH2-3-OMe-Ph 8-487 2- Tfm HH OH -CH2-4-OMe-Ph 8-488 2-Tfm HH OH -CHr2,3-diF-Ph 8-489 2-Tfm HH OH -CHr2,4-diF-Ph 202- 200401770 8-490 2 -Tfm HH OH -CH2-255-diF ^ Ph 8-491 2-Tfm HH OH -CHr2,6-diF-Ph 8-492 2-Tfm HH OH -CH2-3,4-diF-Ph 8-493 2 -Tfm HH OH -CHr3,5-diF-Ph 8-494 2-Tfm HH OH -CH2-354-diCl-Ph 8-495 2-Tfm HH OH -CH2-3,5-diCl-Ph 8-496 2 -Tfm HH OH -CH2-3-Cl-4-F-Ph 8-497 2-Tfm HH OH -CH2-3-Me-4-Cl-Ph 8-498 2-Tfm HH OH -CH2-3,4 -Mtdo-Ph 8-499 2-Tfm HH OH -CH2-3 , 4-diMe-Ph 8-500 2-Tfm HH OH -CH2-355-diMe-Ph 8-501 2-OMe HH OH Ph 8-502 2-OMe HH OH 1-Nap 8-503 2-OMe HH OH 2-Nap 8-504 2-OMe HH OH Bz 8-505 2-OMe HH OH -CF2 -Ph 8-506 2-OMe HH OH-(CH2) -2-Nap 8-507 2-OMe HH OH -CH2 -3-Me-Ph 8-508 2-OMe HH OH -CH2-4-Me-Ph 8-509 2-OMe HH OH -CH2-3-Br-Ph 8-510 2-OMe HH OH -CH2-4 -Br-Ph 8-511 2-OMe HH OH -CH2-3-Cl-Ph 8-512 2-OMe HH OH -CH2-4-Cl-Ph 8-513 2-OMe HH OH -CH2-3-F -Ph 8-514 2-OMe HH OH -CH2-4-F-Ph 8-515 2-OMe HH OH -CH2-3-Tfm-Ph 8-516 2-OMe HH OH -CH2-4-Tfm-Ph 8-517 2-OMe HH OH -CH2-3-OMe-Ph 8-518 2-OMe HH OH -CH2-4-OMe-Ph 8-519 2 > OMe HH OH -CHr2,3-diF-Ph 8- 520 2-OMe HH OH -CHr2,4-diF-Ph 8-521 2-OMe HH OH -CHr2,5-diF-Ph 8-522 2-OMe HH OH -CHr2,6-diF-Ph 8-523 2 -OMe HH OH -CHr3,4-diF-Ph 8-524 2-OMe HH OH -CH2-3,5-diF-Ph 8-525 2-OMe HH OH -CHr3,4-diCl-Ph 8-526 2 -OMe HH OH -CH2-3? 5-diCl-Ph -203-200401770 8-527 2-OMe HH OH -CH2-3-Cl-4-F-Ph 8-528 2-OMe HH OH -CH2-3 -Me-4-Cl -Ph 8-529 2-OMe HH OH -CH2-3? 4-Mtdo-Ph 8-530 2-OMe HH OH -CH2-354-diMe-Ph 8-531 2-OMe HH OH -CH2-3,5-diMe-Ph 8-532 — 2-AcNH HH OH Ph 8-533 2-AcNH HH OH 1-Nap 8-534 2-AcNH HH OH 2-Nap 8-535 '-2-AcNH HH OH Bz 8-536 2-AcNH HH OH -CF2. -Ph 8-537 2-AcNH HH OH-(CH2) -2-Nap 8-538 2-AcNH HH OH -CH2-3-Me-Ph 8-539 2-AcNH HH OH -CH2-4-Me-Ph 8-540 2-AcNH HH OH -CH2-3-Br-Ph 8-541 2-AcNH HH OH -CH2-4-Br-Ph 8-542 2-AcNH HH OH -CH2-3-Cl-Ph 8- 543 2-AcNH HH OH-(: Η2-4-(: 1-Pl1 8-544 2-AcNH HH OH -CH2-3-F-Ph 8-545 2-AcNH HH OH -CH2-4-F-Ph 8-546 2-AcNH HH OH -CH2-3 > Tfm-Ph 8-547 2-AcNH HH OH -CH2-4-Tfm-Ph 8-548 2-AcNH HH OH -CH2-3-OMe-Ph 8- 549 2-AcNH HH OH -CH2-4-OMe-Ph 8-550 2-AcNH HH OH -CHr2,3-diF-Ph 8-551 2-AcNH HH OH -CH2-234-diF-Ph 8-552 2 -AcNH HH OH -CH2-2,5-diF-Ph 8-553 2-AcNH HH OH -CHr2,6-diF-Ph 8-554 2-AcNH HH OH -CHr3,4-diF-Ph 8-555 2 -AcNH HH OH -CHr3,5-diF-Ph 8-556 2-AcNH HH OH -CH2-354-diCl-Ph 8-557 2-AcNH HH OH -CHr3,5-diCl-Ph 8-558 2-AcN HHH OH -CH2-3-Cl-4-F-Ph 8-559 2-AcNH HH OH -CH2-3-Me-4-Cl-Ph 8-560 2-AcNH HH OH -CHr3,4-Mtdo-Ph 8-561 2-AcNH HH OH -CHr3,4-diMe-Ph 8-562 2-AcNH .HH OH -CH2-3,5-diMe-Ph 8-563 3-Me HH OH Ph -204- 200401770 8- 564 3-Me HH OH 1-Nap 8-565 3-Me HH OH 2-Nap 8-566 3-Me HH OH Bz 8-567 3-Me HH OH -CF2 -Ph 8-568 3-Me HH OH- (CH2) -2-Nap 8-569 3-Me HH OH -CH2-3-Me-Ph 8-570 3-Me HH OH -CH2 ~ 4-Me-Ph 8-571 3-Me HH OH -CH2- 3-Br-Ph 8-572 3-Me HH OH -CH2-4-Br-Ph 8-573 3-Me HH OH -CH2-3-Cl-Ph 8-574 3-Me HH OH -CH2-4 » C1-Ph 8-575 ~ • 3-Me HH OH -CH2-3-F-Ph 8-576 3-Me HH OH -CH2-4-F-Ph 8-577 3-Me HH OH -CH2-3- Tfm-Ph 8-578 3-Me HH OH -CH2-4-Tfm-Ph 8-579 3-Me HH OH -CH2-3-OMe-Ph 8-580 3-Me HH OH -CH2-4-OMe- Ph 8-581 3-Me HH OH -CHr2,3'diF-Ph 8-582 3-Me HH OH -CHr2,4-diF-Ph 8-583 3-Me HH OH -CH2-235-diF-Ph 8 -584 3-Me HH OH -CHr2,6-diF-Ph 8-585 3-Me HH OH • CH2-3,4-diF-Ph 8-586 3-Me HH OH -CH2-3,5-diF- Ph 8-587 3-Me HH OH -CH2-354-diCl-Ph 8-588 3- Me, HH OH -CH2-3,5-diCl-Ph 8-589 3-Me HH OH -CH2-3-Cl-4-F-Ph 8-590 3-Me HH OH -CH2-3-Me-4 -Cl-Ph 8-591 3-Me HH OH -CHr3,4-MtdoPh 8-592 3-Me HH OH -CH2-354-diMe-Ph 8-593 3-Me HH OH -CH2-3,5-diMe -Ph 8-594 3-C1 HH OH Ph 8-595 3-C1 HH OH 1-Nap 8-596 3-C1 HH OH 2-Nap '8-597 3-C1 HH OH Bz 8-598 3-C1 HH OH -CF2 ^ Ph 8-599 3-C1 HH OH-(CH2) -2-Nap 8-600 3-C1 HH OH • CH2-3-Me-Ph -205-200401770 8-601 8-602 8-603 8-604 8-605 8-606 8-607 8-608 8-609 8-610 8-611 8-612 8-613 8-614 8-615 8-616 8-617 8-618 8-619 8- 620 8-621 8-622 8-623 8-624 8-625 8-626 8-627 8-628 8-629 8-630 8-631 8-632 8-633 8-634 8-635 8-636 8 -637 hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhaclclaclclaclaclclclclclclaaclaclclacl-cl-br-Br-Br-Br-Br-Br-Br-Br-ΒΓ-ΒΓ-ΒΓ-ΒΓ-ΒΓ-Γ-3--3-3-3-3-3- -3-3-3-3-3-3-3-3-3-33333 3 3333333333333 hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

gHgggggHJJ-ggggggggggggggggTTgJTHTTTTgjLJTTgHJTgtT -CH2-4-Me-Ph -CH2-3-Br-Ph -CH2-4-Br-Ph -CH2-3-Cl-Ph -CHr4-Cl-Ph -CH2-3-F-Ph- CHr4-F-Ph -CH2-3-Tfm * Ph -CH2-4-Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CH2-253-diF-Ph -CH2-2? 4-diF-Ph -CH2-235-diF-Ph -CH2-256-diF-Ph -CH2-354-diF-Ph -CHr3,5-diF-Ph -CH2-354-diCl-Ph -CHr3,5- diCl-Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CHr3,4-Mtdo-Ph -CH2-3? 4-diMe-Ph -CH2-3? 5-diMe-Ph Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2-4-Me-Ph -CH2 each Br-Ph -CH2- 4-Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph 20 200401770 8-638 3-Br HH OH -CH2-4-F-Ph 8-639 3-Br HH OH -CH2-3-Tfm-Ph 8-640 3-Br HH OH -CHr4-Tfm-Ph 8-641 3-Br HH OH -CH2-3-OMe-Ph 8-642 3-Br HH OH -CH2-4-OMe-Ph 8-643 3-Br HH OH -CH2-2? 3-diF-Ph 8-644 3-Br HH OH -CH2-254-diF-Ph 8-645 3-Br HH OH -CH2-2? 5-diF-Ph 8-646 3-Br HH OH -CHr2,6-diF-Ph 8-647 3-Br HH OH -CHr3,4-diF-Ph 8-648 3-Br HH OH -CHr3,5-diF-Ph 8-649 3-Br HH OH -CH2-3? 4-diCl-Ph 8-650 3-Br HH OH -CH2-355-diCl-Ph 8-6 51 3-Br HH OH -CH2-3-Cl-4-F-Ph 8-652 3-Br HH OH -CH2-3-Me-4-Cl-Ph 8-653 3-Br HH OH -CH2-354 -Mtdo-Ph 8-654 3-Br HH OH -CH2-334-diMe-Ph 8-655 3-Br HH OH -CHr3,5-dilMe-Ph 8-656 3-OH HH OH Ph 8-657 3- OH HH OH 1-Nap 8-658 3-OH HH OH 2-Nap 8-659 3-OH HH OH Bz 8-660 3-OH HH OH -CF2 -Ph 8-661 3-OH HH OH-(CH2) -2-Nap 8-662 3-OH HH OH -CH2-3-Me-Ph 8-663 3-OH HH OH -CH2-4-Me-Ph 8-664 3-OH HH OH -CH2 each Br-Ph 8-665 3-OH HH OH -CH2-4-Br-Ph 8-666 3-OH HH OH -CH2-3-Cl-Ph 8-667 3-OH HH OH -CH2-4-Cl-Ph 8- 668 3-OH HH OH -CH2-3-F-Ph 8-669 3-OH HH OH -CH2-4-F-Ph 8-670 3-OH HH OH -CH2-3-Tfm-Ph 8-671 3 -OH HH OH -CH2-4-Tfm-Ph 8-672 3-OH HH OH -CH2-3-OMe-Ph 8-673 3-OH HH OH di-CHr4-〇Me-Ph '8-674 3-OH HH OH -CH2-2? 3-diF-Ph -207-200401770 8-675 3-OH HH OH -CH2-2,4-diF-Ph 8-676 3 > OH HH OH -CH2-2: 5-diF -Ph 8-677 3-OH HH OH -CH2-256-diF-Ph 8-678 3-OH HH OH -CH2-3,4-diF-Ph 8-679 3-OH HH OH -CH2-355-diF > Ph 8-680 3-OH HH OH -CH2-334-diCl-Ph 8-68 1 3-OH HH OH -CH2-355-diCl-Ph 8-682 3-OH HH OH -CH2-3-Cl-4-F-Ph 8-683 3-OH HH OH -CH2-3-Me-4 -Cl_Ph 8-684 3-OH HH OH -CH2-354-Mtdo-Ph 8-685 3-OH HH OH -CH2-3,4-diMe-Ph 8-686 3-OH HH OH -CH2-3,5 -diMe-Ph 8-687 3-Tfm HH OH Ph 8-688 3-Tfm HH OH 1-Nap 8-689 3-Tfm HH OH 2-Nap 8-690 3-Tfm HH OH Bz 8-691 3-Tfm HH OH -CF2 -Ph 8-692 3-Tfm HH OH-(CH2) -2-Nap 8-693 3-Tfm HH OH -CH2-3-Me-Ph 8-694 3-Tfm HH OH -CH2-4 -Me-Ph 8-695 3-Tfm HH OH -CH2-3-Br-Ph 8-696 3-Tfm HH OH -CH2-4-Br-Ph 8-697 3-Tfm HH OH -CH2-3-Cl -Ph 8-698 3-Tfm HH OH -CH2-4-Cl-Ph 8-699 3-Tfm HH OH -CH2-3-F-Ph 8-700 3-Tfm HH OH -CH2-4-F-Ph 8-701. 3-Tfm HH OH -CH2-3-Tfm-Ph 8-702 3-Tfm HH OH -CH2-4-Tfm-Ph 8-703 3-Tfm HH OH -CH2-3-OMe-Ph 8 -704 3-Tfm HH OH -CHr4-OMe-Ph 8-705 3-Tfm HH OH -CHr2,3-diF-Ph 8-706 3-Tfm HH OH -CH2-234-diF-Ph 8-707 3- Tfm HH OH -CH2-255-diF-Ph 8-708 3-Tfm HH OH -CH2-256-diF-Ph 8-709 3-Tfm HH OH -CH2-334-diF-Ph 8-710 3-Tfm HH OH -CHr3,5-diF-Ph 8-711 3-Tfm H H OH -CHr3,4-diCl-Ph 208- 200401770 8-712 3-Tfm HH OH-^^^-diCl-Ph 8-713 3-Tfm HH OH -CH2 each Cl-4-F-Ph 8-714 3-Tfm HH OH -CH2-3-Me-4-Cl-Ph 8-715 3-Tfm HH OH -CHr3,4-Mtdo-Ph 8-716 3-Tfm HH OH -CH2-3? 4-diMe- Ph 8-717 3-Tfm HH OH -CH2-3? 5-diMe-Ph 8-718 3-OMe HH OH Ph 8-719 3 > OMe HH OH 1-Nap 8-720 3-OMe HH OH 2-Nap 8-721 3-OMe HH OH Bz 8-722 3-OMe HH OH -CF2 -Ph 8-723 3-OMe HH OH-(CH2) -2-Nap 8-724 3-OMe HH OH -CH2-3- Me-Ph 8-725 3-OMe HH OH -CH2-4-Me-Ph 8-726 3-OMe HH OH -CH2-3-Br-Ph 8-727 3-OMe HH OH -CH2-4-Br- Ph 8-728 3-OMe HH OH -CH2-3-Cl-Ph 8-729 3-OMe HH OH -CH2-4-Cl-Ph 8-730 3-OMe HH OH -CH2-3-F-Ph 8 -731 3-OMe HH OH -CH2-4-F-Ph 8-732 3-OMe HH OH -CH2-3-Tfm-Ph 8-733 3-OMe HH OH -CH2-4-Tfm-Ph 8-734 3-OMe HH OH -CH2-3-OMe-Ph 8-735 3-OMe HH OH -CH2-4-OMe-Ph 8-736 3-OMe HH OH -CH2-253-diF-Ph 8-737 3- OMe HH OH -CH2-2,4-diF-Ph 8-738 3-OMe HH OH -CH2-2,5-diF-Ph 8-739 3-OMe HH OH -CHr2,6-diF-Ph 8-740 3-OMe HH OH -CH2-3,4-diF-Ph 8- 741 3-OMe HH OH -CH2-3,5-diF-Ph 8-742 * 3-OMe HH OH • CHr3,4-diCl-Ph 8-743 3-OMe HH OH -CH2-3,5-diCl- Ph 8-744 3-OMe HH OH -CH2-3-Cl-4-F-Ph 8-745 3-OMe HH OH 8-746 · 3-OMe HH OH -CH2-3? 4-Mtdo-Ph 8- 747 3-OMe HH OH -CH2-334-diMe-Ph 8-748 3-OMe HH OH -CH2-335-diMe-Ph 209- 200401770 8-749 3-AcNH HH OH Ph 8-750 3-AcNH HH OH 1-Nap 8-751 3-AcNH H 丨 H OH 2-Nap 8-752 3-AcNH HH OH Bz 8-753 3-AcNH HH OH -CF2 -Ph 8-754 3-AcNH HH OH-(CH2)- 2-Nap 8-755 3-AcNH HH OH -CH2-3-Me-Ph 8-756 3-AcNH HH OH -CH2-4-Me-Ph 8-757 .3-AcNH HH OH -CH2-3-Br -Ph 8-758 3-AcNH HH OH -CH2-4-Br-Ph 8-759 3-AcNH HH OH -Οί2-3-α-Ηι 8-760 3-AcNH HH OH -CH2-4-Cl-Ph 8-761 3-AcNH HH OH -CH2-3-F-Ph 8-762 3-AcNH HH OH -CH2-4-F-Ph 8-763 3-AcNH HH OH -CH2-3-Tfm-Ph 8- 764 3-AcNH HH OH -CH2-4-Tfm-Ph, 8-765 3-AcNH HH OH -CH2-3-OMe-Ph 8-766 3-AcNH HH OH -CH2-4-OMe-Ph 8-767 3-AcNH H. H OH -CH2-233-diF-Ph 8-768 3-AcNH HH OH -CH2-254-diF-Ph 8-769 3-AcNH HH OH -CH2-255-diF-Ph 8-7 70 3-AcNH HH OH -CH2-256-diF-Ph 8-771 3-AcNH HH OH • CH2-3,4-diF-Ph 8-772 3-AcNH HH OH -CH2-3,5-diF-Ph 8-773 3-AcNH HH OH -CH2-3,4-diCl-Ph 8-774 3-AcNH HH OH -ΟΗ2-3,5- (ϋα-Ρ1ι 8-775 3-AcNH HH OH -CH2 Each Cl- 4-F-Ph 8-776 3-AcNH HH OH -CH2-3-Me-4-Cl-Ph 8-777 3-AcNH HH OH -CH2-354-Mtdo-Ph 8-778 3-AcNH HH OH- CH2-3,4-diMe-Ph 8-779 3-AcNH HH OH -CH2-3,5-diMe-Ph 8-780 4-Me HH OH Ph 8-781 4-Me HH OH 1-Nap 8-782 4-Me HH OH 2-Nap 8-783 4-Me HH OH Bz 8-784 4-Me HH OH -CF2 -Ph 8-785 4-Me HH OH-(CH2) -2-Nap 210- 200401770 8- 786 4-Me HH OH -CH2-3-Me-Ph 8-787 4-Me HH OH -CH2-4-Me-Ph 8-788 4-Me HH OH -CH2-3-Br-Ph 8-789 4 -Me HH OH -CH2-4-Br-Ph 8-790 4-Me HH OH -CH2-3-Cl-Ph 8-791 4-Me HH OH -CH2-4-Cl-Ph 8-792 4-Me HH OH -CH2-3-F-Ph 8-793 4-Me HH OH -CH2-4-F-Ph 8-794 4-Me HH OH -CH2-3-Tfm-Ph 8-795 4-Me HH OH -CH2-4-Tfm-Ph 8-796 4-Me HH OH -CH2-3-OMe-Ph 8-797 4-Me HH OH -CH2-4-OMe-Ph 8-798 4-Me HH OH -CH2 -233-diF-Ph 8-799 4-Me HH OH -CHr2, 4-diF-Ph 8-800 4-Me HH OH -CH2-2,5-diF-Ph 8-801 4-Me HH OH -CH2-2,6-diF-Ph 8-802 4-Me HH OH " CH2-3,4-diF-Ph 8-803 • 4-Me HH OH -CH2-355-diF-Ph 8-804 4-Me HH OH -CH2-3? 4-diCl-Ph 8-805 4-Me HH OH -CH2-3? 5-diCl-Ph 8-806 4-Me HH OH -CH2-3-Cl-4-F-Ph 8-807 4-Me HH OH -CH2-3-Me-4-Cl -Ph 8-808 4-Me HH OH -CHr3,4-Mtdo-Ph 8-809 4-Me HH OH -CHr334-diMe-Ph 8-810 4-Me HH OH -CH2-355-diMe-Ph 8- 811 4-C1 HH OH 'Ph 8-812 4-C1 HH OH 1-Nap 8-813 4-C1 HH OH 2-Nap * 8-814 4-C1 HH OH Bz 8-815 4-C1 HH OH -CF2 -Ph 8-816 4-C1 HH OH-(CH2) -2-Nap 8-817 4-C1 HH OH -CH2-3-Me-Ph 8-818 4-C1 HH OH -CH2-^-Me-Ph 8-819 4-C1 HH OH -CH2 each Br-Ph 8-820 4-C1 HH OH -CH2-4-Br-Ph 8-821 4-C1 HH OH -CH2 each Cl-Ph 8-822 4-C1 HH OH-(: Η2-4-α-P1ι 200401770 8-823 4-C1 HH OH -CHr3-F-Ph 8-824 4-C1 HH OH -CH2-4-F-Ph 8-825 4-C1 ' HH OH. -CH2-3-Tfm-Ph 8-826 4-C1 HH OH -CH2-4-Tfm-Ph 8-827 4-C1 HH OH -CH2-3-OMe-Ph 8-828 4-C1 HH OH -CH2-4-OMe-Ph 8-829 4-C1 HH OH -CH2-2,3- diF-Ph 8-830 4-C1 HH OH -CHr2,4-diF-Ph 8-831 4-C1 HH OH -CH2-235-diF-Ph 8-832 4-C1 HH OH -CH2-2,6- diF-Ph 8-833 4-C1 HH OH -CH2-3,4-diF-Ph 8-834 4-C1 HH OH -CH2-3,5-diF-Ph 8-835 4-C1 HH OH -CH2- 3? 4-diCl-Ph 8-836 4-C1 HH OH -CH2-355-diCl-Ph 8-837 4-C1 HH OH -CH2-3-Cl-4-F-Ph 8-838 4-C1 HH OH -CH2-3-Me-4-Cl-Ph 8-839 4-C1 HH OH -CHr3,4-Mtdo-Ph 8-840 4-C1 HH OH -CH2-3? 4-diMe-Ph 8-841 4-C1 HH OH -CH2-355-diMe-Ph 8-842 4-Br HH OH Ph 8-843 4-Br HH OH 1-Nap. 8-844 4-Br HH OH 2-Nap 8-845 4- Br HH OH Bz 8-846 4-Br HH OH -CF2 -Ph 8-847 4-Br HH OH-(CH2) -2-Nap 8-848 4-Br HH OH -CH2-3-Me-Ph 8- 849 4-Br HH OH -CH2-4-Me-Ph 8-850 4-Br HH OH -CHr3IPh 8-851 4-Br HH OH -CHr4-Br-Ph 8-852 4-Br HH OH -CH2-3 -Cl-Ph 8-853 4-Br HH OH -CH2-4-Cl-Ph 8-854 4-Br HH OH -CH2-3-F-Ph 8-855 4-Br HH OH -CH2-4-F -Ph 8-856 4-Br HH OH -CH2-3-Tfm-Ph 8-857 4-Br HH OH -CH2-4-Tfm-Ph 8-858 4-Br HH OH -CH2-3-OMe-Ph 8-859 4-Br HH OH -CH2-4-OMe-Ph 212- 200401770 8-860 4-Br Η ΟΗ -CHr2,3-diF-Ph 8-861 4-Βγ Η Η 〇 Η -CH2-2? 4-diF-Ph 8-862 4-Βγ Η Η ΟΗ -CH2-2? 5-diF-Ph 8- 863 4-Βγ Η Η ΟΗ -CH2-2? 6-diF-Ph 8-864 4-Βγ Η Η ΟΗ -CH2-354-diF-Ph 8-865 4-Βγ Η Η ΟΗ -CH2-3,5- diF-Ph 8-866 4-Βγ Η Η ΟΗ -CHr3,4-diCl-Ph 8-867 4-Βγ Η Η ΟΗ -CH2-3? 5-diCl-Ph 8-868 4-Βγ Η Η ΟΗ -CH2 -3-Cl-4-F-Ph 8-869 4-Βγ Η Η ΟΗ -CH2-3-Me-4-Cl-Ph 8-870 4-Βγ Η Η ΟΗ -CH2-3,4-Mtdo-Ph 8-871 4-Βγ Η Η ΟΗ -CH2-3,4-diMe-Ph 8-872 4-Βγ Η Η ΟΗ -CH2-3,5-diMe-Ph 8-873 4-〇Η Η Η ΟΗ Ph 8- 874 4-ΟΗ Η Η ΟΗ 1-Nap 8-875 4-〇Η Η Η ΟΗ 2-Nap 8-876 4-〇Η Η Η ΟΗ Bz 8-877 4-〇Η Η Η ΟΗ -CF2 -Ph 8-878 4- ΟΗ Η Η ΟΗ-(CH2) -2-Nap 8-879 4-〇Η Η Η Ο Η -CH2-3-Me-Ph 8-880 4-〇Η Η Η Η -CH2 ~ 4-Me-Ph 8-881 4 -ΟΗ Η Η ΟΗ -CH2-3-Br-Ph 8-882 4-〇Η Η Η ΟΗ -CH2-4-Br-Ph 8-883 4-〇Η Η Η CH -CH2-3-Cl-Ph 8-884 4-ΟΗ Η Η ΟΗ -CH2-4-Cl-Ph 8-885 4-〇Η Η Η ΟΗ -CH2-3-F-Ph 8-886 4-〇Η Η Η Η -CH2-4-F-Ph · 8-887 4-ΟΗ Η Η Ο Η -CH2-3-Tfm-Ph 8-888 4-〇Η Η Η Ο Η -CH2-4-Tfm-Ph 8-889 4-〇Η Η Η ΟΗ -CH2-3-OMe-Ph 8-890 4-〇Η Η Η ΟΗ -CH2 Bucket OMe-Ph 8-891 4-〇Η Η Η ΟΗ -CH2-2,3-diF-Ph 8-892 4- ΟΗ Η Η ΟΗ -CH2-2,4-diF-Ph 8-893 4-ΟΗ Η Η ΟΗ -CH2-2? 5-diF-Ph 8-894 4-〇Η Η Η ΟΗ -CH2-2,6-diF -Ph 8-895 4-〇Η Η Η ΟΗ -CH2-3,4-diF-Ph 8-896 4-〇Η Η Η Ο Η -CHr3,5-diF-Ph 213- 200401770 8-897 4-OH HH OH- CHs-S ^ -diCl-Ph 8-898 4-OH HH OH -CH2-3,5-diCl-Ph 8-899 4-OH HH OH -CH2-3-Cl-4-F-Ph 8-900 4 -OH HH OH -CH2-3-Me-4-Cl-Ph 8-901 4-OH HH OH -CH2-354-MtdorPh 8-902 4-OH HH OH -CH2-354-diMe-Ph 8-903 4 -OH HH OH -CH2-375-diMe-Ph 8-904 4-Tfm HH OH Ph 8-905 4-Tfm HH OH 1-Nap 8-906 4-Tfm HH OH 2-Nap 8-907 4-Tfm HH OH Bz 8-908 4-Tfm HH OH • CF2 -Ph 8-909 4-Tfm HH OH-(CH2) -2-Nap 8-910 4-Tfm HH OH -CH2-3-Me-Ph 8-911 4 -Tfm HH OH -CH24Me-Ph 8-912 4-Tfm HH OH -CH2-3-Br-Ph 8-913 4-Tfm HH OH -CH2-4-Br-Ph 8-914 4-Tfm HH OH -CH2 Each Cl-Ph 8-915 4-Tfm HH OH • CH2-4-Cl-Ph 8-916 4-Tfm HH OH -CH2-3-F-Ph 8-917 4-Tfm HH OH -CH2- 4-F-Ph 8-918 4-Tfm HH OH -CH2-3-Tfm-Ph 8-919 4-Tfm HH OH -CH2-4-Tfm-Ph 8-920 4-Tfm HH OH -CH2-3- OMe-Ph 8-921 4-Tfm HH OH -CH2-4-OMe-Ph 8-922 4-Tfm HH OH -CH2-253-diF-Ph 8-923 4-Tfm HH OH -CH2-254-diF- Ph 8-924 4-Tfm HH OH -CH2-2? 5-diF-Ph 8-925 4-Tfm HH OH • CHr2,6-diF-Ph 8-926 4-Tfm HH OH -CH2-334-diF- Ph 8-927 4-Tfm HH OH -CH2-355-diF-Ph 8-928 4-Tfm HH OH • CHr3,4-diCl-Ph 8-929 4-Tfm HH OH -CH2-355-diCl-Ph 8 -930 4-Tfm HH OH • CHr3-Cl-4-F-Ph 8-931 4-Tfm HH OH -CH2 Me-4-Cl-Ph 8-932 4-Tfm HH OH -CH2-3,4- Mtdo-Ph 8-933 4-Tfm HH OH > CH2-354-diMe-Ph 214- 200401770 8-934 4-Tfm HH OH -CH2 > 335-diMe-Ph 8-935 4-OMe HH OH Ph 8- 936 4-OMe HH OH 1-Nap 8-937 4-OMe HH OH 2-Nap 8-938 4-OMe HH OH Bz 8-939 4-OMe HH OH -CF2 -Ph 8-940 4-OMe HH OH- (CH2) -2-Nap 8-941 4-OMe HH OH -CH2-3-Me-Ph 8-942 4-OMe HH OH -CH2-4-Me-Ph 8-943 4-OMe HHO H -CH2-3-Br-Ph 8-944 4-OMe HH OH -CH2-4-Br-Ph 8-945 4-OMe HH OH -CH2-3-Cl-Ph 8-946 4-OMe HH OH- CHd-Cl-Ph 8-947 4-OMe HH OH -CH2-3-F-Ph 8-948 4-OMe HH OH -CH2-4 «F-Ph 8-949 4-OMe HH OH -CH2-3- Tfm-Ph 8-950 4-OMe HH OH -CH2-4-Tfm-Ph 8-951 4-OMe HH OH -CH2-3-OMe-Ph 8-952 4-OMe HH OH -CH2-4-OMe- Ph 8-953 4-OMe HH OH -CH2-253-diF-Ph 8-954 4-OMe HH OH -CH2-2? 4-diF-Ph 8-955 4-OMe HH OH -CH2-2,5- diF-Ph 8-956 4-OMe HH OH -CH2-256-diF-Ph 8-957 4-OMe HH OH -CHr3,4-diF-Ph 8-958 4-OMe HH OH -CH2-335-diF- Ph 8-959 4-OMe HH OH -CH2-3? 4-diCl-Ph 8-960 4-OMe HH OH-^-S ^ -diCl-Ph 8-961 4-OMe HH OH -CH2-3-Cl -4-F-Ph 8-962 4-OMe HH OH -CH2-3-Me-4-Cl-Ph 8-963 4-OMe HH OH -CH2-354-Mtdo-Ph 8-964 4-OMe HH OH -CH2-354-diMe-Ph 8-965 4-OMe HH OH -CH2-355-diMe-Ph 8-966 4-AcNH HH OHPh 8-967 4-AcNH HH OH 1-Nap 8-968 4- AcNH HH OH 2-Nap 8-969 4-AcNH HH OH Bz 8-970 4-AcNH HH OH -CF2 -Ph 215- 200401770

8-971 4-AcNH HH OH 8-972 4-AcNH HH OH 8-973 4-AcNH H .H OH 8-974 4-AcNH HH OH 8-975 4-AcNH HH OH 8-976 4-AcNH HH OH 8-977 4-AcNH HH OH 8-978 4-AcNH HH OH 8-979 4-AcNH HH OH 8-980 4-AcNH HH OH 8-981 4-AcNH HH OH 8-982 4-AcNH HH OH 8- 983 1 4-AcNH HH OH 8-984 4-AcNH HH OH 8-985 4-AcNH HH OH 8-986 4-AcNH HH OH 8-987 4-AcNH HH OH 8-988 4-AcNH HH OH 8-989 4-AcNH HH OH 8-990 4-AcNH HH OH 8-991 4-AcNH HH OH 8-992 4-AcNH HH OH 8-993 4-AcNH HH OH 8-994 4-AcNH HH OH 8-995 4- AcNH HH OH 8-996 4-AcNH HH OH 8-997. 1-FHH OH • 8-998 1-FHH OH 8-999 1-FHH OH 8-1000 1-FHH OH 8-1001 1-FHH OH 8- 1002 1-FHH OH 8-1003 1-FHH OH 8-1004 1-FHH OH 8-1005 1-FHH OH 8-1006 1-FHH OH 8-1007 1-FHH OH-(CH2) -2-Nap -CH2 -3-Me-Ph -CHr4-Me-Ph -CH2-3-Br-Ph -CH2-4-Br-Ph -CH2 Each Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CHr2,3-diF-Ph -CH2 -2? 4-diF-Ph -CH2-255-diF-Ph -CH2-2,6-diF-Ph -CH2-3 ? 4-diF-Ph -CH2-3? 5-diF-Ph -CH2-3? 4-diCl-Ph -CH2-3? 5-diCl-Ph -CHr3-Cl-4-F-Ph -CH2-3 -Me-4-Cl-Ph -CH2-354-Mtdo-Ph -CH2-3? 4-diMe-Ph • -CH2-355-diMe-Ph

Ph 1- Nap 2- Nap

Bz -CF2 -Ph-(CH2) -2-N.ap -CH2-3-Me-Ph -CH2-4-Me-Ph -CHr3-Br-Ph -CH2-4-Br-Ph -CH2-3- Cl-Ph -216- 200401770 8-1008 1-FHH OH -CH2-4-Cl-Ph 8-1009 1-FHH OH -CH2-3-F-Ph 8-1010 1-FHH OH -CH2-4-F -Ph 8-1011 1-FHH OH -CH2-3-Tfm-Ph 8-1012 1-FHH OH -CH2-4-Tfm-Ph 8-1013 1-FHH OH -CHr3-OMe-Ph 8-1014 1- FHH OH -CH2-4-OMe-Ph 8-1015 1-FHH OH -CH2-2,3-diF-Ph 8-1016 1-FHH OH -CH2-2? 4-diF-Ph 8-1017 1-FHH OH -CH2-2? 5-diF-Ph 8-1018 1-FHH OH -CH2-256-diF-Ph 8-1019 1-FHH OH -CH2-3,4-diF-Ph 8-1020 1-FHH OH -CH2-3? 5-diF-Ph 8-1021 1-FHH OH -CHr3,4-diCl-Ph 8-1022 1-FHH OH -CH2-3,5-diCl-Ph 8-1023 1-FHH OH- CH2-3-Cl-4-F-Ph 8-1024 1-FHH OH -CH2-3-Me-4-Cl-Ph 8-1025 1-FHH OH -CH2-3,4-MtdoPh S-1026 1- FHH OH -CH2-334-diMe-Ph 8-1027 1-FHH OH -CH2-3,5-diMe-Ph 8-1028 2-FHH OH Ph 8-1029 2-FHH OH 1-Nap 8-1030 2- FHH OH 2-Nap 8-1031 2-FHH OH Bz 8-1032 2-FHH OH -CF2 -Ph 8-1033 2-FHH OH-(CH2) -2-Nap 8-1034 2-FHH OH -CH2-3 -Me-Ph 8-1035 2-FHH OH -CH2-4-Me-Ph 8-1036 2-FHH OH -CHr3-Br-Ph 8-1037 2-FHH OH -CH2-4-Br-Ph 8-1038 2-FHH OH -CH2-3-Cl- Ph 8-1039 2-FHH OH -CH2-4-Cl-Ph 8-1040 2-FHH OH -CH2-3-F-Ph 8-1041 2-FHH OH -CH2-4-F-Ph 8-1042 2 -FHH OH -CH2-3-Tfm > Ph 8-1043 2-FHH OH > CH2-4-Tfm-Ph 8-1044 2-FHH OH -CH2-3-〇Me-Ph -217- 200401770 8-1045 8-1046 8-1047 8-1048 8-1049 8-1050 8-1051 8-1052 8-1053 8-1054 8-1055 8-1056 8-1057 8-1058 8-1059 8-1060 8-1061 8- 1062 8-1063 8-1064 8-1065 8-1066 8-1067 .8-1068 8-1069 8-1070 8-1071 8-1072 8-1073 8-1074 8-1075 8-1076 8-1077 8-1078 8-1079 8-1080 8-1081 -FFFFFFFFF 2-2-22-22222

Tr- ^ UATrFTrTrTrTrTr hhhhhhhhhh fffffffff --------- 222223333 hhhhhhhhh -F-F-F-F-F-F-F-F-F 3-3-3-3-3-3-3-33 hhhhhhhhhhh -F-F-F-F-F-F-F-F-333-F-F-333

H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH H OH -CH2-4-OMe-Ph-CHr2,3-diF-Ph -CH2-274-diF-Ph -CH2 -2,5-diF-Ph -CHr2,6-diF-Ph -CH2-354-diF-Ph -CH2-355-diF-Ph -CH2-3,4-diCl-Ph -CH2-3? 5-diCl -Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CH2-3,4-Mtdo-Ph -CH2-354-diMe-Ph -CH2-3,5 -diMe-Ph Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH24Me-Ph -CH2 each Br-Ph -CH2-4-Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CHr3 -OMe-Ph -CH2-4-OMe-Ph -CHr253-diF-Ph -CH2-234-diF-Ph -CH2-255-diF-Ph -CH2-256-diF-Ph -CH2-334-diF-Ph -218- 200401770 8-1082 3-FHH OH -CHr335-diF-Ph. 8-1083 3-FHH OH -CH2-3? 4-diCI-Ph 8-1084 3-FHH OH -CHr3,5-diCWPh 8- 1085 3-FHH OH -CHr3-Cl-4-F-Ph 8-1086 3-FHH OH -CH2-3-Me-4-Cl-Ph 8-1087 3-FHH OH -CH2-3,4-Mtdo- Ph 8-1088 3-FHH OH -CH2-3? 4-diMe-Ph 8-1089 3-FHH OH -CH2-335-diMe-Ph 8-1090 4-FHH OH Ph 8-1091 4-FHH OH 1-Nap 8-1092 4-FHH OH 2-Nap. 8-1093 4-FHH OH Bz 8 -1094 4-FHH OH -CF2 -Ph 8-1095 4-FHH OH-(CH2) -2-Nap 8-1096 4-FHH OH 'CH2-3-Me-Ph 8-1097 4-FHH OH -CH2- 4-Me > Ph 8-1098 4-FHH OH -CH2-3-Br-Ph 8-1099 4-FHH OH -CH2-4-Br-Ph 8-11CQ 4-FHH OH -CH2-3-Cl-Ph 8-1101 4-FHH OH -CH2-4-Cl-Ph 8-1102 4-FHH OH -CH2-3-F-Ph 8-1103 4-FHH OH -CH2-4-F-Ph 8-1104 4- FHH OH -CH2-3-Tfm-Ph 8-1105 4-FHH OH -CH2-4-Tfm-Ph 8-1106 4-FHH OH -CH2-3-OMe-Ph 8-1107 4-FHH OH -CH2- 4-OMe> Ph 8-1108 4-FHH OH -CH2-2,3-diF-Ph 8-1109 4-FHH OH -CHr2,4-diF-Ph 8-1110 4-FHH OH -CH2-255-diF -Ph 8-1111 4-FHH OH > CH2-236-diF-Ph 8-1112 4-FHH OH -CH2-3,4-diF-Ph 8-1113 4-FHH OH -CH2-3,5-diF -Ph 8-1114 4-FHH OH -CH2-354-diCl-Ph 8-1115 4-FHH OH -CHz-B ^ -diCl-Ph 8-1116 4-FHH OH > CH2-3-Cl-4- F-Ph 8-1117 4-FHH OH -CH2-3-Me-4-Cl-Ph 8-1118 4-FHH OH -CHr3,4-Mtdo-Ph 219 200401770

8 -1119 8-1120 8-1121 8-1122 8-1123 8-1124 8-1125 8-1126 8-1127 8-1128 8-1129 8-1130 8-1131 8-1132 8-1133 8-1134 8- 1135 8-1136 8-1137 8-1138 8-1139 8-1140 8-1141 8-1142 8-1143 8-1144 8-1145 8-1146 8-1147 8-1148 8-1149 8-1150 8-1151 8 -1152 8-1153 8-1154 8-1155 4-F

4-F 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1- OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1-OMe 1- OMe 2 > OMe 2 -OMe 2-OMe 2-OMe

H

2- T 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2-OMe 2- OMe 3- OMe hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh ggggggggPJJGJJJGJQJJGJQ -CH2-3? 4-diMe-Ph -Ch > 3? 5-diMe-Ph Ph 1- Nap 2- Nap Bz -CF2-Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH24Me -Ph -CH2-3-Br-Ph -CH2-4-Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph »CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CHr2 > diF-Ph -CH2-2? 4-diF-Ph -CH2 -2? 5-diF-Ph -CH2-2,6-diF-Ph -CHr3,4-diF-Ph -CH2-3,5-diF-Ph -CHr3,4-diCl-Ph -CH2-355-diCl -Ph -CH2-3-Cl-4-F-Ph -Οί2-3-Μ ^ 4-α-Ρ1ι -CHr3,4-MtdoPh -CH2-3,4-diMe-Ph -CH2-355-diMe-Ph Ph 1- Nap 2- Nap Bz 3-OMe 3-OMe 3-OMe 220- 200401770 8-1156 2-OMe 3-OMe H OH -CF2 -Ph 8-1157 2-OMe 3-OMe H OH-(CH2) -2-Nap 8-1158 2-OMe 3-OMe H OH -CH2-3-Me-Ph 8-1159 2-OMe 3-OMe H OH -CH2-4-Me-Ph 8-1160 2-OMe 3- OMe H OH -CH2-3-Br-Ph 8-1161 2-OMe 3-OMe HO H -CH2-4-Br-Ph 8-1162 2-OMe 3-OMe H OH -CHd-Cl-Ph 8-1163 2-OMe 3-OMe H OH -CH2-4-Cl-Ph 8-1164 2- OMe 3-OMe H OH -CH2-3-F-Ph 8-1165 2-OMe 3-OMe H OH -CH2-4-F-Ph 8-1166 2-OMe 3-OMe H OH -CH2-3-Tfm -Ph 8-1167 2-OMe 3-OMe H OH -CH2-4-Tfm-Ph 8-1168 2-OMe 3-OMe H OH -CH2-3-OMe-Ph 8-1169 2-OMe 3-OMe H OH -CHr4-〇Me-Ph 8-1170 2-OMe 3-OMe H OH -CHr2,3-diF-Ph 8-1171 2-OMe 3-OMe H OH -CH2-2? 4-diF-Ph 8- 1172 2-OMe 3-OMe H OH -CH2-255-diF-Ph 8-1173 2-OMe 3-OMe H OH -CHr2,6-diF-Ph 8-1174 2-OMe 3-OMe H OH -CH2- 3,4-diF-Ph 8-1175 2-OMe 3-OMe H OH -CH2-3,5: diF-Ph 8-1176 2-OMe 3-OMe H OH -CHs-S ^ -diCl-Ph 8- 1177 2-OMe 3-OMe H OH -CH2-355-diCl-Ph 8-1178 2-OMe 3-OMe H OH -CH2-3-Cl-4-F-Ph 8-1179 2-OMe 3-OMe H OH -CH2-3-Me-4-Cl-Ph 8-1180 2-OMe 3-OMe H OH -CH2-3,4-Mtdo-Ph 8-1181 2-OMe 3-OMe H OH -CH2-354- diMe-Ph 8-1182 2-OMe 3-OMe H OH -CHr3,5-diMe-Ph 8-1183 1,2-Mtdo H OH Ph 8-1184 1,2-Mtdo H OH 1-Nap 8-1185 1 , 2-Mtdo H OH 2-Nap 8-1186 l, 2-Mtdo H OH Bz 8-1187 l: 2-Mtdo H OH ~ CF2- Ph 8-1188 1,2-Mtdo H OH-(CH2) -2-Nap 8-1189 1,2-Mtdo H OH -CH2-3-Me-Ph 8-1190 1,2-Mtdo H OH -CH2- 4-Me-Ph 8-1191 1,2-Mtdo H OH -CH2-3-Br-Ph 8-1192 1,2-Mtdo H OH -CH2-4-Br-Ph -221- 200401770 8-1193 l; 2-Mtdo H OH -CHr3-Cl-Ph 8-1194 1,2-Mtdo H OH-CHr4-Cl-Ph 8-1195 l32-Mtdo H OH -CH2-3-F-Ph 8-1196 l? 2- Mtdo H OH -CH2-4-F-Ph 8-1197 l, 2-Mtdo H OH -CH2 Tfm-Ph 8-1198 l, 2-Mtdo H OH -CH2-4-Tfm-Ph 8-1199 1, 2-Mtdo H OH -CH2-3-OMe-Ph 8-1200 l, 2-Mtdo H OH -CH2-4-OMe-Ph 8-1201 1,2-Mtdo H OH -CH2-2,3-diF- Ph 8-1202 1,2-Mtdo H OH -CHr2,4-diF-Ph 8-1203 1,2-Mtdo H OH -CH2-255-diF-Ph 8-1204 1,2-Mtdo H OH -CH2- 2,6-diF-Ph 8-1205 1,2-Mtdo H OH ^ CH2-3,4-diF-Ph 8-1206 1,2-Mtdo H OH -CH2-3,5-diF-Ph 8-1207 1,2-Mtdo H OH -CH2-354-diCl-Ph 8-1208 1,2-Mtdo H OH -CHr3,5-diCl-Ph 8-1209 1,2-Mtdo H OH -CH2-3-Cl- 4-F-Ph 8-1210 1,2-Mtdo H OH -CH2-3-Me-4-Cl-Ph 8-1211 1,2-Mtdo H • OH, CHr3,4-Mtdo-Ph 8-1212 1 , 2-Mtdo H OH -CH2-3,4-diMe-Ph 8-1213 1,2-Mtdo H OH -CHr3,5-diMe-Ph 8-1214 2 , 3-Mtdo H OH Ph 8-1215 2,3-Mtdo H OH 1-Nap 8-1216 2,3-Mtdo H OH 2-Nap 8-1217 2,3-Mtdo H OH Bz 8-1218 2,3 -Mtdo H OH -CF2 -Ph 8-1219 2,3-Mtdo H OH-(CH2) -2-Nap 8-1220 2,3-Mtdo H OH -CH2- 3-Me-Ph 8-1221 2,3 -Mtdo H OH -CH2-4-Me-Ph 8-1222 2,3-Mtdo H OH -CH2-3-Br-Ph 8-1223 2,3-Mtdo H OH -CH2-4-Br-Ph 8- 1224 2,3-Mtdo H OH -CH2-3-Cl-Ph 8-1225 2,3-Mtdo H OH -CH2-4-Cl-Ph 8-1226 2,3-Mtdo H 〇H · -CH2-3 -F-Ph 8-1227 2,3-Mtdo H OH > CH2-4-F-Ph 8-1228 2,3-Mtdo H OH > CH2-3-Tfm ^ Ph 8-1229 2,3-Mtdo H OH -CH2-4-Tfm-Ph 222 200401770 8-1230 2,3-Mtdo H OH -CH2-3-OMe-Ph 8-1231 2,3-Mtdo H OH -CHr4-〇Me-Ph 8-1232 253-Mtdo H OH -CH2-233-diF-Ph 8-1233 2,3-Mtdo H OH -CH2-254-diF-Ph 8-1234 2,3-Mtdo H OH -CHr2,5-diF-Ph 8 -1235 2,3-Mtdo H OH -CH2-2? 6-diF-Ph 8-1236 2? 3-Mtdo H OH -CH2-354-diF-Ph 8-1237 2,3-Mtdo H OH -CHr3, 5-diF-Ph 8-1238 2,3-Mtdo H OH -CH2-354-diCl-Ph 8-1239 2,3-Mtdo H OH -CHrSJ-diCl-Ph 8-1240 2,3-Mtdo H OH- CH2-3-Cl-4-F-Ph 8-1241 2,3-Mtdo H OH -CH2-3-Me-4-Cl -Ph 8-1242 253-Mtdo H OH -CHr3,4-Mtdo-Ph 8-1243 2,3-Mtdo H OH -CHr3,4-diMe-Ph 8-1244 2,3-Mtdo H OH -CHr3,5 -diMe-Ph 8-1245 2-F 3-FH OH Ph 8-1246 2-F 3-FH OH 1-Nap 8-1247 2-F 3-FH OH 2-Nap 8-1248 2-F 3-FH OH Bz 8-1249 2-F 3-FH OH -CF2 -Ph 8-1250 2-F 3-FH OH-(CH2) -2-Nap 8-1251 2-F 3-FH OH -CH2-3-Me -Ph 8-1252 2-F 3-FH OH -CH2-4-Me-Ph 8-1253 2-F. 3-FH OH -CH2-3-Br-Ph 8-1254 2-F 3-FH OH- CH2-4-Br-Ph 8-1255 2-F 3-FH OH -CH2-3-Cl-Ph 8-1256 2-F 3-FH OH -CH2-4-Cl-Ph 8-1257 2-F 3 -FH OH -CH2-3-F-Ph 8-1258 2-F 3-FH OH -CH2-4-F-Ph 8-1259 2-F 3-FH OH -CH2-3-Tfm-Ph 8-1260 2-F 3-FH OH -CH2-4-Tfm-Ph 8-1261 2-F 3-FH OH -CH2-3-OMe-Ph 8-1262 2-F 3-FH OH -CH2-4-〇Me -Ph 8-1263 2-F 3-FH OH -CH2-253-diF-Ph 8-1264 2-F 3-FH OH -CH2-2: 4-diF-Ph 8-1265 '2-F 3-FH OH-CHr2,5-diF-Ph 8-1266 2-F 3-F .H OH -CHr2,6-diF-Ph • 223-200401770 8-1267 2-F 3-FH OH -CHr3,4-diF- Ph 84268 2-F 3-FH OH -CHr3,5-diF-Ph 8-1269 2-F 3-FH OH -CHr3,4-diCl-Ph 8-1270 2-F 3-FH OH -C Hr3,5-diCl-Ph 8-1271 2-F 3-FH OH -CH2-3-Cl-4-F-Ph 8-1272 · 2-F 3-FH OH -CHs-S-Me ^ -Cl- Ph 8-1273 2-F 3-FH OH -CH2-3,4-Mtdo-Ph 8-1274 2-F 3-FH OH -CHr3,4-diMe-Ph 8-1275 2-F 3-FH OH- CH2-3,5-diMe-Ph 8-1276 1-C1 2-OMe H OH Ph 8-1277 1-C1 2-OMe H OH 1-Nap 8-1278 1-C1 2-OMe H OH 2-Nap 8 -1279 1-C1 2-OMe H OH Bz 8-1280 1-C1 2-OMe H OH -CF2 -Ph 8-1281 1-C1 2-OMe H OH-(CH2) -2-Nap 8-1282 1- C1 2-OMe H OH -CH2-3-Me-Ph 8-1283 1-C1 2-OMe H OH -CH2-4-Me-Ph 8-1284 1-C1 2-OMe H OH -CH2-3-Br -Ph 8-1285 1-C1 2-OMe H OH -CH2-4-Br-Ph 8-1286 1-C1 2-OMe H OH -CH2-3-Cl-Ph 8-1287 1-C1 2-OMe H OH -CH2-4-Cl-Ph 8-1288 1-C1 2-OMe H OH -CH2-3-F-Ph 8-1289 1-C1 2-OMe H OH -CH2-4-F-Ph 8-1290 1-C1 2-OMe H OH -CH2-3-Tfm-Ph 8-1291 1-C1 2-OMe H OH -CH2-4-Tfm-Ph 8-1292 1-C1 2-OMe H OH -CH2 for each QMe -Ph 8-1293 1-C1 2-OMe H OH -CH2-4-OMe-Ph 8-1294 1-C1 2-OMe H OH -CH2-233-diF-Ph 8-1295 1-C1 2-OMe H OH -CHr2,4-diF-Ph 8-1296 1-C1 2-OMe H OH -CH2-235-diF-Ph 8-1297 1-C1 2-OMe H OH -CH2-236-diF-Ph 8 -1298 1-C1 2-OMe H OH -CH2-354-diF-Ph 8-1299 1-C1 2-OMe H OH -CH2-3,5-diF-Ph 8-1300 1-C1 2-OMe H OH -CH2-334-diCl-Ph 8-1301 1-C1 2-OMe H OH -CHr3,5-diCl-Ph 8-1302 1-C1 2-OMe H OH -CH2-3-Cl-4-F-Ph 8-1303 1-C1 2-OMe H OH -CH2-3-Me-4-Cl-Ph 224- 200401770 8-1304 1-C1 2-OMe H OH -CHr354-MtdoPh 8-1305 1-Cl 2-OMe H OH .-CH2-354-diMe-Ph 8-1306 1-C1 2-OMe H OH -CH2-335-diMe-Ph 8-1307 1-OMe 2-C1 H OH Ph 8-1308 1-OMe 2- C1 H OH 1-Nap 8-1309 1-OMe 2-C1 H OH 2-Nap 8-1310 1-OMe 2-C1 H OH Bz 8-1311 1-OMe 2-C1 H OH -CF2 -Ph 8-1312 1-OMe 2-C1 H OH-(CH2) -2-Nap 8-1313 1-OMe 2-C1 H OH -CH2-3-Me-Ph 8-1314 1-OMe 2-C1 H OH -CH2-4 -Me-Ph 8-1315. 1-OMe 2-C1 H OH -CH2-3-Br-Ph 8-1316 1-OMe 2-C1 H OH -CH2-4-Br-Ph 8-1317 1-OMe 2 -C1 H OH -CH2-3-Cl-Ph 8-1318 1-OMe 2-C1 H OH -CH2-4-a-Ph 8-1319 1-OMe 2-C1 H OH -CH2-3-F-Ph 8-1320 1-OMe 2-C1 H OH -CH2-4-F-Ph 8-1321 1-OMe 2-C1 H OH -CH2-3-Tfm-Ph 8-1322 1-OMe 2-C1 H OH- CH2-4-Tfm-Ph 8-1323 1-OMe 2-C1 H OH -CH2-3-OMe-Ph 8-1324 1-OMe 2-C1 H OH -CH2- 4-OMe-Ph 8-1325 1-OMe 2-C1 H OH -CH2-253-diF-Ph 8-1326 1-OMe 2-C1 H OH -CH2-2,4-diF-Ph 8-1327 1- OMe 2-C1 H OH -CH2-2,5-diF-Ph 8-1328 1-OMe 2-C1 H OH -CH2-2? 6-diF-Ph 8-1329 1-OMe 2-C1 H OH -CH2 -354-diF-Ph 8-1330 1-OMe 2 > C1 H OH -CH2-3,5-diF-Ph 8-1331 1-OMe 2-C1 H OH -CH2-354-diCl-Ph 8-1332 1 -OMe 2-C1 H OH -CH2-3? 5-diCl-Ph 8-1333 1-OMe 2-C1 H OH -CH2-3-Cl-4-F-Ph 8-1334 1-OMe 2-C1 H OH -CHr3-Me-4-Cl-Ph 8 -1335 1-OMe 2-C1 H OH -CH2-354-Mtdo-Ph 8-1336 1-OMe 2-C1 H OH -CH2-334-diMe-Ph 8 -1337 1-OMe 2-C1 H OH -CHr3,5-diMe-Ph 8-1338 1-OMe 2-Me H OH Ph 8-1339 1-OMe 2-Me H OH 1-Nap 8-1340 1-OMe '2-Me H OH 2-Nap 225-200401770 8-1341 1-OMe 2-Me H OH Bz 8-1342 1-OMe 2-Me H OH -CF2 -Ph 8-1343 1-OMe 2-Me H OH -(CH2) -2-NaP 8-1344 1-OMe 2-Me H OH -CH2-3-Me-Ph 8-1345 1-OMe 2-Me H OH -CH2-4-Me-Ph 8 -1346 1 -OMe 2-Me H OH -CH2-3-Br-Ph 8 -1347 1-OMe 2-Me H OH -CH2-4-Br-Ph 8-1348 1-OMe 2-Me H OH -CH2-3- Cl-Ph 8-1349 1-OMe 2-Me H OH -CH2-4-Cl-Ph 8-1350 1-OMe 2-Me H OH -CH2-3-F-Ph 8-1351 1-OMe 2-Me H OH -CH2-4-F-Ph 8-1352 1-OMe 2-Me H OH -CH2-3-Tfm-Ph 8-1353 1-OMe 2-Me. H OH -CH2-4-Tfm-Ph 8-1354 1-OMe 2-Me H OH .-CH2-3-OMe-Ph 8-1355 1-OMe 2-Me H OH -CHr4-OMe-Ph 8-1356 1- OMe 2-Me H OH -CH2-2,3-diF-Ph 8-1357 1-OMe 2-Me H OH -CH2-2? 4-diF-Ph 8-1358 1-OMe 2-Me H OH -CH2 -235-diF-Ph 8-1359 1-OMe 2-Me. H OH -CH2-256-diF-Ph 8-1360 1-OMe 2-Me H OH -CH2-354-diF-Ph 8-1361 1- OMe 2-Me H OH -CH2-355-diF-Ph 8-1362 1-OMe 2-Me H OH -CH2-354-diCl-Ph 8-1363 1-OMe2-Me H OH -CH2-355- diCl-Ph 8-1364 1-OMe 2-Me H OH -CH2-3-Cl-4-F-Ph 8-1365 1-OMe 2-Me H OH -CH2-3-Me-4-Cl-Ph 8 -1366 1-OMe 2-Me H OH -CH2-354-Mtdo-Ph 8-1367 1-OMe 2-Me H OH -CH2-354-diMe-Ph 8-1368 1-OMe 2-Me H OH -CH2 -3,5-diMe-Ph 8-1369 1-OMe 3-OMe H OH Ph 8-1370 1-OMe 3-OMe H OH 1-Nap 8-1371 1-OMe 3-OMe H OH 2-Nap 8- 1372 1-OMe 3-OMe H OH Bz 8-1373 1-OMe 3-OMe H OH -CF2 -Ph 8-1374 1-OMe 3-OMe H OH-(CH2) -2-Nap 8-1375 1-OMe 3-OMe H OH -CH2-3-Me-Ph 8-1376 1-OMe 3-OMe H OH -CH2 ~ 4-Me-Ph 8-1377 lOMe 3-OMe H OH -CH2-3-Br-Ph 226- 200401770 8-1378 1-OMe 3-OMe H OH -CHr4-Br-Ph 8-1379 1-OMe 3-OMe H OH -CHa-S-Cl -Ph 8-1380 1-OMe 3-OMe H OH -CH2-4-Cl-Ph 8-1381 1-OMe 3-OMe H OH -CH2-3-F-Ph 8-1382 1-OMe 3-OMe H OH -CH2-4-F-Ph 8-1383 1-OMe 3-OMe H OH -CH2 Tfm-Ph 8-1384 1-OMe 3-OMe H OH -CH2-4-Tfm-Ph 8-1385 1- OMe 3-OMe H OH -CH2-3-OMe-Ph 8-1386 1-OMe 3-OMe H OH -CH2-4-OMe-Ph 8-1387 1-OMe 3-OMe H OH -CH2-2? 3 -diF-Ph 8-1388 1-OMe 3-OMe H OH -CH2-254-diF-Ph 8-1389 1-OMe 3-OMe H OH -CH2-2,5-diF-Ph 8-1390 1-OMe 3-OMe H .OH -CH2-256-diF-Ph 8-1391 1-OMe 3-OMe H OH -CH2-354-diF-Ph 8-1392 1-OMe 3-OMe H OH -CH2-355-diF -Ph 8-1393 1-OMe 3-OMe H OH -CH2-3? 4-diCl-Ph 8-1394 1-OMe 3-OMe H OH -CH2-335-diCl-Ph 8-1395 1-OMe 3- OMe H OH -CH2-3-Cl-4-F-Ph 8-1396 1-OMe 3-OMe H OH -CH2-3-Me-4-Cl-Ph 8-1397 1-OMe 3-OMe H OH- CH2-3,4-Mtdo-Ph 8-1398 1-OMe 3-OMe H OH -CH2-3,4-diMe-Ph 8-1399 1-OMe 3-OMe H OH -CH2-335-diMe-Ph 8 -1400 1-Me 2-Me H OH Ph 8-1401 1-Me 2-Me H OH 1-Nap 8-1402 1-Me 2-Me H OH 2-Nap 8-1403 1-Me 2-Me H OH Bz 8-1404 1-Me 2-Me H OH -CF2 -Ph 8-1405 1-Me 2-Me H OH-(CH2) -2- Nap 8-1406 1-Me 2-Me H OH -CH2-3-Me-Ph 8-1407 1-Me 2-Me H OH .CH2-4-Me-Ph 8-1408 1-Me 2-Me H OH -CH2-3-Br-Ph 8-1409 1-Me 2-Me H OH -CH2-4-Br-Ph 84410 1-Me 2-Me H OH -CH2-3-Cl-Ph 8-1411 1-Me 2-Me H OH -CHr4-Cl-Ph 84412 1-Me 2-Me H OH -CH2-3-F-Ph 8-1413 1-Me 2-Me H OH -CH2-4-F-Ph 8-1414 1-Me 2-Me H OH -CH2-3-Tfm-Ph 227- 200401770

8-1415 1-Me 2-Me H OH 8-1416 1-Me 2-Me H OH 8-1417 1-Me 2-Me H OH 8-1418 1-Me 2-Me H OH 8-1419 1-Me .2-Me H OH 8-1420 1-Me 2-Me H OH 8-1421 1-Me 2-Me H OH 8-1422 1-Me 2-Me H OH 8-1423 1-Me 2-Me H OH 8-1424 1-Me 2-Me H OH 8-1425 1-Me 2-Me H OH 8-1426 1-Me 2-Me H OH. 8-1427 1-Me 2-Me H OH 8-1428 1- Me 2-Me H OH 8-1429 1-Me 2-Me H OH 8-1430 1-Me 2-Me H OH 8-1431 1-Me 3-Me H OH 8-1432 1-Me 3-Me H OH 8-1433 1-Me 3-Me H OH 8-1434 1-Me 3-Me H OH 8-1435 1-Me 3-Me H OH 8-1436 1-Me 3-Me H OH 8-1437 1-Me 3-Me H OH 8-1438 1-Me 3-Me H OH 8-1439 1-Me 3-Me H OH 8-1440 1-Me 3-Me H OH 8-1441 1-Me 3-Me H OH 8 -1442 1-Me 3-Me H OH 8-1443 1-Me 3-Me H OH 8-1444 1-Me 3-Me H OH 8-1445 1-Me 3-Me H OH 8-1446 1-Me 3 -Me H OH 8-1447 1-Me 3-Me H OH 8-1448 1-Me 3-Me H OH 8-1449 1-Me 3-Me H OH 8-1450 1-Me 3-Me H OH 8- 1451 1-Me 3-Me H OH -CH2-4-Tfm-Ph -CHr3-〇Me-Ph -CH2-4-OMe-Ph -CH2-253-diF-Ph -CH2-254-diF-Ph ·- CH2-2,5-diF-Ph -CH2-256-diF-Ph -CHr3,4-diF-Ph -CHr3,5-diF-Ph -CH2-354 -diCl-Ph -CH2-355-diCl-Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4-Cl-Ph -CHr3,4-MtdoPh -CH2-3,4-diMe -Ph -CH2-355-diMe-Ph

Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2-Nap -CH2-3-Me-Ph -CH2 ~ 4-Me-Ph -CH2-3-Br-Ph -CH2-4-Br -Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CHr3-F-Ph -CH2-4-F-Ph -CHr3-Tfm-Ph -CH2-4-Tfm-Ph -CH2-3 -OMe-Ph -CH2-4-OMe-Ph ^ CH2-253-diF-Ph -CHr2,4-diF-Ph -CHr2? 5-diF-Ph 228- 200401770 8-1452 1-Me 3-Me H OH -CHr2,6-diF-Ph 8-1453 i-Me 3-Me. H OH -CHr3? 4-diF-Ph 8-1454 l > Me 3-Me H OH -CH2-355-diF-Ph 8-1455 1-Me 3-Me H OH -CHr3,4-diCl-Ph 8-1456 1-Me 3-Me H OH -CH2-3? 5-diCl-Ph 8-1457 1-Me 3-Me H OH -CHr3 -Cl-4-F-Ph 8-1458 1-Me 3-Me H OH -CH2-3-Me-4-Cl-Ph 8-1459 1-Me 3-Me H OH -CHr3,4-Mtdo-Ph 8-1460 1-Me 3-Me H OH -CHr3,4-diMe-Ph 8-1461 1-Me 3-Me H OH -CH2-3,5-diMe-Ph 8-1462 1-Me 2-C1 H OH Ph 8-1463 1-Me 2-C1 H OH 1-Nap 8-1464 1-Me 2-C1 H OH 2-Nap 8-1465 1-Me 2-C1 H OH Bz 8-1466 1-Me 2- C1 H OH -CF2 -Ph 8-1467 1-Me 2-C1 H OH-(CH2) -2-Nap 8-1468 1-Me 2-C1 H OH -CH2-3-Me-Ph 8-1469 1- Me 2-C1 H OH -CH24Me-Ph 8-1470 1-Me 2-C1 H OH -CH2-3-Br-Ph 8-1471 1-Me 2-C1 H OH -CH2-4-Br-Ph 8- 1472 1-Me 2-C1 H OH -CHr3-Cl-Ph 8-1473 1-Me 2-C1 H OH -CH2-4-Cl-Ph 8-1474 1-Me 2-C1 H OH -CH2-3-F-Ph 8-1475 1- Me 2-C1 H OH -CH2-4-F-Ph 8-1476 1-Me 2-C1 H OH -CH2-3-Tfm-Ph 8-1477 1-Me 2-C1 H OH -CH2-4-Tfm -Ph 8-1478 1-Me 2-C1 H OH. -CH2-3-OMe-Ph 8-1479 1-Me 2-C1 H OH -CH2-4-OMe-Ph 8-1480 1-Me 2-C1 H OH -CH2-2,3-diF-Ph. 8-1481 1-Me 2-C1 H OH -CHr2,4-diF-Ph 8-1482 1-Me 2-C1 H OH -CH2-235-diF- Ph 8-1483 1-Me 2-C1 H OH -CH2-2? 6-diF-Ph 8-1484 1-Me 2-C1 H OH -CHr3,4-diF-Ph 8-1485 1-Me 2-C1 H OH -CHr3,5-diF-Ph 8-1486 1-Me 2-C1 H OH -CH2-3,4-diCl > Ph 8-1487 1-Me 2-C1 H OH -CH2-3,5-diCl -Ph 8-1488 1-Me 2-C1 H OH -CH2-3-Cl-4-F-Ph -229- 200401770 8-1489 1-Me 2-C1 H OH -CH2-3-Me-4-Cl -Ph 8-1490 1-Me 2-C1 H OH -CH2-354-Mtdo-Ph 8-1491 1-Me 2-C1 H OH -CHr3,4-diMe-Ph 8-1492 1-Me 2-C1 H OH -CH2-3,5-diMe-Ph 8-1493 1-Me 2-OMe H OH Ph 8-1494 1-Me 2-OMe H OH 1-Nap 8-1495 1-Me 2-OMe H OH 2- Nap 8-1496 1-Me 2-OMe H OH Bz 8-1497 1-Me 2-OMe H OH -CF2 -Ph 8-1498 1-Me 2-OMe H OH-(CH2) -2-Nap 8-1499 1-Me 2-OMe H OH -CH2-3-Me-Ph 8-1500 1-Me 2-OMe H OH -CH2-4-Me-Ph 8-1501 1-Me 2-OMe H OH -CH2-3-Br- Ph 8-1502 1-Me 2-OMe H OH -CH2-4-Br-Ph 8-1503 1-Me 2-OMe H OH -CH2-3-Cl-Ph 8-1504 1-Me 2-OMe H OH -CH2-4-Cl-Ph 8-1505 1-Me 2-OMe H OH -CH2-3-F-Ph 8-1506 1-Me 2-OMe H OH -CH2-4-F-Ph 8-1507 1 -Me 2-OMe H OH -CH2-3-Tfm-Ph 8-1508 1-Me 2-OMe H OH -CH2-4-Tfm-Ph 8-1509 1-Me 2-OMe H OH -CH2-3- OMe-Ph 8-1510 1-Me 2-OMe H OH -CH2-4-OMe-Ph 8-1511 1-Me 2-OMe H OH -CH2-2,3-diF-Ph 8-1512 1-Me 2 -OMe H OH -CHr2,4-diF-Ph 8-1513 1-Me 2-OMe H OH -CH2-235-diF-Ph 8-1514 1-Me 2-OMe H OH -CH2-2? 6-diF -Ph 8-1515 1-Me 2-OMe H OH -CH2-354-diF-Ph 8-1516 1-Me 2-OMe H OH -CH2-355-diF-Ph 8-1517 1-Me 2-OMe H OH -CH2-354-diCl-Ph 8-1518 1-Me 2-OMe H OH -CH2-335-diCl-Ph 8-1519 1-Me 2-OMe H OH -CHrS-ClIF-Ph 8-1520 1- Me 2-OMe H OH -CH2-3-Me-4-Cl-Ph 8-1521 1-Me 2-OMe H OH -CH2-354-Mtdo-Ph 8-1522 1-Me 2-OMe H OH -CH2 -3,4-diMe-Ph 8-1523 1-Me 2-OMe H OH -CH2-355-diMe-Ph 8-1524 1-C1 2-Me H OH Ph 8-1525 1-C1 2- Me H OH 1-Nap -230-200401770 8-1526 1-C1 2-Me. H OH 2-Nap 8-1527 1-C1 2-Me H OH Bz 8-1528 1-C1 2-Me H OH -CF2 ~ Ph 8-1529 1-C1 2-Me H OH-(CH2) -2-Nap 8-1530 1-C1 2-Me H OH -CH2-3-Me-Ph 8-1531 1-C1 2-Me H OH -CH2-4-Me-Ph 8-1532 1-C1 2-Me H OH -CH2-3-Br-Ph 8-1533 1-C1 2-Me H OH -CH2-4-Br-Ph 8-1534 1-C1 2-Me H OH -CH2-3-Cl-Ph 8 -1535 1-C1 2-Me H OH -CH2-4-Cl-Ph 8-1536 1-C1 2-Me H OH -CH2-3 -F-Ph 8-1537 1-C1 2-Me H OH -CH2-4-F-Ph 8-1538 1-C1 2-Me H OH -CH2-3-Tfm-Ph 8-1539 1-C1 2- Me H OH -CH2-4-Tfm-Ph 8-1540 1-C1 2-Me H OH -CH2 OMe-Ph 8-1541 1-C1 2-Me H OH -CH2-4-OMe-Ph 8-1542 1-C1 2-Me H OH -CH2-233-diF-Ph 8-1543 1-C1 2-Me H OH -CKr2,4-diF-Ph 8-1544 1-C1 2-Me H OH -CH2-2 , 5-diF-Ph 8 -1545 1-C1 2-Me. H OH -CH2 ~ 2; 6-diF-Ph 8-1546 1-C1 2-Me H OH -CH2-354-diF-Ph 8-1547 1-C1 • 2-Me H OH -CH2-3,5-diF-Ph 8-1548 1-C1 2-Me H OH -CH2-354-diCl-Ph 8-1549 1-C1 2-Me H OH- CHr3,5-diCl-Ph 8-1550 1-C1 2-Me H OH -CH2-3-Cl-4-F-Ph 8-1551 1-C1 2-Me H OH -CH2-3-Me-4- Cl-Ph 8 -155 2 1-C1 2-Me H OH -CHr3,4-Mtdo-Ph 8-1553 1-C1 2-Me H OH -CH2-354-diMe-Ph 8-1554 1-C1 2-Me H OH -CH2- 355-diMe-Ph 8-1555 1-C1 2-C1 H OH Ph 8-1556 1-C1 2-C1 H OH 1-Nap 8-1557 1-C1 2-C1 H OH 2-Nap 8 -1558 1- C1 2-C1 H OH Bz 8-1559 1-C1 2-C1 H OH -CF2 -Ph 8-1560 1-C1 2-C1 H OH-(CH2) -2-Nap 8-1561 1-C1 2-C1 H OH -CH2-3-Me-Ph 8-1562 1-C1 2-C1 H OH -CH24Me-Ph -231-200401770 8-1563 1-C1 2-C1 H OH -CHr3-Br-Ph 8-1564 1 -C1 2-C1 H OH -CH2-4: Br-Ph 8-1565 1-C1 2-C1 H OH-CHr3-Cl-Ph 8-1566 1-C1 2-C1 H OH -CH2-4-Cl- Ph 8-1567 1-C1 2-C1 H OH -CH2-3-F-Ph 8-1568 1-C1 2 > C1 H OH -CH2-4-F > Ph 8-1569 1-C1 2-C1 H OH -CH2-3-Tfm-Ph 8-1570 1-C1 2-C1 H OH -CH2-4-Tfm-Ph 8-1571 1-C1 2-C1 H OH -CH2-3-OMe-Ph 8-1572 1 -Cl 2-C1 H OH -CH2-4-OMe-Ph 8-1573 1-C1 2-C1 H OH -CH2-253-diF-Ph 8-1574 1-C1 2-C1 H OH -CH2-254- diF-Ph 8-1575 1-Cl 2-C1 H OH -CH2-235-diF-Ph 8-1576 1-C1 2-C1 H OH -CHr2,6-diF-Ph 8-1577 1-C1 2-Ci H OH -CH2-3? 4-diF-Ph 8-1578 1-C1 2-C1 H OH -CH2-355-diF-Ph 8-1579 1-C1 2-C1 H OH -CH2-3,4-diCl-Ph 8-1580 1-C1 2-C1 H OH -CHr3,5-diCl-Ph 8-1581 1-C1 2-C1 H OH -CH2-3-Cl-4 -F-Ph 8-1582 1-C1 2 ~ C1 H OH -CH2-3-Me-4-Cl-Ph 8-1583 1-C1 2-C1 H OH -CHr3,4-Mtdo-Ph 8-1584. 1-C1 2-C1 H OH -CH2-3? 4-diMe-Ph 8-1585 1-C1 2-C1 H OH -CH2-3? 5-diMe-Ph 8-1586 1-ci 3-C1 H OH Ph 8-1587 1-C1 3-C1 H OH 1-Nap 8-1588 1-C1 3-C1 H OH 2-Nap 8 -1589 1-C1 3-C1 H OH Bz 8-1590 1-C1 3-C1 H OH -CF2 -Ph 8-1591 1-C1 3-C1 H OH-(CH2) -2-Nap 8-1592 1-C1 3-C1 H OH -CH2-3-Me-Ph 8-1593 1-C1 3-C1 H 'OH -CH2 ~ 4-Me-Ph 8-1594 1-C1 3-C1 H OH -CH2-3-Br-Ph 8-1595 1-C1 3-C1 H OH -CH2-4-Br -Ph 8-1596 1-C1 3-C1 H OH -CH2-3-Cl-Ph 84597 1-C1 3-C1 H OH -CH2-4-Cl-Ph 8-1598 1-C1 3-C1. H OH -CHr3-F-Ph 8 -1599 1-C1 3-C1 H OH -CH2-4-F-Ph -232- 200401770 8-1600 1-C1 3-C1 H OH -CH2-3-Tfm-Ph 8- 1601 1-C1 3-C1 H OH -CHr4-Tfm-Ph 8-1602 1-C1 3-C1 H OK -CH2-3-OMe-Ph 8-1603 1-C1 3-C1 H OH -CH2 DooMe -Ph 8-1604 1-C1 3-C1 H OH -CHr2,3-diF-Ph 8-1605 1-C1 3-C1 H OH -CH2-254-diF-Ph 8-1606 1-C1 3-C1 H OH -CHr2 , 5-diF-Ph 8-1607 1-C1 3-C1 H OH -CHr2,6-diF-Ph 8-1608 1-C1 3-C1 H OH -CHr3,4-diF-Ph 8-1609 1-C1 3-C1 H OH -CH2-355-diF-Ph 8-1610 1-C1 3-C1 H OH -CH2-3,4-diCl-Ph 8-1611 1-C1 3-C1 H OH -CH2-3? 5-diCl-Ph. 8-1612 1-C1 3-C1 H OH -CH2-3-Cl-4-F-Ph 8-1613 1-C1 3-C1 H OH -CH2-3-Me-4-Cl -Ph 8-1614 1-C1 3-C1 H OH -CH2-354-Mtdo-Ph 8-1615 1-C1 3-C1 H OH -CH2-354-diMe-Ph 8-1616 1-C1 3-C1 H OH -CH2-3,5-diMe-Ph 8-1617 2-Me 3-Me H OH Ph 8-1618 2-Me 3-Me H OH 1-Nap 8-1619 2-Me 3-Me H OH 2- Nap 8-1620 2-Me 3-Me H OH Bz 8-1621 2-Me 3-Me H OH -CF2 -Ph 8-1622 2-Me 3-Me H OH-(CH2) -2-Nap 8-1623 2-Me 3-Me H OH -CH2-3-Me-Ph 8-1624 2-Me 3-Me H OH .CH2-4-Me-Ph 8-1625 2-Me 3-Me H OH -CH2-3 -Br-Ph 8-1626 2-Me 3-Me H OH -CH2-4IPh 8-1627 2-Me 3-Me H OH -CH2-3-Cl-Ph 8-1628 2-Me 3-Me H OH- CH2-4-Cl-Ph 8-1629 2-Me 3-Me H OH -CH2-3-F-Ph 8-1630 .2-Me 3-Me H. OH -CH2-4-F-Ph 8-1631 2-Me " 3-Me H OH -CH2-3-Tfm-Ph 8-1632 2-Me 3-Me H OH -CHr4-Tfm-Ph 8-1633 2-Me 3-Me .H OH -CH2-3 -OMe-Ph 8-16 34 2-Me 3-Me H OH -CH2-4-OMe-Ph 8-1635 2-Me 3-Me H OH -CH2-2? 3-diF-Ph 8-1636 2-Me 3-Me H OH- CH2-254-diF-Ph 233 200401770 8-1637 2-Me 3-Me H OH-CHr2,5-diF-Ph 8-1638 2-Me 3-Me H OH -CH2-2,6-diF-Ph 8 -1639 2-Me 3-Me H OH-CH2-3,4-diF-Ph 8-1640 2-Me 3-Me H OH -CHr3,5-diF-Ph 8-1641 2-Me 3-Me H OH • CH2-3,4-diCl-Ph 8-1642 2-Me 3-Me H OH -CH2-335-diCl-Ph 8 -1643 2-Me, 3-Me H OH-CH2 each Cl-4-F- Ph 8-1644 2-Me 3-Me H OH -CH2-3-Me-4-Cl-Ph 8-1645 2-Me 3-Me H OH -CHr3,4-Mtdo-Ph 8-1646 2-Me 3 -Me H OH -CH2_3,4-diMe-Ph 8-1647 2-Me 3-Me H OH -CH2-3? 5-diMe-Ph 8-1648 2-Me 3-C1 H OH Ph 8-1649 2- Me 3-C1 H OH 1-Nap 8-1650 2-Me 3-C1 H OH 2-Nap 8-1651 2-Me 3-C1 H OH Bz 8-1652 2-Me 3-C1 H OH -CF2 -Ph 8-1653 2-Me 3-C1 H OH-(CH2) -2-Nap 8-1654 2-Me 3-C1 H OH -CH2-3-Me-Ph 8-1655 2-Me 3-C1 H OH- CH2-4-Me-Ph 8-1656 2-Me 3-C1 H OH -CH2-3-Br-Ph 8-1657 2-Me 3-C1 H OH -CH2-4-Br-Ph 8-1658 2- Me 3-C1 H OH -CHd-Cl-Ph 8-1659 2-Me 3-C1 H OH -CH2-4-Cl-Ph 8-1660 2-Me 3-C1 H OH -CH2-3-F-Ph 8-16 61 2-Me 3-C1 H OH -CH2-4-F-Ph 8-1662 2-Me 3-C1 H OH -CH2-3-Tfm-Ph 8-1663 2-Me 3-C1 H OH -CH2- 4-Tfm-Ph 8-1664 2-Me 3-C1 H OH -CH2-3-OMe-Ph 8-1665 2-Me 3-C1 H OH -CH2-4-OMe-Ph 8-1666 2-Me 3 -C1 H OH > CH2-253-diF-Ph 8-1667 2-Me 3-C1 H OH -CH2-254-diF-Ph 8-1668 2-Me 3-C1 H OH -CH2-255-diF- Ph 8-1669 2-Me 3-C1 H OH -CHr2,6-diF-Ph 8-1670 2-Me 3-C1 H OH -CHr3,4-diF-Ph 8-1671 2-Me 3-C1 H OH -CHr3,5-diF-Ph 8-1672 2-Me 3-C1 H OH 8-1673 2-Me 3-C1 H OH -CH2-3; 5-diCl-Ph 234 200401770 8-1674 2-Me 3 -C1 H OH -CHr3-Cl-4-F-Ph 8-1675 2-Me 3-C1 H OH -CH2-3-Me-4-Cl-Ph 8-1676 2-Me 3-C1 H OH -CH2 -3? 4-Mtdo-Ph 8-1677 2-Me 3-C1 H OH -CH2-3,4-diMe-Ph 8-1678 2-Me 3-C1 H OH -CH2-3? 5-diMe-Ph 8-1679 2-Me 3-OMe H OH Ph 8-1680 2-Me 3-OMe H OH 1-Nap 8-1681 2-Me 3-OMe H OH 2-Nap 8-1682 2-Me 3-OMe H OH Bz 8-1683 2-Me 3-OMe H OH -CF2 -Ph 8-1684 2-Me 3-OMe H OH-(CH2) _2-Nap 8-1685 2-Me 3-OMe H OH -CH2-3 -Me-Ph 8-1686 2-Me 3-OMe H OH -CH2-4-Me-Ph 8-1687 2-Me 3-OMe H OH -CHr3-Br-Ph 8-1688. 2- Me 3-OMe H OH -CH2-4-Br-Ph 8-1689 2-Me 3-OMe H OH -CH2-3-Cl-Ph 8-1690 2-Me 3-OMe H OH -CH2-4-Cl -Ph 8-1691 .2-Me 3-OMe H OH -CH2-3-F-Ph 8-1692 2-Me 3-OMe H OH -CH2-4-F-Ph 8-1693 2-Me 3-OMe H OH -CH2-3-Tfm-Ph 8-1694 2-Me 3-OMe H OH -CH2-4-Tfm-Ph 8-1695 2-Me 3-OMe H OH -CH2-3-OMe-Ph 8- 1696 2-Me 3-OMe H OH -CH2-4-OMe-Ph 8-1697 2-Me 3-OMe H OH -CH2-253-diF-Ph 8-1698 2-Me 3-OMe H OH -CH2- 254-diF-Ph 8-1699 2-Me 3-OMe H OH -CHr2,5-diF-Ph 8-1700 2-Me 3-OMe H OH -CHr2,6-diF-Ph 8-1701 2-Me 3 -OMe H OH -CH2-3,4-diF-Ph 8-1702 2-Me 3-OMe H OH -CH2-3? 5-diF-Ph 8-1703 2-Me 3-OMe H OH -CH2-354 -diCl-Ph 8-1704 2-Me 3-OMe H OH • CHr3,5-diCl-Ph 8-1705 2-Me 3-OMe H OH -CH2-3-Cl-4-F-Ph 8-1706 2 -Me 3-OMe H OH -CH2-3-Me-4-Cl-Ph 8-1707 2-Me 3-OMe H OH -CH2-354-Mtdo-Ph 8-1708 2-Me 3-OMe H OH- CHr3,4-diMbPh 8-1709 2-Me 3-OMe H OH: CHr3 > diMbPh 8-1710 2-C1 3-Me H OH Ph 235-200401770 8-1711 2-C1 3 > Me H OH 1-Nap 8 -1712 2-C1 3-Me H OH 2-Nap 8-1713 2-C1 3-Me H OH Bz 8-1714 2-C1 3-Me H OH -CF2 -Ph 8-1715 2-C1 3-Me H OH-(CH2) -2-Nap 8-1716 2-C1 3-Me H OH -CH2-3-Me-Ph 8-1717 2-C1 3 -Me 'H OH -CH2-4-Me-Ph 8-1718 2-C1 3-Me H OH -CH2-3-Br-Ph 8-1719 2-C1 3-Me H OH -CH2-4-Bx- Ph 8-1720 2-C1 3-Me H OH -CH2-3-Cl-Ph 8-1721 2-C1 3-Me H OH -CH2-4-Cl-Ph 8-1722 2-C1 3-Me H OH -CH2-3-F-Ph 8-1723 2-C1 3-Me H OH -CH2-4-F-Ph 8-1724 2-C1 3-Me H OH -CH2-3-Tfm-Ph 8-1725 2 -C1 3-Me H OH -CH2-4-Tfm-Ph 8-1726 2-C1 3-Me H OH -CH2-3-OMe-Ph 8-1727 2-C1 3-Me H OH -CH2-4- OMe> Ph 8-1728 2-C1 3-Me H OH -CH2-253-diF-Ph 8-1729 2-C1 3-Me H OH -CH2-2? 4-diF-Ph 8-1730 2-C1 3 -Me H OH -CH2-2,5-diF-Ph 8-1731 2-C1 3-Me H OH -CH2-236-diF-Ph 8-1732 2-C1 3-Me H OH -CH2-3,4 -diF-Ph 8-1733 2-C1 3-Me H OH -CH2-335-diF-Ph 8-1734 2-C1 3-Me H OH -CH2-354-diCl-Ph 8-1735 2-C1 3- Me H OH -CH2-3? 5-diCl-Ph 8-1736 2-C1 3-Me H OH -CH2-3-Cl-4-F-Ph 8-1737 2-C1 3-Me H OH -CH2- 3-Me-4-Cl-Ph 8-1738 2-C1 3-Me H OH -CH2-3,4-Mtdo-Ph 8-1739 2-C1 3-Me H OH -CH2-354-diMe-Ph 8 -1740 2-C1 3-Me H OH -CH2-3,5-diMe-P h 8 -1741 2-C1 3-C1 H OH Ph 8-1742 2-C1 3-C1 H OH 1-Nap 8-1743 2-C1 3-C1 H OH 2-Nap 8-1744 2-C1 3-C1 H OH Bz 8-1745 2-C1 3-C1 H OH -CF2 ^ Ph 8-1746 2-C1 3-C1 H OH-(CH2) -2-Nap 8-1747 2-C1 3-C1 H OH -CH2 -3-Me-Ph 236-200401770 8-1748 2-C1 3-C1 H OH-CH24Me-Ph 8-1749 2-C1 3-C1 H OH -CH2-3-Br-Ph 8-1750 2-C1 3 -C1 H OH -CH2-4-Br-Ph 8-1751 2-C1 3-C1 H OH -CH2-3-Cl-Ph 8-1752 2-C1 · 3-C1 H OH -CH2-4-Cl- Ph 8-1753 2-C1 3-C1 H OH -CH2-3-F-Ph 8-1754. 2-C1 3-C1 H OH -CH2-4-F-Ph 8-1755 2-C1 3-C1 H OH -CH2-3-Tfm-Ph 8-1756 2-C1; 3-C1 H OH -CH2-4-Tfm-Ph 8-1757 2-C1 3-C1 H OH -CH2-3-OMe-Ph 8- 1758 2-C1 3-C1 H OH -CH2-4-OMe-Ph 8-1759 2-C1 3-C1 H OH -CH2-2,3-diF-Ph 8-1760 2-C1 3-C1 H OH- CH2-254-diF-Ph 8-1761 2-C1 3-C1 H OH -CH2-235-diF-Ph 8-1762 2-C1 3-C1 H OH -CH2-2,6-diF-Ph 8-1763 2-C1 3-C1 H OH -CH2-3? 4-diF-Ph 8-1764 2-C1 3-C1 H OH -CH2-335-diF-Ph 8-1765 2-C1 3-C1 H OH -CH2 -3? 4-diCl-Ph 8-1766 2-C1 3-C1 H OH -CH2-3? 5-diCl-Ph 8-1767 2-C1 3-C1 H OH -CH2-3-Cl-4-F -Ph 8-1768 2-C1 > C1 H OH -CH2-3-Me-4-Cl-Ph 8-1769 2-C1 3-C1 H OH-CH2-3,4-Mtdo-Ph 8-1770 2-C1 3 > C1 H OH -CH2-3? 4-diMe-Ph 8-1771 2-C1 3-C1 H OH -CH2-355-diMe-Ph 8-1772 2-C1 3-OMe H OH Ph 8-1773 2-C1 3 -OMe H OH 1-Nap 8-1774 2-C1 3-OMe H OH 2-Nap 8-1775 2-C1 3-OMe H OH Bz 8-1776 2-C1 3-OMe H OH -CF2 -Ph 8- 1777 2-C1 3-OMe H OH-(CH2) -2-Nap 8-1778 2-C1 3-OMe H OH -CH2-3-Me-Ph 8-1779 2-C1 3-OMe H OH -CH2 ~ 4-Me-Ph 8-1780 2-C1 3-OMe H OH -CH2-3-Br-Ph 8-1781 2-C1 3-OMe H OH -CHr4-Br-Ph. 8-1782 2-C1 3- OMe H OH -CH2-3-Cl-Ph 8-1783 2-C1 3-OMe H OH -CH2-4-Cl-Ph 8-1784 2-C1 3-OMe H OH -CH2-3-F-Ph- 237-200401770 8-1785 2-C1 3-OMe H OH -CHr4-F-Ph 8-1786 2-C1 3-OMe H OH -CH2-3-Tfm-Ph 8-1787 2-C1 3-OMe H OH ~ CH2-4-Tfm-Ph 8-1788 2-C1 3-OMe H OH -CH2-3-OMe-Ph 8-1789. 2-C1 3-OMe. H OH -CH2-4-OMe-Ph 8- 1790 2-C1 3-OMe H OH -CH2-2,3-diF-Ph 8-1791 2-C1 3-OMe H OH -CH2-2? 4-diF-Ph 8-1792 2-C1 3-OMe H OH -CH2-2,5-diF-Ph 8-1793 2-C1 3-OMe H OH -CH2-236-diF-Ph 8-1794 2-C1 3-OMe H OH ^ CH2- 354-diF-Ph 8-1795 2-C1 3-OMe H OH -CH2-3? 5-diF-Ph 8-1796 2-C1 3-OMe H OH -CH2-3? 4-diCl-Ph 8- 1797 2-C1 3-OMe H OH ^ CH2-3? 5-diCl-Ph 8-1798 2-C1 3-OMe H OH -CH2-3-Cl-4-F-Ph 8-1799 2-C1 3- OMe H OH -CH2-3-Me-4-Cl-Ph 8-1800 2-C1 3-OMe H OH -CH2-3,4-Mtdo-Ph 8-1801 2-C1 3-OMe H OH ^ CH2- 3? 4-diMe-Ph 8-1802 2-C1 3-OMe H OH -CH2-3,5-diMe-Ph 8-1803 2-OMe 3-Me H OH Ph 8-1804 2-OMe 3-Me H OH 1-Nap 8-1805 2-OMe 3-Me H OH 2-Nap 8-1806 2-OMe 3-Me H OH Bz 8-1807 2-OMe 3-Me H OH -CF2 -Ph 8-1808 2- OMe 3-Me H OH-(CH2) -2-Nap 8-1809 2-OMe 3-Me H OH -CH2-3-Me-Ph 8-1810 2-OMe 3-Me H OH -CH24Me-Ph 8- 1811 2-OMe 3-Me H OH -CH2-3-Br-Ph 8-1812 2-OMe 3-Me H OH -CH2-4-Br-Ph 8-1813 2-OMe 3-Me H OH -CHACl- Ph 8-1814 2-OMe 3-Me H OH -CH2-4-Cl-Ph 8-1815 2-OMe 3-Me H OH • CH2-3-F-Ph 8-1816 2-OMe 3-Me H OH -CH2-4-F-Ph 8-1817 2-OMe 3-Me H OH -CH2-3-Tfm-Ph 8-1818 2-OMe 3-Me H OH -CH2-4-Tfm-Ph 8-1819 2 -OMe 3-Me H OH -CHr3-OMe-Ph 8-1820 2-OMe 3-Me H OH -CH2-4-OMe-Ph 8-182.1 2-OMe 3-Me H OH -CHr2 , 3-diF-Ph 238- 200401770

2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2'OMe 3-Me H 2 -OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Me H 2-OMe 3-Cl H 2-OMe 3-C1 H 2- OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3-C1 H 2-OMe 3 -C1 H 2-OMe 3-C1 H 8-1822 8-1823 8-1824 8-1825 8-1826 8-1827 8-1828 8-1829 8-1830 8-1831 8-1832 8-1833 8-1834 8 -1835 8-1836 8-1837 8-1838 8-1839 8-1840 8-1841 8-1842 8-1843 8-1844 8-1845 8-1846 8-1847 8-1848 8-1849 8-1850 8-1851 8-1852 8-1853 8-1854 8-1855 8-1856 8-1857 8-1858 OH -CHr2,4-diF-Ph OH -CHr2,5-diF-Ph OH -CH2-2? 6-diF-Ph OH -CH2-334-diF-Ph OH -CH2-3? 5-diF-Ph OH -CH2-3,4-diCl-Ph OH -CU2 ^^ Cim OH -CH2-3-Cl-4-F-Ph OH -CH2-3-Me-4-Cl-Ph OH -CH2-3,4-Mtdo-Ph OH -CH2-3,4-diMe-Ph OH -C H2-3? 5-diMe-Ph OH Ph OH 1-Nap OH 2-Nap, OH Bz OH -CF2 -Ph OH-(CH2) -2-Nap OH -CH2-3-Me-Ph OH -CH2-4 -Me-Ph OH -CH2-3-Br-Ph OH -CH2-4-Br-Ph. OH -CH2-3-Cl-Ph OH -CH2-4-Cl-Ph · OH -CH2-3-F- Ph OH -CH2-4-F-Ph OH -CH2 each fm-Ph OH -CH2-4-Tfm-Ph OH -CH2-3-OMe-Ph OH -CH2-4-OMe-Ph OH -CH2-2 , 3-diF-Ph OH -CHr2,4-diF-Pli OH -CHr2,5-diF-Ph OH -CHr2,6-diF-Ph OH -CHr3,4-diF-Ph OH -CH2-3,5- diF-Ph OH -CH2-354-diCl-Ph

239-200401770 8-1859 2-OMe 3-C1 H OH -CHr3,5-diCl-Ph 8-1860 2-OMe 3 ^ C1 H OH -CH2-3-Cl-4-F-Ph 8-1861 2- OMe 3-C1 H OH -CH2-3-Me-4-Cl-Ph 8-1862 2-OMe 3-C1 H OH -CH2-3,4-Mtdo-Ph 8-1863 2-OMe 3-C1 H OH -CH2-354-diMe-Ph 8-1864 2-OMe 3-C1 H OH -CH2-355-diMe-Ph 8-1865 1-F 2-FH OH Ph 8-1866 1-F 2-FH OH 1- Nap 8-1867 1-F 2-FH OH 2-Nap 8-1868 1-F 2-FH OH Bz 8-1869 1-F 2-FH OH -CF2 -Ph 8-1870 1-F 2-FH OH- (CH2) -2-Nap 8-1871 1-F 2-FH OH -CH2-3-Me-Ph 8-1872 1-F 2-FH OH -CH2-4-Me-Ph 8-1873 1-F 2 -FH OH -CH2-3-Br-Ph 8-1874 1-F 2-FH OH -CH2-4-Br-Ph 8-1875 1-F 2-FH OH -CH2-3-Cl-Ph 8-1876 1-F 2-FH OH -CHr4-Cl-Ph 8-1877 1-F 2-FH OH -CH2-3-F-Ph 8-1878 1-F 2-FH OH -CH2-4-F-Ph 8 -1879 1-F 2-FH OH -CH2-3-Tfm-Ph 8-1880 1-F 2-FH OH -CH2-4-Tfm-Ph 8-1881 1-F 2-F .H OH -CH2- 3-OMe-Ph 8-1882 1-F 2-FH OH -CH2-4-OMe-Ph 8-1883 1-F 2-FH OH -CH2-253-diF-Ph 8-1884 1-F 2-FH OH -CH2-234-diF-Ph 8-1885 1-F 2-FH OH -CH2-255-diF-Ph 8-1886 1-F 2-FH OH -CH2-256-diF-Ph 8-1887 1- F 2-F H OH -CHr3,4-diF-Ph 8-1888 1-F 2-FH OH -CHr3,5-diF-Ph. 8-1889 1-F 2-FH OH -CHr3,4-diCl-Ph 8-1890 1-F 2-FH OH -CHr3,5-diCl-Ph 8-1891 1-F 2-FH OH -CH2-3-Cl-4-F-Ph 8-1892 1-F 2-FH OH -CHr3- Me-4-Cl-Ph 8-1893 1-F 2-FH OH -CHr3,4-Mtdo-Ph 8-1894 1-F 2-F 'H OH -CHr3,4-diMe-Ph 8-1895 1- F 2-FH OH -CHr3,5-diMe-Ph 240- 200401770 8-1896 8-1897 8-1898 8-1899 8-1900 8-1901 8-1902 8-1903 8-1904 8-1905 8-1906 8 -1907 8-1908 8-1909 8-1910 8-1911 8-1912 8-1913 8-1914 8-1915 8-1916 8-1917 8-1918 8-1919 8-1920 8-1921 8-1922 8 -1923 8-1924 8-1925 8-1926 8-1927 8-1928 8-1929 8-1930 8-1931 8-1932

1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1 -F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1- F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2-Me H 1-F 2 -Me H 1-F 2-Me H 1-F 2-Me 'H 1-F 2-OMe H 1-F 2-OMe H 1-F 2-OMe H 1-F 2-OMe H 1-F 2 -OMe H 1-F 2-OMe H OH Ph OH 1-Nap OH 2-Nap OH Bz OH -CF2 -Ph OH-(CH2) -2-Nap OH -CH2-3-Me-Ph OH -CH2- ^ -Me-Ph OH -CH2-3-Br-Ph OH -CH2-4-Br-Ph OH -CHs ^ -Cl-Ph OH -CH2-4-Cl-Ph OH -CH2-3-F-Ph OH- CH2-4-F-Ph OH -CH2-3-Tfm-Ph OH > CH2-4.Tfm-Ph OH -CH2-3-OMe-Ph OH -CHr4-OMe-Ph OH -CH2-233-diF- Ph OH -CH2-254-diF-Ph OH -CH2-255-diF-Ph OH -CHr2,6-diF-Ph OH -CHr3,4-diF-Ph OH -CH2-3,5-diF-Ph OH- CH2-3,4-diCl-Ph OH -CHr3,5-diCl-Ph OH -CH2-3-Cl-4-F-Ph OH -CH2-3-Me-4-Cl-Ph OH -CHr3,4- Mtdo-Ph OH > CH2-354-diMe-Ph OH -CH2-335-diMe-Ph OH Ph OH 1- Nap OH 2-Nap OH Bz OH -CF2 -Ph OH-(CH2) -2-Nap -24b 200401770 8-1933 1-F 2-OMe H OH -CH2-3-Me-Ph 8-1934 1-F 2-OMe H OH -CH2-4-Me-Ph 8-1935 1-F 2-OMe H OH -CH2-3-Bi-Ph 8-1936 1-F 2-OMe H OH -CH2-4-Br- Ph 8-1937 1-F 2-OMe H OH -CH2-3-Cl-Ph 8-1938 1-F 2-OMe H OH -CHr ^ CUh 8-1939 1-F 2-OMe H OH -CHr3-F -Ph 8-1940 1-F 2-OMe H OH -CH2-4-F-Ph 8-1941 1-F 2-OMe H OH -CHr3-Tfm-Ph 8-1942 1-F 2-OMe H OH- CH2-4-Tfm-Ph 8-1943 1-F 2-OMe H OH -CH2-3-OMe-Ph 8-1944 1-F 2-OMe H OH -CH2-4-OMe-Ph 8-1945 1- F 2-OMe H OH -CH2-2? 3-diF-Ph 8-1946 1-F 2-OMe H OH -CH2-234-diF-Ph 8-1947 1-F 2-OMe H OH -CH2-2 , 5-diF-Ph 8-1948 1-F 2-OMe H OH -CH2-2? 6-diF-Ph 8-1949 1-F 2-OMe H OH -CHr3,4-diF-Ph 8-1950 1 -F 2-OMe H OH -CH2-3? 5-diF-Ph 8-1951 1-F 2-OMe H OH -CH2-354-diCl-Ph 8-1952 1-F 2-OMe H OH -CHr3, 5-diCl-Ph 8-1953 1-F 2-OMe H OH -CH2-3-Cl-4-F-Ph 8-1954 1-F 2-OMe H OH -CH2-3-Me-4-Cl- Ph 8-1955 1-F 2-OMe H OH -CH2-354-Mtdo-Ph 8-1956 1-F 2-OMe H OH -CH2-3? 4-diMe-Ph 8-1957 1-F 2-OMe H OH -CHr3,5-d iMe-Ph 8-1958 1-F 2-Br H OH Ph 8-1959 1-F 2-Br H OH 1-Nap 8-1960 1-F 2-Br H OH 2-Nap 8-1961 1-F 2 -Br H OH Bz 8-1962 1-F 2-Br H OH -CF2 -Ph 8-1963 1-F 2-Br H OH-(CH2) -2-Nap 8-1964 1-F 2-Br H OH -CH2-3-Me-Ph 8-1965 1-F 2-Br H OH -CH2-4-Me-Ph 8-1966 1-F 2-Br H OH • -CH2-3-Br-Ph 8-1967 1-F 2-Br H OH -CH2-4-Br-Ph 8-1968 1-F 2-Br H OH -CHrS-Cl-Ph 8-1969 1-F 2-Br H OH -CHr ^ Cl-Ph -242- 200401770 8-1970 1-F 2-Br H OH 8-1971 1-F 2-Br H OH -CH2-4-F-Ph 8-1972 1-F 2-Br H OH -CH2-3- Tfm-? H 84973 1-F 2-Br H OH -CH2-4-Tfm-Ph 8-1974 1-F 2-Br H OH -CHr3-OMe-Ph 8-1975 1-F 2-Br H OH- CH2-4-OMe-Ph 8-1976 1-F 2-Br H OH -CH2-253-diF-Ph 8-1977 1-F 2-Br H OH -CH2-2? 4-diF-Ph 8-1978 1-F 2-Br H OH • CH2-2,5-diF-Ph 8-1979 1-F 2-Br H OH -CH2-256-diF-Ph 8-1980 1-F 2-Br H OH -CH2 -354-diF-Ph 8-1981 1-F 2-Br H OH -CH2-3? 5-diF-Ph 8-1982 1-F 2-Br H OH -CH2-3? 4-diCl-Ph 8- 1983 1-F 2-Br H OH -CH2-355-diCl-Ph 8-1984 1-F 2-Br H OH -CH2-3-Cl-4-F-Ph 8-1985 1-F 2-Br H OH -CH2-3-Me-4-Cl-Ph 8-1986 1-F 2-Br H OH -CH2-354-Mtdo-Ph 8-1987 1-F 2-Br H OH -CH2-354-diMe-Ph 8-1988 1-F 2-Br H OH -CH2-3 , 5-diMe-Ph 8-1989 2-F 3-C1 H OH Ph 8-1990 2-F 3-C1 H OH 1-Nap 8-1991 2-F 3-C1 H OH 2-Nap 8-1992 2 -F 3-C1 H OH Bz 8-1993 2-F 3-C1 H OH -CF2 -Ph 8-1994 2-F 3-C1 H OH-(CH2) -2-Nap 8-1995 2-F 3- C1 H OH -CH2-3-Me-Ph 8-1996 2-F 3-C1 H OH -CH2-4-Me-Ph 8-1997 2-F 3-C1 H OH -CH2-3-Br-Ph 8 -1998 2-F 3-C1 H OH -CH2-4-Br-Ph 8-1999 2-F 3-C1 H OH -CH2-3-Cl-Ph 8-2000 2-F 3-C1 H OH -CH2 -4-Cl-Ph 8-2001 2-F 3-C1 H OH -CH2-3-F-Ph 8-2002 2-F 3-C1 H OH -CH2-4-F-Ph 8-2003 2-F 3-C1 H OH -CH2-3-Tfm-Ph 8-2004 2-F 3-C1 H OH -CH2-4-Tfm-Ph 8-2005 2-F 3-C1 H OH -CH2-3-OMe- Ph 8-2006 '2-F 3-C1 H OH • CHr4-〇Me-Ph 243-200401770 8-2007 2-F 3-C1 H OH ^ CH2-253-diF-Ph 8-2008 2-F 3- C1 H OH -CH2-2? 4-diF-Ph 8-2009 2-F 3-C1 H OH • CH2-2,5-diF-Ph 8-2010 2-F 3-C1 H OH -CH2-256- diF-Ph 8-2011 2-F 3-C1 H OH -CH2-354-diF-Ph 8-2012 2-F 3-C1 H OH -CH2-355-diF-Ph 8-2013 2-F 3-C1 H OH -CHr3,4-diCl-Ph 8-2014 2 -F 3-C1 H OH -CH2-355-diCl-Ph 8-2015 2-F 3-C1 H OH -CH2-3-Cl-4-F-Ph 8-2016 2-F 3-C1 H OH- CH2-3-Me-4-Cl-Ph 8-2017 2-F 3-C1 H OH -CH2-354-Mtdo-Ph 8-2018 2-F 3-C1 H OH -CH2-3,4-diMe- Ph 8-2019 2-F 3-C1 H OH -CH2-3,5-diMe-Ph 8-2020 2-F 3-Me H OH Ph 8-2021 2-F 3-Me 'H OH 1-Nap 8 -2022 2-F 3-Me H OH 2-Nap 8-2023 2-F 3-Me H OH Bz 8-2024 2-F 3-Me H OH -CF2 -Ph 8-2025 2-F 3-Me H OH-(CH2) -2-Nap 8-2026 2-F 3-Me H OH -CH2-3-Me-Ph 8-2027 2-F 3-Me H OH -CH2-4-Me-Ph 8-2028 2-F 3-Me H OH -CH2-3-Br-Ph 8-2029 2-F 3-Me H OH -CH2-4-Br-Ph 8-2030 2-F 3-Me H OH -CH2-3 -Cl-Ph 8-2031 2-F 3-Me H OH -CH2-4-Cl-Ph 8-2032 2-F 3-Me H OH -CH2-3-F-Ph 8-2033 2-F 3- Me H OH -CH2-4-F-Ph 8-2034 2-F 3-Me H OH -CH2-3-Tfm-Ph 8-2035 2-F 3-Me. H OH -CH2-4-Tfm-Ph 8-2036 2-F 3-Me H OH -CHr3-〇Me-Ph 8-2037 2-F 3-Me H OH -CH2-4-OMe-Ph 8-2038 2-F 3-Me H OH -CH2 -253-diF-Ph 8-2039 2-F 3-Me H OH -CH2-234-diF-Ph 8-2040 2-F 3-Me H OH -CH2-2? 5 > diF-Ph 8-2041 2 -F 3-Me H OH -CH2-236-diF-Ph 8-2042 2-F 3-Me HO H -CH2-3? 4-diF-Ph 8-2043 2-F 3-Me H OH -CH2-355-diF-Ph 244- 200401770 8-2044 2-F 3-Me H OH -CHr3,4-diCl -Ph 8-2045 2-F 3-Me H OH -CH2-3? 5-diCl-Ph 8-2046 2 «F 3 ^ Me H OH -CH2-3-Cl-4-F-Ph 8-2047 2 -F 3-Me H OH -CH2-3-Me-4-Cl-Ph 8-2048 2-F 3-Me H OH • CHr3,4-MtdoPh 8-2049 2-F 3-Me H OH -CHr3, 4-diMe-Ph 8-2050 2-F 3-Me H OH -CH2-355-diMe-Ph 8-2051 1-Me 2-FH OH Ph 8-2052 1-Me. 2-FH OH 1-Nap 8 -2053 1-Me 2-FH OH 2-Nap 8-2054 1-Me 2-FH OH Bz 8-2055 1-Me 2-FH OH -CF2 -Ph 8-2056 1-Me 2-F. H OH- (CH2) -2-Nap 8-2057 1-Me 2-FH OH -CH2-3-Me-Ph 8-2058 1-Me 2-FH OH -CH2-4-Me-Ph 8-2059 1-Me 2 -FH OH -CH2-3-Br-Ph 8-2060 1-Me 2-FH OH -CH2-4-Br-Ph 8-2061 l ~ Me 2-FH OH -CH2-3-Cl-Ph 8-2062 1-Me 2-FH OH -CH2-4-Cl-Ph 8-2063 1-Me 2-FH OH -CH2-3-F-Ph 8-2064 1-Me. 2-FH OH -CH2-4-F -Ph 8-2065 1-Me 2-FH OH -CH2-3-Tfm-Ph 8-2066 1-Me 2-FH OH -CH2-4-Tfm-Ph 8-2067 • 1-Me 2-FH OH- CH2-3-OMe-Ph 8-2068 1-Me 2-F. H OH -CH2-4-OMe-Ph 8-2069 1-Me 2-FH OH -CH2-2,3-diF-Ph 8-2070 1-Me 2 -FH OH -CH2-2,4-diF-Ph 8-2071 1-Me 2-FH OH -CH2-2,5-diF-Ph 8-2072 1-Me 2-FH OH -CH2-2,6- diF-Ph 8-2073 1-Me 2-FH OH -CHr3,4-diF-Ph 8-2074 1-Me 2 孑 H OH -CH2-3,5-diF-Ph 8-2075 1-Me 2-FH OH -CH2-354-diCl-Ph 8-2076 1-Me 2-FH OH -CH2-355-diCl-Ph 8-2077 1-Me 2-FH OH -CH2-3-Cl-4-F-Ph 8 -2078 1-Me 2-FH OH -CH2-3-Me-4-Cl-Ph 8-2079 1-Me 2-FH OH -CHr3,4-Mtdo-Ph 8-2080 1-Me 2-FH OH CHr3 , 4-diMe-Ph -245-200401770 8-2081 1-Me 2-FH OH -CHr3? 5-diMe-Ph 8-2082 2-Me 3-FH OH Ph 8-2083 2-Me 3-FH OH 1 -Nap 8-2084 2-Me 3-FH OH 2-Nap 8-2085 2-Me 3-FH OH Bz 8-2086 2-Me 3-FH OH -CF2 -Ph 8-2087 2-Me 3-FH OH -(CH2) -2-Nap 8-2088 2-Me 3-FH OH -CH2-3-Me-Ph 8-2089 2-Me 3-FH OH -CH2-4-Me-Ph 8-2090 2-Me 3-FH OH -CH2-3-Br-Ph 8-2091 2-Me 3-FH OH -CH2-4-Br-Ph 8-2092 2-Me 3-FH OH -CHr3-Cl-Ph 8-2093 2 -Me 3-FH OH -CE ^ -Cl-Ph 8-2094 2-Me 3-FH OH -CH2-3-F-Ph 8-2095 2-Me 3-FH OH -CH2-4-F-Ph 8 -2096 2-Me 3-FH OH -CH2-3-Tfm-Ph 8-2097 2-Me 3-FH OH -CH2-4-Tfm-Ph 8-2098 2-Me 3-F H OH -CH2-3-OMe-Ph 8-2099 2-Me 3-FH OH -CH2-4-OMe-Ph 8-2100 2-Me 3-FH OH -CH2-2? 3-diF-Ph 8- 2101 2-Me 3-FH .OH -CH2-254-diF-Ph 8-2102 2-Me 3-FH OH -CHr2,5-diF-Ph 8-2103 2-Me 3-FH OH -CH2-2, 6-diF-Ph 8-2104 2-Me 3-FH OH -CH2-3,4-diF-Ph 8-2105 * 2-Me 3-FH OH -CH2-3? 5-diF-Ph 8-2106 2 -Me 3-FH OH -CH2-354-diCl-Ph 8-2107 2-Me '3-F. H OH -CH2-335-diCl-Ph 8-2108 2-Me 3-FH OH -CH2-3- CM-F-Ph 8-2109 2-Me 3-FH OH -CH2-3-Me-4-Cl-Ph 8-2110 2-Me 3-FH OH -CHr3,4-Mtdo-Ph 8-2111 2- Me 3-FH OH -CHr3,4-diMe-Ph 8-2112 2-Me 3-FH OH -CH2-3? 5-diMe-Ph 8-2113 1-C1 2-FH OH Ph 8-2114 1-C1 2-FH OH · 1-Nap 8-2115 1-C1 2-FH OH 2-Nap 8-2116 1-C1 2-FH OH Bz 8-2117 1-C1 2-FH OH -CF2 -Ph -246- 200401770 8-2118 1-C1 2-FH OH-(CH2) -2-Nap 8-2119 1-C1 2-FH OH -CH2-3-Me-Ph 8-2120 1-C1 2-FH OH -CH2-4 -Me-Ph 8-2121 1-C1 2-FH OH -CH2-3-Br-Ph 8-2122 1-C1 2-FH OH -CH2-4-Br-Ph 8-2123 1-C1 2-FH OH -CH2-3-Cl-Ph 8-2124 1-C1 2-FH OH -CHr4-cm 8-2125 1-C1 2-FH OH -CH2-3-F-Ph 8- 2126 1-C1 2-FH OH -CH2-4-F-Ph 8-2127 1-C1 2-FH OH -CHr3-Tfm-Ph 8-2128 1-C1 2-FH OH -CH2-4-Tfm-Ph 8-2129 1-C1 2-FH OH -CH2-3-OMe-Ph 8-2130 1-C1 2-FH OH -CH2-4-OMe-Ph 8-2131 1-C1 2-FH OH -CH2-2 ? 3-diF-Ph 8-2132 1-C1 2-FH OH -CH2-2,4-diF-Ph 8-2133 1-C1 2-FH OH -CH2-2? 5-diF-Ph 8-2134 1 -C1 2-FH OH -CH2-2,6-diF-Ph 8-2135 1-C1 2-FH OH -CH2-334-diF-Ph 8-2136 1-Cl 2-FH OH -CH2-355-diF -Ph 8-2137 1-C1 2-FH OH -CH2-3,4-diCl-Ph 8-2138 1-C1 2-FH OH -CH2-355-diCl-Ph 8-2139 1-C1 2-FH OH -CH2-3-Cl-4-F-Ph 8-2140 1-C1 2-EH OH -CH2-3-Me-4-Cl-Ph 8-2141 1-C1 2-FH OH -CH2-334-Mtdo -Ph 8-2142 1-C1 2-FH OH -CH2-334-diMe-Ph 8-2143 1-C1, 2-FH OH -CH2-3? 5-diMe-Ph 8-2144 1-Tfm 2-C1 H OH Ph 8-2145 1-Tfm 2-C1 H OH 1-Nap 8-2146 1-Tfm 2-C1 H OH 2-Nap 8-2147 1-Tfm 2-C1 H OH Bz 8-2148 1-Tfm 2 -C1 H OH -CF2-Ph '8-2149 1-Tfm 2-C1 H OH-(CH2) -2-Nap 8-2150 1-Tfm * 2-C1 H OH -CH2-3-Me-Ph 8- 2151 1-Tfm 2-C1 H OH -CH2-4-Me-Ph 8-2152 1-Tfm 2-C1 H OH -CH2-3-Br-Ph 8-2153 1-Tfm 2-C1 H OH -CH2-4-Br-Ph 8-2154 1-Tfm 2-Cl H OH -CHACl-Ph 247 200401770 8-2155 1-Tfm 2-C1 H OH -CH2-4-Cl-Ph 8-2156 1- Tfm 2-C1 H OH -CH2-3-F-Ph 8-2157 l »Tfm 2-C1 H OH -CH2-4-F-Ph 8-2158 1-Tfm 2-C1 H OH -CH2-3-Tfm -Ph 8-2159 1-Tfm 2-C1 H OH -CH2-4-Tfm-Ph 8-2160 1-Tfm 2-C1 H OH -CH2-3-〇Me-Ph 8-2161 1-Tfm 2-C1 H OH -CH2-4-OMe-Ph 8-2162 1-Tfm 2-C1 H OH -CH2-233-diF-Ph 8-2163 1-Tfm 2-C1 H OH -CH2-2,4-diF-Ph 8-2164 1-Tfm 2-C1 H OH -CH2-2? 5-diF-Ph 8-2165 1-Tfm 2-C1 H OH -CH2-2,6-diF-Ph 8-2166 1-Tfm 2- C1 H OH -CH2-354-diF-Ph 8-2167 1-Tfm 2-C1 H OH -CH2-3,5: diF-Ph 8-2168 1-Tfm 2-C1 H OH-(: Η2-3, 4 · (ϋα-Ρ1ι 8-2169 1-Tfm 2-C1 H OH -CH2-355-diCl-Ph 8-2170 1-Tfm 2-Cl H OH -CH2-3-Cl-4-F-Ph 8- 2171 1-Tfm 2-C1 H OH -CHs-S-Me ^ -Cl-Ph 8-2172 1-Tfm 2-C1 H OH -CH2-3? 4-Mtdo-Ph 8-2173 1-Tfm 2-C1 H OH -CH2-3,4-diMe-Ph 8-2174 1-Tfm 2-C1 H OH -CH2-355-diMe-Ph 8-2175 1-OMe 2-OMe 3-OMe OH Ph 8-2176 1- OMe 2-OMe 3-OMe OH 1-Nap 8-21T7 1-OMe 2-OMe 3-OMe OH 2-Nap, 8-2178 1-OMe 2-OMe 3- OMe OH Bz .8-2179 1-OMe 2-OMe 3-OMe OH -CF2 -Ph 8-2180 1-OMe 2-OMe 3-OMe OH-(CH2) -2-Nap 8-2181 1-OMe 2- OMe 3-OMe OH -CH2-3-Me-Ph 8-2182 1-OMe 2-OMe 3-OMe OH -CH2-4-Me-Ph 8-2183 1-OMe 2-OMe 3-OMe OH -CH2- 3-Br-Ph 8-2184 1-OMe 2-OMe 3-OMe OH -CH2-4-Br-Ph 8-2185 1-OMe 2-OMe 3-OMe OH -CH2-3-Cl-Ph 8-2186 1-OMe 2-OMe 3-OMe OH -CH2-4-Cl-Ph 8-2187 1-OMe 2-OMe 3-OMe OH -CH2-3-F-Ph 8-2188 1-OMe 2-OMe 3- OMe OH -CH2-4-F-Ph 8-2189 1-OMe 2-OMe 3-OMe OH -CH2〇-Tfm-Ph 8-2190 1-OMe 2-OMe 3-OMe OH -CH2-4-Tfm- Ph 8-2191 1-OMe 2 > OMe 3-OMe OH -CHr3-〇Me-Ph -248- 200401770 8-2192 1-OMe 2-OMe 3-OMe OH -CH2-4-OMe-Ph 8-2193 1 -OMe 2-OMe 3-OMe OH -CHr2,3-diF-Ph 8-2194 1-OMe 2-OMe 3-OMe OH -CHr2,4-diF-Ph 8-2195 1-OMe 2-OMe 3-OMe OH -CH2-255-diF-Ph 8-2196 1-OMe 2-OMe 3-OMe OH -CH2-2? 6-diF-Ph 8-2197 1-OMe 2-OMe 3-OMe OH -CH2-3? 4-diF-Ph 8-2198 1-OMe 2-OMe 3-OMe OH -CH2-3? 5-diF-Ph 8-2199 1-OMe 2-OMe 3-OMe OH -CH2-3? 4-diCl- Ph 8-2200 1-OMe 2-OMe 3-OMe OH -CH2-335-diCl-Ph 8-2201 1-OMe 2-OMe 3-OMe OH -CH2-3-Cl-4-F-Ph 8-2202 1-OMe 2-OMe 3-OMe OH -CH2-3-Me-4-Cl-Ph 8-2203 1-OMe 2-OMe 3-OMe OH -CH2-3? 4-Mtdo-Ph 8-2204 1-OMe 2-OMe 3-OMe OH -CH2-3,4-diMe-Ph 8-2205 1-OMe 2-OMe 3-OMe OH -CHr3,5-diMe-Ph 8-2206 1-C1 2-OMe 3-OMe OH Ph 8-2207 1-C1 2-OMe 3-OMe OH 1-Nap 8-2208 1-Ce 2-OMe 3-OMe OH 2-Nap 8-2209 1-C1 2-OMe 3-OMe OH Bz 8-2210 1-C1 2-OMe 3-OMe OH -CF2 -Ph 8-2211 1-Ce 2-OMe 3-OMe OH-( CH2) -2-Nap 8-2212 1-C1 2-OMe 3-OMe OH -CH2-3-Me-Ph 8-2213 1-C1 2-OMe 3-OMe OH -CH2-4-Me-Ph 8- 2214 1-C1 2-OMe 3-OMe OH -CH2-3-Br-Ph 8-2215 1-C1 2-OMe 3-OMe OH -CH2-4-Br-Ph 8-2216. 1-C1 2-OMe 3-OMe OH -CH2-3-Cl-Ph 8-2217 1-C1 2-OMe 3-OMe OH -CH2-4-Cl-Ph 8-2218 1-C1 2-OMe 3-OMe OH -CH2-3 -F-Ph 8-2219 1-C1 2-OMe 3-OMe OH -CH2-4-F-Ph 8-2220 1-C1 2-OMe 3-OMe OH -CH2-3-Tfm-Ph 8-2221 1 -C1 2-OMe 3-OMe OH -CH2-4-Tfm-Ph 8-2222 1-C1 2-OMe 3-OMe OH -CH2-3-OMe-Ph 8-2223 1-C1 2-OMe 3-OMe OH -CH2-4-OMe-Ph 8-2224 1-C1 2-OMe 3-OMe OH -CH2-2? 3-diF-Ph 8-2225 1-C1 2-OMe 3-OMe OH -CH2-254- di F-Ph 8-2226 1-C1 2-OMe 3-OMe OH -CH2-255-diF > Ph 8-2227 1 > C1 2-OMe 3-OMe OH -CHr2,6-diF-Ph 8-2228 1- C1 2-OMe 3-OMe OH-CHr3,4-diF-Ph -249-200401770

8-2229 l-Cl 2-OMe 3-OMe OH 8-2230 1-C1 2-OMe 3-OMe OH 8-2231 l ^ Cl 2-OMe 3-OMe OH 8-2232 1-C1 2-OMe 3- OMe OH 8-2233 1-C1 2-OMe 3-OMe OH 8-2234 1-C1 2-OMe 3-OMe OH 8-2235 1-C1 2-OMe 3-OMe OH 8-2236 1-C1 2-OMe 3-OMe OH 8-2237 1-C1 2-C1 3-C1 OH 8-2238 1-C1 2-C1 3-C1 OH 8-2239 1-C1 2-C1 3-C1 OH 8-2240 1-C1 2 -C1 3-C1 OH 8-2241 1-C1 2-C1 3-C1 OH 8-2242 1-C1 2-C1 3-C1 OH 8-2243 1-C1 2-C1 3-C1 OH 8-2244 1- C1 2-C1 3-C1 OH 8-2245 1-C1 2-C1 3-C1 OH 8-2246 1-C1 2-C1 3-C1 OH 8-2247 1-C1 2-C1 3-C1 OH 8-2248 1-C1 2-C1 3-C1 OH 8-2249 1-C1 2-C1 3-C1 OH 8-2250 1-C1 2-C1 3-C1 OH 8-2251 1-C1 2-Cl 3-C1 OH 8 -2252 1-C1 2-C1 3-C1 OH 8-2253 1-C1 2-C1 3-CI OH 8-2254 1-Cl 2-C1 3-C1 OH 8-2255 1-C1 2-C1 3-C1 OH 8-2256 1-C1 2-C1 3-C1 OH 8-2257 1-C1 2-C1 3-C1 OH 8-2258 1-C1 2-C1 3-C1 OH 8-2259 1-C1 2-C1 3 -C1 OH 8-2260 1-C1 2-C1 3-C1 OH 8-2261 1-C1 2-C1 3-C1 OH 8-2262 1-C1 2-C1 3-C1 OH 8-2263 1-C1 2- C1 3-C1 OH 8-2264 1-C1 2-C1 3-C1 OH 8-2265 1-C1 2-C1 3-C1 OH -CHr3,5-diF-Ph -CH2 -3,4-diCl-Ph -CH2-3-Cl-4-F-Ph -CH2 Me-4-Cl-Ph -CH2-334-Mtdo-Ph -CH2-3? 4-diMe-Ph-CHr3 , 5-diMe-Ph Ph 1- Nap 2- Nap Bz -CF2 -Ph-(CH2) -2 > Nap -CH2-3-Me-Ph -CH2-4-Me-Ph -CHr3-Br-Ph-CHr4 -Br-Ph -CH2-3-Cl-Ph -CH2-4-Cl-Ph -CH2-3-F-Ph -CH2-4-F-Ph -CH2-3-Tfm-Ph -CH2-4-Tfm -Ph -CH2-3-OMe-Ph -CH2-4-OMe-Ph -CH2-253-diF-Ph -CH2-254-diF-Ph -CH2-255-diF-Ph -CH2-236-diF-Ph -CH2-354-diF-Ph -CH2-355-diF-Ph -CH2-3,4mh -CH2-355-diCl-Ph -CH2-3-Cl-4-F-Ph -CH2-3-Me-4 -Cl-Ph > CH2-354-Mtdo > Ph -250- 200401770 8-2266 1-C1 2-C1 3-C1 OH > CH2-354-diMe-Ph 8-2267 1-C1 2-C1 3- C1 OH -CH2-3? 5-diMe-Ph 8-2268 1-Me 2-OMe 3-Me OH Ph 8-2269 1-Me 2-OMe 3-Me OH 1-Nap 8-2270 1-Me 2- OMe 3-Me OH 2-Nap 8-2271 l ^ Me 2-OMe 3-Me OH Bz 8-2272 1-Me 2-OMe 3-Me OH -CF2 -Ph 8-2273 1-Me 2-OMe 3- Me OH-(CH2) -2-Nap 8-2274 1-Me 2-OMe 3-Me OH -CH2—3-Me-Ph 8-2275 1-Me 2-OMe 3-Me OH -CH2-4-Me -Ph 8-2276 1-Me 2-OMe 3-Me OH -CH2-3-Br-Ph 8-2277 1-Me 2-OMe 3-Me OH -CH2-4-Br-Ph 8-2278 1-Me 2-OMe 3-Me OH -CH2-3-Cl-Ph 8-22 79 1-Me 2-OMe 3-Me OH -CH2-4-Cl-Ph 8-2280 1-Me 2-OMe 3-Me OH -CH2-3-F-Ph 8-2281 1-Me 2-OMe 3 -Me OH -CH2-4-F-Ph 8-2282 1-Me 2-OMe 3-Me OH -CH2-3-Tfm-Ph 8-2283 1-Me 2-OMe 3-Me OH -CH2-4- Tfm-Ph 8-2284 1-Me 2-OMe 3-Me OH -CH2-3-OMe-Ph 8-2285 1-Me 2-OMe 3-Me OH -CH2-4-OMe-Ph 8-2286 1- Me 2-OMe 3-Me OH -CH2-2? 3-diF-Ph 8-2287 1-Me 2-OMe 3-Me OH -CH2-2,4-diF-Ph 8-2288 1-Me 2-OMe 3-Me OH -CH2-2? 5-diF-Ph 8-2289 1-Me 2-OMe 3-Me OH -CH2-256-diF-Ph 8-2290 1-Me 2-OMe 3-Me OH /- CH2-3,4-diF-Ph 8-2291 1-Me 2-OMe 3-Me OH -CH2-3? 5-diF-Ph 8-2292 1-Me 2-OMe 3-Me OH -CH2-3? 4-diCl-Ph 8-2293 1-Me 2-OMe 3-Me OH -CH2-335-diCl-Ph 8-2294 1-Me 2-OMe 3-Me OH -CH2-3-Cl-4-F- Ph 8-2295 1-Me 2-OMe 3-Me OH -CH2-3-Me-4-Cl-Ph 8-2296 1-Me 2-OMe 3-Me OH -CH2-354-Mtdo-Ph 8-2297 1-Me 2-OMe 3-Me OH -CH2-354-diMe-Ph 8-2298 1-Me 2-OMe 3-Me OH -CH2-3? 5-diMe-Ph 8-2299 HHH OH -CH2-2 -BzO-Ph 8-2300 2-〇H 3-C1 H OH Bz 8-2301 2-Me 3-OH H OH Bz 8-2302 1-C1 2-OMe .3-C1 OH Bz -251-200401770 8- 2303 1-Br 2-C1 H OH Bz 8-2304 2-C1 3-Br H OH Bz 8-2305 2-OH 3-OMe H OH Bz

-252- 200401770 Among the above-exemplified compounds, the preferred compounds are the compounds of the following exemplary compound numbers: Bu 2,1- 4,1 · 8,1- 1 0,1-1 3,1-1 4,1-1 7, 1-1 8 5 1-22, 1-26, 1 -3 2, 1-45, 1-48, Bu 54, 1 -70, 1-76, 1-92, 1-98, 1- 114 , 1-120, 1-136, Bu 142, 1-180, 1-186, 1-202, 1-208, 2-2, 2- 3, 2-4, 2-5, 2-6, 2- 9, 2-10, 2-29, 2-30, 2-31, 2-32, 2-61, 2-63, 2-96, 2-101, 2- 1 02, 2- 1 8 8, 2 -1 9 3, 2-1 945 2-2 80, 2-2 8 5, 2- 286, 2-372, 2-377, 2-378, 2-464, 2-469, 2-470, 2- 556, 2-561, 2-562, 2-740, 2-745, 2-746, 2-832, 2-837, 2-838, 3-4,

3- 7, 3-8, 3-9, 3-10, 3-11, 3-13, 3-15, 3-16, 3-17, 3-26, 3-27, 3-28, 3- 29, 3-30, 3-31, 3-32, 3-33, 3-34, 3-35, 3-36, 3-37, 3-38, 3-39, 3-40, 3-41, 3-42, 3-43, 3-44, 3-45, 3-46, 3-48, 3-49, 3-52, 3-55, 3-58, 3-61, 3-64, 3- 71, 3-74, 3-75, 3-76, 3-77, 3-79, 3-81, 3-82, 3-88, 3-89, 3-93, 3-96, 3-97, 3-110,

3-113, 3-115, 3-118, 3-119,3-121, 3-125, 3-126, 3-127, 3-129, 3-132, 3-133, 3-136, 3- 140, 3-142, 3-144, 3-146, 3-157, 3-160, 3-163, 3-164, 3-167, 3-169, 3-171, 3-173, 3-175, 3 -177, 3-188, 3-191, 3-194, 3-195, 3-198, 3-202, 3-204, 3-206, 3-208, 3-219, 3-222, 3- 225, 3-226, 3-229, 3-233, 3-235, 3-237, 3-239, 3-250, 3-253, 3-256, 3-257, 3-260, 3-264, 3-266, 3-268, 3-270, 3-281, 3-284, 3-287, 3-288, 3-291, 3-295, 3-297, 3-299, 3-301, 3- 312, 3-346, 3-349, 3-350, 3-353, 3-357, 3-359, 3-361, 3-363, 3-374, 3-377, 3-380, 3-381, 3-384, 3-388, 3-390, 3-392, 3-394, 3-405, 3-408, 3-411, 3-412, 3-415, 3-419, 3-421, 3- 423, 3-425, 3-436, 3-439, 3-442, 3-443, 3- -25 3- 200401770 446, 3-450, 3-452, 3-454, 3-456, 3-467 , 3-470, 3-473, 3-474, 3-477, 3-481, 3-483, 3-485, 3-487, 3-498, 3-501, 3-504, 3-505, 3 -508, 3-512, 3-514, 3-516, 3-518, 3-529 3-532, 3-535, 3-536, 3-539, 3-543, 3-545, 3-547, 3-549, 3-560, 3-563, 3-566, 3-567, 3- 570, 3-574, 3-576, 3-578, 3-580, 3-591, 3-594, 3-597, 3-598, 3-601, 3-605, 3-607, 3-609, 3-611, 3-622, 3-625, 3-628, 3-629, 3-632, 3-636, 3-638, 3-640, 3-642, 3-653, 3-656, 3- 659, 3-660, 3-663, 3-667, 3-669, 3-671, 3-673, 3-684, 3-687, 3-690, 3-691, 3-694, 3-698, 3-700, 3-702, 3-704, 3-715, 3-718, 3-721, 3-722, 3-725, 3-729, 3-731, 3-733,3-735, 3- 746, 3-749, 3-752, 3-75 3 ,, 3-756, 3 -760, 3-762, 3-764, 3-766, 3-777, 3-783, 3-814, 3- 845, 3-876, 3-907, 3-938, 3-997, 3-1000, 3-1001, 3-1004, 3-1008, 3-1010, 3-1012, 3-1014, 3-1025, 3-1028, 3-1031, 3-1032, 3-1035, 3-1039, 3-1041, 3-1043, 3-1045, 3-1056, 3-1059, 3-1062, 3-1063, 3- 1066, 3- 1070, 3-1072, 3-1074, 3-1076, 3-1087, 3-1093, 3-1121, 3- 1124, 3-1125, 3-1128, 3-1132, 3-1134, 3-1136, 3-1138, 3- 1149, 3-1152, 3 -1155, 3-1156, 3-1158, 3-1159, 3-1160, 3- 1161, 3-1162, 3-1163, 3-1164, 3-1165, 3-1166, 3-1167, 3- 1168 , 3-1169, 3-1180, 3-1183, 3-1186, 3-1 1 8 7, 3-1 1 9 0, 3-1194, 3-1196, 3-1198, 3-1200, 3-1211 , 3-1214, 3-1217, 3- 1218, 3-1221, 3-1225, 3-1227, 3-1229, 3-1231, 3-1242, 3- 1245, 3-1248, 3-1249, 3 -1252, 3-1256, 3-1258, 3-1260, 3- 1262, 3-1273, 3-1276, 3-1279, 3-1280, 3-1283, 3-1287, 3- -254- 200401770 1 2 8 9, 3-1291, 3-1293, 3-1 13 14, 3-1318, 3-1320, 3-1 1341, 3-1342, 3-1345, 3-1 1 3 6 6, 3-1369 , 3-1372, 3-1 1 3 8 4, 3-1386, 3-1397, 3-1 14 11, 3-1413, 3-1415, 3-1 1 43 5, 3-1438, 3-1442, 3-1 1 462, 3-1465, 3-1466, 3-1 1 47 9, 3-1490, 3-1493, 3-1 1 5 06, 3-1508, 3-1510, 3-1 1531, 3 -1535, 3-1 5 3 7, 3-1 1 5 5 8, 3-1559, 3-1562, 3-1 1 5 8 3, 3-1586, 3-1589, 3-1 1601, 3-1603 , 3-1614, 3-1 1 628, 3-1630, 3-1632, 3-1 1 65 2, 3-1655, 3-1659, 3-1 1679, 3-1682, 3-1683, 3-1 1 696, 3-1707, 3-1 710, 3-1 1 723, 3-1725, 3-1727, 3-1 1 748, 3-1752, 3-1754, 3-1 1 7 7 5, 3-1776, 3-1779, 3-1 1 8 00, 3-1803, 3-1806, 3-1 18 18, 3-1820, 3-1831, 3-1 1 8 4 5, 3-1847, 3-1849, 3-1, 3-1307, 3 -1310, 3-1311, 3-, 3-1324, 3-1335, 3-1338, 3-, 3-1351, 3-1353, 3-1355, 3-, 3-1376, 3-1380, 3- 1382, 3-, 3-1403, 3-1404, 3-1407, 3-, 3-1428, 3-1431, 3-1434, 3-, 3-1446, 3-1448, 3-1459, 3-, 3-1473, 3-1475, 3-1477, 3-, 3-1497, 3-1500, 3-1504, 3-, 3-1524, 3-1527, 3-1528, 3-, 3-1541, 3 -1552, 3-1555, 3-, 3-1568, 3-1570, 3-1572, 3-, 3-1593, 3-1597, 3-1599, 3-, 3-1620, 3-1621, 3- 1624, 3-, 3-1645, 3-1648, 3-1651, 3-, 3-1663, 3-1665, 3-1676, 3-, 3-1690, 3-1692, 3-1694, 3-, 3-1714, 3-1717, 3-1721, 3-, 3-1741, 3-1744, 3-1745, 3-, 3-1758, 3-1769, 3-1772, 3-, 3-1785, 3 -1787, 3-1789, 3-, 3-1810, 3-1814, 3-1816, 3-, 3-1837, 3-1838, 3-1841, 3-, 3-1862, 3-1865, 3- 1868, 3- -255- 200401770 1 8 6 9, 3-1 8 7 2, 3-1876, 3-1878, 3-1880, 3-1882, 3-1893, 3- 1 8 96, 3-1 8 9 9, 3-1900, 3-1903, 3-1907, 3-1909, 3-1911, 3- 19 13, 3-1924, 3-1927, 3-1930, 3-1931, 3-1934, 3-1938, 3- 1 940, 3-1942, 3-1944, 3-1955, 3-1958, 3-1961, 3-1962, 3- 1 9 65, 3-1969, 3-1971, 3-1973, 3-1975, 3-1986, 3-1989, 3- 1 99 2, 3-1993, 3-1996, 3-2000, 3-2002, 3-2004, 3-2006, 3- 2017, 3-2020, 3-2023, 3-2024, 3-2027, 3-2031, 3-2033, 3- 2 03 5, 3-2037, 3-2048, 3-2051, 3-2054, 3-2055, 3-2058, 3- 2062, 3-2064, 3-2066, 3-2068, 3-2079, 3-2082, 3-2085, 3- 20 8 6, 3-2089, 3-2093, 3-2095, 3-2097, 3-2099, 3-2110, 3- 2113, 3-2116, 3-2117, 3-2120, 3-2124, 3-2126, 3-2128, 3- 2129, 3-2141, 3-2144, 3-2147, 3-2148, 3-2151, 3- 2155, 3- 2157, 3-2159, 3-2161, 3-2172, 3-2175, 3-2178, 3-2179, 3- 2182, 3-2186, 3-2188, 3-2190, 3-2192, 3-2203, 3-2206, 3- 2209, 3-2210, 3-2213, 3-2217, 3-2219, 3-2221, 3-2223, 3- 2234, 3-2237, 3-2240, 3- 2241, 3-2244, 3-2248, 3-22 50, 3- 2252, 3-2254, 3-2265, 3-2268, 3-2271, 3-2272, 3-2275, 3- 2279, 3-2281, 3-2283, 3-2285, 3-2296, 3-2300 to 3-2341, 4-1, 4-4, 4-8, 4-25, 4-31, 4-34, 4-37, 4-43, 4-110, 4-119, 4- 122, 4-126, 4-143, 4-149, 4-152, 4-155, 4-161, 4-227, 6-1, 6-4, 6-8, 6-25, 6-31, 6-34, 6-37, 6-43, 6-110, 6-119, 6-122, 6-126, 6- 143, 6-146, 6-149, 6-152, 6-155, 6- 161, 6-228, 7-1, 7-4, 7- 32, 7-35, 7-63, 7-66, 7-94, 7-97, 7-125, 7-128, 7-156, 7-159, 7-187, 7-190, 7-218, 7-221, 7-249, 7-252, 7-280, 7-283, 200401770 7- 311, 7-314, 7-342, 7 -345, 7-373, 7-376, 7-404, 7-407, 7-435, 7-438, 7-466, 7-469, 7-497, 7-500, 7-528, 7-531 , 7-577 to 7-581, 8-4, 8-7, 8-129, 8-132, 8-160, 8-163, 8-191, 8-194, 8 -222, 8 -22 5, 8-2 5 3, 8 -2 5 6, 8 -284, 8 -2 8 7, 8 -346, 8 -3 4 9, 8 -377, 8-380, 8-408, 8-411, 8- 439, 8-442, 8-470, 8-473, 8-501, 8-504, 8-532, 8-535, 8-563, 8-566, 8-594, 8-597, 8-625, 8-628, 8-656, 8'659, 8-687, 8-690, 8-718, 8-721, 8-749, 8-752, 8- 783, 8-814 ,: 8-845, 8- -876, 8-907, 8-938, 8-997, 8-1000, 8- 1 02 8, 8-1031, 8-1059, 8-1062, 8-1093, 8-1121, 8-1124, 8-1152, 8-1155, 8-1183, 8-1186, 8-1214, 8-1217, 8-1245, 8- 1 24 8, 8-1276, 8-1279, 8-1307, 8-1310, 8-1338, 8-1341, 8- 1 3 69, 8-1372, 8-1400, 8-1403, 8-1431, 8-1434, 8-1462, 8- 1 46 5, 8-1493, 8-1496, 8-1524, 8-1527, 8-1555, 8-1558, 8- 1 5 8 6, 8-1589, 8-1617, 8-1620, 8 -1648, 8-1651, 8-1679, 8- 1 6 8 2, 8-1710, 8 -1713, 8-1741, 8-1744, 8-1772, 8-1775, 8- 1 8 0 3, 8 -1806, 8-1834, 8-1837, 8-1865, 8-1868, 8-1896, 8- 1 8 99, 8-1927, 8-1930, 8-1958, 8-1961, 8-1989, 8 -1992, 8- 2 020, 8-2023, 8-2051, 8-2054, 8-2082, 8-2085, 8-2113, 8- 2 116, 8-2144, 8-2147, 8-2175, 8 -2178, 8-2206, 8-2209, 8- 22 3 7, 8-2240, 8-2268, 8-2271, and 8-2300 to 8-2305;

More preferred compounds are the compounds of the following exemplary compound numbers: 1-4, 1-10, 1-32, Bu 54, 1-76, 1 -9 8, 1-1 20, 1-142, 1-186, 1- 2 0 8, 2-4, 2-96, 2-188, 2-280, 2-372, 2-464, 2-556, 2-740, 2-832, 3-4, 3-7, 3- 11, 3-15, 3-27, 3-28, 3-30, 3-31, 3-33, 3-34, 3-35, 3-36, -257- 200401770 3-37, 3-39, 3-40, 3-45, 3-46, 3-79, 3-113, 3-115, 3-126, 3-127, 3-132, 3-136, 3-140, 3-146, 3- 163, 3-167, 3-169, 3-171,

3-173, 3-175, 3-177, 3-194, 3-198, 3-202, 3-208, 3-225, 3-229, 3-233, 3-239, 3-256, 3- 260, 3-264, 3-270, 3-349, 3-353, 3-357, 3-363, 3-380, 3-384, 3-388, 3-394, 3-411, 3-415, 3-419, 3-425, 3-442, 3-446, 3-450, 3-456, 3-473, 3-477, 3-481, 3-487, 3-504, 3-508, 3- 512, 3-518, 3-535, 3-539, 3-543, 3-549, 3-566, 3-570, 3-574, 3-580, 3-597, 3-601, 3-605, 3-611, 3-628, 3-632, 3-636, 3-642, 3-659,3-663, 3-667, 3-673, 3-690, 3-694, 3-698, 3- 704, 3: 721, 3-725, 3-729, 3-735, 3-752, 3-756, 3-760, 3-766, 3-814, 3-1000, 3-1004, 3-1008, 3-1014, 3-1031, 3-1035, 3-1039, 3-1045, 3-1062, 3-1066, 3-1070, 3-1076, 3-1093, 3-1124, 3-1155, 3- 1156, 3-1159, 3-1161, 3- 1163, 3-1165, 3-1169, 3-1186, 3-1190, 3-1194, 3-1200, 3- 1217, 3-1221, 3-1225, 3-1231, 3-1248, 3-1252, 3-1256, 3- 1262, 3-1279, 3-1283, 3-1287, 3-1293, 3-1310, 3-1314, 3-

1318, 3-1324, 3-1341, 3-1345, 3-1349, 3-1355, 3-1403, 3- 1407, 3-1411, 3-1417, 3-1434, 3-1438, 3-1442, 3-1448, 3- 1465, 3-1469, 3-1473, 3-1479, 3-1496, 3-1500, 3-1504, 3- 1510, 3-1527, 3-1531, 3-1535, 3- 1541, 3-1558, 3-1562, 3- 1566, 3-1572, 3-1589, 3-1593, 3-1597, 3-1603, 3-1620, 3- 1624, 3-1628, 3-1634, 3-1651, 3-1655, 3-1659, 3-1665, 3- 1682, 3-1686, 3-1690, 3-1696, 3-1713, 3-1717, 3-1721, 3- 1 7 27, 3-1 744, 3- 1 7 4 8, 3-1 7 5 2, 3-1 7 5 8, 3-1 7 7 5, 3-1 7 7 9, 3- -25 8- 200401770 1783, 3 -1789, 3-1806, 3-1810, 3-1814, 3-1820, 3-1837, 3- 1841, 3-1845, 3-1851, 3-1868, 3-1872, 3-1876, 3-1882 , 3- 1899, 3-1903, 3-1907, 3-1913, 3-1930, 3-1934, 3-1938, 3- 1944, 3-1961, 3-1965, 3-1969, 3-1975, 3 -1992, 3-1996, 3- 2000, 3-2006, 3-2023, 3-2027, 3-2031, 3-2037, 3-2054, 3- 2058, 3-2062, 3-2068, 3-2085 , 3-2089, 3-2093, 3-2099, 3- 211 6, 3-2120, 3-2124, 3-2129, 3-2147, 3-2151, 3-2155, 3- 2161, 3-2178, 3-2209, 3-2213, 3-2217, 3-2223, 3-2240, 3- 2244, 3-2248, 3-2254, 3-2271, 3-2275, 3-2279, 3-2285, 3- 2300 to 3-2341, 4-4, 4-25, 4- 31, 4-43, 4-122, 4-143, 4-149, 4-161, 6-4, 6-25, 6-31, 6-43, 6-122, 6-143, 6-149, 6-161, 7- 4, 7-35, 7-66, 7-97, 7-128, 7-159, 7-190, 7-221, 7-2 8 3, 7-314, 7-345, 7-376, 7-407, 7-438, 7-469, 7-500, 7-577 to 7-581, 8- 7, 8-132, 8-163, 8-194, 8-225, 8- 256, 8-287, 8-349, 8-380, 8-411, 8-442, 8-473, 8-504, 8-535, 8-566, 8-597, 8-628, 8-659, 8-690, 8-721, 8-752, 8-783, 8-814, 8-845, 8-876, 8-907, 8-938, 8- 1 000, 8-1031, 8-1062, 8 -1093, 8-1124, 8-1155, 8-1186, 8-1217, 8-1248, 8-1279, 8-1310, 8-1341, 8-1372, 8-1403, 8-1434, 8- 1465, 8-1496, 8-1527, 8-1558, 8-1589, 8- 1 62 0, 8-1651, 8-1682, 8-1713, 8-1744, 8-1775, 8-1806, 8- 1 8 3 7, 8-1868, 8-1899, 8-1930, 8-1961, 8-1992, 8-2023, 8- 20 5 4, 8-2085, 8-2116, 8-2147, 8-2178, 8-2209, 8-2240, 8- 2271 and 8-2300 to 8-2305; The best compound is the following Exempl. Comp. No. -259- 200401770 compound:

Exemp. Comp. No · ll〇: 2-trifluoromethyl-3- [4- [2,2,2-trifluoro_ι · yl-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone,

Exemp. Comp. No. 2-4: 2-cyclobutyl- 3- [4- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-7: 2-benzyl-3- [4- [2,2,2-trifluoro-1-meryl · 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No · 3-11: 2- [Difluoro (phenyl) methyl] -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No · 3-28: 2- (4-methylbenzyl) -3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3 Η) -oxazolinone,

Exemp. Comp. No. 3-34: 2- (4-chlorobenzyl) -3- [4- [2,2,2-trifluorosmall hydroxyl-1- (trifluoromethyl) ethyl] benzene Phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-35: 2- (2-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone,

Exemp · Comp. No. 3-36: 2- (3-fluorobenzyl) -3- [4- [2,2,2-trifluoro_1_hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3H) -quinazolinone,

Exemp. Comp · No. 3-37: 2- (4-fluorobenzyl) -3- [4- [2,2,2-trifluoro · ι_hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3Η) -quinazolinone,

Exemp. Comp. No. 3-39: 2- (3-trifluoromethylbenzyl) -3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-40: 2- (4-trifluoromethylbenzyl) -3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone, 200401770

Exemp. Comp · No. 3-46: 2- (4-methoxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp · Comp · No. 3-79: 2- (2,4-difluorobenzyl) -3- [4- [2,2,2_ trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. C om ρ · N 〇 3-1 1 3: 2-(3,4 -methylenedioxybenzyl) · 3-[4 _ [2,2,2-trifluoro-buhydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-132: 2-benzyl-5-methyl- 3- [4- [2,2,2_ trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-163: 2-benzyl-5-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3 Η) -quinazolinone,

Exemp. Comp. No. 3-167: 5-Chloro-2-(4-methylbenzyl) -3-[4- [2,2,2 -Diwin-1-meryl-1- (di Methyl) ethyl] phenyl] -4 (3H) -Mu-II-sitolinone,

Exemp. Comp. No. 3-169: 2- (4-Bromobenzyl) -5-chloro-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, Exemp. Comp. Νο. 3-171: 5-chloro-2- (4-chlorobenzyl) -3- [4 · [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone, Exemp. Comp. No. 3-173: 5 -Chloro-2- (4-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone, Exemp. Comp. No. 3-225: 2-benzyl-5-mercapto-3- 3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone,

Exemp. Comp. No. 3-349: 2-benzyl-6-methyl- 3- [4- [2,2,2-tri 200401770 fluoro-1-hydroxy-1- (trifluoromethyl) ethyl Phenyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-3 8 0: 2-benzyl-6 -chloro-3-[4-[2,2,2-trioxo-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-411: 2-benzyl-6-bromo · 3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl] benzene Group; | -4 (3Η) -quinazolinone,

Exemp. Comp. No. 3-442: 2-benzyl-6-meryl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone, '

Exemp. Comp. N 0.3-50 4: 2-benzyl-6 -methoxy-3-[4-[2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -oxazolinone, Exemp. Comp. No. 3-535: 2-benzyl-6-ethoxyamino-3- [4 · [2 , 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone, Exemp. Comp. No. 3-597: 2-benzene Methyl-7-chloro-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone ,

Exemp. Comp. No. 3-659: 2-benzyl-7-meryl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone,

Exemp. Comp · No · 3-690: 2-benzyl-7-trifluoromethyl-3-[4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-721: 2-benzyl-7-methoxy- 3- [4- [252,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3H) -quinazolinone, Exemp. Comp. No. 3-8 1 4 -1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone,

Exemp. Comp · No. 3-1000: 2-benzyl-5-dai-3- [4- [2,2,2-trifluoro ^ 1-hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3H) -quinazolinone 200401770

Exemp. Comp · No. 3-1031: 2-benzyl-6-fluoro-3- [4- [2,2,2-trifluoro_ 1-hydroxy-1- (trifluoromethyl) ethyl] Phenyl] -4 (3H) -_ azolinone,

Exemp. Comp. No. 3-1155: 2-benzyl-6,7-dimethoxy-3- [4- [2,2,2-difluoro-1-meryl-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Com. -l-hydroxy-bu (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp · Comp. No · 3-1161: 2- (4-bromobenzyl) -6,7-dimethoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) _quinazolinone,

Exemp. Comp. No. 3-1163: 2- (4-chlorobenzyl) -6,7-dimethoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-1165: 6,7 -dimethoxy- 2- (4-Gaphenylmethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp.No. 3-1217: 6,7-Methylenedioxy-2-benzyl-3- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp · N 〇 3-1 2 4 8: 6,7 -difluorene-2 · benzyl-3-[4-[2,2,2-trifluoro-buhydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, Exemp. Comp. No. 3-1 279: 6-methoxy-5 -chloro-2 -benzyl-3- [4_ [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazoline 200401770 ketone, E xe mp. Comp. No. 3-1 4 0 3: 5,6-dimethyl-2 -benzyl-3-[4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-1 465: 6 -chloro-5 -methyl-2-benzyl-3- [4- [2,2,2-trifluoro · hydroxyl-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-1496: 6-methoxy-5-methyl-2, benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No · 3-1558: 5,6-dichloro-2-benzyl-3 · [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3Η) -quinazolinone, Exemp. Comp. No. 3-1589: 5,7-dichloro-2-benzyl-3- [4- [2,2, 2-trifluoro-l-hydroxy-l · (trifluoromethyl) ethyl] phenyl] · 4 (3H) -quinazolinone, Exemp. Comp. No. 3-1 620: 6, 7 -di Methyl-2 -benzyl-3-[4- [2,2,2-Diwin-1-acyl-1- (di-trimethyl) ethyl] phenyl] -4 (3Η) -Π Quinazemone,

Exemp. Comp. No. 3 -1682: 7-methoxy-6-methyl-2-benzyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone,

Exemp. Comp. No. 3-1713: 7-methyl-6-chloro-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, -264- 200401770

ExempComp. No. 3- 1 744: 6,7-dichloro-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, EX emp. Comp. No. 3-1775: 7-methoxy-6-chloro-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-1806: 7-methyl-6-methoxy-2-benzyl 3 [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3Η) -quinazolinone,

Exemp. Comp. No. 3-1 8 37: 7-Chloro-6-methoxy-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy ·, 1- (Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 3-1 992: 7 -chloro-6 -fluoro-2 -benzyl-3-[4-[2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, Exemp · Comp. No. 3-2085: 7-fluoro-6-methyl-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] .- 4 (3H) -quinazolinone,

Exemp. Comp, No. 3-2209: 6,7-Dimethoxy-5-chloro-2-benzyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 4-122: 2-benzyl-3-[4- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] Benzo [g] quinazolin-4 (3H) -one,

Exemp. Comp. No. 7-159: 2-benzyl-3-[3-methyl-4-[2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone, 200401770

Ex emp. Comp. No. 7-2 2 1: 2-benzyl-3-[3 -methoxy-4-[2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, Exemp. C 0 mp. N 0 · 8-1 6 3: 2 _ benzyl-5 -chloro-3-[3-[2 , 2,2-trifluoro · 1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp.No. 8-1155: 2-benzyl-6,7-dimethoxy-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (31 ^)-quinazolone,

Exemp. Comp. No. 8-1248: 6,7-difluoro-2 " · benzyl-3- [3- [252,2-trifluoro-l-hydroxy-l- (trifluoromethyl) ethyl Phenyl] phenyl: l · 4 (3H) -quinazolinone, Exemp. Comp. No. 8-1 465: 6-chloro-5 -methyl-2-benzyl-3_ [3_ [2,2 , 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (311) -quinazolinone,

Exemp. Comp. No. 8- 1 496: 6-methoxy-5-methyl-2-benzyl- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- ( Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 8- 1 620: 6,7-dimethyl-2 -benzyl-3-[3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinolinone,

Exemp. Comp. No. 8-1713: 7-methyl-6-chloro-2 · benzyl-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone,

Exemp. Comp. No. 8-1775: 7-methoxy-6-chloro-2-benzyl- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -quinazolinone, -266- 200401770

ExempComp. No. 8-1806: 7-methyl-6-methoxy-2-benzyl-3- [3_ [2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -quinazolinone, EX emp. Comp. No. 8-1837: 7-chloro-6-methoxy-2-benzyl-3- [ 3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, and

Exemp. C omp · N 〇 8-2 0 8 5: 7 -fluoro-6 -methyl-2 -benzyl-3-[3-[2,2,2-trifluoro-buhydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3H) -oxazolinone. The compound of formula (I) of the present invention can be prepared via the following methods A to Q. 200401770

C-2-(I) (RaO) 3C-Y (IX)

D-2 (Ra〇) 3C-Y (IX) -268 200401770

-269 200401770 method 丨

(lh)

(ϋ) (Ik) -270- 200401770

Method L

Method N

271- 200401770

Method P

Method Q

In the compound equation of the above methods A to Q, R1, R2, R3, R4, R,. A, X, and Y are as defined above; Ra represents C "C6 alkyl; Rb represents C" C6i: end group or via C6 C6 alkyl substituted with 7 halogen atoms; Re and ... are the same or different, and each represents a hydrogen atom or C6 C6 alkyl, or together with a nitrogen atom to form a saturated heterocyclic group containing a nitrogen atom; Re represents C, C6 alkyl; L represents a leaving group; η represents an integer from 1 to 6; Prota represents an amine protecting group; Protb represents a hydroxyl protecting group; and Hal represents a halogen atom. The leaving group L is not completely limited to Provided, which can be substituted in the reaction by a nucleophilic reagent, suitable leaving groups include, for example, hydroxyl groups; halogen atoms as described above; Groups; halogenated lower alkylsulfonyloxy groups, such as trifluoromethanesulfonyloxy; aromatic sulfonyloxy groups, such as arylsulfonyloxy groups, such as benzenesulfonyloxy, low alkylated aryl groups An ethoxy group, such as p-toluenesulfonyloxy, or a halogenated arylsulfonyloxy group, -272- 200401770, such as p-chlorobenzenesulfonyloxy. Preferably, the leaving group L is a halogen atom.

The Prota2 amine protecting group is not completely limited to the provider, it can protect the amine group in the reaction. This protecting group can be removed via chemical reactions (such as hydrogenation, hydrolysis, electrolysis, and photolysis), and examples of aliphatic fluorenyl include alkylcarbonyl, such as methyl, ethyl, propyl, propyl, and butyl. , Isobutylfluorenyl, pentamyl, trimethylacetamyl, pentamyl, isopentamyl, octyl, dodecyl, hexadecyl or octadecyl, halogenated lower alkylcarbonyl groups, such as ethyl chloride Fluorenyl, dichloroethenyl, trichloroethenyl or trifluoroethenyl, lower alkoxy lower alkylcarbonyl, such as methoxyethenyl, or unsaturated alkylcarbonyl, such as (E)- 2-methyl-2-butenylfluorenyl; aromatic fluorenyl, examples include arylcarbonyl, such as benzamyl, α-naphthylmethyl, or / 5-naphthylmethyl, halogenated arylcarbonyl, such as 2-bromobenzyl or 4-chlorobenzyl, low alkylated arylcarbonyl, such as 2,4,6-trimethylbenzyl or 4-tolylmethyl, (low alkoxy Group) arylcarbonyl, such as 4-p-methoxybenzyl, nitroated arylcarbonyl, such as 4-nitrobenzyl or 2-nitrobenzyl, (lower alkoxycarbonyl) Examples of arylfluorenyl 2- (methoxyloxy) benzylfluorenyl, or arylated arylfluorenyl, such as 4-phenylbenzylfluorenyl; alkoxycarbonyl, examples include lower alkoxycarbonyl 'such as methoxy Carbonyl, ethoxycarbonyl, t-butoxycarbonyl or isobutoxycarbonyl 'or a lower alkoxycarbonyl group substituted with a halogen atom or a tri (lower alkyl) silyl group, such as 2,2,2-trichloro Ethoxycarbonyl or 2-trimethylsilylethoxycarbonyl; alkenyloxycarbonyl, such as vinyloxycarbonyl, allyloxycarbonyl or 2-butenyloxycarbonyl; optionally via a lower alkyl, Benzyloxycarbonyl substituted with a lower alkoxy or halogen atom, such as benzyloxycarbonyl, 4-methylbenzyloxy, 4-methoxybenzyloxycarbon, or 4-chlorobenzyloxy Carbonyl groups; -273- 200401770 substituted methylene groups that form Shiff bases, such as xylylene; and benzyl groups, such as benzene, which are optionally substituted with lower alkyl, lower alkoxy, or halogen atoms Methyl, 4-methylbenzyl, 4-methoxybenzyl, or 4-chlorobenzyl; preferably, Prota is a lower alkyl group or optionally a lower alkyl group, Low-oxygen Or a halogen atom substituted permethoxy group, and more preferably, it is a t-butoxycarbonyl group or a benzyloxycarbonyl group. The hydroxy-protecting group Protb is not completely limited to the provider 'which protects the hydroxy group in the reaction. This protecting group can be removed via chemical reactions (such as hydrogenation, hydrolysis, electrolysis, and photolysis), and examples of aliphatic fluorenyl include alkylcarbonyl, such as methyl, ethyl, propyl, propyl, and butyl. , Isobutylfluorenyl, pentamyl, trimethylacetamyl, pentamyl, or isopentamyl, (lower alkoxy)-(lower alkyl) 'carbonyl, such as methoxyacetamyl, or unsaturated Alkylcarbonyl, such as (E) -2-methyl-2-butenyl; examples of aromatic fluorenyl include arylcarbonyl, such as benzamidine, α-naphthylmethyl, or / 3-naphthylmethyl Fluorenyl, halogenated arylcarbonyl, such as 2-bromobenzyl, or 4-chlorobenzylfluorenyl, low alkylated arylcarbonyl, such as 2,4,6-trimethylbenzyl, or 4- Tolylmethyl, low alkoxyarylcarbonyl, such as 4-p-methoxybenzyl, nitroated arylcarbonyl, such as 4-nitrobenzyl or 2-nitrobenzyl, Lower alkoxycarbonylarylcarbonyl, such as 2- (methoxycarbonyl) benzyl, or arylated arylcarbonyl, such as 4-phenylbenzyl; saturated lower alkyl, such as methyl, Ethyl, propyl, isopropyl Butyl or third butyl; unsaturated lower alkyl, such as vinyl, allyl, or 2-butenyl; lower alkoxyalkyl, such as methoxymethyl, ethoxyethyl, tetrahydro Piperanyl or tetrahydrofuranyl; (lower alkoxy)-(lower alkoxy) alkyl, such as methoxyethoxymethyl; optionally via lower alkyl, -274- 200401770 lower alkoxy or Benzyl substituted by a halogen atom, such as benzyl, 4-methylbenzyl, 4-methoxybenzyl, or 4-chlorobenzyl; and tri-benzyl substituted by lower alkyl or phenyl Substituted silyl, such as third butyldimethylsilyl, third butyldiphenylsilyl, or triphenylsilyl; preferably,? 1 * 〇1 is a saturated lower alkyl group, a lower alkoxyalkyl group, or a benzyl group optionally substituted with a lower alkyl group, a lower alkoxy group, or a halogen atom; and more preferably, it is a methyl group, a methoxy group Methyl or benzyl. The protection of the amine or hydroxy group with the aforementioned protecting groups or the removal of these protecting groups can be accomplished according to standard methods (described in, for example, T.H.  G r e e n e t a 1. , P r o t e c t i v e groups in organic synthesis, JOHN WILEY & SONS, INC. ) ° The steps of methods A to Q are described in detail below. (Method A) (Step Al) Step A-1 is a method for preparing a compound of formula (1) by preparing a compound of formula (π) (which can be prepared according to the following method T, which is a known compound or can be obtained from a known compound). A compound of formula (II) (which is a known compound or can be easily prepared from a known compound) and a compound of formula (IV) (which can be prepared according to the following method R or S, in the presence of a base) Known compounds can be easily prepared from known compounds). The solvent used is not completely limited to the provider, it does not inhibit the reaction and bathe the starting material to a certain range. The solvent may be, for example, an aromatic hydrocarbon such as benzyl or xylene; a halogenated hydrocarbon such as dichloromethane , Chloroform, carbon tetrachloride, monochloroethane, chlorobenzene or dichlorobenzene; esters such as ethyl formate, ethyl-275-200401770 ethyl acetate, propyl acetate, butyl acetate or diethyl carbonate; ether, For example, diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or bis (ethylene glycol) dimethyl ether; nitriles, such as acetonitrile or isopropylnitrile; ammonium, such as formamidine, N , N-dimethylformamidine, N, N-dimethylacetamide, N-methyl-2-Piodinone, N-methylpyrrolidone or trimethylamine hexamethyl phosphate Arsenic, such as dimethylarsine or cyclobutane; or organic bases, such as N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N -Methylhexahydropyridine, pyridine, 4-pyrrolidinopyridine, mepyridine, 4- (N, N-dimethylamino) pyridine, 2,6-bis (third butyl) -4- Methylpyridine, quinoline, N, N-dimethylaniline or N, N-diethylaniline; preferably it is an organic base; and more preferably eft π 疋. The reagent used may be a phosphate triester, such as triphenyl phosphate or trimethyl phosphate, and preferably it is a triphenyl phosphate. The base used may be, for example, N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylhexahydropyridine, piridine , 4-pyrrolidinopyridine, mepyridine, 4- (N, N-dimethylamino) pyridine, 2,6-bis (third-butyl) -4-methylpyridine, quinoline, N, N -dimethylaniline, n, N_diethylaniline, 1,5-diazabicyclo [4,3,0] non-5-ene (DBN), l54_diazabicyclo [2,2, 2] Octane (DABCO) or 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU); and preferably pyridine. If organic base is used as solvent [1], it is not necessary to add. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually in the range of 20 ° C to 150 ° C; preferably 50 ° C to 120 ° C. The reaction time varies depending on the solvent, starting materials, reagents, and reaction temperature, and is -276- 200401770 and usually ranges from 1 to 24 hours; preferably 1 to 8 hours. After the reaction, 'the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, via the following, 丨) adding water and an organic solvent (such as benzene, diacetic acid, g, etc.) which is difficult to mix with water ) To the reaction mixture, 2) extract the desired compound from the resulting mixture '3) wash the organic layer with water' 4) dry the organic layer on a desiccant (such as anhydrous sulfuric acid, etc.), and 5) transfer In addition to organic solvents, the desired compound is obtained 'if necessary, it can be further purified by conventional methods (such as recrystallization, Shenyangdian or silica gel column chromatography), the desired compound in this step can be used without purification In the next step. (Method B) (Step B > · 1) Step B-1 is a method for preparing a compound of formula (VI) by preparing a compound of formula (π) (which can be prepared according to the following method T, which is a known compound or can be prepared from A coupling reagent of a known compound is easily prepared) is reacted with a compound of formula (V) (is a known compound or can be easily prepared from a known compound) in the presence or absence of a coupling reagent. The reaction in this step is completed by two mutually replaceable paths: (B -la) when L is a hydroxyl group, the reaction is completed in the presence of a coupling agent, and (B-lb) when L is different from a hydroxyl group, The reaction is completed in the absence of a coupling agent. (B-la) The coupling agent used may be: (1) a combination of a phosphate ester compound (such as diethylphosphonium cyanide or diethylphosphonium azide) and the following base; -277- 200401770 ( 2) Carbodiimide compounds, such as 1,3-dicyclohexylcarbonyldiamidoimine, 1,3-monoisopropyl ^ > Saya I, 1-ethyl-3 (3-dimethyl Aminoaminopropyl) mine diimine and the like; a combination of the above carbodiimide compound with the following base; or a combination of the above carbodiimide compound and an N-hydroxy compound (such as N-hydroxysuccinimide, 1-Hydroxybenzotriazole or N-Hydroxy-5-norbornenyl-2,3-dicarboximide); (3) Disulfide compounds (eg 2,2'-dipyridyldi) A combination of a sulfide or 2,2, -dibenzothiazolyl disulfide) with a phosphine compound (such as triphenylphosphine or tributylphosphine); (4) a carbonate compound such as N, N'-di Succinimide iminocarbonate, diethylpyrocarbonate, di-2-pyridylcarbonate or s, S, -bis (1-phenyl-1H-tetrazol-5-yl) dithiocarbonate; (5) phosphorus chloride compounds, such as N, N'-bis (2-keto-3- 酮) (Pyridinyl) phosphorus chloride; (6) Early acid vinegar compounds, such as N, N′-No. 2 acetonitrile oxalate, n, N, -dinaphthyl imidate oxalate, N, N ′ -Bis (5-norbornenyl-2,3-dicarboxyamidoimidyl) oxalate, 1, Γ-bis (benzotriazolyl) oxalate, 1, i, _bis (6 _Chlorobenzotriazolyl) oxalate or 1,1′-bis (6-trifluoromethylbenzotriazolyl) oxalate; (7) The above-mentioned phosphine compound and azodicarboxylate compound ( For example, a combination of diethylazodicarboxylate) or an azobiscarboxamide compound (for example, 15l,-(azodicarbonyl) dihexahydropyridine); a combination of the above-mentioned phosphine compound with the following base; (8 ) N- (lower alkyl) -5-arylisoxazolium-3'-sulfonate compounds, such as N-ethyl-5-phenylisoxazolium sulfonate; -27 8- 200401770 ( 9) a diheteroaryl diselenide compound, such as a di-2-pyridyl diselenide; (10) an arylsulfonyltriazole compound, such as a p-nitrobenzenesulfonyltriazole compound; (1) 1) 2-halo-1-(low-alkyl) pyridine hydrazone, such as 2-chloro-1 -methylpyridine hydrazone iodide or 2-bromo-1 -Ethylpyridinium chloride; (12) imidazole compounds, such as 1,1'-oxazolyldiimidazole or n, N, -carbonyldiimidazole; (13) 3- (low alkyl) -2-halogen- Benzothiazolium fluoroborate compounds, for example * such as 3-ethyl-2-chlorobenzothiazolium fluoroborate; (14) 3- (lower radical) -benzo [gnsz-2 -selenone ( (selone) compounds, such as 3-methylbenzobenzazole-2-selenone; (1 5) phosphate compounds, such as phenyl dichlorophosphate or polyphosphate; (16) halosulfonyl isocyanate Salt compounds, such as chlorosulfonyl isocyanate; (1 7) Halosilane compounds, such as trimethylsilyl chloride or triethylsilyl chloride; (1 8) (low alkane) sulfonyl halides (E.g. methanesulfonyl chloride) in combination with the following bases; or (19) N, N, N ', N'-tetrakis (low alkyl) halomidonium chloride compounds, e.g. N, N, N', N'-tetramethylchloroformammonium chloride. Preferably, the coupling agent is a carbodiimide compound or an imidazole compound; and more preferably 1,3-dicyclohexylcarbonyldiimide or N, N'-carbonyldiimidazole. The solvent used is not completely limited to the provider, it does not inhibit the reaction -279- 200401770 and dissolves the starting material to a certain range. The solvent may be, for example, an aliphatic hydrocarbon such as hexane or heptane; an aromatic hydrocarbon such as Benzene, toluene or xylene; halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene or dichlorobenzene; esters such as ethyl formate, ethyl acetate, propyl acetate, acetic acid Butyl or diethyl carbonate; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or bis (ethylene glycol) dimethyl ether; nitriles, such as acetonitrile or isopropyl nitrile Or amidine, such as formamidine, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyrrolidone, N-methylzolin Ketone or trimethylamine hexamethyl phosphate. The base used may be, for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate or lithium carbonate; an alkali metal hydrocarbon such as sodium hydrogen carbonate, potassium hydrogen carbonate or lithium hydrogen carbonate; or an organic base such as N-methyl Morpholine, triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylhexahydropyridine, pyridine, 4-pyrrolidinopyridine, formylpyridine, 4- (N , N-Dimethylamino) pyridine, 2,6--di-dibutyl) -4-methylpyridine, D-Quulin, N, N-methylaniline or Ν, Ν · diethyl Aniline; the base used is preferably an organic base; and more preferably triethylamine, diisopropylethylamine or piridine. The reaction temperature varies depending on the solvent, starting material, reagent, etc., and usually ranges from -20 ° C to 12 ° C; preferably 0 ° C to 120 ° C. The reaction time depends on the solvent, starting material, reagent, reaction The temperature varies, and usually ranges from 30 minutes to 2 days; preferably from 1 to 12 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by丨) If necessary, the reaction mixture can be neutralized, 2) If this substance is present, remove the non-soluble substances> 280- 200401770 by filtration, 3) Add water and organic solvents (such as ethyl acetate, etc.) that are difficult to mix with water ) To the reaction mixture, 4) extract the desired compound from the resulting mixture, 5) wash the organic layer with water, 5) dry the organic layer on a desiccant (such as anhydrous magnesium sulfate, etc.), and 6) remove In addition to organic solvents, the desired compound is obtained 'if necessary' and can be further purified by conventional methods such as recrystallization or silica gel column chromatography. (B-lb) The solvent used is not completely limited to the supplier, it does not inhibit the reaction and dissolves the starting material to a certain range. The solvent may be, for example, an aromatic hydrocarbon such as benzene, toluene or xylene; a halogenated hydrocarbon, Such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane, chlorobenzene or dichlorobenzene; esters such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate or diethyl carbonate; ether, For example, diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or bis (ethylene glycol) dimethyl ether; nitriles, such as acetonitrile or isopropionitrile; ammonium, such as formamidine, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyridinone, N-methylpyrrolidone, or trimethylamine hexamethylphosphate Or organic bases, such as N-methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylhexahydropyridine, pyridine, 4-pyrrolidine Acylpyridine, methylpyridine, 4- (N, N-dimethylamino) pyridine, 2,6-bis (third butyl) -methylpyridine, quinoline, N, N-dimethylaniline or N, N-diethylaniline . The base used may be, for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate or lithium carbonate; an alkali metal hydrocarbon such as sodium hydrogen carbonate, potassium hydrogen carbonate or lithium hydrogen carbonate; or an organic base such as N-methyl Morpholine, triethylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylhexahydropyridine, pyridine, -281- 200401770 4-pyrrolidinopyridine, methylpyridine, 4- ( N, N-dimethylamino) pyridine, 2,6-bis (third butyl) -cardiaclopyridine, quinoline, N, N-dimethylaniline or N, N-diethylaniline; The base used is preferably an organic base; and more preferably triethylamine, diisopropylethylamine or pyridine. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually in the range of -20 ° C to 120 ° C; preferably 0 ° C to 120. (: The reaction time varies depending on the solvent, starting materials, reagents, and reaction temperature, and usually ranges from 30 minutes to 2 days; preferably from 1 to 12 hours. After the reaction, the desired compound in this step can be prepared by conventional methods. Isolation in the reaction mixture: The desired compound can be obtained, for example, by 1) neutralizing the reaction mixture if necessary, 2) if this material is present, removing insoluble materials by filtration, 3) adding water and mixing with water that is difficult Organic solvent (such as ethyl acetate) into the reaction mixture, 4) extracting the desired compound from the resulting mixture, 5) washing the organic layer with water, 5) in a desiccant (such as anhydrous magnesium sulfate, etc.) The organic layer is dried, and 6) the organic solvent is removed, so that the desired compound is obtained, and if necessary, can be further purified by conventional methods (such as recrystallization or silica gel column chromatography). .  (Step B-2) Step B-2 is a method for preparing a compound of the formula (I) by reacting a compound of the formula (VI) (prepared according to step B-1) and a compound of the formula (IV) (can be performed according to the following method R Or S is a known compound or can be easily prepared from a known compound). The solvent used is not completely limited to the provider 'which does not inhibit the reaction -282- 200401770 and dissolves the starting materials to a certain range. The solvent may be, for example, arylbenzene, toluene or xylene; halogenated hydrocarbons such as dichloromethane, Carbon, dichloroethane, chlorobenzene or dichlorobenzene; esters such as ethyl formate, propyl acetate, butyl acetate or diethyl carbonate; ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethyl Oxydiol) dimethyl ether; nitriles, such as acetonitrile or isopropionitrile; amidoamine, N, N-dimethylformamide, n, N-dimethylacetamide, pyridone, N-methylpyrrolidone or trimethylamine hexamethylphosphate such as dimethylsulfinium or cyclobutane. The reaction in this step can also be carried out in the following manner. The reagent used may be a phosphate tri-ester, such as triphenyl phosphate, and preferably triphenyl phosphate. The reaction temperature varies depending on the solvent, starting materials, reagents, etc. It is usually 20 ° C to 180 ° C; preferably 50. (: To 150 ° C. The reaction time depends on the solvent, starting materials, reagents, and reaction. The range is usually 1 to 24 hours; preferably 1 to 8 hours. After the reaction, the desired compound in this step can be traditionally prepared. Compound separation: the desired compound can neutralize the reaction mixture when obtained, for example, 2) if this substance is present, then dissolve the substance, 3) add water and organic solvents (esters, etc.) that are difficult to mix with water to In the reaction mixture, 4) the compound from the resulting mixture, 5) the organic layer is washed with water, 6) the organic layer is dried over a desiccant (magnesium acid, etc.), and 7) the organic solvent is removed, If necessary, it can be via conventional methods (eg, hydrocarbons such as chloroform, ethyl tetrachloroate, ether, such as diethane or di (ethyl, such as formamidine N-methyl-2-pyridine; Ester or phosphoric acid is present, and the range is changed by temperature, and the method is mixed by reaction. 1) If necessary, remove by filtration, for example, ethyl acetate, to extract the desired, such as anhydrous sulfur, so as to obtain recrystallization or -283- 200401770 silicone gel tube. Column chromatography) for further purification. (Method c) (Step C-1) Step C-1 is a method for preparing a compound of formula (VIII) by reacting a compound of formula (VII) (which can be prepared according to the following method τ or can be easily obtained from a known compound) Base), and a compound of formula (IV) (can be prepared according to the following method R or S, is a known compound or can be easily prepared from a known compound), this step includes the protecting group Prota (step c-lb) Concentrated reaction after removal | Step B-2 is a method for preparing a compound of formula (I), which is known by using a compound of formula (VI) (prepared according to step B-1) and a compound of formula (IV) (preparable according to the following method R or S). Compounds can be easily prepared from known compounds). (Step C-la) Step C-la can be performed according to a similar method as described in step B-la. (Step C-lb) The removal of the protecting group Prota in step C-lb changes according to the properties of Prota, and can be performed after a method well known in the field of organic chemistry. When Prota is aliphatic fluorene, aromatic fluorenyl, alkoxycarbonyl, alkenyloxycarbonyl or substituted methylene which forms Schiff's test, it can be removed by treatment with acid or base in an aqueous solvent . The acid used is not completely limited to the one provided, it is conventionally used as an acid and does not inhibit the reaction, and is preferably an inorganic acid such as hydrochloric acid, -284-200401770 sulfuric acid, phosphoric acid or hydrobromic acid. The base used is not completely limited to the provider, it does not affect other parts of the compound, and is preferably a metal alkyl oxide, such as sodium methoxide, an alkali metal carbonate, such as sodium carbonate, potassium carbonate or Lithium carbonate, an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or lithium hydroxide, or ammonia 'such as an aqueous ammonia solution or concentrated ammonia-methanol. The solvent used is not completely limited to the one provided, it is traditionally used in hydrolysis reactions, and is preferably water or a mixture of water and an organic solvent. Examples include alcohols such as methanol, ethanol, or eta-propanol, and Ethers, such as tetrahydrofuran or dioxane. The reaction temperature and reaction time are changed according to the starting material, solvent, acid or base used, and are preferably used for the suppression of side reactions. The range of the reaction temperature is 0 ° C to 150 ° C, and the reaction time The range is from 1 to 10 hours. When Prota is a benzyloxy group optionally substituted with a lower alkyl group, a lower alkoxy group, or a halogen, or an r benzyl group optionally substituted with a lower group, a lower group, or a halogen group. The solvent is removed by treatment with a catalyst, preferably hydrogenation in the presence of a catalyst at room temperature, or treatment with an oxidant. The solvent used in the hydrogenation reaction is not completely limited to the provider, it does not inhibit the reaction and is preferably an alcohol such as methanol, ethanol or isopropanol, an ether such as diethyl ether, tetrahydrofuran or dioxane, aromatic Hydrocarbons such as toluene, benzene or xylene 'aliphatic hydrocarbons such as hexane or cyclohexane, esters such as ethyl acetate or propyl acetate' aliphatic carboxylic acids such as acetic acid, or a mixture of water and this organic solvent . The catalyst used in the hydrogenation reaction is not completely limited to the supplier, -285- 200401770 which can be generally used in the hydrogenation reaction, and is preferably palladium-carbon, palladium hydroxide-carbon, Raney nickel, platinum oxide, Platinum black, germanium-alumina, triphenylphosphine-germanium chloride or palladium-barium sulfate. This reaction is usually carried out at a pressure from atmospheric pressure to a hydrogen pressure of 10,000 hPa. The reaction temperature and reaction time vary depending on the starting materials, solvents, and catalysts used. The reaction temperature is usually in the range of 0 ° C to 100 ° C, and the reaction time is in the range of 5 minutes to 24 hours. The solvent used in the removal reaction using an oxidant is not completely limited to the supplier, it does not inhibit the reaction and is preferably an organic solvent containing water. This organic solvent may preferably be a ketone, such as acetone, a halogenated hydrocarbon , Such as dichloromethane, chloroform, or carbon tetrachloride, nitriles, such as acetonitrile, ethers, such as diethyl ether, tetrahydrofuran, or dioxane, amidine, such as dimethylformamide, dimethylacetamide, or hexamethyl Triamidine phosphate, or arsenic, such as dimethylarsine. The oxidant used is not completely limited to the provider, it can usually be used for the oxidation reaction, and is preferably potassium persulfate, sodium persulfate, ammonium nitrate (0-8 "or 2,3-dichloro-5, 6-dicyano-?-Benzoquinone (00 (5). The reaction temperature and reaction time vary depending on the starting materials, solvents, oxidants, etc. used. The reaction temperature is usually in the range of 0 ° C to 150 ° C, and The reaction time is in the range of 10 minutes to 24 hours. When Prota is a 2-alkenyloxycarbonyl group such as an allyloxycarbonyl group or a 2-butenyloxycarbonyl group, it may also use tetrakis (triphenylphosphine) palladium or Nickel tetracarbonyl was removed with minor side reactions (T. H. Green et a.  1. 5 Protective groups in organic synthesis, JOHN WILEY & SONS, INC. ). -286- 200401770 After the above reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by i) neutralizing the reaction mixture if necessary, 2) if the substance If present, insoluble matter is removed by filtration, 3) adding water and organic solvents (such as ethyl acetate, etc.) that are difficult to mix with water to the reaction mixture, 4) extracting the desired compound from the resulting mixture '5) Rinse the organic layer with water, 6) dry the organic layer on a desiccant (such as anhydrous sulphuric acid), and 7) remove the organic solvent, so that the desired compound is obtained, if necessary, by conventional methods (such as recrystallization) Or silica gel column chromatography) for further purification. ® (Step C-2) Step C-2 is a method for preparing a compound of formula (I) by reacting the acid of the compound of formula (VIII) (prepared in the above step ci) with the compound of formula (IX) ( Known compounds or can be easily prepared from known compounds). The solvent used is not completely limited to the provider, it does not inhibit the reaction and dissolves the starting material to a certain range. The solvent may be, for example, an aromatic hydrocarbon such as benzene, toluene or xylene; Chloroform, carbon tetrachloride, dichloroethane, chlorobenzene or dichlorobenzene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane'dimethoxyethane or di (ethylene glycol) Dimethyl ether; or organic bases, such as N-methylhexahydropyridine, pyridine, 4-pyrrole D-pyridine, pyridine, methylpyridine, 4- (N, N-dimethylamino) pyridine, 2 , 6-bis (second butyl) -4-methylpyridine, thialine, N, N-dimethylaniline or N, N-diethylaniline. The acid used may be, for example, an organic sulfonic acid, such as p-toluenesulfonic acid, camphoric acid or trifluoromethanesulfonic acid, or a salt thereof, such as p-toluenesulfonic acid pyridine; > 287- 200401770 and preferably Ground is pyridinium p-toluenesulfonate. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually in the range of room temperature to 150 ° C; preferably 50. 0 to 120 ° C. The reaction time varies depending on the solvent, starting materials, reagents, and reaction temperature, and is usually in the range of 1 to 48 hours; preferably 1 to 12 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: The desired compound can be obtained, for example, by 1) neutralizing the reaction mixture if necessary, 2) if the substance is present, then removing it by filtration. In addition to insoluble matter, 3) add water and organic solvents (such as ethyl acetate, etc.) that are difficult to mix with water to the reaction mixture, 4) extract the desired compound from the resulting mixture, 5) wash the organic layer with water , 6) drying the organic layer on a desiccant (such as anhydrous magnesium sulfate, etc.), and 7) removing the organic solvent, so that the desired compound can be obtained 'if necessary' by conventional methods (such as recrystallization or a silica gel column) Chromatography) for further purification. (Method D) (Step D-1) Step D-1 is a method for preparing a compound of formula (VIII) by combining a compound of formula (χ) (which is a known compound or can be easily prepared from a known compound) and formula ( IV) Compounds (can be prepared according to the following method R or S, are known compounds or can be easily prepared from known compounds). This step includes a concentration reaction (step D · la) after the reduction of the nitro group (step D_lb). (Step D-la) Step D-1a can be performed according to a method similar to that described in step B & -288- 200401770 (Step D-lb) Step D-lb can be a catalytic reaction or a reduction reaction using a metal or a metal salt. [Catalytic reaction] The catalytic reaction is performed under a hydrogen pressure in a solvent containing a catalyst. The solvent used is not completely limited to the provider, it does not inhibit the reaction and dissolves the starting material to a certain range. The solvent may be, for example, an ester, such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate, or carbonic acid. Diethyl esters; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or bis (ethylene glycol) dimethyl ether; alcohols, such as methanol, ethanol, η-propyl Alcohol, isopropanol, η-butanol, isobutanol, t-butanol, isoamyl alcohol, bis (ethylene glycol), glycerol, octanol, cyclohexanol or 2-methoxyethanol; nitriles, such as acetonitrile Or isobutyronitrile; ammonium, such as formamidine, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyrrolidone, N-methyl Pyrrolidone or trimethylamine hexamethylphosphate; acetic acid; or water; and preferably the solvent is an alcohol, acetic acid, or water. The catalyst used is not completely limited to the provider, it can be used to catalyze the reaction, and can be, for example, metal palladium black, palladium-carbon, palladium hydroxide-carbon, platinum black, platinum-carbon, platinum oxide, or Raney's Nickel; and preferably palladium-containing carbon or palladium hydroxide-carbon. This reaction is usually carried out under a pressure ranging from atmospheric pressure to hydrogen pressure of 1000 hPa, preferably atmospheric pressure to 500 hPa. The reaction temperature varies depending on the solvent, starting material, catalyst, etc. used, and is usually -20. (: To 120 ° C; preferably 0 ° C to 5CTC. The reaction time varies depending on the solvent, starting material, catalyst, reaction-289-200401770 temperature, etc. used, and is usually within 1 to 48 hours. Range: preferably 1 to 10 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by filtering the catalyst and removing the organic solvent from the filtrate. Therefore, the desired compound can be obtained, and if necessary, can be further purified by conventional techniques (such as recrystallization or sand gel column chromatography). [Reduction reaction using metal or metal salt] The solvent used is not completely limited to the Provider, which does not inhibit the reaction and dissolves the starting material to a certain range. The solvent may be, for example, an ester such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate, or diethyl carbonate; an ether such as di Diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or bis (ethylene glycol) dimethyl ether; alcohols such as methanol, ethanol, η-propanol, isopropanol, η-Alcohol, isobutyl alcohol, t - butanol. Isoamyl alcohol, bis (ethylene glycol), glycerol, octanol, cyclohexanol or 2-methoxyethanol; nitriles, such as acetonitrile or isobutyronitrile; ammonium, such as formamidine, N, N-dimethyl Formamidine, Ν, Ν · dimethylacetamide, N-methyl-2-pyrrolidone, N-methylpyrrolidone, or trimethylamine hexamethylphosphate; fluorene, such as dimethyl fluorene Or cyclobutane; acetic acid; or water; and preferably the solvent is an alcohol, acetic acid, or water. The metal or metal salt used may be, for example, iron, tin, zinc, tin (II) chloride or titanium (II) chloride, and is preferably zinc. The acid used may be, for example, an inorganic acid such as hydrochloric acid or an acidic salt of an inorganic acid such as ammonium chloride, and is preferably hydrochloric acid. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually in the range of -290-200401770 20QC to 150 ° C; preferably 0 ° C to 100 ° C. The reaction time varies depending on the solvent, starting material, reagent, reaction temperature, etc. used, and is usually in the range of 1 to 24 hours; preferably i to 8 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by 1) removing insoluble matter by filtration, 2) concentrating the reaction mixture, 3) adding water and refractory Organic solvent (such as ethyl acetate, etc.) mixed with water into the reaction mixture, 4) the desired compound is extracted from the resulting mixture, 5) the organic layer is washed with water, 6) in a desiccant (such as anhydrous sulfuric acid) The organic layer is dried over magnesium, etc., and 7) the organic solvent is removed, so that the desired compound is obtained, and if necessary, can be further purified by conventional methods (such as recrystallization or silica gel column chromatography). (Step D-2) Step D-2 is a method for preparing a compound of formula (I) 'which is performed by combining the compound of formula (VIII) and compound of formula (IX) (which is a known compound or Compounds are easily prepared). Step D-2 can be performed in a similar manner as described in step C-2 above. (Method E) (Step E-1) Step E-1 is a method for preparing a compound of formula (VIII) by combining a compound of formula (χι) (which is a known compound or can be easily prepared from a known compound) and formula (IV ) Compound (can be prepared according to the following method r or s, is a known compound or can be easily prepared from a known compound). The solvent used is not completely limited to the provider, it does not inhibit the reaction> 291- 200401770 and dissolve the starting material to a certain range. The solvent may be, for example, an aromatic hydrocarbon such as benzene, toluene or xylene; an ester such as Ethyl formate, ethyl acetate, propyl acetate, butyl acetate, or diethyl carbonate; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or di (ethylene glycol) ) Dimethyl ethers; nitriles, such as acetonitrile or isobutyronitrile; amidines, such as formamide, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl- 2-pyrrolidone, N-methylpyrrolidone or trimethylamine hexamethylphosphate; or an organic acid such as formic acid, acetic acid or propionic acid; and preferably acetic acid. The reagent used may be an organic acid such as formic acid, acetic acid or propionic acid, and is preferably acetic acid. When the organic acid used is used as a solvent, it is not necessary to add an organic acid as a reagent. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually 20 ° C. c to 150 ° C; preferably 50 ° C to 120. Alas. The reaction time varies depending on the solvent, starting material, reagent, reaction temperature, etc. used, and is usually in the range of 1 to 24 hours; preferably 1 to 8 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: The desired compound can be obtained, for example, by 1) adding water and an organic solvent (such as ethyl acetate, etc.) that is difficult to mix with water to the reaction In the mixture, 2) extract the desired compound from the resulting mixture, 3) wash the organic layer with water, 4) dry the organic layer on a desiccant (such as anhydrous magnesium sulfate, etc.), and 5) remove the organic solvent , So the desired compound is obtained, if 'can be further purified by conventional methods (such as recrystallization, re-sinking or sand gel column chromatography). The desired compound in this step can be used in the next reaction step without purification. -292- 200401770 (Step E-2) Step E-2 is a method for preparing a compound of formula (i) 'which is prepared by combining the compound of formula (VIII) and compound of formula (IX) ( Compounds can be easily prepared from known compounds). Step E-2 can be performed in a similar manner as described in step c-2 above. (Method F) (Step F-1) Step F-1 is a method for preparing a compound of formula (Ib), which is prepared by compounding a compound of formula (Ia) (using the above-mentioned methods A to E or the following Η to Q), and Wherein X in formula (I) is a radical, and is reacted with a compound of formula (XII) which is a known compound or can be easily prepared from a known compound. The solvent used is not completely limited to the provider, it does not inhibit the reaction and dissolves the starting materials to a certain range. The solvent may be, for example, an aromatic hydrocarbon such as benzene, toluene or xylene; a halogenated hydrocarbon such as dichloromethane, Chloroform, carbon tetrachloride, dichloroethane, chlorobenzene or dichlorobenzene; esters such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate or diethyl carbonate; ethers such as diethyl ether, diethyl ether Isopropyl ether, tetrahydrofuran, dioxin, dimethoxyethyl or dimethyl (ethylene glycol) dimethyl ether; ammonium, such as formamidine, Ν, Ν -dimethylformamide, Ν, Ν -Dimethylacetamide, N-methyl-2-pyrrolidone, N-methylpyrrolidone, or trimethylamine hexamethyl phosphate; or saffron, such as dimethyl stilbene or cyclamidine; Preferably it is a halogenated hydrocarbon, ether or amidine; and more preferably methylene chloride, tetrahydrofuran or dimethylformamide. The reagent used may be, for example, an alkali metal carbonate, such as sodium carbonate, carbon-293-200401770 potassium acid, lithium carbonate, or carbonic acid; a metal bicarbonate, such as sodium bicarbonate, potassium bicarbonate, or lithium bicarbonate; alkali Metal hydrides, such as lithium hydride, sodium hydride, or potassium hydride; alkali metal hydroxides, such as sodium hydroxide, potassium hydroxide, barium hydroxide, or lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide; alkali metals Fluoride, such as sodium fluoride or potassium fluoride; alkali metal alkyl oxides, such as sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, potassium tert-butoxide, or lithium methoxide; or inorganic silver compounds such as silver oxide or Silver carbonate; and preferably sodium hydride, absolute carbonate or silver carbonate. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually at 0. A range of c to 100 ° C; preferably 20. C to 50. C. The reaction time varies depending on the solvent, starting material, reagent, reaction temperature, etc. used, and is usually in the range of 1 to 24 hours; preferably 1 to 8 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by i) adding water and an organic solvent (such as ethyl acetate, etc.) that is difficult to mix with water to the reaction In the mixture, 2) extract the desired compound from the resulting mixture, 3) wash the organic layer with water '4) dry the organic layer on a desiccant (such as anhydrous magnesium sulfate, etc.) and 5) remove the organic 彳Cereals' thus obtain the desired compound, and if necessary, can be further purified by conventional methods (such as recrystallization or sand gel column chromatography). The desired compound in this step can be used in the next reaction step without purification. (Method G) (Step G-1)

-294- 200401770 Step G-1 is a method for preparing a compound of formula (Ic) by preparing a compound of formula (Ia) (which can be prepared according to the above or the following Hg0 method, and wherein X in formula (I) is a hydroxyl group )reduction. Step G-1 is performed according to the method described in the literature or an improved method thereof: J. Chem. Perkin Trans. 1, 1 5 74] 5 8 5 (1 97 5). (Method H) (Step H-1) Step H-1 is a method for preparing a compound of formula (Ie) by preparing a compound of formula (Id) (which can be prepared according to any one of the methods A to G above, and wherein In the formula (ii), γ is a halogen alkyl group) and a compound of the formula (χιπ) (is a known compound or can be easily prepared from a known compound). The solvent used is not completely limited to the provider, it does not inhibit the reaction and dissolves the starting materials to a certain range. The solvent may be, for example, an aromatic hydrocarbon such as benzene, toluene or xylene; a halogenated hydrocarbon such as dichloromethane, Chloroform, carbon tetrachloride, dichloroethane, chlorobenzene or dichlorobenzene; esters such as ethyl formate, ethyl acetate, propyl acetate, butyl acetate or diethyl carbonate; ethers such as diethyl ether, Diisopropyl ether, tetrahydrofuran, dioxane, dimethoxyethane, or bis (ethylene glycol) dimethyl ether; nitriles, such as acetonitrile or isopropionitrile; amidines, such as formamidine, Ν, Ν · Dimethylformamide, Ν, Ν · dimethylacetamide, N-methyl-2-pyrrolidone, N-methylpyrrolidone, or trimethylamine hexamethylphosphonate; or sulfamidine, Examples are dimethylarsine or cyclobutane; preferably aromatic hydrocarbons, ethers or fluorenamines; and more preferably toluene, tetrahydrofuran or dimethylformamide. The base used may, for example, be an alkali metal carbonate, such as sodium carbonate, potassium-295-200401770 potassium or lithium carbonate; an alkali metal bicarbonate, such as sodium bicarbonate, potassium bicarbonate, or lithium bicarbonate; an organic base such as N -Methylmorpholine, triethylamine, tripropylamine, tributylamine, diisopropylethylamine, dicyclohexylamine, N-methylhexahydropyridine, pyridine, 4-pyrrolidinopyridine, methylpyridine, 4 -(N, N-dimethylamino) pyridine, 2,6-bis (third butyl) -4-methylpyridine, quinoline, N, N-dimethylaniline, N, N-diethyl Aniline, 1,5-diazabicyclo [4,3,0] non-5-ene (DBN), 1,4-diazabicyclo [2,2,2] octane (〇 八 3 (3〇) Or 1,8-diazabicyclo [5,4,0] undec-7-ene (DBU); or a metal base such as butyllithium, lithium diisopropylamide, or bis (trimethylsilane) Base) lithium amidoamine; preferably an alkali metal carbonate or an alkali metal bicarbonate; and more preferably potassium carbonate or sodium bicarbonate. An excess of the compound of formula (XIII) may also be used in addition to the addition of a base. The reaction temperature varies depending on the solvent, starting materials, reagents, etc., and is usually in the range of 0 ° C to 120 ° C. It is preferably 20QC to 100 ° C. The reaction time varies depending on the solvent, starting material, reagent, reaction temperature, etc. used, and is usually in the range of 1 to 24 hours; preferably 1 to 8 hours. Reaction Thereafter, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by 1) condensation reaction mixture, 2) adding water and an organic solvent (such as ethyl acetate) which is difficult to mix with water Ester, etc.) into the reaction mixture, 3) extract the desired compound from the resulting mixture, 4) wash the organic layer with water, 5) dry the organic layer on a desiccant (such as anhydrous magnesium sulfate, etc.), and 6 ) The organic solvent is removed, so that the desired compound is obtained ', if necessary, can be further purified by conventional methods such as recrystallization, reprecipitation or sand gel column chromatography. The desired compound in this step can be used in the next reaction step without purification. -296- 200401770 (Method i) (Step Il) Step 1-1 is a method for producing a compound of formula (Ig) by removing the Protb group from the compound of formula (If), and the (If) compound is in formula (I Ring A) has a -0-Protb group and can be prepared according to the above methods A to Η or the following methods j to Q. The method for removing the protective group Protb varies depending on the nature of Protb, and can be performed according to various known methods within the scope of organic chemistry. When Protb is an aliphatic fluorenyl group or an aromatic fluorenyl group, it can be removed by treatment with an aqueous solvent containing an acid or a base. The acid used is not completely limited to those provided, it is conventionally used as an acid and does not inhibit the reaction, and is preferably an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid. The base used is not completely limited to the provider, it does not affect other parts of the compound, and is preferably a metal alkyl oxide, such as sodium methoxide, an alkali metal carbonate, such as sodium carbonate, potassium carbonate or Lithium carbonate, an alkali metal hydroxide, such as sodium hydroxide, potassium hydroxide, or lithium hydroxide, or ammonia, such as an aqueous ammonia solution or concentrated ammonia-methanol. The solvent used is not completely limited to the one provided, it is traditionally used in hydrolysis reactions, and is preferably water or a mixture of water and an organic solvent. Examples include alcohols such as methanol, ethanol, or eta-propanol, and Ethers, such as tetrahydrofuran or dioxane. The reaction temperature and reaction time vary according to the starting material, solvent, acid or base used, and are preferably used for the suppression of side reactions. The range of reaction temperature -297- 200401770 is 0. C to 1 5 0. C, and the reaction time ranges from 1 to 10 hours. When P r 〇tb is a saturated low alkyl group, an unsaturated low alkyl group, a low alkyl group, a (low alkoxy M low alkoxy) alkyl group, or optionally a low alkyl group, a low alkoxy group, or In the case of a halogen-substituted benzyl group, it can be removed by treatment with an acid or Lewis acid. The acid used is not completely limited to the provider, it does not affect other parts of the compound, and is preferably a hydrohalic acid, such as hydrobromic acid or hydroiodic acid. The Lewis acid used is not completely limited to the provider, it does not affect other parts of the compound, and is preferably trimethylsilyl iodide, or boron trihalide, such as boron trichloride or tribromo Boron halide. The solvent used to react with the acid is not completely limited to the provider, it is traditionally used for this removal reaction, and preferably water; alcohols such as methanol, ethanol or eta-propanol; ethers such as tetrahydrofuran or Dioxane; aliphatic carboxyl, such as acetic acid; or mixtures thereof. The reaction temperature and reaction time vary according to the starting material used, the solvent'acid, etc., and are preferably used for the suppression of side reactions. The reaction temperature ranges from 50 ° C to 150 ° C, and the reaction time ranges from 1 to 24 hours. The solvent used in the reaction with the Lewis acid is not entirely limited to the provider, it is traditionally used in this removal reaction, and is preferably an aromatic hydrocarbon such as benzene or toluene; a halogenated hydrocarbon such as dichloromethane, chloroform Or dichloroethane; or a nitrile, such as acetonitrile or isopropionitrile. The reaction temperature and reaction time vary depending on the starting materials, solvents, and Lewis acid used, and are preferably used for the suppression of side reactions. The reaction temperature ranges from 0 ° C to 100 ° C, and the reaction time ranges from 1 to 24 hours. -298- 200401770 When Protb is a tri-substituted silyl group substituted with a lower alkyl group or a phenyl group, it can be removed by treatment with the following compounds, which can generate fluoride anions, such as tetrabutylammonium fluoride, Potassium fluoride or pyridinium fluoride is preferably tetrabutylammonium fluoride. The solvent used is not completely limited to the provider, it does not inhibit the reaction and is preferably an ether such as tetrahydrofuran or dioxane. The reaction temperature and reaction time vary according to the starting materials, solvents, reagents, etc. used, and are preferably used for the suppression of side reactions. The reaction temperature range is -2 (TC to 150 ° C, and the reaction time range is 1). Up to 30 hours. The above-mentioned tri-substituted silyl groups can also be removed by treatment with an acid or alkali-containing aqueous solvent: they can be removed, for example, by 1) dioxane containing hydrochloric acid, 2) containing Tetrahydrofuran of acetic acid and water, 3) dichloromethane containing trifluoroacetic acid, or 4) methanol and water containing potassium hydroxide. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by 1) condensing the reaction mixture, 2) adding water and an organic solvent (such as acetic acid) which is difficult to mix with water Ethyl ester, etc.) into the reaction mixture, 3) extracting the desired compound from the resulting mixture, 4) washing the organic layer with water, 5) drying the organic layer on a desiccant (such as anhydrous magnesium sulfate, etc.), and 6) The organic solvent is removed, so that the desired compound is obtained, and if necessary, can be further purified by conventional methods (such as recrystallization or silica gel column chromatography). When PrOtb is a benzyl group substituted with a lower alkyl group, a lower alkoxy group, or a halogen atom, it can be removed by treatment with a solvent containing a reducing agent, preferably at room temperature in the presence of a catalyst. hydrogenation. -299- 200401770 The solvent used in the hydrogenation reaction is not completely limited to the provider, it does not inhibit the reaction and is preferably an alcohol such as methanol, ethanol or isopropanol; an ether such as diethyl ether, tetrahydrofuran or Pinane; aromatic hydrocarbons such as benzene, toluene or xylene; aliphatic hydrocarbons such as hexane or cyclohexane; esters such as ethyl acetate or propyl acetate; aliphatic carboxylic acids such as acetic acid; or water and the above A mixture of organic solvents. The catalyst used is not completely limited to the provider, it can be traditionally used for hydrogenation reactions, and is preferably palladium-carbon, palladium hydroxide-carbon, Raney nickel, platinum oxide, platinum black, rhodium-alumina , Triphenylphosphine-germanium chloride or palladium-barium sulfate. This reaction is usually carried out at a pressure from atmospheric pressure to a hydrogen pressure of 10000 hPa. The reaction temperature and reaction time vary depending on the starting materials, solvents, and catalysts used. The reaction temperature is usually in the range of 0 ° C to 100 ° C, and the reaction time is in the range of 5 minutes to 24 hours. After the reaction, the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by filtering the catalyst and removing the organic solvent from the filtrate, so that the desired compound can be obtained, if necessary, It can be further purified by conventional techniques such as recrystallization or silica gel column chromatography. (Step 1-2) Step 1-2 is a method for preparing a compound of formula (Ih) by combining a compound of formula (Ig) (prepared from the above step 1-1) with a compound of formula (XΠ) (a known compound or It can be easily prepared from known compounds). -300- 200401770 Steps 1-2 can be performed according to a similar method as described in step F-;!. (Method J) (Step J-1) Step J-1 is a method for preparing a compound of formula (Ij) by preparing a compound of formula (Ii) (which can be prepared according to the above methods A to Η, and in formula (1) Ring a has a halogen atom), and reacts with a compound of formula (XIII), which is a known compound or can be easily prepared from a known compound. Step J-1 can be based on the literature (Org · Let ·, 4,581-584 (2002); J. Organometallic Chem ·, 5 76, 1 2 5-1 46 (1 999)) or the literature cited here The method described is carried out. (Method K) (Step K-1) Step K-1 is a method for preparing a compound of formula (Ik) by preparing a compound of formula (Ii) (which can be prepared according to the above methods A to Η in the presence or absence of a catalyst) And has a halogen atom on the A ring in formula (I)) and reacts with metal cyanide. The metal cyanide used is not completely limited to the provider, it can be traditionally used in cyanation reactions, and is preferably an alkali metal cyanide, such as lithium cyanide, sodium cyanide or potassium cyanide, trialkyl Silyl cyanide, such as trimethylsilyl cyanide, or transition metal cyanide, such as nickel cyanide, zinc cyanide, copper (I) cyanide, or silver cyanide. When copper cyanide or silver cyanide is used, the reaction can be performed in the absence of a catalyst. The catalyst used is not entirely limited to the provider 'which contains 0- or 2-301-200401770 valence palladium and can be used in organic synthesis. The catalyst may be, for example, metal palladium, palladium-carbon, palladium hydroxide, palladium (II) chloride, palladium (II) acetate, tris (diphenylmethyleneacetone) dipalladium-chloroform, allylpalladium chloride, [1,2-bis (diphenylphosphino) ethane] palladium chloride, bis (tri-0-tolylphosphine) palladium dichloride, bis (triphenylphosphine) palladium dichloride, tetrakis (tris) Phenylphosphine) palladium or dichloro [151, -bis (diphenylphosphino) bis (cyclopentadiene) ferrous] palladium. If necessary, the reaction solution may have a ligand capable of forming an effective catalyst with the above catalyst, which may be, for example, 1,1, -bis (diphenylphosphino) di (cyclopentadiene) ferrous, bis (2- Diphenylphosphinophenyl) ether, 2,2f-bis (diphenylphosphino) -1,1'-bisnaphthol, 1,3-bis (diphenylphosphino) propane, 14-bis ( Diphenylphosphino) butane, tri-o-tolylphosphine, 2-diphenylphosphino-2, -methoxybisnaphthyl or 2,2'-bis (diphenylphosphinobisnaphthyl) The catalyst is preferably a combination of palladium (II) acetate, tris (diphenylmethyleneacetone) dipalladium-chloroform, palladium (II) acetate and bis (2-diphenylphosphinophenyl) ether, or three A combination of (diphenylene.methylacetone) dipalladium-chloroform and 1,1'-bis (diphenylphosphino) bis (cyclopentadiene) ferrous; and more preferably palladium (II) acetate In combination with bis (2-diphenylphosphino) ether, or tris (diphenylmethyleneacetone) -dipalladium-chloroform with the ligand 1,1, _bis (diphenylphosphino) bis (cyclo The combination of pentadiene and ferrous iron. The solvent used is not completely limited to the supplier, it does not inhibit the reaction The solvent can be, for example, an ester such as methyl ethyl, ethyl acetate, propyl acetate, butyl acetate, or diethyl carbonate; and a solvent such as diethyl ether, diisocyanate. Propyl ether, tetrahydrofuran, dioxane, dimethoxyethane or bis (ethylene glycol) dimethyl ether; alcohols such as methanol, ethanol, η-propanol, isopropanol, η-butanol, isopropyl alcohol Butanol, butanol, isoamyl alcohol, bis (ethylene glycol), glycerol, octanol, cyclohexanol, or octamethoxyethanol; nitriles, such as acetonitrile or isobutyl-302-200401770 nitriles; ammonium, such as formazan Amidoamine, N, N-dimethylformamide, N, N-dimethylacetamide, N-methyl-2-pyrrolidone, N-methylpyrrolidone or hexamethyl phosphate Hydrazine; acetic acid; or water; and preferably alcohols, acetic acid or water. The reaction temperature varies depending on solvents, starting materials, reagents, etc., and is usually between -20 ° C to 120 ° C; It is preferably between 0 ° C. and 50 ° C. The reaction time varies depending on the solvent, starting material, reagent, reaction temperature, etc. used, and is usually in the range of 1 to 48 hours; The ground is 1 to 10 hours. After the reaction, 'the desired compound in this step can be separated from the reaction mixture by a conventional method: the desired compound can be obtained, for example, by 1) neutralizing and concentrating the reaction mixture, 2) adding water And organic solvents (such as ethyl acetate, etc.) that are difficult to mix with water into the reaction mixture, 3) the desired compound is extracted from the resulting mixture, 4) the organic layer is washed with water, 5) the drying agent (such as Dry the organic layer over anhydrous magnesium sulfate, etc., and 6) remove the organic solvent, so that the desired compound is obtained, and if necessary, can be further purified by conventional methods (such as recrystallization, reprecipitation, or silica gel column chromatography) . (Method L) (Step L-1) Step L-1 is a method for preparing a compound of formula (11) by 'compiling a compound of formula (Ii) (which can be prepared according to the above methods A to Η in the presence of carbon monoxide and The ring A in formula (I) has a halogen atom) and reacts with a compound of formula (XIV) (which is a known compound or can be easily prepared from a known compound). Step L-1 can be based on the literature (j. 〇rgan〇metallic chem ·, 645, 152-303- 200401770 1 5 7 (2002); Direct Synthesis of Carbonyl Compounds?

Plenum Press, New York, p 18 8 (1 99 1); Palladium reagents and Catalysts, Wiley, Chinchester, Applied Homogeneous Catalyst with Organometallic Compounds 15 VCH, Weinheim, pl48 (1996); Chem. Rev., 94, 1047-1062 (1994)), or as described in the literature cited herein. (Method M) (Step M-1) Step M-1 is a method for preparing a compound of formula (lm) by preparing a compound of formula (Ii) (which can be prepared according to the above methods A to VII) in the presence of carbon monoxide and The ring A in the formula (I) has a halogen atom) and reacts with a compound of the formula (XIII) (which is a known compound or can be easily prepared from a known compound). Step M-1 can be performed according to the method described in the literature cited in Step L-1. (Method N) (Step N-1) ^ Step N-1 is a method for preparing a compound of formula (10) by combining a compound of formula (which can be prepared according to the above-mentioned methods A to Η, and in the formula (1) γ is a halogenated phenylalkyl group, and is reacted with a compound of formula (XIII), which is a known compound or can be easily prepared from a known compound. This step can be performed according to the method described in the literature cited in step j_i. (Method 0) -304- 200401770 (Step ο -1) Step 0 -1 is a method for preparing a compound of formula (Ip), which is carried out by using a compound of formula (In) in the presence or absence of a catalyst (based on the above) Processes A to η are prepared 'and hydrazone in formula (I) is a halogenated phenylalkyl) and is reacted with a metal cyanide. Step 0-1 can be performed according to a similar method as described in step K-1. (Method P) (Step P · 1) Step P-ι is a method for preparing a compound of formula (Iq) by preparing a compound of formula (In) (which can be prepared according to the above methods A to Η in the presence of carbon monoxide and Rhenium in formula (I) is a halogenated phenyl group, and is reacted with a compound of formula (XIV), which is a known compound or can be easily prepared from a known compound. Step P-1 can be performed according to the method described in the literature cited in Step L-1. (Method Q) (Step Q-1) Step Q-1 is a method for preparing a compound of formula (Ir) by preparing a compound of formula (In) in the presence of carbon monoxide (which can be prepared according to the above methods a to Η, and (I) is a halogenated phenylalkyl group, and is reacted with a compound of formula (XIII), which is a known compound or can be easily prepared from a known compound. Step L-1 can be performed according to the method described in the literature cited in Step L-1. The compound of formula (IV) used in the methods A to E can be prepared according to the following method R or S. The compound of the formula (π) used in the methods A and B can be prepared according to the following method -305-200401770.

(Method R) (Step R-1) Step R-1 is a method for preparing a compound of formula (IVa) by the following reaction ... (Step R-la) is a compound of formula (XV) (is a known compound or can be obtained by It is known that the compound is easily prepared) by reaction with hexafluoroacetone or hexafluoroacetone hydrate; and (step R-ib) is a subsequent selective conversion of the hydroxyl group to other substituents χ. (Step R-la) Step R-1 can be performed according to the method described in the literature: Bull. Acad. Sci,

-306- 200401770 U S S R D i v · C h e m. S c i · (E n g 1 · T r a n s 1 ·), 3 2 3-3 2 8 (1 9 9 0); or WO 00/5 47 5 9. (Step R-lb) If necessary, step R-lb can be performed according to a similar method to that used in step F-1 or step G-i. (Method.S) (Step S-1) Step S-1 is a method for preparing a compound of formula (IVb) by the following reaction: (Step S-1a) includes nitrating a compound of formula (X v I) (known The compound may be easily prepared from a known compound), and (step S-lb) is a subsequent nitro reduction reaction. Step S-1 can be carried out according to the method described in Example 15 of WO 00/54759 or a modification thereof. (Method T) (Step T-1) Step T-1 is a method for preparing a compound of formula (XVIII) by subjecting a compound of formula (XVII) (which is a known compound or can be easily prepared from a known compound) to a hydroxyl group Aminoacetamidation, and the resulting compound is then subjected to isatin (isatin) cyclization. Step T-1 can be based on the literature (Organic Synthesis Collective Volume 1, p3 27; Indian J. Chem. Sect. B, 5 78-5 8 1 (1 9 9 0); J. Chem. Research (M), 3 1 5 5-3 1 72 (1 9 9 3); J. Med. Chem., 36, 7 3 3 -746 (1 993); Synthesis, 993 (1 99 3); Synthetic

Communication, 24, 5 3 3-5 4 8 (1 994)) or its improvement method 200401770 method. (Step T-2) Step T-2 is a method for producing a compound of formula (II), which is performed by oxidizing the compound of formula (XVIII) prepared in the above step T-1. Step T-2 can be based on the literature (J. Chem. Research (M), 3155-3172 (1993); J. Med. Chexn., 36, 733-746 (1993); or Synthetic Communication, 24, 5 3 3- 5 4 8 (1 994)) or an improved method thereof. The compound of formula (I) of the present invention or a pharmacologically acceptable salt or ester thereof exhibits excellent binding affinity for LXR. The compound of formula (1) of the present invention and its pharmacologically acceptable salts and esters have and absorb , Distribution, half-life of blood concentration, and other excellent pharmacokinetic properties, and low toxicity to kidneys, liver and other organs. Therefore, the compound of formula (I) and its pharmacologically acceptable salts and esters of the present invention can be used as medicines for warm-blooded animals, preferably humans; especially for treatment and / or prevention including derivatization Arteriosclerosis in the following diseases: atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, such as chronic rheumatoid arthritis, Osteoarthritis, allergic diseases, asthma, sepsis, psoriasis and osteoporosis, autoimmune diseases such as systemic lupus erythematosus, ulcerative colitis and Crohn's disease, cardiovascular diseases such as anemia heart disease and Heart failure, cerebrovascular disease, kidney disease, diabetes, diabetic dysfunction such as retinopathy, nephropathy, neuropathy and coronary artery disease, obesity, nephritis, hepatitis, cancer and Alzheimer's disease; preferably Atherosclerosis, atherosclerosis-308- 200401770 sclerosis, atherosclerosis, derived from diabetes, hyperlipidemia, fat-related diseases, Inflammatory diseases of the regulation of inflammatory cytokines, and diabetes; and most preferably is arteriosclerosis. When the compound of formula (I) and its pharmacologically acceptable salts and esters are used as medicines, they can be combined with other medicines according to the intended use. This medicine is not completely limited to the provider, and its basis The purpose is to exhibit a desired effect, and is preferably an HMG-CoA reductase inhibitor, an ACAT inhibitor, an vasopressin II inhibitor, and a diuretic, and more preferably an HMG-CoA reductase inhibitor. The above HMG-CoA reductase inhibitor is not completely limited to the provider, it has HMG-CoA reductase inhibitory activity and can be used as a medicine, and can be, for example, Japanese Patent Application (Publication) No. Sho 57-2240 (USP4 , 346,227) Pravastatin or (+)-(3R, 5R) -3,5-dihydroxy-7-[(13,23,63,83,8 & 11) -6-hydroxy -2-methyl-8-[(3) -2-methylbutylfluorenyloxy] -1,2,6,7,8,8 & -hexahydro-1-naphthyl] heptanoic acid monosodium salt ( Pravastatin Sodium), Japanese Patent Application (Publication) No. Sho 57-163374 (USP 4,231,938) (+)-(lS, 3R, 7S, 8S, 8aR) -1,2,3 , 7,8,8a-Hexamin-3,7-dimethyl-8- [2-[(2R, 4R) -tetrahydro-4-hydroxy-6-keto-2H-piperan-2-yl ] Ethyl] -1-naphthyl (S) -2-methylbutyrate (lovastatin), Japanese Patent Application (Kokai) No. Sho 5 6- 1 223 75 (USP 4,44457 84 ) Mentioned in (+)-(13,311,73,83,8 & 10-1,2,3,7,8,8 & -hexahydro-3,7-dimethyl-8- [2- [ (2R, 4R) -tetrahydro-4-hydroxy-6-keto-2H-piperan-2-yl] ethyl] -1-naphthyl 2,2-dimethylbutyrate (simvastatin; simvastatin), Japan Patent Application (Kohyo) No. Sho 60- 5 000 1 5 (USP 4,7 3 9,07 3) (Taxi)-200401770 (3R *, 5S *, 6E) -7- [3- ( 4-fluorophenyl) -1- (1-methylethyl) -lH-D arch [indole-2-yl] -3,5-dihydroxy-6-heptenoic acid (fluvastatin), Japanese Patent Application (Kokai) No. Hei 1-2 1 6974 (USP 5,006,5 3 0) described in (3R, 5S56E) -7- [4- (4-fluorophenyl) -2,6-di -(l-methylethyl) -5-methoxymethylpyridin-3-yl] -3,5-dihydroxy-6-heptenoic acid (rivastatin; cerivastatin), Japanese Patent Application (Kokai ) No. Hei 3-58967 (USP 5,273,995) described in (311,53) -7- [2- (4-fluorophenyl) -5- (1-methylethyl) -3-phenyl-4 -Phenylaminocarbonyl-1H-pyrrole-1-yl] -3,5-dihydroxyheptanoic acid (atorvastatin), Japanese Patent Application (Kokai) No. Hei 1- 279866 (USP 5,854,259 And (E) -3,5-dihydroxy-7- [4 '-(4 ”-fluorophenyl) -2cyclopropylquinoline-3'-yl] -6-heptene as described in USP 5,856,336) Acid (pitavastatin), described in Japanese Patent Application (Kokai) No. Hei 5- 1 78841 (USP 5,260,440) (+)-(311 53) -7- [4- (4-fluorophenyl) -6-isopropyl-2- (N -methyl-N -methanesulfonylamino) pyrimidin-5-yl] -3,5- Dimeryl-6 (E) -heptenoic acid (rosuvastatin), or a pharmacologically acceptable salt thereof. The above AC AT inhibitor is not completely limited to the provider, it has AC AT inhibitory activity and can be used as a drug, and may be, for example, N- [4- (3,4-dimethylphenyldiazacyclohexyl]-( 2E)-(3,5-dimethoxy-4-octyloxyphenyl)-2-propenamide, (3) -2 ', 3', 5'-trimethyl-4'-hydroxy- [Dodecylthio-"-phenylacetamidoaniline, trans-1,4-bis [[1-cyclohexyl-3- (4-dimethylaminophenyl) ureido] methyl] cyclohexyl Alkanes, 1- (2,6-diisopropylphenyl) -3- [4 (R), 5 (R) -dimethyl-2- (4-phosphonophenyl) -1,3- Difluoren-2-ylmethyl] urea, or 2,6-diisopropylphenyl [(2,4,6-triisopropylphenyl) ethenyl] aminosulfonate. -310- 200401770 The above vasopressin π inhibitor is not completely limited to the provider, it has vasopressin II inhibitory activity and can be used as a drug, and can be, for example, Kangding described in EP 45 9 1 3 6 or EP 5 2042 3 Sata (candesartan) or 2-ethoxy-1- [ρ- (〇-1Η-tetrazol-5-ylphenyl) benzyl] -7-benzimidazolecarboxylic acid 1- (cyclohexyloxy Ferro) ethyl vinegar (Candesartan cilexetil), WO 91/14679 of 2-n-butyl-4-spirocyclopentane-tetrazol-5-yl) bisphenyl-4-yl) methyl] -2-imidazolin-5-one (Ibessa He; irbesartan), Japanese patent application (Kokai) No. Hei 5-78328 (USP 5,459,148) described in Omisata (〇11 ^ 531 ^ 11), (5-methyl-2-keto- 1,3-Difluorenyl-4-yl) methyl 4- (1-hydroxy-1-methylethyl) -2-propyl-1-[[2 '-(1H-tetrazole-5- Group) bisphenyl-4-yl] methyl] imidazole-5-carboxylate (olmesartan medoxomil), Japanese patent application (publication) No. Hei 5 -3 20 1 3 9 The 2-propyl-8-keto-1-[(2 '-(1′-tetrazol-5-yl) bisphenyl-4_yl) methyl] _4,5,6,7-tetra Hydrocycloheptimidazole (pratosartan), EP 5 0 2 3 1 4 described in the 4 '-[(1,4'-dimethyl-2, -propyl [2,6'_bis- 1H-benzimidazole] -1'-yl) methyl]-[1,1'-bisphenyl] -2-carboxylic acid (tommisartan), described in EP 443 9 8 3 (S ) -N-pentamyl-N-([2f- (lH-tetrazol-5-yl) bisphenyl-4-yl] methyl) valine (valsartan), described in EP 403159 Ipsa prosartan), 3- [1- (4-carboxylic acid phenylmethyl) -2-η-butylimidazol-5-yl] -2-thienylmethyl-2-acrylic acid methanesulfonate (Ipsa Methane sulfonate), rusata (108 & 1 ^ 11) as described in EP 2 5 3 3 1 0 or EP 51 1767, 2-butyl-4-chloro-1-[[2'- (111-tetrazol-5-yl Ml, 1'_bisphenyl] -4-yl] methyl] -1Η_imidazole-5-methanol monopotassium salt (lusata potassium), or a pharmacologically acceptable Acceptable salts. -311- 200401770 The above-mentioned diuretics are not completely limited to the providers, they exhibit diuretic activity and can be used as medicines, and may be, for example, chlorothiazide (ch 1 〇 〇 〇thiazide), monohydrochlorothiazide (dihydrocholrothiazide), fosimidin (furosemide), piretanide, or azosemide. When the compound of formula (I) of the present invention or a pharmacologically acceptable salt or ester thereof is used as a drug for treating or preventing the above-mentioned diseases The compound of formula (I) or a pharmacologically acceptable salt or ester thereof may be administered alone or in combination with pharmaceutically acceptable excipients, diluents and the like in a pharmaceutical dosage form, such as a lozenge, Capsules, granules, powders or syrups, or parenteral administration in pharmaceutical dosage forms, such as injections, suppositories, gels or topical preparations. These pharmaceutical dosage forms can be prepared by well-known methods using additives such as excipients, lubricants, binding agents, disintegrating agents, emulsifiers, stabilizers, correction agents, diluents and the like. The excipient may be, for example, an organic excipient or an inorganic excipient. Organic excipients include, for example, sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, α-M powder or dextrin, cellulose derivatives such as crystals Cellulose; acacia; dextran; or amylopectin. Inorganic excipients can be, for example, silicate derivatives such as light silicic anhydride, synthetic aluminum silicate, calcium silicate or magnesium aluminate metasilicate; phosphates, such as calcium hydrogen phosphate; carbonates, such as carbonate ; Or sulfates, such as calcium sulfate. Lubricants may be, for example, stearic acid; metallic stearates such as sodium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or cetyl wax; -312- 200401770 boric acid; adipate Acids; sulfates, such as sodium sulfate; glycols; fumaric acid; sodium benzoate; DL-leucine; dodecyl sulfate, such as sodium dodecyl sulfate or magnesium dodecyl sulfate; silicic acid derivatives, Examples are silicic anhydride or silicic acid hydrate; or starch derivatives as described above. The binding agent may be, for example, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, poly (ethylene glycol), or a derivative of the aforementioned excipient. The decomposing agent may be, for example, a cellulose derivative, such as low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, or internally cross-linked carboxymethyl cellulose sodium; chemically modified dusting-fiber Derivatives, such as residual methyl starch or sodium carboxymethyl starch; or cross-linked polyvinyl pyrrolidone. Emulsifiers can be, for example, colloidal clays, such as bentonite or vee gum; metal hydroxides, such as magnesium hydroxide or aluminum hydroxide; anionic surfactants, such as sodium dodecyl sulfate or hard Calcium fatty acid; cationic surfactants such as benzyl chloride (benza 1 k nium chloride); or non-ionic surfactants such as polyoxyalkylene ether, fatty acid polyoxyethylene Sorbitan esters or sucrose esters of fatty acids. The stabilizer may be, for example, a paraben, such as methylparaben or propylparaben; alcohols, such as chlorobutanol, benzyl alcohol, or phenylethanol; benzyl ammonium chloride Phenol derivatives, such as phenol or cresol; ethylmercury sodium thimerosal; dehydroacetic acid; or sorbic acid. The corrective agent may be, for example, a traditional sweetener, acidifier, flavoring agent, and the like. The dosage concentration of the compound of formula (I) or a pharmacologically acceptable salt or ester thereof varies depending on the disease to be treated, the age of the patient, etc., and the appropriate daily unit concentration per adult per adult is 1 nlg (preferred) Oral administration in the range of 30 mg) to 2000 (1500 mg better than -313-200401770), and 0.5 mg (preferably 5 mg) to 500 mg (preferably It is administered intravenously in the range of 250 mg), and the above dose is preferably administered 1 to 6 times a day depending on the degree of the disease and the course of the disease. [Embodiment] The present invention is further described by the description of the following examples, test examples and deployment examples, and the scope of the present invention is not limited to these examples, test examples and deployment examples. (Example 1) 2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quine Zazolinone (Exemplified Compound No. 3-7) Anthranilic acid (150 mg, 1.1 mmol), phenylacetic acid (150 mg, 1.1 mmol) and triphenyl phosphate (0.29 ml, 1.1 mmol) were dissolved in pyridine (2 ml ), And the resulting solution was 100 under nitrogen pressure. After stirring for 2 hours, 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (259 mg, 1 mmol) was added to the reaction mixture, and all The resulting mixture was further stirred for 3 hours. At the end of this time, the reaction mixture was concentrated under reduced pressure by evaporation, and the residue thus obtained was subjected to silica gel column chromatography (using a volume of 4: 1 hexane) The mixture with ethyl acetate was purified as the eluent) to give the title compound (364 mg, yield: 76%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 2 1 6 ° C. IR (KBr): vmax 3 03 2, 1 65 6, 1 5 8 9, 1271, 1187, 96 7 cnT1 · W-NMR (400MHz, CDC13): 5 8 · 2 8 (1 H 5 d 5 J = 8 · 0 H z), 7 · 8 4 (1H, m) 5 7 · 83 (1H, d, J = 1.6 Hz), 7 · 68 (2H, d, J = 8.8 Hz), 7.54 (1H, m), 7.15-7.07 (3H, m), 6.96 (2H, d, J = 8.8 Hz) 5 200401770 6.71 (2H5 d, J = 7.2 Hz), 4.46 (1H, s), 3.92 (2H, s) FABMS (m / z): 501 ([M + Na] +, 479 ([M + H].) FABHRMS (m / z): calcd. For C24H17F6N202 ([M + H] +): 479.1 1 95; found: 479.1 20 1 · Anal, calcd. For C24H16F6N2 02: C, 60.26; H, 3.37; N, 5.86; found: C? 60.18; H? 3.42; N5 5.8 6. ( Example 2) 2- (4-Bromobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 ( 3 ii) -quinazolinone (Exemplary Compound No. 3-31) In a similar manner as described in Example 1, o-aminobenzoic acid (99 mg, 0.72 mmol), 4-bromophenylacetic acid (155 mg, 0.72 mmol) ), Triphenyl phosphate (0.19 ml, 0.72 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (187 mg, 0.72 mmol ) To obtain the title compound Color solid (3 09 mg, yield: 77%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. Mp 267-268 ° C. IR (KBr): v max 3 3 0 8, 1 6 8 6, 1661, 1 5 92, 1 267, 1216, 1108, 936 cm'1. 'H-NMR (400MHz? COC \ 3): d 8 · 2 8 (1 H, d, J = 8 · 0 H z) 5 7 · 8 4 (1H, m), 7.81 (1H, d, J = 8.0 Hz), 7.76 (1H, d, J = 8.8 Hz), 7.54 (1H, m ), 7.2 5-7.2 3 (3 H, m), 7.04 (2H, d, J = 8.8 Hz), 6.61 (2H, d, J = 8.0 Hz), 4.10 (1H5 s), 3.86 (2H, s). FABMS (m / z): 5 5 9, 5 5 7 ([M + H] +). FABHRMS (m / z): calcd. for C 2 4 H! 6 7 9 B r F 6N 2 O 2 ([M + H] +): 5 5 7.022 9; found: 5 5 7.0 3 3 2. Anal, calcd. For C24H15BrF6N202: 200401770 C, 51.73; Η, 2.71; N, 5.03; found: C, 51.65; Rhenium, 2.73; N, 5.01. (Example 3) 2- (3-Bromobenzyl) -3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl [Phenyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-30) In a similar manner as described in Example 1, o-aminobenzoic acid (i 50 mg, 1.;! Mmol) 3-bromobenzene Acetic acid (237 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro 2-propanol (259 mg, 1.0 mmol) to give the title compound as a colorless solid (320 mg, yield: 58%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate. A colorless orthorhombic crystal is produced. mp 186-187 ° C. IR (KBr): z; max 3 2 8 3, 1 6 5 8, 1 5 90, 1 474, 1 270, 1214, 1192, 935 cm " 1. W-NMR (400MHz, CDC13): δ 8 · 28 (1H5 d, J = 8.0 Hz), 7.83 (1H, m), 7.81 (1H5 d, J = 7.2 Hz), 7.76 (2H, d, J = 8.8 Hz), 7.55 (1H, m), 7.32 (1H, d, J = 8.8 Hz), 7.03 (2H, d5 J = 8.8 Hz), 7.01 (1H, m), 6.97 (1H, t, J = 8.0 Hz), 6.59 ( 1H, d, J = 7.6 Hz), 4.15 (1H, s), 3.87 (2H, s). FABMS (m / z): 5 5 9, 5 5 7 ([M + H] +). FABHRMS (m / z): calcd · for C24H1679BrF6N202 ([M + H] +): 5 5 7.0229; found: 5 5 7.03 00. Anal, calcd. for C24H j 5BrF6N202: C, 51.73; H, 2.71; N, 5.03; found : C, 51.76; H, 2.65; N, 5.00. (Example 4) -316- 200401770 2- (2-bromobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified Compound No. 3-29) In a similar manner as described in Example 1, an o-aminobenzoic acid (丨50 mg, 1.1 mmol), 2-bromophenylacetic acid (237 mg, 1.1 mmol), triphenylacetic acid diacetate (0.29 ml, 1.1 mmol), and 2- (4-amino Base) -1,1,1,3,3,3-hexafluoro-2-propanol (259 mg, 1.0 mmol) to obtain the title compound as a colorless solid (472 mg, yield: 85%) This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 233-234 ° C. φ IR (KB〇: u max 3 270, 1 65 7, 1 5 94, 1 474, 1 269, 1215, 1192, 936 cm · 1 · W-NMR (400MHz, CDC13) · · Δ 8.28 (1H, d, J = 8.0 Ηζ), 7.81 (1H, m), 7.76 (2H, d, J = 8.8 Hz), 7.75 (1H, d, J == 8.0 Hz), 7 · 5 3 (1 H, m), 7 · 3 9 (1 H, d, J = 8 · 8 H z), 7.2 1-7 · 2 0 (2 H, m), 7 · 11 (2H, d, J = 8.8 Hz), 7.09 (1H, m), 4.02 (2H, s), 3.60 (1H, brs).

FABMS (m / z): 5 5 9, 5, 5 7 ([M + H] +). FABHRMS (m / z): calcd. For C24H 1 6 7 9 BrF6N2〇2 ([M + H] +): 557.0229; found: 557.0302. Anal, calcd. For C74H15BrF6N〇09: C5 51.73; H, 2.71; N, 5.03; found: C5 51.93; H5 3.02; N, 4.71. (Example 5) 2- (4-Difluoromethyl Phenylbenzyl) _3- [4_ [2,2,2-trifluoro-1- mesityl trifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -dazinonone (illustrated compound number 3 _ 4 〇) -317- 200401770 In a similar manner to that described in Example 1, o-aminobenzoic acid (150 mg, 1.1 mmol), 4-trifluoromethylphenylacetic acid (224 mg, 1.1 mmol), and triphosphate Phenyl ester (0.29 ml, 1.1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoropropanol (25 9 mg, 1.0 mmol) to obtain the title compound A colorless solid (475 mg, yield: 87%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 267-268 ° C. IR (KB〇: u max 3177, 1 663, 1 5 94, 1 329, 1219, 1122, 1 0 6, 8, 939 cm-1.) H-NMR (400MHz5 CDC13): ^ 8.2 9 (1 H, dd, J = 8 · 4, 1 · 2 H z) 5 7.85 (1H, dt, J = 6 · 8, 1.2 Hz), 7.81 (1H, d, J = 8 0 Hz), 7.73 (2H, d, J = 8.4 Hz), 7.55 (1H, dt, J = 6.8, 1.2 Hz), 7.37 (2H, d5 J = 8.0 Hz ), 7.03 (2H, d, J = 8.4 Hz), 6.88 (2H5 d, J = 8.0 Hz), 3.98 (3H, s) · FABMS (m / z): 547 ([M + H] +). FABHRMS (m / z): calcd. for C25H16F9N202 ([M + H] +): 5 47.1 069; found: 547.1 052. Anal, calcd. for C 2 5 H j 5 F 9N 2 O 2: C5 5 4.96; H 2.77; N? 5.13; found: C, 54.77; H5 2.8 4; N, 5.19. (Example 6) 2- (3-trifluoromethylbenzyl) -3_ [4- [2,2,2- Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (Exemplified Compound No. 3-39) In a similar manner as described in Example 1, Aminobenzoic acid (150 mg, 1.1 mmol), 3-trifluoromethylphenylacetic acid (224 mg, 1.1 mmol) triphenylacetic acid phosphate (0.29 ml, 1.1 mm) and 2- (4-aminobenzene) -318- 200401770 propanol (2 5 9 mg (1.0 mmol) to give the title compound as a colorless solid (394 mg5 yield: 72%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. Mp 200-201 ° C. IR ( KBr): umax 3 2 7 1, 1 664, 1 5 94, 1 3 3 4, 1218, 1 1 22, 9 3 5 cm.1 · iH-NMR (400MHz, CDC13): δ 8.28 (1H, d5 J = 8.0 Hz), 7.86 (1H, dt, J = 7.2, 1.6 Hz), 7.82 (1H, d, J = 8.0 Hz), 7.75 (2H, d5 J = 8.8 Hz), 7.56 ( 1H, t, J = 7.2 Hz) 5 7 · 46 (1H, d, J = 7.2 Hz), 7.25 (1H, t, J = 7.6 Hz), 7.08 (1H, s), 6.9 7 ( 2H, d, J = 8.8 Hz), 6.98 (1H, t, J = 8.0 Hz), 4.54 (1H, s), 3.95 (2H, s). FABMS (m / z): 547 ([M + H] +). FABHRMS (m / z): calcd. For C25H16F9N2 02 ([M + H] +): 547.1 069; found · 547.1 07 1 · Anal · calcd · for C25H15F9N202 ·· C, 5 4.96; H , 2.77; N, 5.13; found: C? 54.90; H, 2.62; N, 5.22. (Example 7) 2- (2-_ ^ Mercaptomethyl) _3- [4- [2,2,2- Dichloro-1-meryl-1- (dichloromethyl) ethyl] phenyl] -4 (3 fluorene) -quinazolinone (Exemplified Compound No. 3_38) In a similar way, o-aminobenzoic acid (274 mg, 2.0 mmol), 2-trifluoromethylphenylacetic acid (408 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) to obtain the title compound as a colorless solid, which was obtained from hexane and acetic acid The ethyl acetate was recrystallized from a mixed solvent to produce colorless orthorhombic crystals (317 mg, yield: 36%). mp 22 6-22 7 ° C. 200401770 IR (KBr): y max 3 2 8 45 1 6 6 0, 1 5 9 6,1 3 1 45 1 2 6 8? 1 2 1 5 5 1 1 1 3? 769 cm'1.! H-NMR (400MHz, DMSO-d6): 5 8 · 8 7 (1 H, s), 8 · 1 5 (1 H, dd, J = 8 · 0, 1.2 Hz) , 7.87 (1H, m), 7.69 (2H, d, J = 8.4 Hz), 7.65 (1H, d, J = 8.0 Hz), 7.60-7.5 6 (3H, m), 7.46- 7.3 9 (4H5 m), 3.97 (2H, s) · FABMS (m / z): 547 ([M + H] +). FABHRMS (m / z): calcd. For C25H16F9N2 02 ([M + H] + ): 547.1 06 8; found: 547.1 066 · Anal, calcd · for C25H15F9N2 0 2: C, 54.96; H, 2.77; N, 5.13; found: C, 5 5.05; H, 2.65; N, 5.24. (Example 8 ) 2- (4-hydroxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _4 (3 H) -Quinazolinone (Exemplary Compound No. 3-43) In a similar manner to that described in Example 1, o-aminobenzoic acid (150 mg, 1.1 mmol), 4-mercaptophenylacetic acid (167 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (25 9 mg, 1.0 mmol) to give the title compound as a colorless solid (264 mg, yield: 53%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 264-267 ° C (dec.). IR (KBr): w max 3298, 1 674, 1 5 93, 1516, 1271, 1191, 1106, 938 cm'1 'H-NMR (400MHz5 DMSO-d6): δ 9.2 3 (1 H 5 s), 8 · 9 2 (1 H, s), 8 · 11 (1H, d, J = 8.0 Hz), 7.89 (1H, t, J = 8.0 Hz) 5 7 · 75 (1H, -320- 200401770 d, J = 8.0 Hz), 7.70 (2H5 d, J = 8.8 Hz), 7.56 (1H, t, j = 8 0 Hz), 7.30 (2H, d5 J = 8.8 Hz), 6.48 (4H, s), 3,72 (2H, s). FABMS (m / z): 49 5 ([M + H] +). FABHRMS (m / z): Calcd. For C24H17F6N2〇 3 ([M + H] +): 495.1 1 44; found: 4 9 5. 1 1 1 5. Anal. Calcd. For C24h j 6F6N2 03: C? 58.31; H, 3.26; N, 5.67; found: C , 58.01; H, 3.43; n, 5.51 · (Example 9) 2- (3-Cyridylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3_42) In a similar manner to that described in Example 1, o-aminobenzoic acid (150 mg, U mmol) was used. , 3-Ethylphenylacetic acid (167 mg, 1.1 mmol), triphenyl diacetate (0.29 ml, 1.1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3, 3-hexafluoro-2-propanol (25 9 mg, 1.0 mmol) The title compound was obtained as a colorless solid (241 mg, yield: 49%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals.

mp 254-256 ° C. IR (KBr): v max 3 3 20,1 682,1 5 93,1 267,1 2 1 4,1 1 73,9 3 3 cm · 1 · iH-NMR (400MHz, DMSO-d6): 5 9 · 2 0 (1 H, s), 8 · 9 0 (1 H, s), 8 · 13 (1H, d, J = 8 · 0 Hz), 7.90 (1H, t, J = 8.8 Hz), 7.76 (1H, d, J = 8.0 Hz), 7.70 (2H, d · J = 8.0 Hz), 7.58 (1H, t, J = 7.2 Hz), 7.33 (2H, d , J = 8.8 Hz), 6.83 (1H, t, J = 8.0 Hz), 6.54 (1H, d, J = 8.0 Hz), 6.44 (1H, s), 5.95 (1H, d, J = 7.2 Hz ), 3.74 (2H, s). -321- 200401770 FABMS (m / z): 495 ([M + H] +). FABHRMS (m / z): calcd. For C24H17F6N2 03 ([M + H] +) : 495.1 1 44; found: 49 5.1 1 3 1. Anal, calcd. For C24H, 6F6N2 0 3: C? 58 · 31; H, 3.26; N5 5.6 7; found: C, 5 8.5 0; H, 3.42; N, 5.60. (Example 10) Di-^-benzyloxybenzylbenzene ^ "^^ factory trifluoro-丨-hydroxy" trifluoromethyl) ethyl] phenyl; 1-4 (3 H) -quinazolinone (Exemplified Compound No. 3-229 9) In a similar manner as described in Example 1, o-aminobenzoic acid (23 8 1Tlg, 丨 .74 mmol), 2-benzyloxyphenylacetic acid (42 〇mg, 174 mmol), Triphenyl phosphate (0.46 ml, 1.74 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (409 mg, 1.58 mmol) The title compound was a colorless solid (400 mg, yield: 43%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 164-1650C.

IR (KBr): u max 3 26 6,1 66 1,1 594,1 269, 1214, 1 108, 9 3 5 cnT, 'H-NMR (400MHz, CDC13): δ 8.27 (1H5 d? J = 8.0 Hz)? 7.77 (1H, t5 J = 6.4 Hz), 7.67 (1H, d, J = 8.0 Hz), 7.64 (2H, d, J = 8.8 Hz), 7.50 (1H, t, J = 6.4 Hz), 7.25-7.10 (6H, m), 6.95 (2H, d, J = 8.8 Hz), 6.93 (1H, m), 6.83 (1H, d, J = 7.6 Hz), 6.79 (1H, d, J = 8 · 8 Hz), 4.80 (2H, s), 4.15 (1H, s), 3.87 (2H, s). FABMS (m / z): 5 8 5 ([M + H] +) · FABHRMS ( m / z): calcd. for C31H23F6N203 ([M + H] +): 585.1613; found: 585.1610. Anal, calcd. for C31H22F6TSi203: C, -322- 200401770 63.70; H, 3.79; Ν, 4.79; found : C, 64.0 8; H, 4.12; N, 4.68. (Example 11) 2- (2-hydroxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-l- (Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-41) Wet carbon containing 20% palladium hydroxide [50% (w / w) , 40 mg] was added to the 2- (2-benzyloxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3 H) -panconazole Ketone (I50mg, 2 5 7 # m ο 1) in methanol (3 m 1) solution, and then the resulting mixture was stirred under hydrogen pressure for 1 hour. The catalyst was removed by filtration through Celite, and The filtrate was concentrated, and the resulting residue was purified by silica gel column chromatography (using a 3: 1 volume of a mixture of hexane and ethyl acetate as the eluent) to give the title compound (94 mg, yield: 76 %). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 206-207 ° C. IR (KBr): v max 3 299, 1 6 8 3, 1 5 96, 1 47 5, 1 270, 1216, 1 108, 934 cm'1. W-NMR (400MHz, CDC13 ): δ 10.50 (1H, s) 5 8.2 5 (1 H, d, J = 8.4 Hz), 8.01 (2H, d, J = 8.8 Hz), 7.82 (1H, t, J = 8.8 Hz), 7.73 (1H, d, J = 7.6 Hz), 7.53 (1H, t, J = 8.4 Hz), 7.38 (2H, d5 J = 8.8 Hz), 7.16 (1H, t, J = 7.6 Hz), 6.96 (1H5 d, J = 8.0 Hz), 6.71 (1H5 t5 J = 7.6 Hz), 6.26 (1H? d5 J = 8.0 Hz), 4.07 (1H, s), 3.81 (2H, s). > 323- 200401770 FABMS ( m / z): 495 ([M + H] +). FABHRMS (m / z): calcd. for C24H17F6N2〇3 ([M + H] +): 495.1 143; found: 495.1 166. Anal, calcd · for C24H16F6N203: C, 58.31; H, 3.26; N 3 5.6 7; found: C? 58.12; H, 3.52; N, 5.50. (Example 12) 2- (3,4-methylenedioxybenzyl)- 3- [4- [2,2,2-trifluoro-l-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (Exemplified compound number 3- 113) In a similar manner as described in Example 1, from o-aminobenzoic acid (150 mg, 1.1 mmol), 3,4-methylenedioxyphenylacetic acid (198 mg, 1.1 mmol), Triphenyl acid (0.29 ml, 1.1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (259 mg, 1.0 mmol) were obtained The title compound was a colorless solid (4 34 mg, yield: 83%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 200-202 ° C. IR (KBr): v max 3 3 6 1,1 674,1 5 93,1 49 1,1 246,1 1 92, 93 3 cm'1. 'H-NMR (400MHz? CDC13): δ 8.28 (1H? D5 J = 7.2 Hz)? 7.82 (2H, m), 7.75 (2H, d5 J = 8.8 Hz), 7.53 (1H, t, J = 8.0 Hz), 7.04 (2H , D, J = 8.8 Hz), 6.51 (1H, d, J = 7.2 Hz), 6.34 (1H, d, J = 1.6 Hz), 6.01 (1H, dd, J = 7.2, 1.6 Hz) , 5.89 (2H, s), 4.21 (1H, s), 3.82 (2H, s). FABMS (m / z): 52 3 ([M + H] +). FABHRMS (m / z): caled. For C25H17F6N2 04 ([M + H] +): -324- 200401770 523.1093; found: 523.1081. Anal · calcd. For C ”HFN 〇 · C 57 · 48; H, 3.09; N, 5.36; found: C, 5 7.5 4; H, 3.31; N, 5.29 · (Example 13) 2- [4- (t-butoxycarbonylamino) benzyl] _3- [4 · [2,2,2_trifluoro- ^ hydroxy _ 1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified Compound No. 3- 7 1) In a similar manner as described in Example 1, an o-aminobenzoic acid ( 150 mg, 1.1 mmol), 4- (t-butoxycarbonylamino) phenylacetic acid (276 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol), and 2- (4 -Aminophenyl) -1 1,1,3,3,3-hexafluoro-2-propanol (259 11 ^, 1.011111111) was obtained as the colorless solid of the title compound (176 mg, yield: 30%). Recrystallized from a mixed solvent of alkane and ethyl acetate to produce colorless orthorhombic crystals. Mp 240-241 ° C. IR (KBr): vmax 3331, 1727, 1659, 1594, 1525, 1271, 1230, 1168, 93 7 cm · 1. 'H-NMR (400MHz? DMSO-d6): (5 9 · 2 6 (1 H, s), 8 · 9 3 (1 H, s), 8.11 (1H, d, J = 8.8 Hz) , 7.90 (1H, t, J = 8.0 Hz), 7.74 (1H, d, J = 8.0 Hz), 7.72 (2H, d5 J = 8 · 8 Hz), 7.55 (1H, t, J = 8.0 Hz), 7.35 (2H? D, J = 8.0 Hz) 5 7.2 2 (2 H? D? J = 8.8 Hz), 6.60 (1H, d, J = 8.8 Hz), 3.75 (2H, s). 1.45 (9H, s). FABMS (m / z): 5 94 ([M + H] +). FABHRMS (m / z): calcd · for C29H26F6N3 04 ([M + H] +): 594.1827; found: 594.1821 Anal, calcd. For C29H25F6N304: C5 58.69; H, 4.25; N? 7.08; found: C? 58.71; H, 4.25; N? 6.98. -325- 200401770 (Example 14) 2- (2-fluorobenzyl ) -3- [4- [2,2,2-trifluoro-1-hydroxy-1_ (fluorenylmethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (exemplified compounds No. 3-35) In a similar manner to that described in Example 1, an o-aminobenzoic acid (274 mg, 5 mmol), 2-fluorophenylacetic acid (308 mg, 2.0 mmol), and triphenyl phosphate (0 52 ml, 2.0 mmol) and 2- (4 · aminophenyl) -1,1,1,3,3,3-hexafluoro_2-propanol (415 mg, 1.6 mmol) to give the title compound as a colorless solid, this product Recrystallization from a mixed solvent of hexane and ethyl acetate gave colorless orthorhombic crystals (343 mg, yield: 43%). mp 239-240 ° C. IR (KBr): V max 3 23 9, 1 676, 1 5 9 8, 1 264, 1 23 0, 1 1 75, 93 3 cm · 1.! H-NMR (400MHz? DMSO-d6): δ 8.93 (1H, s)? 8.13 (1H5 dd? J = 8.0, 1.2 Hz), 7.87 (1H, m), 7.71 (2H, d, J = 8 · 4 Hz), 7.68 (1H, d, J = 8.0 Hz), 7.57 (1H, m), 7.41 (2H, d, J = 8.8 Hz), 7.25 (1H, m), 7.15 (1H, m), 7.04 ( 1H, m), 6.94 (1H, m), 3.85 (2H? S). FABMS (m / z): 497 ([M + H] +). FABHRMS (m / z): calcd · for C24H16F7N202 ( [M + H] +): 497.1 1 00; found: 497.1 0 95. Anal · calcd · for C24H15F7N202: C, 58.0 7; H, 3.05; N, 5.64; found: C, 5 7.99; H, 3.28; N , 5.52. (Example 15) 2- (3-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl ] -4 (3 H) -azolidone (Exemplified compound number 3-36) 200401770 In a similar manner to that described in Example 1, o-aminobenzoic acid (274 mg, 2.0 111111〇1), 3-fluorophenyl Acetic acid (3081 ^, 2.0111111〇1), triphenyl phosphate (0.52 ml, 2.0 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2- Propanol (415 mg, 1.6 mmol) was obtained Of the title compound as a colorless solid, this product was produced as a colorless prismatic crystal (2 1 8 m g, yield: 27%) of a mixed solvent of hexane and ethyl acetate recrystallized. mp 222-223 ° C. IR (KBr): ^ max 3079,1656,1590,1270,1245,1213,1186,969,939 cm · 1.iH-NMR (400MHz, DMSO-d6): 5 8.91 (lH , S), 8.13 (lH, dd, J = 8.0, 1.2 Hz), 7.89 (1H, m), 7.73 (3H, m), 7.57 (1H, m), 7.39 (2H, d, J = 8.8 Hz), 7.16 (1H, m), 6.99 (1H, m), 6.65 (1H, d5 J = 7.6 Hz), 6.60 (1H, dd, J = 10.0, 2 · 0 Hz), 3 .8 7 (2H, s) · FABMS (m / z): 497 ([M + H] +). FABHRMS (m / z): calcd. For C24H16F7N202 ([M + H] +): 497.1 1 00 ; found: 497.1 1 1 1. Anal, calcd. for C24H15F7N202: C, 58.07; H? 3.05; N, 5.64; found: C? 58.02; H? 2.91; N, 5.62. (Example 16) 2- (4- Fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) · quinazolinone (Exemplified Compound No. 3-37) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 mmol), 4-fluorophenylacetic acid (308 mg, 2.0 mmol), and triphenyl phosphate ( 52 ml, 2.0 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol-327- 200401770 (415 mg, 1.6 mmol Colorless title compound Thereof, this product was a mixed solvent of ethyl hexyl CAS and recrystallized yield a colorless prismatic crystal (291 mg of, yield: 37%). mp 225-226 ° C. IR (KBr). Umax 327 3, 1663, 1593, 1511, 1269, 1222, 1107, 935 cm " 1. j-NMR (400MHz, DMSO-d6) ... (5 8.96 (1H , S), 8 · 12 (1H, dd5 J = 8 · 0, 1.2 Hz), 7.89 (1H, m), 7.72 (3H, m), 7.57 (1H, t, J = 8 · 0 Hz), 7.36 (2H, d, J = 8.8 Hz), 6.92 (1H, m), 6.80 (1H, m), 3.85 (2H, s) · FABMS (m / z): 497 ([M + H] +). FABHRMS (m / z): calcd. For C24H16F7N202 ([M + H] +): 497.1 100; found: 497.1097. Anal, calcd. For C24H15F7N202: C, 5 8.0 7; H, 3.05; N5 5.64; found: C? 5 8.00; H? 3.02; N. 5.59. (Example 17) 2- (2-chlorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-32) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg , 2.0 mmol), 2-chlorophenylacetic acid (341 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-aminophenyl) -1,1 513,3 , 3-Hexafluoro-2-propanol (415 mg, 1.6 mmol) to obtain the title compound as a colorless solid. This product was reconstituted from a mixed solvent of hexane and ethyl acetate. Crystals to produce colorless orthorhombic crystals (28.8 mg, yield: 35%). 200401770 mp 226-227 ° C. IR (KB〇 ·· vmax 3296,1657,1593,1475,1268,1214,1 192 , 1107, 9 3 5 cm.1. W-NMR (400MHz, DMSO-d6): (5 8.91 (1H5 s)? 8.13 (ih dd J = 8.0, 0.8 Hz), 7.85 (1H, m ), 7.76 (2H, d5 J = 8,4 Hz), 7.63 (1H, d, J = 8.0 Hz), 7.56 (1H, m), 7.47 (2H, d5 J = 8.4 Hz), 7.3 1-7.22 (4H5 m) 5 3.91 (2H, s). FABMS (m / z): 513 ([M + H] +). FABHRMS (m / z): calcd · for C24H16ClF6N2〇2 ([M-fH ] +) 513.0804; found: 513.0798. Anal, calcd. For C24H15C1F6N202 · C, 56.21; H, 2.95; N, 5.46; found: C, 56.24; H, 3.1〇; N, 5.18 · (Example 18) 2- (3-chlorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -Quinazolinone (Exemplified Compound No. 3-33) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 mmol), 3-chlorophenylacetic acid (341 mg, 2.0 mmol) ), Triphenyl phosphate (0.52 ml, 2.0 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro_2-propanol (4 1 5 mg, 1 · 6 m m ο 1) The title compound was obtained as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (412 mg, yield: 50%). mp 197-198 ° C. IR (KBr): U max 3 2 8 4, 1, 679, 1591, 1 474, 1269, 1214, 1 107, 935 cm'1. -329- 200401770 'H-NMR (400MHz? DMSO-d6): δ 8.96 (1H? S) 5 8.13 (1H? D? J = 8.0 Hz), 7.88 (1H, m), 7.75 (2H5 d, J = 8.4 Hz), 7.72 (1H5 d, J = 8.0 Hz), 7.57 (1H, t, J = 8.0 Hz), 7.43 (2H, d5 J = 8.8 Hz), 7.25 (1H, m), 7.16 (lH, t, J = 8.0 Hz), 6.94 (1H, s) 5 6.78 (1H, d? J = 8.0 Hz) 5 3.8 4 (2 H, s). FABMS (m / z): 513 ([M + H] +) · FABHRMS (m / z): calcd. for C24H16C1F6N202 ([M + H] +): 513.0804; found: 513.0797. Anal, calcd. for C24H15C1F6N202 * C5 56.21; H, 2.95; N? 5.46; found: C, 56.78; H , 3.05; N, 5.29. (Example 19) 2- (4-chlorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl [Phenyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-34) In a similar manner to that described in Example 1, o-aminobenzoic acid (12 0 mg, 0.4 1 mmol), 4- Chlorophenylacetic acid (70 mg, 0.41 mmol), triphenyl phosphate (0.22 ml, 0.82 mmol), and 2- (4-aminophenyl) -1,1,1,3,3, 3-hexafluoro-2-propanol (11 7 mg, 0.45 mmol) to give the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless orthorhombic crystal (120 mg, yield: 57%). mp 240-24 1 ° C. IR (KBr): vmax 3 1 80,1 66 1,1 5 92,1 474,1 270,1 2 1 6,1 1 92, 1 1 07 cm'1. W- NMR (400MHz, DMSO-d6): δ 8.93 (1H, s), 8.13 (1H, dd, J = 8.0, 1.2 Hz), 7.88 (1H, m), 7.72 (3H, m) , 7.57 (1H, t, J = 8.0 200401770 Ηζ), 7.39 (2H, d, J = 8.8 Ηζ), 7.16 (2H, d, J = 8.0 Hz), 6 82 (2H, d , J = 8.4 Hz), 3.85 (2H, s), FABMS (m / z): 513 ([M + H] +), FABHRMS (m / z): calcd. For C 2 4 H 丨 6 C1F 6N 2 O 2 ([M + H · 5 1 3.0 8 04; found: 5 1 3.0794. Anal · calcd · for C24H15ciF6N2〇 · C, 56.21; H, 2.95; N, 5.46; found: C, 56.23; H, 2.7 7; n, 5 44 (Example 20) 2- (2-methoxybenzylmethyl) -3- [4- [2,2,2-didi-1-yl-1- (trifluoro Methyl) ethyl] phenyl: 1-4 (3Η) -quinazolinone (Exemplary Compound No. 3-44) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2 ′ mmol) , 2-methoxyphenylacetic acid (332 mg, 2.0 mmol), triphenyl phosphonate (0.52 ml, 2.0 mmol), and 2. (4-aminophenyl) -1,1,1,3,3 Obtained from 3-hexafluoro-2-propanol (415 mg 5 1.6 mmol) Colorless peripheries of the title compound. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (418 mg, yield: 51%). Mp 203-204 ° C. IR (KBr): vmax 3273,1663,1593,1472,1268,1214,1189,1108, 9 3 5 cm'1.! H-NMR (400MHz? DMSO-d6): δ 8.90 (1H5 s) 5 8.12 (1H? dd5 J = 8.0, 1.2 Hz), 7.85 (1H, m)? 7.72 (2H? D? J = 8.4 Hz), 7.65 (1H, d, J = 8.0 Hz), 7.55 (1H, t, J = 7.6 Hz) , 7.38 (2H, d, J = 8.4 Hz), 7.19 (1H, m), 7.05 (1H, η), 6.82 (2H, m), 3.74 (2H, s), 3.53 (3H, s ) FABMS (m / z): 5 0 9 ((M + H) +) 200401770 FABHRMS (m / z): calcd for C25H19F6N203 ([M + H] +): 5 09.1 3 0 0; found: 5 09.1 2 7 1. Anal, calcd. For C 2 5 H j 8 F 6N 2 O 3: C5 59.06; H5 3.5 7; N? 5.51; found: C? 5 9.0 8; H, 3.36; N 5 5.5 4 (Example 2 1) 2- (3 -methoxybenzyl) -3- [4- [2,2,2-difluoro-1-meryl-1- (trifluoromethyl) ethyl] Phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-45) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 mmol), 3-methyl Oxyphenylacetic acid (341 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3- Hexafluoro-2-propanol (415 mg, 1.6 mmol) gave the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (462 mg, yield: 57%). ). mp 1 65-1 6 7 ° C. IR (KBr): z > max 3296,1675,1591,1473,1269,1214,1 107, 934, 7 0 9 cm " 1.

iH-NMR (400MHz, DMSO-d6): δ 8.92 (1H, s), 8.12 (1H, m), 7.89 (1H, m), 7.74 (3H, m), 7.57 ( 1Η, t, J = 7.6 Hz), 7.37 (2H, d, J = 8.4 Hz), 7.03 (1H, t, J = 7.6 Hz), 6.74 (1H, dd, J = 8.4, 2.4 Hz), 6.42 (1H, s), 6.33 (1 H, d, J = 7 · 6 H z), 3.81 (2H, s), 3.63 (3H, s). FABMS (m / z): 5 0 9 ([M + H] +). FABHRMS (m / z): calcd. For C25H19F6N203 ([M + H] +): 509.1300; found: 509.1270. Anal, calcd. For C25H18F6N20 3: C5 5 9.0 6; H? 3.57; N ? 5.51; found: C? 5 9.2 2; H, 3.35; N 5 5.5 5. -332- 200401770 (Example 22) 2_ (4-methoxybenzyl) -3- [4- [2,252-trifluoro -1-Hydroxy-1, (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplary Compound No. 3-46) In a similar manner to that described in Example 1, from o-amine Benzoic acid (2 74 mg, 2.0 mmol), 4-methoxyphenylacetic acid (341 mg, 2.0 mmol), triphenyl phosphate (0.52 ml5 2.0 mmol), and 2 · (4-aminophenyl) -1 , 15153,3,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) to give the title compound as a colorless solid. This product was obtained from hexane and ethyl acetate A mixed solvent of recrystallization yield a colorless prismatic crystal (210 mg, yield: 26%). mp 22 5 -226 ° C. IR (KBr): vmax 3340,1659,1593,1512,1270,1247,1213, 1 180, 1108,93 5 cm'1. ^ -NMR (400MHz? DMSO-d6): δ 8.92 (1H? s)? 8.11 (1H? d5 J = 7.6 Hz), 7.89 (1H, m), 7.74 (1H, d, J = 8.0 Hz), 7.70 (2H, d, J = 8.4 Hz), 7.56 (1H, t, J = 7.6 Hz), 7.31 (2H, d, J = 8.4 Hz), 6.65 (4H, s), 3.78 (2H, s) 5 3.67 (3H, s), FABMS (m / z): 5 09 ([M + H] +). FABHRMS (m / z): calcd. for C25H19F6N203 ([M + H] +): 5 09.1 3 0 0; found: 5 09.1 270. Anal , calcd. for C25H18F6N2 0 3: C, 59.06; H? 3.57; N5 5.51; found: C, 59.00; H5 3.37; N, 5.52. (Example 23) 2- (2-methylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-26) 200401770 In a similar manner as described in Example 1, o-aminobenzoic acid (2 74 mg, 2.0 mmol), 2-methylphenylacetic acid (341 mg, 2.0 mmol), and triphenyl phosphate (0.52 ml, 2.0 mmol) were used. ) And 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) to give the title compound as a colorless solid, this product Recrystallization from a mixed solvent of hexane and ethyl acetate gave colorless orthorhombic crystals (130 mg5 yield: 17%). mp 209-210 ° C. IR (KBr) ·· vmax 3281, 1658, 1594, 1473, 1269, 1215, 1192, 1107, 9 3 5 cm'1. H-NMR (400MHz, DMSO-d6): δ 8 91 (1H, s) 5 8.13 (1H, dd, J = 8.0, 1.2 Hz) 5 7.8 8 (1 H, m), 7.72 (1H, d, J = 8.0 Hz) , 7.68 (2H, d, J = 8.4 Hz), 7.57 (1H, m), 7.31 (2H, d, J: = 8.4 Hz), 7.10-6.96 (4H, m) 5 3.8 0 (2 H, s), 1.73 (3H, s) · FABMS (m / z): 493 ([M + H] +). F ABHRMS (m / z): calcd. For C25H19F6N2 0 2 ([m + h ] +) · 493.1 3 5 1; found: 4 9 3.1 3 7 3. Anal, calcd. For C25H18F6N202 · C 60.98; H5 3.68; N, 5.69; found: C, 60.91; H, 3.90; n, 5.31. ( Example 24) 2- (3-methylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (Hfluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-27) In a similar manner to that described in Example 1, o-aminobenzoic acid (274 mg, 2_0 mmol), 3-methylphenylacetic acid (341 mg 5 2.0 mmol), triphenylphosphonic acid (0.52 ml, 2.0 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3, hexafluoro_2-propanol 200401770 alcohol (415 mg , 1.6 mmol) to obtain the title compound Solid, The product from a mixed solvent of hexane and ethyl acetate recrystallized yield a colorless prismatic crystals (23 6 mg, yield: 30%). mp 188-189 ° C. IR (KBr): y max 3 2 8 3, 1 65 6, 1591, 1 269, 1212, 1 182, 1 108, 936 cm " 1. -NMR (400MHz, DMSO-d6) : δ 8.92 (lH, s), 8.12 (lH, dd, J = 8 · 0, 0 · 8 Hz), 7.89 (1H, m), 7.76 (1H, d, J = 8 · 0 Hz), 7.70 (2H, d5 J = 8.0 Hz), 7.56 (1H, t, J = 7.2 Hz), 7.31 (2H, d, J = 8.8 Hz), 6.97 (2H, m), 6.55 (2H, m), 3.80 (2H, s), 2.15 (3H, s) · FABMS (m / z): 493 ([M + H] +). FABHRMS (m / z): calcd. for C25H19F6N〇02 ([M + H] +): 493.1351; found: 493.1363 · Anal, calcd · for C25H18F6N202: C, 6 0.9 8; H? 3.68; N5 5.69; found: C? 60.76; H, 3.54; N5 5.57. (Example 25) 2 -(4-methylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -Quinazolinone (Exemplary compound number 3-2 8) In a similar manner as described in Example 1, o-aminobenzoic acid (82 mg, 0.6 mmol), 4-methylphenylacetic acid (90 mg, 0.6 mmol), triphenyl phosphate (0.16 ml, 0.6 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (155 mg (0.6 mmol) The compound as a colorless solid, The product from a mixed solvent of hexane and ethyl acetate recrystallized yield a colorless prismatic crystal -335- 200401770 (1 7 0 m g, yield 57 ·%). mp 22 9-23 0oC. IR (KBr): z ^ max 3272, 1655,1592,1513, 1475,1270,1213,1183, 9 3 7 cm'1. 'H-NMR (400MHz? DMSO-d6): δ 8.91 (1H? s) 5 8.11 (1H5 dd? J = 8.0, 1.2 Hz), 7.88 (1H, m), 7.74 (1H, d, J = 8.0 Hz), 7.70 (2H, d, J = 8.4 Hz), 7.56 (1H, t, J = 8.0 Hz), 7.31 (2H, d, J = 8.8 Hz), 6.91 (2H, d, J = 7.6 Hz), 6.63 ( 2H, d, J = 8.0 Hz),

3.80 (2H, s), 2.22 (3H, s), FABMS (m / z): 493 ([M + H] +), FABHRMS (m / z): calcd. For C25H19F6N202 ([M + H] +): 49 3.1 3 5 1; found: 49 3.1 348. Anal, calcd. For C25H18F6N202: C, 60.98; H, 3.68; N, 5.69; found: C, 61.09; H, 3.53; N, 5.63. (Example 26) 2- (2,3,4,5,6-pentafluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl [Phenyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-12 1) In a similar manner as described in Example 1, o-aminobenzoic acid (27 4 mg, 2.0 mmol), pentafluoro Phenylacetic acid (452 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3 -hexafluoro-2 -Propanol (415 mg, 1.6 mmol) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (170 mg, yield: 19%). . -336- 200401770 mp 232-233 ° C. IR (KBr): v max 3 3 26, 1 67 5, 1 5 9 8, 1 5 09, 1 268, 1216, 1 009, 970 cm " 1. 'H -NMR (400MHz5 DMSO-d6): δ 8.97 (1H? S) 5 8.13 (1H? D, J = 8.0 Hz), 7.85 (3H, m), 7.68 (2 H, d, J = 8 · 4 H z ), 7.60 (1H5 d, J = 8.0 Hz), 7.56 (1H, d, J = 7.6 Hz), 3.91 (2H, s). FABMS (m / z): 5 69 ([M + H ] +). FABHRMS (m / z): c al cd. For C24H12F11N2〇2 ([M + H] +): 5 69.0723; found: 5 69.0690. Anal, calcd. For C 24U] {¥ x ^ 2〇 2: C? 50.72; H? 1.95; N, 4.93; found: C? 49.55; H, 1.94; N, 4.89. (Example 27) 2- (2,6-difluorobenzyl) -3- [4 -[2,2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (exemplified by North compound No. 3-81) A similar method as described in 1, consisting of anthranilic acid (274 mg, 2.0 mmol), 2,6-difluorophenylacetic acid (344 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol) And 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (4 15 mg, 1.6 mmol) to give the title compound as a colorless solid. This product was obtained from hexane versus A mixed solvent of ethyl recrystallized yield a colorless prismatic crystals (361 mg, yield: 44%). mp 271-272 ° C. IR (KBr): 2 ^ max 3 243,1 68 1,1 5 9 8,1 472,1 26 7,1211,1177, 1017 cm'1. JH-NMR (400MHz5 DMSO- d6): δ 8.94 (1H? s)? 8.13 (1H3 m)? -337- 200401770 7.82 (3H, m) 5 7.62 (2H, d5 J = gg Hz), 7.55 (2H? m) 5 7.39- 7.31 ( 1H, m) 5 7.0 1 -6.9 5 (2 H, m), 3.81 (2H, s). FABMS (m / z): 515 ([M + H] +). FABHRMS (m / z): calcd. for C24H15F8N202 ([M + Hf]: 5 1 5.1 006; found: 5 1 5.0984 Anal · calcd · for C24H14F8N202: C, 5 6.04; H, 2.74; N, 5.45; found: C5 5 6.0 2; H? 2.68; N, 5.68. (Example 28) 2- (2,4-difluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl [Phenyl] phenyl] -4 (3 fluorene) -quinowalone (Exemplified Compound No. 3-79) In a similar manner to that described in Example 1, o-aminobenzoic acid (274 mg, 2.0 mmol), 2,4- Monofluorophenylacetic acid (344 mg, 2.0 mmol), triphenyl phosphonate (0.52 ml, 2.0 mm (? L), and 2- (4 · aminophenyl) -l, l, l, 3, 3,3-Hexafluoro-2-propanol (415 mg, 1.6 mmol) to give the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give Orthorhombic crystals (241 mg, yield: 29%). Mp 222-223 ° C. IR (KBr): ^ max 3 3 1 7,1 66 6,1 5 9 5,1 5 0 8,1 269, 1 2 1 6,1 1 93, 97 1 cm-1. J-NMR (400MHz, DMSO-d6): 5 8.92 (lH, s), 8.13 (lH, dd, J = 8.0, 0.8 Hz), 7.87 ( 1H, m), 7.75 (2H, d, J = 8.4 Hz), 7.66 (1H, d, J = 8.4 Hz), 7.57 (1H, t, J = 7.6 Hz), 7.46 (2H, d, J = 8.4 Hz), 7.20 (1H, m), 6.99-6.90 (2H, m), 3.82 (2H, s), FABMS (m / z): 515 ([M + H] +). 200401770 FABHRMS ( m / z): calcd. for C24H15F8N2〇2 ([M + H] +): 5 1 5.1 0 06; found: 5 1 5.09 84 Anal, calcd. for C24Hl4F8N 〇 · C 5 6.04; H, 2.74; N, 5.45; found: C, 5 5.96; H5 2.6 9; N 5 69 · (Example 29) 2- (bonaphthylmethyl) -3- [4- [2,2,2-trifluoro-buhydroxy-1- ( Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-14) In a similar manner as described in Example 1, o-aminobenzoic acid (2 74 mg, 2 «0 mmol), 1-naphthylacetic acid (372 mg, 2.0 mmol), triphenylacetic acid phosphate (0.52 ml, 2.〇111111〇1), and 2- (4-aminophenyl) -1,1 , 1,3,3,3-hexafluoro-2 -Propanol (415 11 ^, 1.6 mmol) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (171 mg, yield: 20%). ). mp 277-278 ° C. IR (KBr): u max 3 26 5, 1 678, 1 594, 1 267, 1210, 1 174, 9 3 3, 776 cm · 1 · 'H-NMR (400MHz, DMSO- d6): δ 8.87 (1H, s), 8.13 (1H, dd, J = 8.0, 1.2 Hz), 7.8 9-7.7 8 (4H, m), 7.70 (2H, d, J = 8.4 Hz), 7.5 9-7.5 5 (2H, m), 7.52 (2H, d, J = 8.4 Hz), 7.47 -7.3 8 (2H, m), 7.30 (1H, t, J = 7.6 Hz), 7.03 (1H, d , J = 6.8 Hz), 4.25 (2H, s). FABMS (m / z): 5 29 ([M + H] +). FABHRMS (m / z): calcd. For C28H19F6N 2 02 ([M + H ] +): 529.1350; found: 529.1357. Anal, calcd. For C28Hi8F6N202: C, 63.64; H? 3.43; N? 5.30; found: C, 63.71; H? 3.42; N? 5.25. -339- 200401770 (Example 30 ) 2- (2-naphthylmethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η ) -Quin D quinolinone (Exemplified Compound Nos. 3 to 15) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 mmol), 2-naphthylacetic acid (372 mg, 2.0 mmol) Triphenyl phosphate (0.52 ml5 2.0 mmol) and 2- (4-aminophenyl) -1,1,1,353,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) The compound as a colorless solid, this product is produced by a mixed solvent of hexane and ethyl acetate was recrystallized as colorless rhombic crystals (3 5 3 mg, yield: 42%). mp 207-208 ° C. IR (KBr): V max 31 12, 1 65 9, 1 592, 1 269, 1214, 1 187, 7 73, 7 0 7 cm-1. 'H-NMR (400MHz5 DMSO- d6): δ 8.92 (1H? s) 5 8.13 (1H? dd? J = 8.0, 1.2 Hz) 5 7.9 1-7.8 2 (2 H5 m). 7.75 (1H? d? J = 8.0 Hz), 7.7 6 -7.6 5 (4H, m), 7.57 (1H, t, J = 7.6 Hz), 7.47-7.43 (2H, m), 7.38 (1H, d, J = 8.8 Hz), 7.27 (1H, s) 5 7 · 02 (1H, d, J = 8.4 Hz), 4.25 (2H, s). FABMS (m / z): 5 29 ([M + H] +). FABHRMS (m / z): calcd for C28H19F6N202 ([M + Hf]: 529.1 3 5 0; found: 5 29.1 3 4 8. Anal, calcd. for C28H18F6N2 02: C, 63.64; H, 3.43; N? 5.30; found: C, 63.63; H , 3.40; N5 5.28 (Example 3 1) 2- (4-isopropylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-55) 200401770 In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 mmol), 4-iso Propylphenylacetic acid (356 mg, 2.0 mmol), triphenyl phosphonate (0.52 ml, 2.0 mmol) and 2- (4-aminophenylhum% hexafluoro-2-propanol (415 mg, 1.6 mmol) Get the title The product is a colorless solid. This product is recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals (5 3 2 mg, yield: 64%). Mp 224-225 ° C. IR (KBr) : v max 3 0 8 9, 2963, 1 65 6, 1591, 1 269, 1 184, 967, 938 cm'1.

! H-NMR (400MHz, DMSO-d6): δ 8.90 (1H? S)? 8.12 (1H? Dd5 J = 8 · 0 5 1 · 2 H z), 7.9 1-7 · 8 7 (1 H, m ), 7.7 6 (1 H, d, J = 8 · 〇hz), 7.65 (2H, d, J = 8.4 Hz), 7.57 (1H, t, J = 7.6 Hz), 7.27 (2H, d, J = 8.4 H z), 6 · 9 5 (2 H, d, J = 8 · 0 H z), 6 · 6 4 (2 H, d, J = 8 · 0 Hz), 3.83 (2H, s) , 2.84-2.74 (1 H, m), 1.14 (6H, d, J = 6.8

Hz). FABMS (m / z): 521 ([M + H] +). FABHRMS (m / z): calcd. For C27H23F6N202 ([M + H] +): 521.1663; found: 521.1669. Anal, calcd. for C27H ”F6N202: C, 62.31; H, 4.26; N, 5.38; found: C? 62.56; H, 4.09; N? 5.35. (Example 32) 2- (l, l'-bisphenyl-4-yl Methyl) -3- [4- [2,2,2-trifluoro-1 · hydroxy (trifluoromethyl) ethyl] phenyl] -4 (3 H) -oxazolinone (Exemplified compound number 3 -125) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 200401770 mmol), 4-bisphenylacetic acid (524 mg, 2.0 mmol), and triphenyl phosphate (0.52 ml, 2.0 mmol) and 2- (4-aminophenyl) -151,1,3,3,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) to obtain the title compound as a colorless solid. This product was obtained from hexane and Recrystallization from a mixed solvent of ethyl acetate gave colorless orthorhombic crystals (521 mg, yield: 59%). Mp 259-260 ° C. IR (KBr): v max 3 27 0, 1 65 7, 1 592, 1 270,1 2 1 5,1 1 8 1,93 5,699 cm'1. 'H-NMR (400MHz5 DMSO-d6): δ 8.94 (1H5 s)? 8.14 (1H? Dd5 J = 8.0, 1.2 Hz ), 7.90 (1H, m), 7.77 (1H, d5 J = 8.0 Hz), 7.71 (2H, d, J = 8.4 Hz), 7.58 (3H, m), 7.47-7.34 (7H, m), 6.86 (2H, d, J = 8.0 Hz), 3.90 (2H, s), FABMS (m / z): 5 5 5 ([M + H] +) · FABHRMS (m / z): calcd. For C30H21F6N2O2 ([M + H] +): 555.1507; found: 555.1505. Anal, calcd. For C30H20F6N2O2: C, 64.98; H, 3.64; N, 5.05; found: C, 64.99; H, 3.51; N, 5.07. (Example 3 3) 2- (2,4-dimethylbenzyl) -3- [4- [2,2, 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-115) A similar method described in Example 1 was used. From o-aminobenzoic acid (139 mg, 1.01 mmol), 2,4-dimethylphenylacetic acid (173 mg, 1.05 mmol), triphenyl phosphate (350 mg, 1.13 mmol) And 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (259 mg, 1.0 mmol) to give the title compound as a colorless solid. Recrystallization from alkane gave colorless needles (268 mg, yield: 200401770 5 6%). mp 1 8 2- 1 8 2.5 ° C. IR (KBr): > max 3269,1659,1593,1473,1271, 1214,1192, 936 cm'1. 'H-NMR (400MHz5 CDC13): δ 8 · 2 8 (1 H, d, J = 8 · 8 H z), 7.8 5 -7.7 8 (2H, m), 7.67 (2H, d, J = 8.8 Hz), 7.55-7.51 (1H, m), 6.98 (2H, d, J = 8,0 Hz), 6.8 6-6.8 2 (2H, m) 5 6.7 8 (1 H, s), 3.83 (3H, s), 2.25 (3H, s), 1.64 (3H, s) ·

FABMS (m / z) 5 07 ((M + H) +).

Anal, calcd. For C26H20F6N2O2: C? 61.66; H, 3.98; N? 5.53; F, 22.51; found: C, 61.58; H, 4.02; N? 5.46; F5 2 2.6 5. (Example 3 4) 2- ( 3-nitrobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1 · (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quine Zazolinone (Exemplified Compound No. 3-48) In a similar manner as described in Example 1, o-aminobenzoic acid (511 mg, 3.73 mmol), 3-nitrophenylacetic acid (680 mg, 3.75 mmol), Triphenyl phosphate (1.17 g, 3.76 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (975 mg, 3.76 mmol) were obtained The title compound was a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless needles (1.13 g, yield: 58%). mp 22 9.5 -2 3 0.5 ° C. IR (KBr): vmax 3207,1665,1595,1354,1270,1215,1 193, 937 cm'1. -343- 200401770 iH-NMR (400MHz, DMSO-d6) : δ 8.91 (1H, s), 8.14-8.05 (2H5 m), 7.90-7.83 (2H, m), 7.73-7.68 (3H, m), 7.60-7.55 (1H5 m) 5 7.4 8 -7.42 (3 H , M), 7.32 (1H, d, J = 8.1 Hz), 4.00 (2H, s). FABMS (m / z): 524 ([M + H] +).

Anal · calcd · for C24H15F6N3 04: C, 5 5.0 8; H, 2.89; N, 8.03; F5 21.78; found: C? 55.13; H, 3.08; N, 8.12; F5 22.11. (Example 3 5) 2-benzene Methyl-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (exemplified compounds No. 8-7) Add 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (259 111§, 1 mmol) to N-benzene Ethylacetamido o-aminobenzoic acid (280 mg, 1.1 mmol) (According to Yu et al. [Yu, M. J ·, McCowan, J. R ·, Mason, NR ·, Deeter, J. B ·, Mendelsohn, L. G, J. Med. Chem., 35, 2534-2542 (1 992)]) and triphenyl phosphate (0.29 ml, 1.1 mmol) in pyridine (2 ml) solution, and The resulting mixture was stirred for 3 hours under nitrogen pressure. After this time, the reaction mixture was evaporated under reduced pressure, and the residue thus obtained was subjected to silica gel column chromatography (using a volume of 4: 1). A mixture of hexane and ethyl acetate was used as an eluent) to give the title compound (3 99 mg, yield: 84%). This product was obtained from hexane and ethyl acetate. Solvent of recrystallization yield a colorless prismatic crystal. mp 140-141 ° C. IR (KBr): v max 3 2 8 1,1 6 8 5,1 5 86,1 267,1 2 1 1, 96 9 cm · 1. 'H-NMR (400MHz? CDC13 ): 〇8.25 (lH, d, J = 7.6 Hz), 7.83 (1H, dt, J = 7.6, 1.6 Hz), 7.82 (1H, d, J = 7.6 Hz), 7.73 (1H, 200401770 d, J = 8.0 Hz), 7.52 (1H, m), 7.44 (1H, s), 7.39 (1H, t, J = 8.0 Hz), 7.17-7.10 (3H, m), 6.97 (1H, d, J = 8.8 Hz) , 6.79 (2H, d, J = 6.8 Hz), 4.41 (1H, s), 3.97 (1H, d, J = 14.8 Hz), 3.85 (1H, d5 J = 14.8 Hz) FABMS (m / z): 47 9 ([M + H] +) FABHRMS (m / z): calcd. For C24H17F6N202 ([M + H] +): 479.1 1 95; found: 47 9.1 205. Anal , calcd. for C24H16F6N202: C5 60.26; H5 3.3 7; N 5 5.8 6; found: C? 60.5 2; H? 3.39; N 5 5.8 8. (Example 36) 2-benzyl-6-bromo-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-411) In a similar manner as described in Example 1, 5-bromo-o-aminobenzoic acid (237 mg, 1.1 mmol), phenylacetic acid (150 mg, 1.1 mmol), and triphenyl phosphate (0.29 ml, 1.1111111〇1) ) And 2- (4-aminobenzene ) -1,1,1,3,3,3-hexafluoro-2-propanol (25 9 11 ^, 1 mmol) to obtain the title compound as a colorless solid (4 12 mg, yield: 74%). Recrystallization from a mixed solvent of alkane and ethyl acetate resulted in colorless orthorhombic crystals. mp 175-176 ° C. IR (KBr): v max 3317, 1 66 8, 1591, 1 469, 1 27 0, 1216, 1 1 0 8, 93 4 cm · 1. 'H-NMR (400MHz, CDC13 ): δ 8.39 (1H5 d5 J = 2 · 8 Hz), 7.91 (1H, dd5 J = 8.8, 2.0 Hz), 7.71 (2H, d, J = 8.8 Hz), 7.68 (1H, d, J = 8.8 Hz), 7.19-7.08 (3H, m), 6.98 (2H, d, J = 8.8 Hz), 6.70 (2H, d, J = 6.8 Hz), 3.95 (1H, s), 3.90 ( 2H, s). 200401770 FABMS (m / z): 5 5 7 ([M + H] +). FABHRMS (m / z): calcd. For C24H1679BrF6N2〇2 ([M + H] +): 557.0293; found : 557.0293 · Anal, calcd. For C24h 丨 5BrF6N202: C, 51.73; H, 2.71; N, 5.03; found: C, 51.77; H, 2.69; N, 5.01. (Example 37) 2-benzyl- 5-Fluoro 3- [4 · [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone ( Exemplified compound number 3-1〇00) In a similar manner as described in Example 1, 6-fluoroanthranilide (34〗 mg, 2.2 111111〇1), phenylacetic acid (300 11 ^, 2.2 111111〇1 ), Triphenyl phosphate (0.5811115 1.1111111〇1) and 2- (4-aminophenyl) -1,1,153,3,3-hexafluoro-2-propanol (518 11 ^, 2 mmol) to obtain the title compound as a colorless solid (642 mg, yield: 65%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 166-167 ° C. IR (KBr): v 3327,1684,1595,1476,1268,1214,1 192, 933 cm " 1.! H-NMR (400MHz? CDC13): 6 7.7 5 (1 H, dt? J = 8.8, 3.2 Hz), 7.69 (2H, d, J = 8.0 Hz), 7.60 (1H5 d, J = 8.0 Hz), 7.19-7.06 (4H, m), 6.97 (2H, d, J = 8.8 Hz), 6.71 (2H, d, J = 7.2 Hz), 3.93 (1H, s), 3.89 (2H, s), FABMS (m / z): 49 7 ([m + H ] +). FABHRMS (m / z): calcd. For C24H16F7N202 ([M + H] +): 49 7.1 1 00; found ·· 49 7.1 1 07 · Anal · calcd. For C24HI5F7N202: C, -346- 200401770 5 8 · 0 7; Rhenium, 3 · 0 5; N, 5 · 6 4; found: C, 5 7, 9 0; Rhenium, 2 · 9 1; N 5 7 8. (Example 38) 2-Benzyl 6-6-fluoro- 3- [4- [2,2,2-trifluoro-1-hydroxytrifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -quinolium peroxolinone (exemplified compounds No. 3-1031) In a similar manner to that described in Example 1, 5-fluoroanthranilide (34 mg, 2.2 mmol), phenylacetic acid (300 mg, 2.2 mmol), and triphenyl phosphate ( 0.58 ml, 1.1111111〇1) and 2- (4-aminophenyl) -1,1,1,353,3-hexafluoro-2-propanol (518 111 names, 2 mmol) to give the title compound as colorless Member (643 mg, yield: 65%), This product was produced as a colorless prismatic crystal having a mixed solvent of hexane and ethyl acetate recrystallized. mp 194-195 ° C. IR (KBr): 3 265,1 669,1 5 95,1 4 8 7,1 27 1,1 2 1 7,1 1 94, 9 3 2 cm-1.! Η- NMK (400MHz5 CDC13): δ 7 · 9 0 (1 H, dd 5 J = 8 · 8, 2 · 8 Hz), 7.82 (1H, dd, J = 8.〇, 4.8 Hz), 7.70 (2H , D, J = 8.8 Hz), 7.55 (1H, dt, J = 8.8, 3.2 Hz), 7.17-7.06 (3H, m), 6.97 (2H, d, J = 8 · 0 H z), 6.7 0 (2 H, d, J = 7 · 2 H z), 4 · 0 3 (1 H, s), 3 · 9 1 (2 H, s). FABMS (m / z): 497 ([M + H] +). FABHRMS (m / z): calcd. For C24HI6F7N2〇 ^ ([M + H] +): 497.1100; found: 497.1093. Anal · calcd · for C24H15F7N202: C, 58.07; H? 3.05; N5 5.64 ; found: C? 58.11; H, 2.89; N, 5.75. (Example 39) 200401770 2-benzyl-6,7-difluoro- 3- [4- [2,2,2-trifluoro-1- Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1 24 8) (1) 4,5-Difluoro-2-nitrate Benzoic acid (447 mg5 2.2 mmol) was added to a suspension of carbon [50 (w / w) wet, 40 mg] in methanol (10 ml) containing 20% palladium hydroxide, and the resulting mixture was placed in Stir at room temperature under hydrogen pressure for 2 hours, 4,5 generates agent was removed by filtration, and the filtrate was concentrated via celite - difluoro-o-benzoic acid (380 mg, yield: 100%). (2) In a similar manner as described in Example 1, 4,5-difluoroanthranilic acid (380 mg, 2.2 mmol), phenylacetic acid (300 mg, 2.2 mmol) prepared from Example 3 9 (1) above , Triphenyl phosphonate (0.58 ml, 2.2 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (518 11 ^ (2.001111111)) to obtain the title compound as a colorless solid (521 mg, yield: 51%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 205 -206 ° C. IR (KBr): > max 3 3 5 0, 1 686, 1 5 97, 1501, 1 3 7 8, 1271, 1217, 1106 cm'1. ^ -NMR (400MHz, CDC13 ): (5 8,0 2 (1 H, t, J = 9 · 6 H z), 7 · 7 2 (2H, d, J = 8.4 Hz), 7.59 (1H, dd, J = 10.8, 7.2 Hz), 7.17 (1H, t, J = 7.6 Hz), 7.10 (2H, t, J = 7.6 Hz), 6.98 (2H, d, J = 8.4 Hz), 6.70 (2H, d, J = 7.6 Hz), 4.71 (1H, s), 3.89 (2H, s). FABMS (m / z): 515 ([M + H] +) FABHRMS (m / z): calcd · for C24H14F8N202Na ([M + Na] +): 537.0826; found: 537.0800. Anal, calcd. For C24H14F8N202: C? 56.04; H? 2.74; N? 5.45; found: C5 56.18; H, 3.01; N, 5.70. -348- 200401770 (Example 40) 2-benzyl-5-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-163) In a similar manner to that described in Example 1, 6-chloroanthranilic acid (188 mg, 1.1 mmol), phenylacetic acid (150 mg, 1.1 mmol) ), Triphenyl phosphonate (0.29 ml, 1.1111111〇1) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (259 11 ^ , 1 mmol) The compound is a colorless solid (467 mg, yield: 91%). This product is recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. Mp 133-134 ° C. IR (KBr): v max 3 3 9 1,1 68 9,1 5 92,1 2 70,1215,1 193,931 cnT1 · ^ -NMR (400MHz, CDC13): δ 7.72-7.70 (3H? M)? 7.68 (1H5 d5 J = 7.2 Hz), 7.51 (1H, dd, J = 7.6, 1.6 Hz), 7.17-7.01 (3H, m), 6.99 (2H, d, J = 8.8 Hz), 6.72 (2H, d, J = 7.2 Hz), 3.88 (2H, s), 3.69 (1H, s) · FABMS (m / z): 5 1 3 ([M + H] +) · · F ABHRMS (m / z): calcd. For C24H1635C1F6N202 ([M + H] +): 5 1 3.0 8 04; found: 5 1 3.0 800. Anal, calcd. For C 2 4 H, 5 C 1F 6N 2 O 2: C? 56.21; H, 2.95; N , 5.46; found: C, 56.28; H, 3.24; N? 5.47. (Example 41) 2-benzyl-6-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl: 1-4 (3Η) -quinazolinone (Exemplified Compound No. 3-38) In a similar manner as described in Example 1, 5-chloroanthranilide ( 188 mg, 1.1-349-200401770 mmol), phenylacetic acid (150 mmol), triphenyl phosphate (0.29 ml 5 1 .1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (259 ^^, 1 mmol) to give the title compound as a colorless solid ( 4 09 mg, yield: 80%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 1 8 9- 1 90oC. IR (KBr): u max 3329, 1 67 8, 1591, 1 472, 1 270, 1216, 1 108, 934 cm · 1. 'H-NMR (400MHz, CDC13): δ 8.22 (1H? T? J = 1.6 Hz)? 7.76 (2H, m), 7.71 (2H, d, J = 8.8 Hz), 7.19-7.08 (3H, m), 6.98 (2H, d, J = 8.8 Hz), 6.70 (2H, d, J = 6.8 Hz), 3.90 (3H, s) · FABMS (m / z): 513 ([M + H] +). FABHRMS (m / z): calcd. For C24H 1 6 3 5 C1F6N2 02 ([M + H] +): 5 1 3.0804; found: 5 1 3.0 806. Anal, calcd. For C 2 4 H! 5 C1F 6N 2 O 2: C, 56.21; H, 2.95; N5 5.46; found: C5 56.32; H, 2.79; N, 5.46. (Example 42) 2-benzyl-7-chloro-3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenyl; M (3H) -quinazolinone (Exemplified Compound No. 3-5 9 7) In a similar manner as described in Example 1, Formic acid (188 mg, 1.1 mmol), phenylacetic acid (150 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1111111〇1), and 2- (4-aminophenyl)-; 1 , 1,1,3,3,3-hexafluoro-2-propanol (259 11 ^, 1 mmol) to obtain the title compound as a colorless solid (2 3 9 mg, yield: 47%) 'This product was obtained from hexane A mixed solvent of ethyl acetate and recrystallized -350-200401770 yield a colorless prismatic crystal. mp 22 1 -222 ° C. IR (KBr): V max 3 290, 1 666, 1591, 1 270, 1215, 1 175, 9 3 5 cnT1 · W-NMR (400MHz, CDC13)): 5 8 · 2 0 (1 H, d, J = 8 · 0 H z), 7.81 (1H, d, J = 2.0 Hz), 7.71 (2H, d, J = 8.8 Hz), 7.47 (1H, dd5 J = 8 · 0, 1.2 Hz), 7.19-7.08 (3H, m) 5 6.99 (2 H, d, J = 8.8 Hz), 6.70 (2H, d, J = 6.8 Hz) 5 3.9 0 (2 H , S). FABMS (m / z): 513 ([M + H] +). FABHRMS (m / z): calcd. For C 2 4 H, 6 3 5 C 1 F 6N2 0 2 ([M + H ] +): 5 1 3.0 8 04; found: 5 1 3.0 8 05. Anal, calcd. For C24H15C1F6N202: C5 56.21; H? 2.95; N? 5.4 6; found: C? 56.33; H5 3.01; N, 5.21. (Example 43) 2-benzyl-8-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1 · (trifluoromethyl) ethyl] phenyl] -4 ( 3 H) -quinazolinone (Exemplified Compound No. 3-814) (1) Add platinum oxide (3 9 mg) to 3-chloro-2-nitrobenzoic acid (5.61 g, 27.8 mmol) In a solution of tetrahydrofuran (10 ml) and ethyl acetate (40 ml) in a mixed solvent solution, the resulting mixture was stirred at room temperature under hydrogen pressure for 12 hours. After this time, the reaction mixture was filtered and mixed. And the resulting filtrate was concentrated to obtain a crude crystalline solid, which was recrystallized in a mixed solvent of ethyl acetate and hexane to give a yellow needle of 3-chloroanthranilic acid (1 · 3 4 g 5 yield: 28%). (2) In a similar manner as described in Example 1, 3-chloroanthranilic acid (54 8 mg, 3.19 mmol) and phenylacetic acid (44 5 mg, 3.26 200401770 mmol) prepared from Example 43 (1) above. , Triphenyl phosphonate (1.04 g, 3.35 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (831 mg, 3.21 mmol ) The title compound was obtained as a colorless solid. This product was recrystallized from benzene to give colorless crystals (1.18 g, yield: 72%). Mp 243-244 ° C. IR (KBr): v max 3177, 1661 , 1591, 1 27 3, 1221, 1 194, 9 3 6 cm., ^ -NMR (400MHz? DMSO-d6): δ 8.92 (1H? S) 5 8.0 9-8.0 3 (2 H? M), 7.70 (2H, d, J = 8.8 Hz), 7.54 (1H, t, J = 8.1 Hz), 7.33 (2H, d, J = 8.8 Hz), 7.19-7 · 09 (3H, m), 6.77 (2H, d, J = 7.3 Hz), 3.89 (2H, s). FABMS (m / z): 513 ([M + H] +) ·

Anal, calcd. For C 2 4 H, 5 F 6 C 1N 2 O 4: C5 5 6.2 1; H? 2.95; N, 5.46; F. 22.23; Cl, 6.9 1; found: C, 5 6.3 2; H , 2.89; N, 5.54; F, 22.3 7; Cl5 6.6 2. (Example 4 4) 2-benzyl-5-methyl- 3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinone-one (Exemplified Compound No. 3-132) In a similar manner to that described in Example 1, from 6-methyl-o-amine Benzoic acid (3 2 2 mg, 2.2 mmol), phenylacetic acid (300 mg, 2.2 mmol) triphenyl phosphate (0.58 ml, 1.1 mmol) and 2- (4-aminophenyl) -151, i , 3,3,3-hexafluoro-2-propanol (518 mg, 2 mmol) to obtain the title compound as a colorless solid (544 mg, yield · 55%). This product was a mixed solvent of hexane and ethyl acetate. Medium recrystallizes to produce colorless orthorhombic crystals. -352- 200401770 mp 1 89- 1 90 ° C. IR (KBr): v max 3 3 5 3, 1 67 0, 1 5 9 6, 1 472, 1 269, 1214, 1175, 932 cm'1. ' H-NMR (400MHz5 CDC13): δ 7 · 6 9 (2 H, d, J = 8 · 8 H z), 7.67-7.65 (2H, m), 7.28 (1H, m), 7.17-7.06 (3H, m), 6.98 (2H, d, J = 8.8 Hz), 6.71 (2H, d5 J = 7.2 Hz), 3.88 (2H, s), 3.87 (1H, s), 2.82 (3H, s) FABMS (m / z): 493 ([M + H] +). FABHRMS (m / z): calcd. For C25H19F6N202 ([M + H] +): 49 3.1 3 5 1; found: 493.1 3 60. Anal, calcd. For C 2 5 H, 8 F 6N 2 O 2: C, 60.98; Η, 3.68; N, 5.69; found: C, 61.20; H, 3.46; N, 5.77. (Example 45 ) 2-benzyl-6-methyl- 3- [4- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl;! -4 ( 3))-quinazolinone (Exemplified Compound No. 3-349) In a similar manner as described in Example 1, 5-methyl o-aminobenzoic acid (3 2 2 mg, 2.2 mmol), phenylacetic acid (300 mg, 2.2 mmol), triphenyl phosphate (Q58 ml, 1.1 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro_2-propanol (518 mg, 2 mmol) to give the title compound as a colorless solid (7 64 mg, yield: 78%) 'This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 175-176 ° C. IR (KBr): ^ max 3 1 9 6,1 6 5 2,1 5 9 1,1 492,1 27 5,1 1 92, 9 3 7 cm'1.iH-NMR (400MHz, CDC13): δ 8.06 (1H, s), 7.72 (1H, d, J = 200401770 8.0 Hz), 7.68 (2H, d5 J = 8.8 Ηζ), 7.66 (1H, dd, J = 8 · 〇, 2.4 Hz), 7.17-7.06 (3H, m), 6.96 (2H, d5 J = 6.8 Hz), 6.69 (2H, d, J = 7.2 Hz), 3.97 (1H, s) , 3.90 (2H, s) 5 2 · 52 (3H, s). FABMS (m / z): 493 ([M + H] +). FABHRMS (m / z): calcd. For C25H19F6N2 02 ([M + H] +): 493.1351; found: 493.1354. Anal, calcd. For C25H18F6N2 02: c 60.9 8; H 5 3.6 8; N 5 5.6 9; found: C? 60.94; H? 3.43; N 5 5.7 2. ( Example 46) 2-benzyl-5-trifluoromethyl-3 · [4_ [2,2,2_trifluoro-hydroxy · l (trifluoromethyl) ethyl] phenyl] -4 (3 H ) -Quinazolinone (Exemplified Compound No. 3-25) 6) In a similar manner as described in Example 1, 6-trifluoromethyl o-aminobenzoic acid (3.08 mg 5 1.5 mmol), phenylacetic acid (204 mg , 1.5 mmol), triphenyl vinegar (0.39 ml, 1.5 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (3 63 mg5 1.4 mmol) The compound as a colorless solid (5 3 5 mg, yield: 70%) The product from a mixed solvent of hexane and ethyl acetate to produce the recrystallization colorless prismatic crystals. mp 98-101 ° C. IR (KBr): 2; max 340 1,1 695,1 5 97,1 3 1 0.1 2 1 6,1 1 5 2, 9 3 1 cm'1. W-NMR (400MHz , CDC13): δ 8.02 (1H, d, J = 8.0 Hz), 7.93 (1H, d, J = 8.0 Hz) 5 7 · 87 (1H, t, J = 8.0 Hz), 7.72 (2H, d, J = 8.0 Hz), 7.18 (1H, t, J = 6.8 Hz), 7.11 (2H, t, J = 6.8 Hz), 7.01 (2H, d, J = 8.0 Hz), 6.72 (2H, d , J = 7.6 Hz), 3.91 (2H, s). 3.83 (1H5 s). -354- 200401770 FABMS (m / z): 547 ([M + H] +) · FAB HRM S (m / z): calcd. for C25H16F9N2 02 ([M + H] +): 547.1068; found: 547.1062. (Example 47) 2-benzyl-7-trifluoromethyl- 3- [4- [2, 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3 -690) Similar to that described in Example 1 Methods: 4-Trifluoromethyl o-aminobenzoic acid (422 mg, 2.06 mmol), phenylacetic acid (286 mg, 2.1 mmol), triphenyl phosphate (0.55 ml, 2.1 mmol) and 2- (4-amine Phenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5 18 mg, 2.0 mmol) to obtain the title compound as a colorless solid (5 54 mg, yield: 51%) , This product consists of A mixed solvent of ethyl acetate-hexane and recrystallization of the produced colorless prismatic crystals. mp 207-208 ° C. IR (KBr): umax 3091, 1660, 15 9 1, 1321, 1271, 1219, 1 174, 1133, 9 6 9 cm'1.

] H-NMR (400MHz5 CDC13): δ 8.39 (1H? D3 J-8.8 Hz), 8.10 (1H, s), 7.74 (2H, d5 J = 8.0 Hz), 7.72 (1H, d, J = 8.8 Hz), 7.18 (1H, t, J = 6.8 Hz), 7 · 11 (2H, t, J = 6.8 Hz), 7.01 (2H, d, J = 8.8 Hz) 5 6.7 3 (2 H, d , J = 7 · 6 Hz), 3.93 (2H, s), 3.91 (1H, s) · FABMS (m / z): 547 ([M + H] +). FABHRMS (m / z): calcd for C25H16F9N2 02 ([M + H] +): 5 4 7.1 068; found: 5 47.1 069. -355- 200401770 (Example 48) 2-benzyl-6-acetamido- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-535) The similar method consists of 5-acetamido-o-aminobenzoic acid (2 1 3 mg, 1.1 mmol), phenylacetic acid (150 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol) ) And 2- (4-aminophenyl) -1,1,153,3,3-hexafluoro-2-propanol (259 mg, 1 mmol) to give the title compound as a colorless solid (183 mg, yield: 34%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp > 300 ° C. IR (KB〇 ·· vmax 3 299, 1 6 6 3, 1591, 1 493, 1 270, 1215, 1191, 937 cm'1.

W-NMR (400MHz, DMSO-d6): δ 10 · 32 (1H, s), 8.90 (1H, s), 8.39 (1H, d, J = 2.0 Hz), 8.05 (1H, dd , J = 8.8, 2.0 Hz), 7.71 (1H, d, J = 8.8 Hz), 7.68 (2H, d, J = 8.8 Hz), 7.30 (2H, d, J = 8.8 Hz), 7.18-7.08 (3H, m), 6.74 (2H, d, J = 6.8 Hz), 3.82 (2H, s), 2.09 (3H, s), FABMS (m / z): 5 3 6 ([M + H] +) FABHRMS (m / z): calcd. For C26H20F6N3O3 ([M + H] +): 536.1409; found: 536.1413. Anal, calcd. For C26H19F6N3 03: C, 5 8.3 2; H 5 3.5 8; N ? 7.85; found: C5 5 8.0 4; H, 3.29; N, 7.90. (Example 49) 2-benzyl-5-methoxy- 3- [4- [2,2,2-trifluoro-1 -Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-2 8 7) -356- 200401770 In a similar manner as described in Example 1, 6-methoxy-o-aminobenzoic acid (514 mg5 3.07 mmol), phenylacetic acid (423 mg, 3.10 mmol), triphenyl phosphate (0.80 ml, 3.07 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (717 mg, 2.77 mmol) to obtain the title compound as a colorless solid (317.4 mg, yield: 23% ), This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a colorless crystalline powder. mp 1 24- 1 27 ° C. IR (KBr): vmax 3254,1 672,1 5 96,1 5 67,1 266,1 2 1 4,1 1 94, 93 4 cm-1 .iH-NMR ( 5 00MHz, CDC13): 5 7.7 2 (1 H, t, J = 7 · 8 H z), 7 · 5 8 (2H, d, J = 7.8 Hz), 7.37 (1H, d, J = 8.8 Hz) , 7.04-7.12 (3H, m), 6.93 (1H, d, J = 8.8 Hz), 6.78 (2H, d, J = 8.8 Hz), 6.66 (2H, d, J = 7.9 Hz), 3 · 98 (2H, s) · FABMS (m / z): 547 ([M + K] +)? 5 09 ([M + H] +).

Anal, calcd. For C25H18F6N2 0 3: C, 60.26; H, 3.37; N5 5.8 6; found: C, 60.18; H, 3.42; N, 5.86. (Example 50) 2-benzyl-6-formyl Oxyoxy-3- [4- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (exemplified compounds No. 3-504) In a similar manner as described in Example 1, 5-methoxy-o-aminobenzoic acid (8 17 mg, 4.89 mmol), phenylacetic acid (667 mg, 4.90 mmol), and triphenyl phosphate ( 1.28 ml, 4.90 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (1152 mg, 4.45 mmol) Colorless solid (801 mg, yield: 35%). This product was crystallized from -357- 200401770 in a mixed solvent of dichloromethane and hexane to produce colorless orthorhombic crystals. mp 163-165 ° C. IR (KBr): v max 3264, 1 6 8 0, 1 5 92, 1 493, 1 270, 1214, 1 174, 935 cm'1. FABMS (m / z): 547 ( [M + K] +) 5 5 0 9 ([M + H] +). FABHRMS (m / z): calcd. For C25H18F6N203 ([M + H] +) · 5 5 7.0229; found: 5 09.1 2 80. Anal, calcd. For C 2 5 H j 8 F 6N 2 〇3: C 5 5 9.06; H, 3.57; N, 5.51; found: C, 5 9.5 5; H, 5.30; N, 5.73. (Example 5 1) 2-benzyl-7-methoxy-3 · [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 3-7 2 1) In a similar manner as described in Example 1, 4-methoxy-o-aminobenzoic acid (489 mg, 2.92 mmol) ( According to pavlidis et al. [VH Pavlidis and PJ

Perry, Synthetic Communications, 24, 5 3 3 (1 994)]), phenylacetic acid (367 mg, 2.69 mmol), triphenyl phosphate (912 mg, 2.94 mmol) and 2- (4- Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (759 mg, 2.93 mmol) to give the title compound as a colorless solid, which was recrystallized from ethyl acetate And colorless crystals were produced (45 7 mg, yield: 31%). mp 224-225 ° C. IR (KBr): v max 3 25 0,1 69 5,1 6 1 5,1 5 67,1 27 2,1 204,1 1 1 0, 93 5 cm'1.! H-NMR (400MHz5 CDC13): (5 8.17 (1H, d, J = 8.1 Hz), 7. 7 (2H, d, J = 8.1 Hz), 7.2 0- 7.07 (5 H, m), 6.96 ( 2H, d, J = 8.1 Hz), 6.71 (2H, d, J = 8.1 Hz), 3.98 (3H, s), 3.95 (lH, s), 3.89 -35 8- 200401770 (2H, s) · FABMS ( m / z): 5 09 ([M + H] +). Anal, calcd. for C 2 5 H j 8 F 6 N 2 0 3 · C5 59.06; H5 3.57; N? 5.51; F, 22.42; found: C? 59.19; H5 3.61; N, 5.45; F, 22.49 · (Example 52) 2-benzyl-8-methoxy-3- [4- [2,2,2 -dicut-1-ene -1- (difluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound Nos. 3-9 3 8) In a similar manner as described in Example 1, O-aminobenzoic acid (273 mg, 1.63 mmol), phenylacetic acid (224 mg, 1.64 mmol), triphenyl phosphate (0.43 ml, 1.65 mmol), and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (387 mg, 1.49 mmol) to obtain the title compound as a colorless solid (544 mg, yield: 72%). This product was obtained from dichloro Methane and hexane mix Recrystallized in a solvent to produce colorless crystalline powder. Mp 2 1 8-2 1 9 ° C. IR (KBr): v max 3 29 8, 1 6 7 3, 1 5 92, 1 4 8 5, 1271, 1215, 1 193,934 cm'1. ^-NMR (400MHz, CDC13): 5 7.88 (lH, d, J = 8.1 Hz), 7.63 (2H, d, J = 7.3 Hz), 7.48 (1H, t, J = 8.1 Hz), 7.30 (1H, d, J = 8.1 Hz), 7.03-7.14 (3H, m) 5 6 · 90 (2Η, d, J = 8.8 Hz), 6.66 (2H, d, J = 7.3 Hz) , 4.10 (3H, s), 4.03 (2H, s). FABMS (m / z): 547 ([M + K]), 5 0 8 (M +)? 5 09 ([M + H] +).

Anal · calcd. For C25H18F6N2 0 3: C, 5 9.06; H, 3.57; N, 5.51; found: C? 58.73; H? 3.30; N, 5.65. -359- 200401770 (Example 5 3) 2-benzyl -5,6-dimethoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H)-喳Zazolinone (Exemplary Compound No. 3-1 124) (1) Aqueous solution of potassium permanganate (6.56 g, 41.5 mmol) (1 50 ml) was added dropwise to the solution containing 5,6-dimethoxyl over 40 minutes with stirring. 2-nitrobenzaldehyde (5.02 g, 2 3.8 mmol) (prepared according to the method described by Fukuyama et al. [Y. Fukuyama et al., Tetrahedron, 54, 1 0007 (1 998)]) in acetone solution ( (120 ml), after stirring at room temperature for 30 minutes, the acetone was evaporated in vacuo. The obtained suspension was filtered by suction to remove the precipitate, which was washed with hot water, and the combined filtrate was placed in an ice-water bath. After cooling, it was acidified with concentrated hydrochloric acid, and the precipitated crystals were filtered to give colorless crystals of 5,6-dimethoxy-2-nitrobenzoic acid (4.31 g, yield: 80%). (2) Add 10% palladium-containing carbon [containing 50% (v / v) water, 5 5 6 mg] to the 5,6-dimethoxy-2-nitrate prepared in the above Example 53 (1) Benzoic acid (3.63 g, 16.0 mmol) in ethyl acetate (30 ml), and the resulting mixture was stirred at room temperature under hydrogen pressure for 4 hours, the catalyst was removed by filtration, and the filtrate was concentrated to give 5,6- Dimethoxyanthranilic acid (3.23 g, yield: 100%). (3) In a similar manner as described in Example 1, 5,6-monomethoxy-o-aminobenzoic acid (668 mg, 3.39 mmol) and phenylacetic acid (474 mg, 3.48 mmol), triphenyl phosphate (ι · ΐ7 g, 3.77 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (862 111§3.33 111111〇1) to obtain the title compound as a colorless solid. This product was recrystallized from toluene to give colorless needles (502 mg, yield: 28%). mp 1 0 6.5-1 0 8 ° C. -360- 200401770 IR (KBr) ·· v max 3310, 1 679, 1 5 95, 1 4 8 8, 1 2 82, 1214, 1194, 933 cm " 1. ! H-NMR (400MHz5 DMSO-d6): δ 8.90 (1H? S)? 7.6 7-7.6 5 (3 H, m), 7.49 (1H, d, J = 8.8 Hz), 7.26 (2H, d5 J = 8.1 Hz), 7.17-7.07 (3H, m) 5 6.73 (2H, d, J = 7.3 Hz), 3.90 (3H5 s), 3.76 (2H, s), 3.71 (3H, s). FABMS (m / z): 5 3 9 ([M + H] +).

Anal · calcd. For C26H20F6N2O4: C, 5 8.00; H, 3.74; N, 5.20; F, 21.17; found: C, 5 7.96; Η, 3.75; N, 5.25; F, 20.99. (Example 54 ) 2-benzyl-6,7-dimethoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl]- 4 (3 H) -oxazolinone (Exemplified Compound No. 3-1155) In a similar manner to that described in Example 1, 4,5-dimethoxy-o-aminobenzoic acid (217 mg, 1.1 mmol), phenyl Acetic acid (150 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propane Alcohol (259 mg, 1 mmol) gave the title compound as a colorless solid (319 mg5 yield: 59%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 253-255 ° C. IR (KBr): vmax 3087,1 650,1 613,1501,1396,1271,1212,937 cm · 1.! H-NMR (400MHz, CDC13): < 5 7.68 (2H , D, J = 8.4 Hz) 5 7.61 (1H, s) 5 7 · 23 (1H, s), 7.17-7 · 〇6 (3H, m), 6.95 (2H, d · J = 8.4 200401770

Hz), 6.69 (2H, d, J = 6.4 Hz), 4.56 (1H, s), 4.0 · 6 (3H, s), 4.00 (3H, s), 3.89 (2H5 s). FABMS (m / z ): 5 3 9 ([M + H] +). FABHRMS (m / z): calcd. For C26H21F6N204 ([M + H] +): 5 3 9.1 40 5; found: 5 3 9.1 420. Anal, calcd for C26H20F6N2O4: C5 58.00; H, 3.74; N? 5.20; found: C? 57.99; H? 3.38; N? 5.23. (Example 55) 2-benzyl-6-chloro-7-methyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-1713) (1) A water (230 ml) solution containing a mixture of sodium sulfate (100.4 g) and chloric acid hydrate (15.76 g, 95.3 mmol) was added to a solution containing 4-chloro-3-methylaniline (10.0 · 6 g, 7 4.9 mm ο 1), a mixture of concentrated hydrochloric acid (7.5 m 1) and water (100 m 1), and then added to a mixture containing hydroxylamine hydrochloride (18.76 g, 270 mmol) Water (270 ml) solution, and the resulting mixture was stirred at 100 ° C. for 1 hour, after cooling in an ice-water bath, the resulting precipitate was filtered, and the obtained precipitate was washed with ice-water and dried To obtain N- (4-chloro-3-methylphenyl) -2- (hydroxyl Yl) acetyl amine (15.45 g5 Yield: 97%). (2) The N- (4-chloro-3-methylphenyl) -2_ (hydroxyimino) acetamidine (15.45 g, 7 2.7 mmol) prepared in Example 55 (1) above was placed at 50 ° C was added to the concentrated sulfuric acid (75 ml) with a small amount of stirring, and the resulting mixture was stirred at 80 ° C for 15 minutes. After cooling to room temperature, the reaction mixture was poured into ice-water and the formed precipitate was filtered. The obtained precipitate was completely rinsed with cold water and dried to produce 5-chloro-4-methylacetamidine indole. A mixture of quinone and 5-chloro-6-methylacetoindolinone (1 4.0 4 g, yield: 98%). 200401770 (3) 30% aqueous hydrogen peroxide solution (3.0 ml) was added dropwise over 5 minutes to the acetamidine indoloquinone isomer (2.00 g, 10.2 mmol) prepared in Example 55 (2) above. In a 2N aqueous solution of sodium hydroxide (15 ml) of the mixture, after stirring at room temperature for 1 hour, the reaction mixture was acidified with 1 N hydrochloric acid to pH 5 and then concentrated in vacuo. The obtained residue was repeated twice for silica. Purification by gel column chromatography (using a 1: 1 mixture of ethyl acetate and hexane as the eluent), and 5-chloro-4-methylanthranilic acid (271 mg, Yield: 14%) of orange crystals, and 5-chloro-6-methyl-o-aminobenzoic acid (208 mg, yield ·· 11%) was produced from the multipolar portion. (4) In a similar manner as described in Example 1, 5-chloro • 4-methylanthranilide (580.11, 3.12 111111〇1), phenylacetic acid ( 42811 ^, 3.14 mmol), triphenyl vinegar phosphate (976 mg, 3.15 mmol), and 2- (4-aminophenyl) -1,1,1,3,3 5 3 -hexafluoro-2-propanol ( 82〇111§, 3.16 111111〇1) to obtain the title compound as a colorless solid (1.04 g, 63% yield). This product was recrystallized from acetonitrile to produce colorless orthorhombic crystals. IR (KBr): v max 3 5 9 8, 1 679, 1591, 1 468, 1 270, 1215, 970, 93 3, 7 0 8 cm-1 ·! H-NMR (400MHz, DMSO-d6): 5 8 · 9 2 (1 H, s), 8 · 0 3 (1 H, s), 7.77 (1H5 s) 5 7.7 0 (2 H? D5 J = 8.8 Hz), 7.33 (2H3 d5 J = 8.8 Hz) , 7.18-7.09 (3H, m) 5 6.77 (2H, d, J = 7.3 Hz), 3.83 (2H, s), 2.5 1 (3H5 s). F ABMS (m / z): 5 27 ([M + H] +). Anal. Calcd. For C25H17C1F6N2 02: C, 56 · 99; H, 3.25; N, 5.32; F 5 2 1.64; Cl, 6.73; found: C, 56.98; H, 3.10; N, 5.40; F, 21.62; Cl, 6.73. -363- 200401770 (Example 56) 2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl [Phenyl] benzo] benzo [g] quinazolin-4 (3H) -one (Exemplified Compound No. 4-122) In a similar manner as described in Example 1, 3-amino-2-naphthoic acid (3 74 mg, 2.0 mmol), phenylacetic acid (272 mg, 2.0 mm ο 1), triphenyl phosphate (0.52 ml, 2.011111〇1), and 2- (4-aminophenyl) -1,1 1,1,3,3,3-hexafluoro-2-propanol (414 1 ^ 5 1.6 mmol) to obtain the title compound as a colorless solid (3 6 3 mg, yield: 43%). This product was obtained from hexane and ethyl acetate ester A mixed solvent recrystallized to yield a colorless prismatic crystal. mp225-226 ° C. IR (KBr): v max 3296,1698,1595,1509,1269,1214,1192, 9 3 5 5 7 0 8 cm

'H-NMR (400MHz, DMSO-d6): δ 8.92 (1H? S)? 8.85 (1H? S)? 8 · 3 2 (1 H, s) 5 8 · 2 5 (1 H, d, J = 8 · 1 H z), 8 · 1 5 (1 H, d, J = 8.1 Hz), 7.7 Bu 7.68 (3H, m), 7.62-7.5 8 (1 H, m) 5 7 · 38 (2H, d, J = 8.8 Hz), 7.19-7.10 (3H, m), 6.81 (2H, d5 J = 6.6 Hz), .87 (2H, s). FABMS (m / z): 5 29 ([ M + H] +). FABHRMS (m / z): calcd. For C28H19F6N202 ([M + H] +): 5 29.1 3 5 1; found: 5 2 9.1 3 5 3. (Example 57) 2-benzyl Methyl-5-chloro- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 8-163) -3 64- 200401770 In a similar manner to that described in Example 1, 6-chloro-o-aminobenzoic acid (359 mg, 2.1 mmol), phenylacetic acid (286 mg, 2.1 mmol) ), Triphenyl phosphate (0.55ml, 2.1111111〇1) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (518 1118, 2.0 mmol) to obtain the title compound as a colorless solid (763 mg 5 yield 75%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 1 8 9- 1 90 ° C. IR (KBr): vmax 3 3 1 6,1 68 6,1 5 8 7,1 45 8,1 26 8,1 2 1 1, 9 6 8 cm ! H-NMR (400MHz? CDC13): 6 7 · 7 4 (1 H, d, J = 8 · 0 H z), 7 · 7 0 (1H, dd, J = 8 · 0, 1.6 Hz) , 7.66 (1H, t, J = 8.0 Hz), 7.51 (1H, dd, J = 8.0, 2.0 Hz), 7.46 (1H, brs), 7.40 (1H5 t, J = 8.0 Hz), 7.20-7.12 (3H , M), 6.97 (1H, dd, J = 8.0, 2.0 Hz), 6.79 (2H, d, J = 8.0 Hz), 3.94 (1H, s), 3.92 (1H, d, J = 14.8 Hz), 3.81 (1H, d, J = 14.8 Hz) · FABMS (m / z): 513 ([M + H] +) · FABHRMS (m / z): calcd. For C24H16 3 5 ClF6N2〇2 ([ M + H] +): 5 1 3.0 8 04; found: 5 1 3.0 804. Anal, calcd. For C24H15C1F6N202: C, 56.21; H, 2.95; N, 5.46; found: C, 56.05; H, 3.04; n (5,50.) (Example 58) 2-benzyl-6-meryl-3- [4- [2,2,2-difluoro-1-meryl-1- (trichloromethyl) ethyl ] Phenyl] -k (3H) -quinazolinone (Exemplified Compound No. 3-442) In a similar manner as described in Example 1, 5-hydroxy-o-aminobenzoic acid (168 mg, 1.1 mmol), phenylacetic acid (150 mg, 1.1 mmol), triphenyl phosphate (0.29 -365- 200401770 ml, 1.1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2 5 9 mg, 1 mm ο 1) The compound was a colorless solid (24.3 mg, yield: 49%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 270-272 ° C. IR (KBr): vmax 3 3 8 0,1 662,1 5 93,1 496,1 2 69,1 2 1 3,1 1 7 3, 931 cm " 1. W-NMR (400MHz, DMSO-d6): 6 8 · 91 (1H, s), 7.66 (2H, d, J = 8.8 Hz), 7.62 (1H, d, J = 8.8 Hz), 7.41 (1H, d, J = 3.2 Hz), 7.33 (1H, dd, J = 8.8, 3.2 Hz), 7.26 (2H, d, J = 8.8 HZ), 7.16-7.17 (3H, m), 6.72 (2H, d, J = 7.2 Hz), 3.81 (2H, s). FABMS (m / z): 49 5 ([M + H] +). FABHRMS (m / z): calcd. For C24H17F6N2 03 ([M + H] +): 495.1144; found: 495.1136. Anal, calcd. For C24H16F6N203: C, 58.31; H, 3.26; N, 5.67; found: C, 5 8.3 9; H, 3.48; N, 5, 40. (Example 59) 2-benzyl-8-hydroxy- 3- [4- [2,2,2-trifluoro-1-hydroxy-1 · (trifluoromethyl) ethyl] phenyl] _4 (3H) -quinazolinone (Exemplified Compound No. 3 -876) A solution of 1N boron tribromide in dichloromethane (0.45 ml, 0.45 0 mmol) was added dropwise to -78 ° C to the solution containing the above-mentioned Example 52. 2-Benzyl-8-methoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 ( 3H) -Mu II Sitolinone (7 4 · 1 mg, 0 · 1 4 6 mm 01) bis In the solution of chloroform (10 m 1), -7-8. (: After stirring for 30 minutes, the reaction temperature was warmed to room temperature, and -366- 200401770 saturated aqueous ammonium chloride solution was added. The mixture was further stirred at room temperature for 30 minutes, and then dichloromethane (15 ml X 2) was added. After extraction twice, the combined organic layer was successively washed with water (15 ml) and saturated sodium chloride aqueous solution (15 ml), and then dried over anhydrous magnesium sulfate. The solvent was evaporated in vacuo to produce a crude product. Preliminary silica gel thin layer chromatography analysis (using a volume of 19: 1 ethyl acetate and methanol mixture as eluent) was purified to yield the title compound as a colorless solid (4 1.4 mg, yield: 66%). The product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce a colorless crystalline powder. Mp 215-217 ° C. IR (KB r): ymax 3298,1672,1592,1485,1270,1227,1215, 1 192, 968, 934 cm-1 ·! H-NMR (400MHz5 DMSO-d6): δ 9.79 (1H? S) 5 8.91 (1H? S) 5 7 · 65 (2H, d, J = 8.1 Hz), 7.53 (1H , D, J = 7.3 Hz), 7.38 (1H, t, J = 7.1 Hz), 7.28 (1H, d), 7.24 (2H, d, J = 8.8 Hz), 7 · 14 (1H, d, J = 7.2 H z), 7 · 0 8 (2 H, t , J = 7 · 3 H z), 6 · 7 0 (2 H, d, J = 7.3 Hz), 3.90 (2H, s). FABMS (m / z): 5 3 3 ([M + K]) , 495 ([M + H] +). FABHRMS (m / z): calcd. F〇r C24H16F6N 203 ([M + H] +): 494.3 85 9; found: 49 5.1 1 4 8.

Anal, calcd · for C24H16F6N2 0 3: C, 58.31; H, 3.26; N, 5.67; found: C, 5 7.66; H, 3.03; N, 5.51. (Example 60) 2-benzyl-5-hydroxy- 3- [4- [2,2,2-trifluoro-hydroxyltrifluoromethyl) ethyl 200401770 group] phenyl] -4 (3Η) -quinazolinone (Exemplified compound number 3_225) In the above Example 5 9A similar method, 2-_benzyl-5-methoxy_3- [4- [2,2,2-trifluoro-1_ meridyl — I · (trifluoro (Methyl) ethyl] benzyl] -4 (3Η) -quinazolinone (206 mg, 0.405 mmol) to obtain the title compound as a colorless solid (170 mg, yield: 89%). The ethyl acetate was recrystallized from a mixed solvent to give a colorless crystalline powder. mp 175-1780C. IR (KBr): v max 3 2 8 3, 1 6 5 8, 1 5 90, 1 474, 1 270, 1214, 1 192, 935 cm'1. ·

^ -NMR (400MHz, CDC13): 5 1 1. 3 1 (1 H, s), 7 · 6 9 (1 H, t, J = 7.8 Hz), 7.43 (2H, d, J = 7.8 Hz ), 7.27 (1H, d, J = 7.8 Hz), 7.11-7 · 17 (3H, m), 7.05 (2H, d, J = 8.8 Hz), 6.74 (2H, d , J = 7.8 Hz), 3.90 (2H5 s). FABMS (m / z): 5 3 3 ([M + K]), 495 ([M + H] +) ·

Anal · calcd · for C24H16F6N 2 0 3: C, 58.31; H, 3.26; N, 5.67; found: C5 5 8.2 0; H, 2.98; N, 5.81. Φ (Example 61) 2-benzyl-7- Hydroxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinolinium citrinone (exemplified compounds No. 3-6 5 9) The 2-benzyl-7 · methoxy-3 · [4- [2,2,2-trifluoro] prepared from the above Example 5 1 in a similar manner to the above Example 5 9 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -sepamone (228 mg, 0.448 mmol) to obtain the title compound as a colorless solid (114 mg, yield: 52 %). This product was recrystallized from a mixed solvent of hexane and acetic acid-368-200401770 ethyl ester to give a colorless crystalline powder. mp 242-244 ° C. IR (KBr): u max 3 249, 1 664, 1 605, 1494, 1271, 1216, 1194, 969, 9 3 5 cm'1.] H-NMR (5 00MHz, CDC13) : (5 1 1. 3 3 (1 H, s), 7 · 6 8-7.7 4 (3 H, m), 7 · 29 (1H, d, J = 7 · 8 Hz), 7 · 15 (1H , T, J = 7 · 8 Hz), 7 · 08 (2H, t, J = 7 · 8 Hz), 6.94-6 · 99 (3H, m), 6.68 (2H5 d, J = 6.8 Hz) , 6.65 (2H, d, J = 7.8 Hz), 3.89 (2H, s) · FABMS (m / z): 5 3 3 ([M + K]), 495 ([M + H] +).

Anal, calcd. For C24Hi6F6N203: C, 58.31; H, 3.26; N, 5.67; found: C, 56.59; H, 2.87; N, 5.76. (Example 62) 2-benzyl- 3- [3-methoxy 4--4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 7-221) (1) Mix a mixture containing m-methoxyaniline (2.84 g, 23.1 mmol), hexafluoroacetone trihydrate (5.66 g, 25.7 mmol) and p-toluenesulfonic acid (229 mg, 1.20 mmol) in 1 Stir at 40 ° C for 20 hours. After cooling to room temperature, dissolve the reaction mixture in ethyl acetate, wash with saturated aqueous sodium bicarbonate solution and saturated sodium chloride solution, dry and concentrate. The obtained residue is Purified by silica gel column chromatography (using a 15: 1 volume of hexane and ethyl acetate as eluent) to obtain 2- (4-amino-2-methoxyphenyl) -1, 1,1,3,3,3-hexafluoro-2-propanol (1.94 g, yield: 29%). (2) In a similar manner to Example 1 above, o-aminobenzoic acid (145 mg, 1.06-369-200401770 mmol), phenylacetic acid (144 mg, 1.06 mmol), and diphenyl phosphate (0.28 ml, 1.07 mmol) and 2- (4-amino-2-methoxyphenyl) -1,1,1,3,3,3-hexafluoro-2- prepared from Example 62 (a) above Propanol (277 mg, 0.9 5 8 mmol) obtained the title compound as a colorless solid (112 mg, yield: 21%). This product was recrystallized from a mixed solvent of dichloromethane and hexane to produce a colorless crystalline powder. . mp 236-237 ° C. IR (KBr): ^ max 340 1,1 6 8 6,1 5 9 3,1 4 72,1 26 5,1 209,1 1 95, 943 cm · 1.] H- NMR (400MHz5 DMSO-d6): δ 8.45 (1H? S)? 8.07 (1H? D5 J = 7 · 8 Hz) 5 7 · 83 (1H, t5 J = 7 · 3 Hz), 7.74 (1H, d, J = 8.1 Hz), 7.70 (1H5 d5 J = 8.1 Hz), 7.51 (1H, t, J = 7.9 Hz), 7.05-7.13 (3H, m), 6.97 (1H, d, J = 8.4 Hz) , 6.67-6.76 (3 H, m), 3.82 (2H, q, J = 7 · 7 Hz), 3.40 (3H, s) · FABMS (m / z): 5 0 9 ([M + H] +) FABHRMS (m / z): calcd · for c25H18F6N203 ([M + H] +): 509.0229, found: 509.1285. Anal, calcd. For C25H 丨 8F6N2〇2: C, 59.06; H, 3.57; N5 5.51; found : C? 58.77; H? 3.50; N? 5.60. (Example 63) 2-benzyl-3- [2-methoxy-4- [2,2,2-trifluoro-i_hydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified Compound No. 7-128) (1) In a similar manner to that described in Example 6 2 (1) above, Oxyaniline (. 5 4 g, 12.5 mmol), hexafluoroacetone trihydrate ((.M g, ns mmC) 1) & p-toluenesulfonic acid (121 mg, 0.636 mfnol) to obtain 2- (4- Amino-3-methoxyphenyl 200 401 770 151 15353,3-hexafluoro-2-propanol (1.28 g, yield: 36%). (2) In a similar manner as described in Example 1, o-aminobenzoic acid (2 3 3 mg, 1.70 mmol) was used. , Phenylacetic acid (233 mg, 1.71 mmol), triphenyl phosphate (0.45 ml, 1.72 mmol), and 2- (4-amino-3-methoxy) prepared from Example 63 (1) above Phenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (448 111§, 1.55 111111〇1) to obtain the title compound as a colorless solid (171.4 mg, yield: 20%) This product was recrystallized from a mixed solvent of dichloromethane and hexane to produce a colorless crystalline powder. mp 1 84- 1 86 ° C. IR (KBr): v max 3 200, 1 65 3, 1 5 9 3, 1 468, 1 269, 121 1, 1 190, 963 cm'1. 'H-NMR ( 500MHz, DMSO-d6): 5 8 · 9 5 (1 H, s), 8 · 10 (1 H, d, J = 7.8 Hz), 7.8 8-7.92 (1 H, m), 7.77 ( 1H, d, J = 7.8 Hz), 7.57 (1H, d, J = 7.8 Hz), 7.43 (1H, d, J = 8.8 Hz), 7.14-7.18 (2H, m) 5 6.6 8 ( 2 H, d, J = 7.8 Hz), 3.82 (2H, s), 3.35 (3H, s). FABMS (m / z): 547 ([M + K] +), 5 09 ([ M + H] +) (Example 64) 2-benzyl- 3- [3-methyl-4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 7-1 59) (1) In a similar manner to the above Example 62 (1), m-toluidine (1.56 g , 14.6 mmol), hexafluoroacetone trihydrate (3.55 g, 16.1 mmol) and p-toluene acid (140 mg, 0.735 mmol) to obtain 2- (4-amino-2-methylphenyl) · 1,1,1,3,3,3-hexafluoro-2-propanol (330.11, yield: 8 ° /.). (2) Using a method similar to that described in Example 1, from o-aminobenzoic acid (86 mg, 0.627 -371- 200401770 mmol), phenylacetic acid (86 mg, 0.632 mmol), and triphenyl phosphate (0.17 mi 0.652 mmol) And 2- (4-amino-2-methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (146 11 ^ , 0.53 111111〇1) to obtain a colorless solid (320 mg, yield: 58%) of the title compound, the product was recrystallized from a mixed solvent of dichloromethane and hexane to produce a colorless crystalline powder. mp 195-196 ° C. IR (KBr): vmax 3283,1658,1590,1474,1270,1214,1 192, 935 cm1.! Η-Ν MR (400MHz? DMSO-d6): δ 8.70 (1H s) 5 8.13 (1H? d5J = 8.1 Hz), 7.89 (1H, t, J = 7.4 Hz), 7.74 (1H, d, J = 7.3 Hz), 7.60 (1H, t, J = 7.3 Hz), 7.54 (1H, d, J = 7.3 Hz), 7.10-7 · 19 (4H5 m), 6.82 (1H, s), 6.78 (2H, d, J = 6.6 Hz), 3.84 (2H, q, J = 7.8 Hz), 2.44 (3H, s). FABMS (m / z): 531 ([M + K])? 49 3 ([M + H] +). F ABHRMS (m / z): calcd. For C25H18 F6N2 0 2 ([M + H] +): 5 5 7.022 9; found: 49 3.1 3 7 0. Anal, calcd. For C25H] 8 F6N2 02: C, 60.98 H, 3.68; N, 5.69; found: C, 60.8 9; H, 3.40; N, 5.78. (Example 65) 2-benzyl-3- [2-methyl-4- [2,2,2 -Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 7-66) (1) In the above Example 62 (1) In a similar method, 0-toluidine (1.60 g, 14.9 mmol), hexafluoroacetone trihydrate (3.62 g, 16.5 mmol) and P-toluenesulfonic acid (1 4 5 mg, 0.7 6 1 mm ο 1 ) To obtain 2-(4-amino-3 -methylphenyl)-200401770 1,1,1,3,3,3-hexafluoro-2-propanol (1.75§, yield: 43%). (2) In a similar manner as described in Example 1, an o-aminobenzoic acid (182 mg, 1.33 mmol), phenylacetic acid (18 1 mg 5 1.33 mmol), and triphenyl phosphate (0.35 ml, 1.34 mmol) and 2- (4-amino-3-methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (33 (0.011, 1.27 111111). The title compound was obtained as a colorless solid (319 mg, yield: 54%). This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a colorless crystalline powder. mp 195 ° C. IR (KBr): ymax 3 282, 1 672, 1 594, 1 474, 1 270, 1 207 cm · 1. H-NMR (400MHz? DMSO-d6): δ 8.69 (1H5 s)? 8.11 (1H5 d? J = 8.1 Hz), 7.89 (1H, t, J = 7.4 Hz), 7.76 (1H, d, J = 7.3 Hz), 7.57 (1H, t , J = 7.3 Hz), 7.51 (1H, d, J = 7.3 Hz), 7.11-7 · ι6 (4H, m), 6.96 (1H, s), 6.76 (2H, d, J = 6.6 Hz), 3.85 (2H, q, j = 7.8 Hz), 2.45 (3H, s). FABMS (m / z): 531 ([M + K]), 493 ([M + H ] +).

Anal · calcd · for C25H18F6N202: C, 60.9 8; H, 3.68; N, 5.69; found: C, 60.81; H, 3.37; N5 5.86. (Example 6 6) 2-benzyl- 3- [2 , 6-dimethyl-4- [2,2,2-trifluoro / -1-hydroxy- i- (trifluoromethyl) ethyl] phenyl] -4 (3 Η)-Πquinazolinone (Exemplified compound number 7-2 5 2) (1) In a similar manner to that described in Example 62 (1) above, 2,6-dimethylaniline (2.00 g, 16.5 mmol), hexafluoroacetone trihydrate (4.00 g , 18.2 mmol) and p-toluenesulfonic acid (159.4 mg, 0.838 mmol) to obtain 2- (4-amino-3,5-dimethylbenzene 200401770) -151,1,3,3 5 3 -hexafluoro 2-propanol (3.14 § 5 yield: 66%). (2) In a similar manner as described in Example 1, from o-aminobenzoic acid (351 mg, 2.56 mmol), phenylacetic acid (349 mg, 2.56 mmol), triphenyl phosphate (0.67 ml5 2.57 mmol), and from the above examples 66 (1) 2- (4-amino-3,5-dimethylphenyl) -1,1,1,3,3,3-hexazo-2-propanol (623 mg, 2 17 mmol) to obtain the title compound as a colorless solid (440 mg, yield: 40%). This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a colorless crystalline powder. mp 2 1 8-2 1 9 ° C. IR (KBr): vmax 3283,1658,1590,1474,1270,1214,1192, 962 cm'1.! H-NMR (400MHz, DMSO-d6): δ 8.82 (1H, s), 8.04-8.06 (1H, m), 7.84 (1H, t, J = 7.3 Hz), 7.73 (1H, d, J = 8.1 Hz), 7.50 (1H, t , J = 7.3 Hz), 7.37 (2H, s), 7.12 (1H, t, J = 7.3 Hz), 7.02 (2H, d, J = 6.6 Hz), 6.59 (2H, d? J = 6.6 Hz), 3.59 (2H, s), 1.60 (6H, s) · FABMS (m / z): 54 5, ([M + K]), 5 07 ([M + H] +) · · (Example 67) 2-benzyl-3- [2-chloro ~ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -Quinazolinone (Exemplified Compound No. 7-97) (1) In a similar manner to that described in Example 62 (1) above, 2-chloroaniline (1.74 g5 13.6 mmol), hexafluoropropylpropane dihydrate (3.33 g , 15.1 mmol) and p-toluanthin acid (129 mg, 0.679 mmol) to give 2-amino 4-amino-3-chlorophenyl) _1,1,1,3,3,3 ~ hexafluoro-2- Propanol (3 16 mg, yield: 8%). -374- 200401770 (2) In a manner similar to that described in Example 1, from o-aminobenzoic acid (88 mg, 0.642 mmol), phenylacetic acid (87 mg, 0.639 mmol), and triphenyl phosphate (0.17 ml, 0.652 mmol) ) And 2- (4-amino-3-chlorophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (159 11 ^ , 0.541111111〇1) to obtain the title compound as a colorless solid (156 mg, yield: 56%). This product was recrystallized from a mixed solvent of dichloromethane and hexane to give colorless orthorhombic crystals. mp 182-183 ° C. IR (KB〇: vmax 3290,1678,161 1,1593,1474,1265,1216,1195, 9 6 5 cm-1. 'H-NMR (400MHz5 DMSO-d6): 5 9.18 (1H, s) 5 8.06-8.08 (1H, m), 7.8 5 -7.8 9 (1 H, m), 7.74 (1H, d, J = 8.1 Hz), 7.60-7.67 (3H, m), 7.56 ( 1H, t, J = 7.7 Hz), 7.01-7.14 (3H, m), 6.66 (2H, d, J = 6.6 Hz), 3.79 (2H, q). FABMS (m / z): 551 ([M + K]), 513 ([M + H] +).

Anal, calcd. For C 2 4 H, 5 C 1F 6N 2 O 2: C? 56.21; H? 2.95; N, 5.46; found: C5 56.09; H, 2.72; N? 5.63. (Example 68) 2_ (4 · Bromobenzyl) _5_chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η)- Quinolinone (Exemplified Compound Nos. 3-1 6 9) In a similar manner as described in Example 1, 6-chloro-o-aminobenzoic acid (3 67 mg, 2.15 mmol), 4-bromophenylacetic acid (462 mg , 2.15 mmol), triphenyl phosphate (0.57 ml, 0.72 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (187 mg , 0.72 mmol) to obtain the title compound as a colorless solid (309 mg, yield: 77). This product was crystallized from a mixed solvent of dichloromethane and hexane at -375-200401770 to give a colorless crystalline powder. mp 260-261 ° C. IR (KBr): y max 3402, 1 68 6, 1 5 9251 45 6, 126 7, 1212, 931 cm · 1 · W-NMR (5 00MHz, DMSO-d6): δ 8 92 (1H, s) 5 7.78 (1H, t5 J = 8.3 Hz), 7.71 (2H, d, J = 8.8 Hz), 7.65 (1H, d, J = 7.8 Hz), 7.58 (1H, d, J = 7.8 Hz), 7.39 (2H, d, J = 8.8 Hz), 7.30 (2H, d, J = 8.8 Hz), 6.78 (2H, d, J = 8.8 Hz), 3.78 (2H, s) · FABMS ( m / z): 59 1 ([M + H] +) FABHRMS (m / z): calcd. for C24H14BrClF6N202 ([M + H] +): 5 5 7.02 2 9; found: 5 90.99 1 5. Anal calcd. for C24H14BrClF6N202: C? 48.72; H5 2.3 8; N5 4.73; found: C5 4 8.6 5; H? 2.5 1; N, 4.56. (Example 69) 5-chloro-2- (4-chlorobenzyl) ) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _4 (3 H) -quinazolinone (Exemplified compound number 3 -171) In a similar manner to that described in Example 1, 6-chloroanthranilic acid (3 93 mg, 2.29 mmol), 4-gas phenylacetic acid (390 mg, 2.29 mmol), and triphenyl phosphonate (0.60 ml, 2.29 mmol) and 2- (renaminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (542 mg, 2.09 mmol) to obtain the title compound The product was a colorless solid (98.8.2 mg, yield: 86%). This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a colorless crystalline powder. mp 236-238 ° C. IR (KBr): vmax 3 3 9 1,1 692,1 5 92,1 45 7,1 2 6 8,1 1 75,1 1 08, 93 2 200401770 cm.】 H- NMR (500MHz, DMSO-d6): δ 8.93 (1H, s) 5 7.78 (1H, t, J = 8.3 Hz), 7.71 (2H, d, J = 8.8 Hz), 7.65 (1H, d, J = 7.8 Hz), 7.58 (1H, d5 J = 7.8 Hz) 5 7 · 39 (2H, d, J = 8.8 Hz), 7.16 (2H, d5 J = 8.8 Hz), 6.83 (2H, d, J = 7 8 Hz), 3.80 (2H, s) FABMS (m / z): 5 8 5 ([M + K] +, 479 ([M + H] +).

Anal · calcd. For C24Hi4C12F6N202: C, 52.67; H, 2.58; N, 5 ″ 2; found: C, 52.59; H, 3.05; N, 4.88. (Example 70) 5-Chloro-2- (4-fluorobenzene (Methyl) -3- [4- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone ( Exemplified compound number 3-1 7 3) In a similar manner as described in Example 1, 6-chloro-o-aminobenzoic acid (3 69 mg, 2.15 mmol), 4-fluorophenylacetic acid (334 mg, 2.16 mmol), Triphenyl phosphate (0.56 ml, 2.15 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro · 2-propanol (505mg, l · 96mmol) were obtained The title compound was a colorless solid (909 mg, yield: 88%). This product was recrystallized from a mixed solvent of dichloromethane and hexane to give colorless orthorhombic crystals. mp 183-1850C. IR (KBr): vmax 3359,1686,1593,1510,1458,1270,1227,1195, 9 3 3 cm'1. lH-NMR (5 00MHz, DMSO-d6): δ 8 · 9 2 (1 H, s), 7 · 7 8 (1 H, t, J = 7.8 Hz), 7.71 (2H, d5 J = 7.8 Hz), 7.66 (1H, d, J = 8.8 Hz), 7.59 (1H, d5, 7.8 Hz), 7.37 (2H, d, J = 7.8 Hz), 7.92 (2H, 200401770 t? J = 7.8 Hz) 5 6.8 2 (2 H, m) 5 3.80 (2H? S). FABMS (m / z): 531 ([M + H] +). Anal. Calcd. F〇r C 2 4 H i 4 C1F7N2 0 2: C, 5 4.3 0; H, 2.66; N, 5.28; found: c5 5 4.3 4; H, 2.66; N, 5.30. (Example 71) 5 -Chloro-2- (4-methylbenzyl) -3- [4- [2,2 , 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-167) In a similar manner to that described in Example 1 By 6-chloro-o-aminobenzoic acid (3 4 6 mg, 2.01 mmol), 4-methylphenylacetic acid (306 mg 5 2.03 mmol), triphenyl phosphate (0.53 ml, 2.03 mmol) and 2 -(4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (478 mg, 1.85 mmol) to obtain the title compound as a colorless solid (896 mg, yield: 9 2%), this product is composed of dichloromethane and Recrystallization from a mixed solvent of hexane resulted in colorless orthorhombic crystals. mp 2 1 2 ° C. IR (KBr): v max 3 3 9 5,1 689,1 5 92,1 45 6,1 2 66,1 2 1 1, 93 1 cm-1. 'H-NMR ( 5 00MHz? DMSO-d6): δ 8.91 (1H? S)? 7.78 (1H5 t? J = 8.3 Hz), 7.70 (2H, d, J = 8.8 Hz), 7.67 (1H, d, J = 8.8 Hz) , 7.57 (1H, d, J = 7.8 Hz), 7.33 (2H, d5 J = 7.8 Hz), 6.92 (2H, d? J = 7.8 Hz), 6.65 (2H? D? J = 7.8 Hz), 3.75 ( 2H? S) 5 3.33 (3H, s) · FABMS (m / z): 5 2 7 ([M + H] +) · FABHRMS (m / z): calcd. For C 2 5 H i 7 C 1 F 6 N 2 O 2 ([M + H] +): 5 5 7.0 22 9; found: 5 2 7.0969. Anal, calcd. For C 2 5 H j 7 C 1F 6N 2 O 2: -378- 200401770 C5 56.99 ; Hf, 3.25; N5 5.32; found: C3 57.02; H, 2.99; N, 5.36. (Example 72) 6,7-dimethoxy-2- (4-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy ·;!-(Trifluoromethyl) ethyl] phenyl: 1-4 (3 H) _quinazolinone (Exemplified Compound No. 3-1165) to A similar method as described in Example 1, consisting of 4,5-dimethoxy-o-aminobenzoic acid (433 mg5 2.2 mmol), 4-fluorophenylacetic acid (339 mg, 2.2 mmol), and triphenyl phosphate (0.58 ml, 2.2 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3 -Hexafluoro-2-propanol (5 18 mg, 2.0 mmol) to obtain the title compound as a colorless solid (48 3 mg, yield: 43%). This product was produced by recrystallization from a mixed solvent of hexane and ethyl acetate. Colorless orthorhombic crystal. mp 2 5 5-2 5 6 ° C. IR (KBr): v max 1676,1610,1505,1273,1220,1174 cm'1. 1H-NMR (400MHz, CDC13): δ 7 · 7 0 (2 H , D, J = 8 · 8 H z), 7 · 6 2 (1H, s), 7.22 (1H, s), 6.95 (2H, d, J = 8.8 Hz) 5 6.82-6.76 (2H, m), 6.68-6.63 (2H, m), 4.86 (1H, s), 4.07 (3H, s), 4.01 (3H, s), 3.85 (2H, s). FABMS (m / z): 557 ( [M + H] +). FABHRMS (m / z): calcd. For C26HI9F7N204Na ([M + Naf]: 5 79.1 1 3 1; found: 5 79.1 1 29. Anal, calcd. For C26H19F7N2 04: C, 56.12; H? 3.44; N5 5.0 3; found: C? 5 6.22; H? 3.48; N5 5.10. (Example 73) 2- (4-chlorobenzyl) -6,7-dimethoxy- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- -379- 200401770 (trifluoromethyl) ethyl] phenyl; 1-4 (3 Η) -thiazolinone (illustrated compound numbers 3-1 163) In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (43 3 mg, 2.2 mmol), 4-chlorophenylacetic acid (3 75 mg, 2 · 2 mmol), triphenyl phosphate (0.58 ml, 2.2 mmol) and 2- (4-aminophenylhum, hexafluoro-2-propanol (5 18 mg, 2.0 mmol)) to give the title compound as a colorless solid ( 7 5 1 mg Yield: 66%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. Mp 244-245 ° C. IR (KBr): v max 1 6 75, 1 6 1 3,1 5 03,1 27 1,1 2 1 2,1 1 74 cm'1. ^ -NMR (400MHz? CDC13): δ 7.72 (2H5 d? J = 8.8 Hz)? 7.62 (1H, s), 7.21 (1H, s), 7.08 (2H, d, J = 8.0 Hz), 6.98 (2H, d, J = 8.8Ηζ), 6.64 (2H, d, J = 8.0 Hz), 4.87 (1H, s), 4.07 (3H, s), 4.01 (3H, s), 3.84 (2H, s) · FABMS (m / z) · 5 73 ([M + H] +). FABHRMS (m / z ): calcd · for C26H19ClF6N204Na ([M + Na] +): 595.0836; found: 595.0842. (Example 74) 2_ [4- (bromophenyl) methyl] -6,7-dimethoxy- 3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1161) Example A similar method as described in 1, consisting of 4,5-dimethoxy-o-aminobenzoic acid (433 mg, 2.2 mmol), 4-bromophenylacetic acid (473 mg, 2.2 mmol), phosphorus 200301770 triphenyl ester (0.58 ml, 2.2 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (518 mg, 2.0 mmol) to obtain the title compound A colorless solid (875 mg, yield: 71%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 255-256 ° C. IR (KBr): v max 1 6 8 6, 1612, 1501, 1 272, 1213, 1 176 cm- 丨. 'H-NMR (400MHz5 CDC13)): (5 7 · 7 2 (2 H, d, J = 8 · 8 H z), 7.62 (1H, s), 7.23 (2H, d, J = 8. 0 Hz), 7.21 (1H, s), 6.97 (2H, d, J = 8.8 Hz), 6.59 (2H, d, J = 8.0 Hz), 4.94 (1H, s), 4.06 (3H, s), 4.01 (3H, s), 3.82 ( 2H, s) · FABMS (m / z): 619, 617 ([M + H] +). FABHRMS (m / z): calcd. For C26H19 7 9 BrF6N204Na ([M + Na] +: 6 3 9.03 3 0; found: 639.0322. Anal, calcd. For C26H19BrF6N204 • 1/4 C6H14: C? 51.70; H? 3.55; N5 4.38; found: C5 5 1.94; H? 3.55; N, 4.36. (Example 75) 6,7 -Dimethoxy-2- (4-methylbenzyl) -3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1159) In a similar manner to that described in Example 1, 4,5-dimethoxy-o-aminobenzoic acid (433 mg, 2.2 mmol), 4- Methylphenylacetic acid (330 mg, 2.2 mmol), triphenyl phosphate (0.58 ml, 2.2 mmol), and 2- (4-aminophenyl) _ 1,1,153,3,3-hexafluoro 2-propanol (518 1! ^, 2.〇1111 1101) The title compound was obtained as a colorless solid (634 mg, yield: 57%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate-381-200401770 ester to give colorless rhombic crystals. Mp 255-256 ° C. IR (KBr): v max 1 66 0, 1613, 1501, 1 270, 1212, 1 174 cm. ^ -NMR (400MHz? CDC13): 5 7.67 (2H? D? J = 8.0 Hz) 5 7.62 (1H5 s), 7.23 (1H, s), 6.93 (2H, d5 J = 8.0 Hz), 6.89 (2H, d, J = 8.0 Hz), 6.57 (2H, d, J = 8.0 Hz), 5.00 (1H, brs), 4.06 (3H, s), 4.01 (3H, s) 5 3.83 (2Η, s), 2.26 (3Η, s). FABMS (m / z): 5 5 3 ([M + H] +). FABHRMS (m / z): calcd. For C27H23F6N2〇4 ([M + H] +): 5 5 3.1 5 62; found: 5 5 3.1 5 64. Anal, calcd for C27H22F6N204: C5 58.70; H, 4.01; N5 5.07; found: C? 58.69; H? 4.10; N, 5.05. (Example 76) 2- [Amino (phenyl) methyl] -3- [4- [2,2,2-trifluoro-1-hydroxy-1 · (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-9) (1) A similar method described in Example 1 was performed using o-aminobenzoic acid (150 mg, 1.1 mmol), t-butoxycarbonylamino (phenyl Acetic acid (2 7 6 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro 2-propanol (25 9 111§, 1.01 ^ 111〇1) to obtain 2-[(^ butoxycarbonylamino) phenylmethyl] -3- [4- [2,2,2 -Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone as a colorless solid (176 mg, yield · 30%), this product Recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. (2) Trifluoroacetic acid (about 0.5 ml) was stirred at 0 under nitrogen pressure. (: Added to 200401770 containing 2-[(t_Toxycarbonylamino) phenylmethyl] -3- [4- [2,2,2-trifluoro- 丨 _hydroxy prepared in Example 76 (1) above) (Trifluoromethyl) ethyl] phenylb 4 (3Η) -quinazolinone (120 mg, 202 / zmol) in dichloromethane (2 ml) solution and the resulting mixture was stirred 2.5 After the end of this time, the reaction mixture was neutralized with a saturated aqueous solution of sodium bicarbonate and extracted twice with ethyl acetate (20 ml each time). The obtained organic layer was continuously washed with water (30 ml) and saturated chlorination. Rinse with an aqueous sodium solution (30 ml) and remove the solvent in vacuo to give the title compound as a colorless solid (97 mg, yield: 97%). This product is recrystallized from a mixed solvent of hexane, ethyl acetate and methanol Colorless orthorhombic crystal. Mp 230-234 ° C (dec.). IR (KB r): umax 3339, 3364, 1686, 1597, 1474, 12 72, 1181, 1143, 940 cm-1. · IH- NMR (400MHz, DMSO-d6): δ 8.93 (1H, s) 5 8 · 13 (1H5 d, J = 7.2 Hz), 7.93 (1H, t, J = 7.2 Hz), 7.90 (1H, dd, J = 7.6, 2.0 Hz), 7.83 (1H, d, J = 8.0 Hz), 7.75 (1H, dd, J = 8.8, 2.4 Hz), 7.59 (1H, t, J = 7.2 Hz), 7.47 (1H, d, J = 9.2 Hz), 7.20-7.10 (3H, m) 5 6 · 79 (2H, d, J = 7.2 Hz ), 6.72 (1H, dd, J = 8.0, 2.0 Hz), 4.59 (1H? S). FABMS (m / z): 494 ([M + H] +). FABHRMS (m / z): calcd. For C24H18F6N 3 0 2 ([M + H] +): 494.1 303; found: 494.1 3 07. Anal, calcd. For C24H] 7F6N3 0 2: C, 5 8.42; H, 3.47; N? 8.52; found: C? 58.19; H5 3.4 0; N, 8.46. (Example 77) -383- 200401770 2- (buphenylethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- ( Trifluoromethyl) ethyl] phenyl: 1-4 (3H) -quinazolinone (Exemplified Compound No. 3-8) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 111111〇1), 2-phenylpropionic acid (30〇11 ^, 2.011111〇1), triphenyl phosphate (0.52 1! 11, 2.〇111111〇1) and 2- (4- Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (415 11 ^ 5 1.6) mmol to give the title compound as a colorless solid (1 67 mg, yield: 21 %). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 220-22 1 ° C. IR (KBr): v max 3 2 9 8, 1 667, 1591, 1 268, 1214, 1 107, 96 7.93 4, 7 0 0 cm'1. lH-NMR ( 400MHz5 DMSO-d6): 5 8.9 0 (1 H, s), 8 · 1 2 (1 H, d, J = 8.0 Hz), 7.93 -7.76 (4H, η), 7.58 (1H, t, J = 8.0 Hz), 7.38 (1H, d, J = 9.5 Hz), 7.16-7.06 (3H, m), 6.68 (2H, d, J = 6.6 Hz)? 6.54 (1H? Dd, J = 8.8, 2.2 Hz), 3.8 9-3.94 (1 H, m), 1.51 (3H? D5 J = 7.3 Hz). FABMS (m / z): 493 ([M + H] +). FABHRMS (m / z): ca 1 cd for C 2 5 H! 8 F 6N 2 0 2N a ([M + N a] +): 515.1170; found: 5 15.1148. (Example 78) 2- (1,2-diphenylethyl) ) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Illustrated compound numbers 3-17) In a manner similar to that described in Example 1, from o-aminobenzoic acid (274 mg, 2.0 mmol), 2,3-diphenylpropionic acid (45 3 mg, 2.0 mmol), and trisphosphate Phenyl ester (0.5 2 -384- 200401770 ml, 2.0 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (4 15 mg, 1.6 mmol) to give the title compound as a colorless solid (106 mg, Yield: 11%) The product from a mixed solvent of hexane and ethyl acetate recrystallized yield a colorless prismatic crystal. mp 205-206 ° C. IR (KBr): v max 3 2 8 2, 1 65 7, 1 5 9 1, 1 26 8, 1214, 1 193, 93 4, 7 7 3, 6 9 8 cm · 1 · 'H-NMR (400MHz, DMSO-d6): δ 8.94 (1H, s), 8.11 (1H, dd5 J = 8.1, 1.5 Hz), 7.9 5 -7.8 6 (3 H, m) 5 7.6 0 -7.4 5 (3 H5 m), 7.15-7 · 04 (6H, m), 6.91 (2H, d, J = 7.3 Hz), 6.75 (1H, dd, J = 8.1, 2.2 Hz), 6.70 (2H, d5 J = 8.1 Hz) 5 3.9 3-3.8 9 (1 H, m) 5 3.61 ^ 3.56 (1H, m)? 3.1 1-3.06 (1H, m). FABMS (m / z): 5 69 ((M + H] +) · FABHRMS (m / z): c al cd · for C 31 H 2 2 F 6N 2 O 2N a ([M + N a] +): 591.1483; found: 591.1485. Anal, calcd. For C31H22F6N202: C? 65.49; H? 3.90; N, 4.93; found: C, 65.36; H, 3.80; N5 4.99. (Example 79) 2- [Difluoro (phenyl) methyl] -3- [4- [ 2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1 1) A similar method was described, consisting of o-aminobenzoic acid (274 mg, 2.0 mmol), difluoro (phenyl) acetic acid (344 mg, 2.0 mmol) (according to Middleton et al. [Middleton, WJ5 Bingham, EM, J. Org Chem. 5 45, 2 8 8 3 -2 8 87 (1 9 8 0)], triphenyl phosphate (0.52 ml, 2.0 mmol) and 2- (4-aminophenyl) -1,1,1,3 , 3,3 ~ hexafluoro-2-propanol (41 5 mg, 200401770 1.6 mmol) to obtain the title compound as a colorless solid (101 mg, yield: 12%). This product was obtained from a mixed solvent of hexane and ethyl acetate. Recrystallization gave colorless orthorhombic crystals. mp 193-194 ° C. IR (KB r): y max 3 3 2 6,16651 5 9 8,1 3 42,1 2 67,1 2 1 9,1 1 93, 1 1 3 5, 93 6, 77 5, 700 cm · 1. ^ -NMR (400MHz? DMSO-d6): δ 8.87 (1H5 s)? 8.18 (1H5 d5 J = 8.1 Hz), 8.00-7.96 (lH, m), 7 · 90 (1H, d, J = 7.3 Hz), 7.71 (1H, t, J = 8 · 1 Hz), 7.53 (2H, d, J = 8.8 Hz), 7.46 (1H, t, J = 7 · 3 Hz), 7 · 28 (2H, t, J = 8.1 Hz), 7 · 15 (2H, d, J = 8 · 8 Hz), 7 · 18 (2H, d, J = 8.1 Hz) · FABMS ( m / z): 515 ([M + H] +). F ABHRMS (m / z): calcd. for C24H14F8N202Na ([M + Na] +): 5 3 7.082 5; found: 5 3 7.0 822 · Anal, calcd · for C24H14F8N202: C, 56.04; H? 2.74; N? 5.45; found: C, 55.78; H, 2.84; N? 5.47. (Example 80) 2- [methoxy (phenyl) methyl] -2 -[4_ [2,2,2 -Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -B quinazolinone (Exemplified compound number 3-13) In a similar manner as described in Example 1, o-aminobenzoic acid (2.0 2 g, 1 4.7 mmol), methoxy (phenyl) acetic acid (2.45 g, 14.7 mmol), and triphenyl phosphate (3.86 ml, 14.7 mmol) ) And 2- (4-aminophenyl) -1,1,1,3, 3,3-hexafluoro-2-propanol (3.48 g, 13.4 mmol) to obtain the title compound as a colorless solid (2.15 g, yield: 32%). This product was reconstituted from a mixed solvent of hexane and ethyl acetate. Crystallize to produce colorless orthorhombic crystals. > 3 86- 200401770 mp 234 ° C. IR (KBr): v max 3318, 1671, 1 5 96, 1 473, 1 269, 1214, 1 195, 969, 93 5 cm-1 · ^ -NMR (5 00MHz? CDC 1 3): (5 8.2 8 (1 H5 d5 J = 6.8 Hz), 7.95 (1H, d, J = 7.8 Hz), 7.83 (2H, q, J = 5.9 Hz), 7.65 (1H , T5 J = 7.8 Hz), 7.55 (1H, t5 J = 7.8 Hz) 5 7.1 6-7.2 0 (3 H, m), 6.93 (2H, d, J = 7.8 Hz), 6.77 (1H, q , J = 5.8 Hz), 5.00 (1H5 s), 3.31 (3H5 s). FABMS (m / z): 547 ([M + K]), 5 09 ([Μ + ΗΓ) · Anal, calcd. for C25H18F6N2 03: C? 5 9.05; H? 3.57; N? 5.51; found: C? 5 8.77; H? 3.26; N, 5.69. (Example 81) 2- (2-thienylmethyl) -3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _4 (3H) _quinazolinone (Exemplified compound number 2-61) Example 1 The similar method consists of o-aminobenzoic acid (274 mg, 2.0 mmol), 2-thienylacetic acid (284 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-amine Phenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) to obtain the title compound as a solid, which was obtained from hexane and ethyl acetate Recrystallized in a mixed solvent to produce colorless orthorhombic crystals (524 mg, yield: 68%). Mp 219-220 ° C. IR (KBr): u max 3 1 1 1, 1 6 5 6, 1 5 92,1 269,1 2 1 3,1 1 83,9 3 8,705 cm-1 ·] H-NMR (400MHz, DMSO-d6): δ 8.93 (1H, s), 8.13 (1H, d , J = 200401770 7.2 Hz), 7.92-7.87 (1H, m), 7.7 6-7.74 (3 H, m), 7.58 (1H, t5 J = 7.2 Hz), 7.41 (2H, d, J = 8.4 Hz) , 7.32 (1H, d, J = 5.2 Hz), 6.78 (1H, dd, J = 5.2, 3.2 Hz), 6.34 (1H5 d5 J = 2.8 Hz), 4.04 (2H? S). FABMS (m / z): 4 8 5 ([M + H] +). FABHRMS (m / z): calcd · for C22H15F6N202S ([M + H] +): 485.07 59; found: 48 5.07 5 8. Anal, calcd. for C 2 2 H j 4 F 6N 2 O 2 S: C, 54.55; H5 2.91; N5 5.78; found: C, 54.63; H, 2.84; N, 5.77. (Example 82) 2- (3-pyridylmethyl ) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4oH) -quinazolinone (Exemplified compound number 2 -63) In a manner similar to that described in Example 1, from o-aminobenzoic acid (274 mg, 2.0 111111〇1), 3-pyridylacetic acid (34711 ^, 2.0 111111〇1), and triphosphate Phenyl ester (0.52 ml, 2.0 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (415 mg, 1.6 mmol) to obtain the title compound Colorless solid (25 mg, yield: 30/0). mp 125-126 ° C. IR (KBr): > max 3 067, 1 6 8 6, 1 5 97, 1 2 69, 1214, 1 1 89, 940, 708 cm-1. iH-NMR (400MHz, DMSO-d6): δ 8.95 (1Η, s) 5 8 · 3 9 (1Η, d5 J = 3.7 Hz), 8.13-8.08 (2H, m), 7.88 · 7 · 84 (1H, m), 7 78 (2H5 d, J = 8.8 Hz), 7.67 (1H, d, J = 8.0 Hz), 7.56 (1H, t, J = 8.1 Hz) 5 7.52 (2H? D, J = 8.8 Hz), 7.35-7.33 (1H, m) 5 7.20 (1H? Dd? J = 7.3, 4.4 Hz), 3.83 (2H? S). FABMS (m / z): 48 0 ([M + H] +). 200401770 FABHRMS (m / z): calcd. for C23H16F6N3 02 ([M + H] +): 4 8 0.1 1 47; found: 4 8 0.1 1 3 6. (Example 83) 2-benzyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] pyridine [2,3-d] pyrimidin-4 (3H) -one (Exemplified Compound No. 6- 122) In a similar manner as described in Example 1, from 2-aminonicotinic acid (152 mg, 1.1 mmol), phenylacetic acid (150 mg 5 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1111111〇; 1) and 2- (4-aminophenyl) -1,1,1,3 5 3,3-hexafluoro-2-propanol (2 5 9 11 ^, 1.0 mole) Compound as a colorless solid (121 mg, yield: 25%), This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 198-199 ° C. IR (KBr): v max 3 06 7, 1691, 1591, 1 43 8, 1 270, 1216, 1 1 92, 93 8 cm'1. 'H-NMR (400MHz? CDC 13 ): 6 9.02 (1 H5 dd5 J = 4.4, 2.0 Hz)? 8.60 (1H, dd, J = 8.0, 2.0 Hz), 7.77 (2H, d5 J = 8.8 Hz), 7.49 (1H, dd, J = 8 · 05 4.4 Hz), 7.16-7.09 (3H, m) 5 6.9 8 (2 H, d, J = 8.8 Hz), 6.75 (2H5 d5 J = 7.2 Hz), 3.99 (2H? S). FABMS (m / z): 48 0 ([M + H] +). FABHRMS (m / z): calcd. for C23H15F6N302Na ([M + Na] +): 502.0966; found: 502.0961. Anal, calcd. for C23H15F6N302: C, 57.63 ; H, 3.15; N? 8.77; found: C5 58.41; H, 3.11; N? 8.74. (Example 84) 200401770 2-benzyl-3- [3- [2,2,2-trifluoro-1- Hydroxy-1- (trifluoromethyl) ethyl] phenyl] ft D [2,3-d] pyrimidin-4 (3H) -one (Exemplified Compound No. 6-4) A similar method as described in Example 1 By 2-aminonicotinic acid (290 mg, 2.1 mmol), phenylacetic acid (286 mg, 2.1 mmol), triphenyl phosphate (0.55 ml, 2.1 mmol), and 2 · (3-amine Phenyl) -1,1,1,3 5 3 5 3 -hexafluoro-2-propanol (518 mg, 2.0 mmol) to give the title compound as a colorless solid (2 74 mg, yield: 29%) 'This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 240-24 1 ° C. IR (KBr): Vmax 3 3 93, 1 695, 1 5 8 3, 1 43 8, 1 269, 1 206, 9 66 cm1.] H-NMR (400MHz5 DMSO-d6) : 5 8.99 (lH, dd, J = 4.8, 1.6Hz), 8.94 (1H, s), 8.51 (1H, dd, J = 8.0, 2.4 Hz), 7.80 (1H, brs), 7.79 ( 2H, d, J = 8.0 Hz), 7.58 (1H, t, J = 8.0 Hz), 7.57 (1H, t, J = 8.0 Hz), 7.36 (1H, d, J = 8.0 Hz), 7.22-7.18 ( 3H, m), 6.91 (2H5 m), 3.89 (1H, d, J = 16.0 Hz), 3.79 (1H, d, J = 16.0

Hz). FABMS (m / z): 480 ([M + H] +). FABHRMS (m / z): calcd. For C23H16F6N3〇2 ([M + H] +): 480.1147; found: 480.1158. Anal, calcd. for C23H15F6N302: C, 5 7.6 3; H5 3.15; N? 8.77; found: C5 5 7.9 3; H, 3.48; N? 8.38. (Example 85) 2- (4-trifluoromethylbenzyl) -3- [4- [2,2,2-trifluoro-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified compound number 3-126) 200401770 (1) Chlorosulfuric acid benzoic acid vinegar (71 mg, 413 // mol) was added to the 2- (4-trifluoromethylbenzyl) prepared in Example 5 under stirring at room temperature under nitrogen pressure -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (150mg, 27 5 / / mol) in a mixed solvent solution of dichloromethane (3 ml) and pyridine (1 ml), the resulting solution was stirred for 4 hours, then the reaction mixture was concentrated, and the obtained residue was dissolved in ethyl acetate (50 m 1), continuously rinse with 2 N hydrochloric acid (20 m 1), water (20 m 1), and saturated aqueous sodium chloride solution (20 ml), and dry over anhydrous sodium sulfate to remove Solvent and coagulate the obtained residue with silica Purification by column chromatography (using a 2: 1 volume mixture of hexane and ethyl acetate as eluent) to yield 2- (4-trifluoromethylbenzyl) -3- [4- [2,2 , 2-trifluoro-1-[[(phenylthio) carbonthio] oxy] -1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -oxazolinone (122 mg, yield: 65%) 0 (2) 2- (4-trifluoromethylbenzyl) -3- [4- [2,2,2-tri Fluoro-1-[[(phenylthio) carbonthio] oxy] -1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (120mg, 176 // mol), a solution of tributyltin hydride (71 // 1,264 // mol) and azobisisopropionitrile (10 mg, 62 // mol) in toluene (4 ml) under a nitrogen pressure at 110 ° C was stirred for 4 hours. After this time, the reaction mixture was concentrated, and the obtained residue was purified by silica gel column chromatography (using a 1: 1 mixture of hexane and ethyl acetate as a eluent). The title compound was obtained as a colorless solid (33 mg, yield: 3 6%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 186-1870C. -391- 200401770 IR (KBr): x; max 2 9 5 2,1 6 8 6,1 5 9 6,1 3 2 8,1 2 7 3,1 1 5 1,1 093 cm '1.] H-NMR (400MHz? CDC13): 5 8.29 (1H5 d5 J = 8.0 Hz), 7.85 (1H, t, J = 7.2 Hz), 7.82 (1H, d, J = 7.2 Hz), 7.54 (1H, t, J = 7.2 Hz), 7.43 (2H, d, J = 8.0 Hz), 7.37 (2H, d, J = 8.0 Hz), 7.01 (2H5 d · J = 8.0 Hz), 6.89 (2H, d, J = 8.0 Hz), 4.15 (1H, sept ·, J = 8.0 Hz), 3.99 (2H, s) · FABMS (m / z): 531 ([M + H] "· FABHRMS (m / z): calcd. for C25H16F9N20 ([M + H] +): 531.1119; found: 531.1111. Anal, calcd · for C25H15F9N20: C, 56.61; H, 2.85; N, 5.28; found: C, 56.62; H, 2.77; N, 5.24. (Example 86) 2- (4-difluoromethylbenzyl) -3- [4- [2,2,2-difluoro-1-methoxy, yl-l- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplary Compound No. 3-127) Silver carbonate (756 mg, 2.75 mmol) and iodoformin (0.21 ml, 3.3 mmol) Add at room temperature under nitrogen pressure to the 2- (4-trifluoromethylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1] prepared in Example 5 above. -(Trifluoromethyl) B [Phenyl] phenyl] -4 (3H) -quinazolinone (150 mg, 27 5 // m ο 1) in a methylene chloride (100m 1) solution, and the resulting mixture was stirred for 4 8 hours The reaction mixture was then diluted with dichloromethane (50 ml) and filtered through Celite ™. The resulting solution was concentrated, and the obtained residue was subjected to silica gel column chromatography (using a volume of 2). : 1 mixture of hexane and ethyl acetate was used as eluent) to give the title compound as a colorless solid (102 mg, yield: 66%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate. Produces colorless -392- 200401770 orthorhombic crystal. mp 1 8 8-1 8 9 ° C. IR (KBr): ^ max 1 69 3, 1 5 94, 1 3 28, 1 2 24, 1 130, 1 1 10, 948 cm ·,] H-NMR ( 400MHz, CDC13): ό 8 · 2 9 (1 H, d, J = 8 · 0 H z), 7 · 8 5 (1H5 t, J = 7.2 Hz), 7.82 (1 H 5 d, J = 7 · 2 H z), 7.60 (2 H, d, J = 8.0 Hz), 7.55 (1H, t, J = 7.2 Hz), 7.37 (2H, d5 J = 8.0 Hz), 7.07 (2H, d, J = 8.0 Hz), 6.89 (2H, d, J = 8.0 Hz), 4.00 (2H, s), 3.54 (3H, s). FABMS (m / z): 561 ([M + H] +). FABHRMS (m / z): calcd. for C26H18F9N2 02 ([M + H] ”: 561.1225; found: 561.1206. Anal, calcd. for C26H17F9N202: C5 5 5.72; H? 3.06; N, 5.00; found: C? 5 5.64 ; H, 2.93; N, 5.06. (Example 87) 2-[(methylamino) (phenyl) methyl] -3- [4- [2,2,2-trifluoro-1-methoxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) _quinazolinone (Exemplified Compound No. 3-10) (1) Sodium hydride (4 2 mg, 1.06 mm ο 1) At room temperature under nitrogen pressure, add to the 2- [t-butoxycarbonyl-amino (phenyl) methyl group prepared in Example 76 (1) above: 1-3- [4- [2, 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] Group] -4 (3H) -quinazolone (250 mg, 422ymol) in a tetrahydrofuran (5 ml) and N, N-dimethylformamide (3 ml) mixed solvent solution, and the resulting The mixture was stirred for 1 hour. At the end of this time, methyl iodide (0.13 ml, 2.11 mmol) was added and the resulting mixture was stirred for an additional 4 hours, after which the reaction mixture was poured into water and ethyl acetate (30 ml each ) Extracted twice, and the organic-393- 200401770 layer was successively washed with water (20 ml) and a saturated aqueous sodium chloride solution (20 ml), and dried over anhydrous sodium sulfate, the solvent was removed and the obtained residue was Purified by silica gel column chromatography (using a 1: 1 mixture of hexane and ethyl acetate as eluent) to produce 2-[[N- (t-butoxycarbonyl) -N-methyl Amine] (phenyl) methyl] -3- [4_ [2,2,2-trifluoro-bumethoxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 to- Quinazolinone (152 1 1 ^, yield: 58%). (2) Add trifluoroacetic acid (0.5 ml) at 0 ° C under nitrogen pressure to the 2-[[N- (t-butoxycarbonyl) -N-methyl group prepared in the above Example 87 (1) Amine] (phenyl) methyl] -3- [4- [2,2,2-tri-l-methoxy-1- (di-trimethyl) ethyl] phenyl] -4 (3H) -Azolidone (149 mg, 240 // mol) in dichloromethane (4 ml), and the resulting mixture was stirred at room temperature for 5 hours, then the reaction mixture was poured into a saturated aqueous sodium bicarbonate solution , And extracted twice with ethyl acetate (30 ml), the organic layer combined was successively washed with water (20 ml) and saturated aqueous sodium chloride solution (20 ml), and dried over anhydrous sodium sulfate, Removal of the solvent gave the title compound as a colorless solid (125 mg, yield: 100%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 6 1 -64 ° C. IR (KBr): v max 343 5,1 690,1 5 94,1 284,1 2 1 9,1 20 1,1 1 1 1,948 cm'1.

1H-NMR (400MHz, CDC13): δ 8.28 '(lH, dd, J = 8.0, 1.6Hz), 7.90 (1H5 d5 J = 7.2 Hz) 5 7.8 7 (1 H5 dt? J = 8.0, 1.6 Hz)? 7.81 (1H, d, J = 8.0 Hz), 7.54 (1H, dt5 J = 8.0, 1.6 Hz), 7.47 (1H, dd, J = 8.8, 2.4 Hz), 7.38 (1H , d, J = 8.0 Hz), 7.21 (1H, t, J 200401770 = 6.0 Hz), 7.13 (2H, t, J = 7.6 Hz), 6.76 (2H, t5 J = 7.6 Hz) , 6.48 (1H, dd, J = 8.0, 2.4 Hz), 4,33 (1H, s), 3.55 (3H, s) 5 2 · 33 (3H, s) · FABMS (m / z): 5 22 ([M + H] +). FABHRMS (m / z): calcd. For C26H21F6N 3 02 ([M + H] +): 522.1616; found: 522.1610. Anal, calcd. For C26H21F6N302: C5 59.89; H, 4.06; N? 8.06; found: C5 59.59; H, 4.04; N, 7.93. (Example 88) 2-phenyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- ( Trifluoromethyl) ethyl] phenyl; j-4 (3H) -quinazolinone (Exemplified Compound No. 3-4) In a similar manner as described in Example 1, o-aminobenzoic acid (150 mg, 1.1 mmol ), Benzoic acid (134 mg, 1.1 mmol), triphenylphosphonate (0.39 ml, 1.1 111111〇1), and 2- (4-aminophenyl) -1,1,1,3,3, 3-hexafluoro-2-propanol ( 259 111 §5 1.0 mmol) to obtain the title compound as a colorless solid (90 mg5 yield: 19%) 'This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 265-266 ° C. 'H-NMR (400MHz, CDC13;): δ 8 · 3 7 (1 Η, d, J = 8 · 0 Η z), 7.84 (2H, m), 7.66 (2H, d , J = 8.4 Hz), 7.57 (lH, m), 7.27-7.17 (7H5 m). FABMS (m / z): 465 ([M + H] +). (Example 89) 2- (2-phenyl Ethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] -395- 200401770 phenyl] -4 (3 Η) -quinazole Porphyrinone (Exemplified Compound Nos. 3 to 6) In a similar manner as described in Example 1, o-aminobenzoic acid (150 mg, 1.1 mmol), 3-phenylpropionic acid (165 mg, 1.1 mmol), and triphenyl phosphate were used. Esters (0.29 ml, 1.1111111〇1) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2 5 9 mg, 1 · 0 mmol) to obtain the title compound as a colorless solid (290 mg, yield: 5 9). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 1 9 1-192 ° C. IR (KBr): max 3169, 1 64 5, 1591, 1 272, 1213, 1 196, 9 3 9 cm · 1 · ^ -NMR (400MHz? CDC13): 5 8.2 4 (1 H, d, J = 8 · 0 Hz), 7 · 8 6 (2H, d, J = 8.4 Hz), 7.77 (1H, t, J = 8.0 Hz), 7.72 (1H, d5 J = 8.0 Hz), 7.47 (1H, t, J = 8.0 Hz), 7.22 (2H, d, J = 8.8 Hz), 7.18-7.10 (3H, m)? 6.84 (2H? D5 J = 7.2 Hz ), 4.18 (1H, s)? 2.95 (2H, t, J = 7.2 Hz), 2.67 (2H, t, J = 7.2 Hz), FABMS (m / z): 493 ([M + H] +) FABHRMS (m / z): calcd. For C25H19F6N202 ([M + H] +): 493.1351; found: 493.1348. Anal, calcd. For C25H18F6N202 · 1/4 H20: C? 60.43; H, 3.75; N? 5.63; found: C? 60.42; H, 4.15; N5 5.4 8. (Example 90) 6-bromo-2-methyl- 3- [4- [2,2,2-trifluoro-1- Ethyl-1 · (trifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -quinazolinone (Exemplified Compound Nos. 1-4 5) In a similar manner as described in Example 1, Anthranilic acid (2.1 6 g, 10-396- 200401770 mmol), acetic acid (0.57 ml, 10 mmol), triphenyl phosphate (2.62 ml5 10 mmol), and 2- (4-aminophenyl) -1,1,1,3,3 , 3-hexafluoro, 2-propanol (2.59 g, 10 mmol) to obtain the title compound as a colorless solid (2.11 g, yield: 44%). This product was produced by recrystallization from a mixed solvent of hexane and ethyl acetate. Colorless orthorhombic crystal. mp 254-2550C. (KBr): v max 3 29 8, 1 68 8, 1 5 94, 1 470, 12 7 4, 1 2 1 6, 93 5 cur1 · W-NMR (400MHz, CDC13): δ 8.38 (1H, d, J = 2.0 Hz), 7.95 (1H, d, J = 8.0 Hz), 7.86 (1H, dd, J = 8.8, 2.0 Hz), 7.57 (1H, d, J = 8.8 Hz), 7.37 (2H, d, J = 8.8 Hz), 4.30 (1H, brs), 2.23 (3H, s). FABMS (m / z): 482, 480 (M +). FABHRMS (m / z): calcd. For C18Hn79BrF6N2 02 (M +): 479.9908; found: 4 7 9.9900. (Example 91) 2-ethyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) (Ethyl) ethyl] phenyl] -4 (311) -quinazolinone (Exemplified Compound No. 1_2) (1) Will contain isatin derivatives (ethinoindolequinone; 3.26 g, 20 mmol) and 2- ( 4-Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5.18 @, 20 mm ο 1) A solution of acetic acid (60 ml) was refluxed for 2 hours, and then The reaction mixture was concentrated and the obtained residue was purified by silica gel column chromatography (using a 2: 1 mixture of hexane and ethyl acetate as an eluent) to produce 2-amino-N- [4 -[2,2,2-Difluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] benzidine Colored solid 200401770 (3.23 g, 43% yield ··). (2) containing 2-amino-N- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzene prepared in the above Example 91 (1) Yl] benzamide (3 7 8 mg, 1.0 mmol), 1,1,1-triethoxypropane (352 mg, 2.0 mmol) and p-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) of a pyridine (3 ml) solution of the mixture was stirred at 100 ° C under nitrogen pressure for 2 hours. After this time, the reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography. Purification (using a 2: 1 mixture of hexane and ethyl acetate as eluent) yielded the title compound as a colorless solid (210 mg, yield: 51%). This product was a mixed solvent of hexane and ethyl acetate. Medium recrystallizes to produce colorless orthorhombic crystals. mp 223-224 ° C. IR (KBr): ^ max 1 6 5 6,1 5 9 5,1 26 8,1 2 1 6,1 1 84,1 1 07, 968, 9 3 7,77 3 cm .1 ·】 H-NMR (400MHz, DMSO-d6): δ 8.95 (1H, s), 8.10 (1H, dd, J = 8.1, 1.5 Hz), 7.8 8 -7.8 4 (3 H5 m)? 7.71 ( 1H, d5 J = 8.1 Hz), 7.64 (2H, d, J = 8.8 Hz), 7.53 (1H, t, J = 6.6 Hz), 2.34-2 · 29 (2H, m), 1.35 ( 3ii, t, J = 6.6Hz). FABMS (m / z): 417 ([M + H] +). FABHRMS (m / z): calcd. For C j 9H 14F6N202Na ([M + Na] +): 43 9.0 8 5 8; found: 43 9.0 8 72. Anal, calcd · for C19H14F6N202: C, 5 4.8 2; H, 3.39; N, 6.7 3; found: C, 54.60; H, 3.38; N, 6.81. ( Example 92) 2- (1-methylethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] 200401770 phenyl] -4 (3 Η) -quinazone-one (Exemplary Compound Nos. 1-4) In a similar manner as described in Example 1, o-aminobenzoic acid (2 74 mg, 2.0 mmol), 2-methylpropionic acid (176 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2- Propanol (415 mg, 1.6 mmol) to give the title compound as a colorless solid (122 mg, yield: 18 ° / 0), this product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 253-254 ° C. IR (KBr): v max 1 65 4, 1 5 9 0, 1 262, 1185, 1 1 07, 96 8, 9 3 8,776 cm · 1 W-NMR (400MHz, DMSO-d6 ”Δ 8.95 (1H, s), 8.10 (1H, dd, J = 8.1, 1.5Hz), 7.8 9-7.8 3 (3 H, m), 7.71-7.66 (3H, m), 7.55-7.51 ( 1H, m), 2.5 5 -2.45 (1 H, m), 1.15 (6H, d, J = 6.6 Hz) · FABMS (m / z): 431 ([M + H] +). FABHRMS (m / z ): calcd. for C20H16F6N2O2Na ([M + Na] +): 45 3.1 0 1 4; found: 45 3.1 026. Anal, calcd. for C20H16F6N2O2: C, 5 5.8 2; H? 3.75; N? 6.51; found: C? 5 5.7 9; H? 3.49; N? 6.62. (Example 93) 2- (2,2-dimethylpropyl) -3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenyl; 1-4 (3H) -quinazolinone (Exemplary Compound No. 1-8) In a similar manner as described in Example 1, o-aminobenzoic acid (150 mg, 1.1 mmol), tert-butylacetic acid (128 mg, 1.1 mmol), triphenyl phosphate (0.29 ml, 1.1 mmol), and 2- (4-aminophenyl) -1,1,1,3, 3,3-hexafluoro-2-propanol (259 mg, 1.0 mmol) to obtain the title compound as a colorless solid (158 mg, 200401770 yield: 34%). This product was composed of hexane and ethyl acetate Recrystallized in a mixed solvent to produce colorless orthorhombic crystals. Mp 232-235 ° C. IR (KBr): umax 31 13,2963,1652,1586,1265,1 183,969 cm ·, ^ -NMR (400MHz? CDC13) : 〇8.27 (1H, dd, J = 8.0, 1.6 Hz), 7.91 (2H, d, J = 8.0 Hz), 7.79 (1H, dt, J = 7.2, 1.6 Hz), 7.73 (1H, d, J = 7.2 Hz), 7.49 (1H, dt, J = 7.2, 1.6 Hz), 7.34 (2H, d, J = 8.0 Hz), 4.23 ( 1H, s), 2.38 (2H, s) 5 0.9 9 (9 H, s) 5 1.65 -0.80 (1 0 H 5 m). FABMS (m / z): 45 9 ([M + H] +) . FABHRMS (m / z): calcd. For C22H21F6N202 ([M + H] +): 45 9.1 5 07; found: 45 9.1 5 0 1. Anal, calcd. For C 2 2 H 2 〇F 6N 2 O 2 : C? 5 7.64; H, 4.40; N, 6.11; found: C? 5 7.6 8; H? 4.31; N? 6.00. (Example 94) 2-trifluoromethyl- 3- [4- [2,2 1,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4oH) -quinazolinone (Exemplified compound number 1-10) (1) Trifluoroacetic anhydride (14.3 ml, 101 mmol) at 0. (: Added to a solution of o-aminobenzoic acid (9.25 g, 67.5 mmol) and triethylamine (18.8 ml, 135 mmol) in tetrahydrofuran (100 ml) under nitrogen pressure, the resulting mixture was at room temperature After stirring for 7 hours, the reaction mixture was concentrated, poured into water and extracted twice with ethyl acetate (200 ml). The combined organic layers were successively mixed with water (100 ml), IN hydrochloric acid (100 ml), and water ( 100 ml) and saturated sodium chloride aqueous solution (100 ml), and dried over anhydrous sodium sulfate, the solvent was removed to produce a colorless solid (10.5 g) of N- (trifluoroacetamido) anthranilic acid. (Yield: 67%). -400- 200401770 (2) N, N-carbonyldiimidazole (5.36 g, 33 mmol) was stirred at room temperature under nitrogen pressure to prepare the product containing the above Example 94 (1). N- (trifluoroacetamido) anthranilic acid (7.69 g, 33 mmol) in a solution of tetrahydrofuran (80 ml), and the resulting mixture was stirred for 1 hour. At the end of this time, '2- ( A solution of 4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5.7008, 22 111111〇1) in tetrahydrofuran (60 ml) was added to the reaction mixture, and The resulting mixture was stirred at 70 ° C. for 6 hours under nitrogen pressure. After that, the reaction mixture was concentrated, poured into water and extracted twice with ethyl acetate (200 ml). The combined organic layer was continuously mixed with water (100 ml). , 1N hydrochloric acid (100 ml), water (100 ml) and saturated sodium chloride aqueous solution (100 ml), rinsed, and dried over anhydrous sodium sulfate, the solvent was removed, and the obtained residue was subjected to silica gel. Purification by column chromatography (using a 5: 1 mixture of hexane and ethyl acetate as the eluent) gave the title compound as a colorless solid (1.48 g, yield: 15%). This product consisted of hexane and ethyl acetate. Recrystallization in a mixed solvent of esters produces colorless orthorhombic crystals. Mp 183 ° C. IR (KBr): u max 3173, 1 670, 1 3 7 3, 1 227, 1173, 966 cm · 1 · ^ -NMR ( 400MHz5 CDC13): d 8.3 4 (1 H, d, J = 8 · 2 H z), 7 · 9 1 (4H, m), 7.68 (1H, m), 7.42 (2H, d, J = 8.2 Hz), 3.86 (1H, s). FABMS (m / z): 45 7 ([M + H] +). F ABHRMS (m / z): calcd. For C18H9F9N202Na ([M + Na] A: 479.04 1 8; found: 479.043 1. Anal, calcd. For C18H9F9N202: C5 47.3 8; H5 1.99; N, 6.14; found: C, 46.98; H, 2.24; N? 6.54. (Example 95) 2-chloromethyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- ( Trifluoromethyl) ethyl] benzene-401-200401770-based] -4 (3H) -quinazolinone (Exemplified Compound No. 1-13) In a similar manner to the above Example 91 (2), from the above Example 91 ( 1) 2-amino-N- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] benzamide (378 mg, 1.0 mmol), 2-chloro-1,1,1-trimethoxyethane (352 mg, 2.0 mmol) and p-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) to give the title compound as a colorless solid (35 mg, yield: 81%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 1 90-191 ° C. IR (KBr): v max 3310, 1661, 1 5 97, 1 2 68, 1217, 1 1 08,970, 93 6, 774, 70 8 cm · 1 · 丨 H-NMR (400MHz , DMSO-d6): δ 8.97 (1H, s) 5 8.15 (1H, d, J = 8.0Hz), 7.95 -7.87 (3H, m), 7.79 (lH, d, J = 7.3Hz), 7.73 -7.69 (2H, m), 7.65-7.61 (1H, m) 5 4 · 35 (2H, s) · FABMS (m / z): 43 7 ([M + H] +). FABHRMS (m / z) : calcd. for C18H12C1F6N202 ([M + H] +): 437.0492; found: 43 7.047 1. Anal, calcd. for C j 8H j! C1F6N202: C5 49.50; H5 2.54; N, 6.41; found: C5 49.24; H5 2.71; N? 6.47. (Example 96) 2-Dichloromethyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 1-14) In a similar manner to that described in Example 91 (2) above, 2-amino-N- [4- [ 2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] benzamide (37 78 mg, 1.0 mmol), 2,2-dichloro-1 , 1,1-trimethoxyethane-402- 200401770 (462 mg, 2.0 mmol) and p-toluenesulfonic acid monohydrate (10 mg, 0.05 mmol) to obtain the title compound as a colorless solid (307 mg (Yield: 65%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp235-236 ° C. IR (KBr): v max 3 290, 1 6 8 8, 1 5 97, 1 268, 1213, 1 172, 1 108, 93 3, 773, 7 1 7 cm '^ -NMR ( 400MHz? DMSO-d6): δ 8.98 (1H5 s)? 8.17 (1H? Dd5 J = 8.1.1, 1.5 Hz), 7.99-7.84 (4H, m), 7.78-7.66 (3 H, xn) 5 6.56 (lH, s) FABMS (m / z): 471 ([M + H] +) FABHRMS (m / z): calcd. For C18H10Cl2F6N2O2Na ([M + Na] +): 492.992 1; found: 492.9923 Anal, calcd. For C18H10Cl2F6N2O2: C, 45.88; H, 2.14; N, 5.95; found: C, 46.00; H, 2.23; N, 5.88. (Example 97) 2- (1-chloroethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound Nos. 1-18) ( 1) Add 2-chloropropanyl chloride (4.2 g, 33.1 mmol) dropwise to methyl o-aminobenzoate (5 g, 33.1 mmol) and diisopropylethylamine (5.1 g, 39.7) under ice-cooling. mmol) in a solution of dichloromethane and stirred, after stirring at 0 ° C for 30 minutes and at room temperature for 3 hours, a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the organic layer was separated. Extraction, combined organic layers continuously Qing and aqueous sodium chloride solution, dried and concentrated to yield 2 - [(2-chloropropyl acyl) amino] benzoate (7.75 g, yield: 97%). • 403 · 200401770 (2) Add 1N lithium hydroxide aqueous solution (40 ml, 40 mmol) to methyl 2-[(2-chloropropanyl) amino] benzoate prepared in Example 97 (1) above (7.75 g, 32.1 mmol) in a solution of tetrahydrofuran (40 ml), and the resulting mixture was stirred at 50 ° C for 3 hours. After the tetrahydrofuran was removed by evaporation in a vacuum, the resulting aqueous layer was treated with 1N hydrochloric acid It was acidified and extracted with ethyl acetate. The organic layer was washed with water and saturated aqueous sodium chloride solution, dried and concentrated. The obtained residue was subjected to silica gel column chromatography (using hexane and a volume of 1: 4). The ethyl acetate mixture was purified as an eluent) to give 2-[(2-chloropropanyl) amino] -benzoic acid as a colorless solid (7.1 g, yield: 97%). (3) A 2M solution of dichloromethane (2.4 ml, 4.8 mmol) containing phosphorus trichloride was added dropwise to the 2-[(2-chloro) prepared in Example 97 (2) over 5 minutes. Propionyl) amino] benzoic acid (1.1 g, 4.8 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (1.25 @ , 4.8 111111〇1) in toluene (15 ml) solution, the resulting mixture was refluxed for 1.5 hours, then water was added to the reaction mixture under ice-cooling, and the dichloromethane was removed by evaporation in vacuo The remaining aqueous layer was extracted with ethyl acetate, and the organic layer was washed with water and a saturated sodium chloride aqueous solution, dried and concentrated. The obtained residue was subjected to silica gel column chromatography (hexane: ethyl acetate). = 1 〇: 1 to 1: 1), and the title compound (0.43 g, yield: 20%) was produced. ^ -NMR (CDC13): δ 8.22 (1H5 d? J = 7.8 Hz) 5 7.8 8 (1 H? D? J = 8.5 Hz), 7.84 (1H, d, J = 8.4 Hz), 7.76 (m, 2H ), 7.55 (dd, 1H, J = 8.5, 2.2 Hz), 7.50 (m, 1H), 7.23 (dd, 1H, J = 8.4 and 2.3 Hz), 4.45 (1H, q, J = 6.6 Hz), 3.8 (1H, bs), 1.83 (3H, d, J = 6.6 Hz). -404- 200401770 ESI MS (m / z): 451 ([M + H] +). (Example 98) 2- (1-Br Ethyl) -3- [4_ [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (exemplified compounds No. 1-17) In a similar manner to the above Example 91 (2), the 2-monthlynyl-N- [4- [2,2,2 · difluoro] prepared from the above Example 9 1 (1) < -1-Phenyl-i- (difluoromethyl) ethyl] phenyl] benzamide (378mg, 1.0mmmol), 2-bromo-1,1,1-triethoxy Propane (510 mg, 2.0 toluenesulfonic acid monohydrate (10 mg, 0.05 mmol)) to obtain the title compound as a colorless solid (1 90 mg, yield: 38%). This product was a mixed solvent of hexane and ethyl acetate. It recrystallizes in medium to produce colorless orthorhombic crystals. Mp 227-228 ° C. IR (KBr): umax 1 65 8, 1591, 1 3 6 8, 1 267, 1214, 1 1 84, 967, 7 75 cm_ 1 iH-NMR (400MHz, DMSO-d6): δ 8.98 (1H, s), 8.15 (1H, d, J = 8.8Hz), 7.95 -7.8 8 (3 H, m), 7.80 (lH, d, J = 8.1Hz), 7.77-7 · 60 (3H, m), 4.56 (1H, m), 2.00 (3H, d, J = 6.6 Hz). FABMS (m / z): 495, 497 ([M + H] ”· FABHRMS (m / z): calcd. For C19H 1 3 7 9 BrF6N202Na ([M + Na] +): 516.9962; found: 516.9954. Anal, calcd. For C19H13BrF6N2 02: C5 46.08; H, 2.65; N5 5.66; found: C5 46.33; H5 2.62; N5 5.75. (Example 99) 2- (diethylaminomethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Illustrated Compounds 1-22) -405- 200401770 Diethylamine (2 3 8 // 1, 2.30 mmol) was added at room temperature to the 2-chloromethyl-3- [4- [2 , 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (200 mg, 0.46 mmol) in toluene ( 3 ml) solution, and the resulting mixture was stirred at 1 ° C. for 4 hours under a nitrogen pressure, and then the reaction mixture was concentrated, and the obtained residue was subjected to silica gel column chromatography using a volume of 2: 1 mixture of hexane and ethyl acetate as an eluent) was purified to give the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (32 mg, product Rate: 1 5%). Mp 178-179 ° C. IR (KBr): vmax 3 296, 2972, 1 659, 1 594, 1 473, 1214, 1 1 92, 968, 773, cm · 1. IH- NMR (400MHz, DMSO-d6): δ 8.88 (1H, s) 5 8.13-8.11 (1H, m), 7.90-7.70 (4H, m), 7.5 9-7.5 5 (3 H, m), 3.33 (2H, s), 2.22-2.17 (4H, m), 0 · 59 (6H, t, J = 7.3 Hz). FABMS (m / z): 474 ([M + H] +) · FABHRMS ( m / z): calcd. for C2 2H22F6N302 ([M + H] +): 474.1 6 1 7; found: 474.1 620. (Example 100) 2- (1-pyrrolidinylmethyl) -3- [4- [2,2,2-trifluoro 1-Hydroxy-1- (trifluoromethyl) ethyl] phenylb 4 (3H) -quinazolinone (Exemplified Compound No. 2-29) Prepared in a similar manner to that described in Example 99 above and prepared in Example 95 above. 2-chloromethyl-3 · [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (200 mg, 0.46 mmol) and [I slightly diodine (192 // 1, 2.30 -406 · 200401770 mmol) to obtain the title compound as a colorless solid, which was produced by recrystallization from a mixed solvent of hexane and ethyl acetate Colorless orthorhombic crystal (120 mg, yield: 55%). mp 191-192 ° C. IR (KBr): vmax 3290, 2967, 2797, 1680, 1598, 1268, 1214, 935, 774 cm · 1. ^ -NMR (400MHz5 DMSO-d6): δ 8.90 (1H? s )? 8.14 (1H? Dd5 J = 8.1, 1.5 Hz), 7.9 0-7.8 5 (1 H, m), 7.80 (2H, d, J = 8.8 Hz), 7.74 (1H, d , J = 8.1 Hz), 7.60-7.5 5 (3 H, m), 3.38 (2H, s), 2.28-2.09 (4H_, m), 1.5 9- 1.48 (4H? M). FABMS (m / z): 472 ([M + H] +) · F ABHRMS (m / z): calcd. for C22H20F6N3〇2 ([M + H] +): 472.1459; found: 472.1444. (Example 101) 2- (Bu Hexahydropyridylmethyl) -3- [4- [2,2,2-trifluoro-l-hydroxy 4- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazoline Ketone (Exemplified Compound No. 2-30) 2-chloromethyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (109 mg, 0.25 mmol) and hexahydropyridine [[ding (99 // 1, 1.00 mmol) to obtain the title compound A colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals (23 mg, yield: 99%). mp 219-220 ° C. -407- 200401770 IR (KBr): max 3 2 8 3, 29 3 8, 1 670, 1 5 96, 1 268, 1213, 93 5 cm · 1 · ^ -NMR (400MHz5 DMSO -d6): δ 8.88 (1H? s)? 8.14 (1H5 dd5 J = 8.1, 1.5 Hz), 7.89-7 · 85 (1H, m), 7.81 (2H, d, J = 8.8 Hz), 7.74 (1H, d, J = 8.1 Hz), 7.62-7.5 5 (3 H, m), 3.16 (2H, s), 2.08, 1.93 (4H, m), 1.28- 1.19 (6H, m) FABMS (m / z): 486 ([M + H] +) FABHRMS (m / z): calcd. For C23H22F6N3 0 2 ([M + H] +): 4 8 6.1 6 1 6; found: 48 6.1 6 1 9. (Example 102) 2- (l-PY heptylmethyl) -3_ [4- [2,2,2 · trifluoro-1-hydroxy-1- (tri Fluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 2-31) 2-chloromethyl prepared from Example 95 above in a similar manner to that described in Example 9 9 above. -3- [4- [2,2,2 · Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _ 4 (3H) -quinU-sitolinone (200 mg, 0.46 mmol) and hexamethyleneimine (259 // 1, 2.30 mmol) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (1 42 mg, Yield: 62%). mp 17 1-172 ° C. IR (KBr): vmax 3299, 2929, 1671, 1 5 95, 1 2 69, 1213, 934, 707 cm-1 · iH-NMR (400MHz, DMSO-d6): δ 8 · 89 (1H, s) 5 8 · 13 (1H, d5 J = 8.1 Hz), 7.89-7 · 85 (1H, m) 5 7.81 (2H, d, J = 8.1 Hz), 7.74 ( 1H, d3 J = 8.0 Hz), 7.62-7.5 5 (3 H, m), 3.37 (2H, s), 2.23-2.21 (4H, -408- 200401770 m) 5 1.40- 1.2 7 (8 H, m) FABMS (m / z): 500 ([M + H] +) FABHRMS (m / z). Calcd for P w τ? Xt ^ V caica. Tor ^ 24H24F6N3〇2 ([M + H] +): 5 00.1 77 3; found: 5 0 0.1 76 8. (Example 103) 2- (1-acrylcyclomethyl) _3_ [4 · [2,2,2_trifluoro-hydroxyl (trifluoromethyl ) Ethyl] phenyl] -4 (3 Η) · quinazolinone (Exemplified Compound No. 2_32) 2-Chloromethyl-3- [4- [2,2,2-Difluoro-1-meryl-1- (trimethyl) ethyl] phenyl] -4 (3Η) -ΠQuinlinone (200 rng, 0.46 mmol) and heptalidene Imine (291 # 1, 2.30 mmol) to give the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless oblique Square crystal (5 mg, yield: 65%). mp 176-1770C. IR (KBr): v max 3 2 8 3, 2 9 2 3, 1 6 5 7, 1 5 9 4, 1 4 7 3, 1 2 6 8, 1 2 1 3, 93 5,774 cm -1. 'H-NMR (400MHz, DMSO-d6): δ 8.91 (1H5 s) 5 8.13 (1H? D? J = 8.1 Hz), 7.89-7.82 (3H, m) 5 7.74 (1H, d, J = 8.1 Hz), 7.61 (2H, d, J = 8.8 Hz), 7.5 9 -7.5 5 (1 H, m), 3.41 (2H, s), 2.34 (4H, t, J = 5.9 Hz) 5 1.4 6-1.2 7 (1 0 H? M). FABMS (m / z): 514 ([M + H] +). F ABHRMS (m / z): calcd. For C25H26F6N302 ([M + H] +) : 5 1 4.1 929; found: 5 1 4.1 908. -409- 200401770 (Example 104) 2-cyclobutyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1 · (tri Fluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified Compound No. 2-4) In a similar manner as described in Example 1, 'from o-aminobenzoic acid (274 mg, 2.0 mmol) , Cyclobutanecarboxylic acid (200 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.011111〇1), and 2- (4-aminophenyl) -1,1,1,3 , 3,3-hexafluoro ^ -2-propanol (415 111§, 1.6 mmol) to obtain the title compound as a colorless solid (163 mg, yield: 23%). This product was obtained from a mixed solvent of hexane and ethyl acetate. Crystalline colorless prismatic crystals generated. mp 236-237 ° C. IR (KBr): v max 1 65 2, 1 5 89, 1 26 8, 1215, 1187, 1 10 7, 968, 93 7, 772, 70 8 cm-1. W-NMR (400MHz, DMSO-d6): δ 8.94 (1H, s), 8.10 (1H, dd, J = 8.1, 1.5 Hz), 7.8 8-7.8 3 (3 H, m), 7.74 ( 1H, d, J = 8.1 Hz), 7.60 (2H, d, J = 8.8 Hz), 7.56-7.5 2 (1 H? M), 3.30-3.22 (1 H, m), 2.45- 1.34 (2H, m ), 1.7 3-1. 5 9 (4 H, m). FABMS (m / z): 443 ([M + H] +). FABHRMS (m / z): calcd. For C 2! H j 6 F 6N 2 O 2N a ([M + Na] +): 465.1013; found: 465.0997. (Example 105) 2-cyclopentyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 2-5) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg, 2.0 -410- 200401770 mmol), cyclopentanecarboxylic acid (228 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.011111〇1), and 2- (4-aminophenyl) -1,1 , 1,3,3,3-hexafluoro-2-propanol (4 1511 ^, 1.6 mmol) to obtain the title compound as a colorless solid (194 mg, yield: 27%). This product was obtained from hexane and ethyl acetate Mixed solvents of esters Recrystallized yield a colorless prismatic crystal. mp 239-240 ° C. IR (KBr): vmax 3245, 2959,1657,1590,1268,1214,1 185, 1 107, 968, 9 3 7,776,707 cm · 1'H-NMR (400MHz , DMSO-d6): δ 8.94 (1H? S)? 8.09 (1H5 dd, J = 8.1,1,5 Hz) 5 7.8 8-7.8 2 (3 H? M)? 7.68 (1H, d, J = 7.3 Hz), 7.64 (2H, d5 J = 8.8 Hz), 7.52 (1H, t, J = 7.3 Hz), 2.71-2.63 (1H, m), 2.00-1.92 (2H, m), 1.74-1.57 (4H, m), 1.43-1.37 (2H, m). FABMS (m / z): 45 7 ([M + H] +). FABHRMS (m / z): calcd. for C 2 2 H! 8 F 6N 2 O 2N a ([M + Na] +): 479.1 1 73; found: 479.1 1 73. (Example 106) 2-cyclohexyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified Compound Nos. 2 to 6) In a similar manner as described in Example 1, o-aminobenzoic acid (274 mg , 2.0 mmol), cyclohexanecarboxylic acid (256 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.011111101) and 2- (4-aminophenyl) -1,15153 , 3,3-hexafluoro-2-propanol (41511 ^ 1.6 mmol) to obtain the title compound as a colorless solid (151 yield ♦ · 20 -411- 200401770%). This product was mixed with hexane and ethyl acetate. Recrystallization solvent to yield a colorless prismatic crystal. mp 238-239 ° C. IR (KB r): v max 3 26 8, 8, 293 3,1 65 8,1 5 8 9,1 2 66,1 2 1 3,1 1 89, 969, 93 5, 77 3,707 cnT1 · 'H-NMR (400MHz, DMSO-d6): δ 8.97 (1H? S)? 8.10 (1H? Dd5 J = 8.1, 1.5 Hz), 7.89-7.83 (3H, m), 7.70-7.64 (3 H, m), 7.52 (1H, t, J = 6.6 Hz), 2.1 Bu 2.04 (1H, m), 1.80 (2H, d, J = 12.4 Hz), 1.6 8-1.5 2 (5 H5 m)? 1.21-1.09 (1H? m), 0.82-0.7 3 (2H5 m). FABMS (m / z): 471 ([M + H] +). FABHRMS (m / z): calcd. for C 2 3 H 2 0 F 6N 2 0 2N a ([M + N a] +): 493.1 326; found: 49 3.1 337. Anal, calcd, for C23H20F6N2O2: C, 5 8.73; H, 4.29; N, 5.96; found : C, 58.71; H, 3.98; N, 6.04. (Example 107) 2- (2,2,3,3-tetramethylcyclopropyl) -3- [4- [2,2,2- Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 2-2) In a similar manner as described in Example 1, Aminobenzoic acid (274 mg, 2.0 mmol), 2,2,3,3-tetramethylcyclopropanecarboxylic acid (284 mg, 2.0 mmol), triphenyl phosphate (0.52 xnl, 2.0 mmol) and 2. (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro · 2- Propanol (4 15 mg, 1.6 mmol) gave the title compound as a colorless solid (172 mg, yield: 22%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless bevel. Square crystal. -412- 200401770 mp 244-245 ° C. IR (KBr): vmax 1 65 5, 1 590, 1 473, 1 268, 1217, 1190, 1107, 93 7, 774, 707 cm '! H-NMR (400MHz DMSO-d6): 5 8 · 9 4 (1 H, s), 8 · 1 0 (1 H, dd, J = 8.1, 1.5 Hz), 7.89-7.81 (3H, m), 7.63 -7.6 0 (3 H, m), 7.52 (1Η, t5 J = 8.1 Hz), 1.16 (lH, s), 1.14 (6H, s), 0.68 (6H, s). FABMS (m / z) : 48 5 ([M + H] +). FABHRMS (m / z): calcd. For C24H22F6N2 02Na ([M + Na] +): 507.1546; found: 507.1476. (Example 108) 2- (2-phenyl Cyclopropyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -quinololine (Exemplified compound numbers 2-3) In a similar manner as described in Example 1, o-aminobenzoic acid (27.4 mg, 2.0 mmol), 2-phenyl-1-cyclopropanecarboxylic acid (324 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol ( (415 mg, 1.6 mmol) to obtain the title compound as a colorless solid (71 mg, yield: 9%). mp 1 99-200 ° C. (KBr): u max 3284, 1661, 1 5 90, 1 473, 1 267, 1214, 1192, 934, 774, 697 cm · 1. ^ -NMR (400MHz, DMSO-d6 ): Δ 8.80 (1H5 s), 8.11 (1H? Dd? J = 8.1, 1.5Hz), 7.87-7.80 (2H, m), 7.69-7.65 (2H, m), 7.53-7.40 (3H, m), 7.15-7.07 (3H, m), 6.88 (2H, d, J = 6.6 Hz), -413- 200401770 2.51-2.46 (1H, m), 2.05-2.01 (1H, m), 1.47-1 · 43 (1H, m), 1.3 6- 1.3 2 (1 H, m). FABMS (m / z): 5 0 5 ([M + H] +). FABHRMS (m / z): calcd. For C26H j 8F6N2 0 2Na ([M + Na] +): 527.1 1 70; found: 5 27.1 1 66. Anal · calcd · for C26H18F6N202: C, 61.91; H? 3.60; N5 5.5 5; found: C? 62.18; H 3.64; N? 5.54. (Example 109) 2- (cyclopentylmethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3Η) -quinazolinone (Exemplified Compound No. 2-9) In a similar manner as described in Example 1, o-aminobenzoic acid (2 8 8 mg, 2.1 mmol), cyclopentylacetic acid (269 mg, 2.1 mmol), triphenyl phosphate (0.55 ml, 2.1111111〇1), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2 -Propanol (5 1 8 ^^, 2.0 mmol) to obtain the title compound as a colorless solid (715 mg, yield · 76%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 207 ° C. IR (KBr): max 3114, 295 7, 1 656, 1 592, 1 270, 1218, 1189, 937 cm'1. ^ -NMR (400MHz? CDC13): δ 8.27 (lH, d, J = 8.0 Hz), 7.92 (2H, d, J = 8.4 Hz), 7.79 (1H, t, J = 7.6 Ηζ), 7.73 (1H, d, J = 8.0 Hz), 7.49 ( 1H, t, J = 8.0 Hz), 7.36 (2H, d, J = 8.8 Hz), 4.05 (1H, s), 2.43 (2H, d, J = 7.2 Hz), 2.26 (1H, m ), 1.80-0 · 80 (8H, m). -414- 200401770 FABMS (m / z): 471 ([M + H] +). F ABHRMS (m / z): calcd. For C23H21F6N2 02 ([M + H] +): 47 1.1 5 07; found: 4 7 1.1 497. Anal, calcd. For C23H21F6N202: C, 5 8.73; H? 4.29; N? 5.96; found: C5 5 8.64; H 5 4.3 0; N 5 5.9 9. (Example lio) 2- (cyclohexylmethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenylbenzene 4 (3 H) -quinazolinone (Exemplified Compound Nos. 2-10) In a similar manner to that described in Example 1, o-aminobenzoic acid (150 mg, 1.1 mmol) and cyclohexylacetic acid (156 mg, 1.1 mmol) were used. Triphenyl phosphate (0.29 ml, 1.1111111〇1) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2 5 9 11 ^ 5 1.0 mmo l) The title compound was obtained as a colorless solid (224 mg, yield: 46%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 217-218 ° C. IR (KBr): v max 3265, 2 9 2 5, 1 6 5 4, 1 5 9 2, 1 2 6 9, 1 2 1 4, 1 1 8 6, 937 cm " 1 . 'H-NMR (400MHz, CDC13): δ 8.28 (lH, dd, J = 8.0, 1.6Hz), 7.90 (2H, d, J = 8.0 Hz), 7.80 (1H, dt, J = 7 · 2, 1.6 Hz), 7.73 (1H, d, J = 7.2 Hz), 7.50 (1H, dt5 J = 7.2, 1.6 Hz), 7.34 (2H, d5 J = 8 · 8 Hz ), 4 · 40 (1H, s), 2.32 (2H, d, J = 7.2 Hz), 1.70 (1H, m) 5 1.6 5-0.8 0 (1 0H, m). FABMS (m / z) : 48 5 ([M + H] +) FABHRMS (m / z): calcd. For C24H23F6N202 ([M + H] +): -415- 200401770 485.1 1 63; found: 48 5.1 1 60. Anal, calcd for C24H ”F6N202: C, 5 9.5 0; H, 4.58; N, 5.78; found: C, 5 9.5 5; H, 4.45; N, 5.74. (Example 111) 2- (¾hexylmethyl) -5 -气-3- [4- [2,2,2 · Diacyl-1-meryl-1- (dichloromethyl) ethyl] phenyl] _4 (3H) _quinazolinone (exemplified compound numbers 2-102) In a similar manner as described in Example 1, 6-chloroanthranilic acid (359 mg, 2.1 mmol), cyclohexylacetic acid (298 mg, 2.1 mmol), and triphenyl phosphonate ( 0.55 ml, 2.1111111〇1) and 2- (4-amine Phenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5 18 1 ^, 2.0 mmol) to obtain the title compound as a colorless solid (60 8 mg, yield: 59%), This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. Mp 2 1 0-2 1 2 ° C. IR (KBr): v max 3 2 5 3, 2926, 28 50, 1 673, 1 5 93, 1 45 8, 1 269, 1214, 932 cm-1. 'H-NMR (400MHz, CDC13;): δ 7 · 9 2 (2 H, d, J = 8 · 0 H z) , 7.62 (2H5 d, J = 4.4 Hz), 7.47 (1H, t, J = 4.8 Hz), 7.36 (2H, d, J = 8.8 Hz), 3.89 (1H, s) , 2 · 28 (2H, d, J = 6.4 Hz), 1.75 (1H, m) 5 1 · 65 · 0 · 82 (10H, m) · FABMS (m / z): 519 ([M + H] + ). FABHRMS (m / z): calcd. For C24H22C1F6N202 ([M + H] +): 5 1 9.1 274; found: 519.1262. Anal, calcd. For C24H21C1F6N20 2: C? 55.55; H? 4.08; N? 5.40 ; found: C5 55.69; H5 4.13; N5 5.46. (Example 112) -416- 200401770 2-benzyl-5-chloro-6,7-dimethoxy-3- [3- [2,2,2 -Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 8-2209) (1) Trifluoromethanesulfonic acid ( 0 .96 ml, 11 mmol) was added at 0 ° C under nitrogen pressure to a solution containing 2-chloro-3,4-dimethoxybenzaldehyde (2.0 g, 10 mmol) and potassium nitrate (1.11 g, 11 mmol). Acetic acid (5 ml) solution, and the resulting mixture was stirred at room temperature under nitrogen pressure for 4 hours, after which the reaction mixture was poured into water, neutralized with a saturated aqueous sodium hydrogen carbonate solution, and ethyl acetate (100 ml) extraction twice, the combined organic layer was water (80 ml) and saturated aqueous sodium chloride solution (80 ml), and dried over anhydrous sodium sulfate, after filtration, the solvent was removed in vacuo, and The obtained residue was purified by silica gel column chromatography (using a mixture of hexane and ethyl acetate with a volume of 4 ·· 1 as an eluent) to produce 2-chloro-3,4-dimethoxy -6-nitrobenzaldehyde as a colorless solid (1.36 mg, 56.6% yield). (2) Add sodium chlorite (80% purity, 954 mg, 8.48 mmol) under nitrogen pressure and stir at room temperature to the 2-chloro-3,4-dimethoxy group prepared in Example 112 (1) above. T- of 6-nitrobenzaldehyde (1.04 g, 4.24 mmol), 2-methyl-2-butene (14.9 g, 212 mmol) and sodium dihydrogen phosphate dihydrate (13.2 g, 85 mmol) Butanol (40 ml) and water (10 ml) mixed solvent solution, and the resulting mixture was stirred for 2 hours, then the reaction mixture was poured into water and extracted twice with ethyl acetate (100 ml). The organic layer was washed with water (80 ml) and a saturated aqueous sodium chloride solution (80 m 1), and dried over anhydrous sodium sulfate. After filtration, the solvent was removed in vacuo to produce 2-chloro-3,4 -Colorless solid of dimethoxy-6-nitrobenzoic acid (0.71 g, yield: 64%). -417 · 200401770 (3) Add 20% palladium hydroxide-containing carbon [50 (w / w) wet, 26 mg] to 2-chloro-3,4-di, which was prepared in Example 112 (2) above. In a solution of methoxy-6-nitrobenzoic acid (261 mg, 1.0 mmol) in methanol (4 ml), the resulting mixture was stirred at room temperature under hydrogen pressure for 30 minutes, and removed by filtration through a plug of plastic. The catalyst and the filtrate was concentrated in vacuo to give 6-chloro-4,5-dimethoxyanthranilic acid as a brown oil (170 mg). (4) In a similar manner as described in Example 1, 6-chloro-4,5-dimethoxy-o-aminobenzoic acid (170 mg, 736 // mol), benzene prepared from Example 1 12 (3) above, Glycolic acid (100 mg, 736 // mol), triphenyl phosphate (0.19 ml, 736 // mol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexa Fluoro-2-propanol (173 11 ^, 669 // mol) to obtain the title compound as a colorless solid (138 mg, yield: 47%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce a colorless Orthorhombic crystal. mp 210-211 ° C. IR (KBr): v max 3 3 7 1, 1 686, 1 5 85, 1477, 1 266, 1 208, 1 002 cm · 1. 'H-NMR (400MHz5 CDC13): < 5 7 · 7 3 (1 H, d, J = 8 · 8 H z), 7 · 4 5 (1H, s), 7.39 (1H, t, J = 8.0 Hz), 7.18-7.12 (3H, m), 7.17 (1H5 s), 6.97 (1H, d, J = 8.0 Hz), 6.79 (2H, dd, J = 8.0, 2.0 Hz), 4.04 (3H, s), 4.02 ( 1H, s), 3.91 (3H, s), 3.89 (1H, d, J = 14.8 Hz), 3.78 (1H5 d, J = 14.8 Hz). FABMS (m / z): 573 ( [M + H] +) · FABHRMS (m / z): calcd. For C26H20ClF6N2O4 ([M + H] +): 5 7 3.1 0 1 6; found: 573.1 02 1. Anal. Calcd · for C26H19C1F6N204: C, 54.5 1; H, 3.34; N, 4.89; Found: C, 54.5 7; H, 3.25; N, -418- 200401770 4.77. (Example 113) 2-benzyl-5-chloro-6,7-dimethyl Oxy-3--3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (exemplified compound numbers 3-2209) In a similar manner as described in Example 1, from the above example: 6-gas-4,5-monomethoxy-o-aminobenzoic acid (385 mg, 1.67 mmol) prepared from 1 12 (3) , Phenylacetic acid (227 mg, 1.67 mmol), triphenyl phosphate (0.44 ml, 1.67 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3_hexa Fluoro-2_propanol (389 11 ^, 1.50 mm ol) The title compound was obtained as a colorless solid (390 mg, yield: 41%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 203-204 ° C. IR (KBr): umax 3354,1677,1590,1477.1374,1265,1209, 1107, 1 000,93 0 cm · 1 · 'H ^ NMR (400MHz? CDC13): < 5 7 · 6 9 (2 H, d, J = 8 · 8 H z), 7 · 1 8 (lH, s), 7.18-7.08 (3H, m), 6.98 (2H, d, J = 8.8 Hz), 6.71 (2H, d, J = 7.2 Hz), 4.04 (3H, s), 3.92 (3H, s), 3.85 (3H, s). FABMS (m / z): 5 7 3 ([M + H] +) · FABHRMS (m / z): calcd · for C26H20ClF6N2O4 ([M + H] +): 573.1 0 1 6; found: 5 7 3.1 022. Anal. Calcd. For C 2 6 H 2 9 C1F 6N 2 O 4: C, 54.5 1; H, 3.34; N? 4.89; Found: C, 54.7 3; H, 3.42; N, 4.68. (Example 114) -419- 200401770 2-benzyl- 6,7-difluoro-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl; 1-4 (3 H) -quinazole Porphyrinone (Exemplified Compound No. 8-1 24 8) (1) In a similar manner to Example 3 9 (1) above, 4,5-difluoro-o-amine was obtained from 4,5-difluoro-2-nitrobenzoic acid. benzoic acid. (2) In a similar manner as described in Example 1, 4,5-difluoroanthranilic acid (378 mg, 2.2 mmol), phenylacetic acid (300 mg, 2 · 2 mmol), triphenyl phosphate (0.58 ml, 2.2 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5 18 mg, 2.0 mm) 1) The title compound was obtained as a colorless solid (3 43 mg, yield 33%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 1 2 9-1 3 0 ° C. IR (KBr): umax 3 326, 1 686, 1 499, 1 2 68, 1214, 1153, 970 cm · 1. 'H-NMR (400MHz, CDC13)): δ 7 · 8 1 (1 Η, dd, J = 1 0 · 0, 8 · 8 Hz), 7.78 (1H, d, J = 8 · 0 Hz), 7.58 (1H, dd, J = 10.8, 7.2 Hz), 7.45 (1H, t, J = 8.0 Hz), 7.44 (1H, s), 7.19-7.13 (3H, m), 7.00 (2H, dd5 J = 8.0, 2.4 Hz), 6.79 (2H, d, J = 6.4 Hz), 4.00 (1H, s), 3.93 (1H, d5 J = 14.8 Hz), 3.83 (1H, d, J = 14.8 Hz), FABMS (m / z): 515 ([M + H] +). FABHRMS (m / z): calcd. for C24H15F8N202 ([M + H] +): 5 1 5.1 006; found: 515.0977 Anal. Calcd. for C24H14F8N2〇2 1/2 H20: C, 55.08; H, 2.89; N, 5.35; Found: C, 54.94; H, 2.81; N? 5.35. (Example 115) 2-benzyl-6,7- Dimethoxy-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl-420- 200401770 group) ethyl] phenyl] -4 (3 H) -_ Zazolinone (Exemplified Compound No. 8-1 155) In a similar manner as described in Example 1, 4,5-dimethoxy-o-aminobenzoic acid (414 mg, 2.1 mmol), phenylacetic acid (286 mg, 2.1 mm〇l), triphenyl phosphate ( 0.58 ml, 2.1 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (518 mg, 2.0 mmol) to give the title compound as a colorless solid (584 mg, yield 54%), this product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 225-226 ° C. IR (KBr): vmax 3220, 1 677, 1613, 1501, 1 269, 1 209,969 cm · 1 · ^ -NMR (400MHz5 CDC13): 5 7 · 7 4 (1 H, d, J = 8 · 0 H z) 5 7, 5 8 (1H, s), 7.44 (1H, s), 7.40 (1H, t, J = 8.0 Hz), 7.22 (1H, s), 7.18-7.11 (3H, m), 6.99 (1H, d, J = 8.8 Hz), 6.79 (2H, d, J = 6.8 Hz), 4.37 (1H, s), 4.06 (3H , S), 3.98 (3H, s), 3.93 (1H, d, J = 14.4 Hz), 3.83 (1H, d, J = 14.4 Hz). FABMS (m / z): 539 ([M + H ] +). FABHRMS (m / z): calcd. For C26H21F6N204 ([M + H] +): 539.1405; found: 539.1397.

Anal. Calcd. For C26H20F6N2O4: C, 5 8 · 0 0; H, 3 · 7 4; N, 5 · 2 0; Found: C5 5 7.9 9; H, 3.54; N, 5.14. (Example 116) 2- Benzyl-5,6,7-trimethoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 ( 3 H) -quinazolinone (Exemplified Compound No. 3-2178) -421- 200401770 (1) Trifluoromethanesulfonic acid (2.1 ml, 24 mmol) was added to 0. (: Add to a solution of 2,3,4-trimethoxybenzoic acid (4 · 24 g, 20 mmol) and potassium nitrate (2.22 g, 22 mmol) in acetic acid (15 ml) with stirring under nitrogen pressure. The resulting mixture was stirred at room temperature for 4 hours. After this time, the reaction mixture was poured into water and extracted twice with ethyl acetate (100 ml). The organic layer was combined with water (80 ml) and saturated sodium chloride aqueous solution (80 ml), and dried over anhydrous sodium sulfate. After filtration, the solvent was removed in vacuo, and the obtained residue was subjected to silica gel column chromatography (using A 1: 1 mixture of hexane and ethyl acetate was used as an eluent) to produce a colorless solid of 2,3,4-trimethoxy-6-nitrobenzoic acid. (2) 20% hydroxide Pinned carbon [50 (w / w) wet, 90 mg] was added to the 2,3,4-trimethoxy-6-nitrobenzoic acid (990 mg, 3.85) prepared in Example 1 16 (1) above. mmol) in methanol (20 ml) solution, and the resulting mixture was stirred at room temperature under hydrogen pressure for 1 hour. The catalyst was removed by filtration through a plug of plastic, and the obtained filtrate was concentrated in vacuo to produce A brown solid (880 mg) of 4,5,6-trimethoxyanthranilic acid. (3) In a similar manner to that described in Example 1, 4,5, prepared from Example 116 (2) above, 6-trimethoxy-o-aminobenzoic acid (454 mg, 2.0 mmol), phenylacetic acid (272 mg, 2.0 mmol), triphenyl phosphate (0.52 ml, 2.0 mmol), and 2- (4-aminobenzene ) -1,1,1,3,3,3-hexafluoro-2-propanol (466 11 ^, 1.8〇111111〇1) to obtain the title compound as a colorless solid (3 46 mg, yield: 34%) This product is recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals 0 mp 2 6 8 ° C. -422- 200401770 IR (KBr) ·· vmax 3298, 1691,1592,1484,1375, 1268, 1208, 1106, 934 cm · 1. 'H-NMR (400MHz, CDC13): δ 7 · 6 7 (2 H, d, J = 8 · 0 H z), 7.18-7.08 (3H, m), 7 · 06 (1H, s) 5 6 · 96 (2H, d, J = 8.8 Hz), 6 · 70 (2H, d, J = 7.2 Hz), 4.14 (1H, s), 4.03 (3H, s), 3.96 (3H, s), 3.94 (3H, s), 3.84 (2H, s), FABMS (m / z): 5 69 ([M + H] +). FABHRMS (m / z): calcd. for C27H23F6N205 ([M + H] +): 5 69.1 5 1 2; found: 569.1 5 1 6.

Anal · Calcd · for C27H22F6N2 05: C5 5 7.0 5; H, 3.90; N, 4.93; Found: C? 56.97; H? 3.73; N? 4.81. (Example 117) 2-Benzyl-5,6 , 7-trimethoxy- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) · quinazoline Ketone (Exemplified Compound No. 8-2178) 4,5,6-dimethoxy-o-aminobenzoic acid (412 mg, 1.81 mmol) prepared from Example 1 16 (2) in a similar manner as described in Example 1 ), Phenylacetic acid (246 mg, 1.81 mmol), triphenyl phosphate (0.47 ml, 1.81 mmol), and 2- (3-aminophenyl) -1,1,1,3,3,3- Hexafluoro-2-propanol (427 mg, 1.65 mmol) The title compound was obtained as a colorless solid (34.2 mg, yield: 36%). This product was produced by recrystallization from a mixed solvent of hexane and ethyl acetate. Colorless orthorhombic crystal. mp 220-221 ° C. IR (KB〇 ... ^ ^ x 329 7,1673,1599,1483,1376,1268,1207, 1 105, -423- 200401770 968 cm'1. W-NMR (400MHz, CDC13 ): (5 7 · 7 2 (1 H, d 5 J = 8 · 4 H z), 7 · 4 5 (1H, s), 7.38 (1H, t, J = 8.0 Hz), 7.18-7.12 (3H , M), 7.04 (1H, s), 6.96 (1H, dd, J = 8.0.0, 2.4 Hz), 6.79 (2H, d, J = 6.0 Hz), 4.15 (1H , S), 4.02 (3H, s), 3.94 (6H, s), 3.89 (1H, d, J = 15.2 Hz), 3.78 (1H, d, J = 15.2 Hz). FABMS (m / z): 5 69 ([M + H] +). FABHRMS (m / z): calcd. for C27H23F6N2 0 5 ([M + H] +): 5 69.1 5 1 2; found: 5 69.1 522. Anal. Calcd. For C27H22F6N205: C, 57.05; H5 3,90; N. 4.93; Found: C, 56.94; H, 3.60; N, 4.98. (Example 1 1 8) 2-benzyl-7-fluoro-6- Methyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (exemplified compounds No. 3 -208 5) (1) 4-fluoro-5-methyl-o-aminobenzoic acid was obtained from 3-fluoro-4-methylaniline by a similar method to that described in Example 55 (1), (2), and (3) above. (2) In a similar manner as described in Example 1, 4 prepared from Example 1 18 (1) above -Fluoro-5-methyl o-aminobenzoic acid (372 mg, 2.2 mmol), phenylacetic acid (300 mg, 2.2 mmol) 'triphenyl phosphate (0.58 ml, 2.2 mmol), and 2- (4- Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (518 11 ^, 2.011111111) to give the title compound as a colorless solid, which was obtained from hexane and acetic acid Recrystallization in a mixed solvent of ethyl esters gave colorless orthorhombic crystals (5 97 mg, yield: 58%). Mp 183-184 ° C. IR (KBr): > max 3 248, 1 675, 1 593, 1 487, 1271, 1214, 1146, 935 -424- 200401770 cm. ^ -NMR (400MHz5 CDC13): δ 8 · 10 (1H, d, J = 8.0 Hz), 7.69 (2H, d, J = 8 · 0 Hz), 7.42 (1H, d, J = 10.4 Hz), 7.18-7.07 (3H, m), 6.96 (2H. D, J = 8.8 Hz), 6.69 (2H, d, J = 7.6 Hz), 4.21 (1H, s), 3.88 (2H, s), 2.43 (3H, s), FABMS (m / z): 511 ([M + H] +). FABHRMS (m / z): calcd . for C25H18F7N202 ([M + H] +): 51 1.1256; found: 51 1.1256. Anal. Calcd. for C25H17F7N202: C? 5 8.8 3; H? 3.36; N 5 5.49; Found: C? 58.91; H? 3.23 ; N, 5.45. (Example 119) 2-benzyl-7-fluoro-6-methyl- 3- [3- [2,2,2-trifluoro-1 -Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 8-20 8 5) In a similar manner to that described in Example 1, from the above examples 1 1 8 (1) of 4-gas-5 -methyl o-aminobenzoic acid (372 mg, 2.2 mmol), phenylacetic acid (300 mg, 2.2 mmol), triphenyl phosphate (0.58 ml, 2.2 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (518 111§, 2.2 111111〇1) to obtain the title compound Colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (601 mg, yield: 59%). mp 1 62 ° C. IR (KBr): u max 3271, 1 680, 1 5 8 7, 1 4 87, 1 26 8, 1215, 1 149, 969 cm · 1. JH-NMR (400MHz5 CDC13): δ 8.0 9 (1 H, d, J = 8 · 8 H z), 7 · 7 5 (1H, d, J = 8.0 Hz), 7.43 (1H, s), 7.42 (1H, d, J = 10.4 Hz), -425- 200401770 7.42 (1H, t5 J = 8.0 Hz), 7.18-7.10 (3H, m) 5 6 · 99 (1H, dd5 J = 8.8, 3.2 Hz), 6.78 (2H, d, J = 7.2 Hz), 4.12 (1H, s), 3.93 (1H, d, J = 14.8 Hz), 3.83 (1H, d, J = 14.8 Hz), 2.41 (3H5 d, J = 1.6 Hz). FABMS (m / z): 511 ([M + H] +). FABHRMS (m / z): calcd. For C25H18F7N202 ([M + H] +): 511.1256; found: 51 1.1257. Anal. Calcd. For C25H17F7N202 : C3 5 8.8 3; H, 3.36; N, 5.49; Found: C, 5 8.8 5; H, 3.17; N, 5.49. (Example 120) 2-benzyl-5-fluoro, 6-methyl-3 -[4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3- 1 899) (1) By a method similar to the above-mentioned Example 55 (1) to (3), 6-fluoro-5-methylanthranilic acid was obtained from 3-fluoro-4-methylaniline. (2) In a similar manner as described in Example 1, 6-fluoro-5-methyl-o-aminobenzoic acid (100 mg, 0.59 mmol) and phenylacetic acid (80 mg, 0.59 mmol) prepared from Example 120 (1) above. ), Triphenyl diacetate (0.15 ml, 0.59 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (139 11 ^, 0.53 111111〇1) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (128 mg, yield: 47%). mp 1 6 0 ° C. IR (KBr): > max 3 3 2 9, 1 690, 1 5 95, 1 48 8, 1 269, 1214, 93 3 cm · 1 · 'H-NMR (400MHz? CDC13 ): δ 7 · 6 9 (2 Η, d, J = 8 · 4 Hz), 7 · 6 3 (1H, t5 J = 8.0 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.16-7.08 (3H, -426- 200401770 m), 6.98 (2H, d, J = 8.8 Ηζ), 6.70 (2H, d, J = 7.2 Hz), 3.87 (3H, s), 2.40 (3H, d, J = 2.4 Hz) FABMS (m / z): 511 ([M + H] +). FABHRMS (m / z): calcd. For C25H18F7N2 02 ([M + H] +): 511.1256; found: 5 1 1.1 2 5 6.

Anal. Calcd · for C25H17F7N202 · 1 / 2H20: C, 57.81; H, 3.49; N, 5.39; Found: C, 57.73; H, 3.16; N, 5.18. (Example 121) 2-benzyl-6,7 -Dimethyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinone (Exemplified compound number 3-1 6 2 0) (1) By a method similar to the above-mentioned Examples 55 (1) to (3), 4,5-dimethylanthranilic acid was obtained from 3,4-dimethylaniline . (2) In a similar manner as described in Example 1, 4,5-dimethyl-o-aminobenzoic acid (758 mg, 4.59 mmol), phenylacetic acid (656 mg, 4.82 mmol) prepared from Example 121 (1) above Triphenyl phosphate (1.32 ml, 5.05 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (1.192, 4.59 111111〇1 ) The title compound was obtained as a colorless solid (487 mg, yield: 21%). ! H-NMR (400MHz, CDC13): 5 8 · 0 1 (1 Η, s), 7 · 6 6 (2 Η, d, J = 8.8 Hz), 7.60 (1H, s), 7.16-7.04 (3H , M), 6.94 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 6.6 Hz), 4.34 (1H, s), 3.88 (2H, s ), 2.46 (3H, s), 2.42 (3H, s) · FABMS (m / z): 507 ([M + H] +). (Example 122) -427 · 200401770 2 benzyl_5,6 · Dimethyl 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzyl] -4 (3 Η) -quinazolinone ( Exemplified compound number 3-1 40 3) (1) A method similar to that described in Example 55 (1), (2), and (3) above was used to obtain 5,6-dimethyl-o-amine from 3,4-dimethylaniline. benzoic acid. (2) Using a method similar to that described in Example 1, from Example 2 2 (1) 5,6-dimethyl o-aminobenzoic acid (165111§, 10111111〇1), phenylacetic acid ( 14811 ^ 5 1.05 mmol), diphenyl phosphate (0286 ml, 1.01 mmol) and 2- (4-amine base) -1,1,1,3,3,3-hexafluoro-2-propanol (233 mg, 0.9 mmol) to obtain the title compound as a colorless solid (198 mg, yield: 43%). ] H-NMR (400MHz5 CDC13): δ 7.6 8 (2 Η, d, J = 8 · 8 Η ζ), 7 · 6 1 (1Η, d, J = 8 · 1 Hz), 7.57 (1Η, d, J = 8 · 1 Ηζ), 7.19-7 · 05 (3Η · m), 6.97 (2Η, d, J = 8.8 Ηζ), 6.71 (2Η, d, J = 7 · 3 Ηζ), 3 · 86 (2Η, s), 3.78 (1Η, s), 2.78 (3Η, s), 2.43 (3Η, s) · FABMS (m / z): 5 07 ([Μ + +] +) (Example 123) 2-benzyl-6-methoxy-7-methyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl Phenyl] phenyl] -4 (3Η) -quinazolinone (Exemplified Compound No. 3-1 806) (1) A method similar to the above Example 55 (1) to (3), -Methylaniline to give 5-methoxy-4-methylanthranilic acid. (2) In a similar manner as described in Example 1, 5-methoxy-4-methyl o-aminobenzoic acid (318 mg, 1.76 mmol) and phenylacetic acid (250 mg) obtained from Example 123 (1) above , 1.84 mmol), triphenyl phosphonate (0.5 ml, 1.93 mmol) and 2- (4- 200401770 aminophenyl) -l, l, l, 3,3,3 -hexa-2--2-propane Alcohol (410 mg, 1.58 mmol) gave the title compound as a colorless solid (466 mg, yield: 56%). ^ -NMR (400MHz? CDC13 + DMSO-d6): δ 7 · 8 3 (1 Η, s), 7 · 7 4 (2Η, d, J = 8.8 Ηζ), 7.59 (1Η, s), 7 · 52 (1Η, s), 7.17-7 · 05 (3Η, m)? 6.96 (2H5 d5 J = 8.8 Hz)? 6.70 (2H? D? J = 6.6 Hz), 3.94 (3H, s) 5 3.88 (2H, s), 2.41 (3H, s). FABMS (m / z): 523 ([M + H] +). (Example 124) 2-benzyl-6 -methoxy-5 -Methyl- 3- [4- [2,2,2 -trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (exemplified Compound No. 3 · 1 496) (1) 5-methoxy-6-methyl-o-methyl was obtained from 3-methoxy-2-methylbenzoic acid by a method similar to that described in Example 116 (1) and (2) above. Aminobenzoic acid. (2) In a similar manner as described in Example 1, 5-methoxy-6-methyl o-aminobenzoic acid (181 mg, 1.0 mmol) and phenylacetic acid (143 mg, 1.05 mmol), triphenyl phosphonate (0.286 ml, 1.1 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2 3 3 (11, 0.9, 111, 111) (1) to obtain the title compound as a colorless solid (202 mg, yield: 39%). W-NMR (400MHz, CDC13): δ 7.70-7.64 (3H, m), 7.42 (1H, d, J = 8.8 Hz), 7.17-7.05 (3H, m), 6.96 (2H, d, J = 8.8 Hz), 6.70 (2H, d, J = 7.3 Hz), 4.05 (1H, bs), 3.94 (3H, s), 3.85 (2H, s), 2.7 3 (3H, s). FABMS (m / z): 5 23 ([M + H] +). -429- 200401770 (Example 125) 2-benzyl-6,7-dimethyl-3-3- [3- [2 , 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 ^ __ quinazolinone (Exemplified Compound No. 8-1 620)) A similar method was described, consisting of 4,5-dimethyl o-aminobenzoic acid (190 mg, 1.15 mmol), phenylacetic acid (164 mg, 1.21 mmol), triphenyl phosphate (0.33 ml, 1.27 mmol), and 2- (3-Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (268 mg, 1.04 mmol) to obtain the title compound as a colorless solid (203 mg, yield: 34%) ). 'H-NMR (400MHz? CDC13): 5 7.9 8 (1 Η, s), 7 · 7 1 (1 Η, d, J = 8.1 Hz), 7.57 (1H, s), 7 · 41 (1H, s), 7.35 (1H, t5 J = 8.1 Hz), 7.17-7 · 07 (3H, m), 6.93 (1H, dd, J = 8.1, 1.5 Hz), 6.76 ( 2H, d, J = 6.6 Hz), 4.32 (1H, s), 3,92 (1 H, d, J = 14.6 Hz), 3.81 (1H, d, J = 14.6 Hz), 2.45 (3H, s), 2.40 (3H, s), FABMS (m / z): 5 07 ( [M + H] +) (Example 126) 2-benzyl-5,6-monomethyl-3- [3- [2,2,2-dichloro-1-meryl-1- (tri Fluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 8-1 403) In a similar manner to that described in Example 1, 5,6-dimethyl-o-aminobenzoic acid was used. (丨 6 mg, 1.02 mmol), phenylacetic acid (146 mg, 1.07 mmol), triphenyl phosphate (0.293 ml, 1.13 mmol), and 2- (3-aminophenyl) -1,1,1, 3,3,3-Hexa-2-propanol (23 9 mg, 0.92 mmol) to obtain the title compound as a colorless solid (169 mg, yield: 33%). W-NMR (400MHz, CDC13): δ 7.70 (1H, d, J = 8.8 Hz), 7.59 (1H, d, J = 8.8 Hz), 7.55 (1H, d, J = 8.8 Hz), 7.44 (1H, s) -430- 200401770 7.32 (1H, t, J = 8.1 Hz), 7.16-7.06 (3H, m), 6.88 (1H, dd, J = 1.5, 8.1 Hz), 6.75 (2H, d, J = 6.6 Hz), 4.81 (1H, s), 3.90 (1H, d, J = 14.6 Hz), 3.75 (1H, d, J = 14.6 Hz), 2.74 ( 3H, s), 2.41 (3H, s) · FABMS (m / z): 5 0 7 ([M + H] +). (Example 12 7) 2-benzyl-6-methoxy-7- Methyl-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (exemplified compounds No. 8-1 806) In a similar manner to that described in Example 1, 5-methoxy-4-methyl-o-aminobenzoic acid (202 mg, 1 · 1 1) prepared from the above Example 1 2 3 step (1) mmol), phenylacetic acid (159 mg, 1.17 mmol), triphenyl phosphate (0.32 ml, 1.23 mmol) and 2- (3-aminophenyl) -l, l, l, 3,3,3-hexa Fluoro-2-propanol (73 mg, 0.27 mmol) gave the title compound as a colorless solid (295 mg, yield: 51%). ^ -NMR (400MHz, CDC13): (5 7 · 7 2 (1 Η, d, J = 8 · 1 Η z), 7 · 5 9 (1H, s), 7.53 (1H, s), 7 41 (1H, s), 7.36 (1H, t, J = 8.1 Hz), 7.17-7.08 (3H, m), 6.95 (1H, dd, J = 8.1, 1.5 Hz) , 6.76 (2H, d, J = 6.6 Hz), 4.26 (1H, s), 4.93 (3H, s), 3.91 (1H, d, J = 14.6

Hz), 3.81 (1H5 d5 J = 14.6 Hz) 5 2.40 (3 H, s). FABMS (m / z): 5 23 ((M + H) +). (Example 128) 2_ 本 methyl-6 -Methoxy-5_methyl- 3 · [3_ [2,2,2 -trifluoroacryl • (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinaziolinone ( Exemplified Compound No. 8 _ 200401770 1 496) In a similar manner as described in Example 1, 5-methoxy-6-methyl-o-aminobenzoic acid (175 mg, 0.97 mmol) prepared from Example 124 (1) above, Phenylacetic acid (138 mg, 1.01 mmol), triphenyl phosphate (0.28 ml, 1.06 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro /- 2-propanol (225 1118, 0.887 111111101) to obtain the title compound as a colorless solid (167 mg, yield: 33%). 'H-NMR (400MHz? CDC13): δ 7.69 (1Η? D? J = 8.1 Ηζ)? 7.65 (1Η, d, J = 8.8 Ηζ), 7.43 (1Η, s), 7.40 (1Η, d, J = 8.8 Ηζ), 7 · 33 (lH, t, J = 8.1 Hz), 7.16-7.06 (3H, m) 5 6 · 89 (1H, dd, J = 6.6, 2.2 Hz), 6.74 (2H, d, J = 2.2, 8.1 Hz), 4.51 (1H, s), 3.93 (3H, s), 3.89 (1H, d, J = 14.6 Hz), 3.75 (1H, d, J = 14.6 Hz), 2.70 (3H5 s). FABMS (m / z): 5 23 ([M + H] +). (Example 129) 2-benzyl-5,7-dimethyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-1 434) (1 ) By a method similar to the above Examples 5 5 (1) to (3), 4,6-dimethyl-o-aminobenzoic acid was obtained from 3,5-dimethylaniline. (2) In a similar manner as described in Example 1, 4,6-dimethyl o-aminobenzoic acid (205 111§, 1.24111111〇1), phenylacetic acid (177 mg, 1.3 mm〇1), triphenyl phosphate (0.3 5 6 ml, 1.37 mmol) and 2- (4-aminophenyl) -1,151,3,3,3-hexafluoro-2-propanol (2 89 11 ^, 1.12 111111〇1) to obtain the title compound as a colorless solid (186 mg, yield · 33%). -432- 200401770 'H-NMR (400MHz5 CDC13): δ 7.68 (2H? D? J = 8.8 Hz), 7.45 (1H, s), 7.17-7 · 06 (4H, m), 6.97 ( 2H, d5 J = 8.8 Hz), 6.71 (2H, d? J = 7.3 Hz)? 3.86 (2H, s) 5 3.8 2 (1 H, s)? 2.77 (3H? S)? 2.48 (3H? S) FABMS (m / z): 5 07 ([M + Hf]. (Example 130) 2-benzyl-5,7-dimethyl- 3- [3- [2,2,2-trifluoro- 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -oxazolinone (Exemplified Compound No. 8-1 434) In a similar manner to that described in Example 1, from the above Example 4,6-Dimethyl o-aminobenzoic acid (2 1 3 mg, 1.2 mm) 1 prepared by 129 (1), phenylacetic acid (18 4 mg, 1.35 mmol), triphenyl phosphate (0.37 ml, 1.42 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (30〇11 ^, 1.16 111111〇1 ) The title compound was obtained as a colorless solid (3 39 mg, yield: 58%). 'H-NMR (400MHz5 CDC13): 5 7 · 6 8 (1 H, d, J = 8 · 1 Hz), 7 · 44 (2H, d? J = 6.6 Hz), 7.31 (1H? T? J = 8.1 Hz), 7.15-7.06 (4H, m), 6.88 (1H, dd, J = 8.1, 1.5 Hz) , 6.75 (2H, dd, J = 8.1, 1.5 Hz), 4.7 6 (1H, s), 3.89 (1H, d, J = 14.6 Hz), 3.75 (1H, d, J = 14.6 Hz), 2.74 (3H, s), 3.4 7 (3H, s) · FABMS ( m / z): 507 ([M + H] +). (Example 13 1) 2-benzyl-6-fluoro-7-chloro- 3- [4- [2,2,2-trifluoro-1 -Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-1 992) (1) From the above Examples 55 (1) to (3 ) A similar method was obtained from 3-chloro-4-fluoroaniline-433-200401770 to give 4-chloro-5 -fluoroanthranilic acid. (2) Using a similar method as described in Example 1, from the above example 丨 3 1 (1) 4-chloro-5-fluoroanthranilic acid (45 mg, 0.24 mmol), phenylacetic acid (34 mg, 0.25 mmol), triphenyl phosphate (0.068 ml, 0.26 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (62 mg, 0.24 mmol) to give the title compound as a colorless solid (54 mg, yield: 43%). ] H-NMR (400MHz, CDC13): 5 7.9 6 (1 Η, d, J = 8.0 Hz), 7.9 0 (1H, d, J = 7.6 Hz), 7.72 (2H, d, J = 8.8 Hz ), 7.0 8-7.2 0 (3H, m), 7.00 (2H, d, J = 8.8 Hz), 6.70 (2H, d, J = 7.6 Hz), 3.89 (2H, s) · FABMS (m / z): 5 69 ([M + K] +, 531 ([M + H] +) FABHRMS (m / z): calcd. For C24H15C1F7N202 ([M + H] +): 5 3 1.0 7 1 1; found: 5 3 1.072 8. (Example 132) 2-benzyl-6-chloro-7-methoxy-3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-1 775) (1) Similar to Examples 5 5 (1) to (3) above In this way, 5-chloro-4-methoxy-o-aminobenzoic acid was obtained from 4-chloro-3-methoxyaniline. (2) Prepared in a manner similar to that described in Example 1, and prepared from Example 132 (1) above. 5-chloro-4-methoxy-o-aminobenzoic acid (105 mg, 0.52 mmol), phenylacetic acid (75 mg, 0.55 mmol), triphenyl ortho acid (0.15 ml, 0.58 mmol), and 2- (4-Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (135 11 ^, 0.52 111111〇1) to obtain the title compound as a colorless solid (145 mg, Yield: 51%) -434 · 200401770 ^ -NMR (400MHz, DMSO-d6): δ 8 · 92 (1H, s), 8.04 (1H, s), 7.69 (2H, d, J = 8.8 Hz), 7.38 ( 1H, s), 7.32 (2H, d, J = 8.8 Hz), 7.09-7.20 (3H, m), 6.77 (2H5 d, J = 8.0 Hz), 4.04 (3H, s), 3.83 ( 2H, s) · FABMS (m / z): 581 ([M + K] +), 543 ([M + Hf]. FABHRMS (m / z): calcd. For C25H18C1F6N203 ([M + H] +): 543.0910; found: 543.0903. (Example 133) 2-benzyl-6-chloro-7-methoxy- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 8_; 1 775) Prepared in a manner similar to that described in Example 1, from Example 1 2 (1) above. 5-chloro-4-methoxy-o-aminobenzoic acid (78 mg, 0.39 mmol), phenylacetic acid (55 mg, 0.41 mmol), triphenyl phosphate (0.11 ml, 0.43 mmol), and 2- (3-Aminophenyl) -1,151,3,3,3-hexafluoro-2-propanol (10011, 0.39 111111101) to obtain the title compound as a colorless solid (90 mg, yield: 43%). iH-NMR (400MHz, CD3OD): δ 8 · 1 4 (1 Η, s), 7.8 2 (1 Η, d, J = 8. · 4 Ηζ), 7.66 (1Η, br), 7.44 ( 1Η, t, J = 8.0 Ηζ), 7.33 (1Η, s), 7.10-7.20 (3Η, m), 7.04 (1Η, dd, J = 8.4, 2.4 Hz), 6.81 ( 2Η, dd, J = 7.2, 2.0 Ηζ), 4.07 (3Η, s), 3.98 (1Η, d, J = 15.6 Ηζ), 3.84 (1Η, d, J = 15.6 Hz). FABMS (m / z): 581 ([Μ + Κ] ", 543 ([Μ + Η] +) · FABHRMS (m / ζ): calcd. for C25H18C1F6N20 3 ([M + H] +): 543.0910; found: 543.0912. -435- 200401770 (Example 134) 2-benzyl-6,7-methylenemonooxy- 3- [4- [2,2,2-difluoro (-1-meryl-1- ( Dichloromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1217) (1) By a method similar to the above Example 112 (2) and (3), from 3 4,4-Methylenedioxy-6-nitrobenzaldehyde to obtain 4,5-methylenedioxyanthranilic acid. (2) In a similar manner to that described in Example 1, from the above 4,5-methylene Dioxy o-aminobenzoic acid (200 mg, 1.1 mmol), phenylacetic acid (158 mg, 1.16 mmol), triphenyl phosphate (0.32 ml, 1.21 mol), and 2- (4-aminophenyl) · 1,1,1,3,3,3-hexafluoro-2-propanol (286 11 ^, 1.1010111111) was obtained as the colorless solid of the title compound (208 mg5 yield: 36%). ^ -NMR ( 400MHz? CDC13): δ 7.67 (2Η? D5 J = 8.0 Ηζ)? 7.57 (1Η, s), 7.26 (1Η, s), 7.05-7 · 20 (3Η, m), 6.95 ( 2Η, d, J = 8.0 Ηζ), 6.69 (2Η, d, J = 6.8 Ηζ), 6.14 (2 Η, s), 3.87 (2Η, s). FABMS (m / z): 561 ( [Μ + Κ] +), 5 2 3 ([Μ + Η] +) · FABHRMS (m / z): calcd. For C25H17F6N204 ([M + H] +): 523.1093; found: 523.1083. (Example 135) 2-benzyl-5-chloro-6-methoxy · 3 · [4- [2,2,2-trifluoro-1-hydroxy-l- (trifluoromethyl) ethyl] phenyl]- 4 (3Η) -quinazolinone (Exemplified Compound No. 3 _] [2 79) (1) 6 was obtained from 3-chloro-4-methoxyaniline by a method similar to that described in Example 55 (1) to (3) above. -Chloro-5-methoxy-o-aminobenzoic acid. (2) In a similar manner as described in Example 1, 6-chloro-5-methoxy-o-aminobenzoic acid (63 mg, 0.31 mmol) and phenylacetic acid (43 mg, • 436) prepared from Example 135 (1) above. -200401770 0.31 mmol), triphenyl phosphate (0.081 ml, 0.31 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexachloro-2-propane Alcohol (73 1118, 0.27 11111 [1001)) gave the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (38 mg, yield: 22%). mp 238-239 ° C. IR (KBr): max 3 3 5 1,1 678,1 594,1 474,1 284,1 2 1 4, 969, 932, 7 0 7 cm'1. 'H-NMR (400MHz? DMSO-d6): δ 8.91 (1H? S)? 7.76-7.65 (4H? M), 7.29 (2H, d, J = 8 · 8 Hz), 7.17-7 · 08 (3H , M), 6.74 (2H, d, J = 7.3Hz), 3.97 (3H, s), 3.77 (2H, s) · FABMS (m / z): 581 ([M + K] +), 5 43 ([M + H] +) FABHRMS (m / z): calcd. For CuH! 8C1F6N203 ([M + H] +): 543.0910; found: 543.0925. (Example 136) 2-benzyl-6- Chloro-5-methyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazoline Ketone (Exemplified Compound No. 3- 1 46 5) In a similar manner to that described in Example 1, 5-chloro-6-methyl-o-aminobenzoic acid (345 mg, 1.86 mmol), benzene, prepared from Example 55 (3) above, Glycolic acid (264 mg 1.94 mmol), triphenyl phosphate (589 mg, 1.90 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro- 2-propanol (482 11 ^, 1.86 111111〇1) to obtain the title compound as a colorless solid (213 mg, yield: 22%). This product was recrystallized from acetonitrile to give colorless flakes. IR (KBr): y max 3610, 1 674, 1 5 99, 1 45 9, 127 1, 1216, 971, 93 2, -437- 200401770 709 cm-1. IH-NMR (400MHz, DMSO-d6): δ 8.91 (1H, s), 7.89 (1H, d5 J = 8.8 Hz), 7.67 (2H, d, J = 8.8 Hz), 7.58 (1H, d, J = 8.8 Hz), 7.29 (2H , D, J = 8.8 Hz), 7.18-7.08 (3H, m) 5 6.75 (2H, d, J = 7.3 Hz), 3.80 (2H5 s), 2.82 (3H, s). FABMS (m / z): 5 27 ([M + H] +) · (Example 137) 2- (3-aminobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-60) Platinum oxide (120 mg) was added to 2 prepared in Example 34 above -(3-nitrobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H)- In a solution of quinazolinone (542 mg, 1.04 mmol) in ethyl acetate (10 ml), the resulting mixture was stirred vigorously at room temperature under hydrogen pressure for 30 minutes. After this time, it was removed by filtration. The catalyst was concentrated and the filtrate was concentrated. The obtained residue was subjected to silica gel column chromatography (using a 1: 1 mixture of hexane and ethyl acetate as a mixture). Dialysate wash) to give the title compound as a colorless Foam of (5 05 mg, yield: 98%), The product from the isopropyl ether recrystallization to produce colorless needles. IR (KBr): v max 3 298, 1 678, 1 5 93, 1 472, 1 270, 1214, 1192, 937 cm1. 'H-NMR (400MHz5 CDC13)): δ 8 · 3 0 (1 Η, d , J = 8 · 1 Η z), 7.86-7.79 (2H, m), 7.63 (2H, d, J = 8.8 Hz), 7.55-7.51 (1H, m), 7.00 (1H, t, J = 8.1 Hz), 6.90 (2H, d, J = 8.8 Hz), 6.57 · -438- 200401770 6.52 (2H, m), 6.33 (1H, brs), 5.50 (1H, s), 3.87 (2H, s ), 3.51 (2H, brs). FABMS (m / z): 494 ([M + H] +). (Example 138) 2- (3-Ethylaminobenzyl) -3- [4 -[2,2,2-difluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-70) will contain 2- (3-Aminobenzyl) -3- [4- [2,2,2-difluoro-1-meryl-1- (difluoromethyl) ethyl] benzene prepared in the above Example 137 [Methyl] -4 (3H) -quinazolinone (80 mg, 0.162 mmol), acetic anhydride (0.1 ml, 1.1 mmol), a mixture of pyridine (0.5 ml) and ethyl acetate (2 ml) at room temperature Stir for 30 minutes, then add ethanol (2 ml) to the reaction mixture, then concentrate the reaction mixture in vacuo, and recrystallize the obtained residue from acetonitrile, Generating colorless prismatic crystals of the title compound (67 mg, yield: 77%). IR (KBr): v max 3 306, 1 667, 1 592, 1 473, 1 2 73, 1218, 1189, 935 cm'1.! H-NMR (400MHz? DMSO-d6): δ 9.78 (1H? S )? 8.89 (1H? S)? 8 · 1 3 (1 H, d, J = 8 · 1 H z), 7 · 9 2-7 · 8 8 (1 H 5 m), 7 · 7 6 (1 H, d, J = 8.1 Hz), 7.67 (2H, d, J = 8.8 Hz), 7.60-7.56 (1H, m), 7.43 (1H, d, J = 8.1 Hz), 7.32 (2H, d , J = 8.8 Hz), 7.20 (1H, s), 6.94 (1H, t, J = 8.1 Hz), 6.18 (1H, d, J = 7.3 Hz), 3.83 (2H, s), 1.96 (3H, s). FABMS (m / z): 494 ([M + H] +). (Example 139) 200401770 2-benzyl-6-chloro-7-methyl- 3- [3- [2 , 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplary Compound No. 8-1713) Similar to that described in Example 1 Method: 5-Chloro-4-methyl-o-aminobenzoic acid (271 mg, 1.46 mmol), phenylacetic acid (204 mg, 1.50 mmol), triphenyl phosphate obtained from Example 5 5 (3) above. Esters (471 mg, 1.52 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (382 111§, 1.47 111111〇1) Colorless foamy product of the title compound (454 m g, yield: 59%). IR (KBr): V max 3 3 02, 1 684, 1 5 8 3, 1 469, 1 267, 1 208, 969, 723 cm-1.iH-NMR (400MHz; CDC13): δ 8 · 20 (1H , S), 7.75 (1H, d, J = 8.1 Hz), 7.67 (1H, s), 7.43 -7.3 9 (2H, m), 7.19-7 · 11 (3H, m), 6.98 ( 2H, d5 J = 8.1 Hz), 6.77 (2H, d, J = 8.1 Hz), 3.92 (1H, d5 J = 14.6 Hz), 3.83 (1H, d, J = 14 · 6 Hz), 3.74 (1H, s), 2.56 (3H, s) · FABMS (m / z): 527 ([M + H] +). (Example 140) 2-benzyl-6-chloro-5 -Methyl-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (exemplified Compound No. 8-1 46 5) In a similar manner as described in Example 1, 5-chloro-6-methyl-o-aminobenzoic acid (203 113 ^, 1.09111111〇1), benzene, prepared from Example 55 (3), Glycolic acid (152111, 1.12 mmol), triphenyl phosphate (353 mg, 1.14 mmol) and 2- (3-aminophenyl) · 1,1,1,3,3,3-hexafluoro-2- Propanol (286 11 ^, 1.101011111) was obtained as the colorless solid of the title compound. This product was recrystallized from toluene to give a colorless powder (400 mg, yield: 70%). -440- 200401770 IR (KBr): v max 3 3 2 5,1 676, 1 5 8 3, 1 459, 1 267, 1 207, 971, 725 cm-1 ·] H-NMR (400MHz5 DMSO-d6) : δ 8.90 (1H? s) 5 7.8 8 (1 H? d? J = 8.8 Hz), 7.76-7.71 (2H, m), 7.5 7-7.4 8 (2H, m), 7.22 (1H, d, J = 8.8 Hz), 7.16-7.14 (3H, m), 6.83-6.81 (2H, m), 3.83 (1H, d, J = 15.4 Hz), 3.72 (1H, d, J = 15.4 Hz) , 2.83 (1H, s) · FABMS (m / z): 5 2 7 ([M + H] +). Anal. C al cd. For C25H17C1F6N2 02: C, 5 6.99; H, 3.25; N 5 5.3 2 ; F, 21.64; Cl5 6.73; found: C, 5 7.09; H? 3.01; N? 5.32; F5 2 1.8 0; Cl5 6.4 7. (Example 141) 2-benzyl-6-nitro- 3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2300)

(1) Add pyridine (2 ml) dropwise to a solution containing 5-nitro-o-aminobenzoic acid (922 mg, 5.06 mmol), phenylacetamidinyl chloride (1.40 ml, 10.6 mmol) and In a mixture of toluene (10mi), the reaction mixture was stirred at 80 ° C for 30 minutes. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate, and successively 5% potassium carbonate aqueous solution, water and saturated chlorination Rinse with an aqueous sodium solution, dry over anhydrous magnesium sulfate and concentrate in vacuo. The obtained residue is recrystallized from ethyl acetate to give 2-benzyl-6-nitro-4H-3, 1_ -441 -200401770 benzopyrene-4-one as a brown crystalline solid (385 mg, yield: 27%). (2) The 2-benzyl-6-nitro-4H-3,1-benzofluorenyl-4-one (289 mg, 1.02 mmol) containing the above-prepared Example 141 (1) Triphenyl phosphate (344 mg, 1.11111111〇1), 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (263 11 ^, 1.01 A mixture of mmol) and pyridine (82 ml) was stirred at 100 ° C. for 3 hours, and then the reaction mixture was concentrated in vacuo. The obtained residue was diluted with ethyl acetate and successively with 5% aqueous potassium carbonate solution, water and saturated chlorine. Rinse with an aqueous sodium chloride solution, dry over anhydrous magnesium sulfate and concentrate in vacuo. The obtained residue was recrystallized from acetonitrile to give the title compound as a yellow flake (3 3 3 mg, yield: 63%). . IR (KBr): ^ max 3 3 8 2, 1 697, 1 5 72, 1 3 47, 1 270, 1 2 1 6, 931 cm · 1. 'H-NMR (400MHz, CDC13): δ 9.11 (1H , D, J = 2.2 Hz), 8.61 (1H, dd, J = 2.2, 8.8 Hz), 7.93 (1 H, d, J = 8 · 8 Hz), 7.75 (2H, d, J = 8.8 Hz), 7.21-7.10 (3H, m) 5 7.02 (2H, d, J = 8.8 Hz), 6.72 (2H, d, J = 7.3 Hz), 3.95 (2H, s), 3.81 ( 1H, s) · FABMS (m / z): 524 ([M + H] +). (Example 142) 2-benzyl-7-gas-6-methoxy- 3- [4- [2, 2,2 -Digas-1-xiangyl-1- (Diyi j methyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3- 1 83 7) (1) By a similar method to that described in Example 55 (1) to (3) above, 4-chloro-5-methoxyanthranilic acid was obtained from 3 · chloro-4-methoxyaniline. (2) In a similar manner as described in Example 1, 4-chloro-5-methoxy-o-aminobenzoic acid (180 mg, 0.89 mmol) and phenylacetic acid (121 -442) prepared from Example 142 (1) above. -200401770 mg, 0.89 mmol), triphenyl phosphonate (0.233 ml, 0.89 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2 -Propanol (185 11 ^, 0.71111111〇1) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (161 mg, yield: 42%). 0 'H-NMR (400MHz5 CDC13): 5 7 · 8 8 (1 Η, s), 7 · 6 9 (3 Η, d, J = 8.0 Hz), 7.17-7.07 (3H, m), 6.95 ( 2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 7.2 Hz), 4.02 (3H, s), 3.88 (2H, s). FABMS (m / z): 543 ([M + H] +). (Example 143) 2-benzyl-7-chloro-6-methoxy-3- [3- [2,2,2-trifluoro-1- Hydroxy · 1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (Exemplified Compound No. 8-1 83 7) In a similar manner to that described in Example 1, from the above Example 142 ( 1) 4-chloro-5-methoxy-o-aminobenzoic acid (130 mg, 0.65 mmol) and phenylacetic acid prepared 88 mg, 0.65 mmol), triphenyl phosphate (0.170 ml, 0.65 mmol), and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propane- ( 15〇111§, 0.58 111111〇1) to obtain the title compound as a colorless solid, which was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (84 mg, yield: 27). 'H-NMR (400MHz? CDC13): (5 7 · 8 6 (1 Η, s), 7 · 7 5 (1 Η, d, J = 8.0 Hz), 7.65 (1H, s), 7.42-7.3 8 (2H, m), 7.17-7.11 (3H, m), 6.98 (1H, d5 J = 7.8 Hz), 6.76 (2H, d, J 2 7.4 Hz), 3.99 ( 3H, s), 3.96-3.7 9 (2H, m) · FABMS (m / z): 543 ([M + H] +). 200401770 (Example 144) 2-benzyl-5,7-dichloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -oxazolinone (Exemplified Compound No. 3- 1 5 8 9) (1) By a method similar to that in Example 55 (1) to (3) above, 4,6-dichloroanthranilic acid was obtained from 3,5-dichloroaniline. (2) As described in Example 1 In a similar way, 4,6-dichloroanthranilic acid (75 mg, 0.36 mmol), phenylacetic acid (49 mg, 0.36 mmol), and triphenyl phosphate (prepared from Example 144 (1) above) 0.094 ml, 0.36 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (75 11 ^, 0.29 111111〇1) Colorless solid of the title compound. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (40 mg, yield: 25%).] H-NMR (400MHz5 CDC13): δ 7.73 (1Η5 d5 J = 8.8 Hz), 7.69 (2Η, d5 J = 8 · 4 Hz), 7.48 (1Η, d, J = 8 · 8 Ηζ), 7.18-7.08 (3Η , M), 6.98 (2H, d, J = 8.8 Hz), 4.02 (3H, s), 3.86 (2H, s), FABMS (m / z): 547 ([M + H] +). (Example 145) 2-benzyl-7-methoxy-6-methyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1 682) (1) A method similar to that described in Example 55 (1) to (3) above, from 3-methoxy 4-methylaniline to obtain 4-methoxy-5-methylanthranilic acid. (2) In a similar manner to that described in Example 1, the 4-methoxy group prepared from the above Example 4 5 (1) Methyl-5-methyl-o-aminobenzoic acid (181 mg,! · 〇〇〇〇〇〇), phenylacetic acid-444- 200401770 (136 mg, 1.00 mmol), triphenyl phosphate (.262 ml, 1.00 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (230 mg, 0.89 mmol) to give the title compound as a colorless solid. Recrystallized from a mixed solvent of alkane and ethyl acetate to produce colorless orthorhombic crystals (52 mg, yield: 10W-NMR (4 00MHz, CDC13): δ 7.99 (1H, s), 7.65 (2H, d5 J = .8.8 Hz), 7.15-7.06 (4Η, m), 6.93 (2Η, d, J = 8.0 Hz), 6 · 69 (2Η, d, J = 7.6 Hz), 4.00 (3Η, s), 3.88 (2H, s), 2.35 (3H, s). FABMS (m / z): 523 ([M + H ] +). (Example 146) 2-benzyl-5-ethoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 3-2 3 0 1)

In a similar manner as described in Example 1, 6-ethoxy o-aminobenzoic acid (46 mg, 0.25 mmol), phenylacetic acid (34 mg, 0.25 mmol), and triphenyl phosphate (0.065 ml, 0.25 mmol) were used. And 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (61 mg, 0.24 mmol) to give the title compound as a colorless solid. This product was obtained from dichloro Recrystallization from a mixed solvent of methane and hexane gave a colorless crystalline powder (12 mg, yield: 10%). -445- 200401770 W-NMR (400MHz, CDC13): δ 11.29 (1H, s), 7.71 (1H, t5 J = 8.0 Hz), 7.58 (2H, d, J = 8.0 Hz), 7. · 29 (1H, d, J = 8.1 Hz), 7.17 (1H, t, J = 7.3 Hz), 7.10 (2H, J = 7.3 Hz), 7.01 (2H, d, J = 8.8 Hz), 6 · 96 (1H, d, J = 8.1 Hz), 6.70 (2H, d, J = 7.3 Hz), 3.92 (2H, s) 5 3 · 69 (2H, q, J = 7.6 Hz), 1.35 (3H, t, J = 7.6 Hz). FABMS (m / z): 5 2 3 ([M + H] +). (Example 147) 2-benzyl-6,7-dichloro- 3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -quinazolinone (Exemplified compound number 3-1 7 buckets 4) (1) By a method similar to the above-mentioned Example 55 (1) to (3), 4,5-dichloroanthranilic acid was obtained from 3,4-dichloroaniline. (2) In a similar manner as described in Example 1, 4,5-dichloroanthranilic acid (148 mg, 0.72 mmol) and phenylacetic acid (98 mg, 0.72) were prepared from Example 147 (1) above. mmol), triphenyl phosphate (0.19 ml, 0.72 mmol), and 2- (4-amine base) -1,1,1,3,3,3-hexam-2-propanol (168 1118, 0.65 1] 1111〇1) to obtain the title compound as a pale yellow solid. This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a pale yellow crystalline powder (111 mg, yield · 31 iH-NMR (400MHz , DMSO-d6) ... δ 8.92 (1H, s) 5 8.2 2 (1 H, s) 5 8 · 06 (1Η, s), 7.69 (2Η, d, J = 8.8 Ηζ), 7.34 (2Η, d , J = 8.2

Hz), 7.09-7.17 (3H5 m) 5 6.7 7 (2H5 d, J = 7.3 Hz)? 3.84 (2H? S). FABMS (m / z): 5 8 5 ([M + K] +), 547 ((Μ + ΗΓ) -446- 200401770 (Example 148) 2-benzyl-5,6-dichloro-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) Ethyl] phenyl] -4 (3 Η) -Πquinazolinone (Exemplified Compound No. 3-1 5 5 8) (1) A method similar to the above Example 55 (1) to (3) , 5,6-Dichloro-o-aminobenzoic acid is obtained from 3,4-dichloroaniline. (2) In a similar manner as described in Example 1, 5,6-dichloroanthranilic acid (207 mg, 1.00 mmol) and phenylacetic acid (1 37 mg, 1.00 mmol), triphenyl phosphate (0.26 ml, 1.00 mmol), and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (23 7 mg, 0.91 mmol) to obtain the title compound as a colorless solid. This product was recrystallized from a mixture of dichloromethane and hexane to give a colorless, amorphous solid (319 mg, yield: 64%). 'H-NMR (400MHz, DMSO-d6): δ 8.91 (1Η? S)? 8.06 (1Η5 d5 J = 8.8Hz), 7.68-7.71 (3H, m), 7.33 (2H, d, J = 8.8Hz) , 7'09-7 · 19 (3H, m), 6.77 (2H, d, J = 6.6 Hz), 3.81 (2H, s) · FABMS (m / z): 5 8 5 ([M + K] +), 547 ([M + H] +) · (Example 149) 2-benzyl-7-chloro-6-methyl- 3- [4- [2,2,2 · trifluoro- 1 · Hydroxy-1- (trioxymethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1651) (1) From the above Examples 55 (1) to (3) In a similar manner, 4-chloro-5-methyl-o-aminobenzoic acid was obtained from 2-chloro-4-aminotoluene. (2) In a similar manner as described in Example 1, 4-chloro-5-methyl-o-aminobenzoic acid (135 mg, 0.73 mmol) and phenylacetic acid (100 mg) prepared from Example 149 (1) above 0.73 mmol), triphenyl diacetate (0.19 ml, 0.73 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (171111§ , 0.66 111111〇1) to obtain the colorless solid of the title compound -447- 200401770, the product was recrystallized from dichloromethane and hexane to produce colorless orthorhombic crystals (69mg, yield iH-NMR (400MHz, DMSO-d6): δ 8.91 (1H, s), 8 〇8 (1H s) 7.82 (1H, s), 7.68 (2H, d, J = 8.8 Hz), 7.31 (2H, d; = 8 i Hz), 7.09-7.18 (3H, m), 6.74 (2H, d5 J = 7.3 Hz), 3 8 3 (2H g) 2.49 (3H? s). FABMS (m / z) : 5 2 7 ([M + H] +). (Example 150) 2-benzyl-5-chloro-6-methyl-3- [4- [2,2,2 · trifluoro-1-hydroxyl -Trichloromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (Exemplified Compound No. t 1 527) (1) A method similar to the above Example 55 (1) to (3), from 2 -Chlorine and 4-aminotoluene give 6-chloro-5-methyl-o-aminobenzoic acid. (2) In a similar manner as described in Example 1, 6-chloro-5-methyl-o-aminobenzoic acid (260 mg, 1.40 mmol) and phenylacetic acid (191 mg, 1 · 40 mmol), triphenyl phosphate (0.36 ml, 1.40 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (33111 ^, 1.28 111 «1001) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of dichloromethane and benzene to give a colorless and crystalline solid (478 mg, yield: 7U). W-NMR (400MHz, DMSO-d6): δ 8.92 (1H, s), 7.83 (1H, d, J = 8. · 1 Ηζ), 7.68 (2Η, d, J = 8.1 Ηζ), 7 · 60 (1Η, d, J = 8.8Ηζ), 7.30 (2Η, d, J = 8.8Ηζ), 7.09-7.18 (3Η, m), 6.7 5 (2Η, d, J = 7 · 3 Ηζ), 3.80 (2Η, s), 2.46 (3Η, s) · FABMS (m / z): 527 ([Μ + Η] +). • 448- 200401770 (Example 15 1) 2-benzyl-5,6-dichloro-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H ) -Quinazolinone (Exemplified Compound No. 8-1558) In a similar manner to that described in Example 1, from the above example; [4 8 (1) 5,6-monochloroanthranilic acid (304 mg, 1.48) mmol), phenylacetic acid (202 mg, 1.48 mmol), triphenyl phosphate (0.38 ml, 1.48 mmol), and 2- (3-amine basic group) -1,1,1,3,3, 3-hexamidine-2-propanol (348 111§, 1.34 111111〇1) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a colorless crystalline powder (293 mg, Yield: 40%). 'H-NMR (400MHz5 DMSO-d6): δ 8.91 (1Η? S); 8.03 (1Η? D? J = 8 · 8 Ηζ), 7.76 (2Η, br), 7.66 (1Η, d, J = 8 · 8 Ηζ), 7.52 (1Η, t, J = 8 · 1 Ηζ), 7.26 (1Η, d, J = 8 · 1 Ηζ), 7.15-7.18 (3Η, m), 6.84-6 87 (2H, m), 3.78 (2H, m), FABMS (m / z): 547 ([M + H] +). (Example 152) 2-benzyl-7-chloro-6- Methyl-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenylb 4 (3 Η) -quinazolinone (Exemplified compound numbers 8-1651) In a similar manner as described in Example 1, the chloro-5-methyl o-aminobenzoic acid (281 mg, 151 mmol) and phenylacetic acid (206 mg, 1 ·) were prepared from the above Example 149 (1). 51 mmol), triphenyl phosphate (0.40 ml, 1.52 mmol), and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol ( 3 5 8 11 ^, 1.38 111111〇1) to obtain the title compound as a colorless solid. This product was recrystallized from a mixed solvent of dichloromethane and hexane to give a colorless crystalline powder (3〗 5 mg, yield: 43%) . -449- 200401770 W-NMR (400MHz, DMSO-d6) ·· δ 8 · 87 (1H, s) 5 8 · 05 (1H, s), 7.69-7 · 76 (3H, m), 7.50 ( 1H, t, J = 8.1 Hz), 7 · 23 (1H, d, J = 7.3 Hz) 5 7.11-7.14 (3H? M) 5 6.7 9-6.8 1 (2H? M) 5 3.7 9 (2 H5 m) 5 2.45 (3H, s). FABMS (m / z): 5 27 ([M + H] +). (Example 153) 6-Amino-2-benzyl- 3- [4- [ 2,2,2-triwin-1-yl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-23 〇2)

In a similar manner to Example 137 above, by using platinum oxide (2.88 mg) to reduce the 2-benzyl-6-nitro-3- [4- [2,2,2- Trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (2.80 g, 5.35 mmol) to obtain the title compound as pale yellow crystals, This product was recrystallized from a mixed solvent of ethyl acetate and hexane to give colorless needles (2.23 g, yield: 84%). IR (KBr): V max 3407, 1 667, 1591, 1 49 5, 1 273, 1 22 0, 1192, 939 cm · 1 ·] H-NMR (400MHz, CDCl3 + DMSO-d6): δ 7.72 (2H , d, J = 7.3 Hz), 7.62 (1H, d, J = 8.8 Hz), 7.55 (1H, s), 7.42 (1H, d, J = 2.2 Hz), 7.19-7.06 (3H, m) , 6.94 (2H, d, J = 8.8 Hz), 6.69 -450- 200401770 (2H, d, J = 7.3 Hz), 4.12 (2H, s) 5 3.8 6 (2 H, s) · FABMS (m / z): 4 9 4 ([M + H] +) (Example 154) 2-benzyl-5-chloro-6-methyl- 3- [3- [2,2,2-tri Fluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplary compound number 8-1 5 2 7 :)

In a similar manner as described in Example 1, 6_chloro-5-methyl-o-aminobenzoic acid (209 mg, 1.13 mmol), phenylacetic acid (157 mg, 1.14 mmol) prepared from the above Example 150 (1) ), Triphenyl phosphonate (0.30 ml, 1.14 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (265 11 ^, 1.02 111111〇1) to obtain the title compound as a colorless solid (398 mg, yield: 74%). This product was recrystallized from a mixed solvent of ethyl acetate and ethyl acetate to produce colorless orthorhombic crystals. mp 202-203 ° C. IR (KBr): V max 337 7, 3 0 3 2, 1 672, 1 5 8 5, 1 468, 95 9 cm · 1 · ^ -NMR (400MHz, DMSO-d6): δ 8 · 9 0 (1 H, s) 5 7 · 8 1 (1 H, d, J = 8.1 Hz), 7.75 (1H, d, J = 8.1 Hz), 7.72 (1H, s), 7.57 (1H, d, J = 8.1 Hz), 7.51 (1H, t, J = 8.1 Hz), 7.23 (1H, d, J = 8.1 Hz), 7.16-7 · 15 (3H , M), 6.85-6.82 (2H, m), 3.84-3.69 (2H, m), 2.46 (3H? S). FABMS (m / z): 5 27 ([M + H] +). • 451- 200401770 FABHRMS (m / z): calcd. For C24H17F6N202 ([M + H] +): 526.8579; found: 527.0978. (Example 155) 2-benzyl-6,7-dichloro-3- 3- [3- [ 2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 8-1 744)

In a similar manner as described in Example 1, 4,5-dichloroanthranilic acid (231 mg, 1.12 mmol), phenylacetic acid (154 mg, 1.13 mmol), and phosphoic acid prepared from Example 147 (1) above were prepared. Triphenyl ester (0.30 ml, 1.14 mmol) and 2- (3-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (268 mg, 1.03 mmol) The title compound was obtained as a colorless solid (280 mg, yield: 50%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 1 9 8- 1 99 ° C. IR (KBr): y… 303 2, 1 68 8, 1 5 83, 1 450, 1 267, 1 208, 969 cm1. 'H-NMR (400MHz? DMSO-d6 ): δ 8.91 (lH, s), 8.23 (lH, s), 8.03 (1H, s), 7.78-7.76 (2H, m), 7.53 (1H, t, J = 8.1 Hz), 7.28 (1H, d , J = 8.8 Hz), 7.17-7.15 (3H, m), 6.85 -6.84 (2H, m), 3.89-3.74 (2H, m) · FABMS (m / z): 547 ([M + H] +) FABHRMS (m / z): calcd. For C 2 4 H! 4 C12 F 6N 2 O 2 ([M + H] +): -452- 200401770 547.2761; found: 547.0397. (Example 156) 2-Benzyl Methyl-5-chloro-6-methoxy- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H ) -Fuzazolinone (Exemplified Compound No. 8_ 12 7 9)

In a similar manner as described in Example 1, 6-.chloro-5-methoxy-o-aminobenzoic acid (2 8 5 mg, 1.42 mmol), phenylacetic acid (193 mg, 1.42 mmol), triphenyl phosphate (0.37 ml, 1.42 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol ( (292 1 ^, 1.13 111111〇1) to obtain the title compound as a colorless solid (58 mg, yield: 10%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 214-215 ° C. IR (KBr): v max 3 269, 1 67 9, 1 5 89, 1 475, 1 28 5, 1214, 969 cnT1 · W-NMR (400MHz, DMSO-d6): δ 8 · 88 (1H, s), 7.75-7 · 67 (4Η, m), 7.49 (lH, t, J = 8.0Hz), 7.22 (lH, d, J = 8.0Hz), 7.16-7 · 14 (3H, m) 5 6.84-6.81 (2H, m), 3.97 (3H, s), 3 · 82-3 · 67 (2H, m) · -453 · 200401770 FABMS (m / z): 543 ([M + H] +) (Example 157) 2-benzyl-7-methoxy-6-methyl-3 [3- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 8_ 1 682)

In a similar manner as described in Example 1, 4-methoxy-5-methyl o-aminobenzoic acid (331 mg, 1.82 mmol) and phenylacetic acid (248 mg, 1.82 mmol), triphenyl phosphate (0.48 ml, 1.82 mmol), and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (378 11 ^ (1.46 mmol) to obtain the title compound as a colorless solid (101 mg, yield: 13%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 226-227 ° C. IR (KBr): V max 3 23 5, 1, 666, 1618, 1 4 8 8, 1 3 74, 1 268, 1 207, 723 W-NMR (400MHz, DMSO-d6): δ 8.87 (1H, s), 7.86 (1H, s), 7.75 (1H, d, J = 8.4 Hz), 7.64 (1H, s) 7.52 (1H, t, J = 8.0 Hz) 7.24 (1H, d, J = 8.8 Hz), 7.16-7.14 (4H, m), 6.84-6.81 (2H, m), 3.96 (3H, s), 3.86-3.73 (2H, m) · • 454 -200401770 FABMS (m / z): 523 ((M + H) +). (Example 158) 2-benzyl-6-methoxy-5,7-dimethyl-3- [4- [2 , 2,2-trifluoro_1_ meridyl_1 · (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound No. 3- 2271)

(1) A method similar to that described in Example 55 (1) to (3) above was used to obtain 4,6-dimethyl-5-methoxy-o-aminobenzene from 3,5-dimethyl-4-oxyaniline. Formic acid. (2) Using a method similar to that described in Example 1, from the above Example 1 5 8 (1) | 2 4,6-dimethyl-5-methoxy-o-aminobenzoic acid (3 00 mg, 1.54 mm) ), Phenylacetic acid (210 mg, 1.54 mmol), triphenyl phosphate (0.40 ml, 1.54 mmol), and 2- (4-aminophenyl) -l, l, l, 3,3,3- Hexafluoro-2 -propanol (319 mg, 1.23 mmol) to obtain the title compound as a colorless solid (ία mg, yield: 22%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce a colorless rhombus Crystal. mp 216-217 ° C. IR (KBr): v max 3310, 1661, 1 5 92, 1 468, 1 3 5 8, 1 26 7, 9 3 3, 709 iH-NMR (400MHz, DMSO-d6): δ 8.89 (1H5 s) 5 7.66 (2H, d, -455- 200401770 J = 8.4 Hz), 7.45 (1H, s), 7.25 (2H, d, J = 8.8 Hz), 7.16-7.08 (3H, m) , 6.73 (2H, d, J = 6.4 Hz), 3.77 (2H, s), 3.68 (3H, s), 2.63 (3H, s), 2.40 (3H, s) 'FABMS (m / z): 5 3 7 ([M + H] ”· (Example 159) 2-benzyl-6-fluorenyloxy-5,7-dimethyl-3- [3- [2,2 , 2-trifluoro-l · hydroxy-l- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 8-2271)

In a similar manner as described in Example 1, 4,6-monomethyl-5 -methoxy-o-aminobenzoic acid (300 mg, 1.54 mmol) and phenylacetic acid (210 mg5) obtained from Example 158 (1) above 1.54 mmol), triphenyl phosphonate (0.40 ml, 1.54 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol ( 319 (11 ^, 1.23 mmol) to obtain the title compound as a colorless solid (140 mg, yield: 21%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 10 1 -10 ° C. IR (KBr): u max 3 3 09, 1681, 1 5 8 8, 1 468, 1 3 5 9, 1212, 970, 724 cm * 1. 'H-NMR ( 400MHz, DMSO-d6): δ 8.88 (1H5 s) 5 7.74 (1H? D? J = 8.0 Hz), 7.63 (1H, s), 7.49 (1H, t, J = 8.0 Hz), 7 43 (1H, s), -456- 200401770 7.18-7.14 (4H, m), 6 · 81-6 · 7 9 (2H, m), 3.82-3.70 (3 H, m) 5 2.64 (3H, s ) 5 2 · 39 (3H, s) · FABMS (m / z): 5 3 7 ([M + H] +). (Example 160) 2-benzyl-6,7-methylenedioxy- 3- [3- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 8-1217 )

In a similar manner as described in Example 1, 4,5-methylenedioxy-o-aminobenzoic acid (200 mg, 1.10 mmol), phenylacetic acid U58 mg, 1.10 mmol) prepared from Example 134 (1) above , Triphenyl phosphate (0.32 ml, 1.20 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (286 11 ^, 1.1. 111111〇1) to obtain the title compound as a colorless solid (113 mg, yield 20%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 177-178 ° C. IR (KBr): vmax 3 2 64, 1 662, 1 5 72, 1 472, 1 264, 1214, 724 cm · 1. 'H-NMR (400MHz, CDC13): δ 7 · 72 (1H, d, J = 8.0 Hz), 7.54 (1H, s), 7.43 (1H, br), 7.38 (1H, t, J = 8.0 Hz), 7.17-7 · 1〇 (4H, m), 6.96 (1H, d, J = 8.0 Hz), 6.77 (2H, d, J = 8.0 Hz), 6.14 (2H, s), 4.35 (1H, br), 3. · 91 (1H, d, J = 15.2 Hz), 3.81 (1H, d, J = 15.2 Hz). -45 7- 200401770 FABMS (m / z): 5 2 3 ([M + H] +). FABHRMS (m / z): calcd. For C25H17F6N204 ([M + H] +): 523.1093; found: 523.1098. (Example 161) 2-benzyl-5-chloro-6-hydroxy- 3- [4- [ 2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3 -23 03)

In a similar manner to the above Example 59, 2-benzyl-5-chloro-6-methoxy- 3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (60 mg, 0.11 mmol) to obtain the title compound as a colorless solid (20 mg, yield: 34%). 'H-NMR (400MHz, CDC13?): Δ 7.7 2-7 · 6 7 (3 Η, m), 7 · 5 3 (1 Η, d5 J = 9.6 Hz), 7.17-7.07 (3H? M) 5 6.98-6.95 (2H, m)? 6.69 (2H, d, J = 7.6 Hz), 6.34 (1H, s), 4.30 (1H, s) 5 3.87 (2H, s). FABMS ( m / z): 5 2 9 ([M + H] +). (Example 162) 2 · benzyl-7-chloro-6-hydroxy- 3- [3- [2,2,2-trifluoro- 1-Hydroxy-1- (trifluoromethylethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 8-2300) -458- 200401770

In the same manner as in Example 5 9 above, 2-benzyl-7-chloro-6-methoxy- 3- [3- [2,2,2-trifluoro- 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (62 mg, 0.11 mmol) to obtain the title compound as a colorless solid (34 mg, yield: 59%) ). mp 121-122 ° C. IR (KBr): vmax 3284, 1669, 1584, 1 475, 1 440, 1 360, 1 267, i 2 i2, 969, 724 cm1. 'H-NMR (400MHz, CDC13): δ 7 · 8 1 (1 H, s), 7 · 7 4-7 · 7 0 (2 H, t, J = 8.0 Hz), 7.48 (1H, s) 5 7.43 (1H, s), 7.39 (1H, t5 J = 8.0 Hz), 7.15-7.09 (3H, m), 6.95 (1H, dd, J = 8.0, 1.6 Hz), 6.76 (2H, d, J = 6.4 Hz), 4.64 (1H , S) 3.96-3 · 78 (2H, m). FABMS (m / z): 529 ([M + H] +). (Example 163) 2-benzyl-7-hydroxy-6 · methyl -3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound numbers 8-230 1) -459- 200401770

In a similar manner to Example 5 9 above, 2-benzyl-7-methoxy-6-methyl- 3- [3- [2,2,2-trifluoro- 1-Chloro-tris (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (39 mg, 0.07 mm) to give the title compound as a colorless solid (23 mg, product Rate: 57%). mp 147-148 ° C. IR (KBr): vmax 3265, 1 66 551 6 1 6, 1 26 7, 1 2 1 3,969,724 cm-i · 〖H-NMR (400MHz, DMSO-d6): δ 8 · 88 (1H, s), 7.81 (iH, s) 7.72 (1H, d, J = 8.0 Hz), 7.59 (1H, s), 7.49 (1H, t, J = 8.0 Hz) 7.20-7.13 ( 4H, m), 7.01 (1H, s) 6.79 (2H, d, J = 3.6 Hz) 3.84-3.7 0 (2H, m), 2.25 (3H, s). FABMS (m / z): 5 09 ([M + H] +) (Example 164) 2-benzyl-5,6-methylenedioxy-3- [4- [2,2,2-trifluoro-1-hydroxy_ 1_ (trifluoromethyl) ethyl] phenyl] _4 (3 fluorene) -quinazolinone (Exemplified compound number 31 i • 460- 200401770

(1) By a method similar to the above Examples 122 (2) and (3), 5,6-methylenedioxy-o-aminobenzoic acid was obtained from 2,3-methylenedioxy-6-nitrobenzaldehyde. (2) In a similar manner as described in Example 1, 5,6-methylenedioxy o-aminobenzoic acid (219 mg, 1.20 mmol), phenylacetic acid (173 mg, 1.30 mmol), triphenyl diacetate (0.35 ml, 1.30 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol ( 313 11 ^, 1.301011111〇1) The title compound was obtained as a colorless solid (208 mg, yield: 33%). This product was recrystallized from a mixed solvent of Kojiri and ethyl acetate to produce a colorless orthorhombic mrfii body. mp 224-225 ° C. IR (KBr): v max 3 3 5 3, 1 6 8 6, 1 5 96, 1 472, 1 270, 1214, 1 055, 709 cm'1. iH-NMR (400MHz, CDC13): δ 7.67 (2H, d, J = 8.0 Hz), 7.33 (1H, d, J = 8.8 Hz), 7.29 (1H, d, J = 8.8 Hz), 7.18-7.02 (3H, m), 6.96 (2H, d, J = 7.2 Hz), 6.69 (2H, d, J = 7.2 Hz), 6.23 (2H, s), 3.86 (2H, s). FABMS (m / z): 523 ([M + H] +). FABHRMS (m / z): calcd. For C25H17F6N204 ([M + H] +): 523.1093; found: 523.1086. -461- 200401770 (Example 165) 2-benzyl- 5,6-methylenedioxy-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H)- Quinazolinone (Exemplified Compound No. 8-1186)

In a similar manner as described in Example 1, 5,6-methylenedioxy o-aminobenzoic acid (2 15 mg, 1.20 mmol), phenylacetic acid (173 mg, 1.30 mmol) prepared from Example 164 (1) above ), Triphenyl phosphate (0.35 ml, 1.30 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (313 11 ^, 1.3〇111111 〇1) The title compound was obtained as a colorless solid (231 mg, yield: 37%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 191-193 ° C. IR (KBr): ^ max 3 27 2, 1 686, 1 472, 1 269, 1210, 1 05 9,724 cm · 1. iH-NMR (400MHz, CDC13): δ 7 · 7 1 (2 H, d, J = 8 · 0 H z), 7 · 4 8 (1H, s), 7.3 6-7.2 2 (3H, m), 7.17-7.06 (3H, m), 6.90 (1H, d , J = 8.0 Hz), 6.74 (2H, d, J = 8.0 Hz), 6.16 (2H, s), 3.88 (1H, d, J = 14.4 Hz), 3.74 (1H, d, J = 14.4 Hz). FABMS (m / z): 5 2 3 ([M + H] +). FABHRMS (m / z): calcd. for C25H17F6N204 ([M + H] +): 523.1093; found : 5 2 3.1 096. -462- 200401770 (Example 166) 2-benzyl-5,7-dichloro-6-methoxy-3- [4- [252,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-23 04)

(1) A method similar to that described in Example 55 (1) to (3) above. 4,6-Dichloro-5-methoxy-o-aminobenzoic acid was obtained from 3,5-dichloro-4-φoxyaniline. . (2) Using a method similar to that described in Example 1, from 4,6-dichloro-5 -methoxy-o-aminobenzoic acid (48 mg, 0.20 mmol), phenylacetic acid (27 mg, 0.20 mmol), and triphosphate Phenyl ester (52 mg, 0.20 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (42 mg, 0.16 mmol) to obtain the title compound Colorless solid (12 mg, 13% yield). mp 219-220 ° C. IR (KBr): v max 3 3 5 2, 1, 675, 1 5 83, 1462, 1 267, 989, 933, 708 'H-NMR (400MHz, CDC13): δ 7.80 (1H s)? 7.71 (2H5 d5 J = 8.8 Hz), 7.19-7.08 (3H, m), 6.98 (2H, d, J = 8 · 8 Hz), 6.70 (2H, d5 J = 7.2 Hz ), 3.96 (3H, s) 3.84 (2H, s), 3.79 (1H, s), FABMS (m / z): 5 7 8 ([M + H] +). -463- 200401770 ( Example 167) 2-benzyl-5,7-dichloro-6-methoxy-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl)- Ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 8-2 3 02)

In a similar manner as described in Example 1, 4,6-dichloro-5-methoxy-o-aminobenzoic acid (48 mg, 0.20 mmol) and phenylacetic acid (27 mg, 0 · 20 mmol), triphenyl phosphate (52 mg, 0,20 mmol) and 2 · (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-.2-propane Alcohol (42 1 1, 0.16 111 111 0) to obtain the title compound as a colorless solid (21 mg, yield: 22%). mp 217-218 ° C. IR (KBr): y max 3 3 93, 1681, 1581, 1 463, 1 26 8, 1214, 971, 724

! H-NMR (400MHz? CDC13?): (5 7 · 7 9 (1 H, S), 7 · 7 6 (1 H, d, J = 8.0 Hz), 7.45 (1H, s), 7.41 (1H , T, J = 8.0 Hz), 7.19-7.12 (3H, m), 6.97 (1H, d, J = 8.8 Hz), 6.78 (2H, d, J = 6.4 Hz), 3.96 ( 3H, s), 3.89-3.75 (2H, m), 3.67 (1H, s). FABMS (m / z): 5 78 ([M + H] +). (Example 168) 2-benzyl · 5 · Bromo-6-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -464- 200401770 ethyl] phenyl] -4 (3 Η) -Quinazolinone (Exemplified compound number 3_2 3 05)

(1) In a manner similar to that described in Example 55 (1) to (3) above, 3-bromo-5-chloroanthranilic acid was obtained from 3-bromo-4-chloroaniline. (2) In a similar manner as described in Example 1, 6-bromo-5-chloroanthranilic acid (550 mg, 2.20 mmol) and phenylacetic acid (300 mg, 2 · 20 mmol), triphenyl phosphate (0.58 ml, 2.20 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (518 111§, 2.00111101) The title compound was obtained as a colorless solid (570 mg, yield: 48%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 191-192 ° C. IR (KBr): V max 3 394, 1 693, 1581, 1 444, 1 269, 1216, 1 106, 931 W-NMR (400MHz, CDC13): δ 7 · 86 (1H, d, J = 8.0 Hz), 7.71 (3H, d, J = 8.8 Hz), 7.18-7.09 (3H, m), 6.99 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 6.8 Hz), 3.96 (1H, s), 3.87 (2H, s). FABMS (m / z): 5 9 1, 5 9 3 ([M + H] +). FABHRMS (m / z) : calcd. for C24H 1 5 7 9 Br35ClF6N202 ([M + H] +): 5 9 0.99 1 0; found: 590.9898. Anal. calcd. for -465- 200401770 C24H14BrClF6N2 02: C5 4 8.7 2; H? 2.38; N? 4.73; found: C? 48.73; H, 2.61; N5 4.41. (Example 169) 2-benzyl-5-mo-6-chloro- 3- [3- [2,2,2-trigas- 1-Ethyl-1- (dipermethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 8-23 03)

In a similar manner as described in Example 1, 6-bromo-5-chloroanthranilic acid (269 mg, 1.08 mmol), phenylacetic acid (147 mg, 1.08 mmol) prepared from the above Example 168 (1) Triphenyl phosphate (0.28 ml, 1.10 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (25 9 11 ^ (1.001111111)) to obtain the title compound as a colorless solid (341 mg, yield 58%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 2180C. IR (KBr): v max 3 3 92, 1 672, 1 5 80, 1 443, 1 276, 1 168, 1 087, 969 H-NMR (400MHz, CDC13): δ 7.85 (1H, d5 J = 8.4 Hz), 7.73 (1H, d, J = 8.8 Hz), 7.70 (1H, d, J = 8.4 Hz), 7.47 (1H, s), 7.41 (1H, t, J = 8.0 Hz), 7.19 -7.15 (3H, m), 6.96 (1H, dd, J = 8.0, 2.0 Hz), 6.78 (2H, d, J = 6.8 Hz), 3.94 (1H, s), 3.90 (1H , D, J = 14.8 Hz), 3.79 (1H, d5 J = 14.8 Hz) · -466- 200401770 FABMS (m / z): 591, 5 93 ([M + H] +) · FABHRMS (m / z): calcd. for C 2 4 H, 5 7 9 B r3 5 C1 F 6N2 〇9 ([M + HJ4-]: 5 90.99 1 0; found: 590.990 1. Anal. calcd. for C24H14BrClF6N202: C, 48.72 ; H, 2.38; N, 4.73; found: C, 49.04; H? 2.40; N3 4.63. (Example 170) 2-benzyl-6,7-monobasic group-3- [4- [2,2,2 -Trifluoro-1-meryl_i_ (trifluoromethyl) ethyl] phenyl] -4 (3 fluorene) -quinazolinone (Exemplified compound No. 3-2306)

In a similar manner to the above Example 59, the 2-benzyl-6,7-dimethoxy_3- [4- [2,2,2-trifluoro-1-hydroxy (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (1.00 g, to give the title compound as a colorless foam (885 mg, yield: 94%). Mp 171-1730C. IR (KBr): U max 3248, 1 664, 1 622, 1511, 1271, 1 1 95, 9 3 3 cm.1 · iH-NMR (400MHz, DMS0-d6): δ 10.29 (1H, s), 9 · 84 (1H, s), 8.88 (1H, s), 7.65 (2H, d, Bu 8.8 Hz), 7.37 (1H, s), 7.22 (2H, d, J = 8.8 HZ ), 7.15-7 · 07 (3H, m), 7.01 (1H, s), 6.70 (2H, d, J = 7.2 Hz), 3.78 (2H, s) · -467- 200401770 FABMS (m / z): 511 ([M + H] +) FABHRMS (m / z): calcd. for C24H17F6N2 04 ([M + H] +): 5 1 1.1 0 9 2; found: 5 1 1.1 0 8 6. (Example 171) 2-benzyl-7-bromo-6-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3 H) -quinazolinone (Exemplified compound number 3 -23 07)

(1) 4-Bromo-5-chloroanthranilic acid was obtained from 3-bromochloroaniline in a similar manner as in Example 55 (1) to (3) above. (2) In a similar manner as described in Example 1, 4-bromo-5-chloroanthranilic acid (173 mg, 0.692 mmol) and phenylacetic acid (94 mg, 0.692) prepared from Example 17 1 (1) above. mmol), triphenyl phosphate (0.18 ml, 0.692 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (163 11 ^, 0.629 111111〇1) to obtain the title compound as a colorless solid (293 mg, yield: 79%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 206-207 ° C. IR (KBr): u max 3 340, 1 65 9, 1 5 8 9, 1444, 1 270, 1216, 1 107, 968 cm-1.! H-NMR (400MHz, CDC13) : δ 8 · 30 (1H, s), 8.13 (1H, s) 5 7.72 -468- 200401770 (2H, d, J = 8.8 Hz), 7.13-7.09 (3H, m), 6.99 (2H, d , J = 8 · 8 Hz), 6.69 (2Η5 d, J = 7.2 Hz), 3,94 (1H, s), 3.88 (2H, s). FABMS (m / z): 591, 5 93 ( [M + H] +). FABHRMS (m / z): calcd. For C 2 4 H j 5 7 9 B r3 5 C1 F 6 N 2 O 2 ([M + H] +): 5 9 0.99 1 0 ; found: 590.9894. Anal. calcd. for C24H14BrClF6N2 02: C5 4 8.72; H 5 2.3 8; N, 4.73; found: C? 48.8 8; H5 2.3 6; N? 4.73. (Example 172) 2-benzyl -7-bromo-6-chloro-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3HVquinazolinone (Exemplified Compound Nos. 8-23 (Μ)

In a similar manner as described in Example 1, 4-mo-5-chloroanthranilic acid (116 mg, 0.464 mmol), phenylacetic acid (63 mg, 0.464 mmol), Acid triphenyl ester (0.2 ml, 0.464 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (109 11 ^, 0.422 111111〇1) The title compound was obtained as a colorless solid (195 mg, yield: 78%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 194-195 ° C. IR (KBr): V max 3 342, 1 686, 1581, 1444, 1 267, 1 206, 1157, 970 cm · 1. -469- 200401770 'H-NMR (400MHz5 CDC13): (5 8 · 2 8 (1 H, s), 8 · 1 1 (1 H, s), 7.77 (1H, d, J = 8.4 Hz), 7.45 (1H, s), 7.43 (1H, t, J = 8.0 Hz), 7.18-7.14 (3H, m), 6.98 (1H, dd, J = 8.0, 1.6 Hz), 6.77 (2H, d, J = 6.8 Hz), 4.15 ( 1H, s), 3.92 (1H, d, J = 14 · 8 Hz), 3.82 (1H, d, J = 14.8 Hz). FABMS (m / z): 591, 5 93 ([M + H] +) · FABHRMS (m / z): calcd · for C24H 丨 5 7 9 Br35ClF6N202 ([M + H] +): 5 9 0.99 1 0; found: 5 90.99 1 1. Anal. Calcd. For C24H14BrClF6N202: C? 48.72; H 5 2.3 8; N5 4.7 3; found: C? 48.74; H? 2.30; N, 4.75. (Example 173) 2-benzyl-7-fluoro-6-methoxy- 3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified compound number 3-23 08 )

(1) In a similar manner to that described in Example 55 (1) to (3) above, 4-fluoro-5-methoxy-o-aminobenzoic acid was obtained from 3-fluoro-4-methoxyaniline. (2) In a similar manner as described in Example 1, ^ fluoro-5-methoxy-o-aminobenzoic acid (120 mg, 0.648 mmol), phenylacetic acid (8 9 -470- 200401770 mg, 0.650 mmol), triphenyl phosphate (0.17 ml, 0.650 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro- 2-propanol (153 11 ^, 0.5 92 111111〇1) to obtain the title compound as a colorless solid (104 mg, yield: 34%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless oblique Square crystal. mp 236 ° C.

iH-NMR (400MHz, DMSO-d6): δ 8.92 (1H, s) 7.69-7.62 (4H, m), 7.30 (2H, d, J = 8.1 Hz), 7.16-7.08 (3H, m ), 6.73 (2H, d, J = 7.3 Hz), 3.96 (3H, s), 3.82 (2H, s) · FABMS (m / z): 527 ([M + H] +) · (Example 174 ) 2-benzyl-5-bromo-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -1 2 3 4 ( 3 H) -quinazolinone (Exemplified Compound No. 8-1 94)

-471-1 In a manner similar to that described in Example 55 (1) to (3) above, 6-bromo-o-aminobenzoic acid was obtained from 3-bromoaniline. 2 In a similar manner as described in Example 1, 6- 3 bromo-o-aminobenzoic acid (574 mg, 2.66 mmol), phenylacetic acid (362 mg, 2.66 4 mmol), and triphosphate were prepared from Example 174 (1) above. Phenyl ester (0.70 ml, 2.67 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (626 11 ^, 2.42 111111. 1) The title compound 200401770 was obtained as a colorless solid (492 mg, yield: 37%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless powder. IR (KBr): v max 303 2, 1 687, 1 5 86, 1 2 69, 1212, 969 cnT1. 'H-NMR (400MHz? CDC13): δ 7.77-7.74 (3H5 m) 5 7.5 8 (1 H , t5 J = 8.1 Hz), 7.45 (1H, s), 7.40 (1H, t, J = 8.1 Hz), 7.19-7.12 (3H, m), 6.98 (1H, d, J = 8 · 1 Hz), 6.79 (2H, d, J = 8.1 Hz), 3.93 -3.7 9 (2H5 m). FABMS (m / z): 5 95 ([M + K] 4), 5 5 7 ([ M + H] +) (Example 175) 2-benzyl-7-bromo-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3 H) -quinazolinone (Exemplified Compound No. 3-628)

(1) In a manner similar to that described in Examples 5 5 (1) to (3) above, 4-bromo-o-aminobenzoic acid was obtained from 3-bromoaniline. (2) In a similar manner as described in Example 1, 4-bromo-o-aminobenzoic acid (404 mg, 1.87 mmol), phenylacetic acid (255 mg, 1.87 mmol), Triphenyl diacetate (0.49 ml, 1.87 mmol) and 2- (4-aminophenyl) · 1,1,1,3,3,3-hexafluoro-2-propanol (4411 ^, 1.7〇111111 〇1) The title compound was obtained as a colorless solid (521 mg, yield: 55%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate-472-200401770 to give a colorless powder. mp 2 2 0 0 C. IR (KBr ”vmax 3 03 2, 1 65 7, 1 5 89, 1 270, 1215, 1181, 969 cm · 1 · ^ -NMR (400MHz? DMSO-d6): δ 8.9 3 (1H? S)? 8.01 (1H? D5 J = 8.1 Hz), 7.97 (1H, d, J = 2.2 Hz), 7.74 (1H, d, J = 8.4 Hz), 7.69 (2H, d , J = 8.8 Hz), 7.32 (2H, d, J = 8 · 8 Hz), 7.18-7.09 (3H, m) 5 6 · 76 (2H, d, J = 7.3 Hz), 3.84 ( 2Η, s) · FABMS (m / z): 595 ([M + K] +), 5 5 7 ([M + H] +) · (Example 176) 6,7-dimethoxy-2- ( 3-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazole Porphyrinone (Exemplified Compound No. 3-1164)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (1.50 g, 7.60 mmol), 3-fluorophenylacetic acid (1.47 g, 9.54 mmol) and 2- (4-amine Phenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (2.35 g, 9.07 mmol) to obtain the title compound as a colorless solid (1.44 g, yield: 34%). mp 25 5 -25 7 ° C. IR (KBr): umax 3 08 7, 1 65 0, 1613, 1501, 1 396, 1271, 1 208, 937 -473- 200401770 cm.iH-NMR (400MHz, CDC13) : δ 7.69 (2H, d, J = 8.8 Hz), 7.64 (1H, s), 7.22 (1H, s), 7.06-7.01 (1 H, m), 6 · 9 3 (2 H, d, J = 8 · 8 Hz), 6.8 7-6.8 3 (1 H, m), 6.53 (1H, d, J = 10.3 Hz), 6.39 (1H, d, J = 8.1 Hz), 5.56 ( 1H, s), 4 · 07 (3H, s)? 4.02 (3H, s), 3.86 (2H, s) · FABMS (m / z): 5 5 7 ([M + H] +). Anal, calcd . for C 2 6 H 19 F 7 N 2 O 4: C5 56.12; H? 3.44; N, 5.03; found: C5 56.05; H, 3.29; N5 4.93. (Example 177) 6,7-dimethoxy- 2- [4- (trifluoromethyl) benzyl] -3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl]- 4 (3H) -quinazolinone (Exemplified Compound No. 8-1167)

In a similar manner as described in Example 1, from 4,5-dimethoxyanthranilic acid (0.76 g, 3.85 mmol), 4- (trifluoromethyl) phenylacetic acid (0.83 g, 4.07 111111〇1) And 2- (3-aminophenyl) -1,1,153,3,3-hexafluoro-2-propanol (1.00§, 3.86 mmol) to obtain the title compound as a colorless solid (0.89 g, yield: 39 0 / 〇) ° mp 2 2 0-22 3 ° C. -474- 200401770 IR (KBr): y max 3 0 8 1,1 676, 1613, 1 502, 1 396, 1 3 27, 1 209,937 iH-NMR (400MHz, CDC13): (5 7 · 75 (1H, d, J = 8.1 Hz), 7.57 (1H, s) 5 7 · 46 (1H, s), 7.43-7.3 8 (3 H, m ) 5 7.19 (1H, s), 7.0 1 (1H, d, J = 8.1 Hz), 6.91 (2H, d, J = 8.1 Hz), 4.99 (1H, s), 4.05 (3H , S), 3.98 (3H, s), 3.97 (1H, d, J = 15.4 Hz), 3.89 (1H, d5 J = 15.4 Hz). FABMS (m / z): 607 ([M + H] +) · (Example 178) 6,7-Monomethoxy-2- (3-Gabenzyl) -3- [3 · [2,2,2 -Dichloro_-1-meryl-1- (Trifluoromethyl) ethyl] phenyl] -4 (3Η) -thiazolinone (Exemplified compound number 8-1164)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (0.76 g, 3.85 mmol), 3-fluorophenylacetic acid (0.83 g, 5.38 mmol) and 2- (3 -Amine base) -1,1,1,3,3,3-hexachloro-2-propanol (1.08, 3.86 111111〇1) to obtain the title compound as a colorless solid (1.00 g, Yield: 47.7%). mp 213-214 ° C. IR (KBr): V max 3 0 8 3, 1 676, 1613, 1 502, 1 3 97, 1 269, 1 209, 969 -475 · 200401770 iH-NMR (400MHz, CDC13) : δ 7.76 (1H, d, J = 8.8 Hz), 7.59 (1H, s), 7.49 (1H, s), 7.41 (1H, t, J = 8.1 Hz), 7.20 ( 1H, s), 7.12-7.06 (1H, m), 7.01 · 6 · 99 (1H, m), 6.8 8 -6.83 (1 H, m), 6.56-6.5 3 (2H, m), 4 · 22 (1H, s), 4.006 (3H, s) 5 3.98 (3H, s), 3.91 (1H, d, J = 14.7 Hz), 3.80 (1H, d, J = 14.7 Hz). FABMS (m / z): 5 5 7 ([M + H] +). (Example 179) 2-benzyl-6-isopropoxy- 3- [4- [2,2,2-trifluoro- 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified compound number 3-23 09)

Add 2-iodopropane (178 mg, 1.05 mmol) to the 2-benzyl-6-hydroxy-3- 3- [4- [2,2,2-trifluoro-1-hydroxy- Suspension of a mixture of 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (494 mg, 1.00 mmol) and potassium carbonate (27 8 mg, 2.00 mmol) in DMF (1 ml) The resulting mixture was stirred at room temperature for 12 hours, after which the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. And removing the solvent in vacuum, the obtained residue was purified by silica gel column chromatography (using a mixture of hexane and ethyl-476-200401770 ethyl acetate as a eluent in a volume of 3 ·· 1), and The title compound was obtained as a colorless solid (75 mg, yield: 14%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless needles. mp 1 8 3 ° C. IR (KBr): vmax 3250,1664,1592,1488,1371,1270,1215,1110, 974 cm · 1 · 1H-NMR (400MHz, CDC13): 5 7 · 74 (1H, d, J = 8.8 Hz), 7.68 (2H, d, J = 8.8 Hz), 7.64 (1H, d, J = 2.8 Hz), 7.40 (1H, dd, J = 8.8, 2.8 Hz ), 7.14-7.06 (3H, m), 6.94 (2H, d, J = 8.0 Hz), 6.69 (2H, d5 J = 7.6 Hz), 4.71 (1H5 quint ·, J = 6.0 Hz), 4.46 ( 1H, s), 3.89 (2H, s), 1.40 (3H, s), 1.39 (3H, s). FABMS (m / z): 5 3 7 ([M + H] ten) · FABHRMS (m / z): calcd. for C27H22F6N203 ([M + Na] +): 559.1433; found: 559.1445.

Anal, calcd. For C27H22F6N203: C, 60.45; H, 4.13; N, 5.22; found: C? 60.32; H, 3.86; N, 5.20. (Example 180) 6,7-dimethoxy-2- (3,4-methylenedioxybenzyl) -3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _4 ( 3 H) · quinazolinone (Exemplified Compound No. 8-1180) -477- 200401770

In a similar manner as described in Example 1, 4,5-dimethoxy-o-aminobenzoic acid (76 1 mg, 3.86 mmol), 3,4-methylenedioxyphenylacetic acid (73 mg, 40%) 5 mmol) and 2- (3-aminophenyl ^, ^, hexafluoro-m-propanol (100 g, 3.86 mmol) to obtain the title compound as a colorless solid (99 mg, yield: 45%) ° mp 2 1 7-2 1 9 ° C. IR (KBr): P max 3084, 1 662, 1613, 1501, 1 3 9 7, 1 340, 1 207, 1039 cm · 1 · 'H-NMR (400MHz CDC135): δ 7 · 7 6 (1 H, d, J = 8 · 1 H z), 7.58 (1H, s), 7.48 (1H, s), 7.44 (1H, t, J = 8.1 Hz), 7.20 (1H, s), 7.05-7.02 (1H, m), 6.54 (1H, d, J = 8.1 Hz), 6.37-6.36 (1H, m) 5 6.12-6.10 (1H, m) 5 5.8 8 (2 H, s), 4.29 (1H, s), 4.05 (3H, s), 3.98 (3H, s), 3.82 (1H, d, J = 15.4 Hz), 3.72 (1H, d, J = 1 5.4 Hz). FABMS (m / z): 5 8 3 ([M + H] +).

Anal, calcd. For C27H20F6N2O6: C, 5 5.68; H, 3.46; F, 19.5 7; N, 4.81; found: C? 5 5.45; H? 3.36; F? 19.46; N? 4.57. (Example 181) 6, 7-dimethoxy-2- [4- (trifluoromethyl) benzyl] -3- [4- [2,2,2-trifluoro-Bu-478- 200401770 hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 3 -1 1 6 7)

In a similar manner to that described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (2.00 g, 10.1 mm), 4- (trifluoromethyl) phenylacetic acid (2.6 g, 12.7 mmol) And 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (3.00§, 11.6 mmol) to obtain the title compound as a colorless solid (2.20 g, product rate:). mp 22 8 ° C. IR (KBr): max 3 23 8, 1, 65 7, 1612, 1 5 0 1, 1 3 9 6, 1 3 27, 1213, 933 iH-NMR (400MHz, CDC13): δ 7.69 (2H, d, J = 8.8 Hz), 7.62 (1H, s), 7.36 (2H, d, J = 8.8 Hz), 7.21 (1H, s), 6.95 (1H, d, J = 8.8 Hz) , 6.85 (2H, d, J = 8.8 Hz), 5.09 (1H, s), 4.0 7 (3H, s), 4.02 (3H, s), 3.94 (2H, s), FABMS (m / z) : 607 ([M + H] +) · Anal · calcd. For C27H19F9N204: C, 53.48; H, 3.16; F, 28.19; N, 4.62; found: C, 53.24; H, 3.17; F3 28.08; N5 4.60. (Example 182) -479- 200401770 6,7-dimethoxy-2- (4-methoxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (oxazolinone (exemplified compound No. 3-1169)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (1.50 g, 7.61 mmol), 4-methoxyphenylacetic acid (1.50 g, 9.03 mmol), and 2- (4 -Aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2.30§, 8.88 mmol) to obtain the title compound as a colorless solid (i. 25 g, yield: 29%) . mp 210 ° C. IR (KBr): vmax 3249,16 5 951613? 15015139751270512135 934 cm'1. j-NMR (400MHz, CDC13): 5 7 · 6 7 (2 H, d, J = 8 · 4 Hz) , 7 · 6 3 (1H, s), 7.23 (1H, s), 6.91 (2H, d, J = 8.4 Hz), 6.62 (2H, d, J = 8.1 Hz), 6.57 (1H, d, J = 8.1 Hz), 5.43 (1H, s), 4.06 (3H, s) 5 4.01 (3H, s), 3.82 (2H, s), 3.73 (3H, s) . FABMS (m / z): 569 ([M + H] +).

Anal · calcd. For C27H22F6N205: C, 57 · 05; H, 3.90; N, 4.93; found: C, 56.84; H, 3.69; N, 4.84. (Example 183) -480- 200401770 6,7-two Methoxy-2- (3,4-methylenedioxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3-1180) p

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (1.50 g, 7.61 mmol), 3,4-methylenedioxyphenylacetic acid (1.70 g, 9.43 mmol) ) And 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (2.30 g, 8.88 mmol) to obtain the title compound as a colorless solid (2.00 g, product Rate: 45 mp 2 11 ° C. IR (KBr): max 3 25 3,1 65 3,1 6 1 1,1 5 02,1 3 9 8,1 34 1,1 2 1 3, 1039

'H-NMR (400MHz, CDC13): δ 7 · 7 2 (2 H, d, J = 8 · 8 H z), 7 · 6 2 (1H, s) 5 7.2 2 (1 H, s), 6 · 99 (2H, d, J = 8.8 Hz), 6.50 (1H, d, J = 8.1 Hz), 6.34 (1H, d, J = 1 · 5 Hz), 5 · 9 9 (1 H, dd , J = 1,5 Hz and 8.1 Hz), 5.89 (2H, s), 5.12 (1H, s), 4.06 (3H, s), 4.01 (3H, s), 3.78 (2H, s) FABMS (m / z): 5 8 3 ([M + H] +). Anal, calcd. For C 2 7 H 5 〇F 6N 2 O 6: C, 55.68; H5 3.46; F, 19.57; N5 4.81 ; found: C5 55.61; H, 3.44; -481- 200401770 F, 19.76; N? 4.44. (Example 184) 2-benzyl-7-bromo-3- 3- [3- [2,2,2-trifluoro 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplary Compound No. 8-628)

In a similar manner as described in Example 1, 4-bromo-o-aminobenzoic acid (3.88 mg, 1.80 mmol), phenylacetic acid (245 mg5 1,80 mmol), Triphenyl phosphate (0.47 ml, 1.80 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (423 11 ^ (1.63 111111〇1) to obtain the title compound as a colorless solid (5 74 mg, yield: 63%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless powder. mp 18 8 ° C. IR (KBr): 2 ^ max 3 03 3, 1 682, 1 5 84, 1 269, 1212, 1 1 8 3,969 cm · 1. W-NMR (400MHz, DMSO-d6): δ 8.89 (1H, s), 8.03 (1H, d, J = 8.8 Ηζ), 7.93 (1Η, s), 7.77-7.72 (3Η, m), 7.52 (1Η, t , J = 8.1 Hz), 7.26 (1H, d, J = 7.3 · 3ζ), 7.16-7.15 (3H, m), 6.84-6.83 (2H, m), 3.82 (2H, m). FABMS (m / z): 5 95 ([M + K] +), 5 5 7 ([M + H] +) · (Example 185) 6,7 -dimethoxy-2- (4 -Methoxybenzyl) · 3- [3- [2,2,2-trifluoro-1-hydroxy-482- 200401770 -1- (trifluoromethyl) ethyl] phenyl] _4 (3 Η ) _Quinazolinone (Exemplified Compound No. 8-1169)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (700 mg 5 3.5 5 mmol), 4-methoxyphenylacetic acid (619 mg, 3.73 mmol), triphenyl phosphate Ester (1.02 ml, 3.89 mmol) and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (92〇11 ^, 3.55 1111 ] 101) The title compound was obtained as a colorless solid (574 mg, yield: 28%). mp 205-206 ° C. IR (KBr): v max 3 2 74, 1 67 8, 1613, 1501, 1 396, 1 268, 1 207, 969 'H-NMR (400MHz, CDC13): (5 7.74 ( lH, d, J = 8.1 Hz), 7.57 (1H, s), 7.46 (1H, s), 7.41 (1H, t, J = 8.1 Hz), 7.23 (1H, s), 6.98 (1H, d, J = 8. 1 H z), 6 · 6 7 (4 H, s), 4.5 6 (1 H, s), 4 · 0 5 (3 H, s), 3.98 (3H, s ), 3.87 (1H, d, J = 14.7 Hz), 3.76 (1H, d, J = 14.7 Hz), 3.74 (3H, s). FABMS (m / z): 5 69 ([M + H] +). (Example 186) 2-benzyl-6-hydroxy-7-methoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri-483 -200401770 fluoromethyl) -ethyl] phenyl] -4 (3 fluorene) -quinazolinone (Exemplified compound number 3_ 23 10)

(1) By a method similar to the above Example 1 12 (1), hydroxy-4 -methylamino-2-nitrobenzylbenzene was obtained from isovanillin. (2) Contains 5-hydroxy-4-methoxy-2-nitrobenzaldehyde (4 · 29 g, 21.8 mmol), tert-butyldimethylsilyltriamine, prepared in Example 186 (1) above. A dichloromethane (100 ml) solution of a mixture of fluoromethanesulfonate (7.49 ml, 32.6 mmol) and diisopropylethylamine (7.50 ml, 43.6 mmol) was stirred under ice-water cooling for 30 minutes. The reaction mixture was diluted with dichloromethane, and the resulting solution was successively washed with cold water and a saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous magnesium sulfate and the solvent was removed in vacuo. The obtained residue was subjected to silica gel. Purification by column chromatography (using a mixture of hexane and ethyl acetate in a volume of 1: 2 as the eluent) yields 5- (third butyldimethylsilyloxy) -4-methoxy-2- Colorless oil of nitrobenzaldehyde (3.32 g, yield: 49%). (3) 5- (Third-butyldimethylsilyloxy) -4-methoxy-2 prepared from Example 186 (2) by a method similar to Example 112 (2) and (3) above. -Nitrobenzaldehyde to obtain 5- (third butyldimethylsilyloxy) -4-methoxy-o-aminobenzoic acid 0 -484- 200401770 (4) In a similar manner to that described in Example 1, from the above example 5- (Third-butyldimethylsilyloxy) -4-methoxy-o-aminobenzoic acid (4 70 mg, 1.58 mmol), phenylacetic acid (235 mg, 1.73) prepared in 186 (2) mmol), triphenyl phosphate (0.45 ml, 1.73 mmol), and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (614 mg, 2.37 mmol) to obtain the title compound as a colorless solid (650 mg, yield: 78%). mp 22 1 -222 ° C. IR (KBr): ymax 3345,1658,1497,1271,121 1,709 cm · 1 · iH-NMR (400MHz5 DMSO-d6): δ 8.88 (1H? s)? 7.67 ( 2H? D? J = 8.8 Hz)? 7, 3 8 (1H, s), 7.26 (2H, d, J = 8.8 Hz), 7.18 (1H, s), 7.15-7.09 (3H. M) 5 6 · 73 (2H, d, J = 7.2 Hz), 3.94 (3H, s), 3.80 (2H, s). FABMS (m / z): 5 2 5 ([M + H] +) (Example 187) 2-benzyl-6-hydroxy-7-methoxy- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl [Phenyl] phenyl] · 4 (3 fluorene) -quinolinone (Exemplified compound number 8-23 05)

In a similar manner as described in Example 1, 5- (Third-butyldimethylsilyloxy) -4-methoxy-o-aminobenzoic acid (73 mg, 0.24 mmol) prepared from Example 186 (3) above , Phenylacetic acid (36 mg, 0.26 mmol), triphenyl phosphate (0.88-485-200401770 ml, 0.26 mmol) and 2- (3-aminophenyl) -1,1,1,3,3 , 3-hexafluoro-2-propanol (93 mg, 0.36 mmol) to obtain the title compound as a colorless solid (47 mg, yield: 37%). Mp 1 29-1 13 0 ° C. IR (KBr): ^ max 3 2 7 3, 1 665, 1 496, 1 269, 1 208, 969, 724 cm · 1 · iH-NMR (400MHz, CDC13): δ 7.71 (1H, d, J = 7.2 Hz), 7.60 (1H , S), 7.48 (1H, s), 7.35 (1H, t, J = 6.4 Hz), 7.19 (1H, s), 7.16-7.09 (3H, m), 6.93 (1H, d, J = 6.4 Hz), 6.76 (2H, d, J = 5.6 Hz), 4.03 (3H, s), 3.9 5 -3.7 9 (2H, m). FABMS (m / z): 525 ( [M + H] +). (Example 188) 2-benzyl-6-isopropoxy-7 · methoxy_3 · [4- [2,2,2_trifluoro-hydroxy-^- Trifluoromethyl) -ethyl] phenyl] -4 (3 Η) · Fuzolinone (Exemplified compound No. 3- 2311)

In a similar manner to the above-mentioned Example 17.9, the 2_benzyl-6-hydroxy_7-methoxy_3- [4- [2,2,2-trifluoro] prepared from the above Example 1 8 6 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (30 mg, 0.05 mm), potassium carbonate (16 mg, 0.12 mm 〇1) and 2-iodopropane (0057 ml, 006 mm 〇1) to obtain -486 * 200401770 colorless solid of the title compound (19 mg, yield: 59%). mp 235-236 ° C. IR (KBr): v max 3420, 1 689, 1 608, 1 496, 1 269, 1 206, 9 3 5,708 'H-NMR (400MHz, DMSO-d6): δ 8 91 (1H, s) 5 7 · 67 (2H, d, J = 8 · 8 Hz), 7.41 (1H, s), 7.28 (2H, d, J = 8 · 8 Hz), 7 · 23 (1H, s), 7.16-7.08 (3H, m), 6.73 (2H, d, J = 7.2 Hz), 4.70_4 · 66 (1H, m), 3.94 (3H, s), 3.81 (2H, s), 1.31 (6H, d, J = 5.6 Hz). FABMS (m / z): 567 ([M + H] +). (Example 189) 2-benzyl-6-iodine-3 -[4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl; 1-4 (3 H) -quinazolinone (Exemplified Compound No. 3- 2312)

In a similar manner as described in Example 1, '5-position o-aminobenzoic acid (ι0.5 g, 40.0 111111〇1), phenylacetic acid (5.70§, 42.〇111111〇1), triphenyl phosphate (12〇1111, 46.0 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (10.4 g, 40.0 mmol) Colorless solid of the title compound (183g, yield: 70%) 'This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. -487- 200401770 mp 1 5 3- 1 5 6 ° C. IR (KBr): u max 3 3 2 8, 1 67 8, 1591, 1 467, 1 270, 1215, 934, 709 cm " 1. 'H -NMR (500 MHz, CDC13): 5 8 · 5 9 (1 H, d, J = 2.0 H z), 8 · 0 9 (1H, dd, J = 8.5, 2.0 Hz), 7 · 70 (2H, d, J = 6.0 Hz), 7.54 (1H, d, J = 8.5Hz), 7.18-7.12 (lH, m), 7.12-7.05 (2H, m), 6.99-6.91 (2H, m), 6.68 (2H, d, J = 8.0 Hz), 3.89 (2H, s), FABMS (m / z): 605 ([M + H] +), (Example 190) 2-benzyl-6-ethyl Oxyoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound numbers 3-2313)

The 2-benzyl-6-hydroxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (1- Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (105 mg, 0.21 mmol), potassium carbonate (87 mg, 0.63 mmol), and iodoin (0.07 ml (0.21 mmol) to give the title compound as a colorless solid (30 mg5 yield: 27%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 198-199〇C.

-488- 200401770 IR (KB〇: vmax 3 20751 6 6 6, 1 492, 1 270, 93 8, 8 3 9, 708 cm · 1 ·) H-NMR (400MHz, DMSO-d6): δ 8.90 (1H , S) 5 7 · 7 Bu 7.66 (3H, m), 7.49-7 · 46 (2H, m), 7.29 (2H, d, J = 8.8 Hz), 7.15-7.07 (3H, m), 6.72 (2H, d, J = 6.8Hz), 4.17-4.11 (2H, m) 3.82 (2H, s). 1.37 (3H, t, J = 7.2 Hz) · FABMS (m / z): 5 2 3 ([ M + H] +). (Example 191) 2-benzyl-7-hydroxy-6-methoxy- 3- [4- [2,2,2 -trifluoro-hydroxyl-1- (trifluoro Methyl) -ethyl] phenyl] _4 (3H) _quinazolinone (Exemplified compound number 3-2314)

In a similar manner as described in Example 1, 4-hydroxy group prepared according to the method of the literature (Molina et al. [Molina, P. et al., Tetrahedron, 51, 5 6 1 7-563 0 (1 995)]) -5-methoxy-o-aminobenzoic acid (189 mg, 1.03 mmol), phenylacetic acid (141 mg, 1.03 mmol), triphenyl phosphate (0.27 ml, 1.03 mmol), and 2- (4-amino Phenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (244 11 ^, 0.942 mmol) to obtain the title compound as a colorless solid (20 mg, yield: 4%), this The product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. • 489- 200401770 mp 1 97- 1 99 ° C. IR (KBr): v max 3 03 1, 1 666, 1 5 95, 1 497, 1271, 969 cm · 1. IH-NMR (400MHz, CDC13): 5 7 · 6 6 (2 H, d, J = 8 · 8 H z), 7 · 40 (1Η, s), 7.24 (2H, d, J = 8.8 Hz), 7.15-7.07 (3H, m), 7.04 (1H, s), 6.70 (2H, d, J = 7.3 Hz), 3.87 (3H, s), 3.79 (2H, s), FABMS (m / z): 5 6 3 ([M + K] +), 5 25 ([M + H] +) · (Example 192) 2-benzyl-6-cyano-3- 3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenylb 4 (3 H) -quinazolinone (Exemplified compound number 3-2315)

The 2-benzyl-6-iodo-3- [4- [2,2,2-trifluoro_1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] prepared in the above Example 189 -4 (3H) -quinazolinone (6.04 g, 10 mmol), zinc cyanide (2.35 g, 20 mmol) and tetrakis (triphenylphosphine) palladium (0) (578 mg, 0.5 mmol) Placed in a dry two-necked flask under nitrogen pressure, add N, N_dimethyl-formamidine (25 ml) and stir the mixture at 120 ° C for 2 hours. After this time, add sodium bicarbonate Into the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was washed with water and a saturated sodium chloride aqueous solution. The solution was passed through a rapid pad of anhydrous sodium sulfate and silica gel, and then concentrated in vacuo. The resulting residue was recrystallized from acetonitrile to give -490- 200401770 the title compound as a colorless solid (3.60 g, yield: 72%). mp228-230 ° C. IR (KBr): v max 3 3 8 1, 2 2 2 8 5 1 6 9 6, 1 5 8 7, 1 4 8 4, 1 2 7 0, 1 2 1 6, 93 3,709 cm · 1. UMR (500 MHz, CDC13): δ 8.58 (1H, s), 8.01 (1Η · dd, J = 8.0, 2.0 Hz), 7.88 (1H, d, J = 8 · 5 Hz), 7.74 (2H, d, J = 8.0 Hz), 7.18 (1H, t, J = 8.0 Hz), 7.11 (2H, t, J = 8.0 Hz), 6.99 (2H, d, J = 8.0 Hz), 6.70 (2H, d, J = 8.0 Hz), 4.07 (1H, s), 3.93 (1H, s), FABMS (m / z): 5 04 ([M + H ] +). FABHRMS (m / z): calcd · for C25H15F6N302 ([M + Na] +): 526.0967; found: 526.0980. (Example 193) 2-benzyl-6-ethoxy-7-methoxy -3- [4- [2,2,2-trifluoro-1-hydroxy-i- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound numbers 3- 2316)

In a similar manner to that described in Example 179 above, 2-benzyl-6-hydroxy-7-methoxy- 3- [4- [2,2,2-trifluoro-b-hydroxy- 1- (trifluoro200401770 methyl) ethyl] phenyl] -4 (3H) -quinazolinone (120 mg, 0.23 mmol), potassium carbonate (103 mg, 0.75 mmol), and iodoethane (0.020 ml, 0.25 mmol) to obtain the title compound as a colorless solid (62 mg, yield: 49%). mp 142-143 ° C. IR (KBr): vmax 1678,1592,1515,1491,1361,1215,1193,1100, 947,709 cm · 1 · ^ -NMR (400MHz, DMSO-d6): 5 8 · 8 9 (1 H, s), 7 · 6 7 (2 H, d, J = 6.0 Hz), 7 · 40 (1H, s), 7 · 28 (2H, d, J = 7.2 Hz), 7.22 (1H, s), 7.16-7.09 (3H, m), 6.74 (2H, d, J = 6.0 Hz), 4.12-4 · 10 (2H, m)? 3.95 (3H? S) 3.81 (2H5 s), 1.38 (3H5 t3 J = 5.6 Hz) FABMS (m / z): 5 3 3 ((M + H) +) (Example 194) 6,7-dimethoxy-2- (3 -Pyridylmethyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-bu (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone ( (Exemplified compound number 2-799)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (7 0 0 mg, 3.60 mmol), 3 · pyridylacetic acid hydrochloride (6 2 0 mg, 3 · 6 0 mmol), triphenyl phosphate (1.1 g, 3.60 mmol), and 2- (4-aminophenyl) -492- 200401770 1,1,1,3,3,3-hexafluoro-2-propanol ( 92.011, 3.60.111101)) to obtain a non-pure white powder of the title compound (4 90 mg, yield: 26%). mp 265-266 ° C (dec.). IR (KBr): vmax 3050,1685,1612,1499,1395,1268,1210,1177, 9 4 0 cm " 1. 'H-NMR (400MHz, DMSO-d6 ): δ 8.94 (1H5 s) 5 8.3 9 (1 H? dd5 J = 5 · 1, 1.5 Hz), 8.08 (1H, d, J = 2.2 Hz), 7.77 (2H, d, J = 8 · 1 Hz), 7.46 (2H, d, J = 8.8 Hz), 7.42 (1H, s), 7.3 5 -7.3 2 (1 H, m), 7.22-7.19 (1H, m), 7.12 ( 1H, s), 3.92 (3H, s), 3.87 (3H, s), 3.79 (2H, s). FABMS (m / z): 5 40 ([M + H] +) · (Example 195) 2-benzyl-5,6 · dihydroxy-3- [4- [2,2,2-trifluoro-1 · hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2317)

In a similar manner to Example 59 above, 2-benzyl-5,6-dimethoxy-3- [4 · [2,2,2-trifluoro-1-hydroxy-1] prepared from Example 53 above -(Trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (187 mg, 0.347 mmol) to obtain the title compound as a colorless foamy product (66 mg, yield · 37%) . -493- 200401770 IR (KBr): v… 3611, 1 662, 1 5 8 3, 1 497, 1 463, 1 2 70, 1216,932

^ -NMR (400MHz5 CDC13): (5 1 1. 2 5 (1 H, s), 7 · 7 3 (2 H, d, J = 8.8 Hz), 7.45 (1H, d, J = 8.8 Hz), 7.28 (1H, d, J = 8.8 Hz), 7.18-7.08 (3H, m), 7.02-6.99 (2H, m), 6.69 (2H, d, J = 8.8 Hz), 5. · 60 (1H, s), 3.89 (2H, s), 3.59 (1H, s), FABMS (m / z): 511 ([M + H] +) (Example 196) 6,7- — ^ Methoxy- 2- (4-nitrobenzyl) -3- [4- [2,2,2-dichloro-1-meryl-1- (trifluoromethyl) -ethyl] Phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2318)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (700 mg, 3.60 mmol), 4-nitrophenylacetic acid (640 mg, 3.60 mmol), triphenyl phosphate Ester (1.1 g, 3.60 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (920 mg, 3.60 mmol) gave the title compound Yellow powder (760 mg, yield: 37%). The product was recrystallized from a mixed solvent of ethanol and diethyl ether to give a light yellow powder. -494- 200401770 mp 260-262 ° C (dec.). IR (KB r): vmax 3263,1678,1611, 1524,1502,1348,1271, 1210, 9 3 4 cm ^ -NMR (400MHz, CDC13) : 5 7 · 9 9 (2 H, d, J = 8 · 8 H z), 7.7 4 (2H, d, J = 8.1 Hz), 7.61 (1H, s), 7.19 (1H, s), 7.02 (2H, d, J = 8.8 Hz), 6.94 (2H, d, J = 8.8 Hz), 4.91 (1H, s), 4.06 (3H, s), 4.01 (3H, s) 5 3.9 7 (2H, s) FABMS (m / z): 5 84 ([M + H] +). (Example 197) 6,7-dioxo-2- [4- (methyl Thio) benzyl] -3- [4- [2,2,2-trifluoro = 1_hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -_ oxazoline Ketone (Exemplified Compound No. 3-2319)

In a similar manner as described in Example 1, 4,5-dimethoxy-o-aminobenzoic acid (500 mg, 2.50 mmol), 4- (methylthio) phenylacetic acid (460 mg, 2.50 mmol) ), Triphenyl phosphate (790 mg, 2.50 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (66〇11 (2,5011111111)) to obtain a non-pure white powder of the title compound (350 mg, yield: 24%). -495- 200401770 mp 225-226 ° C. IR (KBr): v max 3 23 6,1661,1612,1501,1 396,1 270,1212,934! H-NMR (400MHz? CDC13): 5 7.7 0 (2 H, d, J = 8 · 1 Hz), 7 · 6 1 (1H, s), 7.21 (1H, s), 6.99 (2H, d, J = 2.9 Hz), 6.97 (2H , D, J = 2 · 9 Hz), 6.61 (2H, d, J = 8.1 Hz), 4.85 (1H, s), 4.06 (3H, s), 4.00 (3H, s), 3.83 ( 2H, s), 2.42 (3H5 s). FABMS (m / z): 5 8 5 ([M + H] +). (Example 198) 2- (4-aminobenzyl) -6,7- Monomethoxy-3- [4- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2 3 20)

In a similar manner to the above Example 137, the 6,7-dimethoxy-2- (4-nitrophenylmethyl) -3- [4- [2,2,2-trifluoro] prepared from the above Example 196 -1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (750 mg, 1.30 mmol) to give the title compound as a pale-powdered powder (200 mg, Yield: 28%). The product was recrystallized from a mixed solvent of methanol and diethyl ether to give a pale yellow powder. mp 24 1-244 ° C (dec.). -496- 200401770 IR (KBr): v 3 3 8 5,1 670,1 6 1 3,1 5 00,1 396,1 270,1 2 1 1, 93 6 'H-NMR (400MHz? DMSO-d6): δ 8.91 (1H? S)? 7.71 (2H? D? J = 8.8 Hz), 7.40 (1H, s), 7.27-7.23 (3 H, m), 6.30 (4H, s), 4.91 (2H, s), 3.95 (3H, s), 3.86 (3H, s), 3.60 (2H, s), FABMS (m / z) : 5 5 4 ([M + H] +). (Example 199) 2-benzyl-7-ethoxy-6-methoxy-3- [4- [2,2,2-trichloro- 1-Ethyl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 3- 2321)

In a similar manner to the above Example 179, 2-benzyl-7-hydroxy-6-methoxy- 3- [4- [2,2,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (89 mg, 0.17 mmol), potassium carbonate (25 mg, 0.18 mmol), and iodoethane (29 mg, 0.19 mmol) to obtain the title compound as a colorless solid (28 mg, yield: 30%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless powder. mp 25 0-25 2 ° C. 'H-NMR (400MHz? DMSO-d6): δ 8.91 (1H? s)? 7.67 (2H, d5 J = • 497- 200401770 8.1 Hz) 7.41 (1H , S) 5 7 · 27 (2H, d, J = 7.3 Ηζ), 7.20 (1H, s), 7.16-7.09 (3H, m), 6.73 (2H, d, J = 6.6 Hz), 4.22 (2H, q, J = 7.3 Hz), 3.87 (3H, s), 3.81 (2H, s), 1.41 (3H, t, J = 6.6 Hz) FABMS (m / z): 591 ([M + K] +), 5 5 3 ([M + H] +) · (Example 20 (3) 2-benzyl-7-isopropoxy-6-methoxy- 3- [4- [2, 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3 H) -quinazolinone (Exemplified compound number 3- 2 3 22)

In a similar manner to the above Example 179, 2-benzyl-7-hydroxy-6-methoxy-3- [4- [2,2,2-trifluoro- 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (174 mg, 0.33 mmo 1) 'Potassium carbonate (50 mg, 0.35 mmol) and 2-iodine Propane (68 mg, 0.40 mmol) gave the title compound as a colorless solid (99 mg, yield 53%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless powder. mp 242 ° C. IR (KBr): umax 3 03 2, 1 649, 1 496, 1 269, 1195, 964 cnT1 · W-NMR (400MHz, DMSO-d6) · δ 8.89 (1H, s), 7 · 66 (2H, d, J = 8.1 Hz), 7.41 (1H, s), 7.26 (2H, d, J = 8.8 Hz), 7.23 (1H, s), -498 · 200401770 7.17 -7.08 (3H, m), 6.72 (2H, d, J = 6.6 Hz), 4.92-4.86 (1 H, m), 3.85 (3H, s), 3.81 (2H, s), 1.35 (6H, d, J = 5.9 Hz) FABMS (m / z): 605 ([M + K] +) 5 5 6 7 ([M + H] +). (Example 201) 2-Benzyl -6,7-dimethoxy-3 · [2-chloro-4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 ( 3H) · quinazolinone (Exemplified compound Nos. 7-5 69)

(1) Phenylacetamidinyl chloride (48 · 3 ml, 3 6 5 mmol) was added at 0 ° C to a solution containing 4,5-dimethoxy-o-aminobenzoic acid (34.17 g, 173 mmol) and pyridine ( 50 ml) of dichloromethane (200 ml) solution, the resulting mixture was stirred at 0 ° C for 30 minutes and at room temperature for 4 hours, after which the reaction mixture was concentrated, and ethyl acetate and ice-water were added to The resulting residue, the mixture was extracted with ethyl acetate, and the organic layer was successively washed with a saturated aqueous sodium hydrogen carbonate solution, water and a saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The pale yellow solid was recrystallized from hexane and ethyl acetate to give 2-benzyl-6,7-dimethoxy-4 H-3,1-benzofluorenyl-4-one as a colorless powder (40.0 g, yield: 78%). lH-NMR (400MHz? CDC13): δ 7.49 (1Η? s) 5 7.4 9-7.2 6 (5 Η? m) 5 -499- 200401770 7.01 (1H, s), 3.99 (3H, s), 3 · 96 (5H, s) · (2) Will contain 2-benzyl-6,7-dimethoxy-4Η-3,1 prepared in the above Example 201 (1) -Ketone (477 mg, 1.60 mmol), triphenyl phosphate (0.42 ml, 1.60 mmol), 2- (4-amino-3-chlorophenyl) -1,1 prepared in Example 67 (1) above, A mixture of 1,3,3,3-hexafluoro-2-propanol (472 11 ^, 1.6010111111) and pyridine (4 ml) under nitrogen pressure at 100. 〇: stirred for 7 hours, after which the reaction mixture was concentrated in vacuo, and the obtained residue was purified by silica gel column chromatography (using a 4: 1 mixture of hexane and ethyl acetate as an eluent), The title compound was obtained as a colorless solid (391 mg, yield: 43%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless powder. mp 2 6 8 ° C. IR (KBr) jmax 1 6 5 0, 1612, 1 5 00, 1271, 1 208, 1194, 95 8 cm '' H-NMR (400MHz, DMSO-d6): δ 9.21 (1Η s) 5 7.72-7.70 (2Η? m), 7.63 (1Η, d, J = 8 · 8 Ηζ), 7.43 (1Η, s), 7.28 (1Η, s), 7.18 (1Η, t , J = 7 · 3 Ηζ), 7.10 (2Η, t5 J = 7.3 Ηζ), 6.72 (2Η, d, J = 7 · 3 Ηζ), 3.97 (3Η, s), 3.88 (3Η, s ), 3.80 (2Η, m) · FABMS (m / z): 611 ([Μ + Κ] +) 5 5 7 3 ([Μ + Η] +). FABHRMS (m / z): calcd. For C24H17F6N202 ([Μ + Η] +): 572.8833; found: 573.1031. (Example 202) 6-chloro-7-methoxy- 2-[(2-methyl-1,3-thiazol-4-yl) methyl Group] -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (exemplified compounds No. 3 -23 2 3) -500- 200401770

F

In a similar manner as described in Example 1, 5-chloro-4 -methoxy-o-aminobenzoic acid (217 mg, 1.13 mmol) prepared from Example 1 3 2 (1) above was prepared according to the method described in USP 3296250. (2-methyl-1,3-thiazol-4-yl) acetic acid (178 mg, 1.13 mmol), triphenyl phosphonate (0.31 ml, 1.18 mmol), and 2- (4-aminophenyl) -1 1,1,3,3,3-hexafluoro < -2-propanol (2511118, 0.97 111111〇1) to obtain the title compound as a colorless solid (4 3 2 mg, yield: 71%). Re-knot in a mixed solvent of alkane and ethyl acetate. Crystallize to produce colorless orthorhombic crystals 0 mp 234-236 ° C. IR (KBr): w max 3425, 1 68 5, 1 602, 1 482, 1444, 1372, 1 269, 1214, 1 174, 9 3 6 cm · 1. 'H-NMR (400MHz? CD C13 + DMSO-d 6): δ 8.19 (1H? S)? 8,08 (1H, s), 7. · 84 (2H, d5 J = 8.4 Hz), 7.24 (1H, s) 5 7 · 13 (2H, d, J = 8.4 Hz), 6.24 (1H, s), 4.04 (3H, s), 4.00 (2H, s), 2.60 (3H, s). FABMS (m / z): 5 64 ([M + H] +) (Example 20 3) 6-methoxy- 2-[(2-methyl -1,3-thiazol-4-yl) methyl] -3- [4- [2,2,2-trifluoro-501- 200401770-1-hydroxy-1- (tri Methyl) ethyl] phenyl] -4 (3 Η) - -quinazolinone (Exemplified Compound No. 3--2339)

F

In a similar manner as described in Example 1, 5-methoxy o-aminobenzoic acid (219 mg, 1.31 mmol), (2-methyl · 1,3 · thiazol-4-yl) acetic acid (216 xng, 1 · 38 mmol), triphenyl phosphate (0.38 ml, 1.44 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (3 05 11 ^, 1.18 111111〇1) to obtain the title compound as a colorless solid (528 mg, yield: 76%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 228-229 ° C. IR (KB r): vmax3348,1685,1662,1617,1595,1493,1275 cm1'H-NMR (400MHz? CDC13): < 5 7 · 7 4 (2 H, d , J = 8 · 4 H z), 7 · 1 1 (1H, d, J = 8.8 Hz), 7.64 (1H, d, J = 2 · 9 Hz), 7 · 40 (1H, dd, J = 2.9, 8.8 Hz), 7.11 (2H, d, J = 8.4 Hz), 6.38 (1H, s), 5.03 (1H, bs), 4.01 (2H, s), 3.92 (3H, s), 2.58 (3H, s) · FABMS (m / z): 5 3 0 ([M + H] +) · (Example 204) 2-benzyl-6,7-dimethoxy- 3- [2-methyl-4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (exemplified (Compound No.-502- 200401770 7-565)

In a similar manner to Example 201 (2) above, 2-benzyl-6,7-dimethoxy-4 H-3, l-benzopyrene-4 was prepared from Example 201 (1). -Ketone (872 mg, 2.93 mmol), triphenyl phosphate (0.77 mi, 2.94 mmol) and 2- (4-amino-3-methylphenyl) -1,1 prepared in Example 65 (1) above 1,3,3,3-hexafluoro-2-propanol (802 mg, 2.93 mmol) to obtain the title compound as a colorless solid (480 mg, yield: 30%). This product was obtained from hexane and ethyl acetate. Recrystallization in a mixed solvent produces a colorless powder. mp 279-2 84 ° C (dec.). IR (KBr): vmax 1 65 5,1 5 9 1,1 500,1 27 1,1 209,1 1 69,970 cm · 1. 'H-NMR (400MHz5 DMSO-d6): δ 8.89 (1H? S)? 7.62 (1H? D? J = 8.1 Hz), 7.49-7, 45 (2H, m), 7.43 (1H, s), 7.28 (1H, s) 5 7.19 (1H, t, J = 8.1 Hz), 7.10 (2H, t, J = 7.3 Hz), 6.66 (2H, d, J = 7.3 Hz), 3.97 (3H, s), 3 88 (3H, s), 3.78-3.73 (2H, m), 1.51 (3H, s). FABMS (m / z): 55 3 ([M + H] +). (Example 205) 2-Benzyl -6-methoxy- 3- [2-chloro-4- [2,2,2-trifluoro-1 · hydroxy-1 · (trifluoro-503- 200401770 methyl) -ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified Compound No. 7-5 63)

In a similar manner as described in Example 1, 5-methoxy-o-aminobenzoic acid (157 mg, 0.939 mmol), phenylacetic acid (128 mg, 0.940 mmol), and triphenyl phosphonate (0.25 ml, 0.95 mmol) were used. And 2- (4-amino-3-chlorophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (245 11 ^, 0.834) prepared in Example 67 (1) above. 111111〇1) The title compound was obtained as a colorless solid (168 mg, yield: 37%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give a colorless powder. ^ -NMR (400MHz, DMSO-d6): δ 9.19 (1Η? S)? 7.73 (1Η5 d? J = 8.8Hz), 7.72-7.68 (2H, m), 7.63 (lH, d, J = 8.8Hz) , 7.52-7.42 (2H, m), 7.15 (1H, t, J = 7.3 Hz), 7.07 (2H, t, J = 7.3 Hz), 6.68 (2H, d, J = 8 · 1 Hz), 3.87 (3H, s), 3.84-3 · 75 (2H, m). FABMS (m / z): 5 42 ([M + H] +). F ABHRMS (m / z ): calcd. for C24H17F6N202 ([M + H] +): 542.8573; found: 543.0896. (Example 206) 6,7-dimethoxy-2-[(6-methyl-3-pyridyl) methyl ] -3- [4- [2,2,2-trifluoro_1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Illustration- 504- 200401770 Article number 3-2 3 2 4)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (316 mg, 1.60 mmol), according to the literature (Sperber et al. [Sperber et al., J. Am. Chem. Soc ·, 6-methyl-3-pyridylacetic acid hydrochloride (330 mg, 1.76 mmol), triphenyl phosphonate (5 50 mg, 1.76 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (45 6 11 ^, 1.76 111111〇1) Light orange powder of the compound (133 mg, yield · 15%). mp 267-272 ° C (dec.). IR (KBr): umax 3429, 1681, 1612, 1 5 00, 1 3 9 5, 1 270, 1211, 939 cm'1. 'H-NMR (400MHz? DMSO -d6): δ 8.95 (1H? s)? 7.94 (1H? s)? 7.76 (2H5 d, J = 8.1 Hz), 7.45 (2H, d, J = 8.1 Hz), 7.39 ( 1H, s), 7.19 (1H, dd, J = 8.1, 2.2 Hz), 7.3 5 -7.3 2 (1 H, m), 7.10 (1H, s), 7.04 (1H, d, J = 7.3 Hz ), 3.90 (3H, s), 3.84 (3H, s), 3.71 (2H, s), 2.38 (3H, s). FABMS (m / z): 554 ([M + H] +). (Example 207 ) -505- 200401770 2-benzyl-6-methoxy- 3- [2-methyl-4- [2,2,2-trifluoro-1-hydroxy-1 · (trifluoromethyl) ethyl Phenyl] phenyl] -4 (3 fluorene) -quinazolinone (Exemplified compound number 7-5 5 9)

In a similar manner as described in Example 1, methoxy o-aminobenzoic acid (585 mg, 3.34 mmol), phenylacetic acid (455 mg, 3.34 mmol), and triphenyl phosphate (0.88 ml, 3.35 mmol) ) And 2- (4-amino-3-methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (822 11 ^ , 3.000111111〇1) to obtain the title compound as a colorless solid (394 mg, yield: 25%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 2 0 6 ° C. IR (KBr): v max 1 663, 1 592, 1 492, 1271, 121 1,971 cm · 1. iH-NMR (400MHz, DMSO-d6): δ 8 · 89 (1H , S) 5 7 · 76 (1H, d, J = 8.8 Hz), 7.63 (1H, d, J = 8.8 Hz), 7.53-7.46 (4H, m), 7.18 (1H, t, J = 7.3 Hz) , 7.09 (2H, t, J = 8.1 Hz), 6.65 (2H, d, J = 8.1 Hz), 3.88 (3H, s), 3.83 (2H, m), 1.50 (3H, s ). FABMS (m / z): 561 ([M + K] +) 5 5 2 3 ([M + H] +). FABHRMS (m / z): calcd. For C24H17F6N202 ([M + Hf]: 522.43 9 1; found: 5 2 3.1 454. (Example 208) 506- 200401770 2-benzyl-6-[(2,2-dimethylpropanyl) amino; 1-3- [4- [2 , 2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2 3 2 5)

Trimethylacetamido chloride (0.10 ml, 0.81 mmol) was added dropwise at 0 ° C to the 6-amino-2-benzyl-3- [3] prepared in Example 153 above with stirring. 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3H)-[I quinazolinone (400 mg, 0.81 mmol) And triethylamine (0.34 ml, 2.4 mmol) in dichloromethane (4 ml), and then the resulting reaction mixture was stirred at room temperature for 1 hour. After this time, the reaction mixture was poured into It was extracted with water and dichloromethane. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The obtained residue was subjected to silica gel column chromatography (using a 2: 1 mixture of hexane and ethyl acetate). Purified as an eluent) to give the title compound as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (375 mg, yield: 80%). mp 235-236 ° C. IR (KBr): v max 3316, 1 673, 1591, 1492, 1 270, 1 190, 934, 707 cm-1. 'H-NMR (400MHz5 CDC13): δ 8.43 ^ 8.40 ( 1H, m)? 7.99 (1H5 d? J = 2.0 Hz), 7.80 (1H, d, J = 9.6 Hz), 7.69 (2H, d, J = 8.8 Hz), -507 · 200401770 7 · 58 ( 1H, s), 7.16-7.07 (3H, m), 6.97 (2H, d, J = 8.0 Hz), 6.69 (2H, d, J = 7.6 Hz), 4.06 (1H, s) , 3.88 (2H, s), 1.36 (9H, s) · FABMS (m / z): 5 7 8 ([M + H] +). (Real luxury! J 209) 6,7-dimethoxy- 2-[(4-methyl-1,3-thiazol-2-yl) methyl] -3- [4- [2,2,2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl Phenyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2 3 2 6)

Containing (4-methyl-1,3) prepared according to the method described in the literature (Erlenmeyer et al · [Erlenmeyer et al ·, Helv. Chim · Acta ·, 31, 1 342-1 348 (1 948)]) -Thiazol-2-yl) acetic acid (141 mg, 0.90 mmol) and N, N'-carbonyldiimidazole (160 mg, 0.99 mmol) in acetonitrile (5 ml) was stirred at room temperature for 30 minutes, and then added 4, 5-Dimethoxy-o-aminobenzoic acid (195 mg, 0.9 9 mmol), and the resulting mixture was stirred for 1 hour. At the end of this time, the formed precipitate was filtered, and the obtained precipitate and phosphoric acid were filtered. Triphenyl ester (0.19 ml, 0.74 mmol) was dissolved in pyridine (2 ml), and the resulting mixture was at 1000. 〇 Stir for 2 hours, and at the end of this time, add 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2 5 9 1 ^, 1.0 〇111111〇1), and -508- 200401770, the resulting mixture was stirred for 3 hours, and then the reaction mixture was concentrated in vacuo, and the obtained residue was recrystallized from hexane and ethyl acetate to give the title compound. Colorless orthorhombic crystals (56 mg, yield: 11%). mp 282-284 ° C. IR (KBr): u max 1 679, 1612, 1 502, 1 3 96, 1 269, 1213, 1 175, 935 cm'1. 'H-NMR (400MHz, DMSO-d6) : δ 8.90? (1H? s) 5 7.71 (2H, d5 J = 8,4 Hz), 7.43 (1H, s) 5 7 · 38 (2H, d, J = 8.4), 7.21 (1H, s ), 7.07 (1H, s), 4.15 (2H, s), 3.95 (3H, s), 3.88 (3H, s), 2.24 (3H, s), FABMS (m / z ): 560 ([M + H] +). (Example 210) 6-chloro-7-methoxy- 2-[(4 · methyl-1,3-thiazol-2-yl) methyl] -3 -[4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl; h4 (3 Η) -quinazolinone (Exemplified compound number 3-23 27 )

F

In a similar manner as in Example 209 above, (4-methyl-1,3-thiazol-2-yl) acetic acid (153 mg 5 0.7 9 mmol), N, N'-carbonyldiimidazole (141 mg, 0.87 mmol), 5-Chloro-4-methoxyanthranilide 509-200401770 (141 mg, 0.87 mmol), triphenyl phosphonate (0.13 ml, 0.49 mmol) and 2- ( 4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (116 11 ^, 0.45 111111〇1) to obtain the title compound as a colorless solid (45 mg, yield: 14%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 276-277 ° C. IR (KBr): umax 1690,1603,1483,1444,1375,1268,1212,1171, 93 7 cm · 1. W-NMR (400MHz, DMSO-d6): δ 8.92 (1H , S), 8.07 (1H, s) 5 7.73 (2H, d, J = 8,1 Hz), 7.42 (2H, d, J = 8.1 Hz), 7.36 (1H, s), 7.09 ( 1H, s) 5 4.18 (2H, s) 5 4 · 05 (3H, s), 2.25 (3H, s) · FABMS (m / z): 5 64 ([M + H] "· (Example 211). 2-benzyl-6-chloro-7-methoxy- 3- [2-methyl- 4- [2,2,2-trifluoro-b-hydroxy-b (trifluoromethyl) ethyl] benzene Yl] -4 (3H) -quinazolinone (Exemplified Compound No. 7-571)

In a similar manner as described in Example 1, 5_chloro-4-methoxy-o-aminobenzoic acid (190 mg, 0.942 mmol), phenylacetic acid (129 -510- 200401770 mg) 0.947 mmol), triphenyl phosphate (0.25 ml, 0.95 mmol) and 2- (4-amino · 3-methylphenyl) -1,1,1 prepared in Example 65 (1) above, 3,3,3-hexafluoro-2-propanol (249 mg, 0.911 mmol) to obtain the title compound as a colorless solid (280 mg, yield: 55%). This product was obtained from hexane and ethyl acetate. Recrystallization in a mixed solvent produces a colorless powder. mp 2 5 7 0C (dec ·) · IR (KBr): vmax 1 689,1 605,1 593,1 482,1 268,1 208,970 cm · 1. 'H-NMR (400MHz? DMSO-d6): ^ 8 · 8 7 (1 H, s), 8 · 0 3 (1 H, s), 7.62 (1H, d, J = 8.1 Hz), 7.48 (2H, d, J = 8.1 Hz), 7.41 (1H, s), 7.19-7 · 07 (3H, m), 6.66 (2H, d, J = 7.3 Hz), 4.04 (3H, s), 3.82-3.73 (2H? M )? 1.50 (3H? S). FABMS (m / z): 5 5 7 ([M + H] +). FABHRMS (m / z): calcd. For C24H17F6N2 02 ([M + Na] +): 579.8737 ; found: 579.0883. (Example 212). 2-benzyl-6-propyl- 3- [4- [2,2,2-trifluoro-l-hydroxy-1- (trifluoromethyl) ethyl Yl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3 -23 2 8)

In a similar manner as described in Example 1, 2- (4-Aminobenzene_) prepared from 5-propylanthranilide, phenylacetic acid, and step (1) of Example 65 above--511- 200401770 1, 1,1,3,3,3-hexafluoro-2-propanol to obtain the title compound as a colorless solid mpl82-1830C. IR (KBr): v max 3240,1668,1592,1491,1271,1214,1195, 968, 9 3 5,709 cm · 1 · 'H-NMR (400MHz, CDC13): δ 8.08 (1H? D? J = 2.0 Hz)? 7.75 (1H, d, J = 8.0 Hz), 7.70-7.62 (3 H , M), 7 · 1 6-7 · 0 3 (3 H, m), 6 · 89 (2H, d, J = 8.8 Hz), 6.68 (2H, d, J = 7.2 Hz), 3 · 89 (2H, s), 2.76 (2H, t, J = 7.6 Hz), 1 · 8 0-1 · 6 8 (2 H, m), 0 · 9 8 (3 H, t, J = 7.4 Hz). FABMS (m / z): 521 ([M + H] +). (Example 213) 2-benzyl-6 -methoxy- 3- [2-bromo-4- [2,2, 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 7-5 64)

(1) In a similar manner to Example 62 (1) above, 0-bromoaniline (10.87 g, 63.2 mmol), hexafluoroacetone trihydrate (14.97 g, 68.0 mmol), and p-toluenesulfonic acid (272 mg, 1.43 mm ο 1) Obtained 2-(4-amino-3 -bromophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2.94§5 yield: 14%) . -512- 200401770 ^ -NMR (400MHz? CDC13): ^ 7 · 7 6-7.7 5 (1 H, m), 7 4 1 (1 H, d, J = 8.8 Hz), 6.78 (1H, d, J = 8.8 Hz), 4 · 30 (2H, brs), 3 · 29 (1H? S). (2) In a similar manner to Example 20 1 (1) above, 5-methoxy-o-aminobenzoic acid (7.29 g, 43.6 mmol) and phenylacetamyl chloride (13.0 ml, 98.4 mmol) to obtain 2 .. benzyl-6-methoxy-4H-3,1-benzofluorenyl-4-one (5 • 19 g, yield: 45/0). 'H-NMR (400MHz? CDC13): δ 7.55-7.51 (2H5 m)? 7.43-7.26 (6Η, m) 3.96 (2Η, s), 3.89 (3Η, s) · (3) Based on the above Example 201 (2): A method similar to 2-benzyl-6-methoxy-4 H-3, l-benzopyrene-4-one (6 92) prepared from Example 213 (2) above. mg, 2.05 mmol), triphenyl phosphate (635 mg, 2.05 mmol) and 2- (4-amino-3-bromophenyl) -1,1,1,3, prepared in the above Example 213 (2), 3,3-hexafluoro-2-propanol (5 45 mg, 2.04 mmol) to obtain the title compound as a colorless solid (545 mg, yield: 53%). mp 214-214.5 ° C. IR (KBr): vmax 3 090, 1 645, 1615, 1491, 1371, 1 28 5, 1195, 966 cm'1. 'H-NMR (400MHz5 DMSO-d6): δ 9.21 ( 1H5 s), 7.91 (1H? S) 5 7.7 5 -7.70 (2H? M), 7.5 7-7.5 0 (3 H? M) 5 7.20-7.09 (3 H? M) 5 6.73 (2H, d , J = 7.3 Hz), 3.89 (3H, s), 3_82 (1H, d, J = 15.1

Hz), 3.75 (1H, d, J = 15.1 Hz), 3.98 (3H, s), 3.87 (1H, d, J = 14.7 Hz), 3.76 (1Η, d, J = 14.7 Hz), 2.50 (3Η, s). FABMS (m / z): 5 8 7 and 5 89 ([M + H] +) · -513- 200401770 (Example 214) 2- (4 -cyano Benzyl) -6,7-dimethoxy- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) -ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2 3 29)

In a similar manner to the above Example 1 92, 2-[(4-Bromophenyl) methyl] -6,7-dimethoxy-3- (4- [2,2,2] prepared from Example 74 above -Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl) -4 (3H) -quinazolinone (211 mg, 0.34 mmol), zinc cyanide (80 mg, 0.68 mmol) and tetrakis (triphenylphosphine) palladium (0) (39 mg, 0.034 mmol) to obtain the title compound as a colorless solid (58 mg, yield: 30%). This product was recrystallized from acetonitrile to produce a colorless orthorhombic Crystal. mp 274 ° C. IR (KBr): vmax 3297, 2236, 1677, 1612, 1502, 1397, 1272, 1210, 1174 cm · 1. 'H-NMR (400MHz? DMSO-d6): δ 8.90 (1H? s )? 7.70 (2H5 d? J = 8.8 Hz), 7.58 (2H, d, J = 8.0 Hz), 7.42 (1H, s), 7.38 (2H, d, J = 8.8 Hz), 7.17 (1H, s), 7.03 (2H, d, J = 8.0 Hz), 3.93 (3H, s), 3.91 (1H, s), 3.87 (3H, s). -514- 200401770 FABMS ( m / z): 564 ([M + H] +). FABHRMS (m / z): calcd · for C27H19F6N3 04 ([M + Na] +): 586.1 177; found: 586.1 158. Anal, calcd. for C27H19F6N304 : C, 5 7.5 6; H, 3.40; N? 7.46; found: C5 5 7.2 9; H? 3.32; N? 7.36. (Example 215) 2-cyclopropyl-6-methoxy-3- [4 -[2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _4 (3H) -thiazolinone (Exemplified compound numbers 2-5 5 3)

In a similar manner as described in Example 1, 5-methoxy-o-aminobenzoic acid (330 mg, 1.97 mmol), ciprofloxacin (170 mg5 1.97 mmol), and triphenyl phosphate ( 620 mg, 1.97 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (500 mg, 1.97 mmol) to obtain the title compound as impure White powder (180 mg, yield: 20%). This product was recrystallized from a mixed solvent of diisopropyl ether and methanol to give a non-pure white powder. mp 283-284 ° C. IR (KB r): umax 3244, 1680, 1590, 1493, 1366, 1212, 1368, 1 177, 9 3 4 cm · 1. 'H-NMR (400MHz? DMSO-d6): δ 8.98 (1H? br), 7.89 (2H5 d? J = 8.8 Hz), 7.66 (2H, d, J = 8.8 Hz), 7.55 (1H, d, J = 8.8 Hz) 5 7.46-7.41 (2H, m), 3.85 (3H, s), 1.30-1.23 (1H, m), 1.13-1.09 • 515- 200401770 (2H? M) 5 0.8 1-0.7 6 (2 H? M). FABMS (m / z): 459 ([M + H] +). (Example 216) 2-cyanomethyl-6,7-dimethoxy-3- [4- [2,2,2-difluoro-1 -Cyto-1--1- (trifluoro / methyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified Compound No. 343 3 0)

/ 0, 〇

II

N In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (503 mg, 2.55 mmol), cyanoacetic acid (228 mg, 2.68 mmol), triphenyl phosphate (0.73 ml, 2.81 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (661 mg, 2.55 mmol) to obtain the title compound as a colorless powder (456 mg, Yield: 37%). mp 328-330oC. IR (KBr): vmax 3417, 2266,1682,1613,1502,1397,1271, 1211, 1 1 75, 9 34 cm · 1. iH-NMR (400MHz, DMSO-d6): δ 8 96 (1H, s), 7.87 (2H, d, J = 8.8 Hz), 7.63 (2H, d, J = 8.8 Hz), 7.43 (1H, s), 7.23 (1H, s ), 3.97 (3H, s), 3.88 (3H, s), 3.86 (2H, s), FABMS (m / z): 48 8 ([M + H] +). (Example 217) -516- 200401770 6-methoxy- 2- [(2-methyl-1,3--fluorenyl-5-yl) methyl] -3- [4- [2,2,2-tri ··- 1-Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2 3 3 1)

F

In a similar manner as described in Example 1, from 5-methoxy-o-aminobenzoic acid (108 mg, 0.65 mmol), according to FR 2334353 (1 976), DE 2605 8 3 8 (1 97 7) or JP (Kokai) Shou-5 1-1 05056 (1 976) (2-methyl-1,3-thiawa-5-yl) acetic acid (107 mg, 0.68 mmol), triphenyl phosphate (0.185 ml) , 0.71 mmol) and 2- (4 • aminophenyl) -1,1,1,3,3,3_hexafluoro_2_propanol (167 mg, 0.65 mmol) to obtain the title compound as a colorless powder (162 mg, Yield: 47%). mp 223-224 ° C. IR (KBr): umax 1676, 1616, 1592, 1491, 1366, 1270, 1212, 1 186, 93 8 cm · 1. W-NMR (400MHz, CDC13): (5 7 · 9 0 (2 H, d, J = 8 · 4 H z), 7 · 7 1 (1H, d, J = 8.8 Hz), 7.64 (1H, d, J = 2.9 Hz), 7.42 (1H, dd, J = 2.9, 8.8 Hz), 7.19 (2H, d, J = 8.4 Hz), 6.81 (1H, s), 6.70 (1H, s), 3.97 (2H, s), 3.92 (3H, s) , 2.63 (3H, s). FABMS (m / z): 5 3 0 ([M + Hf]. 200401770 (Example 218) 5,6-dimethoxy_2-[(2-methyl_ 1,3-thiazol-5-yl) methyl] -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] _4 (3H ) _Quinazolinone (Exemplified compound number 3 -23 3 2)

F

In a similar way as described in Example 1, from FR 2 3 3 4 3 5 3 (1 9 7 6), DE 2605 83 8 (1 97 7) or JP (Kokai) Shou-5 1-1 05 05 6 ( 1 976), 4,5-dimethoxy-o-aminobenzoic acid (107 mg, 0.54 mm), (2-methyl · 1,3-1-5-2-5-yl) acetic acid ( 90 mg, 0.57 mmol), triphenyl phosphonate (0.156 ml, 0.60 mmol), and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (140 mg, 0.54 mmol) gave the title compound as a colorless powder (61 mg, yield: 20%). mp 246-248 ° C. IR (KBr): u max 1 682, 1612, 1 5 95, 1501, 1 396, 1 270, 1212, 938 cm * 1. iH-NMR (400MHz, CDC13): δ 7.88 ( 2H, d, J = 8.4 Hz) 5 7.59 (1H, s), 7.19 (2H, d5 J = 8.4 Hz), 7.17 (1H, s), 6.73 (1H, s), 6.22 (1H, s), 4.06 (3H, s), 4.00 (3H, s), 3.96 (2H, s), 2.63 (3H, s). -518- 200401770 FABMS (m / z): 5 6 0 ([M + H] +). (Example 219) 5-Chloro-6-methoxy-2-[(2-methyl-1,3-thiazol-5-yl) methyl] -3- [4- [2 , 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2 3 3 3)

F

In a similar manner as described in Example 1, the 5-gas-4-methoxy-o-aminobenzoic acid (109 mg, 0.54 mmol) prepared from the above Example 1 2 (1) was used according to FR 23 343 5 3 (2-methyl-1,3-thiazol-5-yl) prepared by the method described in (1 976), DE 2605 83 8 (1 977) or JP (Kokai) Shou-51-1 05056 (1 976) Acetic acid (89 mg, 0.57 mmol), triphenyl phosphate (0.155 ml, 0.60 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2 -Propanol (1,401, 0.54 mmol) to give the title compound as a colorless powder (165 mg, yield: 54 ° / Q). mp 273-276 ° C. IR (KBvmax 1696,1604,1482,1444,1374,1268,1213, 1 170, 9 3 9 cm · 1. 'H-NMR (400MHz? CDC13 + DMSO-d6): δ 8.19 (1H? S) 5 8.15 (1H, s) 5 7.9 2 (2H, d, J = 8.8 Hz), 7.23 (2H, d, J = 8.8 Hz), 7.20 (1H, s) 5 6.9 3 (1 H , S), 4.07 (3H, s), 3.95 (2H, s), 2.63 -519- 200401770 (3H, s). FABMS (m / z): 5 64 ([M + H] +) (Example 22 0) 6-methoxy-2-[(6-methyl-3-pyridyl) methyl] -3- [4- [2,2,2-trifluoro-1_hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 3-2334)

In a similar manner as described in Example 1, from 5-methoxy-o-aminobenzoic acid (1 15 mg, 0.69 mm ο 1), according to the literature (Sperber et al · [Sperber et al ·, J · Am · Chem. Soc., 81,704-709 (1959)]) 6-methyl-3-pyridylacetic acid (104 mg, 0.69 mmol), triphenyl phosphate (0.197 ml, 0.76 111111〇1) ) And 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (178 11 ^, 0.69 mmol) to obtain the title compound as a colorless powder (42 mg, Yield: 12%) ° mp 205-208 ° C. IR (KBr): v max 1 6 8 3,1 6 1 7,1 5 94,1 49 1,1 274,1 21 5,1 1 9 1 , 93 9 H-NMR (400MHz, CDC13): δ 8 · 4 0 (1 H, s), 7 · 9 0 (2 H, d, J = -520- 200401770 8 · 8 Hz), 7.72 (1H, d, J = 8.8 Hz), 7.64-7.60 (2H, m), 7.49 (1H, dd, J = 8.1, 2.1, Hz), 7.42 (lH, dd, J = 8.8, 2.9Hz), 7.10- 7.02 (3H, m), 3.92 (3H, s), 3.80 (2H, s), 2.52 (3H, s), FABMS (m / z): 524 ([M + H] +). (Example 221 ) 6-Chloro-7-methoxy- 2-[(6-methyl- 3- ¾ Dyl) methyl] -3- [4- [2,2,2-trifluoro-1-meryl- 1- (dihelylmethyl) ethyl] benzene ] -4 (3H) · Π sit quinolin commanded _ (Exemplified Compound No. 3-2335)

In a similar manner as described in Example 1, 5-chloro-4 -methoxy-o-aminobenzoic acid (99 mg, 0.49 mmol) prepared from Example 1 2 (1) above, according to the literature (Sperber et al. [ Sperber et al., J. Am. Chem. Soc., 81, 704-709 (1 959)]), 6-methyl-3-pyridylacetic acid (74 mg, 0.49 mmol), triphosphate Phenyl vinegar (0.140 ml, 0.54 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (127 11 ^, 0.49 111111〇1) A colorless powder of the title compound was obtained (62 mg, 23% yield). mp 2 5 2 ° C (dec.). IR (ICBr): ymax 1683, 1598, 1482, 1444, 1373, 1266, 121 1, 1178, -521- 200401770 940 cm. ^ -NMR (400MHz5 DMSO-d6) : 5 8 · 9 5 (1 H, bs), 8 · 0 4 (1 H, s), 8.00 (1H, d, J = 1.5 Hz), 7.79 (2H, d, J = 8.8 Hz), 7.51 (2H, d5 J = 8.8 Hz), 7.26 (1H, s) 5 7 · 24 (1H, dd, J = 8.1, 1.5 Hz), 7 · 07 (1H, d, J = 8.1 Hz), 4.02 (3H, s), 3.74 (2H, s), 2.40 (3H, s). FABMS (m / z): 5 5 8 ([M + H] +). (Example 222) 2-cyclobutane -6-methoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3 H) -quinazole Porphyrinone (Exemplified compound number 2-5 5 6)

In a similar manner as described in Example 1, 5-methoxy-o-aminobenzoic acid (200 mg, 1.20 mmol), cyclobutyric acid (120 mg, 1.20 mmol), and triphenyl phosphate (3 70 mg, 1.20) mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (310 mg, 1.20 mmol) to give the title compound as a colorless solid (220 mg, Yield: 39%). This product was recrystallized from a mixed solvent of diisopropyl ether and methanol to give a colorless powder. mp 245-246 ° C. IR (KBr): v max 3266, 29 7 3, 2 9 5 0,1 647,1 5 9 1,1492,1 368, -522- 200401770 1217, 9 3 5 cm · 1丨 H-NMR (400MHz, DMSO-d6): δ 8 · 98 (1H, brs), 7.84 (2H, d, J = 8.8 Hz), 7.70-7, 6 8 (1 H, m ), 7.57 (2H, d, J = 7.8 Hz), 7.57-7.46 (2H, m), 3.87 (3H, s), 3.27-3.20 (1H, m) 5 2.39-2.33 (2H, m), 1.71-1.57 (4H, m) FABMS (m / z): 473 ([M + H] +). (Example 223) 2-benzyl- 3- [4- [2,2,2-trifluoro -1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] pyridine [3,2-d] pyrimidin-4 (3H) -one

In a similar manner as described in Example 1, from 3-amino-2-pyridinecarboxylic acid (32 mg 5 0.23 mmol), phenylacetic acid (31 mg, 0.23 mmol), and triphenyl phosphate (72 mg5 0.23 111111). 1) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (59 11 ^, 0.23 mmol) to obtain a non-pure white powder of the title compound ( 22 mg, yield: 20%) ° mp 2 3 8 -240 ° C (dec.). IR (KBr): v max 3 0 8 8, 1 7 0 1, 1 5 82, 1 434, 1 26 8 , 1 1 9 1,9 3 7,7.1 0 -523- 200401770 ^ -NMR (400MHz, DMSO-d6): δ 8 · 9 5 (1 H, brs), 8. 8 3-8 · 8 2 (1H , M), 8.16 (1H, d, J = 6.8 Hz), 7.8 9-7.8 6 (1 H, m), 7.70 (2H, d, J = 8.8 Ηζ), 7.35 (2H, d, J = 8 · 8 Hz), 7 · 18 · 7 · 10 (3H, m), 6.78 (2H, d, J = 6.8 Hz), 3.85 (3H, s) · FABMS (m / z): 48 0 ( [M + H] +). (Example 224) 2-Isopropyl-6,7-monomethoxy-3- [4- [2,2,2 -trigas-1-meryl-1- (Trismethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 2-3 7 3)

In a similar manner as described in Example 1, from 4,5-dimethoxy-o-aminobenzoic acid (380 mg, 1.97 mmol), cyclopropane residual acid (170 mg, 1.97 mmol), triphenyl phosphate (620 mg , 1.97 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (500 mg, 197 mmol) to give the title compound as a non-pure white Powder (240 mg, yield: 26%). This product was recrystallized from a mixed solvent of diisopropyl ether and methanol to give a non-pure white powder. mp 283-284cC. IR (KBr): u max 3 22 3, 1 669, 1 499, 1430, 121 1, 1212, 1 3 6 8, 933 H-NMR (400MHz, DMSO-d6): δ 8 · 98 (1H, brs), 7.88 (2H, d5 200401770 J = 8.1 Hz), 7.63 (2H, d, J = 8.8 Hz), 7.38 (1H, s), 7.05 (1H, s) 5 3.92 (3H, s), 3.85 (3H, s), 1.29-1.23 (1H, m), 1.13-1.10 (2H, m), 0.82-0.77 (2H, m). FABMS (m / z ): 48 9 ([M + H] +) (Example 22 5) 2-benzyl-5,7-dimethyl-3- [4- [2,2,2-trifluoro-1-hydroxyl -1- (trifluoromethyl) ethyl] phenyl] pyridine [2,3-d] pyrimidin-4 (3 H) -one

In a similar manner as described in Example 1, from 2 · amino-4,6-dimethylnicotinic acid (160 mg, 0.96 mmol), phenylacetic acid (131 mg, 0.96 mmol), and triphenyl phosphonate Esters (300 mg, 0.96 mmol) and 2- (4-aminophenyl) -l, l, l, 3,3,3-hexafluoro-2-propanol (250 mg, 0.96 mmol ) Obtained the title compound as a colorless powder (86 mg, yield: 18%). This product was further purified by reverse-phase preparative thin-layer chromatography (using a mixture of acetonitrile and water as a solvent in a volume of 3.1) to produce a colorless powder. mp 1 28- 1 3 0oC (dec.). IR (KBr): u max 3 3 70, 1 690, 1 5 94, 1271, 1214, 934 cm · 1. lH-NMR (400MHz5 DMSO-d6): δ 8.92 (1H5 s)? 7.71 (2H5 d5 J = -525- 200401770 8.8 Hz), 7.36 (2H, d, J = 8.8 Hz), 7.25 (1H, s), 7.20-7.12 (3H, m ), 6.82 (2H, d, J = 6.8 Hz), 3.81 (2H, s) 5 2.68 (3H, s), 2.56 (3H, s) · FABMS (m / z): 5 0 8 ([M + H] +) (Example 226) 2-benzyl-6-chloro-7-methoxy- 3- [2-chloro-4- [2,2,2-trifluoro-1-meryl- 1- (trifluoromethyl) ethyl] phenyl: 1-4 (3 Η) -quinazolinone (Exemplified compound numbers 1-5 75)

In a similar manner as described in Example 1, 5-chloro-4-methoxy-o-aminobenzoic acid (144 mg, 0.71 mmol), phenylacetic acid (97 mg, 0) · 71 mmol), triphenyl phosphate (0.19 ml, 0.72 mmol) and 2- (4-amino-3-chlorophenyl) -l, l, l, 3 prepared in Example 67 (1) above , 3,3-hexafluoro-2-propanol (190 mg, 0.65 mmol) to obtain the title compound as a colorless solid (199 mg, yield · 51%). This product was obtained from a mixed solvent of hexane and ethyl acetate. Recrystallization gave a colorless powder. mp 267 ° C (dec ·) · IR (KBr): 2; max 3 034, 1 700, 1 606, 1 5 92, 1 484, 1 267, 1 2 02, 971 -526 · 200401770 ^ -NMR (400MHz DMSO-d6): δ 9.20 (1H? S)? 8.04 (1H5 s) 5 7.72-7.60 (3H, m), 7.41 (1H, s), 7.15 (1H, t5 J = 7.3 Hz), 7.09 (2H, t, J = 7.3 Hz), 6.71 (2H, d, J = 7.3 Hz), 4.04 (3H, s), 3.81 (2H? M). FABMS (m / z): 5 7 7 ([M + H] +). (Example 227) 2-benzyl-6-methoxy-3- [2-ethyl-4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 7-5 60)

(1) In a similar manner to Example 62 (1) above, 2-ethylaniline (3.12 g, 25.7 mmol), hexafluoroacetone trihydrate (3.6 0 m 1 5 2 5 · 8 mm ο 1), and p -Toluenesulfonic acid (127 mg, 0.68 mmol) to obtain 2- (4-amino-3-ethylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (3.312, yield: 45%) as a colorless powder. 'H-NMR (400MHz, CDC13): δ 7.3 6-7.32 (2H? M)? 6.70 (1Η? D5 J = 8.1 Ηζ), 3.80 (2Η, brs), 3.24 (1Η, brs), 2.53 ( 2Η, q, J = 7.3 Hz), 1 · 26 (3H, t, J = 7.3 Hz): EIM S (m / z): 2 8 7 (M +). (2) Take the above example 20 1 (2 ) A similar method was prepared from the above Example 2 13 (2) -527- 200401770 2-Benzyl-6-methoxy-4H-3,1-benzofluorenyl-4-one (482 mg, 1.80 mmol), triphenyl phosphate (0.47 ml, 1.80 mmol) and the above 2- (4-amino-3-ethylphenyl) -1,1,1,3,3,3 -Hexafluoro-2-propanol (466 11 ^ 51.60 mm ο 1) to obtain the title compound as a colorless solid (3 22 mg, yield: 33%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate. A colorless orthorhombic crystal was produced. mp 195-196 ° C. IR (KBr): vmax 32 3 6, 1 65 2, 1 592, 1 493, 1 3 68, 1 272, 1210 cm · 1. 'H-NMR (400MHz, DMSO-d6) : 6 8 · 8 9 (1 H, s), 7 · 7 3 (1 H, d, J = 9 · 5 Hz), 7.60 (1H, d, J = 8.1 Hz), 7 · 5 3 ( 1 H, s), 7 · 5 0-7 · 4 7 (2H, m), 7.42 (1H, d, J = 8.8 Hz), 7.15 (1H, t, J = 7.3 Hz), 7.07 (2H, t, J = 7.3 Hz), 6.63 (2H, d5 J = 8.1 Hz), 3.91 (3H, s), 3.8 1-3.73 (2H, m), 1.99-1.9 1 (1H, m), 1.67- 1.59 (1 H, m), 0.79 (3H, t, J = 7.3 Hz) · FABMS (m / z): 5 3 7 ([M + H] +). (Example 22 8) 2 -Benzyl-6-methoxy- 3- [2- (l-propyl) -4- [2,2,2-trifluoro-1-hydroxy-1- (difluoromethyl) ethyl] Benzo] -4 (3 Η) -Quinylchizolinone (Exemplified Compound No. 7-561)

• 528- 200401770 (1) In a similar manner to Example 62 (1) above, 2- (bupropyl) aniline (3.01 g, 22.3 mmol), hexafluoroacetone trihydrate (3 · 10 ml, 22 · 3 mmol) ) And p-toluenesulfonic acid (122 mg, 0.641 mmol) to obtain 2- [4-amino-3- (1-propyl) phenyl] -1,1,1,3,3,3-hexafluoro- 2-propanol (2.52§, yield: 38 ° /.) As a reddish powder. ^ -NMR (400MHz? CDC13): δ 7.34-7.31 (2Η5 m) 5 6.6 9 (1Η? D? J = 8 · 1 Ηζ), 3.80 (2Η, brs) 5 3 · 22 (1Η, brs ), 2.49 (2Η, t, J = 7.3 Hz), 1.66 (2H, hextet, J = 7.3 Hz), 0 · 99 (3H, t5 J = 7.3 Hz). EIMS (m / z): 301 ( M +). (2) In a similar manner as described in Example 1, 5-methoxy-o-aminobenzoic acid (352 mg, 2.10 mmol), phenylacetic acid (287 mg, 2,10 mmol), and triphenyl phosphate were prepared. Ester (0.55 ml, 2.10 mmol) and 2- [4-amino-3- (1-propyl) phenyl] -1,1,1,3,3,3-prepared from Example 228 (1) above Hexafluoro-2-propanol (57111 ^, 1.90 mmol) obtained the title compound as a colorless solid (3 90 mg, yield: 37%). This product was produced by recrystallization from a mixed solvent of hexane and ethyl acetate. Colorless Orthorhombic crystal. mp 2 1 4 ° C. IR (KBr): vmax 3 2 3 551 6 5 7? 1 5 9251 492? 1 3 69? 1 267? 1 209 cm · 1. 'H-NMR (400MHz, DMSO-d6) : δ 8.92 (1H, s)? 7.76 (1H? d5 J = 8.7 Hz), 7.61 (1H, d, J = 8.1 Hz), 7.55-7.49 (3H, m), 7.40 (1H, d, J = 8.1 Hz), 7.18 (1H, t, J = 7.3 Hz), 7.10 (2H, t, J = 7.3 Hz), 6.67 (2H, d, J = 7.3 Hz), 3.89 (3H, s ), 3.78 (2H5 s), 1.99-1.93 (1Η, m), 1.66- 1.64 (1 H, m), 1.3 9- 1.3 6 (1 H, m), -529- 200401770 1.18 -1.11 (1H, m) 5 0.6 6 (3 H5 t5 J = 7.3 Hz). FABMS (m / z): 551 ([M + H] +) · (Example 229) 2-benzyl-6 -formyl Oxy 3--3- [2-methyl- 5- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazoline Ketones (Exemplified Compound Nos. 7-5 77)

(1) Add fuming nitric acid (10 ml) dropwise to the containing 2- (p-tolyl) -1,1,1,3,3,3-hexafluoro- 2-propanol (13.95 g, 54.0 mmol) and concentrated sulfuric acid (30 ml), and the resulting mixture was stirred at 0 ° C for 30 minutes and at room temperature for 90 minutes, then the reaction mixture was poured into ice- The precipitate obtained was filtered in water, and the obtained solid was rinsed with cold water and then with η-hexane several times. The solid was dried in a vacuum to give a yellow powder (16.3 g). The carbon containing 10% palladium [ 50% (w / w) wet, 1.70 g] was added to a solution of the obtained product in ethanol (1 0 Ο πι 1), and the resulting mixture was vigorously stirred at room temperature under hydrogen pressure for 5 hours, At the end of this time, the catalyst was removed by filtration, and the filtrate was concentrated. The obtained light brown residue was purified by silica gel column chromatography using a mixture of η-hexane and ethyl acetate in a volume of 1.1 Eluate, and 2--(3-amino-4 -methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2.69 8, product Rate: 18%) of -530 -200401770 light brown orthorhombic crystals, and the use of ethyl acetate as eluent to produce 2-(3,5-diamino · 4-methylphenyl) -1 from the polypolar moiety, Colorless needles of 1,1,3,3,3-hexafluoro-2-propanol (8.65 g, yield: 56%). 2- (3-Amino-4-methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol:! H-NMR (400MHz5 DMSO-d6): δ 8.29 ( 1Η, s) 5 7.00 (1 H? D? J = 8.1 Hz), 6.96 (1H, s), 6.75-6.73 (1 H, m), 5.07 (2H, brs), 2.06 (3H, s) · EIMS (m / z): 273 (M +). 2- (3,5-diamino-4-methylphenyl) -1,1,1,3,3,3-hexafluoro-2- Propanol: iH-NMR (400MHz, DMSO-d6): δ 8 · 03 (1H, s), 6.28 (2H, s), 4.74 (4H, s), 1.80 (3H, s) . EIMS (m / z): 2 8 8 (M +).

(2) A 2-benzyl-6-methoxy-4H-3,1-benzofluorene prepared from the above-mentioned Example 2 1 3 (2) in a similar manner to the above Example 2 01 (2) 4-ketone (427 mg, 1.60 mmol), triphenyl phosphate (0.42 ml, 1.60 mmol) and 2- (3-amino-4-methyl) prepared in Example 229 (1) above Phenyl) -1,1,1,3,3,3-hexafluoro-propan-2-ol (433 mg, 1.60 mmol) to obtain the title compound as a colorless solid (390 mg, yield: 47%). This product Recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. m. p. 1 6 2 ° C IR (KBr): vmax 3 2 5 0, 1 66 6, 1 594, 1 467, 1 3 69, 1 270, 1 203 cm · 1.] H.NMR (400MHz5 DMSO -dJ: ά 8 · 7 9 (1 Η, s), 7 · 6 5-7 · 6 2 200401770 (2H, τπ), 7.59 (1H, d, J = 8.8 Hz), 7.41-7.38 (2H , M), 7 · 24 (1H, d, J = 8.1 Hz), 7.07-7.01 (3H, m), 6.59 (2H, d, J = 6.6 Hz), 3.79-3.5 8 (5 H, m ), 1.35 (3H, s). FABMS (m / z): 5 2 3 ([M + H] +) 5 5 6 1 ([M-fK] +). (Example 2 3 0) 2-Benzyl 4--4-keto-3- [4- [2,2,2-difluoro-1-meryl-1 · (trifluoromethyl) ethyl] phenyl] -3,4 · dihydro-6 -Methyl quinazoline carboxylic acid (Exemplified compound Nos. 3-23 3 6)

The 2-benzyl · 6-iodo-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] prepared in the above Example 189 was used. -4 (3H) -quinazolinone (302 mg, 0.50 mmol), palladium acetate (11) (11 mg, 0.05 mg) and triphenylphosphine (26 mg, 0.1 mmol) under nitrogen pressure Place it in a dry two-necked flask, then add N, N-dimethylformamide (2 ml), triethylamine (0.14 ml, 1.00 mmol) and methanol (0.41 ml, 10.0 mmol), and then The resulting mixture was stirred at 60 ° C for 2.5 hours under carbon monoxide pressure. At the end of this time, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The combined organic layer was saturated with 1 N hydrochloric acid and saturated. Rinse with an aqueous solution of sodium chloride, then pass through a rapid pad of anhydrous sodium sulfate, concentrate the solution in vacuo, and chromatograph the obtained residue on a silica gel column using hexane and ethyl acetate in a volume of 2: 1. The ester mixture was purified as a washing-532-200401770 eluate), followed by high pressure liquid chromatography (HP LC) to give the title compound as a colorless solid (147 mg, yield: 55%). mp 227-228 ° C. IR (KBr): u max 3 26 1,1714, 1 666, 1 590, 1 272, 1 197, 93 5, 708 'H-NMR (400MHz, CDC13 + CD3OD): δ 8 9 2 (1 H, d, J = 2 ♦ 0 Hz), 8.45 (1H, dd, J = 8.8, 2.0 Hz), 7.86 (1H, d, J = 8.8 Hz), 7.75 (2H , D, J = 8.0 Hz), 7.21-7.08 (3H, m), 6.97 (2H, d, J = 8.8 Hz), 6.72 (2H, d, J = 8.0 Hz), 3.98 (3H5 s), 3.95 (2H, s). FABMS (m / z): 5 3 7 ([M + H] +). (Example 23 1) 2-benzyl-6-methoxy-3- [2-isopropyl 4--4- [2,2,2-trifluoro-1-hydroxy-bu (trifluoromethyl) ethyl] phenylbu 4 (3 Η) -quinazolinone (Exemplified compound number 7-562)

(1) In a similar manner to Example 62 (1) above, 2-isopropylaniline (5.05 g, 37.3 mmol), hexafluoroacetone trihydrate (5.5 ml, 39.5 mmol), and p-toluenesulfonic acid (134 mg, 0.704 mmol) to obtain 2- (4-amino-3-isopropylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5.65 @, yield : 50%) of colorless powder -533- 200401770. W-NMR (400MHz, CDC13) ·· 5 7.4 3 (1 H, s), 7 · 3 2-7 · 2 8 (1 H, m), 6.69 (1H, d, J = 8.8 Hz), 4.20-3.00 (3H, br), 2.94-2.84 (1H, m), 1.27 (6H, d, J = 6.6 Hz). EIMS (m / z): 301 (M +). (2) Take an example A similar method as described in 1 was prepared from 5-methoxy-o-aminobenzoic acid (25 1 mg, 1.50 mmol), phenylacetic acid (206 mg, 1.50 mm), and Example 231 (1) above. Triphenyl phosphate (0.40 ml, 1.50 mmol) and 2- (4-amino-3-isopropylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (4111 ^, 1.40 mmol) to obtain the title compound as a colorless solid (1α mg, yield: 20%). This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 1 72 ° C. IR (KBr): P max 3 284,1 654,1 5 92,1 493,1 3 6 8,1 267,1 2 1 1 cnT1. ^ -NMR (400MHz, DMSO-d6) : ό 8 · 9 3 (1 H, s), 7 · 7 4-7 · 7 1 (2H, m), 7.52-7.49 (3 H, m), 7.26 (2H, d, J = 8.1Hz), 7.18-7.11 (2H, m), 6.72 (2H, d, J = 6.6Hz), 3.89 (3H, s), 3.82-3 · 63 (2H, m), 2.45-2.3 9 (1 H, m), 1 · 〇〇 (3H, d, J = 6.6 Hz), 0.8 · (3H, d, J = 7.3 Hz) · FABMS (m / z): 551 ([M + H] +). (Example 23 2 ) 2-benzyl-6-methoxy-3- [3-amino-2-methyl-5- [2,2,2-trifluoro-1-hydroxy-1-(dichloromethyl) -Ethyl] phenyl] -4 (3 fluorene) · Quin 12¾olinone (Exemplified Compound No. -534- 200401770 No. 7-578)

In a similar manner to the above Example 201 (2), the 2-benzyl-6-methoxy-4H-3,1-benzofluorenyl-4-one (391 mg, 1.50 mmol), triphenyl phosphate (0.39 ml, 1.50 mmol) and 2- (3,5-monoamino-4-methylphenyl) -1 prepared in Example 229 (1) above, 1,1,3,3,3-hexafluoro-2-propanol (420 mg, 1.50 mmol) to obtain the title compound as a colorless solid (2 99 mg, yield: 38%). This product was obtained from hexane and ethyl acetate. Recrystallization in a mixed solvent produces colorless orthorhombic crystals. .m .p. 2 0 8 0 C IR (KBr): v max 3 3 7 3, 1 692, 1 675, 1 493, 1 3 69, 1 269, 1 205, 1 172 cm'1.iH-NMR (400MHz, DMSO-d6): δ 8 · 4 7 (1 H, s), 7 · 6 0 (1 H, d, J = 9.5 Hz), 7.39-7 · 36 (2H, m), 7.07 -7.05 (3 H, m), 7.02 (lH, s), 6.78-6.67 (3H, m), 5.22 (2H, s), 3.77 (3H, s), 3.76-3.62 (2H5 m) 5 1.04 (3H , s). FABMS (m / z): 5 3 8 ([M + H] +), 5 76 ([M + K] +). (Example 2 3 3) 2-benzyl-6-isopropyl Aminoamino-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (exemplified Compound No. 3 -23 3 7) -535- 200401770

The 2-benzyl-6-iodo-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl group prepared in the above Example 189 ] -4 (3Η)-quinazolinone (1.20 g, 2.00 mmol), isopropylamine (591 mg, 10.0 mmol), potassium nitrate (85 0 mg, 4.00 mmol), ethylene glycol (0.22 ml , 4.00 mmol) and a solution of 2-propanol (5 ml) in a mixture of cuprous iodide (1) (40 mg, 0.20 mmol) and stirred at 80 ° C. for 12 hours, and then a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture. The mixture was extracted with ethyl acetate, and the combined organic layer was washed with a saturated aqueous solution of sodium chloride. After that, the combined organic layer was continuously passed through a rapid pad of anhydrous sodium sulfate and silica gel, and concentrated in vacuo. The residue was chromatographed on a silica gel column using a 2: 1 hexane and ethyl acetate mixture as eluent to give the title compound as a colorless solid (161 mg, yield: 15%). mp 1 19-120 ° C. IR (KBr): u max 3 2 8 2, 1, 664, 1 5 09, 1 3 83, 1 268, 1214, 9 3 5, 707 cm " 1. iH-NMR (40 0MHz, DMSO-d6) ... δ 8.85 (1H, s), 7.65 (2H, d5 J = 8.8 Hz), 7.50 (1H, d, J = 8.4 Hz), 7.24-7.05 (7H, m) , 6.69 (2H, d, J = 7.2Hz), 6.07 (lH, d, J = 8.0Hz), 3.77 (2H, s), 3.64-3.58 (1H, m), 1,17 (6H, d , J = 5.6 Hz). FABMS (m / z): 5 3 6 ([M + H] +) · -536- 200401770 (Example 234) 2-benzyl-6-iodine 3- 3- [2 -methyl 4--4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (Exemplified compound number 7-5 7 9)

F

In a similar manner as described in Example 1, 5-iodoanthranilic acid (5.80 g, 22.0 mmol), phenylacetic acid (3.00 g, 22.0 mmol), and triphenyl diacetate (5.80 ml, 22.0 mmol) And 2- (4-amino-3 -methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (5.08, 18.3 111111〇1) The title compound was obtained as a colorless solid. This product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals (1.72 g, yield: I5%). mp 176-17 70C. IR (KBr ”vmax 3 280, 1 672, 1591, 1 465, 1 270, 1210, 971, 715 cm'1.] H-NMR (500MHz, DMSO-d6): δ 8.90 (1H5 s) 5 8 · 39 (1H, d5 J = 2.4 Hz), 8.21-8.18 (1H, m), 7.64-7.49 (4 H, m), 7.21-7.07 (3H, m), 6.66 (2H, d, J = 7.6 Hz), 3.8 5 -3.75 (2H, m), 1.51 (3H, s) · FABMS (m / z): 619 ([M + H] +) · (Example 23 5) 2 -Benzyl-4-keto- 3- [4 · [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl-537- 200401770 yl] phenyl] -3, 4 -dihydro-6 -quinaline residue acid (Exemplified compound number 3 -23 3 8)

In a similar manner to the above Example 2 3 0, 2-benzyl-6-iodine 3- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (Trifluoromethyl) ethyl] phenylb 4 (3H) -quinazolinone (518 mg, 0.86 mmol), palladium (Π) acetate (19 mg, 0.086 mmol), triphenylphosphine (45 mg5 0.17 mmol), triethylamine (0.24 ml, 1.70 mmol) and water (0.31 ml, 17.0 mmol) to obtain the title compound as a colorless solid (129 mg, yield: 29%). mp 267-268 ° C. IR (KBr): y max 3 3 9 3, 1 699, 1 590, 1 5 62, 1 270, 1 2 1 7, 9 3 4, 709 ^ -NMR (500MHz, DMSO- d6): δ 8.95 (1H5 s) 5 8.6 3 (1 H5 s) 5 8.32 (1H, d, J = 7.0 Hz), 7.79 (1H, d, J = 8.5 Hz), 7 · 68 (2H, d, J = 8.5 Hz), 7.34 (2H, d, J = 8.5 Hz), 7.18-7 · 06 (3H, m), 6.76 (2H, d, J = 7.0 Hz) , 3.85 (2H, s) · FABMS (m / z): 5 2 3 ([M + H] +). (Example 2 3 6) 2-benzyl-3- [4- [2, 2, 2 -Trifluoro-1 · hydroxy-1- (trifluoromethyl) ethyl] phenyl] pyridine [3,4-d] pyrimidin-4 (3H) -one-538- 200401770

In a similar way as described in Example 1, 3-aminoisonicotinic acid (122 mg, 0.96 mmol), phenylacetic acid (131 mg, 0.96 mmol), triphenyl phosphate (300 mg, 0.96 mmol) and 2 -(4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (250 mg, 0.96 mmol) to give the title compound as a colorless solid (216 mg, Yield: 47%). The resulting product was recrystallized from a mixed solvent of methanol and ethyl acetate to produce colorless orthorhombic crystals. mp 261-262 ° C. IR (KBr): vmax 3393, 3065, 3031, 1690, 1590, 1421, 1269, 1214, 1 190, 93 8 cm1. 'H-NMR (400MHz, DMSO-d6): δ 9.13 (1H5 s) 5 8.9 3 (1 H? S), 8.72 (1H, d, J = 5.1 Hz), 7.97 (1H, d, J = 5.1 Hz), 7.70 (2H, d, J = 8.1 Hz), 7.35 (2H, d, J = 8.1 Hz), 7.19-7.08 (3H, m), 6.78 (2Η, d. J = 8.8 Hz), 3.88 (2H, s). FABMS ( m / z): 48 0 ([M + H] +). (Example 2 3 7) 2-benzyl-6-methoxy-3- [3- [2,2,2-trifluoro-1 -Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone (Exemplified compound number 8-504) 200401770

In a similar manner to the above Example 201 (2), the 2-benzyl-6-methoxy-4H-3,1-benzofluorenyl-4-one (i85) prepared from the above Example 213 (2) mg, 0.692 mmol), triphenyl phosphonate (215 mg, 0.693 mmol), and 2- (3-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol ( 179 11 ^, 0.6911] 1111〇1) The title compound was obtained as a colorless solid (3 29 mg, yield: 94%). The resulting product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless needles. 0 mp 191 -192 ° C. IR (KBr): vmax 1 680, 1618, 1 492, 1 3 70, 1 269, 1 208, 1188, 962 cm'1. 'H-NMR (400MHz? CDC13): δ 7.73 (2H? D? J = 9.5 Hz)? 7.63 (1H, d, J = 2.9 Hz), 7.43 -7.3 6 (3 H, m), 7.17-7.10 (3H, m), 6.96 (1H, d, J = 8.8 Hz), 6.7 8 -6.7 5 (2H, m), 3.97 (1H, s), 3.94-3.81 (2H, m), 3.91 (3H, s). FABMS (m / z): 509 ([M + H] +). (Example 23 8) 6-methoxy- 2-[(5-methyl-2-pyridyl) methyl] -3- [4- [2,2, 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (311) _quinazolinone (exemplified compound number 3-2 3 4 0) -540- 200 401770

In a similar manner to Example 2 0 9 above, (5-methyl-2 -pyridyl) acetic acid (105 mg, 0.69 mmol), ν, N1-carbonyldiimidazole (112 mg, 0.69 mmol), 5 -Methoxy-o-aminobenzoic acid (105 mg, 0.63 mmol), triphenyl phosphonate (180 μΐ, 0.69 mmol), and 2- (4-aminophenyl) -1,1,1,3, 3,3-hexafluoro-2-propanol (163 mg, 0.63 mmol) to obtain the title compound as a colorless solid (72 mg, yield: 27%). The resulting product was reconstituted in a mixed solvent of hexane and ethyl acetate Crystallize to produce colorless orthorhombic crystals. mp 147-150 ° C. IR (KBr): V max 1 6 1 8, 1 5 9 5, 1 49 1, 1 27 1, 1 2 1 5, 1 1 93, 1 1 79, 93 7 cm'1 W-NMR (400MHz, CDC13): δ 8 · 27 (1H, s), 7.98 (1H, s), 7.77 (2H, d, J = 8.8 Hz), 7.65 (1H, d5 J = 8.8 Hz ), 7.64 (1H, d, J = 2.9 Hz), 7.38 (1H, dd, J = 8.8, 2.9 Hz), 7.19 (2H, d, J = 8.8 Hz), 5.23 (1H, s), 4 · 06 (2H, s), 3.92 (3H, s), 2.53 (3H, s). FABMS (m / z): 5 2 5 ([M + H] +). (Example 2 3 9) 6 -Methoxy- 2-[(5-methyl-2-pyridinyl) methyl] -3- [2-methyl- 4- [2,2,2-trifluoro-1-hydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3 Η) -quinazolinone (Exemplified compound number 7-5 8 0) -541- 200401770

In a similar manner to the above Example 209, (5-methyl-2-pyridyl) acetic acid (120 mg, 0.79 mmol), N, N'-carbonyldiimidazole (128 mg, 0.79 mmol), 5- Methoxy o-aminobenzoic acid (120 mg, 0.72 mmol), triphenyl diacetate (206 // 1, 0.079 mmol) and 2- (4-amino group prepared in Example 65 (1) above -3-methylphenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (196 11 ^, 0.72 111111〇1) to obtain the title compound as a colorless solid (145 mg, yield 38%), the resulting product was recrystallized from a mixed solvent of hexane and ethyl acetate to produce colorless orthorhombic crystals. mp 153-1560C. IR (KBr): umax 1680,1617,1597,1490,1362,1273,121 1,1148, 972 cm'1.! H-NMR (400MHz, CDC13): δ 8.28 (1H? s) 7.95 (1H? S)? 7.67 (1H, d, J = 8.8 Hz), 7.67 (1H, s), 7.65 (1H, d, J = 2.9 Hz), 7.58 (1H, d, J = 8.8 Hz), 7.39 (1H, dd, J = 8.8, 2.9 Hz), 7.08 (1H, d, J = 8.8 Hz), 5.38 (1H, s), 4.001-3 · 91 ( 2Η, m), 3.92 (3H, s), 2.53 (3H, s), 2.02 (3H, s). FABMS (m / z): 5 3 9 ([M + H] +). (Example 240)- 542- 200401770 2-benzyl chloride 4- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] pyridine [3,4-d] Pyrimidine-4 (3 Η) -one

In a similar way to Example 1 above, according to the literature ((: 0 (^^ 11 to & 1 · [Cockerill, S., stubberfield, C., Stables, J ·, Carter, M ·, Guntrip, S ·, Smith, K ·, McKeown, S., Shaw, R ·, Topley, P ·, Thomsen, L ·, Affleck, K ·, Jowett, A ·, Hayes, D., Willson, M ·, Woollard, P.5 Spalding, D.5 Bioorg. Med. Chem. Lett., 1 1,1 40 1-1 405 (200 1)]) 5-amino-2-chloroisonicotinic acid (240 mg, 1.39 mmol), phenylacetic acid (190 mg 5 1.39 mmol), triphenyl phosphonate (430 mg, 1.39 mmol), and 2- (4-aminophenyl) -l, l, l, 3,3,3 -Hexafluoro-2-propanol (3 40 mg, 1.3 mmol) to obtain the title compound as a colorless solid (170 mg, yield: 20%). The resulting product was recrystallized from a mixed solvent of hexane and diethyl ether Mp 233-234 ° C. IR (KBr): > max 3 08 8, 1 69 8, 1 5 8 0, 1 269, 1 1 7 8, 93 6 cnT1. 'H- NMR (400MHz5 DMSO-d6): δ 8 · 96 (1H, s) 5 8 · 91 (1H, s), 7.97 (1H5 s)? 7.68 (2H5 d, J = 8.6 Hz) 3 7.3 3 (2 H, d5 J = 8.6 Hz), 7.18-7.0 7 (3H, m), 6.77 (2H, d, J = 7.0 Hz), 3.86 (2H, s). -543- 200401770 FABMS (m / z): 5 1 4 ([Μ + Η] +) · (Example 241) 6-methoxy- 2-[(2-methyl-5-pyrimidinyl) methyl] -3- [4- [2,2,2-trifluoro_1 · 经-1- (diaminomethyl) ethyl] benzyl] -4 (3Η)-卩 quine 坐 坐 坐 醒 (exemplified compound number 3-2341)

In a similar manner to Example 1 above, 5-methoxy-o-aminobenzoic acid (2 mg, 0.67 mmol), (2-methyl-5-pyrimidinyl) acetic acid (102 mg, 0.67 mmol), and dish acid Triphenyl ester (129 μI, 0.74 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (173 mg, 0.67 mmol ) The title compound was obtained as a colorless solid (72 mg, yield: 20%). The resulting product was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 210-212 ° C. IR (KBr): vmax 1684, 1617, 1596, 1492, 1449, 1271, 1215, 1179, 93 8 cm '' H-NMR (400MHz5 DMSO-d6): δ 8.96 (1H? s ) 5 8.3 5 (2 H? S)? 7.85 (2H, d, J = 8.8 Hz), 7.63 (2H, d, J = 8.8 Hz), 7.55 (1H, d, J = 8.8 Hz) , 7.48 (1H, d, J = 2: 9 Hz), 7.43 (1H, dd, J = 8.8, 2 · 9 Hz), 3.87 (3H, s), 3.72 (2H, s) , 2.57 (3H, s). FABMS (m / z): 5 2 5 ([M + H] +). -544- 200401770 (Example 242) 2- [2-benzyl-6-methoxy Methyl-4-keto-3 (4H) -quino-daziolinyl] -5- [2 2 2 -trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzoate (exemplified (Compound No. 7-581)

(1) In a similar manner to that described in Example 62 (1) above, 'Methyl 2-aminobenzoate (12.17 g, 80.5 mmol), hexafluoroacetone trihydrate (1 9.50 g, 8 8.6 mmol), and p -Toluenesulfonic acid (ι · 50 g, 7.90 mmol) to obtain 2-amino-5-5- [2,2,2-trifluoro-1-meryl-1- (trifluoromethyl) ethyl] benzoate Ester (9.70, yield: 36%). (2) In a similar manner to Example 1 above, 5-methoxy-o-aminobenzoic acid (87 9 mg, 5.3 mmol), phenylacetic acid (716 mg, 5.3 mmol), and triphenyl phosphate (1.4 ml5 5.3 mmol) ) And methyl amine [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzoate (1.50 g, (4.7 mmol) to obtain the title compound as a colorless solid (298 mg, yield: 11%). The product produced was recrystallized from a mixed solvent of hexane and ethyl acetate to give colorless orthorhombic crystals. mp 1 96- 1 97 ° C. IR (KBr): 2; max 3 2 3 5, 1 734, 1 65 7, 1 5 9 3, 1 49 2, 1 46 8, 1 268, 1 2 1 6, 9 6 5 cm'1. 1H-NMR (400MHz5 CDC13): δ 8.38 (1H? S) 5 7.77-7.74 (2H5m)? -545- 200401770 7 · 63 (1H, d, J = 2 · 7 Ηζ), 7.41 (1H, dd, J = 6.7 Hz), 7.11-7.02 (3H, m), 6.89 (1H, d, J = 8.2 Hz), 6.65 (2H, d, J = 7.4 Hz) , 5.13 (1H, s), 3.92 (3H, s), 3.90-3.70 (2H, m), 3.54 (3H, s). FABMS (m / z): 5 6 7 ([M + H] +). (Example 243) 2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] thiophene [3,2-d ] Pyrimidin-4 (3H) -one

Phenylacetamyl chloride (940 mg, 6.10 mmol) was added to tetrahydrofuran containing methyl 3-amino-2-thiophenecarboxylate (500 mg, 3.18 mmol) and triethylamine (640 mg, 6.30 mmol). (10 ml) solution, and the resulting mixture was stirred at room temperature for 2 hours. At the end of this time, the reaction mixture was concentrated, and the residue was diluted with water and extracted with ethyl acetate. The organic layer was continuously saturated with hydrogen carbonate. The solution was washed with sodium solution, water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated in vacuo. The obtained residue was purified by preparative thin layer chromatography to give a pale yellow oil (290 mg, product Yield: 33%), this product was dissolved in tetrahydrofuran (3 ml) and methanol (5 ml), and 10% sodium hydroxide solution (5 ml) was added. The resulting mixture was stirred at room temperature for 36 hours, and the reaction The mixture was acidified with 1N-hydrochloric acid and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride water • 546- 200401770 solution, dried over anhydrous sodium sulfate and concentrated in vacuo to give a pale purple solid. This product and triphenyl phosphate (2 82 mg, 0.91 mmol) were dissolved in pyridine (5 ml), and the mixture was stirred at 100 ° C for 2 hours, and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (235 111§, 0.91111111〇1) into the reaction mixture, the mixture was further stirred at 120 ° C for 4 hours, after this time, the reaction mixture was concentrated in vacuo, the residue was diluted with water, and extracted with ethyl acetate, organic The layers were successively washed with 1N hydrochloric acid and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated in vacuo. The obtained residue was purified by silica gel column chromatography to give a pale yellow solid. This product It was further purified by preparative thin layer chromatography to give the title compound as a colorless powder (57 mg, yield · 13%). mp 257-258 ° C. IR (KBr): ymax 3248, 3088, 1660, 1551, 1268, 1213, 1 187, 937, 7 0 8 cm " 1. W-NMR (400MHz, DMSO-d6): δ 8 · 89, (1H, s) 5 7 · 68 (2H, d5 J = 8.6 Hz), 7.61 (1H, d, J = 5.5 Hz), 7.39 (1H, d, J = 5.5 Hz ), 7.33 (2H, d, J = 8.6 Hz), 7.19-7.08 (3H, m), 6.75 (2H, d, J = 6.3 Hz), 3.82 (2H, s) · FABMS (m / z): 485 ([M + H] +) · (Example 244) 2-benzyl-3- [4- [2,2,2 · trifluoro-1-hydroxy-1- (trifluoromethyl) Ethyl] phenyl] thiophene [2,3-d] pyrimidin-4 (3H) -one • 547- 200401770

In a similar manner to Example 243 above, methyl 2-amino-3-thiophenecarboxylate (500 mg, 3.18 mmol), phenylacetamidinyl chloride (590 mg, 3.18 mmol), and triphenyl phosphate (2 3 6 mg, 0.76 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (197 mg, 0.76 mmol) to give the title compound as a colorless powder (221 mg, yield: 14%). mp 242-243 ° C. IR (KBr): v max 3 08 8, 1 656, 1 5 5 9, 1 267, 1 1 8 5, 93 8, 7 1 0 cm ·]. 'H-NMR (400MHz DMSO-d6): δ 8.89? (1H? S)? 8.24 (1H? D5 J = 5.5 Hz), 7.6 7 (2H, d, J = 8.6 Hz), 7.46 (1H, d, J = 5.5 Hz), 7.32 (2H, d, J = 8.6 Hz), 7.18-7.06 (3H, m), 6.73 (2H, d, J = 6.3 Hz), 3.83 (2H, s), FABMS (m / z): 48 5 ([M + H] +). (Example 245) 2-benzyl- 3- [4- [2,2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ) Ethyl] phenyl] thiophene [3,4-d] pyrimidin-4 (3H) -one-548- 200401770

In a similar manner to Example 243 above, 4-amino-3-thiophenecarboxylic acid methyl ester (500 mg, 3.18 mmol), phenylacetamidinyl chloride (590 mg, 3.18 mmol), and triphenyl phosphate (3 2 6 mg, 1.05 mmol) and 2- (4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (272 11 ^, 1.05 111111〇1) to obtain the title compound Colorless powder (146 mg, yield: 10%). mp 253-254 ° C. IR (KBr): 2; max 3 1 1 2,1 66 1,1 59 1,1 270,1 2 1 3,1 1 87, 9 3 8, 70 8 cm-1. iH-NMR (400MHz, DMSO-d6): δ 8.89, (1H, s), 8.54 (1H, d, J = 2.9 Hz), 7.89 (1H, d, J = 2.9 Hz), 7.66 (2H, d, J = 8.8 Hz), 7.29 (2H, d, J = 8.8 Hz), 7.19-7.08 (3H, m), 6.75 (2H, d, J = 6.6 Hz), 3.74 (2H, s ). FABMS (m / z): 4 8 5 ([M + H] +). (Example 246) 2-benzyl-7-nitro- 3- [4- [2,2,2-trifluoro -1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone-549- 200401770

In a similar way as described in Example 1, 4-nitroanthranilide (1.82 g, 10.0 mmol), phenylacetic acid (1.36 g, 10.0 mmol), triphenyl phosphate (2.90 ml, 11.0 mmol) and 2 -(4-aminophenyl) -1,1,1,3,3,3-hexafluoro-2-propanol (2.50 g, 9.60 mmol) to obtain the title compound as a pale yellow solid (2.14 g, yield: 41%). mp 264-266 ° C. IR (KBr): ^ max 3363,1698,1594,1530,1347,1269,1220,1173, 93 3,7 1 1, 934 cm 'iH-NMR (400MHz, CDC13): ό 8.6 5 (1 H, d, J = 2 · 0 H z), 8.4 3 (1H, d, J = 8.8 Hz), 8.27 (1H, dd, J = 8.0, 2.0 Hz), 7.76 ( 2H, d, J = 8.8 Hz), 7.22-7.16 (lH, m), 7.16-7.10 (2H, m), 7.06- 7.00 (2H, m), 6.73 (2H, d, J = 8.0 Hz) , 3.94 (2H, s). ESIMS (m / z): 5 2 3 ([M] +). (Example 247) 7-amino-2-benzyl-3- [4- [2,2, 2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone-550- 200401770

In a similar manner as described in Example 137, 2-benzyl-7-nitro-3- [4- [2,2,2-trifluoro-1-hydroxy-1- ( Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone (1.40 g, 2.70 mmol) and carbon (10 mg) containing 10% palladium hydroxide to obtain the title compound as a colorless solid (1.28 g , Yield: 9 7 0 / 〇) ° mp 262-264 ° C. IR (KB r): vmax 3355, 3226, 1658, 1608, 1374, 1270, 1214, 1187, 93 6, 709 cm · 1. W -NMR (400MHz, CDC13): δ 8.00 (1H, d, J = 8.0 Hz), 7.67 (2H, d, J = 8.4 Hz), 7.16-7.04 (3H, m), 6.94-6.8 8 (3H, m ), 6.79 (1H, dd, J = 8.8, 2.0 Hz), 6.68 (2H, d, J = 8.0 Hz), 3.87 (2H, s) · ESIMS (m / z): 493 ([M] + ). Test Example (Test Example 1) Binding Affinity to LXR (1) Synthesis of 2- (6-hydroxy-3-keto-3H-containing [Jj-9-yl] -5-[[[6-ketone Group-6-[[3-[(phenylsulfonyl) -4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] anilino] propyl] Amine] hexyl] amino] carbonyl] benzoic acid and 2- (6-hydroxy-3-one-551- 200401770- 3H-methyl-1-9-yl) -6-[[[6 -keto-6 -[[3-[(phenylsulfonyl) -4- [2,2,2-tri A mixture of fluoro-hydroxy-1- (trifluoromethyl) ethyl] anilino] propyl] amino] hexyl] amino] carbonyl] benzoic acid (hereinafter the mixture is referred to as compound A).

(a) N- (3-Aminopropyl) -N- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] benzenesulfonium Ammonium Potassium carbonate (168 mg, 1.2 mmol) and 1-bromo-3-chloropropane (0.15 ml, 1.5 mmol) were added to a solution containing N- [4- prepared according to the method described in Example 2 of WO 00/547 5 9 [2,2,2-Trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] -phenyl] benzenesulfonamide (400 mg, 1.0 mmol) in dimethylformamide (5 ml) The solution was stirred at 50 ° C for 7 hours. At the end of this time, the reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate. The organic layer was saturated with sodium chloride aqueous solution. Rinse and dry over anhydrous magnesium sulfate, then remove the solvent in vacuo to give a colorless oily residue. This residue is chromatographed on a silica gel column (using hexane and acetic acid in a volume of 7: 3). The ethyl ester mixture was purified as -552- 200401770 eluent) to give an indivisible mixture (37 ng) of the target compound N- (3-chloropropyl) -N- [4- [2,2,2 -Difluoro-1-meryl-1- (trifluoromethyl) ethyl] phenyl] benzenesulfonamide, and by-product N-allyl-N- [4- [2,2,2 -Trifluoro-b-hydroxy-1- (trifluoromethyl) ethyl] phenyl] benzenesulfonamide. Sodium azide (1 3 1 mg, 2.0 mm ο 1) was added to a dimethylformamide (5 ml) solution containing the mixture obtained above, and the resulting mixture was stirred at 60 ° C After 7 hours, the reaction mixture was diluted with water (100 ml) and extracted with ethyl acetate. The organic layer was then washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate, and the solvent was removed in vacuo to produce a colorless solution. Oily residue (373 mg). 10% palladium-containing carbon (1 13 mg) was added to a solution of ethanol (10 ml) containing the residue obtained in the previous step, and the resulting mixture was vigorously stirred at room temperature under hydrogen pressure for 1 hour At the end of this time, the reaction mixture was filtered, and the filtrate was concentrated in vacuo to give an oily residue. The residue was diluted with ethyl acetate to form a crystalline solid, which was filtered to give the title compound as colorless crystals (124 mg , Yield: 27%). mp 187-188 ° C. IR (neat): v ma x 1 3 4 6, 1 2 6 3, 1 2 1 5, 1 1 6 8 c m_1. 1H-NMR (400MHz5 CDCl3 + DMSO-d6): δ 1.46 (2H? Quintet, J = 7Hz), 2.69 (2H, t, J = 7Hz), 3.54 (2H, t, J = 7 Hz), 7.00-7.03 (2H, m), 7.34-7.61 (7H ， M). MS (FAB) m / z: 45 7 ([M + H] +). HRMS (ESI) (m / z): calcd. For C】 8 H! 9 F 6N 2 0 3 S ([ M + H]) +: 457.1021; found: 457.1027. -553- 200401770 (b) 2- (6-hydroxy-3-keto-yl) -5-[[[6-keto-6-[[3 -[(Phenylsulfonyl) -4- [2,2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] aniline] propyl] amino] hexyl] amino] Carbonyl] benzoic acid and 2- (6-hydroxy-3-keto-3H -_- 9-yl) -6-[[[[6-keto-6-[[3-[(phenylsulfonyl) A mixture of -4- [2,2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] aniline] propyl] amino] hexyl] amino] carbonyl] benzoic acid will fluoresce Fluorescein-5 (6) -carboxyamidohexanoic acid N-succinimide (Fluka) (100 mg, 0.17 418 mmol) and phosphate buffer (0.5 0 ml) at pH6.9 were added to Contains N- (3-aminopropyl) -N- [4- [2,2,2-tri -Buhydroxy-1- (trifluoromethyl) ethyl] phenyl] -benzenesulfonamide (82 mg, 0.18 mmol) in dimethylarsine (3 ml) and the resulting mixture After stirring at room temperature for 2 hours, at the end of this time, the reaction mixture was diluted with ethyl acetate, washed successively with water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and then concentrated in vacuo to give the crude title. Compound, and the obtained crude compound was purified twice by silica gel column chromatography (using ethyl acetate as eluent) to give the title compound (132 mg, yield: 79%). Retention time: 4.95 minutes [HPLC operating conditions: Inertsil ODS-3 (GL science), 4.6 mmF> 250 mmL, acetonitrile: buffer solution [aqueous solution containing 2% acetic acid and 2% triethylamine (Wv)] = 6 : 4 (v / v), and 1 ml / min]. IR (neat): v max 3 3 8 4, 2, 9 3 8, 1, 7 4 2, 1, 6 4 3, 1 6 1 3, 1 5 4 4, 1 5 0 8, 1176, 1111 cm ·, MS ( FAB) m / z: 92 8 ([M + H]) + HRMS (ESI) (m / z): calcd. For C45H40F6N3O10S ([M + H] +): -554- 200401770 92 8.23 3 9; found: 928.2342. (2) Preparation of human LXRa encodes a glutathione-S-transferase [abbreviated " GST ", derived from pGEX-4T-3 (Amersham Pharmacia Biotech)] and human LXR α Ligand-recombinant expression vector of the fusion protein of the binding body (abbreviated as "LBD"), the above fusion protein is referred to as "GST-LXRa LB D", and polymerase chain reaction (abbreviated " PCR ") is used Obtained; E. coli transfected with the vector was cultured, and GST-LXRa LBD was collected from the culture product. First, a sequence recognized by the restriction enzymes Sail or Notl is added to a sequence containing a human LXR α sequence [gene bank catalog number U22 662 5 97 to 1 3 79] [see PJ Willy et al., Genes Dev. 9 (9), 1 03 3- 1045 (1995)]], and an oligonucleotide set having the following nucleotide sequence was synthesized and inserted into the expression vector PGEX-4T-3 (Amersham Pharmacia Biotech). 5, -CACGACGTCGACCATGCCCATCCTTGCCC-3, (α 1); sequence number 1 in the sequence listing. 5, -CACGACGCGGCCGCTCATTCGTGCACATCCCAGAT-3 ,: (α 2); in the order of the sequence listing 歹 [J 号 2. Second, repeat the cycle 6 times to execute pc R. Each cycle consists of heating cycles at 9 4 ° C 4 5 seconds, 1 minute at 5 8 ° C and 1 minute at 7 2 ° C. Human liver cDNA is used. Library [see PJ Willy et al., Genes Dev · 9 (9), 1 0 3 3-1 0 4 5 (19 9 5)] as a template, and the above-mentioned α 丨 and α 2 oligonucleotides as The primers were then subjected to 23 heating cycles consisting of 94 t 45 seconds, 1 minute at 62 ° C and 1 minute at 72 ° C. The amplified polynucleotide fragment was selected into -555- 200401770 TOPOfc fi (Invitrogen) and the inserted nucleotide sequence was determined according to standard methods; the nucleotide sequence number was 5 in the sequence listing. Subsequently, the recombinant vector generated by treatment with the restriction enzymes Sail and Notl, the inserted fragment was recovered and re-selected into the expression vector PGEX-4T-3 (Amersham Pharmacia Biotech). The E. coli strain TOP10F '(InViUogen) was transformed with the generated recombinant vector, and the transformed strain was cultivated in 5 m 1 of L-broth medium containing 100 μg / m 1 apicillin [Prepared by dissolving 10 g of tryptone (Difco), 5 g of yeast extract (Difco), and 5 g of sodium chloride in 1 liter of water], followed by culturing at 37 ° C for 4 hours with shaking. At the end of this time, 0.1-mM isopropyl-cold-D-thiogalactoside (abbreviated as "IPTG", Amersham Pharmacia Biotech) was added and subsequently cultured with shaking at 25% for 17 hours. Done After incubation, centrifugation was performed at 8000 xg for 10 minutes, and then the precipitate was collected and resuspended in 50 ml of Dulbecco's phosphate buffer solution (pH 7.l; Gibco; abbreviated " PBS "). After the suspension was treated with ultrasound, 1% (v / v) Triton X-100 was added and shaken gently at room temperature for 30 minutes. After centrifugation at 11,000 < g for 15 minutes, the supernatant was separated and collected, and 0.5 ml of glutathione agar 4B colloid (Amersham Pharmacia Biotech) was added, followed by shaking for 30 minutes. Colloids were collected by centrifugation and washed three times with pbs and 50-mM Tris HC1 buffer (ρΗ8 · 0), and 2 ml of a 10-mM reduced glutathione solution (50-mM Tris-HCl, Η8 · 0) was added. The product of the supernatant was collected again by centrifugation, and 12.5% polyacrylamide-sodium dodecyl sulfate colloid electrophoresis (abbreviated as " SDS-PAGE ") was performed, and the molecular weight of the resulting fusion protein was -556- 200401770. It was determined to be about 5 8,000. In addition, the protein concentration of the fusion protein was measured by the Bradford method using a protein test dye solution (BIO RAD) and a reference protein (bovine blood albumin). (3) Human LXRP The preparation was performed using a method similar to the preparation method using human LXRa described in Test Example 1 (2), and a recombinant expression vector encoding GST and human LXRP LBD (abbreviated " GST-LXRp LBD ") was obtained by PCR, followed by cultivation The vector was transformed into E. coli and GST-LXRp LBD was collected from the culture product. First, a sequence recognized by the restriction enzyme EcoRI or Xhol is added to a gene containing the LBD sequence encoding human LXR々 [gene bank catalog number U07132, nucleotide numbers 836 to 1063 [see DM Shinar et al., Gene 147 (2 ), 273 -27 6 (1 994)]], and an oligonucleotide set having the following nucleotide sequence at both ends was synthesized and incorporated into the expression vector pGEX-4T-3 (Amersham Pharmacia Biotech). 5, -TCAGCCGAATTCGCCTGGGGCTTCCCCTGGTGG-3 ,: (β 1); sequence number 3 in the sequence listing. 5, -CCTAGCCTCGAGTCACTCGTGGACGTCCCAGA-3 ,: (β 2); sequence number 4 in the sequence listing. Second, PCR was performed according to the same procedure as described in Test Example 1 (2) above, using a polynucleotide encoding human LXR / 3 [see P. J. Willy et al., Genes Dev. 9 (9), 103 3-1 045 (1 995)] as a template, and the above listed oligo 1 and 々 2 oligos as primers, and then inserted into the TOPO vector (Invitrogen) via the selective amplified polynucleotide fragments, and determined the insertion according to standard methods Nucleotide sequence; the nucleotide sequence number is 6 in the sequence listing. -557- 200401770 The recombinant vector generated by restriction enzyme EcoR and Xhol treatment, the inserted fragment was obtained again and cloned into the expression vector PGEX-4T-3 again. The E. coli strain TOP10F '(InVitrogen) was transformed with the generated recombinant vector, and the transformed strain was cultured according to the method described in Test Example 1 (2) above, and collected from the culture product by the method of Test Example 1 (2) above. Desired fusion protein. The molecular weight determined by SDS-PAGE under reducing conditions is about 58,000. In addition, the protein concentration of the fusion protein was measured according to the method described in Test Example 1 (2) above. (4) LXR binding test using fluorescent polarity was added to InM Compound A prepared in Test Example 1 (1) above to a buffer solution [10-mM HEPES, 0.1-mM EDTA 3Na, 10_mM (soil) -dithiothreitol (dithiothreitol, DTT), 20% (v / v) extremely pure bovine globulin (PanVera Corporation); this buffer solution is hereinafter referred to as "binding buffer solution"]; a buffer solution containing compound A is hereinafter referred to as Add "FIT C-ligand binding buffer solution". Put 90 μΐ of FITC-ligand-added binding buffer solution and 10 μΐ of GST-LXRaLBD obtained from the above Test Example 1 (3) obtained in the above Test Example 1 (2) into a 96- Hole in flat plate. The control group was placed in a 96-well flat plate with 90 μ1 of FITC-ligand binding buffer solution and 10 μ1 of 50-mM Tris-HCl buffer solution (PQ8 · 0), and the blank group was combined with a buffer solution and 50 ml Tris-HCl (ρΗ8.0) was placed into the well. The flat plate was then maintained at 4 ° C for 12 hours, and then at room temperature for 1 hour. The fluorescence polarity of the solution was measured with a fluorescence polarimeter (Analyst, LjL Inc.). The measurement conditions were as follows: Dynamic reading Cycle ·· 1 of 1 -558- 200401770 Read start delay: Time delay between dynamic reads: Microdisk format: Oscillation time: Temperature: Serial number: Read sequence: Pattern sequence: Detection mode: Photoreceptor: Excitation edge: Scattering edge: Lamp: Read per well: Time between readings: Integration time: Attenuator mode: Operating set time: z Height: Excitation filter: Divergence filter: Beam shunt: Excitation polarity filter: Diffuse polarity filter: < n / a > Coming Costar 96 PS solid Os room temperature ANO107 column hole FPS HC- 1 20 top continuous 3 10 0ms 100,000 us 0 15 0 ms 2mm number 1 fluorescence 485nm 1 fluorescence 5 3 0nm top fluorescence (5 0 5 nm) ss -559- 200401770 Detector count: Flashing lamp voltage: Delay after flashing: Sensitivity setting: A / D converter groove: Integration groove: Detection mode: Photoreceptor: excitation : Scattering edge: Lamp: Reading per well: Time between readings: Integration time: Attenuator mode: Operation setting time: Z locality: Excitation polarity filter: Divergence polarity filter: Beam shunt: Excitation polarity filter : Divergence polarity filter: Detector count: Flashing lamp voltage: < n / a > < n / a > < n / a > < n / a > < n / a >

FPP HC- 1 20 Top Top Continuous 3 10 0ms 100,000 us out 15 0ms 2 mm number 1 Fluorescent 485 nm 1 Fluorescent 5 3 0 nm Top Fluorescent (5 0 5 nm) s

P-digit < n / a > -560- 200401770 Asking after delay: Sensitivity setting: A / D converter slot: Integration slot: < n / a > < n / a > < n / a > < n / a > The average fluorescent polarity in the control group (mP) is subtracted from the presence of protein (P) to measure the tapeworm photopolarity (ΔηιP). Mapping of protein concentration & 1012. The results indicate that the fluorescence polarity increases with the increase in the white matter fe, and it is confirmed that compound A binds to both gsT-LXR α LBD and GST-LXRf LBD. LXRa LBD ZKd 値 is 143 nM, and cold LBD for GST-LXR is 1.17 // M. These properties were used in the following Test Example 1 (5) to be able to measure Ki 値 of the compound of the present invention. (5) Measurement of Ki 値 Ki 値 of the test compound against LXR was measured as follows. LXR binding buffer solution is prepared with the following composition: LXR binding buffer solution

HEPES: 10 mM EDTA 3Na: 0.1 mM (±) -dithiothreitol (DTT): 10 mM extremely pure bovine globulin 5 mg / ml (PanV era Corporation): 20% (v / v) GST- LXRa LBD or GST-LXRp LBD: 4 0 μ g / m 1 Compound A ··· InM The test compound was dissolved in DMSO to obtain a solution with a concentration of ImM -561- 200401770. This solution was diluted by performing 9 dilution steps. To various concentrations, each step is to obtain a 10-fold dilution of the last dilution. 95 μΐ of LXR binding buffer solution was placed in each well of a 96-well flat plate with a black bottom, and then 5 μ 试验 of the test compound solution was added to each well. One well containing LXR-binding buffer solution was added as the negative control group by adding the same amount of (5 [il] DMSO) to the test compound solution. In addition, 5 μ1 of DMSO was added to 95 μ1 of the above-mentioned test example 1 (4) as “positive control group added FITC-ligand binding buffer solution” as a positive control group, and 5 μΐ of DMSO was added to 95 μΐ of the above test example The "binding buffer solution" defined in 1 (4) was used as the blank solution. After keeping all these solutions at 4 ° C overnight, the solution was allowed to warm to room temperature, and measured in each well using a fluorescence polarimeter (Analyst, LjL Inc.) under the measurement conditions of Test Example 1 (4) above. The fluorescence polarity of the solution. Calculate the inhibition rate of the test compound according to the following equation: Inhibition rate (%) = 100 — (X-A) / (B-A) xl00 X: Fluorescence polarity (mP) of the solution containing the test substance. A: The fluorescence polarity (mP) of the positive control solution. B: Fluorescence polarity (mP) of the negative control solution. The evaluation of the affinity constants of the compounds, calculated from the concentration-dependent inhibition rates measured above, then determines the activity of the test substrate. The compounds of the present invention exhibit excellent binding affinity for LXR. (Test Example 2) Scintillation proximity assay (SPA)

SPA test measures the radioactive signal generated by the binding of 3 2-2 4,2 5 -epoxy cholesterol to LXR α or LXR -562- 200401770/3. The basis of this test is the use of SPA beads containing scintillators, When it is bound to the receptor, it will bring the labeled ligand and beads into the abutment, and the energy from the label will stimulate the scintillator to emit light. This light is measured using a standard microplate scintillation reader, and the ability of the ligand to bind to the receptor can be measured by assessing the degree of competition between the compound and the radiolabeled ligand with known receptor affinity. [1] Desired substance (1) Label: 3H-24,25-epoxy-cholesterol (Amersham) (2) LXR α cell lysate: prepared in the manner described in Test Example 2 [2] below, baculovirus (Baculovirus) shows crude cell lysate produced by LXRa / RXR heterodimer containing RXR with 6-HIS tag. (3) LXR / 3 cell lysate: prepared in the manner described in Test Example 2 [2] below, baculovirus expressing LXRyg / RXR heterodimer containing RXR with 6-HIS tag, and crude cell lysate produced . (4) SPA beads · Ysi copper His-labeled SPA beads (Amersham) (5) Plate: 96-well plate (Coming) without binding surface (6) Protein cell lysate dilution buffer: (20mM Tris -HCl ρΗ7.9, 500mM NaCl, 5mM imidazole) (7) 2x SPA buffer: (40mM Κ2ΗΡ04 / ΚΗ2Ρ04 7,3,100 mM NaCl, 0.05% Tween 20, 20% glycerol, 4mM EDTA) (8) 2x SPA Buffer solution w / o EDTA: (4 0 m Μ K2 Η P 〇 4 / K Η 2 PO 4 ρΗ7.3, 100 mM NaCl, 0.05% Tween 20, 20% glycerol) [2] LXRa and LXR / 3 cell lysate Preparation of human RXR a, LXR a, LXR / 3 baculovirus expression plastids -563- 200401770 The appropriate full-length cDNAs were cloned into the pBacPakhisl vector (Clontech) by standard methods. The cDNAs were inserted into the pBacPakhisl vector polylinker to generate a framework that was fused to the cDNA to form an N-terminal poly-His tag and stored in pBacPakhisl for restriction enzyme mapping and / or sequencing to confirm correct selection. Cell lysates were prepared by infecting healthy Sf9 insect cells with a density of approximately 1.2 5 x 10 06 cells / ml at 27t. The total volume was 500 ml in a spinner flask per 1 L volume and cultured under standard conditions (by the Invitrogen manual : Growth and maintenance of insect cell lines). To prepare LXR α cell lysates, insect cells were co-transfected with an LXR / 3 performance cassette of 0.5 to 0.8 and a RXR performance cassette of about 1.6 and 0.1. To prepare LXR cell lysates, insect cells were co-transfected with an LXR stone performance cassette of about 1.6 and an RXR performance cassette of about 1.6 and 1.0. In both cases, cells were incubated at 27 ° C for 48 hours before harvesting. After incubation, the cells and pellets were collected by centrifugation (IEC HN-SII centrifuge from International equipment company, 500g, 15 minutes). The cell pellet was resuspended in freshly prepared lysis buffer (20 mM Tris pH 8.0, 10 mM imidazole, 400 mM NaCl), containing 1 ED TA-free protease inhibitor tablet per 10 ml of lysis buffer (Roche Catalogue) No. 1 8 36 1 70)). The DOUnce homogenizer was used to slowly homogenize the cells on ice to achieve 80-90% cell lysis. The homogenate was centrifuged in a pre-cooled rotor (Ti50 or Ti70 from Beckman, or equivalent) at 125,000 g at 4 ° C for 30 minutes. The whole mash was frozen in dry ice and stored in freezing at -80 ° C until quantitative and qualitative control. -564- 200401770 The whole number of cell lysates was tested by SPA to ensure consistency ', and after purification, Ni-NTA resin (Qiagen) was used to analyze the SDS-PAGE to "normalize the concentration and expression of proteins before the screening test was used. [3] Mother liquor 0.5 Μ Κ2ΗΡ04 / ΚΗ2Ρ04 ρΗ7.3 0.5 M EDTA ρΗ8.0 5 Μ NaCl 10% Tween-20 Glycerin [4] Preparation of screening reagents (1) [3H] 24,25 epoxy cholesterol (EC) Add 21 / z 1 [3H] EC (specific activity 76.5Ci / mmol, concentration 3.2mCi / mL) in 4.4mL of SPA buffer to a single 3 84-well flat plate (or 400 wells) to a final concentration of 20OnM. Add 19 · 1 // 1 extra [3H] EC and 4.0mL extra 2x SPA buffer to each additional 3 84-well plate. The final concentration of [3H] EC in the well is 50nM 〇 (2) Protein-containing cells decompose Dilution of LXR α Cell Decomposition in Bio-Dilution Buffer Solution 3 8 4-1 4 0 0 // 1 well-diluted cell decomposition product (or 200 wells) and each additional 3 84 -Diluted LXRa cell decomposed product required for the well plate. (3) Made with the dilution solution lxr0 containing the protein cell decomposed solution dilution buffer. 1400 // 1 diluted LXRa cell breakdown (or 200 wells) and 1 for each additional 3 8 4-well plate required 1 1 2 0 // 1 diluted LX Ra fine 200401770 cells Decomposed product. (4) The SPA small plant solution is used in 3 84-wells (or 400 wells), mixed with 3.75 mL of 2x SPA buffer w / o EDTA, 2.25 ml I H20 and 1.5 mL of Ysi His-marked SPA mini Strain (vortex the hole before inserting it), for the additional 3 84_well flat plate 'mix with an additional 3.5mL of 2x SPA buffer w / o EDTA, 2.1mL of H20 and 1.4mL of Ysi His -Mark the SPA strain to the SPA strain solution. [5] Procedure Use the following procedure to perform the desired test. Prepare the appropriate dilution of each compound and aspirate into the appropriate wells of the multiwell plate. 2- in the multiwell plate [3H] EC of 9.1 // L was added to each well of 23 rows. 5 μL of the diluted LXR α cell decomposition product was added to the odd-numbered rows of rows 2-23 of the multiwell plate.

Add 5 // L of diluted LXR / 3 cell breakdown to the even rows of 2-2 and 3 of the multiwell plate. Add 17.5 // L of SPA strain to each well in rows 2-23 of the multi-well plate. Cover the flat plate with a transparent cover, place the flat plate in an incubator, and incubate at ambient temperature for 1 hour.

Use the program n ABASE3H — 384DPM to count, n ABASE3H — 384DPM to set: Counting mode: DPM Sample type: SPA ParaLux mode: Low background-566- 200401770 Counting time: 30 seconds LXRa and LXR / S tests are performed in the same way The measured Ki represents the average of at least two independent dose-response experiments. The binding affinity of each compound can be determined using a nonlinear regression analysis of the equation of Onestec Ompetiti ο η to determine IC5. , Where: Y = bottom + (top-bottom) / (l + l〇z) Z = X-logIC50. It uses a fixed model of linear and non-linear regression biological data (GraphPad Software, Inc.). 〇 Then use The Cheng and Pirusoff equation calculates Ki 値, where:

Ki = IC5Q / (1 + [Concentration of Ligand] / Kd of Ligand) In this test, the general concentration of the ligand is 50nM and the Kd of the EC to the receptor is 200nM, which is determined by saturation binding. [6] Results Ki 値 of the test compounds is shown in Table 9. Table 9 Examples of test compounds Ki (// M) LXR α Ki (// M) LXR / 3 1 0.508 0.123 2 0.160 0.128 5 0.2 18 0.054 12 0.243 0.079 14 0.27 1 0.149 15 0.528 0.116 -567- 0.43 7 0.62 1 0.25 0 0.103 0.452 0.285 0.300 0.308 0.266 0.470 0.298 0.463 0.242 0.114 1.6 1 0.5 18 0.509 0.636 0.113 0.110 0.289 0.053 0.162 0.053 0.104 0.120 0.038 0.028 0.229 0.103 0.065 0.058 0.049 0.050 0.110 0.065 0.086 0.03 0.053 0.175 0.207 0.105 0.090 0.035 0.030 0.137 0.048 0.059 0.032

-568- 0.149 0.407 0.06 1 0.576 0.191 0.209 0.089 0.159 0.284 0.469 0.550 0.285 0.370 0.285 0.106 0.367 0.32 1 0.233 0.389 0.244 0.442 0.060 0.07 0.175 0.062 0.148 0.038 0.092 0.052 0.057 0.032 0.086 0.051 0.304 0.285 0.170 0.230 0.07 1 0.103 0.079 0.072 0.100 0.133 0.135 0.035 0.087 0.024 0.027 0.059

-569- 0.222 0.062 0.121 0.229 0.199 0.224 0.092 0.446 0.248 0.278 0.34 1 0.197 0.179 0.132 0.109 0.216 0.225 0.064 0.03 1 0.197 0.103 0.148 0.45 1 0.143 0.066 0.03 0.062 0.050 0.101 0.079 0.061 0.075 0.063 0.09 0.019 0.091 0.024 0.034 0.042 0.042 0.078 0,066 0,113 0.044 0.010 0.040 0.06 1 0.082 0.042 0.097

-570- 200401770 208 0.119 0.096 2 12 0.144 0.085 2 14 0.163 0.044 2 17 0.207 0.070 220 0.032 0.012 22 1 0.441 0.069 222 0.060 0.028 227 0.064 0.035 229 0.131 0.03 1 23 0 0.102 0.049 23 3 0.123 0.063 236 0.028 0.007 23 7 0.0 7 2 0.023

As shown in Table 9, the compound of the present invention exhibits excellent binding affinity for LXR and is therefore useful as a medicine for treating or preventing arteriosclerosis, atherosclerosis, hyperlipidemia, other fat-related diseases, inflammatory diseases, and the like . (Test Example 3) Co-transfection test To measure the ability of a compound to activate or inhibit the transcriptional activity of LXR in a cell-based test, a co-transfection test can be used, which has shown that LXR functions as a heterodimer containing RXR. In a co-transfection test, plastids expressing LXR and RXR were introduced into mammalian cells by temporary transfection. As the luciferin reporter protoplasts containing a copy of the DNA sequence entered, they were bound by lxr_rxr heterodimer. [LXRE; Willy, P. JN et. Al ”Genes Dev., 9,1033-1045 (1 995)]. Treatment of transfected cells with LXR activator increases LXR transcriptional activity, -571- 200401770 which increases wormworm Photosynthetic activity can be measured, and similarly, LX R antagonist activity can be measured by determining the ability of a compound to competitively inhibit LXR activators. [1] Desired substance (1) CV-1 African green monkey kidney cells ( 2) Co-transfected expression plastids, CMX-hLXR α or CMX-hLXR cold, CMX-RXR, reporter (LXRExl-Tk-luciferase), and control group (CMX-galactosidase expression vector) [Willy, P. J. et al., Genes Dev., 9, 1033-1045 (1995)] (3) Transfection reagents, such as FuGENE6 (Roche) (4) lx cell decomposition buffer (l% Triton X 100 (JT Baker X200-07), 10% glycerol (JT Baker M778-07), 5 mM dithiothreitol (Quantum Bioprobe DTT03; freshly added before decomposition), ImM EGTA (ethylene glycol- (B-aminoethyl ether) -N, N, N, N'-tetraacetic acid) (Sigma E-43 78), 25 mM N-tris (hydroxymethyl) methylglycine (Tricine) ( ICN 807420) ρΗ7 · 8) (5) lx luciferase test buffer (pH7.8) (0.73mM ATP '22.3mMN-tris (hydroxymethyl) methylglycine, O.llmM EDTA, 33.3 mM DTT) (6) lx luciferin / CoA (llmM luciferin, 3.05 μM CoA, 10 mM HEPES) [2] Preparation of screening reagents CV-1 cells were prepared 24 hours before the experiment, by It was placed in a T-l75 flask or 500 cm2 dish so that it reached 70-80% confluence on the day of transfection. The number of transfected -572- 200401770 cells was determined by screening the number of plates. Each 3 84-well plate Requires 1.92X 106 cells or 5,000 cells per well. DNA transfection reagents are prepared by mixing the required plastid DNAs with cationic fat transfection reagents such as DOTAP or FuGENE6 according to the instructions provided by the reagents. Ideal DN A The amount is determined by experimenting with the size of each cell line and transfection bottle. Add 10-1 of 2 mL of medium to the DNA transfection reagent, and add this mixture to a T175 cm2 flask after the culture medium has been withdrawn. Incubate at 37 ° C for at least 5 hours to prepare cells for selection. Preparation of luciferase test reagents by combining them before use (per 10 mL): 10 mL of lx luciferase buffer, 0.54 mL of lx luciferin / CoA, and 0.54 mL of 0.2 M Magnesium sulfate. [3] Step Prepare 0.5 μL of ImM compound per well in a 3 84 well plate to prepare a test plate to a final compound concentration of 10 μM and 1% DM SO. The medium was removed from the screened cells, trypsinized, the cells were collected by centrifugation, and the cells were counted. In the 3 84-well test plate prepared above, 50.0 cells per well were prepared in a volume of about 45 μL. Test plates containing both compounds and screening cells were incubated at 37 ° C for 20 hours. Carefully aspirate the culture medium from the cells and make sure that the cells have not been detached. Add cell lysis buffer (30 μί / well) and incubate at ambient temperature for at least 30 minutes. Add luciferase test buffer (30 μυ wells) and read the test plate on a fluorometer (PE Biosystems Northstar reader with syringe of 573-200401770 or equivalent). The plate was read immediately after the luciferase test reagent was added. EC5 () / IC5 can be established using LXR / LXRE co-transfection assays for intensity and percent activity.値 or inhibition of effectiveness. Efficacy is defined as the activity of the compound relative to the high control group [a LXR activator as a standard, which is optionally selected from natural or synthetic LXR activators, such as an activator referred to in WOOO / 547 59] or Low control group (DMS0 / solvent). The dose-response curve is formed by the concentration difference between the 8-point curve and 1/2 l0G unit, and each point represents the data of the average of 4 wells in a 384-well flat plate. Bring the data from this test into the following equation, its EC5.値 can be solved: Y = bottom + (top-bottom) / (1Ή0ζ) Z = (logEC5Q— X) * slope slope Therefore EC5Q / IC5 () is defined as the stimulant or antagonist to stimulate the top (maximum 値) Concentrations in half of the path between radon and bottom (baseline) radon (fixed model of biological data using linear and non-linear regression, GraphPad Software, Inc.), EC5Q / IC5.値 represents the average 至少 of at least 3 independent experiments. The determination of relative potency or the control of the activator was achieved by comparing the maximum response of the LXR activator as the standard. For antagonist tests, an LXR activator can be added to each well of a 28-well plate to stimulate the response. The inhibition of each antagonist is therefore a measure of the inhibition of the activator activity. In this example, a 100% inhibition indicates that the activity of a specific concentration of LXR activator has been reduced to a baseline amount, defined as the activity of this test in the presence of DMS 0 only. -574- 200401770 The compound of the present invention, when tested in this test, exhibits excellent LXR-modulated activity. (Test Example 4) Anti-inflammatory activity The animals and reagents used in this study are as follows unless otherwise stated. CD1 mice (6-10 weeks old, male and female) were purchased from Charles River Japan, Inc. and fed at controlled room temperature and humidity, and allowed to ingest food and water at will. Group 5 animals adapted to the environment for 5 days. 0.03% (w / v) TP Α / acetone of 10 μΐ of crotyl 12-myristate-13-ethyl ester (TPA) was applied to the inner and outer surfaces of the left ear of the test rat (total 20 μ 1 ) Induces irritant contact dermatitis. The right ear is coated with acetone only, and 45 minutes and 4 hours after TPA application. 20 μ1 of the test compound (10 mM in acetone) is applied to both ear areas. The control group is similarly treated with acetone alone. Animals were used as a solvent control group. Allergic contact dermatitis (2 days) induced by sensitization on CD 1 female mice including hair removal by 4-ethoxymethyl-2-phenyl-2 at 15% (w / v) of 20 μ1 -Oxazolin-5-one (oxazolone) once a day in acetone, followed by 7 days after a single administration of 2% oxazolone / acetone on both surfaces of the left ear, and acetone was applied to the right ear alone . This challenge reaction was then treated with 20 l of the test compound (10 mM in acetone) or acetone for 45 minutes and 4 hours, as described above. 18 hours after induction of an inflammatory response by either TPA or oxazolone, inflammation was assessed as a percentage increase in ear thickness and / or a percentage increase in ear weight of the treated left ear relative to the solvent-treated right ear, using a digital caliper Ear thickness was measured, followed by a biopsy at 6 mm to determine changes in ear weight. The degree of inflammation is quantified according to the following equation. Ear swelling (%) = 100 X [(a)-(b) / (b)], where (a) is the thickness / weight of the treated left ear 'and (b) is untreated Chu-575- 200401770 The thickness / weight of the right ear in the control group. The compound of the present invention exhibits excellent anti-inflammatory activity, making it useful as a medicine for inflammatory diseases. (Test Example 5) Hypoglycemic activity The hypoglycemic activity of the compound of the present invention was measured as follows. Blood samples were collected from the tail vein (4 to 5 months of age) of each KK rat, which was purchased from Japan Clea, Inc. The amount of plasma glucose was centrifuged with a glucose analyzer ("GlucoloaderrGXT", A & T Inc.) Measure. Then diabetic rats were divided into groups (3 or 4 rats in each group), and after three days, the powdery feed (F-2, Funabashi Farm) containing the test compound was 0.1-0.001% (w / w). The rats were given the test compound at the concentration, and the group to which the test compound was given was referred to as the "compound-administered group", while the powder-free group to which the compound was administered was referred to as the "control group". Blood sample and measure plasma glucose concentration. Plasma glucose reduction rate is calculated by the following equation: Plasma glucose reduction rate (%) = (average plasma glucose amount in control group-average plasma glucose amount given to compound group) x 100 / plasma glucose amount in control group The compound of the present invention exhibits excellent hypoglycemic activity, making it useful as a medicine for diabetes. Example of Formulation (Formulation Example 1) A standard separable hard capsule is used A gelatin capsule is loaded with the compound of Example 1 (100 mg), lactose (150 mg), cellulose (50 mg), and magnesium stearate (6 mg) to form a hard capsule. The obtained capsule is washed and dried. -576- 200401770 (Formulation Example 2) A mixture of soft capsule digestible oils such as soybean oil or olive oil and the compound of Example 2 was poured into gelatin to form soft capsules containing 100 mg of the active ingredient, washed and dried to obtain the soft Capsule. (Formulation Example 3) Lozenges The compound of Example 3 (100 mg), colloidal silica (0.2 mg), magnesium stearate (5 mg), fine crystal cellulose (275 mg), starch ( (1 lmg) and lactose (98.8mg) to prepare lozenges, if necessary, this lozenge can be coated. (Formulation Example 4) Emulsion Preparation of a finely powdered compound of Example 4 (100mg), carboxymethyl fiber Emulsion (5mg), sodium benzoate, sorbitol solution emulsion (Japanese pharmacopoeia, 1.0g), and aniline (0.025ml) in each 5ml of emulsion (Recipe Example 5) Cream by adding fine powder The compound of Example 5 (100 mg) to 5 g of cream Shihlin (40wt%), fine crystal wax (3wt%), refined lanolin (10wt%), sorbitan laurate (5wt%), polyoxyethylene (20) sorbitan laurate (0.3 wt%) and water (41.7 wt%). [Possible industrial use] The compound of formula (I) of the present invention and its pharmacologically acceptable salts and esters exhibit excellent binding affinity for LXR. The compound of formula (I) and its pharmacologically acceptable salts and esters of the invention also have excellent pharmacokinetic properties regarding absorption, distribution, half-life of blood concentration, etc., and have low toxicity to kidneys, liver and other organs . Therefore, the compound of formula (I) of the present invention and its pharmacologically acceptable salts and esters are useful as medicines for warm-blooded animals. -577- 200401770 'preferably human; especially as treatment and / or prevention includes Arteriosclerotic medicines derived from diseases including atherosclerosis; diabetes-derived arteriosclerosis; hyperlipidemia; fat-related diseases; inflammatory cytokine-mediated inflammatory diseases such as chronic rheumatoid arthritis, bones and joints Inflammation, allergic diseases, asthma, sepsis, dryness and osteoporosis; autoimmune diseases such as systemic lupus erythematosus, ulcerative colitis, and Crohn's disease; cardiovascular diseases such as anemia heart disease and Heart failure; Cerebrovascular disease; Kidney disease; Diabetes; Diabetic eruption such as retinopathy, nephropathy, neuropathy and coronary artery disease; Obesity; Nephritis; Hepatitis; Cancer and Alzheimer's disease; Arteriosclerosis, atherosclerosis 'derived from diabetes, arteriosclerosis, hyperlipidemia, fat-related diseases' derived from cytokinesis Inflammatory diseases of the media and diabetes; and most preferably atherosclerosis. [Schematic description] and 〇

• 578- 200401770. Sequence Listing < 110 > Sankyo Company, Limited; X-Ceptor Therapeutics, Inc. < 120 >! Fused cyclopyrimidone derivative, its production method and use 1. < 130 > FP-0310 < 140 > < 141 > < 150 > US 60 / 389,662 < 151〉 2002-06-18 < 160 > 6 < 170 > Patentln Ver. 2.1 < 210 > 1 < 211 > 29 < 212 > DNA < 213 > Artificial Sequences < 220 > < 223 > Inventor iKozo Oda; Satoru Kaneko; Takeshi Watanabe; Raju Mohan Inventor SEdwin J. Schweiger; Richard Martin < 220> 1 < 223 > Rework Sequence Explanation: To amplify the DNA forward primer encoding the ligand bound to the human LXRa f body < 400 > 1. Cacgacgtcg accatgccca tccttgccc 29 < 210〉 2 -579- 200401770 < 211 > 35 < 212> DNA < 213 > Artificial Sequence < 220 > 2 < 223 > Description of Artificial Sequence: Used to amplify the DNA forward primer encoding the ligand bound to the human LXRa subject < 400> 2 cacgacgcgg ccgctcattc gtgcacatcc cagat 35 < 210〉 3 < 211 > 33 < 212 > DNA < 213 > artificial sequence < 220 3 < 223 > Description of the artificial sequence: used to amplify the DNA forward primer encoding the ligand bound to the human LXRP subject < 400〉 3 tcagccgaat tcgcctgggg cttcccctgg tgg 33 < 210 > 4 < 211> 32 < 212 > DNA < 213 > Artificial Sequences < 220 > 4 < 223 > Explanations of Artificial Sequences ... Used to amplify and encode DNA forward primers that bind to the human LXRP subject: ligands < 400 > 4 cctagcctcg agtcactcgt ggacgtccca ga 32 -580- 200401770 < 210 > 5 < 211> 783 < 212> DNA < 213 > al stupid < 400 > 5 catgccacat ccttgccccc cagggcttcc tcaccccccc aaatcctgcc ccagctcagc 60 ccggaacaac tgggcatgat cgagaagctc gtcgctgccc agcaacagtg taaccggcgc 120 tccttttctg accggcttcg agtcacgcct tggcccatgg caccagatcc ccatagccgg 180 gaggcccgtc agcagcgctt tgcccacttc actgagctgg ccatcgtctc tgtgcaggag 240 atagttgact ttgctaaaca gctacccggc ttcctgcagc tcagccggga ggaccagatt 300 gccctgctga agacctctgc gatcgaggtg atgcttctgg agacatctcg gaggtacaac 360 cctgggagtg agagtatcac cttcctcaag gatttcagtt ataaccggga agactttgcc 420 a aagcagggc tgcaagtgga attcatcaac cccatcttcg agttctccag ggccatgaat 480 gagctgcaac tcaatgatgc cgagtttgcc ttgctcattg ctatcagcat cttctctgca 540 gaccggccca acgtgcagga ccagctccag gtagagaggc tgcagcacac atatgtggaa 600 gccctgcatg cctacgtctc catccaccat ccccatgacc gactgatgtt cccacggatg 660 ctaatgaaac tggtgagcct ccggaccctg agcagcgtcc actcagagca agtgtttgca 720 ctgcgtctgc aggacaaaaa gctcccaccg ctgctctctg agatctggga tgtgcacgaa 780 tga 783 < 210> 6 < 211 > 795 < 212 > DNA < 213 > • human < 400 > 6 cctggggctt cccctggtgg atctgaggca ggcagccagg gctccgggga aggcgagggt 60 gtccagctaa cagcggctca agaactaatg atccagcagt tggtggcggc ccaactgcag 120 tgcaacaaac gctccttctc cgaccagccc aaagtcacgc cctggcccct gggcgcagac 180 ccccagtccc gagatgcccg ccagcaacgc tttgcccact tcacggagct ggccatcatc 240 tcagtccagg agatcgtgga cttcgctaag caagtgcctg gtttcctgca gctgggccgg 300 gaggaccaga tcgccctcct gaaggcatcc actatcgaga tcatgctgct agagacagcc 360 aggcgctaca accacgagac agagtgtatc accttcttga aggacttcac 42 ctacag 0 gacgacttcc accgtgcagg cctgcaggtg gagttcatca accccatctt cgagttctcg 480 -581- 200401770 cgggccatgc atcttctcgg ccctacgtgg ttcccgcgca caggtcttcg gacgtccacg ggcggctggg cctggacgac gctgagtacg ccctgctcat cgccatcaac ccgaccggcc caacgtgcag gagccgggcc gcgtggaggc gttgcagcag aggcgctgct gtcctacacg cgcatcaaga ggccgcagga ccagctgcgc tgctcatgaa gctggtgagc ctgcgcacgc tgagctctgt gcactcggag ccttgcggct ccaggacaag aagctgccgc ctctgctgtc ggagatctgg agtga 540 600 660 720 780 795 -582-

Claims (1)

200401770 Patent application scope: i. A compound of formula U) or a pharmacologically acceptable salt or vinegar thereof, F Where: A represents a C ^ C, 4-aryl group or a 5- to 7-membered heterocyclic aryl group; R1, R2, and R3 are the same or different and each represents a hydrogen atom, a hydroxyl group, a nitro group, a cyano group, an amine group, or a halogen atom , Carboxyl, carbamoyl, hydrogenthio, CVC6, substituted with 1 to 7 halogen atoms, 2C, C6, C2-C7 alkylcarbonyloxy, oxy, cvc6 alkylthio, cvc6 alkyl Sulfinyl sulfenyl group, 0v <6 alkylsulfonyl group, (^-(^ alkylamino group, bis (cvc6 alkyl) amino group (where alkyl groups are the same or different), c2-c7 alkyl group Carbonylamino, N- (C2-C7 alkylcarbonyl) -N- (C "C6 alkyl) amino, c2-c7 alkoxycarbonylamino, N- (C2-C7 alkoxycarbonyl)- N-((VC6 alkyl) amino, c "c6 alkylsulfonylamino", n- (cvc6 alkylsulfonyl) -n- (c "c6 alkyl) amino, haloalkylsulfonyl Amino group (wherein the haloalkylsulfonylamino group is <^-(: 6 alkylsulfonylamino group) substituted with 1 to 7 halogen atoms, N- (C "C6 haloalkylsulfonyl group Fluorenyl) -N-((ν (: 6 alkyl) amino (wherein the haloalkylsulfonyl is a Ci-c6 alkylsulfonyl substituted with 1 to 7 halogen atoms), c2-c7 alkyl Carbonyl C2-C7 firing mineral-based group, c2- -583- 200401770 , Hydroxyl, amine, same or different) ’or R1 and R2 may form together R4 and R5 are the same or different and each represents a hydrogen atom, a halogen atom, a hydrogenthio group, a cvc6 alkyl group, Thio group; '1 to 7 halogen atoms substituted 2-C7 alkoxycarbonyl or (^-(^ alkyl halogen atom, CrC, alkoxy or substituted by 1 X represents a hydrogen atom, a hydroxyl group, to 7 halogen atoms ( ^-(: 6 alkoxy groups; γ represents c ^ -c: 6 alkyl groups, substituted with 丨 to? Substituents (the substituents are the same or different, and are selected from the group of substituents described below) α), C3-C1 () cycloalkyl, C3-CK cycloalkyl substituted with 1 to 7 substituents (the substituents are the same or different, and are selected from the following substituent group α), 5 To 9-membered heterocyclyl, 5 to 9-membered heterocyclyl substituted with 1 to 7 substituents (the substituents are the same or different and are selected from the substituent group α described below), aryl, 1 to 4 substituents substituted for $ C6-Ci () aryl (the substituents are the same or different 'and selected from the following substituent group 3), cycloalkylalkyl, 1 to 7 substituents Substituted C4-Ci4 cycloalkylalkyl (the substituents are the same or different and are selected from the following substituent groups ^ '(5- to 9-membered heterocyclyl XC ^ C: 4 alkyl), via 1 (5 to 9-membered heterocyclyl) substituted with 7 to 7 substituents The substituents are the same or different and are selected from the following substituent group a), C7-C14 aralkyl, or C7_C14 aralkyl substituted with 1 to 5 substituents (the substituents are the same or different, And selected from the following substituent groups); the substituent group α represents a group consisting of the halogen atom, -584- 200401770 hydroxy, cyano, amino, c2-c7 alkylcarbonyloxy, c "C6 alkyl, c" (: 6 alkoxy, C "C6 alkylthio, (^ -0: 6 alkylsulfinyl sulfenyl, c" c6 alkyl sulfonyl, phenyl, (: " (: 6 alkylamino group, bis (c "c6 alkyl) amino group (where the alkyl groups are the same or different), c2-c7 alkylcarbonylamino group, c" c6 alkylsulfonylamino group and CrC , Haloalkylsulfonamidoamino groups (wherein the Ci-q haloalkylsulfonamidoamino group is Ci-Ce alkylsulfonamidoamino groups substituted with 1 to 7 halogen atoms); and the substituent group representative A group consisting of a halogen atom, a hydroxyl group, a nitro group, a cyano group, an amine group, an alkyl group, an icvq alkyl group substituted with 1 to 7 halogen atoms, a c2-c7 alkylcarbonyloxy group, and a CVC6 alkoxy group , C, c6 alkylthio, C ^ -Ce alkylene Sulfonyl, C6C6 alkylsulfonyl, amine, bis (Ci-C, alkyl) amino (where alkyl is the same or different), C2-C7 alkyl carbonamino, N -(C2-C7 alkyl-based ore-based) -N- (C! -C6 alkyl) amino, C2-C7 alkoxycarbonylamino, N- (C2-C7 alkoxycarbonyl) -N- (CVC6 Alkyl) amino, C "C6alkylsulfonamidoamino, N- (C" c6alkylsulfonamido) -N- (CVC6alkyl) amino, c "c6haloalkylsulfonamidoamine (Wherein the halogenated alkylsulfonylamino group is substituted with 1 to 7 halogen atoms (0 ^ -0: 6 alkylsulfonylamino group), haloalkylsulfonylalkyl group) amine (Wherein (^-(: 6-haloalkylsulfonyl is C ^ -C, alkylsulfonyl substituted by 1 to 7 halogen atoms), C6-Clc aryl, C7-C14 aralkyloxy , CVC4 butanedioxy, c2-c7 alkylcarbonyl, C2-C7 alkoxycarbonyl, c2-c7 alkylaminocarbonyl, and bis (c "c6 alkyl) aminocarbonyl (where alkyl is Same or different); if Y is the following options (i) to (Vii) and A is phenyl, then R4 and R5 -585- 200401770 both represent a hydrogen atom and the 3 or 4 position of phenyl is connected to- C (CF3) 2 (X) The branch represents the -C (CF3) 2 (OH) part: (i) an alkyl group at the first position with an amino group, an alkylamino group, a dialkylamino group, an alkylcarbonylamino group, and an alkylsulfonium Substituted with an amino or haloalkylsulfonylamino, and optionally substituted with an alkyl or phenyl at the first position; (ii) a cycloalkyl, which is substituted with an amino, alkylamino, A dialkylamino group, an alkylcarbonylamino group, an alkylsulfonylamino group, or a haloalkylsulfonylamino group, and optionally substituted with 1 to 6 groups selected from the substituent α; iii) a heterocyclic group having at least one nitrogen atom, which is optionally substituted with 1 or 2 other groups selected from the group consisting of sulfonyl, sulfinyl, sulfinyl, and phenyl; (iv) a ring Yuanji Yuanji, the first position of its foundation part is amine group, Yuanji fee group, Wuyi fee group, Yuan iron group amino group, Yuan group sulfonylamino group or halogen Yuan group. Amino group substitution, the ring group is optionally substituted with 1 to 6 groups selected from the substituent α; (ν) heterocyclyl alkyl, the alkyl portion is amine group at the first position , Sylamino, dialkylamino, alkylcarbonylamino, Alkylsulfonylamino or haloalkylsulfonamido, the heterocyclylalkyl is optionally substituted with another 1 to 6 groups selected from the substituent α; (VI) heterocyclylmethyl 'Its heterocyclyl moiety has at least one nitrogen atom, and is optionally substituted with 1 to 7 groups selected from substituents α, and the methyl moiety is optionally substituted with alkyl or phenyl; and (vii) Aralkyl, the first part of the alkyl part of the amine group, amine group • 586- 200401770 group, dialkylamino group, alkylcarbonylamino group, alkoxycarbonylamino group, alkylsulfonyl group Amine, haloalkylsulfonylamino, N- (alkylcarbonyl) -N- (alkyl) amino, N- (alkoxycarbonyl) -N- (alkyl) amino, N- ( Alkylsulfonyl) -N- (alkyl) amino or N- (haloalkylsulfonyl) (alkyl) amino, the aralkyl is optionally substituted with one to six additional substituents Base / 3 is substituted. 2. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of patent application, wherein R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, a cyanide Group, amine group, fluorine atom, chlorine atom, bromine atom, carboxyl group, carbamoyl group, CVC4 alkyl group, C "C4 alkyl group, CVC4 alkoxy group, c" C4 alkyl group substituted with 1 to 5 halogen atoms Thio, C "C4 alkylamino, bis (C" C4 alkyl) amino (where alkyl groups are the same or different), C2-C5 alkylcarbonylamino, N- (C2-C5 alkylcarbonyl ) -NdC * amine group) amine group, C2_C5 oxo group amine group, C2-C5 fluorenylamino carbonyl group or bis (C "C4 alkyl) amino carbonyl group (where the alkyl groups are the same or different), Or, R1 and R2 can form C "C3 alkylene dioxy together. 3 · As the compound of formula (I) or the pharmacologically acceptable salts or esters thereof in the first scope of the patent application, wherein R1, R2 and R3 is the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, a cyano group, an amine group, a fluorine atom, a chlorine atom, a bromine atom, a carboxyl group, a carbamate group, a methyl group, an ethyl group, a propyl group, a trifluoro group methyl, Fluoroethyl, methoxy, ethoxy, isopropoxy, methylthio, ethylthio, isopropylthio, methylamino, dimethylamino, acetamido, N-methylethyl Fluorenylamino, methoxycarbonyl, ethoxycarbonyl, methylaminoformyl, or dimethylaminoformyl, or R1 and R2 together can form a methylene group-587- 200401770 Base 4. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of patent application, wherein R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a fluorine atom, a chlorine Atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or acetamido, or R1 and R2 may together form a methylenedioxy group. 5. A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 4 of the scope of patent application, wherein R3 is a hydrogen atom. 6. For example, a compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 5, wherein R4 and R5 are the same or different and each is a hydrogen atom or a fluorine atom , A chlorine atom, an alkyl group, a CVC4 alkyl group substituted with 1 to 5 halogen atoms, a CVC4 alkoxy group, a C2-C5 alkoxycarbonyl group, or a CVC4 alkylthio group. 7. The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 5, wherein R4 and R5 are the same or different and each is an ammonia atom, A chlorine atom, a chlorine atom, a methyl group, an ethyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, a methoxycarbonyl group, an ethoxycarbonyl group, a methylthio group, or an ethylthio group. 8. The compound of formula (1) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 5, wherein r4 and R5 are the same or different and each is a hydrogen atom, Chlorine, methyl or methoxy. 9. The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 5, wherein ... and R5 are each a hydrogen atom. -588- 200401770 10. · A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 9, wherein X is a hydrogen atom, an alkyl group, or a C4 alkyl group. Oxy or Ci_C4 alkoxy substituted with 1 to 5 halogen atoms. 1 1. A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 9, wherein X is a hydrogen atom, a chemotactic group, a methoxy group, or a trifluoromethoxy group base. 12. The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 9, wherein X is a hydroxyl group. 13 · The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12, wherein Y is Cl_c6 alkyl or Cl substituted with 1 to 5 substituents -C4 alkyl (the substituents are the same or different and are selected from the substituents α as defined in item 1 of the patent application scope). 14 · A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12 in the scope of application for a patent, wherein ¥ is Cl-C5 alkyl or 1 to 4 C! -C3 alkyl substituted by substituents (the substituents are the same or different and are selected from the substituents αΐ defined below); substituent α 1 represents the following groups: halogen atom, amine group, Ci_C6 Alkylamino and di (C 1 -C 6 alkyl) amino groups (wherein the alkyl groups are the same or different) 〇 1 5 · Formula (I) according to any one of items 1 to i 2 of the scope of patent application Compound or pharmacologically acceptable salt or ester thereof, wherein γ is ethyl, propyl, butyl, isopropyl, second butyl, 3-pentyl, trifluoromethyl, dichloromethyl , Bromoethyl, 1-chloroethyl, diethylaminomethyl or diisopropylamino • 589- 200401770 methyl. 1 6. A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12, in which γ is a C3-C6 cycloalkyl group or a 5- to 9-membered heterocyclic ring base. 1 7. For example, a compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12, wherein Y is cyclobutyl, cyclopentyl, cyclohexyl, hexahydro Pyridyl, perhydroazepine or perhydroazepine. 18 · The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of the items 1 to 12 of the scope of patent application, wherein Y is a C6-Cic) aryl group, or C ^ -C ^^ aryl substituted with 1 to 4 substituents (the substituents are the same or different and are selected from the substituents 01 defined below); the substituent Θ 1 represents a group consisting of: fluorine Atom, chlorine atom, bromine atom, hydroxyl, nitro, cyano, amine, methyl, ethyl, propyl, isopropyl, butyl, second butyl, third butyl, trifluoromethyl, Pentafluoroethyl, ethoxy, propyloxy, methoxy, ethoxy, isopropoxy, methylthio, ethylthio, isopropylthio, dimethylamino, ethamino , Methanesulfonylamino, methylenedioxy, ethylenedioxy, ethylfluorenyl, propylfluorenyl, methoxycarbonyl, ethoxycarbonyl and dimethylaminomethylfluorenyl. 19 · A compound of formula (1) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12 in the scope of the patent application, wherein Υ is phenyl, 1-naphthyl or 2- Naphthyl. 2 0. A compound of formula (1) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12 of the scope of the patent application, wherein Y is C 4 -C13 cycloalkyl-590- 200401770 alkyl C4-C13 cycloalkylalkyl substituted with 1 to 7 substituents (the substituents are the same or different and are selected from the substituents α as defined in item 1 of the patent application scope), (5 to 9 members Heterocyclyl)-(CVC3 alkyl), or (5 to 9-membered heterocyclylalkyl) substituted with i to 7 substituents (the substituents are the same or different and are selected from the first in the scope of patent applications Substituent α). 21 · If the scope of patent application is the first! A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of items 12 to 12, wherein Y is (C3-C1 () cycloalkyl) methyl or (5- to 9-membered heterocyclic group) methyl. 22 · The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims i to 12 of the scope of application for a patent, wherein Y is cyclopentylmethyl, cyclohexylmethyl, cycloheptyl Methyl, 2-thienylmethyl, pyrrolidinylmethyl, 1-hexahydropyridylmethyl, or 1-perhydroazepinyl. 23 · The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims i to 12 of the scope of application for a patent, wherein Y is a C7-C14 aralkyl 'or substituted by 1 to 4 C 7-C i 4 aromatic radicals substituted with phenyl groups (the substituents are the same or different and are selected from the substituents defined in item 1 of the patent application / 3). twenty four . For example, a compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 12, wherein γ is (Ce-Ci.aryl) methyl, (C6- C1Q aryl) ethyl, (c6-C1Q aryl) methyl substituted with 1 to 4 substituents (the substituents are the same or different and are selected from substituents 々1 defined below), or Aryl substituted with 1 to 4 substituents) Ethyl (the substituents are the same or different and are selected from the substituents defined in Items 1 to 8-591- 200401770 in the scope of patent application 1) 25. As the scope of patent application The compound of formula (I), or a pharmacologically acceptable salt or ester thereof, according to any one of items 1 to 12, wherein γ is benzyl, carbomethyl, 2-naphthylmethyl, or a phenyl moiety Benzyl substituted with 1 to * substituents (the substituents are the same or different and are selected from the substituents 02 defined below); the substituent / 3 2 represents a group consisting of: a fluorine atom, Chlorine, bromine, hydroxyl, nitro, methyl, ethyl, isopropyl, trifluoromethyl, methoxy, ethoxy, methylthio, ethylthio, dimethylamino, Methylenedioxy group and an ethylenedioxy stretch. 26. The compound of formula (I) or a pharmacologically acceptable salt or ester as described in any one of items 1 to 25 in the patent application Fe Fei, where A is phenyl, naphthyl, or ethyl B fixed base. 27. A compound of formula (I) or a pharmacologically acceptable salt or ester as described in any one of items 1 to 25 of the patent application Fe, wherein A is phenyl. 28. If the compound of formula (I) or the pharmacologically acceptable salts or esters thereof according to item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, Nitro, cyano, amine, fluorine, chlorine, bromine, cumyl, carbamate, C4 alkyl, CVC4 alkyl substituted with 1 to 5 halogen atoms, C4 C4 oxygen Group, Ci-C # Chenylthio group, C ^ -C ^ Chenylamino group, dialkyl) amino group (where the alkyl groups are the same or different), c2-c5 alkyl_amino group, n- ( c2-c5 alkylcarbonyl) -N- (ίν (: 4-alkyl) amino, c2-c alkoxycarbonylamino, c2-c5 alkylaminocarbonyl, or di (c "c4 alkyl) -592 -200401770 Aminocarbonyl group (where alkyl groups are the same or different), or R1 and R2 can form CVC3 butanedioxy together; R4 and R5 are the same or different and each is a hydrogen atom, a fluorine atom, a chlorine atom, CVC4 alkyl group, CVC4 alkyl group substituted with 1 to 5 halogen atoms, Wuxing group, C2-C5 oxo group or thio group; X is a hydrogen atom, a hydroxyl group, a Ci-C # alkoxy group, or C "c4 alkoxy substituted with 1 to 5 halogen atoms; γ is a cvc6 alkyl group or a CVC4 alkyl group substituted with 1 to 5 substituents (the substituents are the same or different and are selected from the substituent α as defined in item 1 of the scope of the patent application); and A is a phenyl group , Naphthyl or pyridyl. 29. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, Cyano, amine, fluorine, chlorine, bromine, carboxy, carbamoyl, CVC4 alkyl, substituted with 1 to 5 halogen atoms (^ -0: 4 alkyl, CVC4 alkoxy, CVC4 Alkylthio, 0: "0: 4 alkylamino, dialkyl) amino (where alkyl groups are the same or different), C2-C5 alkylcarbonylamino, N- (c2-c5 alkyl Carbonyl group) -N- (cvc4 alkyl) amino group, c2-c5 alkyloxyamine group, C2-C5 alkylamino group or one group) aminocarbonyl group (where the alkyl groups are the same or different ), Or R1 and R2 may form together 〇ν (: 3. Butanedioxy; R4 and R5 are the same or different and each is a hydrogen atom, a fluorine atom, a chlorine atom, a cvc4 alkyl group, a CVC4 alkyl group substituted with 1 to 5 halogen atoms, -593- 200401770 Ci-C4 Oxo, C2-C5 oxo, or Ci-Cg fluorenylthio; X is a hydrogen atom, via a radical, Ci-C # oxo, or substituted with 1 to 5 halogen atoms (: "(: 4 alkoxy; ^ is C3-C6 cycloalkyl or 5 to 9-membered heterocyclic group; and A is phenyl, naphthyl or pyridyl. 30. A compound of formula (I) as described in claim 1 Or a pharmacologically acceptable salt or ester thereof, wherein: R1, R2, and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, a cyano group, a amine group, a fluorine atom, a chlorine atom, or bromine Atom, carboxyl group, carbamoyl group, CVC4 alkyl group, cvc4 alkyl group substituted with 1 to 5 halogen atoms, C, C4 alkylthio group, C ^ -Cj alkylamino group, di (Cc4 Alkyl) amino groups (where the alkyl groups are the same or different), c2-c5 alkylcarbonylamino groups, N- (C2-C5 alkylcarbonyl) -N-((ν (: 4 alkyl) amino groups, C2-C5 alkoxycarbonylamino, C2-C5 alkylaminocarbonyl or di (Ci-q Group) Aminocarbonyl (where the alkyl groups are the same or different), or R1 and R2 can form a CVC3 butanedioxy group; R4 and R5 are the same or different and are each a hydrogen atom, a fluorine atom, a chlorine atom, CVC4 alkyl, Ci_c4 alkyl substituted with 1 to 5 halogen atoms, CVC4 alkoxy, c2-c5 alkoxycarbonyl, or Cl-C4 alkylthio; X is a hydrogen atom, hydroxyl, alkoxy or via Alkoxy substituted with 1 to 5 halogen atoms; γ is CVC !. aryl, or c6-c1Q aryl substituted with 1 to 4 substituents (the substituents are the same or different and are selected from the patent application Substituent / 3/1) as defined in item J 8 of the scope; and -594- 200401770 A is phenyl, naphthyl, or hydrazine. 3 1 · As the compound of formula (I) in item 1 of the scope of patent application or Its pharmacologically acceptable salts or esters, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, a cyano group, an amine group, a fluorine atom, a chlorine atom, a bromine atom , Carboxy, carbamoyl, CVC4 alkyl, C "C4 alkyl, substituted with 1 to 5 halogen atoms, Ci-Cq alkylthio, C] -C4 alkylamino, dioxane ) Amine (where the alkyl groups are the same or different), c2-c5 alkylcarbonylamino, N- (C2-C5 alkylcarbonyl) -N-CCVC4 alkyl) amino, c2-c5 alkoxycarbonyl Amine, C2-C5 alkylaminocarbonyl, or di (C ^ Cq alkyl) aminocarbonyl (where alkyl groups are the same or different), or R1 and R2 can form C i-C 3 alkanedioxy together R4 and R5 are the same or different and each is a hydrogen atom, a fluorine atom, a chlorine atom, a "C4 alkyl group, a" C4 alkyl group, a substituted oxy group, C2-C5 substituted with 1 to 5 halogen atoms, Cioxy carbon group or Ci-C # Cithio group; X is a hydrogen atom, a hydroxyl group, an alkoxy group or a Ci-C4 alkoxy group substituted with 1 to 5 halogen atoms; Y is a c4-c13 cycloalkane Alkyl, c4_cl3 cycloalkylalkyl substituted with 1 to 7 substituents (the substituents are the same or different, and are selected from the above-defined substituents 0, (5 to 9-membered heterocyclyl)- ((^ -c3 alkyl), or (5 to 9-membered heterocyclylalkyl) substituted with 1 to 7 substituents (the substituents are the same or different, and are selected from the first scope of the patent application The substituents α); and A is phenyl, naphthyl or pyridyl. -595- 200401770 32. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, Cyano, amine, fluorine, chlorine, bromine, carboxyl, carbamoyl, CVq alkyl, via! Cl-C4 alkyl, C "C4 alkoxy, Cl-c4 alkylthio, Cl-C4 alkylamino, bis (C ^ -C ^ alkyl) amino (wherein Alkyl groups are the same or different), c2-C5 alkylcarbonyl, and N- (C2-C5 alkyl carbon) fluorenyl) amino, C2-C5 alkoxycarbonylamino, C2-C5 alkyl Amineaminocarbonyl or di (C "C4 alkyl) aminecarbonyl (where alkyl groups are the same or different), or han 1 and R2 can form cvc3 butanedioxy together; R4 and R5 are the same or different And each is a hydrogen atom, a fluorine atom, a chlorine atom, a CVC: 4 alkyl group, a Ci_c4 alkyl group substituted with i to 5 halogen atoms, a CVC4 alkyloxy group, a cvc: 5 alkoxycarbonyl group, or an alkylthio group; X Is a hydrogen atom, a hydroxyl group, an alkoxy group or a C "c4 alkoxy group substituted with 1 to 5 halogen atoms; Y is a crC14 aralkyl group, or an" aralkyl group substituted with i to 4 substituents (the substitution Groups are the same or different, and are selected from the substituents defined in item 1 of the claimed patent application / 5); and A is phenyl, naphthyl or pyridyl. 3 3. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of the patent application, wherein: R1, r2, and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, Cyano, amine, fluorine atom, chlorine atom, bromine atom, carboxyl group, amine methyl -596- 200401770 fluorenyl, methyl, ethyl, propyl, trifluoromethyl, pentafluoroethyl, methoxy, ethyl Oxy, isopropyloxy, methylthio, ethylthio, isopropylthio, methylamino, dimethylamino, acetamido, N-methylacetamido, methoxycarbonyl, Ethoxycarbonyl, methylaminomethyl or dimethylaminomethyl, or R1 and R2 together can form methylenedioxy or ethylenedioxy; R4 and R5 are the same or different and each is Hydrogen atom, fluorine atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl, methylthio or ethylthio; X is A hydrogen atom, a hydroxyl group, a methoxy group, or a trifluoromethoxy group; Y is a CVC5 alkyl group or a CVC3 alkyl group substituted with 1 to 4 substituents (the substituents are the same or different and are selected from the Shu range of the four substituents of the sense Cloth αΐ). 34. The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to item i of the patent application scope, wherein: R1, R2, and R3 are the same or different and each is a chlorine atom, a radical, a nitro group , Cyano, amine, fluorine, chlorine, bromine, carboxy'aminomethyl, methyl, ethyl, propyl, trifluoromethyl, pentafluoroethyl, methoxy, ethoxy, Isopropoxy, methylthio, ethylthio, isopropylthio, methylamino, dimethylamino, acetamido, N-methylacetamido, methoxymine, ethoxy Carbonyl, methylaminomethyl or dimethylaminomethyl 'or R1 and R2 may together form methylenedioxy or ethylenedioxy; R4 and R5 are the same or different and each is hydrogen Atom, fluorine atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl, methylthio or ethylthio; -597- 200401770 χ is a hydrogen atom, a hydroxyl group, a methoxy group, or a trifluoromethoxy group; Y is a C3-C6 cycloalkyl group or a 5- to 9-membered heterocyclic group; and A is a phenyl group, a naphthyl group, or a pyridyl group. 35. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, Cyano, amine, fluorine, chlorine, bromine, residue, carbamate, methyl, ethyl, propyl, trifluoromethyl, pentafluoroethyl, methoxy, ethoxy, Isopropoxy, methylthio, ethylthio, isopropylthio, methylamino, dimethylamino, acetamido, N-methylacetamido, methoxycarbonyl, ethoxy Carbonyl, methylaminomethyl or dimethylaminomethyl 'or R1 and R2 together can form methylenedioxy or ethylenedioxy; R4 and R5 are the same or different and each is an argon atom, Fluorine atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl, methylthio or ethylthio; X is a hydrogen atom, Hydroxy, methoxy or trifluoromethoxy; Y is CVh. An aryl group, or an aryl group substituted with i to 4 substituents (the substituents are the same or different and are selected from the substituents defined in item i 8 of the patent application / 3/1); and A is phenyl , Naphthyl or pyridyl. 3 6. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitro group, Cyano, amine, fluorine atom, chlorine atom, bromine atom, carboxyl group, amine methyl-598- 200401770 fluorenyl, methyl, ethyl, propyl, trifluoromethyl, pentafluoroethyl, methoxy, ethyl Oxy, isopropyloxy, methylthio, ethylthio, isopropylthio, methylamino, dimethylamino, acetamido, N ~ methylacetamido, methoxycarbonyl, Ethoxycarbonyl, methylaminomethyl or dimethylaminomethyl, or R1 and R2 together can form methylenedioxy or ethylenedioxy; R4 and R5 are the same or different and each is Hydrogen atom, fluorine atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, methoxycarbonyl, ethoxycarbonyl, methylthio or ethylthio; X is A hydrogen atom, a hydroxyl group, a methoxy group, or a trifluoromethoxy group; Y is a Cq-C! 3 ring radical, a c_C cycloalkylalkyl group substituted with 1 to 7 substituents (the substituents are the same Or different And is selected from the substituent α as defined in item 1 of the patent scope, (5 to 9-membered heterocyclyl (Ci_c3 alkyl), or substituted with 1 to 7 substituents (5 to 9-membered heterocyclic Cyclopeptide (C "C3") (the substituent is opposite or different 'and is selected from the substituent α defined in item 1 of the patent application scope); and A is phenyl, naphthyl or pyridyl. 3 7. For example, the compound of formula (1) or its pharmacologically acceptable salts or esters in item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a nitrate Group, cyano, amine, fluorine atom, chlorine atom, bromine atom, carboxyl group, carbamoyl group, methyl, ethyl, propyl, trifluoromethyl, pentafluoroethyl, methoxy, ethoxy , Isopropyloxy, methylthio, ethylthio 'isopropylthio, methylamino, dimethylamino, acetamido, methylacetamido, methoxycarbonyl, ethoxy 羯A methyl group, a methylamine formamyl group or a dimethylamine formamidine-599- 200401770 group, or R1 and R2 together may form a methylenedioxy group or a ethylenedioxy group; R4 and R5 are the same or different and each is different Is a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group, an ethyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, a methoxycarbonyl group, an ethyl group, a methylthio group, or an ethylthio group; X is a hydrogen atom, a phenyl group, a methoxy group, or a trifluoromethoxy group; Y is a C 7 -C, 4 aralkyl group, or a C 14 aralkyl group substituted with 1 to 4 substituents (the substitution The bases are the same or different, Item patent application selected range of substituents 1 defined / 3); and A is phenyl, naphthyl or strong [a given group. 38. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to item 1 of the scope of the patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a fluorine Atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy or acetamido, or R1 and R2 can form methylenedioxy together; R4 and R5 are the same or different And each is a hydrogen atom, a chlorine atom, a methyl group, or a methoxy group; X is a hydroxyl group; y is a "C5 alkyl group or a Ci_c3 alkyl group substituted with 1 to 4 substituents (the substituents are the same or different, And is selected from the substituents α 1) defined in item 14 of the scope of patent application; and A is phenyl. For example, the compound of formula (I) or its pharmacologically acceptable salt or ester, Among them: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, and a fluorogen-600-39.   200401770 Atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy or acetamido, or R1 and R2 can form methylenedioxy together; R4 and R5 are the same or the same Different and each is a hydrogen atom, a chlorine atom, a methyl group, or a methoxy group; X is a hydroxyl group; Y is a cyclobutyl group, a pentyl group, a cyclohexyl group, a hexahydrolatinyl group, a perhydroργ heptyl group, or a perhydroacin group A cyclic group; and A is phenyl. 4 0. For example, the compounds of formula (I) or their pharmacologically acceptable salts or esters in the application of the patent scope @table 1, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a fluorine atom , Chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or acetamido, or R1 and R2 may together form a methylenedioxy group; R and R are the same or different and Each is a hydrogen atom, a chlorine atom, a methyl group or a methoxy group; X is a hydroxyl group; Y is a phenyl group, a 1-naphthyl group or a 2-naphthyl group; and A is a phenyl group. 4 1 · If the compound of formula (1) or the pharmacologically acceptable salt or ester thereof according to item 1 of the scope of patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, A fluorine atom, a chlorine atom, a methyl group, an ethyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, or an ethyl group, or R and R2 may form a methylenedioxy group together.R4 and R5 are the same or Are different and are each a hydrogen atom, a chlorine atom, a methyl group or -601- 200401770 methoxy group; X is a hydroxyl group; Y is a (C3-C1Q cycloalkyl) methyl group or a (5- to 9-membered heterocyclic group) methyl group ; And A is phenyl. 42. For example, the compound of formula (I) or its pharmacologically acceptable salts or esters in item 1 of the scope of the patent application, wherein: R1, R2 and R3 are the same or different and each is a hydrogen atom, a hydroxyl group, a fluorine atom, a chlorine atom , Methyl, ethyl, trifluoromethyl, methoxy, ethoxy or acetamido, or R1 and R2 together can form a methylenedioxy group; spring R4 and R5 are the same or different and each is A hydrogen atom, a chlorine atom, a methyl group, or a methoxy group; X is a hydroxyl group; Y is (C ^ Ci.aryl) methyl, (CVCi.aryl) ethyl, and is substituted by 1 to 4 aurino groups (C6_Ciq aryl) methyl (the substituents are the same or different 'and are selected from the substituents defined in item 18 of the patent application / 3 1), or' C6_Ciq substituted with 1 to 4 substituents Aryl) ethyl (the substituents are the same or different and are selected from the substituted can radical points 1) as defined in item 18 of the scope of patent application; and A is phenyl. 4 3 '% application § 靑 The compound of formula (I) or its pharmacologically acceptable salt or ester in item 1 of the patent scope, wherein: R and &amp; 2 are the same or different and each is a hydrogen atom, Hydroxyl, fluorine, chlorine, methyl'ethyl, trifluoromethyl, methoxy, ethoxy, or ethylamino groups, or may form methylenedioxy together; -602- 200401770 R3 is a hydrogen atom R4 and R5 are each a hydrogen atom; X is a hydroxyl group; Y is ethyl, propyl, butyl, isopropyl, second butyl, 3-pentyl, trifluoromethyl, dichloromethyl, 1- Bromoethyl, 1-chloroethyl, diethylaminomethyl, or diisopropylaminomethyl; and A is phenyl. 44.  For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of the patent application, wherein: β R1, R2 and R3 are the same or different and each is a hydrogen atom, a radical, a fluorine Atom, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or acetamido, or R1 and R2 together can form a methylenedioxy group; R3 is a hydrogen atom; R4 and R5 Each is a hydrogen atom; X is a hydroxyl group; Υ is cyclobutyl, cyclopentyl, cyclohexyl, hexahydropyridinyl, perhydroργheptyl, or perhydroacrysyl ring group; and — A is phenyl. 45.  For example, the compound of formula (I) or its pharmacologically acceptable salts or esters in item 1 of the scope of the patent application, wherein: R1 and R2 are the same or different and each is a hydrogen atom, a hydroxyl group, a fluorine atom, a gas atom , Methyl, ethyl, trifluoromethyl, methoxy, ethoxy, or acetamido, or R1 and R2 can together form a methylenedioxy group; R3 is a hydrogen atom; -603- 200401770 R4 and R5 Each is a hydrogen atom; X is a hydroxyl group; γ is phenyl, 1-naphthyl or 2.naphthyl; and A is phenyl. 4 6 • The compound of formula (I) or the pharmacologically acceptable salt or ester thereof according to item 1 of the scope of patent application, wherein: R1 and R2 are the same or different and each is a hydrogen atom, a hydroxyl group, or a fluorine atom , A chlorine atom, a methyl group, an ethyl group, a trifluoromethyl group, a methoxy group, an ethoxy group, or an ethylamidine group, or R1 and R2 may together form a methylenedioxy group; II3 is a hydrogen atom; and R5 are each Hydrogen atom;% is a hydroxyl group; γ is a cyclopentylmethyl group, a cyclohexylmethyl group, a cycloheptylmethyl group, a 2-thienylmethyl group, a 1-lalopyridinylmethyl group, and a hexahydropyridinemethyl group Or perhydroργheptylmethyl; and A is phenyl. 47. For example, the compound of formula (I) or a pharmacologically acceptable salt or ester thereof in item 1 of the scope of the application, wherein: r1, R2, and R3 are the same or different and each is a hydrogen atom, a radical, or a fluorogen Rhenium, chlorine atom, methyl, ethyl, trifluoromethyl, methoxy, and ethoxy groups form acetamido, or R1 and R2 can form a methylenedioxy group together; II3 is a hydrogen atom; p / and R5 Each is a hydrogen atom; X is a hydroxyl group; -604 &gt; 200401770 Y is benzyl, 1-naphthylmethyl, 2-naphthylmethyl, or benzyl substituted with 1 M 4 substituents on the phenyl moiety (The substituents are the same or different 'and are selected from the substituents defined in item 25 of the patent application / 3 2); and A is phenyl. 48. For example, the compound of formula (I) in item 1 of the scope of patent application is selected from the following compounds: 2-trifluoromethyl-3- [4- [2,2,2-trifluoro-buhydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-cyclobutyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- [difluoro (phenyl) methyl] -3- [4- [2,2,2-trifluoro- 1-hydroxy-1- (trifluoromethyl) ethyl] phenyl; 1-4 (3H) -quinazolinone, 2- (4-methylbenzyl) -3- [4- [2, 2,2-trifluoro · 1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (4-chlorobenzyl) -3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (2-fluorobenzyl ) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (3 -Fluorobenzyl) -3- [4- [2,2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (4-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, -605- 200401770 2- (3-trifluoromethylbenzyl) -3- [4- [2,2,2-trifluoro -Hydroxy-1- (trifluoromethyl) ethyl] phenyl: | -4 (3Η) -Πoxazolinone, 2- (4-trifluoromethylbenzyl) -3- [4- [ 2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (4-methoxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxyl, 1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (2, 4-difluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl; -4 (3Η) -quine Azolinone, 2- (3,4-methylenedioxybenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3Η) -quinazolinone, 2-benzyl-5-methyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoro (Methyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-5-chloro-3- [4- [2,2,2 · trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) · quinazolinone, 5-chloro-2- (4-methylbenzyl) -3- [4- [2,2, 2-trifluoro-buhydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (4-bromobenzyl) -5-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazolinone, 5-chloro-2- (4-chlorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazole Porphyrinone, 5-chloro-2- (4-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl ] -4 (3Η) -quinazolinone, 2-benzyl-5-hydroxy- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) 200401770 Ethyl] phenyl: 1-4 (3Η) -quinazolinone, 2-benzyl-6-methyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (Trifluoromethyl) ethyl] phenyl] -4 (3 to -_azolinone, 2-benzyl-6-chloro- 3- [4- [2,2,2-trifluoro-1- Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6-bromo-3- [4- [2,2,2-tri Fluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6-hydroxy-3- 3- [4- [2,2 , 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6-methoxy-3- 3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6-ethyl Fluorenylamino-3- [4 -[2,2,2-trifluoro-hydroxyl-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-7-chloro-3 -[4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -Πquinazolinone, 2-benzyl- 7-hydroxy- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- Benzyl-7-trifluoromethyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H)- Quinazolinone, 2-benzyl-7-methoxy-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -azolidone, 2-benzyl-8-chloro- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl ] Phenyl] -4 (3H) -quinazolinone, 200401770 2-benzyl-5-fluoro-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6-fluoro-3- [4- [2,2,2-trifluoro-1-hydroxy-1 -(Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6,7-dimethoxy-3- [4- [2,2,2 -Trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6.7- Dimethoxy-2- (4-methylbenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzene Yl] -4 (3H) -quinazolinone, 2- (4-bromobenzyl) -6,7-dimethoxy-3- [4- [2,2,2-trifluoro-1- Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2- (4-chlorobenzyl) -6,7-dimethoxy-3- [ 4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6.7-dimethoxy-2- (4-fluorobenzyl) -3- [4- [2,2,2-trifluoro-1-hydroxy-bu (trifluoromethyl) ethyl] phenyl] -4 (3Η) -quinazoline ketone, 6.7- Methylenedioxy-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 ( 3Η) -quinazolinone, 6.7-difluoro-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzene Yl] -4 (3H) -quinazolinone, 6-methoxy-5-chloro-2-benzyl-3- [4- [2,2,2-trifluoro-buhydroxy-1- ( Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 5,6-dimethyl-2-benzyl-3- [heart [2,2,2-trifluoro- 1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3Η) -oxazolinone, 6-chloro-5-methyl-2-benzyl 3- [4- [ 2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl-608- 200401770 group) ethyl] phenyl] -4 (3H) -quinazolinone, 6-methoxy-5- Methyl-2-benzyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazole Porphyrinone, 5.6-dichloro-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 ( 3H) -quinazolinone, 5.7-dichloro-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] benzene Phenyl] -4 (3H) -quinazolinone, 6.7-Dimethyl-2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -Quinazolinone, 7-methoxy-6-methyl-2-benzylmethyl 3- [4- [2,2,2 -dipic-1-yloxy-1- (difluoromethyl ) Ethyl] phenyl] -4 (3H) -quinazolinone, 7-methyl-6-chloro-2-benzyl-3- [4- [2,2,2-trifluoro-1- Hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6,7-dichloro-2-benzyl-3- [4- [2,2, 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 7-methoxy-6-chloro-2-benzylmethyl 3- [4- [2,2,2-dihalf-1-acyl-1- (difluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 7-methylmethoxy-2-benzyl 3- 3- [4- [2,2,2-trifluoro-1-hydroxy-1 · (trifluoromethyl ) Ethyl] phenyl] -4 (3H) -oxazolinone, 7-chloro-6-methoxy-2-benzyl-3- [4- [2,2,2-trifluoro- 1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 7-chloro-6-fluoro-2-benzyl 3- [4- [2 , 2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, -609- 200401770 7-fluoro-6-methyl- 2-benzyl- 3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6.7- monomethoxy-5-gas-2-benzylmethyl 3- 3- [4- [2,2,2-dihalf-1-acyl-1- (trifluoromethyl) ethyl] phenyl ] -4 (3H) -quinazolone, 2-benzyl-3- [4- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl ] Benzo [g] oxazoline-4 (3H) -one, 2-benzyl-3- [3-methyl-4- [2,2,2-trifluoro-1-hydroxy-1- ( Trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl_3_ [3-methoxy_4- [252,2-trifluoro-1-hydroxy- 1- (trifluoromethyl) Ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-5-chloro-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (tri Fluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 2-benzyl-6,7-dimethoxy-3- [3- [2,2,2-trifluoro -1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6.7-difluoro-2-benzyl-3- [3- [2,2 , 2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6-chloro-5-methyl-2-benzyl- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 6-methoxy- 5-methyl-2-benzyl- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H)- Quinazolinone, 6.7-dimethyl-2-benzyl-3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 7-methyl-6-chloro-2-benzyl- 3- [3- [2,2,2-trifluoro-1-hydroxy-1- (trifluoro Methyl 200401770 group) ethyl] phenyl] -4 (3H) _quinazolinone, 7-methoxy-6-¾-2 2-benzylmethyl 3- [3- [2,2,2 -tri Fluorenyltrifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 7-methyl-6-methoxy-2-benzyl-3- [3- [2, 2,2-three Fluoro-b hydroxyl · 丨 · (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, 7-chloro-6-methoxy-2-benzyl-3- [3 -[2,2,2-trifluorohydroxy_ 丨 _ (trifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, and 7 · fluoro-6-methyl-2-benzene Methyl-3- [3- [2,2,2-trifluoro-1-meryltrifluoromethyl) ethyl] phenyl] -4 (3H) -quinazolinone, or a pharmacologically acceptable Acceptable salts or esters. 49. A pharmaceutical composition comprising an effective amount of a pharmacologically active compound and a carrier or diluent, wherein the pharmacologically active compound is the formula (I) according to any one of claims 1 to 48 in the scope of patent application. Compounds or pharmacologically acceptable salts or esters thereof. 50. The composition according to item 49 of the scope of patent application, which is used for treating and / or preventing a warm-blooded animal that can be treated and / or preventable by regulating the LXR function of the warm-blooded animal (may be a human) disease. 5 1 · The composition according to item 49 of the scope of patent application, which is used for the treatment and / or prevention of warm-blooded animals that can be humans, and is selected from arteriosclerosis derived from diseases defined below, including atherosclerosis, Derived from arteriosclerosis of diabetes, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, autoimmune diseases, cardiovascular diseases, cerebrovascular diseases, kidney diseases, diabetes, diabetic Outbreak, obesity, nephritis, hepatitis, cancer and Alzheimer's disease. -611- 200401770 52. If the composition of the scope of patent application No. 49 is used for the treatment and / or prevention of arteriosclerosis, atherosclerosis, arteriosclerosis derived from diabetes, which can be warm-blooded animals that can be humans, Hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, and diabetes. 5 3 · The composition according to item 49 of the scope of patent application, which is used to treat and / or prevent arteriosclerosis in warm-blooded animals that can be humans. 54.-A compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 48 in the scope of patent application, which is used as a medicine. 5 5 ·-at least one compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 48 in the scope of application for a patent for the treatment and / or prevention It is the use of human warm-blooded animal diseases, which can be treated and / or preventable by regulating the LXR function of the warm-blooded animal. 5. The use as described in the scope of patent application No. 55, wherein the Warm-blooded animals with LXR function that are treatable and / or preventable are selected from diseases including arteriosclerosis derived from diseases defined as: atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-related Diseases, inflammatory diseases regulated by inflammatory cytokines, autoimmune diseases, cardiovascular disease, cerebrovascular disease, kidney disease, diabetes, diabetic eruption, obesity, nephritis, hepatitis, cancer and Alzheimer's disease . 57. The use according to item 55 of the scope of patent application, wherein the disease is selected from the group consisting of atherosclerosis, atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-related diseases, and regulation by inflammatory cytokines Inflammatory diseases and diabetes. -612- 200401770 5 8 · If the application in the scope of patent application No. 55 is used, the disease is arteriosclerosis. 59. A method for treating and / or preventing a warm-blooded animal by regulating LXR function of the warm-blooded animal and / or preventing a disease of the warm-blooded animal (which may be a human), comprising administering an application of an effective amount of the warm-blooded animal The compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 48. 60. The method of claim 59, wherein the diseases treatable and / or preventable by modulating the LXR function of the warm-blooded animal are selected from diseases including arteriosclerosis derived from diseases defined below: Atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, fat-related diseases, inflammatory diseases regulated by inflammatory cytokines, autoimmune diseases, cardiovascular diseases, cerebrovascular diseases, kidney diseases, diabetes, Diabetic eruption, obesity, nephritis, hepatitis, cancer and Alzheimer's disease. 6 1 · The method according to item 59 of the scope of patent application, wherein the disease is selected from the group consisting of arteriosclerosis, atherosclerosis, arteriosclerosis derived from diabetes, hyperlipidemia, and fat-related diseases' regulated by inflammatory cytokines Inflammatory diseases and diabetes. 6 2 · The method according to item 59 of the patent application scope, wherein the disease is arteriosclerosis. 6 3 · A pharmaceutical composition comprising a compound of formula (I) or a pharmacologically acceptable salt or ester thereof according to any one of claims 1 to 48 in the scope of patent application, and at least one selected from Η MG-C ο A reductase inhibitor, ACAT inhibitor, vasopressin II inhibitor and pharmacologically active agent of diuretics, and -613- 200401770 carrier or diluent. 64. The pharmaceutical composition of claim 63, wherein the pharmacologically active agent is a HMG-CoA reductase inhibitor. -614- 200401770 (1) Designated representative map: (1) The designated representative map in this case is: (). (2) Brief description of the element representative symbols of this representative diagram: 捌 If there is a chemical formula in this case, please disclose the chemical formula that can best show the characteristics of the invention: β F